[
    {
        "id": 33,
        "title": "3-MeO-PCP",
        "content": "",
        "drug_info": {
            "drug_name": "3-MeO-PCP",
            "search_url": "https://knowdrugs.app/substances/3-meo-pcp",
            "chemical_class": "Arylcyclohexylamine",
            "psychoactive_class": "Dissociative anesthetic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "1-2 mg",
                            "light": "2-5 mg",
                            "common": "5-10 mg",
                            "strong": "10-15 mg",
                            "heavy": "15+ mg"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "1 mg",
                            "light": "2-4 mg",
                            "common": "4-8 mg",
                            "strong": "8-12 mg",
                            "heavy": "12+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 1,
                                "max": 2
                            },
                            "light": {
                                "min": 2,
                                "max": 5
                            },
                            "common": {
                                "min": 5,
                                "max": 10
                            },
                            "strong": {
                                "min": 10,
                                "max": 15
                            },
                            "heavy": {
                                "min": 15,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 1,
                                "max": 2
                            },
                            "light": {
                                "min": 2,
                                "max": 4
                            },
                            "common": {
                                "min": 4,
                                "max": 8
                            },
                            "strong": {
                                "min": 8,
                                "max": 12
                            },
                            "heavy": {
                                "min": 12,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4-8 hours",
                "onset": "15-30 minutes (oral), 5-15 minutes (insufflated)",
                "peak": "1-3 hours",
                "offset": "2-4 hours",
                "after_effects": "Up to 24 hours (residual effects, afterglow)"
            },
            "addiction_potential": "Moderate to high; repeated use can lead to psychological dependence and compulsive redosing. There are reports of mania and psychosis with heavy or prolonged use.",
            "interactions": {
                "dangerous": ["alcohol", "benzodiazepines"],
                "unsafe": ["other dissociatives", "opioids"],
                "caution": ["serotonergic drugs (SSRIs, MAOIs, MDMA)"]
            },
            "notes": "3-MeO-PCP is more potent than ketamine and PCP, with a higher affinity for the NMDA receptor. It is also a serotonin reuptake inhibitor. Overdose can result in severe dissociation, mania, psychosis, and dangerous behavior. Harm reduction practices are strongly advised, including accurate milligram-scale dosing and avoiding combinations with depressants or serotonergic drugs.",
            "subjective_effects": [
                "Dissociation",
                "Euphoria",
                "Mental clarity",
                "Stimulation",
                "Mania (at high doses)",
                "Psychosis (at high doses)",
                "Analgesia",
                "Anxiolysis",
                "Cognitive impairment",
                "Motor impairment",
                "Hallucinations (less common than with PCP or ketamine)"
            ],
            "tolerance": {
                "full_tolerance": "After 3-7 days of repeated use",
                "half_tolerance": "~1-2 weeks",
                "zero_tolerance": "2-4 weeks",
                "cross_tolerances": [
                    "other arylcyclohexylamines (e.g., ketamine, PCP)"
                ]
            },
            "half_life": "4-8 hours (estimates vary)",
            "citations": [
                {
                    "name": "TripSit 3-MeO-PCP",
                    "reference": "https://wiki.tripsit.me/wiki/3-MeO-PCP"
                },
                {
                    "name": "Erowid 3-MeO-PCP Vault",
                    "reference": "https://www.erowid.org/chemicals/3-meo-pcp/3-meo-pcp.shtml"
                },
                {
                    "name": "Isomer Design: Methoxetamine and analogues",
                    "reference": "https://isomerdesign.com/Cdsa/ACMD/methoxetamine2012.pdf"
                },
                {
                    "name": "Drug Users Bible: 3-MeO-PCP",
                    "reference": "https://drugusersbible.org/content/chemscape/dissociatives/3-meo-pcmo/"
                }
            ],
            "categories": ["dissociative", "research-chemical", "hallucinogen"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "3-MeO-PCP",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Based on published literature, user reports, and clinical reviews collected up to 2024.",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 8,
                            "iso": ["PT4H", "PT8H"],
                            "note": "Duration noted is for primary psychoactive effects; after-effects may persist longer."
                        },
                        "onset": {
                            "start": 0.08,
                            "end": 0.25,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT15M"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 3,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 3,
                            "end": 8,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT8H"]
                        },
                        "after_effects": {
                            "start": 8,
                            "end": 24,
                            "iso_start": ["PT8H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 34,
        "title": "Methcathinone",
        "content": "",
        "drug_info": {
            "drug_name": "Methcathinone",
            "search_url": "https://bluedark.org/substance/methcathinone",
            "chemical_class": "Cathinone (\u03b2-keto amphetamine)",
            "psychoactive_class": "Stimulant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5-10 mg",
                            "light": "10-25 mg",
                            "common": "25-50 mg",
                            "strong": "50-100 mg",
                            "heavy": "100+ mg"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5-10 mg",
                            "light": "10-20 mg",
                            "common": "20-40 mg",
                            "strong": "40-80 mg",
                            "heavy": "80+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 25
                            },
                            "common": {
                                "min": 25,
                                "max": 50
                            },
                            "strong": {
                                "min": 50,
                                "max": 100
                            },
                            "heavy": {
                                "min": 100,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 20
                            },
                            "common": {
                                "min": 20,
                                "max": 40
                            },
                            "strong": {
                                "min": 40,
                                "max": 80
                            },
                            "heavy": {
                                "min": 80,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "2-4 hours",
                "onset": "10-30 minutes (oral), 5-10 minutes (insufflated)",
                "peak": "1-2 hours",
                "offset": "1-2 hours",
                "after_effects": "2-6 hours (residual stimulation, possible comedown)"
            },
            "addiction_potential": "High. Methcathinone is considered to have a significant risk of abuse and dependence, similar to other potent stimulants such as methamphetamine.",
            "interactions": {
                "dangerous": ["MAOIs", "SSRIs", "other stimulants"],
                "unsafe": ["alcohol", "benzodiazepines"],
                "caution": ["caffeine", "antidepressants"]
            },
            "notes": "Methcathinone is a controlled substance in many countries (Schedule I in the US). It is structurally similar to methamphetamine and cathinone, and is sometimes referred to as 'cat', 'Jeff', 'Mulka', or 'ephedrone'. It is associated with compulsive redosing, neurotoxicity, and significant cardiovascular risks. Long-term use can result in severe psychological and physical harm.",
            "subjective_effects": [
                "Euphoria",
                "Increased energy",
                "Increased sociability",
                "Talkativeness",
                "Appetite suppression",
                "Increased heart rate",
                "Increased blood pressure",
                "Anxiety",
                "Agitation",
                "Insomnia",
                "Compulsive redosing",
                "Paranoia (at high doses or with chronic use)"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (within days)",
                "half_tolerance": "~3-7 days",
                "zero_tolerance": "1-2 weeks after cessation",
                "cross_tolerances": ["Amphetamines", "Other cathinones"]
            },
            "half_life": "~1.5-2 hours",
            "citations": [
                {
                    "name": "Methcathinone FAQ (Erowid/Rhodium)",
                    "reference": "https://www.erowid.org/archive/rhodium/chemistry/methcatfaq.22.html"
                },
                {
                    "name": "Consideration of the cathinones (isomerdesign.com)",
                    "reference": "https://isomerdesign.com/Cdsa/ACMD/Consideration%20of%20the%20cathinones.pdf"
                },
                {
                    "name": "DrugBank: Methcathinone",
                    "reference": "https://go.drugbank.com/drugs/DB15339"
                }
            ],
            "categories": ["stimulant", "research-chemical", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Methcathinone",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Derived from clinical reports and user experience forums, e.g., Erowid, and relevant academic literature as of 2024.",
                        "units": "hours",
                        "total_duration": {
                            "min": 2,
                            "max": 4,
                            "iso": ["PT2H", "PT4H"],
                            "note": "Reflects full span from first noticeable effects to return to baseline, excluding aftereffects."
                        },
                        "onset": {
                            "start": 0.08,
                            "end": 0.17,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT10M"]
                        },
                        "peak": {
                            "start": 0.17,
                            "end": 1.17,
                            "iso_start": ["PT10M"],
                            "iso_end": ["PT1H10M"]
                        },
                        "offset": {
                            "start": 1.17,
                            "end": 3.17,
                            "iso_start": ["PT1H10M"],
                            "iso_end": ["PT3H10M"]
                        },
                        "after_effects": {
                            "start": 2,
                            "end": 8,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT8H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 36,
        "title": "Trazodone",
        "content": "",
        "drug_info": {
            "drug_name": "Trazodone",
            "search_url": "https://go.drugbank.com/drugs/DB00656",
            "chemical_class": "Triazolopyridine derivative",
            "psychoactive_class": "Antidepressant (Serotonin Antagonist and Reuptake Inhibitor, SARI)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "25 mg",
                            "light": "25-50 mg",
                            "common": "50-150 mg",
                            "strong": "150-300 mg",
                            "heavy": "300-600 mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 10,
                                "max": 25
                            },
                            "light": {
                                "min": 25,
                                "max": 50
                            },
                            "common": {
                                "min": 50,
                                "max": 150
                            },
                            "strong": {
                                "min": 150,
                                "max": 300
                            },
                            "heavy": {
                                "min": 300,
                                "max": 600
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "6-12 hours",
                "onset": "30-60 minutes",
                "peak": "1-3 hours",
                "offset": "6-12 hours",
                "after_effects": "May include drowsiness or sedation for several hours"
            },
            "addiction_potential": "Low addiction potential; not considered habit-forming but abrupt discontinuation can cause withdrawal symptoms in long-term users.",
            "interactions": {
                "dangerous": [
                    "MAOIs (monoamine oxidase inhibitors)",
                    "other serotonergic drugs (risk of serotonin syndrome)"
                ],
                "unsafe": [
                    "Alcohol (increased sedation and risk of CNS depression)"
                ],
                "caution": [
                    "Other CNS depressants",
                    "Antihypertensives (may enhance hypotensive effect)",
                    "Alpha-1 adrenergic antagonists"
                ]
            },
            "notes": "Trazodone is primarily used as an antidepressant and for its anxiolytic and sedative properties. It is often prescribed off-label for insomnia. It can cause drowsiness, orthostatic hypotension, and, rarely, priapism (prolonged erection). Caution is advised in patients with cardiovascular disease. Should not be combined with other serotonergic drugs due to risk of serotonin syndrome.",
            "subjective_effects": [
                "Sedation",
                "Drowsiness",
                "Reduced anxiety",
                "Mood improvement",
                "Mild euphoria (rare)",
                "Dizziness",
                "Dry mouth",
                "Headache"
            ],
            "tolerance": {
                "full_tolerance": "Develops slowly with regular use",
                "half_tolerance": "Not well documented",
                "zero_tolerance": "Several weeks after cessation",
                "cross_tolerances": ["Other serotonergic antidepressants"]
            },
            "half_life": "5-13 hours (varies by individual and formulation)",
            "citations": [
                {
                    "name": "DrugBank: Trazodone Overview",
                    "reference": "https://go.drugbank.com/drugs/DB00656"
                },
                {
                    "name": "DrugBank: Trazodone Biointeractions",
                    "reference": "https://go.drugbank.com/drugs/DB00656/biointeractions"
                },
                {
                    "name": "DrugBank: Trazodone Article A985",
                    "reference": "https://go.drugbank.com/articles/A985"
                },
                {
                    "name": "DrugBank: Trazodone Article A181177",
                    "reference": "https://go.drugbank.com/articles/A181177"
                },
                {
                    "name": "DrugBank: Trazodone Salt Information",
                    "reference": "https://go.drugbank.com/salts/DBSALT000344"
                }
            ],
            "categories": ["antidepressant", "sedative", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Trazodone",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Most clinical and pharmacology sources focus on oral trazodone use; insufflation is not recommended due to potential for mucosal irritation and changes to pharmacokinetics. Available case reports and user anecdotes suggest a slightly faster onset but overall similar duration to oral use.",
                        "units": "hours",
                        "total_duration": {
                            "min": 6,
                            "max": 12,
                            "iso": ["PT6H", "PT12H"],
                            "note": "Insufflation may slightly shorten onset but total effects persist for a comparable timespan as oral administration."
                        },
                        "onset": {
                            "start": 0.5,
                            "end": 1,
                            "iso_start": ["PT0H30M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 3,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 6,
                            "end": 12,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT12H"]
                        },
                        "after_effects": {
                            "start": 12,
                            "end": 18,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT18H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 35,
        "title": "7-Hydroxymitragynine",
        "content": "",
        "drug_info": {
            "drug_name": "7-Hydroxymitragynine (7-OH)",
            "search_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3670991/",
            "chemical_class": "Indole alkaloid",
            "psychoactive_class": "Opioid",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2 mg",
                            "light": "2-10 mg",
                            "common": "10-20 mg",
                            "strong": "20-30 mg",
                            "heavy": "30+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 1,
                                "max": 2
                            },
                            "light": {
                                "min": 2,
                                "max": 8
                            },
                            "common": {
                                "min": 8,
                                "max": 15
                            },
                            "strong": {
                                "min": 15,
                                "max": 25
                            },
                            "heavy": {
                                "min": 25,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4 to 5 hours",
                "onset": "15 minutes",
                "peak": "N/A",
                "offset": "N/A",
                "after_effects": "N/A"
            },
            "addiction_potential": "High potential for addiction due to its opioid-like effects.",
            "interactions": {
                "dangerous": [],
                "unsafe": [],
                "caution": []
            },
            "notes": "7-Hydroxymitragynine is a potent alkaloid found in kratom, reported to be 17 times stronger than morphine. It is recommended to use pure isolates for safer consumption.",
            "subjective_effects": [
                "Analgesia",
                "Euphoria",
                "Sedation",
                "Physical numbness",
                "Anxiolytic",
                "Mood lifting"
            ],
            "tolerance": {
                "full_tolerance": "N/A",
                "half_tolerance": "N/A",
                "zero_tolerance": "N/A",
                "cross_tolerances": ["Opioids"]
            },
            "half_life": "Unknown",
            "citations": [
                {
                    "name": "7-Hydroxymitragynine: An Indole Alkaloid from Mitragyna speciosa with Potent Opioid Agonistic Activity",
                    "reference": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3670991/"
                }
            ],
            "categories": ["opioid", "supplement"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "7-Hydroxymitragynine (7-OH)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Scientific literature and experience reports (2023) indicate that insufflated 7-Hydroxymitragynine has a rapid onset and a short duration compared to oral administration.",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 5,
                            "iso": ["PT4H", "PT5H"],
                            "note": "Duration as reported in case studies and experience reports for insufflated 7-OH."
                        },
                        "onset": {
                            "start": 0.25,
                            "end": 0.5,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT30M"]
                        },
                        "peak": {
                            "start": 0.5,
                            "end": 2,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 3,
                            "end": 5,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT5H"]
                        },
                        "after_effects": {
                            "start": 5,
                            "end": 8,
                            "iso_start": ["PT5H"],
                            "iso_end": ["PT8H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 38,
        "title": "Lithium",
        "content": "",
        "drug_info": {
            "drug_name": "Lithium",
            "search_url": "https://www.drugs.com/lithium.html",
            "chemical_class": "Alkali-metal monovalent cation (Li\u207a) administered as carbonate or citrate salts",
            "psychoactive_class": "Antimanic / mood-stabiliser",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg (lithium-carbonate equivalent)",
                        "dose_ranges": {
                            "threshold": "150 mg",
                            "light": "300 \u2013 450 mg",
                            "common": "600 \u2013 900 mg",
                            "strong": "1050 \u2013 1200 mg",
                            "heavy": "\u22651350 mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 150,
                                "max": 299
                            },
                            "light": {
                                "min": 300,
                                "max": 449
                            },
                            "common": {
                                "min": 600,
                                "max": 899
                            },
                            "strong": {
                                "min": 1050,
                                "max": 1199
                            },
                            "heavy": {
                                "min": 1350,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "12 \u2013 24 h",
                "onset": "0.5 \u2013 2 h",
                "peak": "1 \u2013 5 h (IR) / 4 \u2013 8 h (ER)",
                "offset": "10 \u2013 20 h",
                "after_effects": "Minimal, but fatigue or mild tremor can persist \u226424 h"
            },
            "addiction_potential": "Negligible; no reinforcing properties or physical dependence reported in clinical or user literature.",
            "interactions": {
                "dangerous": [
                    "Thiazide diuretics",
                    "Loop diuretics",
                    "ACE inhibitors / ARBs",
                    "NSAIDs (chronic use)",
                    "Dehydration or sodium-restriction",
                    "Classic psychedelics (\u2191 seizure risk)"
                ],
                "unsafe": [
                    "Serotonergic antidepressants (risk of serotonin syndrome)",
                    "Carbamazepine (neuro-toxicity)",
                    "Metronidazole",
                    "Calcium-channel blockers (verapamil, diltiazem)"
                ],
                "caution": [
                    "Antipsychotics (extrapyramidal effects)",
                    "SSRI/SNRI (monitor levels)",
                    "Caffeine (diuresis \u2192 fluctuating Li\u207a)",
                    "Low-sodium diet"
                ]
            },
            "notes": "Therapeutic window is narrow (0.6 \u2013 1.0 mmol L\u207b\u00b9 serum). Regular 12-h trough level, kidney and thyroid monitoring are essential. Early signs of toxicity include coarse tremor, confusion, and severe GI upset. Maintain stable dietary sodium and hydration.",
            "subjective_effects": [
                "Emotional blunting / mood leveling",
                "Reduced suicidality",
                "Fine hand tremor",
                "Polyuria & polydipsia",
                "Mild cognitive dulling",
                "Weight gain",
                "Metallic taste",
                "Sedation at higher serum levels"
            ],
            "tolerance": {
                "full_tolerance": "None (clinical effect does not diminish with chronic use)",
                "half_tolerance": "N/A",
                "zero_tolerance": "N/A",
                "cross_tolerances": []
            },
            "half_life": "18 \u2013 36 h (mean \u2248 24 h) depending on renal function",
            "citations": [
                {
                    "name": "Mayo Clinic \u2013 Lithium (oral route) prescribing information",
                    "reference": "https://www.mayoclinic.org/drugs-supplements/lithium-oral-route/description/drg-20064603"
                },
                {
                    "name": "StatPearls \u2013 Lithium",
                    "reference": "https://www.ncbi.nlm.nih.gov/books/NBK519062/"
                },
                {
                    "name": "Grandjean & Aubry 2009 \u2013 Clinical pharmacology and therapeutic monitoring of lithium",
                    "reference": "https://pubmed.ncbi.nlm.nih.gov/19374461/"
                },
                {
                    "name": "Malhi et al. 2020 \u2013 Lithium therapy and its interactions",
                    "reference": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7358048/"
                },
                {
                    "name": "Bluelight forum thread: \u201cPsychedelics and lithium\u201d (2024)",
                    "reference": "https://www.bluelight.org/community/threads/psychadelics-and-lithium.939229/"
                },
                {
                    "name": "Reddit r/Lithium discussion on side-effects (2024)",
                    "reference": "https://www.reddit.com/r/Lithium/comments/1e31vbp/can_someone_explain_to_me_the_side_effects_of/"
                },
                {
                    "name": "Drugs.com \u2013 Lithium dosage guide",
                    "reference": "https://www.drugs.com/dosage/lithium.html"
                }
            ],
            "categories": ["antidepressant", "supplement"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Lithium",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Based on clinical data for lithium pharmacokinetics and case reports; see PubMed ID: 29421740 and standard clinical toxicology sources.",
                        "units": "hours",
                        "total_duration": {
                            "min": 12,
                            "max": 24,
                            "iso": ["PT12H", "PT24H"],
                            "note": "Lithium is not typically insufflated; these values are based on oral and parenteral kinetics, extrapolated for unusual routes."
                        },
                        "onset": {
                            "start": 0.5,
                            "end": 2,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT2H"]
                        },
                        "peak": {
                            "start": [1],
                            "end": [5],
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT5H"]
                        },
                        "offset": {
                            "start": 10,
                            "end": 20,
                            "iso_start": ["PT10H"],
                            "iso_end": ["PT20H"]
                        },
                        "after_effects": {
                            "start": 20,
                            "end": 24,
                            "iso_start": ["PT20H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 40,
        "title": "Bromazolam",
        "content": "",
        "drug_info": {
            "drug_name": "Bromazolam",
            "search_url": "https://tripsit.me/factsheets/bromazolam",
            "chemical_class": "Benzodiazepine",
            "psychoactive_class": "Depressant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "0.1 mg",
                            "light": "0.25 - 0.5 mg",
                            "common": "1 - 2 mg",
                            "strong": "2 - 3 mg",
                            "heavy": "3+ mg"
                        }
                    },
                    {
                        "route": "sublingual",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "0.1 mg",
                            "light": "0.25 - 0.5 mg",
                            "common": "1 - 2 mg",
                            "strong": "2 - 3 mg",
                            "heavy": "3+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.1,
                                "max": 0.24
                            },
                            "light": {
                                "min": 0.25,
                                "max": 0.5
                            },
                            "common": {
                                "min": 0.75,
                                "max": 2
                            },
                            "strong": {
                                "min": 2,
                                "max": 3
                            },
                            "heavy": {
                                "min": 3,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "sublingual",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.1,
                                "max": 0.25
                            },
                            "light": {
                                "min": 0.25,
                                "max": 0.5
                            },
                            "common": {
                                "min": 0.5,
                                "max": 2
                            },
                            "strong": {
                                "min": 2,
                                "max": 3
                            },
                            "heavy": {
                                "min": 3,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "8 - 12 hours",
                "onset": "15 - 45 minutes",
                "peak": "1 - 3 hours",
                "offset": "6 - 12 hours",
                "after_effects": "12 - 24 hours (residual sedation possible)"
            },
            "addiction_potential": "High. Bromazolam, like other benzodiazepines, is habit-forming and can lead to physical and psychological dependence, especially with frequent or high-dose use.",
            "interactions": {
                "dangerous": [
                    "Alcohol",
                    "Opioids",
                    "Other benzodiazepines",
                    "Barbiturates"
                ],
                "unsafe": ["GABAergic depressants"],
                "caution": [
                    "Antidepressants",
                    "Antipsychotics",
                    "Muscle relaxants"
                ]
            },
            "notes": "Bromazolam is a potent designer benzodiazepine with significant risk of dependence, overdose, and withdrawal symptoms. It is not approved for medical use and is often sold as a research chemical. Combining with other CNS depressants greatly increases risk of respiratory depression and death. Tapering is required for discontinuation after regular use to avoid severe withdrawal.",
            "subjective_effects": [
                "Anxiolysis",
                "Sedation",
                "Muscle relaxation",
                "Disinhibition",
                "Amnesia",
                "Motor impairment",
                "Euphoria (rare)",
                "Cognitive suppression"
            ],
            "tolerance": {
                "full_tolerance": "Develops within days to weeks of regular use",
                "half_tolerance": "7 - 14 days after cessation",
                "zero_tolerance": "2 - 4 weeks after cessation",
                "cross_tolerances": ["Other benzodiazepines"]
            },
            "half_life": "10 - 20 hours (estimates vary)",
            "citations": [
                {
                    "name": "TripSit Factsheet: Bromazolam",
                    "reference": "https://tripsit.me/factsheets/bromazolam"
                },
                {
                    "name": "Isomerdesign: PIHKAL entry for Bromazolam",
                    "reference": "https://isomerdesign.com/pihkal/explore/3065"
                },
                {
                    "name": "Bluelight: Bromazolam on weekends to relax. Is this bad?",
                    "reference": "https://www.bluelight.org/community/threads/bromazolam-on-weekends-to-relax-is-this-bad.938054/"
                }
            ],
            "categories": [
                "depressant",
                "benzodiazepine",
                "research-chemical",
                "habit-forming"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Bromazolam",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Peer-reviewed literature, user reports, and clinical data on bromazolam pharmacodynamics (2022-2024).",
                        "units": "hours",
                        "total_duration": {
                            "min": 8,
                            "max": 12,
                            "iso": ["PT8H", "PT12H"],
                            "note": "Benzodiazepine effects with a moderate to long duration when insufflated."
                        },
                        "onset": {
                            "start": 0.25,
                            "end": 0.75,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT45M"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 3,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 6,
                            "end": 12,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT12H"]
                        },
                        "after_effects": {
                            "start": 12,
                            "end": 24,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 41,
        "title": "Modafinil",
        "content": "",
        "drug_info": {
            "drug_name": "Modafinil",
            "search_url": "https://go.drugbank.com/drugs/DB00745",
            "chemical_class": "Diphenylmethyl sulfinylacetamide",
            "psychoactive_class": "Stimulant, Eugeroic (wakefulness-promoting agent)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "25 mg",
                            "light": "50-100 mg",
                            "common": "100-200 mg",
                            "strong": "200-400 mg",
                            "heavy": "400+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 25,
                                "max": 50
                            },
                            "light": {
                                "min": 50,
                                "max": 100
                            },
                            "common": {
                                "min": 100,
                                "max": 200
                            },
                            "strong": {
                                "min": 200,
                                "max": 400
                            },
                            "heavy": {
                                "min": 400,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "12-15 hours",
                "onset": "30-90 minutes",
                "peak": "2-4 hours",
                "offset": "8-12 hours",
                "after_effects": "Up to 24 hours (residual stimulation or insomnia)"
            },
            "addiction_potential": "Low to moderate. Modafinil has a lower risk of addiction compared to classical stimulants, but misuse and psychological dependence are possible, especially at higher doses or with chronic use.",
            "interactions": {
                "dangerous": ["MAOIs", "other stimulants"],
                "unsafe": [
                    "CYP3A4 inhibitors or inducers (may alter modafinil levels)"
                ],
                "caution": [
                    "SSRIs",
                    "anticonvulsants",
                    "oral contraceptives (may reduce effectiveness)"
                ]
            },
            "notes": "Modafinil is primarily prescribed for narcolepsy, sleep apnea, and shift work sleep disorder. Off-label, it is sometimes used for ADHD, depression-related fatigue, and cognitive enhancement. It can cause insomnia, anxiety, headaches, and in rare cases, serious skin reactions or psychiatric symptoms. It is not recommended for individuals with a history of cardiac conditions.",
            "subjective_effects": [
                "Wakefulness",
                "Increased alertness",
                "Mild euphoria",
                "Enhanced focus",
                "Reduced fatigue",
                "Appetite suppression",
                "Mild stimulation",
                "Possible anxiety",
                "Headache",
                "Insomnia"
            ],
            "tolerance": {
                "full_tolerance": "Develops slowly with chronic use (weeks to months)",
                "half_tolerance": "Several weeks after cessation",
                "zero_tolerance": "1-2 months after cessation",
                "cross_tolerances": ["Other stimulants (minor)"]
            },
            "half_life": "12-15 hours",
            "citations": [
                {
                    "name": "DrugBank: Modafinil",
                    "reference": "https://go.drugbank.com/drugs/DB00745"
                },
                {
                    "name": "DrugBank: Modafinil absorption and metabolism",
                    "reference": "https://go.drugbank.com/articles/A14889"
                },
                {
                    "name": "DrugBank: Modafinil mechanism of action",
                    "reference": "https://go.drugbank.com/articles/A5550"
                }
            ],
            "categories": ["stimulant", "nootropic", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Modafinil",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Prescribing information, anecdotal reports, and case studies (e.g. PubChem, Drugs.com, BLUELIGHT reports) suggest that insufflation causes faster but not dramatically different absorption compared to oral; traditional onset/duration profile maintained but with slightly quicker onset.",
                        "units": "hours",
                        "total_duration": {
                            "min": 12,
                            "max": 15,
                            "iso": ["P12H", "P15H"],
                            "note": "Insufflation may slightly quicken onset but main duration is similar to oral."
                        },
                        "onset": {
                            "start": 0.5,
                            "end": 1.5,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT90M"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "offset": {
                            "start": 8,
                            "end": 12,
                            "iso_start": ["PT8H"],
                            "iso_end": ["PT12H"]
                        },
                        "after_effects": {
                            "start": 12,
                            "end": 24,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 42,
        "title": "Adrafinil",
        "content": "",
        "drug_info": {
            "drug_name": "Adrafinil",
            "search_url": "https://go.drugbank.com/drugs/DB08925",
            "chemical_class": "Diphenylmethylsulfinylacetamide (related to Modafinil)",
            "psychoactive_class": "Stimulant / Eugeroic / Nootropic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "50 mg",
                            "light": "100-200 mg",
                            "common": "200-300 mg",
                            "strong": "300-600 mg",
                            "heavy": "600+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 50,
                                "max": 100
                            },
                            "light": {
                                "min": 100,
                                "max": 200
                            },
                            "common": {
                                "min": 200,
                                "max": 300
                            },
                            "strong": {
                                "min": 300,
                                "max": 600
                            },
                            "heavy": {
                                "min": 600,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "8-12 hours",
                "onset": "45-90 minutes",
                "peak": "2-4 hours",
                "offset": "6-8 hours",
                "after_effects": "up to 24 hours (mild residual stimulation or insomnia possible)"
            },
            "addiction_potential": "Low to moderate. Adrafinil is considered to have a lower addiction potential compared to classical stimulants, but regular use may lead to psychological dependence.",
            "interactions": {
                "dangerous": ["MAOIs (risk of hypertensive crisis)"],
                "unsafe": [
                    "other stimulants (increased risk of side effects, overstimulation)"
                ],
                "caution": [
                    "SSRIs (possible interaction), CYP enzyme inhibitors (may affect metabolism), liver-impairing drugs (adrafinil is hepatotoxic with long-term use)"
                ]
            },
            "notes": "Adrafinil is a prodrug for modafinil, meaning it is metabolized in the body to produce modafinil. It is not approved for use in the US or many other countries but is sometimes used off-label as a cognitive enhancer. Long-term use may elevate liver enzymes and cause liver toxicity. Regular liver function monitoring is recommended for chronic use.",
            "subjective_effects": [
                "Wakefulness",
                "Increased alertness",
                "Improved focus",
                "Mild euphoria",
                "Reduced fatigue",
                "Mild stimulation",
                "Possible irritability or anxiety",
                "Insomnia (especially at higher doses or late in the day)"
            ],
            "tolerance": {
                "full_tolerance": "Several weeks of daily use",
                "half_tolerance": "3-7 days after cessation",
                "zero_tolerance": "1-2 weeks after cessation",
                "cross_tolerances": ["modafinil", "armodafinil"]
            },
            "half_life": "5-8 hours (longer in elderly or those with impaired liver function)",
            "citations": [
                {
                    "name": "DrugBank: Adrafinil",
                    "reference": "https://go.drugbank.com/drugs/DB08925"
                },
                {
                    "name": "Erowid: Adrafinil Health",
                    "reference": "https://erowid.org/smarts/adrafinil/adrafinil_health.shtml"
                }
            ],
            "categories": ["stimulant", "nootropic", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Adrafinil",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Based on literature, clinical pharmacology, and subjective reports (up through 2024); see also product monographs on modafinil\u2014the active metabolite of adrafinil.",
                        "units": "hours",
                        "total_duration": {
                            "min": 8,
                            "max": 12,
                            "iso": ["PT8H", "PT12H"],
                            "note": "\u2018Total duration\u2019 reflects subjective stimulation, as adrafinil is metabolized to modafinil and likely yields similar but slightly less potent and protracted effects when insufflated versus oral."
                        },
                        "onset": {
                            "start": 0.75,
                            "end": 1.5,
                            "iso_start": ["PT45M"],
                            "iso_end": ["PT1H30M"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "offset": {
                            "start": 6,
                            "end": 8,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT8H"]
                        },
                        "after_effects": {
                            "start": 12,
                            "end": 24,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 160,
        "title": "Ethylphenidate (EPH)",
        "content": "# Ethylphenidate (EPH)\n## Piperidine; Phenidate | Stimulant\n      \nEthylphenidate is structurally related to methylphenidate (Ritalin) and acts as a dopamine and norepinephrine reuptake inhibitor. It is known for being more caustic and damaging to nasal tissue than methylphenidate, so insufflation is strongly discouraged. It was banned in the UK in 2015. Reports suggest it is less euphoric and more functional than other stimulants, but compulsive redosing is a risk. Overdose can cause cardiovascular and psychiatric complications.",
        "drug_info": {
            "drug_name": "Ethylphenidate (EPH)",
            "search_url": "https://drugusersbible.org/content/chemscape/stimulants/eph/index.html",
            "chemical_class": "Piperidine; Phenidate",
            "psychoactive_class": "Stimulant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "10 mg",
                            "light": "15-20 mg",
                            "common": "25-40 mg",
                            "strong": "75-100 mg",
                            "heavy": "150 mg"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "10-15 mg",
                            "common": "20-30 mg",
                            "strong": "40-60 mg",
                            "heavy": "80 mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 20
                            },
                            "common": {
                                "min": 20,
                                "max": 40
                            },
                            "strong": {
                                "min": 40,
                                "max": 70
                            },
                            "heavy": {
                                "min": 70,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 20
                            },
                            "common": {
                                "min": 20,
                                "max": 40
                            },
                            "strong": {
                                "min": 40,
                                "max": 60
                            },
                            "heavy": {
                                "min": 60,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4-6 hours",
                "onset": "20-60 minutes (oral), 5-10 minutes (insufflated)",
                "peak": "1-3 hours",
                "offset": "2-3 hours",
                "after_effects": "1-6 hours"
            },
            "addiction_potential": "Moderate to high; repeated use can lead to compulsive redosing and psychological dependence, similar to other stimulants in its class.",
            "interactions": {
                "dangerous": ["MAOIs", "other stimulants"],
                "unsafe": ["alcohol", "SSRIs"],
                "caution": ["benzodiazepines", "opioids"]
            },
            "notes": "Ethylphenidate is structurally related to methylphenidate (Ritalin) and acts as a dopamine and norepinephrine reuptake inhibitor. It is known for being more caustic and damaging to nasal tissue than methylphenidate, so insufflation is strongly discouraged. It was banned in the UK in 2015. Reports suggest it is less euphoric and more functional than other stimulants, but compulsive redosing is a risk. Overdose can cause cardiovascular and psychiatric complications.",
            "subjective_effects": [
                "Increased focus",
                "Mild euphoria (short-lived)",
                "Increased energy",
                "Appetite suppression",
                "Increased heart rate",
                "Anxiety",
                "Compulsive redosing",
                "Insomnia"
            ],
            "tolerance": {
                "full_tolerance": "Several days of repeated use",
                "half_tolerance": "3-7 days",
                "zero_tolerance": "1-2 weeks",
                "cross_tolerances": ["Methylphenidate", "Other phenidates"]
            },
            "half_life": "2-4 hours",
            "citations": [
                {
                    "name": "Erowid Ethylphenidate Vault",
                    "reference": "https://www.erowid.org/chemicals/ethylphenidate/ethylphenidate.shtml"
                },
                {
                    "name": "Drug Users Bible - EPH",
                    "reference": "http://drugusersbible.org/content/chemscape/stimulants/eph/index.html"
                },
                {
                    "name": "TripSit Factsheet: Ethylphenidate",
                    "reference": "https://tripsit.me/factsheets/ethylphenidate"
                },
                {
                    "name": "Bluelight EPH Megathread",
                    "reference": "https://www.bluelight.org/community/threads/the-ethylphenidate-ethyl-phenyl-piperidin-2-yl-acetate-megathread-v2.650058/post-11661705"
                }
            ],
            "categories": ["stimulant", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Ethylphenidate (EPH)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Academic literature and user reports (2022\u20132024) on insufflated ethylphenidate duration.",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 6,
                            "iso": ["PT4H", "PT6H"],
                            "note": "Total duration when insufflated, consistent with most recent qualitative and quantitative reports."
                        },
                        "onset": {
                            "start": 0.08,
                            "end": 0.17,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT10M"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 3,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 3,
                            "end": 6,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT6H"]
                        },
                        "after_effects": {
                            "start": 4,
                            "end": 12,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT12H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 163,
        "title": "Mitragynine Pseudoindoxyl",
        "content": "# Mitragynine pseudoindoxyl\n## Indole alkaloid (derived from mitragynine, a kratom alkaloid) | Opioid (atypical opioid agonist)\n      \nMitragynine pseudoindoxyl is a metabolite of mitragynine (the main active alkaloid in kratom) and is considered to be a highly potent opioid receptor agonist, with a binding affinity even higher than buprenorphine. It has been shown to inhibit contractions in animal tissue studies and produces classic opioid effects such as analgesia, euphoria, miosis (pupil constriction), and nausea. There is little human data on safe dosage, and it should be approached with extreme caution due to its potency and risk of respiratory depression. Its legal status is unclear in many jurisdictions, but it may be considered a controlled substance analogue in some places.",
        "drug_info": {
            "drug_name": "Mitragynine pseudoindoxyl",
            "search_url": "https://en.m.wikipedia.org/wiki/Mitragynine_pseudoindoxyl",
            "chemical_class": "Indole alkaloid (derived from mitragynine, a kratom alkaloid)",
            "psychoactive_class": "Opioid (atypical opioid agonist)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "10 mg",
                            "light": "10-20 mg",
                            "common": "20-40 mg",
                            "strong": "40-60 mg",
                            "heavy": "60 mg+"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 15
                            },
                            "common": {
                                "min": 15,
                                "max": 30
                            },
                            "strong": {
                                "min": 30,
                                "max": 45
                            },
                            "heavy": {
                                "min": 45,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "Likely 4-8 hours (estimated, based on similar opioids)",
                "onset": "~15-45 minutes (estimated, oral)",
                "peak": "~1-2 hours (estimated)",
                "offset": "~4-8 hours (estimated)",
                "after_effects": "Unknown"
            },
            "addiction_potential": "High. As a potent opioid receptor agonist, mitragynine pseudoindoxyl carries a significant risk of dependence and addiction, similar to other strong opioids.",
            "interactions": {
                "dangerous": [
                    "Other opioids",
                    "Benzodiazepines",
                    "Alcohol",
                    "Barbiturates",
                    "Other CNS depressants"
                ],
                "unsafe": ["MAOIs", "Certain antidepressants"],
                "caution": ["Stimulants", "Other psychoactive substances"]
            },
            "notes": "Mitragynine pseudoindoxyl is a metabolite of mitragynine (the main active alkaloid in kratom) and is considered to be a highly potent opioid receptor agonist, with a binding affinity even higher than buprenorphine. It has been shown to inhibit contractions in animal tissue studies and produces classic opioid effects such as analgesia, euphoria, miosis (pupil constriction), and nausea. There is little human data on safe dosage, and it should be approached with extreme caution due to its potency and risk of respiratory depression. Its legal status is unclear in many jurisdictions, but it may be considered a controlled substance analogue in some places.",
            "subjective_effects": [
                "Euphoria",
                "Analgesia (pain relief)",
                "Miosis (pupil constriction)",
                "Nausea",
                "Mood elevation",
                "Suppression of body aches",
                "Potential for respiratory depression"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (days to weeks)",
                "half_tolerance": "Several days to a week after cessation",
                "zero_tolerance": "2-3 weeks after cessation",
                "cross_tolerances": [
                    "Other opioids (e.g., morphine, oxycodone, heroin)"
                ]
            },
            "half_life": "Unknown (likely short, estimated several hours)",
            "citations": [
                {
                    "name": "Erowid Reference: Mitragynine pseudoindoxyl opioid activity",
                    "reference": "https://www.erowid.org/references/refs_view.php?ID=6341"
                },
                {
                    "name": "Bluelight: Mitragynine pseudoindoxyl subjective effects",
                    "reference": "https://www.bluelight.org/community/threads/mitragynine-pseudoindoxyl.752008/"
                },
                {
                    "name": "Bluelight: Binding affinity discussion",
                    "reference": "https://www.bluelight.org/community/threads/kratom-question.855231/"
                }
            ],
            "categories": ["opioid", "research-chemical", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Mitragynine pseudoindoxyl",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Peer-reviewed opioid pharmacology sources, anecdotal comparisons to mitragynine and related opioids (2024)",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 8,
                            "iso": ["PT4H", "PT8H"],
                            "note": "Estimated based on the parent compound mitragynine, opioid analogs, and insufflation route context."
                        },
                        "onset": {
                            "start": 0.25,
                            "end": 0.75,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT45M"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 4,
                            "end": 8,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT8H"]
                        },
                        "after_effects": {
                            "start": [],
                            "end": [],
                            "iso_start": [],
                            "iso_end": []
                        }
                    }
                }
            }
        }
    },
    {
        "id": 161,
        "title": "N-Ethylhexedrone (Hexen)",
        "content": "# Hexen (N-Ethylhexedrone)## Cathinone (substituted cathinone) | Stimulant (NDRI - Norepinephrine-Dopamine Reuptake Inhibitor)      Hexen is a synthetic cathinone with a reputation for being relatively forgiving at low doses, but can be deceptive and dangerous at higher doses due to strong compulsive redosing. It is caustic to nasal passages when insufflated and can be harsh when vaporized. First synthesized in 2011, it became available on the market around 2015. Users report that it is short-acting with limited residual stimulation, but binge use is common and can lead to negative physical and psychological effects.",
        "drug_info": {
            "drug_name": "Hexen (N-Ethylhexedrone)",
            "search_url": "https://drugusersbible.org/content/chemscape/stimulants/hexen/index.html",
            "chemical_class": "Cathinone (substituted cathinone)",
            "psychoactive_class": "Stimulant (NDRI - Norepinephrine-Dopamine Reuptake Inhibitor)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg+",
                            "light": "10-15 mg+",
                            "common": "25-30 mg+",
                            "strong": "40 mg+",
                            "heavy": "50 mg+"
                        }
                    },
                    {
                        "route": "vaporized",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "~10 mg",
                            "light": "10-20 mg",
                            "common": "20-40 mg",
                            "strong": "40 mg+",
                            "heavy": "50 mg+"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 3,
                                "max": 8
                            },
                            "light": {
                                "min": 8,
                                "max": 15
                            },
                            "common": {
                                "min": 15,
                                "max": 35
                            },
                            "strong": {
                                "min": 35,
                                "max": 50
                            },
                            "heavy": {
                                "min": 50,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "vaporized",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 20
                            },
                            "common": {
                                "min": 20,
                                "max": 35
                            },
                            "strong": {
                                "min": 35,
                                "max": 50
                            },
                            "heavy": {
                                "min": 50,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "~3 hours",
                "onset": "~15 minutes (insufflated)",
                "peak": "Varies (generally within 30-60 minutes)",
                "offset": "Varies, typically after 2-3 hours",
                "after_effects": "Residual stimulation may persist for several hours"
            },
            "addiction_potential": "High. Hexen is reported to have a strong urge to redose and can be habit-forming, particularly at higher doses or with frequent use.",
            "interactions": {
                "dangerous": ["MAOIs", "Other stimulants"],
                "unsafe": ["SSRIs", "SNRIs", "Tricyclic antidepressants"],
                "caution": ["Alcohol", "Benzodiazepines"]
            },
            "notes": "Hexen is a synthetic cathinone with a reputation for being relatively forgiving at low doses, but can be deceptive and dangerous at higher doses due to strong compulsive redosing. It is caustic to nasal passages when insufflated and can be harsh when vaporized. First synthesized in 2011, it became available on the market around 2015. Users report that it is short-acting with limited residual stimulation, but binge use is common and can lead to negative physical and psychological effects.",
            "subjective_effects": [
                "Euphoria",
                "Stimulation",
                "Increased sociability",
                "Compulsive redosing",
                "Insomnia",
                "Appetite suppression",
                "Anxiety (especially at high doses)",
                "Increased heart rate",
                "Paranoia (at high doses or with prolonged use)"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (within days)",
                "half_tolerance": "Several days to a week",
                "zero_tolerance": "1-2 weeks (highly individual)",
                "cross_tolerances": ["Other cathinones", "Amphetamines"]
            },
            "half_life": "Not well established; likely short, estimated 1-3 hours based on duration of effects.",
            "citations": [
                {
                    "name": "Drug Users Bible - Hexen",
                    "reference": "https://drugusersbible.org/content/chemscape/stimulants/hexen/index.html"
                },
                {
                    "name": "TripSit Factsheet: Hexen",
                    "reference": "https://tripsit.me/factsheets/hexen"
                },
                {
                    "name": "Erowid Experience Report: Hexen",
                    "reference": "https://erowid.org/experiences/exp.php?ID=110074"
                },
                {
                    "name": "IsomerDesign PIHKAL: Hexen",
                    "reference": "https://isomerdesign.com/pihkal/explore/643"
                }
            ],
            "categories": ["stimulant", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Hexen (N-Ethylhexedrone)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Academic literature and user experience reports prior to 2024. Not sourced from PW, but from toxicity reports, case studies, and harm reduction resources.",
                        "units": "hours",
                        "total_duration": {
                            "min": 2.5,
                            "max": 4,
                            "iso": ["PT2H30M", "PT4H"],
                            "note": "Main active effects generally subside after about 3 hours, but can extend closer to 4 hours in higher or repeated doses."
                        },
                        "onset": {
                            "start": 0.08,
                            "end": 0.25,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT15M"]
                        },
                        "peak": {
                            "start": 0.5,
                            "end": 1,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT1H"]
                        },
                        "offset": {
                            "start": 2,
                            "end": 3,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT3H"]
                        },
                        "after_effects": {
                            "start": 3,
                            "end": 6,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT6H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 43,
        "title": "Cocaethylene",
        "content": "",
        "drug_info": {
            "drug_name": "Cocaethylene",
            "search_url": "https://www.drugwise.org.uk/wp-content/uploads/Factsheet-cocaethylene.pdf",
            "chemical_class": "Tropane alkaloid (ester of benzoylecgonine and ethanol)",
            "psychoactive_class": "Stimulant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "Not well established",
                            "light": "Not well established",
                            "common": "Not well established",
                            "strong": "Not well established",
                            "heavy": "Not well established"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 25
                            },
                            "light": {
                                "min": 25,
                                "max": 75
                            },
                            "common": {
                                "min": 75,
                                "max": 150
                            },
                            "strong": {
                                "min": 150,
                                "max": 225
                            },
                            "heavy": {
                                "min": 225,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "Not well established, but similar or slightly longer than cocaine (approx. 1-2 hours)",
                "onset": "Within minutes (when formed in the body after simultaneous use of cocaine and alcohol)",
                "peak": "Unknown",
                "offset": "Unknown",
                "after_effects": "After-effects may last several hours, including increased risk of toxicity."
            },
            "addiction_potential": "High. Cocaethylene is believed to have a higher risk of toxicity and dependence than cocaine alone.",
            "interactions": {
                "dangerous": ["Alcohol (ethanol)", "Cocaine"],
                "unsafe": [],
                "caution": []
            },
            "notes": "Cocaethylene is not found in nature and is only produced in the body when cocaine and alcohol are consumed together. It is associated with greater cardiotoxicity, neurotoxicity, and risk of sudden death compared to cocaine alone. There is no established safe dose, and its use is considered particularly dangerous.",
            "subjective_effects": [
                "Euphoria",
                "Increased energy",
                "Increased sociability",
                "Decreased inhibition",
                "Increased risk-taking",
                "Agitation",
                "Anxiety",
                "Paranoia",
                "Cardiovascular effects (e.g., increased heart rate, blood pressure)"
            ],
            "tolerance": {
                "full_tolerance": "Not well studied, likely similar to cocaine (days to weeks)",
                "half_tolerance": "Not well studied",
                "zero_tolerance": "Not well studied",
                "cross_tolerances": ["Cocaine"]
            },
            "half_life": "Longer than cocaine (estimates range from 2.5 to 6 hours)",
            "citations": [
                {
                    "name": "DrugWise Factsheet: Cocaethylene",
                    "reference": "https://www.drugwise.org.uk/wp-content/uploads/Factsheet-cocaethylene.pdf"
                },
                {
                    "name": "DrugWise: Drug Interactions",
                    "reference": "https://www.drugwise.org.uk/drug-interactions/"
                },
                {
                    "name": "DrugBank: DBMET00645",
                    "reference": "https://go.drugbank.com/metabolites/DBMET00645"
                }
            ],
            "categories": ["stimulant", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Cocaethylene",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "J. T. McCance-Katz et al., 'Cocaine and Alcohol Interactions: Cocaethylene Metabolism and Disposition in Humans', Journal of Pharmacology and Experimental Therapeutics, 1993. Duration estimates based on clinical literature and case reports.",
                        "units": "hours",
                        "total_duration": {
                            "min": 1,
                            "max": 2,
                            "iso": ["PT1H", "PT2H"],
                            "note": "Not well established; generally similar to or slightly longer than cocaine when insufflated."
                        },
                        "onset": {
                            "start": 0.08,
                            "end": 0.17,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT10M"]
                        },
                        "peak": {
                            "start": 0.33,
                            "end": 1,
                            "iso_start": ["PT20M"],
                            "iso_end": ["PT1H"]
                        },
                        "offset": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        },
                        "after_effects": {
                            "start": 2,
                            "end": 6,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT6H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 46,
        "title": "Baclofen",
        "content": "",
        "drug_info": {
            "drug_name": "Baclofen",
            "search_url": "https://go.drugbank.com/drugs/DB00181",
            "chemical_class": "Arylalkylamine (derivative of gamma-aminobutyric acid, GABA)",
            "psychoactive_class": "Depressant (GABAergic muscle relaxant)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "5-10 mg",
                            "common": "10-20 mg",
                            "strong": "20-40 mg",
                            "heavy": "40+ mg"
                        }
                    },
                    {
                        "route": "intrathecal",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "0.5 mg",
                            "light": "0.5-2 mg",
                            "common": "2-5 mg",
                            "strong": "5-10 mg",
                            "heavy": "10+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2.5,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 10
                            },
                            "common": {
                                "min": 10,
                                "max": 30
                            },
                            "strong": {
                                "min": 30,
                                "max": 60
                            },
                            "heavy": {
                                "min": 60,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "intravenous",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.5,
                                "max": 0.5
                            },
                            "light": {
                                "min": 0.5,
                                "max": 2
                            },
                            "common": {
                                "min": 2,
                                "max": 5
                            },
                            "strong": {
                                "min": 5,
                                "max": 10
                            },
                            "heavy": {
                                "min": 10,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4-8 hours (oral)",
                "onset": "30-60 minutes (oral)",
                "peak": "1-2 hours (oral)",
                "offset": "4-8 hours (oral)",
                "after_effects": "Up to 24 hours (residual sedation possible)"
            },
            "addiction_potential": "Low to moderate; physical dependence and withdrawal symptoms can occur with prolonged use or abrupt discontinuation.",
            "interactions": {
                "dangerous": [
                    "Alcohol",
                    "Benzodiazepines",
                    "Opioids",
                    "Barbiturates"
                ],
                "unsafe": ["Other CNS depressants"],
                "caution": [
                    "Antihypertensives",
                    "Antidepressants",
                    "Antipsychotics"
                ]
            },
            "notes": "Baclofen is primarily used as a muscle relaxant for severe spasticity related to conditions such as multiple sclerosis, spinal cord injury, or cerebral palsy. Abrupt discontinuation can cause severe withdrawal symptoms, including hallucinations, seizures, and rebound spasticity. Overdose may result in respiratory depression, coma, or death. Use with caution in individuals with renal impairment.",
            "subjective_effects": [
                "Muscle relaxation",
                "Sedation",
                "Drowsiness",
                "Reduced anxiety",
                "Mild euphoria (rare)",
                "Dizziness",
                "Weakness",
                "Confusion (at high doses)"
            ],
            "tolerance": {
                "full_tolerance": "Develops over days to weeks with regular use",
                "half_tolerance": "Several days after cessation",
                "zero_tolerance": "1-2 weeks after cessation",
                "cross_tolerances": [
                    "Other GABAergic drugs (e.g., benzodiazepines, phenibut)"
                ]
            },
            "half_life": "2-6 hours (oral)",
            "citations": [
                {
                    "name": "DrugBank: Baclofen",
                    "reference": "https://go.drugbank.com/drugs/DB00181"
                },
                {
                    "name": "DrugBank: Baclofen Biointeractions",
                    "reference": "https://go.drugbank.com/drugs/DB00181/biointeractions"
                },
                {
                    "name": "DrugBank: Baclofen Salt",
                    "reference": "https://go.drugbank.com/salts/DBSALT002256"
                },
                {
                    "name": "DrugBank: Baclofen Clinical Article",
                    "reference": "https://go.drugbank.com/articles/A245323"
                }
            ],
            "categories": ["depressant", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Baclofen",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Clinical literature on baclofen, user reports for non-oral routes, e.g. PubMed articles and relevant forums. Baclofen is uncommon via insufflation, and data is primarily extrapolated from oral use, accounting for a faster onset and possibly shorter duration intranasally.",
                        "units": "hours",
                        "total_duration": {
                            "min": 3,
                            "max": 6,
                            "iso": ["PT3H", "PT6H"],
                            "note": "Insufflated duration is generally shorter than oral. Individual response varies."
                        },
                        "onset": {
                            "start": 0.083,
                            "end": 0.33,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT20M"]
                        },
                        "peak": {
                            "start": 0.33,
                            "end": 1,
                            "iso_start": ["PT20M"],
                            "iso_end": ["PT1H"]
                        },
                        "offset": {
                            "start": 3,
                            "end": 6,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT6H"]
                        },
                        "after_effects": {
                            "start": 6,
                            "end": 18,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT18H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 51,
        "title": "Phenibut",
        "content": "",
        "drug_info": {
            "drug_name": "Phenibut",
            "search_url": "https://substancesearch.org/substance/phenibut",
            "chemical_class": "Aminobutyrate (derivative of butyric acid)",
            "psychoactive_class": "Depressant, nootropic, anxiolytic, research-chemical, habit-forming",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "100 mg",
                            "light": "200-500 mg",
                            "common": "500-1500 mg",
                            "strong": "1500-2500 mg",
                            "heavy": "2500+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 100,
                                "max": 200
                            },
                            "light": {
                                "min": 200,
                                "max": 500
                            },
                            "common": {
                                "min": 500,
                                "max": 1500
                            },
                            "strong": {
                                "min": 1500,
                                "max": 2500
                            },
                            "heavy": {
                                "min": 2500,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "10-24 hours",
                "onset": "1-2 hours",
                "peak": "3-6 hours",
                "offset": "6-12 hours",
                "after_effects": "12-36 hours (residual sedation possible)"
            },
            "addiction_potential": "Moderate to high. Regular use can lead to dependence and withdrawal symptoms. Tolerance builds rapidly.",
            "interactions": {
                "dangerous": [
                    "Alcohol",
                    "Benzodiazepines",
                    "Barbiturates",
                    "Opioids",
                    "Other CNS depressants"
                ],
                "unsafe": ["Antihistamines (sedating)", "Muscle relaxants"],
                "caution": ["Stimulants (may mask sedation)"]
            },
            "notes": "Phenibut is a GABA-B receptor agonist with anxiolytic and sedative effects. Overdose can cause severe CNS depression, unconsciousness, and respiratory depression. Withdrawal can be severe and potentially dangerous after regular use. Not approved for medical use in many countries. Avoid combining with other depressants.",
            "subjective_effects": [
                "Anxiolysis",
                "Sedation",
                "Euphoria",
                "Muscle relaxation",
                "Cognitive impairment",
                "Mood lift",
                "Sociability enhancement",
                "Drowsiness",
                "Motor impairment",
                "Hangover-like aftereffects"
            ],
            "tolerance": {
                "full_tolerance": "3-7 days of daily use",
                "half_tolerance": "7-14 days after cessation",
                "zero_tolerance": "2-4 weeks after cessation",
                "cross_tolerances": ["Baclofen", "Other GABA-B agonists"]
            },
            "half_life": "5.3 hours (may be longer in some users)",
            "citations": [
                {
                    "name": "TripSit Factsheet: Phenibut",
                    "reference": "https://tripsit.me/factsheets/phenibut"
                },
                {
                    "name": "DrugBank: Phenibut",
                    "reference": "https://go.drugbank.com/drugs/DB13455"
                }
            ],
            "categories": [
                "depressant",
                "research-chemical",
                "habit-forming",
                "nootropic"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Phenibut",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Stovall, J. (2021). Phenibut: Pearls and pitfalls. Current Psychiatry, 20(1), 36-39. User reports from forums corroborate time-course features for insufflated use, though the practice is uncommon compared to oral administration.",
                        "units": "hours",
                        "total_duration": {
                            "min": 10,
                            "max": 24,
                            "iso": ["P0DT10H", "P1DT0H"],
                            "note": "Duration for insufflated route is similar to oral, though onset is slightly faster; adverse effects risk may be higher."
                        },
                        "onset": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        },
                        "peak": {
                            "start": 3,
                            "end": 6,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT6H"]
                        },
                        "offset": {
                            "start": 6,
                            "end": 12,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT12H"]
                        },
                        "after_effects": {
                            "start": 12,
                            "end": 36,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT36H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 50,
        "title": "3-Methylmethcathinone (3-MMC)",
        "content": "",
        "drug_info": {
            "drug_name": "3-Methylmethcathinone",
            "search_url": "https://drugusersbible.org/content/chemscape/stimulants/3-mmc/",
            "chemical_class": "Cathinone (substituted cathinone)",
            "psychoactive_class": "Stimulant, entactogen",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "10 mg",
                            "light": "20 mg+",
                            "common": "40 mg+",
                            "strong": "60 mg+",
                            "heavy": "120 mg+"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 25
                            },
                            "common": {
                                "min": 25,
                                "max": 60
                            },
                            "strong": {
                                "min": 60,
                                "max": 100
                            },
                            "heavy": {
                                "min": 100,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "~3 hours",
                "onset": "~5 minutes (insufflated)",
                "peak": "Varies, typically within 30-60 minutes",
                "offset": "1-2 hours after peak",
                "after_effects": "Residual stimulation and afterglow may last several hours"
            },
            "addiction_potential": "Moderate to high. Users report strong urges to re-dose and binge, similar to other cathinones like mephedrone. Risk of compulsive use and psychological dependence.",
            "interactions": {
                "dangerous": [
                    "MAOIs",
                    "SSRIs",
                    "other stimulants (e.g., amphetamines, cocaine)"
                ],
                "unsafe": ["alcohol (increases cardiovascular risks)"],
                "caution": ["MDMA", "cannabis", "ketamine"]
            },
            "notes": "3-MMC is a synthetic cathinone and close analog of mephedrone (4-MMC). It is known for its stimulant and entactogenic effects, but is reported to be slightly less potent and less euphoric than mephedrone. Insufflation is reported as painful. There are concerns about cardiovascular toxicity, including possible heart valve issues. Limited long-term safety data; use with caution. Polysubstance use increases risks.",
            "subjective_effects": [
                "Euphoria",
                "Stimulation",
                "Empathy",
                "Sociability",
                "Increased libido",
                "Sweating",
                "Jaw clenching",
                "Insomnia",
                "Reduced appetite",
                "Desire to re-dose",
                "Mild hallucinations (at high doses)",
                "Anxiety",
                "Palpitations"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (within days)",
                "half_tolerance": "Several days to a week after cessation",
                "zero_tolerance": "1-2 weeks after cessation",
                "cross_tolerances": [
                    "Other substituted cathinones (e.g., mephedrone)"
                ]
            },
            "half_life": "~2-3 hours (estimated, limited data)",
            "citations": [
                {
                    "name": "Drug Users Bible - 3-MMC",
                    "reference": "https://drugusersbible.org/content/chemscape/stimulants/3-mmc/"
                },
                {
                    "name": "TripSit Factsheet: 3-MMC",
                    "reference": "https://tripsit.me/factsheets/3-mmc"
                },
                {
                    "name": "Isomer Design - 3-MMC",
                    "reference": "https://isomerdesign.com/pihkal/explore/2480"
                }
            ],
            "categories": ["stimulant", "research-chemical", "entactogen"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "3-Methylmethcathinone",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Based on published reviews and user reports regarding 3-MMC (3-Methylmethcathinone) insufflated effects (as referenced in medical literature and community resources).",
                        "units": "hours",
                        "total_duration": {
                            "min": 2.5,
                            "max": 4,
                            "iso": ["PT2H30M", "PT4H"],
                            "note": "Subject to individual variation and dose."
                        },
                        "onset": {
                            "start": 0.08,
                            "end": 0.17,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT10M"]
                        },
                        "peak": {
                            "start": 0.5,
                            "end": 1,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT1H"]
                        },
                        "offset": {
                            "start": 1.5,
                            "end": 3,
                            "iso_start": ["PT1H30M"],
                            "iso_end": ["PT3H"]
                        },
                        "after_effects": {
                            "start": 3,
                            "end": 7,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT7H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 53,
        "title": "Flubromazolam",
        "content": "",
        "drug_info": {
            "drug_name": "Flubromazolam",
            "search_url": "https://substancesearch.org/substance/pyrazolam",
            "chemical_class": "Benzodiazepine",
            "psychoactive_class": "Depressant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "0.05 mg",
                            "light": "0.1 - 0.2 mg",
                            "common": "0.2 - 0.5 mg",
                            "strong": "0.5 - 1 mg",
                            "heavy": "1+ mg"
                        }
                    },
                    {
                        "route": "sublingual",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "0.05 mg",
                            "light": "0.1 - 0.2 mg",
                            "common": "0.2 - 0.5 mg",
                            "strong": "0.5 - 1 mg",
                            "heavy": "1+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.05,
                                "max": 0.1
                            },
                            "light": {
                                "min": 0.1,
                                "max": 0.2
                            },
                            "common": {
                                "min": 0.2,
                                "max": 0.5
                            },
                            "strong": {
                                "min": 0.5,
                                "max": 1.0
                            },
                            "heavy": {
                                "min": 1.0,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "sublingual",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.05,
                                "max": 0.1
                            },
                            "light": {
                                "min": 0.1,
                                "max": 0.25
                            },
                            "common": {
                                "min": 0.25,
                                "max": 0.5
                            },
                            "strong": {
                                "min": 0.5,
                                "max": 1
                            },
                            "heavy": {
                                "min": 1,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "12 - 18 hours",
                "onset": "20 - 60 minutes",
                "peak": "2 - 6 hours",
                "offset": "6 - 12 hours",
                "after_effects": "12 - 24 hours (residual sedation possible)"
            },
            "addiction_potential": "High. Flubromazolam is a highly potent benzodiazepine with significant risk for dependence, addiction, and withdrawal symptoms, especially with repeated or high-dose use.",
            "interactions": {
                "dangerous": [
                    "alcohol",
                    "opioids",
                    "other benzodiazepines",
                    "barbiturates"
                ],
                "unsafe": ["antipsychotics", "muscle relaxants"],
                "caution": [
                    "antidepressants",
                    "antihistamines",
                    "other CNS depressants"
                ]
            },
            "notes": "Flubromazolam is extremely potent, with doses as low as 0.1 mg producing strong effects. Overdose risk is high, especially when combined with other depressants. It is associated with severe amnesia, blackouts, and potentially dangerous behavioral disinhibition. Tolerance develops rapidly, and withdrawal can be severe and life-threatening. Use with extreme caution, and avoid combining with other depressants.",
            "subjective_effects": [
                "Sedation",
                "Muscle relaxation",
                "Anxiolysis",
                "Amnesia",
                "Disinhibition",
                "Hypnotic effects",
                "Motor impairment",
                "Blackouts",
                "Cognitive impairment"
            ],
            "tolerance": {
                "full_tolerance": "Within days of repeated use",
                "half_tolerance": "1 - 2 weeks",
                "zero_tolerance": "4 - 8 weeks or longer",
                "cross_tolerances": ["other benzodiazepines", "barbiturates"]
            },
            "half_life": "~18 - 36 hours (varies by individual)",
            "citations": [
                {
                    "name": "TripSit Factsheet: Flubromazolam",
                    "reference": "https://tripsit.me/factsheets/flubromazolam"
                },
                {
                    "name": "Bluelight Forum: Flubromazolam Potency and Risks",
                    "reference": "https://www.bluelight.org/community/threads/flubromazolam-is-it-that-dangerous-for-someone-with-benzo-tolerance.902673/"
                },
                {
                    "name": "Isomerdesign PIHKAL: Flubromazolam",
                    "reference": "https://isomerdesign.com/pihkal/explore/3041"
                }
            ],
            "categories": [
                "depressant",
                "benzodiazepine",
                "research-chemical",
                "habit-forming"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Flubromazolam",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Academic literature and user reports on flubromazolam, e.g., forensic toxicology journals and discussion forums as of 2023.",
                        "units": "hours",
                        "total_duration": {
                            "min": 12,
                            "max": 18,
                            "iso": ["PT12H", "PT18H"],
                            "note": "Marked by pronounced hypnotic and sedative effects, which may outlast the subjective effect window."
                        },
                        "onset": {
                            "start": 0.33,
                            "end": 1,
                            "iso_start": ["PT20M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 6,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT6H"]
                        },
                        "offset": {
                            "start": 6,
                            "end": 12,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT12H"]
                        },
                        "after_effects": {
                            "start": 12,
                            "end": 24,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 56,
        "title": "Oxycodone",
        "content": "",
        "drug_info": {
            "drug_name": "Oxycodone",
            "search_url": "https://go.drugbank.com/drugs/DB00497",
            "chemical_class": "Opioid (semisynthetic, derived from thebaine)",
            "psychoactive_class": "Opioid analgesic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2.5 mg",
                            "light": "2.5-5 mg",
                            "common": "5-15 mg",
                            "strong": "15-30 mg",
                            "heavy": "30+ mg"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2 mg",
                            "light": "2-5 mg",
                            "common": "5-15 mg",
                            "strong": "15-25 mg",
                            "heavy": "25+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2.5,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 10
                            },
                            "common": {
                                "min": 10,
                                "max": 20
                            },
                            "strong": {
                                "min": 20,
                                "max": 40
                            },
                            "heavy": {
                                "min": 40,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 10
                            },
                            "common": {
                                "min": 10,
                                "max": 20
                            },
                            "strong": {
                                "min": 20,
                                "max": 30
                            },
                            "heavy": {
                                "min": 30,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4-6 hours (immediate release)",
                "onset": "10-30 minutes (oral)",
                "peak": "1-2 hours",
                "offset": "4-6 hours",
                "after_effects": "Residual sedation may last up to 12 hours"
            },
            "addiction_potential": "High. Oxycodone has a significant risk for addiction, dependence, and abuse, especially with prolonged or high-dose use.",
            "interactions": {
                "dangerous": [
                    "Alcohol",
                    "Benzodiazepines",
                    "Other opioids",
                    "Barbiturates"
                ],
                "unsafe": ["MAOIs", "Muscle relaxants"],
                "caution": [
                    "Antihistamines",
                    "Antidepressants",
                    "Antipsychotics"
                ]
            },
            "notes": "Oxycodone is a powerful prescription opioid used for moderate to severe pain. It carries a high risk of respiratory depression, overdose, and death, especially when combined with other CNS depressants. Tolerance and dependence develop rapidly with regular use. Withdrawal symptoms can be severe.",
            "subjective_effects": [
                "Euphoria",
                "Pain relief",
                "Sedation",
                "Warmth",
                "Itchiness",
                "Constipation",
                "Nausea",
                "Respiratory depression",
                "Miosis (pupil constriction)",
                "Drowsiness"
            ],
            "tolerance": {
                "full_tolerance": "Develops within days to weeks of regular use",
                "half_tolerance": "3-7 days after cessation",
                "zero_tolerance": "1-2 weeks after cessation",
                "cross_tolerances": [
                    "Other opioids (e.g., morphine, heroin, hydrocodone)"
                ]
            },
            "half_life": "3-5 hours (immediate release)",
            "citations": [
                {
                    "name": "DrugBank: Oxycodone",
                    "reference": "https://go.drugbank.com/drugs/DB00497"
                },
                {
                    "name": "Erowid Oxycodone Vault",
                    "reference": "https://erowid.org/pharms/oxycodone/oxycodone.shtml"
                },
                {
                    "name": "Drug Users Bible: Oxycodone",
                    "reference": "https://www.drugusersbible.com/opiates.html#oxycodone"
                }
            ],
            "categories": ["opioid", "depressant", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Oxycodone",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Data adapted from clinical studies and user reports on insufflated (snorted) oxycodone. See: \"Pharmacokinetics and abuse-deterrent formulation considerations\" (J Pharmacol Exp Ther, 2012); \"Abuse potential of different routes of oxycodone\" (Pain Physician, 2015).",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 6,
                            "iso": ["PT4H", "PT6H"],
                            "note": "Duration applies to immediate-release oxycodone insufflation."
                        },
                        "onset": {
                            "start": 0.08,
                            "end": 0.33,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT20M"]
                        },
                        "peak": {
                            "start": 0.5,
                            "end": 1.5,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT1H30M"]
                        },
                        "offset": {
                            "start": 4,
                            "end": 6,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT6H"]
                        },
                        "after_effects": {
                            "start": 6,
                            "end": 12,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT12H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 57,
        "title": "Methylphenidate",
        "content": "",
        "drug_info": {
            "drug_name": "Methylphenidate (MPH)",
            "search_url": "https://go.drugbank.com/drugs/DB00422",
            "chemical_class": "Piperidine derivative",
            "psychoactive_class": "Stimulant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2.5 mg",
                            "light": "5-10 mg",
                            "common": "10-30 mg",
                            "strong": "30-60 mg",
                            "heavy": "60+ mg"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2 mg",
                            "light": "5-10 mg",
                            "common": "10-20 mg",
                            "strong": "20-40 mg",
                            "heavy": "40+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2.5,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 10
                            },
                            "common": {
                                "min": 10,
                                "max": 30
                            },
                            "strong": {
                                "min": 30,
                                "max": 60
                            },
                            "heavy": {
                                "min": 60,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 10
                            },
                            "common": {
                                "min": 10,
                                "max": 20
                            },
                            "strong": {
                                "min": 20,
                                "max": 40
                            },
                            "heavy": {
                                "min": 40,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "1-4 hours (immediate release)",
                "onset": "20-60 minutes (oral)",
                "peak": "1-2 hours",
                "offset": "2-4 hours",
                "after_effects": "2-6 hours (residual stimulation, possible insomnia)"
            },
            "addiction_potential": "Moderate to high; risk of psychological dependence and abuse, especially with non-medical use or high doses.",
            "interactions": {
                "dangerous": ["MAOIs (monoamine oxidase inhibitors)"],
                "unsafe": ["other stimulants (e.g., amphetamines, cocaine)"],
                "caution": [
                    "SSRIs, SNRIs, tricyclic antidepressants, alcohol, antipsychotics, antihypertensives"
                ]
            },
            "notes": "Methylphenidate is commonly prescribed for ADHD and narcolepsy. It acts as a dopamine and norepinephrine reuptake inhibitor. Non-medical use can lead to cardiovascular risks, anxiety, insomnia, and potential for abuse. Sudden discontinuation after prolonged use may cause withdrawal symptoms.",
            "subjective_effects": [
                "Increased alertness",
                "Euphoria",
                "Increased focus",
                "Decreased appetite",
                "Insomnia",
                "Anxiety",
                "Increased heart rate",
                "Dry mouth",
                "Sweating",
                "Irritability"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (days to weeks)",
                "half_tolerance": "Several days to a week after cessation",
                "zero_tolerance": "1-2 weeks after cessation",
                "cross_tolerances": ["Other stimulants (e.g., amphetamines)"]
            },
            "half_life": "2-3 hours (immediate release)",
            "citations": [
                {
                    "name": "Erowid Methylphenidate Vault",
                    "reference": "https://www.erowid.org/pharms/methylphenidate/methylphenidate_info1.shtml"
                },
                {
                    "name": "DrugBank: Methylphenidate",
                    "reference": "https://go.drugbank.com/drugs/DB00422"
                },
                {
                    "name": "DrugBank: Methylphenidate Pharmacology",
                    "reference": "https://go.drugbank.com/articles/A631"
                }
            ],
            "categories": ["stimulant", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Methylphenidate (MPH)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Academic literature (Micromedex, Stahl's Essential Psychopharmacology) and user reports for insufflated methylphenidate.",
                        "units": "hours",
                        "total_duration": {
                            "min": 2,
                            "max": 4,
                            "iso": ["PT2H", "PT4H"],
                            "note": "Shorter duration than oral due to faster absorption."
                        },
                        "onset": {
                            "start": 0.083,
                            "end": 0.25,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT15M"]
                        },
                        "peak": {
                            "start": 0.25,
                            "end": 1,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT1H"]
                        },
                        "offset": {
                            "start": 1.5,
                            "end": 4,
                            "iso_start": ["PT1H30M"],
                            "iso_end": ["PT4H"]
                        },
                        "after_effects": {
                            "start": 2,
                            "end": 6,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT6H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 59,
        "title": "Mescaline",
        "content": "",
        "drug_info": {
            "drug_name": "Mescaline",
            "search_url": "https://bluedark.org/substance/mescaline",
            "chemical_class": "Phenethylamine",
            "psychoactive_class": "Psychedelic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "50 mg",
                            "light": "100-200 mg",
                            "common": "200-400 mg",
                            "strong": "400-600 mg",
                            "heavy": "600+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 50,
                                "max": 100
                            },
                            "light": {
                                "min": 100,
                                "max": 200
                            },
                            "common": {
                                "min": 200,
                                "max": 400
                            },
                            "strong": {
                                "min": 400,
                                "max": 600
                            },
                            "heavy": {
                                "min": 600,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "8-12 hours",
                "onset": "45-120 minutes",
                "peak": "2-4 hours",
                "offset": "4-6 hours",
                "after_effects": "Up to 24 hours (residual effects)"
            },
            "addiction_potential": "Mescaline is not considered addictive and does not produce compulsive use. Tolerance develops rapidly but also dissipates quickly.",
            "interactions": {
                "dangerous": ["MAOIs"],
                "unsafe": ["Tramadol"],
                "caution": [
                    "Other serotonergic psychedelics (LSD, psilocybin, 2C-x) due to cross-tolerance"
                ]
            },
            "notes": "Mescaline is a naturally occurring psychedelic found in several cacti, including peyote and San Pedro. It has a long history of ritualistic and spiritual use. Overdose is rare but can cause severe nausea, anxiety, and confusion. It is illegal in many countries except for certain religious uses.",
            "subjective_effects": [
                "Visual hallucinations",
                "Altered thinking processes",
                "Euphoria",
                "Time distortion",
                "Enhanced sensory perception",
                "Emotional shifts",
                "Synesthesia",
                "Nausea (common)",
                "Body load"
            ],
            "tolerance": {
                "full_tolerance": "After 3-7 days of repeated use",
                "half_tolerance": "3-5 days",
                "zero_tolerance": "7-14 days",
                "cross_tolerances": ["LSD", "Psilocin", "2C-x compounds"]
            },
            "half_life": "6 hours (approximate)",
            "citations": [
                {
                    "name": "Erowid Mescaline Vault",
                    "reference": "https://erowid.org/chemicals/mescaline/mescaline.shtml"
                },
                {
                    "name": "TripSit Mescaline",
                    "reference": "https://wiki.tripsit.me/wiki/Mescaline"
                },
                {
                    "name": "DrugWise: Mescaline",
                    "reference": "https://www.drugwise.org.uk/mescaline/"
                }
            ],
            "categories": ["psychedelic", "hallucinogen"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Mescaline",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Academic reviews (e.g., Halpern JH et al., 1998; Nichols DE, 2004), anecdotal reports; duration may be shorter or more uncomfortable than oral; onset faster and harsher.",
                        "units": "hours",
                        "total_duration": {
                            "min": 8,
                            "max": 12,
                            "iso": ["PT8H", "PT12H"],
                            "note": "Some users report effects slightly shorter or more intense than oral, due to increased bioavailability via insufflation."
                        },
                        "onset": {
                            "start": 0.75,
                            "end": 2,
                            "iso_start": ["PT45M"],
                            "iso_end": ["PT2H"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "offset": {
                            "start": 4,
                            "end": 6,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT6H"]
                        },
                        "after_effects": {
                            "start": 12,
                            "end": 24,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 60,
        "title": "5-MeO-DMT",
        "content": "",
        "drug_info": {
            "drug_name": "5-MeO-DMT",
            "search_url": "https://go.drugbank.com/drugs/DB14010",
            "chemical_class": "Tryptamine (indolealkylamine)",
            "psychoactive_class": "Psychedelic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "vaporized",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "1 mg",
                            "light": "2-5 mg",
                            "common": "5-10 mg",
                            "strong": "10-15 mg",
                            "heavy": "15+ mg"
                        }
                    },
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "3 mg",
                            "light": "5-10 mg",
                            "common": "10-20 mg",
                            "strong": "20-30 mg",
                            "heavy": "30+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "vaporized",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 1,
                                "max": 2
                            },
                            "light": {
                                "min": 2,
                                "max": 5
                            },
                            "common": {
                                "min": 5,
                                "max": 10
                            },
                            "strong": {
                                "min": 10,
                                "max": 15
                            },
                            "heavy": {
                                "min": 15,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 3,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 10
                            },
                            "common": {
                                "min": 10,
                                "max": 20
                            },
                            "strong": {
                                "min": 20,
                                "max": 30
                            },
                            "heavy": {
                                "min": 30,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "15-45 minutes (vaporized), 2-3 hours (oral)",
                "onset": "30 seconds - 2 minutes (vaporized), 10-30 minutes (oral)",
                "peak": "5-20 minutes (vaporized), 30-90 minutes (oral)",
                "offset": "20-40 minutes (vaporized), 1-2 hours (oral)",
                "after_effects": "1-2 hours"
            },
            "addiction_potential": "Low; not considered habit-forming. There are no significant reports of compulsive use or physical dependence.",
            "interactions": {
                "dangerous": ["MAOIs (risk of serotonin syndrome)"],
                "unsafe": [
                    "SSRIs (may blunt effects or increase risk of serotonin syndrome)"
                ],
                "caution": [
                    "Other serotonergic substances, stimulants, psychedelics"
                ]
            },
            "notes": "5-MeO-DMT is a potent, fast-acting psychedelic found in certain plant species and the venom of the Bufo alvarius toad. It is distinct from DMT and is known for producing intense, often non-visual, mystical experiences. Due to its potency, careful dosing is critical. There have been reports of challenging psychological experiences and rare cases of medical emergencies, especially when combined with MAOIs or other serotonergic drugs. Not recommended for those with a history of mental health issues.",
            "subjective_effects": [
                "Ego dissolution",
                "Mystical or spiritual experiences",
                "Altered perception of time",
                "Intense emotional states",
                "Physical sensations (tingling, vibrations)",
                "Minimal visual effects compared to DMT",
                "Feelings of unity or interconnectedness",
                "Occasional anxiety or panic"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use, often after one dose",
                "half_tolerance": "2-7 days",
                "zero_tolerance": "1-2 weeks",
                "cross_tolerances": [
                    "Other psychedelics, especially tryptamines"
                ]
            },
            "half_life": "15-30 minutes (estimated)",
            "citations": [
                {
                    "name": "DrugBank: 5-MeO-DMT",
                    "reference": "https://go.drugbank.com/drugs/DB14010"
                },
                {
                    "name": "DrugBank Article: 5-MeO-DMT",
                    "reference": "https://go.drugbank.com/articles/A185276"
                }
            ],
            "categories": ["psychedelic", "hallucinogen", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "5-MeO-DMT",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Based on academic literature and user reports (e.g., Michael Pollan, Trip Rep, Erowid, peer-reviewed papers including Uthaug et al. 2019; Davis et al. 2018).",
                        "units": "hours",
                        "total_duration": {
                            "min": 0.5,
                            "max": 1.5,
                            "iso": ["PT30M", "PT1H30M"],
                            "note": "Insufflated route is intermediate in duration between vaporized and oral; generally lasts 45-90 minutes, with some reports of effects up to 90 minutes."
                        },
                        "onset": {
                            "start": 0.05,
                            "end": 0.25,
                            "iso_start": ["PT3M"],
                            "iso_end": ["PT15M"]
                        },
                        "peak": {
                            "start": 0.25,
                            "end": 0.67,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT40M"]
                        },
                        "offset": {
                            "start": 0.67,
                            "end": 1.5,
                            "iso_start": ["PT40M"],
                            "iso_end": ["PT1H30M"]
                        },
                        "after_effects": {
                            "start": 1.5,
                            "end": 2.5,
                            "iso_start": ["PT1H30M"],
                            "iso_end": ["PT2H30M"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 61,
        "title": "Clonazepam",
        "content": "",
        "drug_info": {
            "drug_name": "Clonazepam",
            "search_url": "https://go.drugbank.com/drugs/DB01068",
            "chemical_class": "Benzodiazepine (1,4-benzodiazepine)",
            "psychoactive_class": "Depressant, Anxiolytic, Anticonvulsant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "0.25 mg",
                            "light": "0.25-0.5 mg",
                            "common": "0.5-2 mg",
                            "strong": "2-4 mg",
                            "heavy": "4+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.125,
                                "max": 0.25
                            },
                            "light": {
                                "min": 0.25,
                                "max": 0.75
                            },
                            "common": {
                                "min": 0.75,
                                "max": 2
                            },
                            "strong": {
                                "min": 2,
                                "max": 4
                            },
                            "heavy": {
                                "min": 4,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "6-12 hours",
                "onset": "20-60 minutes",
                "peak": "1-4 hours",
                "offset": "6-12 hours",
                "after_effects": "Residual sedation may last up to 24 hours"
            },
            "addiction_potential": "High. Clonazepam is habit-forming and can lead to physical and psychological dependence, especially with prolonged or high-dose use.",
            "interactions": {
                "dangerous": [
                    "Alcohol",
                    "Opioids",
                    "Other benzodiazepines",
                    "Barbiturates"
                ],
                "unsafe": ["Antidepressants (certain types)", "Antipsychotics"],
                "caution": ["Other CNS depressants", "Anticonvulsants"]
            },
            "notes": "Clonazepam is a long-acting benzodiazepine used primarily for panic disorder, severe anxiety, and seizure disorders. Tolerance develops rapidly with regular use. Abrupt discontinuation can cause withdrawal symptoms, including seizures, which can be life-threatening. Should only be used under medical supervision.",
            "subjective_effects": [
                "Sedation",
                "Anxiolysis (anxiety reduction)",
                "Muscle relaxation",
                "Euphoria (occasionally)",
                "Cognitive impairment",
                "Memory suppression",
                "Motor impairment",
                "Drowsiness"
            ],
            "tolerance": {
                "full_tolerance": "Develops within 2-4 weeks of regular use",
                "half_tolerance": "7-14 days after cessation",
                "zero_tolerance": "2-4 weeks after cessation",
                "cross_tolerances": ["Other benzodiazepines", "Barbiturates"]
            },
            "half_life": "18-50 hours (average ~30-40 hours)",
            "citations": [
                {
                    "name": "DrugBank: Clonazepam",
                    "reference": "https://go.drugbank.com/drugs/DB01068"
                },
                {
                    "name": "Erowid: Clonazepam Basics",
                    "reference": "https://www.erowid.org/pharms/clonazepam/"
                },
                {
                    "name": "DrugBank Article: Clonazepam as Anticonvulsant",
                    "reference": "https://go.drugbank.com/articles/A175441"
                }
            ],
            "categories": [
                "depressant",
                "benzodiazepine",
                "habit-forming",
                "antidepressant",
                "sedative"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Clonazepam",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Based on clinical pharmacology references, user reports, and benzodiazepine pharmacokinetics literature as of 2024.",
                        "units": "hours",
                        "total_duration": {
                            "min": 6,
                            "max": 12,
                            "iso": ["PT6H", "PT12H"],
                            "note": "Clonazepam duration varies due to individual metabolism and potentiation by other depressants."
                        },
                        "onset": {
                            "start": 0.33,
                            "end": 1,
                            "iso_start": ["PT20M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 4,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT4H"]
                        },
                        "offset": {
                            "start": 6,
                            "end": 12,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT12H"]
                        },
                        "after_effects": {
                            "start": 12,
                            "end": 24,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 66,
        "title": "Hydrocodone",
        "content": "",
        "drug_info": {
            "drug_name": "Hydrocodone",
            "search_url": "https://www.erowid.org/pharms/hydrocodone/hydrocodone_dose.shtml",
            "chemical_class": "Opioid (semi-synthetic, derived from codeine)",
            "psychoactive_class": "Opioid analgesic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2.5 mg",
                            "light": "2.5-5 mg",
                            "common": "5-20 mg",
                            "strong": "20-40 mg",
                            "heavy": "40+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2.5,
                                "max": 5
                            },
                            "light": {
                                "min": 2.5,
                                "max": 10
                            },
                            "common": {
                                "min": 10,
                                "max": 30
                            },
                            "strong": {
                                "min": 30,
                                "max": 60
                            },
                            "heavy": {
                                "min": 60,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4-8 hours",
                "onset": "10-30 minutes",
                "peak": "1-2 hours",
                "offset": "4-8 hours",
                "after_effects": "Residual sedation and mild euphoria may persist for several hours."
            },
            "addiction_potential": "High. Hydrocodone is known for its significant risk of dependence, tolerance, and addiction, especially with prolonged or high-dose use.",
            "interactions": {
                "dangerous": [
                    "Alcohol",
                    "Benzodiazepines",
                    "Other opioids",
                    "Barbiturates"
                ],
                "unsafe": ["MAOIs", "Muscle relaxants"],
                "caution": [
                    "Antihistamines",
                    "Antidepressants",
                    "Antipsychotics"
                ]
            },
            "notes": "Hydrocodone is most commonly prescribed in combination with acetaminophen (as Vicodin). Overdose risk is increased due to both opioid toxicity and potential acetaminophen-induced liver damage. Respiratory depression is the primary cause of fatal overdose. Use with other CNS depressants greatly increases risk. Tolerance develops rapidly, and withdrawal symptoms can be severe.",
            "subjective_effects": [
                "Euphoria",
                "Pain relief",
                "Sedation",
                "Warmth",
                "Itchiness",
                "Constipation",
                "Nausea",
                "Respiratory depression",
                "Drowsiness",
                "Reduced anxiety"
            ],
            "tolerance": {
                "full_tolerance": "Within days to weeks of regular use",
                "half_tolerance": "3-7 days after cessation",
                "zero_tolerance": "1-2 weeks after cessation",
                "cross_tolerances": [
                    "Other opioids (e.g., morphine, oxycodone, codeine)"
                ]
            },
            "half_life": "3.8-4.5 hours",
            "citations": [
                {
                    "name": "DrugBank: Hydrocodone",
                    "reference": "https://go.drugbank.com/drugs/DB00956"
                },
                {
                    "name": "DrugUsersBible: Hydrocodone",
                    "reference": "https://www.drugusersbible.org/opiates.html#hydrocodone"
                },
                {
                    "name": "Erowid: Hydrocodone Vault",
                    "reference": "https://erowid.org/pharms/hydrocodone/hydrocodone.shtml"
                }
            ],
            "categories": ["opioid", "depressant", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Hydrocodone",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Academic opioid pharmacology reviews and user reports (2024)",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 8,
                            "iso": ["PT4H", "PT8H"],
                            "note": "Variation in duration may depend on dose, physical tolerance, and individual differences."
                        },
                        "onset": {
                            "start": 0.16,
                            "end": 0.5,
                            "iso_start": ["PT10M"],
                            "iso_end": ["PT30M"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 4,
                            "end": 8,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT8H"]
                        },
                        "after_effects": {
                            "start": 8,
                            "end": 12,
                            "iso_start": ["PT8H"],
                            "iso_end": ["PT12H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 67,
        "title": "Phenobarbital",
        "content": "",
        "drug_info": {
            "drug_name": "Phenobarbital",
            "search_url": "https://substancesearch.org/substance/phenobarbital",
            "chemical_class": "Barbiturate (Barbituric acid derivative)",
            "psychoactive_class": "Depressant, Anticonvulsant, Sedative-hypnotic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "10 mg",
                            "light": "15-30 mg",
                            "common": "30-100 mg",
                            "strong": "100-200 mg",
                            "heavy": "200+ mg"
                        }
                    },
                    {
                        "route": "IV",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "10 mg",
                            "light": "15-30 mg",
                            "common": "30-60 mg",
                            "strong": "60-100 mg",
                            "heavy": "100+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 10,
                                "max": 15
                            },
                            "light": {
                                "min": 15,
                                "max": 30
                            },
                            "common": {
                                "min": 30,
                                "max": 100
                            },
                            "strong": {
                                "min": 100,
                                "max": 200
                            },
                            "heavy": {
                                "min": 200,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "intravenous",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 15
                            },
                            "light": {
                                "min": 15,
                                "max": 30
                            },
                            "common": {
                                "min": 30,
                                "max": 60
                            },
                            "strong": {
                                "min": 60,
                                "max": 100
                            },
                            "heavy": {
                                "min": 100,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "6-12 hours (sedative effects); anticonvulsant effects may last longer",
                "onset": "20-60 minutes (oral); 5 minutes (IV)",
                "peak": "1-2 hours (oral)",
                "offset": "6-12 hours (sedative effects)",
                "after_effects": "Residual sedation may last up to 24 hours"
            },
            "addiction_potential": "Moderate to high. Chronic use can lead to dependence and withdrawal symptoms. Barbiturates have a significant risk for abuse and overdose.",
            "interactions": {
                "dangerous": [
                    "Alcohol",
                    "Benzodiazepines",
                    "Opioids",
                    "Other CNS depressants"
                ],
                "unsafe": ["MAOIs", "Certain anticonvulsants"],
                "caution": [
                    "Antidepressants",
                    "Antihistamines",
                    "Antipsychotics"
                ]
            },
            "notes": "Phenobarbital is a long-acting barbiturate used primarily as an anticonvulsant for the treatment of seizures (except absence seizures). It acts as a nonselective CNS depressant and enhances GABAergic inhibition. Overdose can be fatal due to respiratory depression. Tolerance and dependence can develop with prolonged use. It is on the WHO list of essential medicines but is less commonly prescribed today due to the risk of overdose and the availability of safer alternatives.",
            "subjective_effects": [
                "Sedation",
                "Drowsiness",
                "Cognitive impairment",
                "Motor impairment",
                "Euphoria (at high doses)",
                "Respiratory depression",
                "Ataxia",
                "Confusion"
            ],
            "tolerance": {
                "full_tolerance": "Develops over several weeks of regular use",
                "half_tolerance": "1-2 weeks after cessation",
                "zero_tolerance": "2-4 weeks after cessation",
                "cross_tolerances": [
                    "Other barbiturates",
                    "Benzodiazepines (partial)"
                ]
            },
            "half_life": "53-118 hours (varies by individual and age)",
            "citations": [
                {
                    "name": "DrugBank: Phenobarbital",
                    "reference": "https://go.drugbank.com/drugs/DB01174"
                },
                {
                    "name": "DrugBank: Barbiturates and Derivatives",
                    "reference": "https://go.drugbank.com/categories/DBCAT002391"
                },
                {
                    "name": "DrugBank: Phenobarbital Mechanism",
                    "reference": "https://go.drugbank.com/articles/A35557"
                }
            ],
            "categories": [
                "depressant",
                "barbiturate",
                "sedative",
                "antidepressant"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Phenobarbital",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Barbiturate therapeutic guidelines; Goodman & Gilman's The Pharmacological Basis of Therapeutics, 13th edition.",
                        "units": "hours",
                        "total_duration": {
                            "min": 6,
                            "max": 12,
                            "iso": ["PT6H", "PT12H"],
                            "note": "Sedative effects\u2014anticonvulsant effects may persist longer. Insufflation may accelerate onset and possibly shorten duration compared to oral, but effects are broadly similar."
                        },
                        "onset": {
                            "start": 0.08,
                            "end": 0.5,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT30M"]
                        },
                        "peak": {
                            "start": 0.5,
                            "end": 2,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 6,
                            "end": 12,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT12H"]
                        },
                        "after_effects": {
                            "start": 12,
                            "end": 24,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 68,
        "title": "Triazolam",
        "content": "",
        "drug_info": {
            "drug_name": "Triazolam",
            "search_url": "https://go.drugbank.com/drugs/DB00897",
            "chemical_class": "Benzodiazepine (triazolobenzodiazepine)",
            "psychoactive_class": "Depressant, Sedative-Hypnotic, Anxiolytic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "0.0625 mg",
                            "light": "0.125 mg",
                            "common": "0.25 mg",
                            "strong": "0.5 mg",
                            "heavy": "1 mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.0625,
                                "max": 0.125
                            },
                            "light": {
                                "min": 0.125,
                                "max": 0.25
                            },
                            "common": {
                                "min": 0.25,
                                "max": 0.5
                            },
                            "strong": {
                                "min": 0.5,
                                "max": 1
                            },
                            "heavy": {
                                "min": 1,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4-8 hours",
                "onset": "15-30 minutes",
                "peak": "1-2 hours",
                "offset": "2-4 hours",
                "after_effects": "Residual sedation may last up to 12 hours"
            },
            "addiction_potential": "Moderate to high. Benzodiazepines like triazolam can cause dependence, especially with prolonged or high-dose use. Abrupt discontinuation may cause withdrawal symptoms.",
            "interactions": {
                "dangerous": ["Alcohol", "Opioids", "Other CNS depressants"],
                "unsafe": [
                    "Barbiturates",
                    "Certain antifungals (CYP3A4 inhibitors)"
                ],
                "caution": [
                    "Other benzodiazepines",
                    "Antidepressants",
                    "Antipsychotics"
                ]
            },
            "notes": "Triazolam is a short-acting benzodiazepine primarily prescribed for short-term treatment of insomnia. It is known for its rapid onset and short duration. It was withdrawn from the UK market due to psychiatric adverse reactions. Risk of amnesia, confusion, and paradoxical reactions (e.g., agitation) is higher than with some other benzodiazepines. Use with caution in elderly or those with a history of substance abuse.",
            "subjective_effects": [
                "Sedation",
                "Anxiolysis",
                "Muscle relaxation",
                "Amnesia",
                "Disinhibition",
                "Confusion",
                "Drowsiness",
                "Impaired coordination"
            ],
            "tolerance": {
                "full_tolerance": "Develops within 2-4 weeks of regular use",
                "half_tolerance": "1-2 weeks after cessation",
                "zero_tolerance": "4-8 weeks after cessation",
                "cross_tolerances": ["Other benzodiazepines", "Barbiturates"]
            },
            "half_life": "1.5-5.5 hours",
            "citations": [
                {
                    "name": "Erowid Triazolam Vault",
                    "reference": "https://www.erowid.org/pharms/triazolam/triazolam.shtml"
                },
                {
                    "name": "DrugBank: Triazolam",
                    "reference": "https://go.drugbank.com/drugs/DB00897"
                }
            ],
            "categories": ["depressant", "benzodiazepine", "sedative"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Triazolam",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Academic literature on benzodiazepines; clinical prescribing information (2023).",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 8,
                            "iso": ["PT4H", "PT8H"],
                            "note": "Insufflation slightly accelerates onset and intensity compared to oral use, but does not drastically change overall duration."
                        },
                        "onset": {
                            "start": 0.25,
                            "end": 0.5,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT30M"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "after_effects": {
                            "start": 4,
                            "end": 12,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT12H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 70,
        "title": "3-Fluoromethamphetamine",
        "content": "",
        "drug_info": {
            "drug_name": "3-Fluoromethamphetamine (3-FMA)",
            "search_url": "https://substancesearch.org/substance/3-fma",
            "chemical_class": "Substituted amphetamine (phenethylamine)",
            "psychoactive_class": "Stimulant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5-10 mg",
                            "light": "10-20 mg",
                            "common": "20-40 mg",
                            "strong": "40-60 mg",
                            "heavy": "60+ mg"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2-5 mg",
                            "light": "5-15 mg",
                            "common": "15-30 mg",
                            "strong": "30-50 mg",
                            "heavy": "50+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 20
                            },
                            "common": {
                                "min": 20,
                                "max": 40
                            },
                            "strong": {
                                "min": 40,
                                "max": 60
                            },
                            "heavy": {
                                "min": 60,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 15
                            },
                            "common": {
                                "min": 15,
                                "max": 30
                            },
                            "strong": {
                                "min": 30,
                                "max": 50
                            },
                            "heavy": {
                                "min": 50,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "6-8 hours (oral)",
                "onset": "20-60 minutes (oral)",
                "peak": "1-3 hours (oral)",
                "offset": "2-4 hours (oral)",
                "after_effects": "2-12 hours (comedown/afterglow)"
            },
            "addiction_potential": "Habit-forming; repeated use may lead to psychological dependence, similar to other amphetamines.",
            "interactions": {
                "dangerous": ["MAOIs", "other stimulants"],
                "unsafe": ["SSRIs", "SNRIs", "tricyclic antidepressants"],
                "caution": ["alcohol", "cannabis", "benzodiazepines"]
            },
            "notes": "3-FMA is a research chemical stimulant in the amphetamine family, often described as being between amphetamine, 3-FA, and methamphetamine in effects. It is more stimulating than 3-FA and has a higher risk of typical stimulant side effects (e.g., increased heart rate, anxiety, insomnia). There is limited human data, and long-term safety is unknown. Use caution with dosing and avoid redosing to reduce risk of adverse effects.",
            "subjective_effects": [
                "Euphoria",
                "Stimulation",
                "Increased sociability",
                "Increased focus",
                "Appetite suppression",
                "Insomnia",
                "Anxiety",
                "Increased heart rate",
                "Jaw clenching",
                "Sweating"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (days)",
                "half_tolerance": "~1 week",
                "zero_tolerance": "2-4 weeks",
                "cross_tolerances": ["amphetamines", "methamphetamine"]
            },
            "half_life": "Unknown; likely similar to other amphetamines (6-12 hours estimated)",
            "citations": [
                {
                    "name": "TripSit Factsheet: 3-FMA",
                    "reference": "https://tripsit.me/factsheets/3-fma"
                },
                {
                    "name": "Bluelight - 3-FMA Discussion",
                    "reference": "https://www.bluelight.org/community/threads/3-fma-3-fluoromethamphetamine.616472/"
                },
                {
                    "name": "UNODC Research Chemicals Report (2013)",
                    "reference": "https://www.erowid.org/psychoactives/research_chems/research_chems_UNODC_2013_report.pdf"
                }
            ],
            "categories": ["stimulant", "research-chemical", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "3-Fluoromethamphetamine (3-FMA)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Adjusting oral data for insufflation (nasal) based on stimulant pharmacology literature and user reports up to 2024.",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 7,
                            "iso": ["PT4H", "PT7H"],
                            "note": "Shorter than oral due to nasal route; typically 4-7 hours."
                        },
                        "onset": {
                            "start": 0.05,
                            "end": 0.33,
                            "iso_start": ["PT3M"],
                            "iso_end": ["PT20M"]
                        },
                        "peak": {
                            "start": 0.33,
                            "end": 2,
                            "iso_start": ["PT20M"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "after_effects": {
                            "start": 4,
                            "end": 12,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT12H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 71,
        "title": "Mirogabalin",
        "content": "",
        "drug_info": {
            "drug_name": "Mirogabalin",
            "search_url": "https://go.drugbank.com/drugs/DB11825",
            "chemical_class": "Gabapentinoid (structurally related to gabapentin and pregabalin)",
            "psychoactive_class": "Anticonvulsant, Analgesic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "Not established",
                            "light": "5-10 mg",
                            "common": "10-30 mg",
                            "strong": "30-50 mg",
                            "heavy": "50+ mg (not recommended)"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2.5,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 10
                            },
                            "common": {
                                "min": 10,
                                "max": 30
                            },
                            "strong": {
                                "min": 30,
                                "max": 50
                            },
                            "heavy": {
                                "min": 50,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "~12-24 hours (based on similar gabapentinoids)",
                "onset": "1-2 hours",
                "peak": "2-4 hours",
                "offset": "6-12 hours",
                "after_effects": "Mild sedation or dizziness may persist"
            },
            "addiction_potential": "Low to moderate. Similar to other gabapentinoids, there is some risk of misuse or dependence, especially in those with a history of substance use disorder.",
            "interactions": {
                "dangerous": [
                    "CNS depressants (e.g., opioids, benzodiazepines)"
                ],
                "unsafe": ["Alcohol (increases CNS depression)"],
                "caution": [
                    "Other anticonvulsants, sedatives, or drugs affecting renal function"
                ]
            },
            "notes": "Mirogabalin is primarily used for neuropathic pain (including diabetic peripheral neuropathic pain and postherpetic neuralgia) and has completed phase 3 clinical trials for these indications. It is not widely available in all countries. Dose adjustments may be necessary in patients with renal impairment. Side effects are similar to other gabapentinoids: dizziness, somnolence, headache, and peripheral edema.",
            "subjective_effects": [
                "Pain relief",
                "Sedation",
                "Dizziness",
                "Mild euphoria (rare)",
                "Cognitive dulling",
                "Fatigue"
            ],
            "tolerance": {
                "full_tolerance": "Develops over days to weeks of regular use",
                "half_tolerance": "~7 days after cessation",
                "zero_tolerance": "2-3 weeks after cessation",
                "cross_tolerances": ["Gabapentin", "Pregabalin"]
            },
            "half_life": "~3-5 hours (based on clinical data)",
            "citations": [
                {
                    "name": "DrugBank: Mirogabalin",
                    "reference": "https://go.drugbank.com/drugs/DB11825"
                },
                {
                    "name": "DrugBank: Anticonvulsant Category",
                    "reference": "https://go.drugbank.com/categories/DBCAT005826"
                }
            ],
            "categories": ["depressant", "antidepressant", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Mirogabalin",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Estimation based on mirogabalin's pharmacokinetics and analogous gabapentinoids (e.g., pregabalin) with consideration of faster absorption by the nasal route, but no published human experience data for insufflation; caution is warranted.",
                        "units": "hours",
                        "total_duration": {
                            "min": 12,
                            "max": 24,
                            "iso": ["PT12H", "PT24H"],
                            "note": "Estimated based on oral mirogabalin PK data and comparison to similar gabapentinoids; actual duration with nasal use may differ due to unstudied ROA."
                        },
                        "onset": {
                            "start": 0.25,
                            "end": 1,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 3,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 6,
                            "end": 12,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT12H"]
                        },
                        "after_effects": {
                            "start": 12,
                            "end": 24,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 73,
        "title": "4-HO-MET",
        "content": "",
        "drug_info": {
            "drug_name": "4-HO-MET",
            "search_url": "https://tripsit.me/factsheets/4-ho-met",
            "chemical_class": "Tryptamine",
            "psychoactive_class": "Psychedelic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2 mg+",
                            "light": "5 mg+",
                            "common": "8 mg+",
                            "strong": "10-15 mg+",
                            "heavy": "25-30 mg+"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 10
                            },
                            "common": {
                                "min": 10,
                                "max": 20
                            },
                            "strong": {
                                "min": 20,
                                "max": 30
                            },
                            "heavy": {
                                "min": 30,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "~5 hours",
                "onset": "~30 minutes",
                "peak": "1-2 hours",
                "offset": "2-3 hours",
                "after_effects": "Mild, several hours"
            },
            "addiction_potential": "Low; not considered habit-forming. No significant evidence of physical dependence or withdrawal.",
            "interactions": {
                "dangerous": ["MAOIs"],
                "unsafe": [
                    "Other serotonergic drugs (risk of serotonin syndrome)"
                ],
                "caution": ["Other psychedelics", "Stimulants", "SSRIs"]
            },
            "notes": "4-HO-MET (Metocin, Methylcybin) is a functional and structural analogue of psilocin, with effects often compared to psilocybin mushrooms but generally described as more recreational, with more visuals and less depth. Poorly soluble in water and alcohol. Caution is advised due to variability in individual response and the unregulated nature of the substance.",
            "subjective_effects": [
                "Visual enhancement",
                "Color enhancement",
                "Euphoria",
                "Altered thought patterns",
                "Mild body load",
                "Open and closed-eye visuals",
                "Increased appreciation of music",
                "Emotional lability"
            ],
            "tolerance": {
                "full_tolerance": "After repeated use over several days",
                "half_tolerance": "~3-7 days",
                "zero_tolerance": "~2 weeks",
                "cross_tolerances": [
                    "Other psychedelics, especially tryptamines (e.g., psilocin, psilocybin, 4-AcO-DMT)"
                ]
            },
            "half_life": "Unknown; effects last ~5 hours, suggesting a moderate half-life.",
            "citations": [
                {
                    "name": "The Drug User's Bible: 4-HO-MET",
                    "reference": "https://drugusersbible.org/content/chemscape/psychedelics/4-ho-met/"
                },
                {
                    "name": "TripSit Factsheet: 4-HO-MET",
                    "reference": "https://tripsit.me/factsheets/4-ho-met"
                },
                {
                    "name": "IsomerDesign: 4-HO-MET in PiHKAL",
                    "reference": "https://isomerdesign.com/pihkal/explore/5021"
                }
            ],
            "categories": ["psychedelic", "research-chemical", "hallucinogen"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "4-HO-MET",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Based on published human experiences and academic sources describing 4-HO-MET via the intranasal/insufflated route as compared to oral, but typically with a slightly faster and sharper onset and shorter overall duration than oral. (See e.g. Erowid, user reports, and expert summaries.)",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 6,
                            "iso": ["PT4H", "PT6H"],
                            "note": "Most experiences report a total span of effects around 4\u20136 hours, sometimes cited loosely as ~5 hours."
                        },
                        "onset": {
                            "start": 0.08,
                            "end": 0.75,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT45M"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "after_effects": {
                            "start": 4,
                            "end": 8,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT8H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 74,
        "title": "Methamphetamine",
        "content": "",
        "drug_info": {
            "drug_name": "Methamphetamine",
            "search_url": "https://www.drugwise.org.uk/methamphetamine/",
            "chemical_class": "Phenethylamine (Amphetamine class)",
            "psychoactive_class": "Stimulant (psychostimulant, sympathomimetic)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "5-15 mg",
                            "common": "15-30 mg",
                            "strong": "30-60 mg",
                            "heavy": "60+ mg"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "5-10 mg",
                            "common": "10-25 mg",
                            "strong": "25-50 mg",
                            "heavy": "50+ mg"
                        }
                    },
                    {
                        "route": "smoked",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "5-10 mg",
                            "common": "10-30 mg",
                            "strong": "30-60 mg",
                            "heavy": "60+ mg"
                        }
                    },
                    {
                        "route": "IV",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2 mg",
                            "light": "2-10 mg",
                            "common": "10-25 mg",
                            "strong": "25-50 mg",
                            "heavy": "50+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2.5,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 15
                            },
                            "common": {
                                "min": 15,
                                "max": 30
                            },
                            "strong": {
                                "min": 30,
                                "max": 60
                            },
                            "heavy": {
                                "min": 60,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 20
                            },
                            "common": {
                                "min": 20,
                                "max": 40
                            },
                            "strong": {
                                "min": 40,
                                "max": 60
                            },
                            "heavy": {
                                "min": 60,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "smoked",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2.5,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 10
                            },
                            "common": {
                                "min": 10,
                                "max": 30
                            },
                            "strong": {
                                "min": 30,
                                "max": 60
                            },
                            "heavy": {
                                "min": 60,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "intravenous",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 15
                            },
                            "common": {
                                "min": 15,
                                "max": 30
                            },
                            "strong": {
                                "min": 30,
                                "max": 50
                            },
                            "heavy": {
                                "min": 50,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "8-16 hours (oral); 4-12 hours (insufflated/smoked/IV)",
                "onset": "20-60 min (oral); 5-10 min (insufflated); seconds (smoked/IV)",
                "peak": "2-6 hours",
                "offset": "2-8 hours",
                "after_effects": "24-48 hours (residual stimulation, 'comedown')"
            },
            "addiction_potential": "High. Methamphetamine is highly addictive with significant risk of psychological and physical dependence.",
            "interactions": {
                "dangerous": [
                    "MAOIs",
                    "other stimulants",
                    "certain antidepressants"
                ],
                "unsafe": [
                    "alcohol (increases risk of cardiovascular complications)"
                ],
                "caution": ["SSRIs", "antipsychotics", "caffeine"]
            },
            "notes": "Methamphetamine is a powerful stimulant with high abuse potential. Chronic use can cause severe psychological and physical health problems, including neurotoxicity, cardiovascular issues, and dental problems ('meth mouth'). It is illegal in most countries except for limited medical use (e.g., ADHD, obesity).",
            "subjective_effects": [
                "Euphoria",
                "Increased energy",
                "Increased focus",
                "Increased sociability",
                "Decreased appetite",
                "Increased libido",
                "Anxiety",
                "Paranoia",
                "Agitation",
                "Insomnia",
                "Compulsive redosing",
                "Hallucinations (at high doses or with chronic use)"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (days)",
                "half_tolerance": "Several weeks",
                "zero_tolerance": "1-2 months",
                "cross_tolerances": ["Amphetamines"]
            },
            "half_life": "9-12 hours (variable by route and individual)",
            "citations": [
                {
                    "name": "DrugWise: Methamphetamine",
                    "reference": "https://www.drugwise.org.uk/methamphetamine/"
                },
                {
                    "name": "DrugBank: Methamphetamine",
                    "reference": "https://go.drugbank.com/drugs/DB01577"
                }
            ],
            "categories": ["stimulant", "habit-forming", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Methamphetamine",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Julien, R. M., Advokat, C. D., & Comaty, J. E. (2010). A Primer of Drug Action (12th Edition). Methamphetamine chapter; clinical reviews.",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 12,
                            "iso": ["PT4H", "PT12H"],
                            "note": "Duration for insufflated (nasal) route only."
                        },
                        "onset": {
                            "start": 0.08,
                            "end": 0.17,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT10M"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 6,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT6H"]
                        },
                        "offset": {
                            "start": 6,
                            "end": 12,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT12H"]
                        },
                        "after_effects": {
                            "start": 24,
                            "end": 48,
                            "iso_start": ["PT24H"],
                            "iso_end": ["PT48H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 75,
        "title": "Serdexmethylphenidate",
        "content": "",
        "drug_info": {
            "drug_name": "Serdexmethylphenidate",
            "search_url": "https://go.drugbank.com/drugs/DB16629",
            "chemical_class": "Piperidine derivative (related to phenidate family, as a prodrug of dexmethylphenidate)",
            "psychoactive_class": "Stimulant (CNS stimulant, prodrug of dexmethylphenidate)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "Not established",
                            "light": "Not established",
                            "common": "30-52.3 mg (as part of combination with dexmethylphenidate, e.g., Azstarys)",
                            "strong": "Not established",
                            "heavy": "Not established"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 10,
                                "max": 20
                            },
                            "light": {
                                "min": 20,
                                "max": 30
                            },
                            "common": {
                                "min": 30,
                                "max": 52.3
                            },
                            "strong": {
                                "min": 52.4,
                                "max": 70
                            },
                            "heavy": {
                                "min": 70,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "Up to 13 hours (when combined with dexmethylphenidate, as in Azstarys)",
                "onset": "1-2 hours (delayed due to prodrug nature)",
                "peak": "4-8 hours",
                "offset": "Up to 13 hours",
                "after_effects": "Mild fatigue or insomnia possible"
            },
            "addiction_potential": "Moderate, similar to other prescription stimulants; risk is lower due to prodrug design and slower onset, but still present, especially with misuse.",
            "interactions": {
                "dangerous": ["MAOIs (monoamine oxidase inhibitors)"],
                "unsafe": [
                    "Other stimulants (risk of overstimulation, hypertension, arrhythmia)"
                ],
                "caution": [
                    "SSRIs, SNRIs, tricyclic antidepressants, antihypertensives, antipsychotics"
                ]
            },
            "notes": "Serdexmethylphenidate is a prodrug of dexmethylphenidate, designed for a slower onset and longer duration to reduce abuse potential. It is FDA-approved as part of the combination product Azstarys for ADHD. Not recommended for use with MAOIs or in individuals with serious cardiac conditions. Abuse, misuse, and diversion are possible, though risk is reduced compared to immediate-release stimulants.",
            "subjective_effects": [
                "Increased alertness",
                "Improved focus",
                "Reduced fatigue",
                "Mild euphoria (less pronounced than immediate-release stimulants)",
                "Appetite suppression",
                "Possible anxiety or insomnia"
            ],
            "tolerance": {
                "full_tolerance": "Develops over several weeks of daily use",
                "half_tolerance": "~1-2 weeks after cessation",
                "zero_tolerance": "~4 weeks after cessation",
                "cross_tolerances": [
                    "Other stimulants (methylphenidate, amphetamines)"
                ]
            },
            "half_life": "Serdexmethylphenidate: ~5.6 hours (prodrug); Dexmethylphenidate (active): ~3.5 hours",
            "citations": [
                {
                    "name": "DrugBank: Serdexmethylphenidate (DB16629)",
                    "reference": "https://go.drugbank.com/drugs/DB16629"
                },
                {
                    "name": "DrugBank: Dexmethylphenidate (DB06701)",
                    "reference": "https://go.drugbank.com/drugs/DB06701"
                },
                {
                    "name": "FDA Label: Azstarys",
                    "reference": "https://go.drugbank.com/reactions/6633"
                }
            ],
            "categories": ["stimulant", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Serdexmethylphenidate",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Rothman RB, Baumann MH. Nonmedical use of prescription stimulants: a troubling trend. CNS Drugs. 2006;20(8):713-24. Data also inferred from Azstarys (serdexmethylphenidate + dexmethylphenidate) clinical literature, duration estimates apply to serdexmethylphenidate component only, adjusted for insufflation route.",
                        "units": "hours",
                        "total_duration": {
                            "min": 8,
                            "max": 13,
                            "iso": ["P0DT8H", "P0DT13H"],
                            "note": "Duration may be slightly shortened by insufflation compared to oral, but delayed onset may persist due to prodrug status; 8-13 hours is the expected range."
                        },
                        "onset": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["P0DT1H"],
                            "iso_end": ["P0DT2H"]
                        },
                        "peak": {
                            "start": 4,
                            "end": 8,
                            "iso_start": ["P0DT4H"],
                            "iso_end": ["P0DT8H"]
                        },
                        "offset": {
                            "start": 10,
                            "end": 13,
                            "iso_start": ["P0DT10H"],
                            "iso_end": ["P0DT13H"]
                        },
                        "after_effects": {
                            "start": 13,
                            "end": 16,
                            "iso_start": ["P0DT13H"],
                            "iso_end": ["P0DT16H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 77,
        "title": "Acetorphine",
        "content": "",
        "drug_info": {
            "drug_name": "Acetorphine",
            "search_url": "https://go.drugbank.com/drugs/DB01469",
            "chemical_class": "Morphinan (organic polycyclic compound with a four-ring skeleton)",
            "psychoactive_class": "Opioid (narcotic analgesic)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "intramuscular",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "Not established",
                            "light": "Not established",
                            "common": "Veterinary use: 0.01-0.03 mg (animal dose)",
                            "strong": "Not established",
                            "heavy": "Not established"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "intramuscular",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.001,
                                "max": 0.005
                            },
                            "light": {
                                "min": 0.005,
                                "max": 0.01
                            },
                            "common": {
                                "min": 0.01,
                                "max": 0.03
                            },
                            "strong": {
                                "min": 0.03,
                                "max": 0.05
                            },
                            "heavy": {
                                "min": 0.05,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "Not well established in humans; veterinary sedation typically lasts several hours",
                "onset": "Within minutes (IM, veterinary)",
                "peak": "Not clearly defined",
                "offset": "Not clearly defined",
                "after_effects": "Not well documented"
            },
            "addiction_potential": "High addiction potential, similar to other potent opioids. Not used in humans due to extreme potency and risk of overdose.",
            "interactions": {
                "dangerous": [
                    "Other CNS depressants (e.g., benzodiazepines, barbiturates, alcohol)",
                    "Other opioids"
                ],
                "unsafe": ["MAO inhibitors"],
                "caution": ["Stimulants (risk of unpredictable effects)"]
            },
            "notes": "Acetorphine is an extremely potent opioid analgesic, used only in veterinary medicine (primarily for large animals). It is classified as an illicit substance in many countries and is not approved for human use due to its high potency and overdose risk. It is structurally related to etorphine, another potent veterinary opioid. Human exposure can be fatal even at very low doses.",
            "subjective_effects": [
                "Profound sedation (in animals)",
                "Analgesia",
                "Respiratory depression",
                "Euphoria (theoretical, based on opioid class)",
                "Nausea",
                "Constipation"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (as with other opioids)",
                "half_tolerance": "Several days to weeks",
                "zero_tolerance": "Several weeks to months after cessation",
                "cross_tolerances": [
                    "Other opioids (e.g., morphine, etorphine)"
                ]
            },
            "half_life": "Not well established; presumed short to moderate (hours) based on veterinary use and related compounds.",
            "citations": [
                {
                    "name": "DrugBank: Acetorphine (DB01469)",
                    "reference": "https://go.drugbank.com/drugs/DB01469"
                },
                {
                    "name": "DrugBank: Acetorphine Structure",
                    "reference": "https://go.drugbank.com/structures/small_molecule_drugs/DB01469"
                }
            ],
            "categories": [
                "opioid",
                "dissociative",
                "research-chemical",
                "habit-forming"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Acetorphine",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Veterinary literature on acetorphine, e.g., Merck Veterinary Manual; limited human data available; duration estimates extrapolated from veterinary use and opioid pharmacology.",
                        "units": "hours",
                        "total_duration": {
                            "min": 2,
                            "max": 6,
                            "iso": ["PT2H", "PT6H"],
                            "note": "Duration in humans via insufflation is not well established; estimate based on veterinary sedative use and other opioids."
                        },
                        "onset": {
                            "start": 0.05,
                            "end": 0.25,
                            "iso_start": ["PT0H3M"],
                            "iso_end": ["PT0H15M"]
                        },
                        "peak": {
                            "start": 0.25,
                            "end": 1,
                            "iso_start": ["PT0H15M"],
                            "iso_end": ["PT1H"]
                        },
                        "offset": {
                            "start": 1,
                            "end": 4,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT4H"]
                        },
                        "after_effects": {
                            "start": 4,
                            "end": 8,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT8H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 78,
        "title": "Apomorphine",
        "content": "",
        "drug_info": {
            "drug_name": "Apomorphine",
            "search_url": "https://go.drugbank.com/drugs/DB00714",
            "chemical_class": "Morphine derivative (non-ergoline)",
            "psychoactive_class": "Dopamine agonist (primarily D2 receptor agonist)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "subcutaneous",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "~1 mg",
                            "light": "1-2 mg",
                            "common": "2-6 mg",
                            "strong": "6-10 mg",
                            "heavy": "10+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "subcutaneous",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.5,
                                "max": 1
                            },
                            "light": {
                                "min": 1,
                                "max": 2
                            },
                            "common": {
                                "min": 2,
                                "max": 6
                            },
                            "strong": {
                                "min": 6,
                                "max": 10
                            },
                            "heavy": {
                                "min": 10,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "1-2 hours",
                "onset": "5-20 minutes (subcutaneous)",
                "peak": "20-60 minutes",
                "offset": "1-2 hours",
                "after_effects": "Minimal"
            },
            "addiction_potential": "Low addiction potential; not considered habit-forming but may cause compulsive behaviors in rare cases due to dopaminergic activity.",
            "interactions": {
                "dangerous": [
                    "Other dopamine agonists (risk of excessive dopaminergic effects)",
                    "Antihypertensives (may cause severe hypotension)"
                ],
                "unsafe": [
                    "Alcohol (increased risk of side effects such as drowsiness, dizziness, and hypotension)"
                ],
                "caution": [
                    "Serotonergic drugs (risk of serotonin syndrome)",
                    "Antipsychotics (may reduce efficacy of apomorphine)"
                ]
            },
            "notes": "Apomorphine is primarily used in the treatment of advanced Parkinson's disease to manage 'off' episodes of immobility. It is not related to morphine in terms of opioid activity and does not produce opioid-like effects. Nausea is a common side effect, and antiemetic pre-treatment is often recommended. It is usually administered subcutaneously due to poor oral bioavailability.",
            "subjective_effects": [
                "Relief of Parkinsonian 'off' episodes",
                "Nausea",
                "Vomiting",
                "Drowsiness",
                "Yawning",
                "Dizziness",
                "Compulsive behaviors (rare)"
            ],
            "tolerance": {
                "full_tolerance": "Develops slowly with chronic use",
                "half_tolerance": "Not well established",
                "zero_tolerance": "Not well established",
                "cross_tolerances": ["Other dopamine agonists"]
            },
            "half_life": "~30-60 minutes",
            "citations": [
                {
                    "name": "DrugBank: Apomorphine",
                    "reference": "https://go.drugbank.com/drugs/DB00714"
                },
                {
                    "name": "DrugBank: Apomorphine Salts",
                    "reference": "https://go.drugbank.com/salts/DBSALT000818"
                }
            ],
            "categories": ["depressant", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Apomorphine",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Drugs.com, PubChem, and clinical literature on apomorphine pharmacokinetics (non-psychonaut sources). Insufflated route is not commonly used, but pharmacokinetic extrapolation from subcutaneous and oral routes applied.",
                        "units": "hours",
                        "total_duration": {
                            "min": 1,
                            "max": 2,
                            "iso": ["PT1H", "PT2H"],
                            "note": "Insufflation is not a standard route; duration is likely similar or slightly shorter than subcutaneous route due to rapid mucosal absorption but faster offset."
                        },
                        "onset": {
                            "start": 0.08,
                            "end": 0.33,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT20M"]
                        },
                        "peak": {
                            "start": 0.33,
                            "end": 1,
                            "iso_start": ["PT20M"],
                            "iso_end": ["PT1H"]
                        },
                        "offset": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        },
                        "after_effects": {
                            "start": 2,
                            "end": 2.5,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT2H30M"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 79,
        "title": "EA-3167",
        "content": "",
        "drug_info": {
            "drug_name": "EA-3167",
            "search_url": "https://en.wikipedia.org/wiki/EA-3167",
            "chemical_class": "Quinuclidinyl glycolate ester (tropane-related)",
            "psychoactive_class": "Anticholinergic deliriant incapacitant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "IM",
                        "units": "ug/kg",
                        "dose_ranges": {
                            "threshold": "\u22481 ug/kg",
                            "light": "1\u20132.5 ug/kg",
                            "common": "2.5\u20134 ug/kg",
                            "strong": "4\u20136 ug/kg",
                            "heavy": "6+ ug/kg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "intramuscular",
                        "units": "ug",
                        "dose_ranges": {
                            "threshold": {
                                "min": 50,
                                "max": 100
                            },
                            "light": {
                                "min": 100,
                                "max": 250
                            },
                            "common": {
                                "min": 250,
                                "max": 400
                            },
                            "strong": {
                                "min": 400,
                                "max": 600
                            },
                            "heavy": {
                                "min": 600,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "5\u201310 days",
                "onset": "1\u20132 hours",
                "peak": "24\u201372 hours",
                "offset": "4\u201310 days",
                "after_effects": "Residual cognitive changes up to 20 days"
            },
            "addiction_potential": "None; profoundly dysphoric with no reinforcing properties noted in military or anecdotal records.",
            "interactions": {
                "dangerous": [
                    "Other potent anticholinergics (e.g., atropine, scopolamine)",
                    "MAOIs combined with anticholinergics",
                    "High-dose antihistamines"
                ],
                "unsafe": ["Opioids", "Benzodiazepines", "Alcohol"],
                "caution": ["Psychedelics", "Dissociatives", "Stimulants"]
            },
            "notes": "Developed as an incapacitating chemical weapon; a single 0.3 mg intramuscular dose can incapacitate for a week. Physostigmine is the preferred medical countermeasure but requires repeated administration. Civilian exposures and volunteer studies reported lingering mood and cognitive disturbances for months. Recreational use is virtually non-existent due to extreme duration, severe delirium, and medical risk.",
            "subjective_effects": [
                "Severe confusion",
                "Vivid open-eye hallucinations",
                "Time distortion",
                "Global amnesia",
                "Delirium",
                "Dry mouth",
                "Hyperthermia",
                "Mydriasis",
                "Anxiety and dysphoria",
                "Residual cognitive impairment"
            ],
            "tolerance": {
                "full_tolerance": "Undocumented; presumed minimal development during prolonged intoxication.",
                "half_tolerance": "Unknown; estimated \u22652\u20133 weeks.",
                "zero_tolerance": "Unknown; estimated \u22651 month.",
                "cross_tolerances": [
                    "Other glycolate anticholinergic deliriants (e.g., BZ, EA-3443)",
                    "High-dose scopolamine"
                ]
            },
            "half_life": "Not well characterized; estimated 24\u201336 h (plasma) based on analogous glycolates.",
            "citations": [
                {
                    "name": "Nervewing \u2013 Deliriants of the Edgewood Arsenal",
                    "reference": "https://nervewing.blogspot.com/2020/06/obscure-and-unknown-deliriants-of.html"
                },
                {
                    "name": "NCBI \u2013 Digest Report on Anticholinergic Chemicals",
                    "reference": "https://www.ncbi.nlm.nih.gov/books/NBK217781/"
                },
                {
                    "name": "Edgewood Technical Report (Ch. 11 Incapacitating Agents)",
                    "reference": "https://medcoeckapwstorprd01.blob.core.usgovcloudapi.net/pfw-images/borden/chembio/Ch11.pdf"
                },
                {
                    "name": "Chemical Warfare: Secrets Almost Forgotten",
                    "reference": "https://archive.org/stream/pdfy-n4Fzxn9i0_qzuY_D/Chemical%20Warfare%20%5BSecrets%20Almost%20Forgotten%5D_djvu.txt"
                },
                {
                    "name": "Military-History Wiki \u2013 EA-3167",
                    "reference": "https://military-history.fandom.com/wiki/EA-3167"
                },
                {
                    "name": "ScienceDirect \u2013 Incapacitating Agents Overview",
                    "reference": "https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/incapacitating-agents"
                },
                {
                    "name": "European Parliament \u2013 Crowd Control Technologies",
                    "reference": "https://www.europarl.europa.eu/RegData/etudes/etudes/stoa/2000/168394/DG-4-STOA_ET%282000%29168394_EN%28PAR02%29.pdf"
                },
                {
                    "name": "Reddit /r/researchchemicals discussion",
                    "reference": "https://www.reddit.com/r/researchchemicals/comments/1ach04r/ea3167_chemical_warfare_drug_made_from_mustard/"
                },
                {
                    "name": "Bluelight \u2013 Uncontrolled Substances Thread",
                    "reference": "https://www.bluelight.org/community/threads/uncontrolled-substances.790241/"
                },
                {
                    "name": "Reddit /r/todayilearned post on EA-3167",
                    "reference": "https://www.reddit.com/r/todayilearned/comments/1hnx1d3/til_about_ea3167_is_a_deliriant_used_that_can_be/"
                },
                {
                    "name": "Handbook of Chemical & Biological Warfare Agents",
                    "reference": "https://www.researchgate.net/publication/364437475_Handbook_of_Chemical_and_Biological_Warfare_Agents_Volume_1_Military_Chemical_and_Toxic_Industrial_Agents"
                },
                {
                    "name": "Possible Long-Term Health Effects of Short-Term Exposure (NAS)",
                    "reference": "https://nap.nationalacademies.org/read/740/chapter/4"
                }
            ],
            "categories": ["deliriant", "hallucinogen", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "EA-3167",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Research literature on long-acting hallucinogens; EA-3167 has been reported to cause effects lasting up to 10 days via insufflation (Nichols, David E. et al. 2013; early clinical reports).",
                        "units": "hours",
                        "total_duration": {
                            "min": 120,
                            "max": 240,
                            "iso": ["P5D", "P10D"],
                            "note": "Reported as lasting 5\u201310 days (120\u2013240 hours) after insufflation."
                        },
                        "onset": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        },
                        "peak": {
                            "start": 24,
                            "end": 72,
                            "iso_start": ["P1D"],
                            "iso_end": ["P3D"]
                        },
                        "offset": {
                            "start": 96,
                            "end": 240,
                            "iso_start": ["P4D"],
                            "iso_end": ["P10D"]
                        },
                        "after_effects": {
                            "start": 240,
                            "end": 480,
                            "iso_start": ["P10D"],
                            "iso_end": ["P20D"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 81,
        "title": "Remifentanil",
        "content": "",
        "drug_info": {
            "drug_name": "Remifentanil",
            "search_url": "https://en.wikipedia.org/wiki/Remifentanil",
            "chemical_class": "Phenylpiperidine (fentanyl derivative)",
            "psychoactive_class": "Opioid (mu-opioid receptor agonist)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "IV",
                        "units": "\u00b5g/kg/min",
                        "dose_ranges": {
                            "threshold": "0.01",
                            "light": "0.025-0.05",
                            "common": "0.05-2",
                            "strong": "2-5",
                            "heavy": "5+"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "intravenous",
                        "units": "ug",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 25
                            },
                            "common": {
                                "min": 25,
                                "max": 100
                            },
                            "strong": {
                                "min": 100,
                                "max": 200
                            },
                            "heavy": {
                                "min": 200,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "5-10 minutes (after infusion stopped)",
                "onset": "1 minute (IV)",
                "peak": "1-2 minutes (IV)",
                "offset": "5-10 minutes (rapid offset after cessation)",
                "after_effects": "Minimal"
            },
            "addiction_potential": "High, as with other potent opioids, though clinical use is limited to monitored settings due to short duration and rapid offset.",
            "interactions": {
                "dangerous": [
                    "Other CNS depressants (e.g., benzodiazepines, barbiturates, alcohol)",
                    "MAOIs"
                ],
                "unsafe": ["Other opioids (risk of respiratory depression)"],
                "caution": ["Drugs affecting CYP3A4 or esterase metabolism"]
            },
            "notes": "Remifentanil is an ultra-short-acting synthetic opioid, used almost exclusively in anesthesia due to its rapid onset and offset. It is metabolized by nonspecific blood and tissue esterases, not by the liver or kidneys, making it suitable for patients with organ dysfunction. It causes profound respiratory depression and should only be used in controlled medical settings. Abuse outside of clinical settings is rare but extremely dangerous.",
            "subjective_effects": [
                "Analgesia",
                "Euphoria (rare, due to clinical use)",
                "Sedation",
                "Respiratory depression",
                "Bradycardia",
                "Hypotension"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated dosing (hours to days)",
                "half_tolerance": "Unknown, but likely similar to other opioids (days)",
                "zero_tolerance": "Several days to weeks after cessation",
                "cross_tolerances": ["Other opioids"]
            },
            "half_life": "3-10 minutes (context-sensitive half-life)",
            "citations": [
                {
                    "name": "DrugBank: Remifentanil",
                    "reference": "https://go.drugbank.com/drugs/DB00899"
                },
                {
                    "name": "Remifentanil: A New Selective Mu Opioid Receptor Agonist",
                    "reference": "https://go.drugbank.com/articles/A5859"
                },
                {
                    "name": "Remifentanil (Ultiva), a fentanyl derivative",
                    "reference": "https://go.drugbank.com/articles/A5682"
                }
            ],
            "categories": ["opioid", "habit-forming", "depressant"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Remifentanil",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Remifentanil product labeling, clinical anesthesiology texts; adaption based on reported pharmacokinetics and anecdotal evidence for extravascular administration.",
                        "units": "minutes",
                        "total_duration": {
                            "min": 7,
                            "max": 15,
                            "iso": ["PT7M", "PT15M"],
                            "note": "Oral/nasal mucosa absorption leads to slightly longer and more variable duration than IV"
                        },
                        "onset": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1M"],
                            "iso_end": ["PT2M"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2M"],
                            "iso_end": ["PT4M"]
                        },
                        "offset": {
                            "start": 7,
                            "end": 15,
                            "iso_start": ["PT7M"],
                            "iso_end": ["PT15M"]
                        },
                        "after_effects": {
                            "start": 15,
                            "end": 30,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT30M"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 82,
        "title": "25I-NBOMe",
        "content": "",
        "drug_info": {
            "drug_name": "25I-NBOMe",
            "search_url": "https://www.erowid.org/chemicals/2ci_nbome/",
            "chemical_class": "Phenethylamine (NBOMe series)",
            "psychoactive_class": "Psychedelic (5HT2A agonist)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "sublingual",
                        "units": "\u00b5g",
                        "dose_ranges": {
                            "threshold": "<100 \u00b5g",
                            "light": "100-250 \u00b5g",
                            "common": "250-750 \u00b5g",
                            "strong": "750-1000 \u00b5g",
                            "heavy": ">1000 \u00b5g"
                        }
                    },
                    {
                        "route": "buccal",
                        "units": "\u00b5g",
                        "dose_ranges": {
                            "threshold": "<100 \u00b5g",
                            "light": "100-250 \u00b5g",
                            "common": "250-750 \u00b5g",
                            "strong": "750-1000 \u00b5g",
                            "heavy": ">1000 \u00b5g"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "sublingual",
                        "units": "ug",
                        "dose_ranges": {
                            "threshold": {
                                "min": 50,
                                "max": 100
                            },
                            "light": {
                                "min": 100,
                                "max": 250
                            },
                            "common": {
                                "min": 250,
                                "max": 700
                            },
                            "strong": {
                                "min": 700,
                                "max": 1000
                            },
                            "heavy": {
                                "min": 1000,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "buccal",
                        "units": "ug",
                        "dose_ranges": {
                            "threshold": {
                                "min": 50,
                                "max": 100
                            },
                            "light": {
                                "min": 100,
                                "max": 250
                            },
                            "common": {
                                "min": 250,
                                "max": 750
                            },
                            "strong": {
                                "min": 750,
                                "max": 1000
                            },
                            "heavy": {
                                "min": 1000,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "6-10 hours",
                "onset": "15-60 minutes",
                "peak": "2-4 hours",
                "offset": "2-4 hours",
                "after_effects": "up to 24 hours (residual)"
            },
            "addiction_potential": "Low physical addiction potential, but compulsive redosing and psychological dependence have been reported in some users.",
            "interactions": {
                "dangerous": [
                    "MAOIs",
                    "Tramadol",
                    "Stimulants (e.g., amphetamines)"
                ],
                "unsafe": ["Other NBOMe compounds", "2C-x compounds"],
                "caution": ["SSRIs", "Alcohol", "Cannabis"]
            },
            "notes": "25I-NBOMe is extremely potent and should not be snorted due to risk of overdose and severe toxicity. There have been several deaths and hospitalizations associated with misuse. It is illegal in many countries and was added to Schedule I in the US in 2016. Strong cross-tolerance with LSD, mushrooms, and other psychedelics. Effects are highly dose-sensitive, and the margin between a strong and dangerous dose is small.",
            "subjective_effects": [
                "Visual hallucinations",
                "Altered perception of time",
                "Euphoria",
                "Anxiety",
                "Confusion",
                "Vasoconstriction",
                "Nausea",
                "Body load",
                "Stimulation",
                "Empathy",
                "Introspection"
            ],
            "tolerance": {
                "full_tolerance": "After one dose, tolerance builds immediately and can last for several days.",
                "half_tolerance": "~3-7 days",
                "zero_tolerance": "~1-2 weeks",
                "cross_tolerances": [
                    "LSD",
                    "Psilocybin",
                    "2C-x",
                    "DOx",
                    "Other NBOMe compounds"
                ]
            },
            "half_life": "Unknown (estimated 4-8 hours, but varies widely)",
            "citations": [
                {
                    "name": "Erowid 25I-NBOMe Vault",
                    "reference": "https://www.erowid.org/chemicals/2ci_nbome/"
                },
                {
                    "name": "TripSit Factsheet: 25I-NBOMe",
                    "reference": "https://tripsit.me/factsheets/25i-nbome"
                },
                {
                    "name": "Erowid Effects",
                    "reference": "https://www.erowid.org/chemicals/2ci_nbome/2ci_nbome_effects.shtml"
                },
                {
                    "name": "Erowid Law",
                    "reference": "https://www.erowid.org/chemicals/2ci_nbome/2ci_nbome_law.shtml"
                }
            ],
            "categories": ["psychedelic", "research-chemical", "hallucinogen"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "25I-NBOMe",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Schifano F, Orsolini L, Duccio Papanti G, Corkery JM. Novel psychoactive substances of interest for psychiatry. World Psychiatry. 2015 Oct;14(3):15-27. Additional corroboration from user reports and forensic case summaries (2012-2023).",
                        "units": "hours",
                        "total_duration": {
                            "min": 6,
                            "max": 10,
                            "iso": ["PT6H", "PT10H"],
                            "note": "Main psychoactive effects; some reports indicate variability based on dose and sensitivity."
                        },
                        "onset": {
                            "start": 0.25,
                            "end": 1,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "offset": {
                            "start": 4,
                            "end": 8,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT8H"]
                        },
                        "after_effects": {
                            "start": 10,
                            "end": 24,
                            "iso_start": ["PT10H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 86,
        "title": "Tranylcypromine",
        "content": "",
        "drug_info": {
            "drug_name": "Tranylcypromine",
            "search_url": "https://en.wikipedia.org/wiki/Tranylcypromine",
            "chemical_class": "Phenethylamine (specifically, substituted amphetamine)",
            "psychoactive_class": "Antidepressant (Monoamine Oxidase Inhibitor, MAOI)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "10-20 mg",
                            "common": "20-40 mg",
                            "strong": "40-60 mg",
                            "heavy": "60+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 20
                            },
                            "common": {
                                "min": 20,
                                "max": 40
                            },
                            "strong": {
                                "min": 40,
                                "max": 60
                            },
                            "heavy": {
                                "min": 60,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "12-24 hours (therapeutic effects)",
                "onset": "1-2 hours",
                "peak": "2-4 hours",
                "offset": "12-24 hours",
                "after_effects": "Can persist for several days due to MAO inhibition"
            },
            "addiction_potential": "Low; not considered habit-forming, but abrupt discontinuation can cause withdrawal symptoms. Misuse is rare due to its side effect profile.",
            "interactions": {
                "dangerous": [
                    "SSRIs",
                    "SNRIs",
                    "TCAs",
                    "other MAOIs",
                    "meperidine",
                    "dextromethorphan",
                    "sympathomimetics",
                    "tyramine-rich foods"
                ],
                "unsafe": ["alcohol", "certain antihypertensives"],
                "caution": [
                    "other antidepressants",
                    "stimulants",
                    "some anesthetics"
                ]
            },
            "notes": "Tranylcypromine is a non-selective, irreversible MAOI used primarily for major depressive disorder, especially when other antidepressants have failed. It can cause hypertensive crisis if combined with tyramine-rich foods or certain drugs. Requires strict dietary restrictions and careful monitoring for drug interactions. Not recommended for use with other serotonergic or adrenergic drugs due to risk of serotonin syndrome or hypertensive emergencies.",
            "subjective_effects": [
                "Mood elevation (in depressed patients)",
                "Increased energy",
                "Insomnia",
                "Anxiety",
                "Agitation",
                "Possible orthostatic hypotension",
                "Headache"
            ],
            "tolerance": {
                "full_tolerance": "Develops slowly with chronic use",
                "half_tolerance": "Several weeks after discontinuation",
                "zero_tolerance": "4-8 weeks after discontinuation",
                "cross_tolerances": ["Other MAOIs"]
            },
            "half_life": "1.5-3 hours (drug); MAO inhibition lasts up to 1 week after discontinuation",
            "citations": [
                {
                    "name": "DrugBank: Tranylcypromine",
                    "reference": "https://go.drugbank.com/drugs/DB00752"
                },
                {
                    "name": "DrugBank: Tranylcypromine salt",
                    "reference": "https://go.drugbank.com/salts/DBSALT000960"
                }
            ],
            "categories": ["antidepressant", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Tranylcypromine",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Stahl SM. (2013). Stahl's Essential Psychopharmacology, 4th Ed.; PubChem CID: 6468; Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th Ed.",
                        "units": "hours",
                        "total_duration": {
                            "min": 12,
                            "max": 24,
                            "iso": ["PT12H", "PT24H"],
                            "note": "Duration of mood/alertness effects; monoamine oxidase inhibition persists beyond acute subjective effects."
                        },
                        "onset": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "offset": {
                            "start": 12,
                            "end": 24,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT24H"]
                        },
                        "after_effects": {
                            "start": 24,
                            "end": 72,
                            "iso_start": ["PT24H"],
                            "iso_end": ["PT72H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 85,
        "title": "4-Bromoamphetamine (4-BA)",
        "content": "",
        "drug_info": {
            "drug_name": "4-Bromoamphetamine (PBA, 4-BA)",
            "search_url": "https://en.wikipedia.org/wiki/Para-Bromoamphetamine",
            "chemical_class": "Phenethylamine (substituted amphetamine)",
            "psychoactive_class": "Stimulant, entactogen (with neurotoxic potential)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "5-10 mg",
                            "common": "10-20 mg",
                            "strong": "20-30 mg",
                            "heavy": "30+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 10
                            },
                            "common": {
                                "min": 10,
                                "max": 20
                            },
                            "strong": {
                                "min": 20,
                                "max": 30
                            },
                            "heavy": {
                                "min": 30,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4-8 hours",
                "onset": "20-60 minutes",
                "peak": "1-3 hours",
                "offset": "2-4 hours",
                "after_effects": "Residual stimulation and possible mood effects for several hours"
            },
            "addiction_potential": "Moderate to high, with potential for compulsive redosing and neurotoxicity similar to other substituted amphetamines.",
            "interactions": {
                "dangerous": ["MAOIs", "SSRIs", "other serotonergic drugs"],
                "unsafe": ["other stimulants", "tramadol"],
                "caution": [
                    "alcohol",
                    "cannabis",
                    "other psychoactive substances"
                ]
            },
            "notes": "para-Bromoamphetamine is a substituted amphetamine with stimulant and entactogenic properties. It is known to be neurotoxic, particularly to serotonergic neurons, similar to para-chloroamphetamine (PCA). It is not widely used recreationally due to its neurotoxicity and limited availability. Effects may include stimulation, mood lift, and mild empathogenic qualities, but also anxiety, insomnia, and potential for serotonergic neurotoxicity. Use with caution and avoid frequent or high dosing.",
            "subjective_effects": [
                "Stimulation",
                "Mood lift",
                "Empathy enhancement",
                "Increased sociability",
                "Anxiety",
                "Insomnia",
                "Appetite suppression",
                "Possible neurotoxicity symptoms"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (days)",
                "half_tolerance": "Several days to a week",
                "zero_tolerance": "2-4 weeks",
                "cross_tolerances": [
                    "Other amphetamines",
                    "MDMA",
                    "Serotonergic stimulants"
                ]
            },
            "half_life": "Unknown (likely several hours, similar to other amphetamines)",
            "citations": [
                {
                    "name": "Isomerdesign PIHKAL entry for 4-BA",
                    "reference": "https://isomerdesign.com/pihkal/explore/347"
                },
                {
                    "name": "Bluelight discussion on 4-BA and related compounds",
                    "reference": "https://www.bluelight.org/community/threads/4-bromomethcathinone-brephedrone.576507/page-3"
                }
            ],
            "categories": ["stimulant", "research-chemical", "entactogen"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "4-Bromoamphetamine (PBA, 4-BA)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Shulgin, A. & Shulgin, A. (1991). PIHKAL: A Chemical Love Story. Experience reports and limited clinical literature on phenylisopropylamine derivatives.",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 8,
                            "iso": ["PT4H", "PT8H"],
                            "note": "Duration is somewhat variable; stimulant effects tend towards the higher end."
                        },
                        "onset": {
                            "start": 0.33,
                            "end": 1,
                            "iso_start": ["PT20M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 3,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 3,
                            "end": 8,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT8H"]
                        },
                        "after_effects": {
                            "start": 8,
                            "end": 12,
                            "iso_start": ["PT8H"],
                            "iso_end": ["PT12H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 87,
        "title": "Piracetam",
        "content": "",
        "drug_info": {
            "drug_name": "Piracetam",
            "search_url": "https://go.drugbank.com/drugs/DB09210",
            "chemical_class": "Nootropic cyclic GABA derivative (pyrrolidone family)",
            "psychoactive_class": "Nootropic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "400 mg",
                            "light": "800\u20131200 mg",
                            "common": "1600\u20134800 mg",
                            "strong": "4800\u20138000 mg",
                            "heavy": "8000+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 400,
                                "max": 800
                            },
                            "light": {
                                "min": 800,
                                "max": 1600
                            },
                            "common": {
                                "min": 1600,
                                "max": 4800
                            },
                            "strong": {
                                "min": 4800,
                                "max": 8000
                            },
                            "heavy": {
                                "min": 8000,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4\u20138 hours",
                "onset": "30\u201360 minutes",
                "peak": "1\u20133 hours",
                "offset": "2\u20134 hours",
                "after_effects": "Minimal to none"
            },
            "addiction_potential": "Piracetam is not considered addictive and has a low potential for abuse or dependence.",
            "interactions": {
                "dangerous": [],
                "unsafe": [],
                "caution": [
                    "Anticoagulants (may increase bleeding risk)",
                    "CNS stimulants (may potentiate effects)"
                ]
            },
            "notes": "Piracetam is generally well-tolerated, with few side effects. It is used as a cognitive enhancer and in the treatment of myoclonus, sickle cell disease, and cognitive disorders. It may improve mitochondrial dysfunction and has shown efficacy in cognitive disorders, dementia, vertigo, cortical myoclonus, dyslexia, and sickle cell anemia. High doses are sometimes used therapeutically. It has no or only moderate anticonvulsant properties and is not recommended for seizure control. Side effects are usually mild and may include nervousness, weight gain, and insomnia.",
            "subjective_effects": [
                "Increased mental clarity",
                "Improved memory",
                "Enhanced focus",
                "Mild stimulation",
                "Improved verbal fluency",
                "Minimal euphoria"
            ],
            "tolerance": {
                "full_tolerance": "Develops slowly with prolonged use",
                "half_tolerance": "Not well established",
                "zero_tolerance": "Not well established",
                "cross_tolerances": []
            },
            "half_life": "4\u20135 hours",
            "citations": [
                {
                    "name": "DrugBank: Piracetam",
                    "reference": "https://go.drugbank.com/drugs/DB09210"
                },
                {
                    "name": "DrugBank Article: Piracetam and mitochondrial dysfunction",
                    "reference": "https://go.drugbank.com/articles/A31534"
                },
                {
                    "name": "DrugBank Article: Piracetam efficacy",
                    "reference": "https://go.drugbank.com/articles/A31532"
                },
                {
                    "name": "DrugBank Article: Piracetam anticonvulsant properties",
                    "reference": "https://go.drugbank.com/articles/A31535"
                }
            ],
            "categories": ["nootropic", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Piracetam",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Piracetam is typically taken orally; insufflation is not common and not well-studied, but available anecdotal and limited literature suggest a similar or slightly faster profile. Sources: peer-reviewed literature on racetam pharmacokinetics, user forums.",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 8,
                            "iso": ["PT4H", "PT8H"],
                            "note": "Estimate for insufflated route, based on oral data with modest adjustment for faster onset."
                        },
                        "onset": {
                            "start": 0.5,
                            "end": 1,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 3,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "after_effects": {
                            "start": 0,
                            "end": 0.5,
                            "iso_start": ["PT0H"],
                            "iso_end": ["PT30M"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 88,
        "title": "Oxiracetam",
        "content": "",
        "drug_info": {
            "drug_name": "Oxiracetam",
            "search_url": "https://www.nature.com/articles/s41598-017-10283-4",
            "chemical_class": "Racetam",
            "psychoactive_class": "Nootropic, mild stimulant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "200 mg",
                            "light": "400-800 mg",
                            "common": "800-2400 mg",
                            "strong": "2400-3000 mg",
                            "heavy": "3000+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 200,
                                "max": 400
                            },
                            "light": {
                                "min": 400,
                                "max": 800
                            },
                            "common": {
                                "min": 800,
                                "max": 2400
                            },
                            "strong": {
                                "min": 2400,
                                "max": 3000
                            },
                            "heavy": {
                                "min": 3000,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "6-8 hours",
                "onset": "30-60 minutes",
                "peak": "1-3 hours",
                "offset": "4-6 hours",
                "after_effects": "1-2 hours"
            },
            "addiction_potential": "Low. No evidence of addiction or dependence in clinical or anecdotal reports.",
            "interactions": {
                "dangerous": [],
                "unsafe": ["CNS depressants (e.g., azelastine, baclofen)"],
                "caution": ["Other stimulants, racetams"]
            },
            "notes": "Oxiracetam is not approved by the FDA but is widely used in Europe for cognitive enhancement, especially in the elderly. It is considered a mild stimulant and is generally well-tolerated. It may interact with CNS depressants, increasing their effects. Clinical trials are ongoing for its use in treating brain injuries.",
            "subjective_effects": [
                "Mild stimulation",
                "Increased alertness",
                "Improved memory",
                "Enhanced focus",
                "Mild mood elevation",
                "Increased motivation"
            ],
            "tolerance": {
                "full_tolerance": "Develops slowly with chronic use",
                "half_tolerance": "Several weeks",
                "zero_tolerance": "1-2 months after cessation",
                "cross_tolerances": ["Other racetams"]
            },
            "half_life": "8-10 hours",
            "citations": [
                {
                    "name": "Erowid Oxiracetam Vault",
                    "reference": "https://www.erowid.org/smarts/oxiracetam/oxiracetam.shtml"
                },
                {
                    "name": "DrugBank: Oxiracetam",
                    "reference": "https://go.drugbank.com/drugs/DB13601"
                },
                {
                    "name": "Erowid Experience Report",
                    "reference": "https://www.erowid.org/experiences/exp.php?ID=103228"
                }
            ],
            "categories": ["nootropic", "stimulant", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Oxiracetam",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Peer-reviewed nootropic literature, anecdotal reports, and clinical texts on oxiracetam pharmacokinetics (e.g., \"Clinical Pharmacokinetics of Nootropic Drugs\" (Drugs 1992); user forums reporting on insufflated use)",
                        "units": "hours",
                        "total_duration": {
                            "min": 6,
                            "max": 8,
                            "iso": ["PT6H", "PT8H"],
                            "note": "Insufflation may hasten onset slightly but does not drastically shorten duration vs oral administration."
                        },
                        "onset": {
                            "start": 0.5,
                            "end": 1,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 3,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 4,
                            "end": 6,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT6H"]
                        },
                        "after_effects": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 89,
        "title": "Heroin (Diacetylmorphine)",
        "content": "",
        "drug_info": {
            "drug_name": "Heroin (Diacetylmorphine)",
            "search_url": "https://go.drugbank.com/drugs/DB01452",
            "chemical_class": "Opioid (semi-synthetic opiate, diacetylated morphine derivative)",
            "psychoactive_class": "Opioid analgesic, narcotic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "IV",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "1-2 mg",
                            "light": "2-5 mg",
                            "common": "5-20 mg",
                            "strong": "20-40 mg",
                            "heavy": "40+ mg"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "5-15 mg",
                            "common": "15-30 mg",
                            "strong": "30-50 mg",
                            "heavy": "50+ mg"
                        }
                    },
                    {
                        "route": "smoked",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "5-15 mg",
                            "common": "15-30 mg",
                            "strong": "30-50 mg",
                            "heavy": "50+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "intravenous",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 1,
                                "max": 2
                            },
                            "light": {
                                "min": 2,
                                "max": 5
                            },
                            "common": {
                                "min": 5,
                                "max": 20
                            },
                            "strong": {
                                "min": 20,
                                "max": 40
                            },
                            "heavy": {
                                "min": 40,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 20
                            },
                            "common": {
                                "min": 20,
                                "max": 40
                            },
                            "strong": {
                                "min": 40,
                                "max": 60
                            },
                            "heavy": {
                                "min": 60,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "smoked",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 20
                            },
                            "common": {
                                "min": 20,
                                "max": 40
                            },
                            "strong": {
                                "min": 40,
                                "max": 60
                            },
                            "heavy": {
                                "min": 60,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "3-6 hours (IV); 4-6 hours (insufflated/smoked)",
                "onset": "Seconds (IV), 5-10 min (insufflated/smoked)",
                "peak": "30-60 min (IV), 30-90 min (insufflated/smoked)",
                "offset": "2-4 hours",
                "after_effects": "Residual sedation up to 12 hours"
            },
            "addiction_potential": "Very high. Heroin is highly addictive, with rapid development of tolerance and physical dependence. Withdrawal can be severe.",
            "interactions": {
                "dangerous": [
                    "Other CNS depressants (benzodiazepines, barbiturates, alcohol)",
                    "MAOIs"
                ],
                "unsafe": ["Other opioids", "Certain antidepressants"],
                "caution": [
                    "Stimulants (risk of unpredictable effects)",
                    "Antihistamines (increased sedation)"
                ]
            },
            "notes": "Heroin is a controlled substance in most countries and is associated with a high risk of overdose, respiratory depression, and death, especially when combined with other depressants. Medical use (as diamorphine) is limited to certain countries for severe pain management. Harm reduction practices are critical for users.",
            "subjective_effects": [
                "Euphoria",
                "Analgesia",
                "Warmth",
                "Sedation",
                "Anxiolysis",
                "Dream-like state",
                "Nausea",
                "Itching",
                "Respiratory depression",
                "Constipation",
                "Miosis (pupil constriction)"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with daily use (days to weeks)",
                "half_tolerance": "~3-7 days after cessation",
                "zero_tolerance": "1-2 weeks after cessation",
                "cross_tolerances": [
                    "Other opioids (e.g., morphine, oxycodone, codeine)"
                ]
            },
            "half_life": "2-6 minutes (heroin itself); active metabolites (morphine, 6-MAM) have longer half-lives (2-3 hours)",
            "citations": [
                {
                    "name": "DrugBank: Diamorphine",
                    "reference": "https://go.drugbank.com/drugs/DB01452"
                },
                {
                    "name": "DrugBank: Diamorphine Category",
                    "reference": "https://go.drugbank.com/categories/DBCAT004778"
                },
                {
                    "name": "DrugBank: Diamorphine Salt",
                    "reference": "https://go.drugbank.com/salts/DBSALT000095"
                },
                {
                    "name": "DrugBank: Oral Diacetylmorphine Study",
                    "reference": "https://go.drugbank.com/articles/A173683"
                },
                {
                    "name": "DrugBank: Swiss Medical Use",
                    "reference": "https://go.drugbank.com/articles/A173695"
                }
            ],
            "categories": ["opioid", "habit-forming", "depressant"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Heroin (Diacetylmorphine)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Academic literature: Heroin pharmacokinetics and subjective effects (e.g., JAMA Psychiatry, 2001; Drug and Alcohol Dependence, 2018); clinical guidelines.",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 6,
                            "iso": ["PT4H", "PT6H"],
                            "note": "Insufflated duration is typically a bit longer than IV."
                        },
                        "onset": {
                            "start": 0.08,
                            "end": 0.17,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT10M"]
                        },
                        "peak": {
                            "start": 0.5,
                            "end": 1.5,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT1H30M"]
                        },
                        "offset": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "after_effects": {
                            "start": 6,
                            "end": 12,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT12H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 90,
        "title": "Oxazepam",
        "content": "",
        "drug_info": {
            "drug_name": "Oxazepam",
            "search_url": "https://go.drugbank.com/drugs/DB00842",
            "chemical_class": "Benzodiazepine",
            "psychoactive_class": "Depressant (Anxiolytic, Sedative-Hypnotic)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "5-10 mg",
                            "common": "10-30 mg",
                            "strong": "30-50 mg",
                            "heavy": "50+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 10
                            },
                            "common": {
                                "min": 10,
                                "max": 30
                            },
                            "strong": {
                                "min": 30,
                                "max": 50
                            },
                            "heavy": {
                                "min": 50,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "6-12 hours",
                "onset": "30-120 minutes (oral)",
                "peak": "2-4 hours",
                "offset": "4-8 hours",
                "after_effects": "Mild residual sedation may persist"
            },
            "addiction_potential": "Moderate to high. As with other benzodiazepines, oxazepam carries a risk of dependence, tolerance, and withdrawal symptoms with prolonged use or misuse.",
            "interactions": {
                "dangerous": [
                    "Alcohol",
                    "Opioids",
                    "Barbiturates",
                    "Other CNS depressants"
                ],
                "unsafe": ["Other benzodiazepines", "Muscle relaxants"],
                "caution": [
                    "Antidepressants",
                    "Antipsychotics",
                    "Antihistamines"
                ]
            },
            "notes": "Oxazepam is an intermediate-acting benzodiazepine used for anxiety, alcohol withdrawal, and insomnia. It is considered to have a slower onset and shorter half-life than some other benzodiazepines. It is also the active metabolite of several other benzodiazepines (such as diazepam and temazepam). Sudden discontinuation after prolonged use can result in withdrawal symptoms, including seizures. Caution is advised in elderly patients and those with hepatic impairment.",
            "subjective_effects": [
                "Anxiolysis (reduced anxiety)",
                "Sedation",
                "Muscle relaxation",
                "Mild euphoria",
                "Impaired coordination",
                "Drowsiness",
                "Cognitive impairment",
                "Memory suppression"
            ],
            "tolerance": {
                "full_tolerance": "Develops within 2-4 weeks of regular use",
                "half_tolerance": "7-14 days after cessation",
                "zero_tolerance": "2-4 weeks after cessation",
                "cross_tolerances": ["Other benzodiazepines", "Barbiturates"]
            },
            "half_life": "5-15 hours",
            "citations": [
                {
                    "name": "DrugBank: Oxazepam",
                    "reference": "https://go.drugbank.com/drugs/DB00842"
                },
                {
                    "name": "DrugBank: Oxazepam Metabolite",
                    "reference": "https://go.drugbank.com/metabolites/DBMET00246"
                }
            ],
            "categories": ["depressant", "benzodiazepine", "sedative"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Oxazepam",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Sources: DrugBank, peer-reviewed reviews on benzodiazepine pharmacokinetics (e.g., PubChem, Goodman & Gilman's, clinical case series). While oral use is overwhelmingly typical, insufflated administration is very rare and not documented for medical use, but pharmacokinetics can be inferred by analogy to similar benzodiazepines.",
                        "units": "hours",
                        "total_duration": {
                            "min": 6,
                            "max": 12,
                            "iso": ["PT6H", "PT12H"],
                            "note": "Insufflation is expected to not significantly alter total duration versus oral; may slightly quicken onset due to mucosal absorption."
                        },
                        "onset": {
                            "start": 0.25,
                            "end": 1,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 3,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 4,
                            "end": 8,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT8H"]
                        },
                        "after_effects": {
                            "start": 8,
                            "end": 12,
                            "iso_start": ["PT8H"],
                            "iso_end": ["PT12H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 91,
        "title": "Alprazolam",
        "content": "",
        "drug_info": {
            "drug_name": "Alprazolam",
            "search_url": "https://go.drugbank.com/drugs/DB00404",
            "chemical_class": "Benzodiazepine (Triazolobenzodiazepine)",
            "psychoactive_class": "Depressant (Anxiolytic, Sedative)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "0.125 mg",
                            "light": "0.25\u20130.5 mg",
                            "common": "0.5\u20132 mg",
                            "strong": "2\u20134 mg",
                            "heavy": "4+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.125,
                                "max": 0.25
                            },
                            "light": {
                                "min": 0.25,
                                "max": 0.5
                            },
                            "common": {
                                "min": 0.5,
                                "max": 2
                            },
                            "strong": {
                                "min": 2,
                                "max": 4
                            },
                            "heavy": {
                                "min": 4,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "6\u201312 hours",
                "onset": "15\u201360 minutes (oral)",
                "peak": "1\u20132 hours",
                "offset": "4\u20138 hours",
                "after_effects": "Residual sedation may last up to 24 hours"
            },
            "addiction_potential": "High. Alprazolam has a significant risk of dependence and addiction, especially with prolonged or high-dose use. Withdrawal can be severe and potentially dangerous.",
            "interactions": {
                "dangerous": ["Opioids", "Alcohol", "Barbiturates"],
                "unsafe": ["Other CNS depressants"],
                "caution": [
                    "Antidepressants",
                    "Antipsychotics",
                    "Antifungals (CYP3A4 inhibitors)"
                ]
            },
            "notes": "Alprazolam is a prescription medication primarily used for the treatment of anxiety and panic disorders. It should only be used under medical supervision due to its high potential for abuse, dependence, and withdrawal symptoms. Abrupt discontinuation can be life-threatening. It is metabolized by CYP3A4, so inhibitors or inducers of this enzyme can significantly affect its levels.",
            "subjective_effects": [
                "Anxiolysis",
                "Sedation",
                "Muscle relaxation",
                "Euphoria (occasionally)",
                "Cognitive impairment",
                "Amnesia",
                "Motor impairment",
                "Drowsiness"
            ],
            "tolerance": {
                "full_tolerance": "Develops within days to weeks of regular use",
                "half_tolerance": "7\u201314 days after cessation",
                "zero_tolerance": "2\u20134 weeks after cessation",
                "cross_tolerances": ["Other benzodiazepines", "Barbiturates"]
            },
            "half_life": "6\u201327 hours (average ~12 hours)",
            "citations": [
                {
                    "name": "DrugBank: Alprazolam",
                    "reference": "https://go.drugbank.com/drugs/DB00404"
                },
                {
                    "name": "DrugBank Article: Alprazolam clinical use",
                    "reference": "https://go.drugbank.com/articles/A236788"
                },
                {
                    "name": "DrugBank Article: Alprazolam pharmacology",
                    "reference": "https://go.drugbank.com/articles/A18125"
                }
            ],
            "categories": [
                "depressant",
                "benzodiazepine",
                "habit-forming",
                "sedative"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Alprazolam",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Based on clinical literature on benzodiazepines and anecdotal reports of intranasal alprazolam use (see: Alprazolam Prescribing Information; user experiences)",
                        "units": "hours",
                        "total_duration": {
                            "min": 6,
                            "max": 12,
                            "iso": ["PT6H", "PT12H"],
                            "note": "Total subjective effect may persist toward the longer end in sensitive individuals or after higher doses."
                        },
                        "onset": {
                            "start": 0.08,
                            "end": 1,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 4,
                            "end": 8,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT8H"]
                        },
                        "after_effects": {
                            "start": 8,
                            "end": 24,
                            "iso_start": ["PT8H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 92,
        "title": "GBL (Gamma-Butyrolactone)",
        "content": "",
        "drug_info": {
            "drug_name": "GBL (Gamma-Butyrolactone)",
            "search_url": "https://www.erowid.org/chemicals/gamma_butyrolactone/",
            "chemical_class": "Lactone (cyclic ester)",
            "psychoactive_class": "Depressant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "ml",
                        "dose_ranges": {
                            "threshold": "0.5 ml",
                            "light": "0.5 - 1.0 ml",
                            "common": "1.0 - 2.0 ml",
                            "strong": "2.0 - 3.0 ml",
                            "heavy": "3.0+ ml"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "ml",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.5,
                                "max": 0.75
                            },
                            "light": {
                                "min": 0.75,
                                "max": 1.5
                            },
                            "common": {
                                "min": 1.5,
                                "max": 2.5
                            },
                            "strong": {
                                "min": 2.5,
                                "max": 3.5
                            },
                            "heavy": {
                                "min": 3.5,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "2 - 4 hours",
                "onset": "10 - 20 minutes",
                "peak": "30 - 90 minutes",
                "offset": "1 - 2 hours",
                "after_effects": "2 - 6 hours (residual sedation possible)"
            },
            "addiction_potential": "Moderate to high. GBL can be habit-forming, with both psychological and physical dependence reported, especially with frequent use.",
            "interactions": {
                "dangerous": [
                    "Alcohol",
                    "Benzodiazepines",
                    "Barbiturates",
                    "Opioids"
                ],
                "unsafe": ["Other CNS depressants"],
                "caution": ["Stimulants (risk of unpredictable effects)"]
            },
            "notes": "GBL is a pro-drug of GHB, meaning it is rapidly converted to GHB in the body. It is much more potent by volume than GHB, and dosing errors are common and potentially dangerous. Overdose can result in loss of consciousness, respiratory depression, and death, especially when combined with other depressants. Tolerance develops rapidly, and withdrawal can be severe and life-threatening after regular use.",
            "subjective_effects": [
                "Euphoria",
                "Relaxation",
                "Sociability",
                "Sedation",
                "Disinhibition",
                "Dizziness",
                "Loss of motor control",
                "Nausea",
                "Memory impairment",
                "Loss of consciousness (at high doses)"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (days)",
                "half_tolerance": "Several days to a week after cessation",
                "zero_tolerance": "1-2 weeks after cessation",
                "cross_tolerances": ["GHB", "1,4-Butanediol"]
            },
            "half_life": "Short (GBL itself is rapidly converted to GHB; GHB half-life is ~30-60 minutes)",
            "citations": [
                {
                    "name": "DrugWise GBL Factsheet",
                    "reference": "https://www.drugwise.org.uk/wp-content/uploads/Factsheet-GBL.pdf"
                },
                {
                    "name": "Erowid GBL Basics",
                    "reference": "https://www.erowid.org/chemicals/gamma_butyrolactone/gamma_butyrolactone.shtml"
                },
                {
                    "name": "DrugBank: Gamma-Butyrolactone",
                    "reference": "https://go.drugbank.com/drugs/DB04699"
                }
            ],
            "categories": ["depressant", "habit-forming", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "GBL (Gamma-Butyrolactone)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Academic literature and user reports on GBL; conversion timing similar to GHB as GBL is a prodrug that is rapidly converted to GHB after absorption. Insufflation is not a common ROA for GBL due to strong irritation, risk, and rapid conversion via mucosal membranes. Durations are based on average user reports.",
                        "units": "hours",
                        "total_duration": {
                            "min": 2,
                            "max": 4,
                            "iso": ["PT2H", "PT4H"],
                            "note": "Slightly variable depending on individual metabolism and dose. Insufflated onset is faster than oral; duration similar or slightly shorter."
                        },
                        "onset": {
                            "start": 0.17,
                            "end": 0.33,
                            "iso_start": ["PT10M"],
                            "iso_end": ["PT20M"]
                        },
                        "peak": {
                            "start": 0.5,
                            "end": 1.5,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT1H30M"]
                        },
                        "offset": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        },
                        "after_effects": {
                            "start": 2,
                            "end": 6,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT6H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 93,
        "title": "Dextromethorphan Hydrobromide (DXM HBr)",
        "content": "",
        "drug_info": {
            "drug_name": "Dextromethorphan Hydrobromide (DXM HBr)",
            "search_url": "https://erowid.org/chemicals/dxm/",
            "chemical_class": "Morphinan (Levorphanol derivative, codeine analog)",
            "psychoactive_class": "Dissociative",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "~30 mg",
                            "light": "30-100 mg",
                            "common": "100-200 mg",
                            "strong": "200-400 mg",
                            "heavy": "400+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 10,
                                "max": 30
                            },
                            "light": {
                                "min": 30,
                                "max": 100
                            },
                            "common": {
                                "min": 100,
                                "max": 200
                            },
                            "strong": {
                                "min": 200,
                                "max": 400
                            },
                            "heavy": {
                                "min": 400,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4-8 hours",
                "onset": "15-60 minutes",
                "peak": "1.5-3 hours",
                "offset": "3-6 hours",
                "after_effects": "Up to 24 hours (residual effects possible)"
            },
            "addiction_potential": "Moderate. Psychological dependence is possible, especially with frequent recreational use. Physical dependence is rare but possible with chronic high-dose use.",
            "interactions": {
                "dangerous": [
                    "MAOIs",
                    "SSRIs",
                    "other serotonergic drugs (risk of serotonin syndrome)"
                ],
                "unsafe": ["Alcohol", "other CNS depressants"],
                "caution": ["Stimulants", "other dissociatives"]
            },
            "notes": "DXM is commonly found in over-the-counter cough syrups and cold medications. Recreational use can result in dose-dependent dissociative and hallucinogenic effects. High doses can cause serious health risks, including serotonin syndrome, liver toxicity (especially with combination products), and dangerous interactions with other drugs. Products containing acetaminophen, chlorpheniramine, or other active ingredients can be especially hazardous at recreational doses.",
            "subjective_effects": [
                "Dissociation",
                "Euphoria",
                "Altered time perception",
                "Visual distortions",
                "Auditory distortions",
                "Confusion",
                "Nausea",
                "Ataxia (loss of coordination)",
                "Hallucinations (at higher doses)",
                "Sedation",
                "Cognitive impairment"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (within days)",
                "half_tolerance": "~1-2 weeks",
                "zero_tolerance": "~3-4 weeks",
                "cross_tolerances": [
                    "Other dissociatives (e.g., ketamine, PCP)"
                ]
            },
            "half_life": "2-4 hours (parent compound); active metabolite dextrorphan: 3-6 hours",
            "citations": [
                {
                    "name": "Erowid DXM General Info",
                    "reference": "https://www.erowid.org/chemicals/dxm/faq/dxm_general_info.shtml"
                },
                {
                    "name": "Erowid DXM Dosage",
                    "reference": "https://www.erowid.org/chemicals/dxm/dxm_dose.shtml"
                },
                {
                    "name": "DrugBank: Dextromethorphan",
                    "reference": "https://go.drugbank.com/drugs/DB00514"
                }
            ],
            "categories": [
                "dissociative",
                "research-chemical",
                "habit-forming"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Dextromethorphan Hydrobromide (DXM HBr)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Academic literature and user experience reports (2023), excluding PsychonautWiki sources.",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 8,
                            "iso": ["PT4H", "PT8H"],
                            "note": "Shorter and more intense than oral; variability exists due to dosage and individual metabolism."
                        },
                        "onset": {
                            "start": 0.25,
                            "end": 1,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 1.5,
                            "end": 3,
                            "iso_start": ["PT1H30M"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 3,
                            "end": 6,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT6H"]
                        },
                        "after_effects": {
                            "start": 6,
                            "end": 24,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 94,
        "title": "4-Methylmethylphenidate (4-Me-TMP)",
        "content": "",
        "drug_info": {
            "drug_name": "4-Methylmethylphenidate (4-Me-TMP)",
            "search_url": "https://drugusersbible.org/content/chemscape/stimulants/4-me-tmp/index.html",
            "chemical_class": "Phenidate (piperidine-based stimulant)",
            "psychoactive_class": "Stimulant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "10 mg",
                            "light": "25 mg+",
                            "common": "40 mg+",
                            "strong": "60 mg+",
                            "heavy": "90 mg+"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 25
                            },
                            "common": {
                                "min": 25,
                                "max": 50
                            },
                            "strong": {
                                "min": 50,
                                "max": 80
                            },
                            "heavy": {
                                "min": 80,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "~6 hours",
                "onset": "~30 minutes",
                "peak": "1-3 hours",
                "offset": "2-3 hours",
                "after_effects": "Mild, may last several hours"
            },
            "addiction_potential": "Likely similar to other phenidate stimulants; potential for psychological dependence, especially with frequent use or high doses.",
            "interactions": {
                "dangerous": ["MAOIs", "other stimulants"],
                "unsafe": ["high doses of serotonergic drugs"],
                "caution": [
                    "alcohol",
                    "benzodiazepines",
                    "other CNS depressants"
                ]
            },
            "notes": "4-Me-TMP is a research chemical stimulant structurally related to methylphenidate. It was briefly available on the market after the UK ban on ethylphenidate and other phenidates. Reports suggest it is less potent than methylphenidate, with a functional, EPH-like stimulation and limited recreational value for most users. Some have reported a recreational edge at higher doses. Little is known about its long-term safety profile.",
            "subjective_effects": [
                "Functional stimulation",
                "Increased focus",
                "Mild euphoria (rare, high doses)",
                "Appetite suppression",
                "Mild cardiovascular stimulation",
                "Insomnia (dose-dependent)",
                "Redosing tendency"
            ],
            "tolerance": {
                "full_tolerance": "Several days of repeated use",
                "half_tolerance": "3-7 days",
                "zero_tolerance": "1-2 weeks",
                "cross_tolerances": ["methylphenidate", "other phenidates"]
            },
            "half_life": "Estimated 2-4 hours (not well-studied)",
            "citations": [
                {
                    "name": "Drug Users Bible: 4-Me-TMP",
                    "reference": "https://drugusersbible.org/content/chemscape/stimulants/4-me-tmp/index.html"
                },
                {
                    "name": "TripSit Factsheet: 4-Methylmethylphenidate",
                    "reference": "https://tripsit.me/factsheets/4-methylmethylphenidate"
                },
                {
                    "name": "Bluelight: New Stimulant 4-Methylmethylphenidate (4-Me-TMP)",
                    "reference": "https://www.bluelight.org/community/threads/new-stimulant-4-methylmethylphenidate-4-me-tmp.754669/"
                }
            ],
            "categories": ["stimulant", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "4-Methylmethylphenidate (4-Me-TMP)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "4-Methylmethylphenidate: Limited clinical and user report data; approximate values synthesized from structurally similar stimulants (e.g., methylphenidate derivatives) and available anecdotal evidence from harm reduction communities (as of mid-2024).",
                        "units": "hours",
                        "total_duration": {
                            "min": 5,
                            "max": 7,
                            "iso": ["PT5H", "PT7H"],
                            "note": "Reported durations are approximate, varies with dose, prior use, and individual sensitivity."
                        },
                        "onset": {
                            "start": 0.25,
                            "end": 0.5,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT30M"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 3,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 3,
                            "end": 6,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT6H"]
                        },
                        "after_effects": {
                            "start": 6,
                            "end": 10,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT10H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 95,
        "title": "Ketamine",
        "content": "",
        "drug_info": {
            "drug_name": "Ketamine",
            "search_url": "https://go.drugbank.com/drugs/DB01221",
            "chemical_class": "Arylcyclohexylamine (phencyclidine derivative)",
            "psychoactive_class": "Dissociative anesthetic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "10 mg",
                            "light": "25-50 mg",
                            "common": "50-100 mg",
                            "strong": "100-200 mg",
                            "heavy": "200+ mg"
                        }
                    },
                    {
                        "route": "intranasal",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "15-30 mg",
                            "common": "30-75 mg",
                            "strong": "75-125 mg",
                            "heavy": "125+ mg"
                        }
                    },
                    {
                        "route": "intramuscular",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "15-30 mg",
                            "common": "30-60 mg",
                            "strong": "60-100 mg",
                            "heavy": "100+ mg"
                        }
                    },
                    {
                        "route": "intravenous",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "10-20 mg",
                            "common": "20-60 mg",
                            "strong": "60-100 mg",
                            "heavy": "100+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 10,
                                "max": 25
                            },
                            "light": {
                                "min": 25,
                                "max": 50
                            },
                            "common": {
                                "min": 50,
                                "max": 100
                            },
                            "strong": {
                                "min": 100,
                                "max": 200
                            },
                            "heavy": {
                                "min": 200,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "intranasal",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 15
                            },
                            "light": {
                                "min": 15,
                                "max": 30
                            },
                            "common": {
                                "min": 30,
                                "max": 75
                            },
                            "strong": {
                                "min": 75,
                                "max": 125
                            },
                            "heavy": {
                                "min": 125,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "intramuscular",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 15
                            },
                            "light": {
                                "min": 15,
                                "max": 30
                            },
                            "common": {
                                "min": 30,
                                "max": 60
                            },
                            "strong": {
                                "min": 60,
                                "max": 100
                            },
                            "heavy": {
                                "min": 100,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "intravenous",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 25
                            },
                            "common": {
                                "min": 25,
                                "max": 60
                            },
                            "strong": {
                                "min": 60,
                                "max": 100
                            },
                            "heavy": {
                                "min": 100,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "1-2 hours (recreational); up to 4-6 hours (medical)",
                "onset": "1-5 minutes (IV/IM); 5-15 minutes (intranasal); 15-30 minutes (oral)",
                "peak": "20-60 minutes",
                "offset": "1-2 hours",
                "after_effects": "1-3 hours (residual effects, grogginess)"
            },
            "addiction_potential": "Moderate. Ketamine can be habit-forming, especially with frequent recreational use. Psychological dependence is more common than physical dependence.",
            "interactions": {
                "dangerous": [
                    "Other dissociatives (e.g., PCP, DXM)",
                    "Alcohol (increased risk of respiratory depression, blackouts)"
                ],
                "unsafe": [
                    "Benzodiazepines (may increase risk of respiratory depression)",
                    "Opioids (increased risk of respiratory depression)"
                ],
                "caution": [
                    "Stimulants (increased cardiovascular risk)",
                    "MAOIs (potential for unpredictable interactions)"
                ]
            },
            "notes": "Ketamine is used medically as an anesthetic and analgesic, especially in trauma and emergency settings. Recreational use can lead to bladder and urinary tract issues (ketamine bladder syndrome) and cognitive impairment with chronic use. It is also being studied and used off-label for treatment-resistant depression (as esketamine).",
            "subjective_effects": [
                "Dissociation",
                "Analgesia",
                "Euphoria",
                "Hallucinations (visual and auditory)",
                "Altered sense of time and space",
                "Sedation",
                "Amnesia",
                "Out-of-body experiences",
                "Motor impairment"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (days to weeks)",
                "half_tolerance": "3-7 days",
                "zero_tolerance": "1-2 weeks after cessation",
                "cross_tolerances": ["Other dissociatives (e.g., PCP, DXM)"]
            },
            "half_life": "2-4 hours (varies by route and individual)",
            "citations": [
                {
                    "name": "DrugBank: Ketamine",
                    "reference": "https://go.drugbank.com/drugs/DB01221"
                },
                {
                    "name": "DrugWise: Ketamine",
                    "reference": "https://www.drugwise.org.uk/ketamine/"
                },
                {
                    "name": "DrugBank Article: Ketamine as an anesthetic",
                    "reference": "https://go.drugbank.com/articles/A2187"
                }
            ],
            "categories": [
                "dissociative",
                "psychedelic",
                "research-chemical",
                "habit-forming",
                "hallucinogen",
                "depressant"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Ketamine",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Academic literature and user reports indicate that recreational insufflated ketamine has a rapid onset and brief but intense peak, with a quick return to baseline and some residual effects. See: Lauretti, G.R. (2017). Ketamine: an update for the pain and palliative care specialist. Brazilian Journal of Anesthesiology; and various clinical usage guidelines.",
                        "units": "hours",
                        "total_duration": {
                            "min": 1,
                            "max": 2,
                            "iso": ["PT1H", "PT2H"],
                            "note": "Acute psychoactive effects last 1-2 hours when insufflated; medical (anesthesia-level) effects last longer."
                        },
                        "onset": {
                            "start": 0.08,
                            "end": 0.25,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT15M"]
                        },
                        "peak": {
                            "start": 0.33,
                            "end": 1,
                            "iso_start": ["PT20M"],
                            "iso_end": ["PT1H"]
                        },
                        "offset": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        },
                        "after_effects": {
                            "start": 2,
                            "end": 3,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT3H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 97,
        "title": "Fentanyl",
        "content": "",
        "drug_info": {
            "drug_name": "Fentanyl",
            "search_url": "https://go.drugbank.com/drugs/DB00813",
            "chemical_class": "Phenylpiperidine opioid",
            "psychoactive_class": "Opioid analgesic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "0.01 mg (10 \u00b5g)",
                            "light": "0.025-0.05 mg (25-50 \u00b5g)",
                            "common": "0.05-0.1 mg (50-100 \u00b5g)",
                            "strong": "0.1-0.2 mg (100-200 \u00b5g)",
                            "heavy": "200+ \u00b5g"
                        }
                    },
                    {
                        "route": "IV",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "0.005 mg (5 \u00b5g)",
                            "light": "0.01-0.025 mg (10-25 \u00b5g)",
                            "common": "0.025-0.05 mg (25-50 \u00b5g)",
                            "strong": "0.05-0.1 mg (50-100 \u00b5g)",
                            "heavy": "100+ \u00b5g"
                        }
                    },
                    {
                        "route": "transdermal",
                        "units": "mcg/hr (patch)",
                        "dose_ranges": {
                            "threshold": "12 mcg/hr",
                            "light": "12-25 mcg/hr",
                            "common": "25-50 mcg/hr",
                            "strong": "50-100 mcg/hr",
                            "heavy": "100+ mcg/hr"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.01,
                                "max": 0.025
                            },
                            "light": {
                                "min": 0.025,
                                "max": 0.05
                            },
                            "common": {
                                "min": 0.05,
                                "max": 0.1
                            },
                            "strong": {
                                "min": 0.1,
                                "max": 0.2
                            },
                            "heavy": {
                                "min": 0.2,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "intravenous",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.005,
                                "max": 0.01
                            },
                            "light": {
                                "min": 0.01,
                                "max": 0.025
                            },
                            "common": {
                                "min": 0.025,
                                "max": 0.05
                            },
                            "strong": {
                                "min": 0.05,
                                "max": 0.1
                            },
                            "heavy": {
                                "min": 0.1,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "transdermal",
                        "units": "ug",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 12
                            },
                            "light": {
                                "min": 12,
                                "max": 25
                            },
                            "common": {
                                "min": 25,
                                "max": 50
                            },
                            "strong": {
                                "min": 50,
                                "max": 100
                            },
                            "heavy": {
                                "min": 100,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "1-4 hours (IV/IM); 24-72 hours (transdermal patch)",
                "onset": "Seconds to minutes (IV/IM); 6-12 hours (patch)",
                "peak": "Minutes (IV/IM); 12-24 hours (patch)",
                "offset": "1-2 hours (IV/IM); 12-24 hours (patch)",
                "after_effects": "Residual sedation may persist for several hours"
            },
            "addiction_potential": "Very high. Fentanyl is highly addictive with a significant risk of dependence, overdose, and death, especially when used outside medical supervision.",
            "interactions": {
                "dangerous": [
                    "Other opioids",
                    "Benzodiazepines",
                    "Alcohol",
                    "Barbiturates",
                    "MAOIs"
                ],
                "unsafe": ["Gabapentinoids", "Muscle relaxants"],
                "caution": [
                    "Antidepressants",
                    "Antipsychotics",
                    "Antihistamines"
                ]
            },
            "notes": "Fentanyl is extremely potent (about 50-100x morphine). Overdose risk is high, especially with illicit or unknown dosages. Illicit fentanyl is a major driver of opioid overdose deaths. Naloxone can reverse fentanyl overdose but may require higher/multiple doses. Use only as prescribed and avoid mixing with other CNS depressants.",
            "subjective_effects": [
                "Euphoria",
                "Pain relief",
                "Sedation",
                "Respiratory depression",
                "Constipation",
                "Nausea",
                "Itching",
                "Drowsiness",
                "Confusion",
                "Pinpoint pupils"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (days to weeks)",
                "half_tolerance": "~3-7 days after cessation",
                "zero_tolerance": "1-2 weeks after cessation",
                "cross_tolerances": [
                    "Other opioids (e.g., morphine, heroin, oxycodone)"
                ]
            },
            "half_life": "3-12 hours (varies by route and individual)",
            "citations": [
                {
                    "name": "DrugBank: Fentanyl",
                    "reference": "https://go.drugbank.com/drugs/DB00813"
                },
                {
                    "name": "DrugWise: Fentanyl DrugWatch",
                    "reference": "https://www.drugwise.org.uk/wp-content/uploads/Fentanyl_DrugWatch.pdf"
                }
            ],
            "categories": ["opioid", "depressant", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Fentanyl",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Peer-reviewed literature and clinical resources on fentanyl pharmacokinetics and pharmacodynamics (insufflated route extrapolated from clinical and case report evidence, e.g. 'Fentanyl: clinical use and new patterns of abuse' [Stanley, 2014]).",
                        "units": "hours",
                        "total_duration": {
                            "min": 1,
                            "max": 4,
                            "iso": ["PT1H", "PT4H"],
                            "note": "Duration is generally similar to IV due to high bioavailability and rapid CNS penetration; onset and duration may have more variability than IV."
                        },
                        "onset": {
                            "start": 0.05,
                            "end": 0.25,
                            "iso_start": ["PT3M"],
                            "iso_end": ["PT15M"]
                        },
                        "peak": {
                            "start": 0.17,
                            "end": 1,
                            "iso_start": ["PT10M"],
                            "iso_end": ["PT1H"]
                        },
                        "offset": {
                            "start": 1,
                            "end": 4,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT4H"]
                        },
                        "after_effects": {
                            "start": 4,
                            "end": 8,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT8H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 99,
        "title": "Cyclazodone",
        "content": "",
        "drug_info": {
            "drug_name": "Cyclazodone",
            "search_url": "https://en.wikipedia.org/wiki/Cyclazodone",
            "chemical_class": "Oxazolone (related to pemoline and 4-methylaminorex)",
            "psychoactive_class": "Stimulant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "5-15 mg",
                            "common": "15-25 mg",
                            "strong": "25-40 mg",
                            "heavy": "40 mg+"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 15
                            },
                            "common": {
                                "min": 15,
                                "max": 25
                            },
                            "strong": {
                                "min": 25,
                                "max": 40
                            },
                            "heavy": {
                                "min": 40,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "5-7 hours",
                "onset": "20-45 minutes",
                "peak": "Not specified",
                "offset": "Not specified",
                "after_effects": "Not specified"
            },
            "addiction_potential": "Potential for psychological dependence, similar to other stimulants. Reports suggest less abuse potential than amphetamines, but caution is advised.",
            "interactions": {
                "dangerous": ["Other stimulants", "MAOIs"],
                "unsafe": ["High doses may increase risk of liver toxicity"],
                "caution": ["Alcohol", "CNS depressants"]
            },
            "notes": "Cyclazodone is a centrally acting stimulant related to pemoline and 4-methylaminorex. It is reported to have a more favorable therapeutic index and margin of safety than amphetamines and pemoline, with less cardio- and hepatotoxicity. However, liver damage may result from heavy or sustained usage. Used off-label by some for ADHD and as a functional stimulant. Long-term safety is not well established.",
            "subjective_effects": [
                "Increased focus",
                "Wakefulness",
                "Motivation",
                "Mild euphoria",
                "Appetite suppression",
                "Increased energy"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with frequent use (days to weeks)",
                "half_tolerance": "Several days to a week after cessation",
                "zero_tolerance": "1-2 weeks after cessation",
                "cross_tolerances": [
                    "Other stimulants (e.g., amphetamines, methylphenidate)"
                ]
            },
            "half_life": "Not precisely established; estimated to be similar to pemoline (approx. 7-12 hours)",
            "citations": [
                {
                    "name": "Cyclazodone Megathread - Bluelight",
                    "reference": "https://www.bluelight.org/community/threads/cyclazodone-megathread.876178/"
                },
                {
                    "name": "Cyclazodone Experience Report - Erowid",
                    "reference": "https://erowid.org/experiences/exp.php?ID=115371"
                },
                {
                    "name": "Cyclazodone Discussion - Bluelight",
                    "reference": "https://www.bluelight.org/community/threads/cyclazodone.498033/"
                },
                {
                    "name": "Cyclazodone Safety Discussion - Bluelight",
                    "reference": "https://www.bluelight.org/community/threads/cyclazodone.889257/"
                }
            ],
            "categories": ["stimulant", "research-chemical", "nootropic"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Cyclazodone",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Cyclazodone durations are derived from analysis of available user reports and pharmacological estimates due to limited formal studies. See anecdotal data on nootropic and research chemical forums (2023-2024).",
                        "units": "hours",
                        "total_duration": {
                            "min": 5,
                            "max": 7,
                            "iso": ["PT5H", "PT7H"],
                            "note": "Range based on typical user experiences. Individual responses may vary."
                        },
                        "onset": {
                            "start": 0.33,
                            "end": 0.75,
                            "iso_start": ["PT20M"],
                            "iso_end": ["PT45M"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 3,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 3,
                            "end": 5,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT5H"]
                        },
                        "after_effects": {
                            "start": 5,
                            "end": 10,
                            "iso_start": ["PT5H"],
                            "iso_end": ["PT10H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 101,
        "title": "Pyrazolam",
        "content": "",
        "drug_info": {
            "drug_name": "Pyrazolam",
            "search_url": "https://tripsit.me/factsheets/pyrazolam",
            "chemical_class": "Benzodiazepine",
            "psychoactive_class": "Depressant, Anxiolytic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "0.25 mg",
                            "light": "0.5 - 1 mg",
                            "common": "1 - 2 mg",
                            "strong": "2 - 3 mg",
                            "heavy": "3+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.25,
                                "max": 0.5
                            },
                            "light": {
                                "min": 0.5,
                                "max": 1
                            },
                            "common": {
                                "min": 1,
                                "max": 2
                            },
                            "strong": {
                                "min": 2,
                                "max": 3
                            },
                            "heavy": {
                                "min": 3,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "6 hours",
                "onset": "15 minutes",
                "peak": "1 - 3 hours",
                "offset": "4 - 6 hours",
                "after_effects": "Minimal"
            },
            "addiction_potential": "As with other benzodiazepines, pyrazolam has the potential for physical and psychological dependence, especially with regular or high-dose use. Lower doses (0.5 - 1 mg) are less likely to be physically addictive, but risk increases with frequency and dose.",
            "interactions": {
                "dangerous": [
                    "Other CNS depressants (e.g., alcohol, opioids, barbiturates, other benzodiazepines)"
                ],
                "unsafe": ["Baclofen (increases CNS depression)"],
                "caution": [
                    "Other sedatives, muscle relaxants, anticholinergics"
                ]
            },
            "notes": "Pyrazolam is notable for its anxiolytic effects without significant sedation or drowsiness, making it more functional than many other benzodiazepines. It was developed in the 1970s but only became available on the research chemical market in the 2010s. It is illegal in several jurisdictions, including the UK. It is not typically used as a hypnotic or sleep aid. Overdose or misuse can lead to typical benzodiazepine risks: respiratory depression, amnesia, and impaired coordination.",
            "subjective_effects": [
                "Anxiolysis (reduced anxiety)",
                "Calmness",
                "Mild muscle relaxation",
                "Minimal sedation",
                "Impaired coordination at higher doses",
                "Reduced social anxiety"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (days to weeks)",
                "half_tolerance": "~1-2 weeks after cessation",
                "zero_tolerance": "~3-4 weeks after cessation",
                "cross_tolerances": ["Other benzodiazepines"]
            },
            "half_life": "~17 hours",
            "citations": [
                {
                    "name": "TripSit Factsheet: Pyrazolam",
                    "reference": "https://tripsit.me/factsheets/pyrazolam"
                },
                {
                    "name": "Drug Users Bible: Pyrazolam",
                    "reference": "https://drugusersbible.org/content/chemscape/anxiolytics_and_sedatives/pyrazolam/"
                },
                {
                    "name": "DrugBank: Pyrazolam Interactions",
                    "reference": "https://go.drugbank.com/drugs/DB14718"
                }
            ],
            "categories": ["depressant", "antidepressant", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Pyrazolam",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Hindmarch, I., et al. (2012). Pyrazolam: pharmacology and experience reports. Literature review and summary of user reports as of 2023.",
                        "units": "hours",
                        "total_duration": {
                            "min": 5.5,
                            "max": 7,
                            "iso": ["PT5H30M", "PT7H"],
                            "note": "Reported total effect period, including fading offset."
                        },
                        "onset": {
                            "start": 0.15,
                            "end": 0.5,
                            "iso_start": ["PT9M"],
                            "iso_end": ["PT30M"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 3,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 4,
                            "end": 6,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT6H"]
                        },
                        "after_effects": {
                            "start": 6,
                            "end": 8,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT8H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 102,
        "title": "4-AcO-DMT (O-Acetylpsilocin)",
        "content": "",
        "drug_info": {
            "drug_name": "4-AcO-DMT (O-Acetylpsilocin)",
            "search_url": "https://www.erowid.org/chemicals/4_acetoxy_dmt/4_acetoxy_dmt.shtml",
            "chemical_class": "Tryptamine",
            "psychoactive_class": "Psychedelic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2.5-5 mg",
                            "light": "5-10 mg",
                            "common": "10-25 mg",
                            "strong": "25-40 mg",
                            "heavy": "40-50+ mg"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2.5-5 mg",
                            "light": "5-10 mg",
                            "common": "10-25 mg",
                            "strong": "25-40 mg",
                            "heavy": "40-50+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2.5,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 10
                            },
                            "common": {
                                "min": 10,
                                "max": 25
                            },
                            "strong": {
                                "min": 25,
                                "max": 40
                            },
                            "heavy": {
                                "min": 40,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2.5,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 10
                            },
                            "common": {
                                "min": 10,
                                "max": 25
                            },
                            "strong": {
                                "min": 25,
                                "max": 40
                            },
                            "heavy": {
                                "min": 40,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4-8 hours",
                "onset": "20-45 minutes (oral), up to 2 hours reported",
                "peak": "3-4 hours",
                "offset": "2-4 hours (after-effects)",
                "after_effects": "2-4 hours"
            },
            "addiction_potential": "Low; not considered physically addictive, but psychological habituation is possible with frequent use.",
            "interactions": {
                "dangerous": ["MAOIs (risk of serotonin syndrome)"],
                "unsafe": [
                    "Other serotonergic drugs (SSRIs, SNRIs, other psychedelics)"
                ],
                "caution": [
                    "Cannabis (may potentiate effects)",
                    "Stimulants (increased anxiety risk)"
                ]
            },
            "notes": "4-AcO-DMT is a synthetic psychedelic closely related to psilocybin and psilocin. It is likely metabolized into psilocin in the body, producing similar effects to psilocybin mushrooms, though some users report a 'warmer' or more euphoric experience. Effects can be highly variable between individuals. Start with low doses to assess sensitivity. Physically well-tolerated, but high doses can be mentally overwhelming. Powder form is most common. Duration and onset may be faster and shorter than mushrooms. Not recommended for those with a personal or family history of psychosis.",
            "subjective_effects": [
                "Visual distortions",
                "Enhanced colors",
                "Euphoria",
                "Emotional release",
                "Altered thought patterns",
                "Time distortion",
                "Synesthesia",
                "Mild body load",
                "Tracers",
                "Spiritual or mystical experiences"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (within days)",
                "half_tolerance": "~3-7 days",
                "zero_tolerance": "~2 weeks",
                "cross_tolerances": [
                    "Psilocybin",
                    "Psilocin",
                    "Other serotonergic psychedelics"
                ]
            },
            "half_life": "Not well established; likely similar to psilocin (1-3 hours)",
            "citations": [
                {
                    "name": "Erowid 4-AcO-DMT Basics",
                    "reference": "https://www.erowid.org/chemicals/4_acetoxy_dmt/4_acetoxy_dmt_basics.shtml"
                },
                {
                    "name": "TripSit Factsheet: 4-AcO-DMT",
                    "reference": "https://tripsit.me/factsheets/4-aco-dmt"
                },
                {
                    "name": "Drug Users Bible: 4-AcO-DMT",
                    "reference": "http://drugusersbible.org/content/chemscape/psychedelics/4-aco-dmt/index.html"
                },
                {
                    "name": "TripSit Wiki: 4-AcO-DMT",
                    "reference": "https://wiki.tripsit.me/index.php?title=4-AcO-DMT&mobileaction=toggle_view_desktop"
                }
            ],
            "categories": ["psychedelic", "research-chemical", "hallucinogen"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "4-AcO-DMT (O-Acetylpsilocin)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Erowid, academic literature, and user experience reports relevant to 4-AcO-DMT (O-Acetylpsilocin), insufflated route.",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 8,
                            "iso": ["PT4H", "PT8H"],
                            "note": "Insufflation onset is generally faster than oral, with comparable or slightly shorter total duration."
                        },
                        "onset": {
                            "start": 0.1,
                            "end": 0.75,
                            "iso_start": ["PT6M"],
                            "iso_end": ["PT45M"]
                        },
                        "peak": {
                            "start": 0.75,
                            "end": 3.5,
                            "iso_start": ["PT45M"],
                            "iso_end": ["PT3H30M"]
                        },
                        "offset": {
                            "start": 3.5,
                            "end": 6,
                            "iso_start": ["PT3H30M"],
                            "iso_end": ["PT6H"]
                        },
                        "after_effects": {
                            "start": 6,
                            "end": 8,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT8H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 103,
        "title": "Clobromazolam (Phenazolam)",
        "content": "",
        "drug_info": {
            "drug_name": "Clobromazolam (Phenazolam)",
            "search_url": "https://www.bluelight.org/community/threads/anyone-have-any-experience-with-clobromazolam-phenazolam-they-are-the-same-benzo-from-what-i-can-tell.943555/",
            "chemical_class": "Benzodiazepine",
            "psychoactive_class": "Depressant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "<0.1 mg",
                            "light": "0.1 - 0.2 mg",
                            "common": "0.2 - 0.5 mg",
                            "strong": "0.5 - 1 mg",
                            "heavy": "1+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.05,
                                "max": 0.1
                            },
                            "light": {
                                "min": 0.1,
                                "max": 0.2
                            },
                            "common": {
                                "min": 0.2,
                                "max": 0.5
                            },
                            "strong": {
                                "min": 0.5,
                                "max": 1
                            },
                            "heavy": {
                                "min": 1,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "8 - 16 hours (estimated)",
                "onset": "20 - 60 minutes (estimated)",
                "peak": "1 - 4 hours (estimated)",
                "offset": "6 - 12 hours (estimated)",
                "after_effects": "12 - 24 hours (residual sedation possible)"
            },
            "addiction_potential": "High. As with most potent benzodiazepines, there is a significant risk of dependence, withdrawal, and abuse, especially with repeated or high-dose use.",
            "interactions": {
                "dangerous": [
                    "alcohol",
                    "opioids",
                    "barbiturates",
                    "other CNS depressants"
                ],
                "unsafe": ["antipsychotics", "muscle relaxants"],
                "caution": ["other benzodiazepines", "sedating antihistamines"]
            },
            "notes": "Clobromazolam (also known as Phenazolam) is a highly potent research chemical benzodiazepine. It is not approved for medical use and is primarily encountered in the grey market. Users report strong sedative, anxiolytic, and amnesic effects. Overdose risk is significant due to its potency and long duration. Sudden cessation after repeated use can result in severe withdrawal symptoms. Use with other depressants can be fatal.",
            "subjective_effects": [
                "Strong sedation",
                "Muscle relaxation",
                "Anxiolysis (anxiety reduction)",
                "Amnesia",
                "Impaired motor coordination",
                "Euphoria (occasionally)",
                "Cognitive impairment",
                "Disinhibition"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (days to weeks)",
                "half_tolerance": "~1-2 weeks after cessation",
                "zero_tolerance": "~3-4 weeks after cessation",
                "cross_tolerances": ["Other benzodiazepines", "Z-drugs"]
            },
            "half_life": "Estimated 10-20 hours (no formal studies; based on similar compounds)",
            "citations": [
                {
                    "name": "Bluelight - Clobromazolam/Phenazolam experience thread",
                    "reference": "https://www.bluelight.org/community/threads/anyone-have-any-experience-with-clobromazolam-phenazolam-they-are-the-same-benzo-from-what-i-can-tell.943555/"
                },
                {
                    "name": "Bluelight - Why was phenazolam/clobromazolam never released?",
                    "reference": "https://www.bluelight.org/community/threads/why-was-phenazolam-clobromazolam-never-released.930330/"
                }
            ],
            "categories": [
                "depressant",
                "benzodiazepine",
                "research-chemical",
                "habit-forming"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Clobromazolam (Phenazolam)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "C. G. Pitt et al., 'Clobromazolam: A Potent Triazolobenzodiazepine with Designer Benzodiazepine Market Presence', Drug Testing and Analysis, 2022; anecdotal reports (Reddit, Bluelight, relevant forums, as of 2024)",
                        "units": "hours",
                        "total_duration": {
                            "min": 8,
                            "max": 16,
                            "iso": ["PT8H", "PT16H"],
                            "note": "Estimates based on structural similarity to other triazolobenzodiazepines and available user reports."
                        },
                        "onset": {
                            "start": 0.33,
                            "end": 1,
                            "iso_start": ["PT20M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 4,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT4H"]
                        },
                        "offset": {
                            "start": 6,
                            "end": 12,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT12H"]
                        },
                        "after_effects": {
                            "start": 12,
                            "end": 24,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 104,
        "title": "alpha-PiHP",
        "content": "",
        "drug_info": {
            "drug_name": "alpha-PiHP (A-PiHP)",
            "search_url": "https://drugusersbible.org/content/chemscape/stimulants/a-php/",
            "chemical_class": "Cathinone (substituted cathinone, pyrrolidinophenone)",
            "psychoactive_class": "Stimulant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "3-5mg",
                            "light": "5-15mg",
                            "common": "15-30mg",
                            "strong": "30-50mg",
                            "heavy": "50mg+"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "1-3mg",
                            "light": "3-10mg",
                            "common": "10-25mg",
                            "strong": "25-40mg",
                            "heavy": "40mg+"
                        }
                    },
                    {
                        "route": "vaporized",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "1-2mg",
                            "light": "2-10mg",
                            "common": "10-20mg",
                            "strong": "20-30mg",
                            "heavy": "30mg+"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 3,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 15
                            },
                            "common": {
                                "min": 15,
                                "max": 30
                            },
                            "strong": {
                                "min": 30,
                                "max": 50
                            },
                            "heavy": {
                                "min": 50,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 1,
                                "max": 3
                            },
                            "light": {
                                "min": 3,
                                "max": 10
                            },
                            "common": {
                                "min": 10,
                                "max": 25
                            },
                            "strong": {
                                "min": 25,
                                "max": 40
                            },
                            "heavy": {
                                "min": 40,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "vaporized",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 1,
                                "max": 2
                            },
                            "light": {
                                "min": 2,
                                "max": 10
                            },
                            "common": {
                                "min": 10,
                                "max": 20
                            },
                            "strong": {
                                "min": 20,
                                "max": 30
                            },
                            "heavy": {
                                "min": 30,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "1-5 hours (depending on route)",
                "onset": "Oral: 30-60 min; Insufflated: 1-2 min; Vaporized: 1 min",
                "peak": "Varies, typically within first 1-2 hours",
                "offset": "Oral: 2-5 hours; Insufflated: 2-4 hours; Vaporized: 1-3 hours",
                "after_effects": "6-12 hours (comedown, residual stimulation, insomnia possible)"
            },
            "addiction_potential": "High. \u03b1-PiHP is reported to have a strong craving and high psychological addiction potential, similar to other pyrrolidinophenone cathinones like \u03b1-PVP. Users unfamiliar with potent stimulants may be overwhelmed.",
            "interactions": {
                "dangerous": [
                    "MAOIs",
                    "other stimulants (e.g., amphetamines, cocaine)",
                    "serotonergic drugs (risk of serotonin syndrome)"
                ],
                "unsafe": [
                    "alcohol (increased cardiovascular risk)",
                    "antidepressants (especially SNRIs, TCAs)"
                ],
                "caution": [
                    "benzodiazepines (may mask stimulant effects, risk of polydrug use)"
                ]
            },
            "notes": "\u03b1-PiHP is a potent synthetic stimulant and a homologue of \u03b1-PVP, with an extra carbon in its alkyl side chain. It is often sold as a white or off-white powder and is typically used by oral, insufflated, or vaporized routes. The body load is often described as unpleasant at higher doses, and adverse psychological effects such as paranoia, anxiety, and psychosis are possible. Overdose risk is significant, especially with vaporization due to rapid onset. Harm reduction practices are strongly recommended.",
            "subjective_effects": [
                "Euphoria",
                "Increased energy",
                "Enhanced focus",
                "Increased sociability",
                "Craving for redosing",
                "Paranoia",
                "Anxiety",
                "Agitation",
                "Insomnia",
                "Increased heart rate",
                "Increased blood pressure",
                "Sweating",
                "Appetite suppression",
                "Possible psychosis at high doses"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (days)",
                "half_tolerance": "~3-7 days",
                "zero_tolerance": "1-2 weeks (highly variable)",
                "cross_tolerances": [
                    "Other cathinones (e.g., \u03b1-PVP, MDPV)"
                ]
            },
            "half_life": "Likely 2-5 hours (not well-studied, but similar to related compounds)",
            "citations": [
                {
                    "name": "The Drug Users Bible \u2013 \u03b1-PHP",
                    "reference": "https://drugusersbible.org/content/chemscape/stimulants/a-php/"
                },
                {
                    "name": "Bluelight \u2013 \u03b1-PiHP Thread",
                    "reference": "https://www.bluelight.org/community/threads/%CE%B1-phip-thread.902999/"
                },
                {
                    "name": "Erowid \u2013 alpha-PHP Experiences",
                    "reference": "https://erowid.org/experiences/subs/exp_alphaPHP.shtml"
                }
            ],
            "categories": ["stimulant", "research-chemical", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "alpha-PiHP (A-PiHP)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Experience reports, review articles, and academic literature on substituted cathinones (alpha-PiHP) via insufflated route. Key references include recent surveys and user forums as of 2023.",
                        "units": "hours",
                        "total_duration": {
                            "min": 1,
                            "max": 4,
                            "iso": ["PT1H", "PT4H"],
                            "note": "Total psychoactive effects for insufflated route are generally within this range, though rare longer durations are reported."
                        },
                        "onset": {
                            "start": 0.02,
                            "end": 0.04,
                            "iso_start": ["PT1M"],
                            "iso_end": ["PT2M"]
                        },
                        "peak": {
                            "start": 0.1,
                            "end": 1,
                            "iso_start": ["PT6M"],
                            "iso_end": ["PT1H"]
                        },
                        "offset": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "after_effects": {
                            "start": 4,
                            "end": 12,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT12H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 105,
        "title": "Chlorpheniramine Maleate (CPM)",
        "content": "",
        "drug_info": {
            "drug_name": "Chlorpheniramine Maleate (CPM)",
            "search_url": "https://go.drugbank.com/drugs/DB01114",
            "chemical_class": "Alkylamine (subclass of first-generation antihistamines)",
            "psychoactive_class": "Antihistamine (H1 receptor antagonist); Deliriant at high doses",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "1 mg",
                            "light": "2-4 mg",
                            "common": "4-8 mg",
                            "strong": "8-16 mg",
                            "heavy": "16+ mg (not recommended)"
                        }
                    },
                    {
                        "route": "IV",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "0.5 mg",
                            "light": "1-2 mg",
                            "common": "2-4 mg",
                            "strong": "4-8 mg",
                            "heavy": "8+ mg (not recommended)"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 1,
                                "max": 2
                            },
                            "light": {
                                "min": 2,
                                "max": 4
                            },
                            "common": {
                                "min": 4,
                                "max": 8
                            },
                            "strong": {
                                "min": 8,
                                "max": 16
                            },
                            "heavy": {
                                "min": 16,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "intravenous",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.5,
                                "max": 1
                            },
                            "light": {
                                "min": 1,
                                "max": 2
                            },
                            "common": {
                                "min": 2,
                                "max": 4
                            },
                            "strong": {
                                "min": 4,
                                "max": 8
                            },
                            "heavy": {
                                "min": 8,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4-8 hours",
                "onset": "30-60 minutes (oral)",
                "peak": "1-3 hours",
                "offset": "4-8 hours",
                "after_effects": "Up to 24 hours (residual sedation possible)"
            },
            "addiction_potential": "Low; not considered addictive, but misuse at high doses can cause toxicity and psychological disturbances.",
            "interactions": {
                "dangerous": [
                    "MAOIs",
                    "other anticholinergics",
                    "alcohol (increases CNS depression)"
                ],
                "unsafe": [
                    "other sedating antihistamines",
                    "tricyclic antidepressants"
                ],
                "caution": ["CNS depressants", "benzodiazepines", "opioids"]
            },
            "notes": "High doses can cause severe and life-threatening symptoms including seizures, respiratory depression, and anticholinergic toxicity (delirium, hallucinations, confusion, tachycardia, urinary retention). Not recommended for recreational use. Overdose risk is significant, especially in combination with other substances such as DXM (dextromethorphan).",
            "subjective_effects": [
                "Sedation",
                "Drowsiness",
                "Dry mouth",
                "Blurred vision",
                "Urinary retention",
                "Confusion (at high doses)",
                "Hallucinations (at high doses)",
                "Delirium (at high doses)",
                "Seizures (overdose)",
                "Respiratory depression (overdose)"
            ],
            "tolerance": {
                "full_tolerance": "Develops over several days of repeated use",
                "half_tolerance": "~3 days",
                "zero_tolerance": "1-2 weeks after cessation",
                "cross_tolerances": ["Other first-generation antihistamines"]
            },
            "half_life": "12-43 hours (varies by individual and route)",
            "citations": [
                {
                    "name": "DrugBank: Chlorpheniramine",
                    "reference": "https://go.drugbank.com/drugs/DB01114"
                },
                {
                    "name": "Erowid: CPM Information",
                    "reference": "https://www.erowid.org/chemicals/dxm/dxm_info2.shtml"
                },
                {
                    "name": "DrugBank: CPM Salt",
                    "reference": "https://go.drugbank.com/salts/DBSALT000987"
                }
            ],
            "categories": [
                "deliriant",
                "antidepressant",
                "sedative",
                "antidepressant",
                "antidepressant"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Chlorpheniramine Maleate (CPM)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "General pharmacological literature and user experience reports (insufflated CPM).",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 8,
                            "iso": ["PT4H", "PT8H"],
                            "note": "Insufflation tends to produce a more rapid onset but similar overall duration compared to oral use."
                        },
                        "onset": {
                            "start": 0.08,
                            "end": 0.33,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT20M"]
                        },
                        "peak": {
                            "start": 0.5,
                            "end": 2,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 4,
                            "end": 8,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT8H"]
                        },
                        "after_effects": {
                            "start": 8,
                            "end": 24,
                            "iso_start": ["PT8H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 106,
        "title": "Canket",
        "content": "# Canket (FXE, 2-F-2'-Oxo-PCE, 2F-NENDCK)",
        "drug_info": {
            "drug_name": "Canket (FXE, 2-F-2'-Oxo-PCE, 2F-NENDCK)",
            "search_url": "https://www.cahma.org.au/article/safer-using-canket/",
            "chemical_class": "Arylcyclohexylamine (fluorinated ketone)",
            "psychoactive_class": "Dissociative anesthetic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5-10 mg",
                            "light": "10-25 mg",
                            "common": "25-50 mg",
                            "strong": "50-80 mg",
                            "heavy": "80+ mg"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "3-8 mg",
                            "light": "8-20 mg",
                            "common": "20-40 mg",
                            "strong": "40-60 mg",
                            "heavy": "60+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 25
                            },
                            "common": {
                                "min": 25,
                                "max": 50
                            },
                            "strong": {
                                "min": 50,
                                "max": 80
                            },
                            "heavy": {
                                "min": 80,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 3,
                                "max": 8
                            },
                            "light": {
                                "min": 8,
                                "max": 20
                            },
                            "common": {
                                "min": 20,
                                "max": 40
                            },
                            "strong": {
                                "min": 40,
                                "max": 60
                            },
                            "heavy": {
                                "min": 60,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "1.5-2.5 hours",
                "onset": "5-15 minutes (insufflated), 20-40 minutes (oral)",
                "peak": "30-60 minutes",
                "offset": "1-2 hours",
                "after_effects": "1-3 hours"
            },
            "addiction_potential": "Moderate, similar to other arylcyclohexylamines. Risk of compulsive redosing and psychological dependence exists, especially with frequent use.",
            "interactions": {
                "dangerous": [
                    "Other dissociatives (e.g., ketamine, MXE)",
                    "Alcohol",
                    "Benzodiazepines"
                ],
                "unsafe": [
                    "Stimulants (risk of increased heart rate, agitation)"
                ],
                "caution": ["Serotonergic drugs (possible serotonin syndrome)"]
            },
            "notes": "2F-NENDCK (also known as CanKet or 2-fluoro-N-ethyl-nor-deschloroketamine) is a novel dissociative in the arylcyclohexylamine class, structurally related to ketamine and 2F-DCK. Reports suggest it is orally active and has a potency and effect profile similar to ketamine, but with a slightly longer duration and a more stimulating, less sedating character. Harm reduction practices are strongly advised due to limited human data and unpredictable effects. Overdoses may result in confusion, agitation, or dissociative delirium.",
            "subjective_effects": [
                "Dissociation",
                "Euphoria",
                "Analgesia",
                "Altered perception of time and space",
                "Visual distortions",
                "Motor incoordination",
                "Cognitive impairment",
                "Stimulation (mild)",
                "Mild sedation",
                "Confusion at high doses"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (days)",
                "half_tolerance": "~1-2 weeks",
                "zero_tolerance": "2-4 weeks after cessation",
                "cross_tolerances": ["Ketamine", "Other arylcyclohexylamines"]
            },
            "half_life": "Unknown; likely similar to ketamine (2-4 hours)",
            "citations": [
                {
                    "name": "Novel arylcyclohexamine 2F-NENDCK found in Australia (Bluelight)",
                    "reference": "https://www.bluelight.org/community/threads/novel-aryclyclohexamine-2f-nendck-found-in-australia.926834/"
                },
                {
                    "name": "2F-NENDCK Dosage & Experiences (Bluelight)",
                    "reference": "https://www.bluelight.org/community/threads/2f-nendck-dosage-experiences.942922/"
                }
            ],
            "categories": ["dissociative", "research-chemical", "hallucinogen"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Canket (FXE, 2-F-2'-Oxo-PCE, 2F-NENDCK)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Current literature and anecdotal reports (2023) from harm reduction resources and user experiences regarding 2-F-2'-Oxo-PCE (FXE, Canket), insufflated route.",
                        "units": "hours",
                        "total_duration": {
                            "min": 1.5,
                            "max": 2.5,
                            "iso": ["PT1H30M", "PT2H30M"],
                            "note": "Reflects typical duration for insufflated route."
                        },
                        "onset": {
                            "start": 0.08,
                            "end": 0.25,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT15M"]
                        },
                        "peak": {
                            "start": 0.5,
                            "end": 1.0,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT1H"]
                        },
                        "offset": {
                            "start": 1.0,
                            "end": 2.0,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        },
                        "after_effects": {
                            "start": 1.0,
                            "end": 3.0,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT3H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 242,
        "title": "Gaboxadol",
        "content": "# Gaboxadol (THIP)\n## Isoxazole derivative | Sedative-hypnotic; GABAergic\n      \nGaboxadol (THIP) is a direct-acting GABA-A receptor agonist, developed as an experimental sleep aid by Lundbeck and Merck. It was investigated for use in insomnia but was discontinued due to side effects and limited efficacy. It is not widely available and has not been approved for medical use in most countries. Overdose or combination with other CNS depressants can cause severe respiratory depression. Notably, it is structurally distinct from benzodiazepines and barbiturates, but shares some sedative properties.",
        "drug_info": {
            "drug_name": "Gaboxadol (THIP)",
            "search_url": "https://en.m.wikipedia.org/wiki/Gaboxadol",
            "chemical_class": "Isoxazole derivative",
            "psychoactive_class": "Sedative-hypnotic; GABAergic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "5-10 mg",
                            "common": "10-20 mg",
                            "strong": "20-30 mg",
                            "heavy": "30+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 10
                            },
                            "common": {
                                "min": 10,
                                "max": 20
                            },
                            "strong": {
                                "min": 20,
                                "max": 30
                            },
                            "heavy": {
                                "min": 30,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4-8 hours",
                "onset": "30-60 minutes",
                "peak": "1-3 hours",
                "offset": "2-4 hours",
                "after_effects": "Mild residual sedation possible for several hours"
            },
            "addiction_potential": "Low to moderate; not considered highly habit-forming but may cause dependence with chronic use, similar to other sedative-hypnotics.",
            "interactions": {
                "dangerous": [
                    "Alcohol",
                    "Benzodiazepines",
                    "Barbiturates",
                    "Other CNS depressants"
                ],
                "unsafe": ["Opioids"],
                "caution": ["Other GABAergic drugs"]
            },
            "notes": "Gaboxadol (THIP) is a direct-acting GABA-A receptor agonist, developed as an experimental sleep aid by Lundbeck and Merck. It was investigated for use in insomnia but was discontinued due to side effects and limited efficacy. It is not widely available and has not been approved for medical use in most countries. Overdose or combination with other CNS depressants can cause severe respiratory depression. Notably, it is structurally distinct from benzodiazepines and barbiturates, but shares some sedative properties.",
            "subjective_effects": [
                "Sedation",
                "Hypnosis (sleep induction)",
                "Muscle relaxation",
                "Mild euphoria",
                "Anxiolysis",
                "Impaired coordination",
                "Dizziness",
                "Mild cognitive impairment"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with daily use (within days to weeks)",
                "half_tolerance": "~7 days",
                "zero_tolerance": "2-4 weeks after cessation",
                "cross_tolerances": [
                    "Other GABA-A agonists (e.g., benzodiazepines, barbiturates)"
                ]
            },
            "half_life": "1-2 hours",
            "citations": [
                {
                    "name": "DrugBank: Gaboxadol",
                    "reference": "https://go.drugbank.com/drugs/DB06554"
                },
                {
                    "name": "Bluelight: Gaboxadol discussion",
                    "reference": "https://www.bluelight.org/community/threads/gaboxadol.370965/"
                }
            ],
            "categories": ["depressant", "sedative", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Gaboxadol (THIP)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Gaboxadol (THIP) insufflated\u2014data aggregated from pharmaceutical studies and user reports.",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 8,
                            "iso": ["PT4H", "PT8H"],
                            "note": "Effects can sometimes last toward the longer end with higher dosages."
                        },
                        "onset": {
                            "start": 0.5,
                            "end": 1,
                            "iso_start": ["PT0H30M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 3,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 3,
                            "end": 7,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT7H"]
                        },
                        "after_effects": {
                            "start": 7,
                            "end": 12,
                            "iso_start": ["PT7H"],
                            "iso_end": ["PT12H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 107,
        "title": "Fluorexetamine (FXE, 3-FXE)",
        "content": "",
        "drug_info": {
            "drug_name": "Fluorexetamine (3'-Fluoro-2-oxo-PCE, 3-FXE)",
            "search_url": "https://en.wikipedia.org/wiki/Fluorexetamine",
            "chemical_class": "Arylcyclohexylamine",
            "psychoactive_class": "Dissociative",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5-10 mg",
                            "light": "10-20 mg",
                            "common": "20-40 mg",
                            "strong": "40-60 mg",
                            "heavy": "60+ mg"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "3-8 mg",
                            "light": "8-15 mg",
                            "common": "15-30 mg",
                            "strong": "30-50 mg",
                            "heavy": "50+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 20
                            },
                            "common": {
                                "min": 20,
                                "max": 40
                            },
                            "strong": {
                                "min": 40,
                                "max": 60
                            },
                            "heavy": {
                                "min": 60,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 3,
                                "max": 8
                            },
                            "light": {
                                "min": 8,
                                "max": 15
                            },
                            "common": {
                                "min": 15,
                                "max": 30
                            },
                            "strong": {
                                "min": 30,
                                "max": 50
                            },
                            "heavy": {
                                "min": 50,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4-6 hours",
                "onset": "15-30 minutes (oral), 5-15 minutes (insufflated)",
                "peak": "1-3 hours",
                "offset": "2-3 hours",
                "after_effects": "Up to 24 hours (residual/afterglow)"
            },
            "addiction_potential": "Moderate; similar to other dissociatives, repeated use can lead to psychological dependence.",
            "interactions": {
                "dangerous": [
                    "Other dissociatives (e.g., ketamine, PCP, MXE)",
                    "Depressants (e.g., alcohol, benzodiazepines)"
                ],
                "unsafe": ["Stimulants (risk of unpredictable effects)"],
                "caution": [
                    "Serotonergic substances (risk of serotonin syndrome)"
                ]
            },
            "notes": "Erowid's DrugsData service has found that samples sold as FXE are sometimes adulterated or misrepresented, so identity confirmation is important. Effects are described as similar to other arylcyclohexylamine dissociatives but with unique characteristics. Reports indicate a potential for confusion, dissociation, and motor impairment. Harm reduction practices are strongly recommended.",
            "subjective_effects": [
                "Dissociation",
                "Euphoria",
                "Analgesia",
                "Altered perception of time and space",
                "Visual distortions",
                "Motor impairment",
                "Confusion",
                "Sedation",
                "Afterglow"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (days)",
                "half_tolerance": "~1-2 weeks",
                "zero_tolerance": "2-4 weeks",
                "cross_tolerances": [
                    "Other arylcyclohexylamines (e.g., ketamine, MXE)"
                ]
            },
            "half_life": "Unknown; estimated to be similar to related compounds (2-4 hours)",
            "citations": [
                {
                    "name": "Erowid Fluorexetamine Experience Reports",
                    "reference": "https://erowid.org/experiences/subs/exp_Fluorexetamine.shtml"
                },
                {
                    "name": "Bluelight Big & Dandy FXE Thread",
                    "reference": "https://www.bluelight.org/community/threads/the-big-dandy-fluorexetamine-3-f-2%E2%80%99-oxo-pce-fxe-thread.907423/page-14"
                },
                {
                    "name": "Erowid DrugsData FXE Note",
                    "reference": "https://erowid.org/experiences/exp.php?ID=116413"
                }
            ],
            "categories": ["dissociative", "research-chemical", "hallucinogen"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Fluorexetamine (3'-Fluoro-2-oxo-PCE, 3-FXE)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Based on published user reports and compiled durations from harm reduction communities and literature as of 2024.",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 6,
                            "iso": ["PT4H", "PT6H"],
                            "note": "Reflects the main psychoactive effects for insufflated route."
                        },
                        "onset": {
                            "start": 0.08,
                            "end": 0.25,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT15M"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 3,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 3,
                            "end": 6,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT6H"]
                        },
                        "after_effects": {
                            "start": 6,
                            "end": 24,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 111,
        "title": "2C-B",
        "content": "",
        "drug_info": {
            "drug_name": "2C-B",
            "search_url": "https://substancesearch.org/substance/2c-b",
            "chemical_class": "Phenethylamine (2C family)",
            "psychoactive_class": "Psychedelic (substituted phenethylamine)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2 mg+",
                            "light": "5\u201310 mg",
                            "common": "15\u201320 mg",
                            "strong": "25\u201335 mg",
                            "heavy": "50\u201355 mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 10
                            },
                            "common": {
                                "min": 12,
                                "max": 20
                            },
                            "strong": {
                                "min": 20,
                                "max": 30
                            },
                            "heavy": {
                                "min": 30,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "~6 hours",
                "onset": "~1 hour",
                "peak": "2\u20134 hours",
                "offset": "2 hours",
                "after_effects": "Mild afterglow possible for several hours"
            },
            "addiction_potential": "Low addiction potential; not considered physically addictive, but psychological habituation is possible with frequent use.",
            "interactions": {
                "dangerous": ["MAOIs (risk of serotonin syndrome)"],
                "unsafe": [
                    "Other serotonergic psychedelics (increased risk of adverse psychological effects)"
                ],
                "caution": [
                    "Stimulants (increased cardiovascular risk)",
                    "SSRIs (may blunt effects)"
                ]
            },
            "notes": "2C-B was first synthesized by Alexander Shulgin in 1974. It was initially used in psychiatric therapy and later became a popular recreational drug, sometimes sold as a legal alternative to MDMA in the 1980s. It is often found in pill form and is sometimes misrepresented as 'pink cocaine' or 'Nexus.' 2C-B is known for its unique combination of psychedelic and entactogenic effects, and was once marketed as an aphrodisiac. Effects can be highly dose-dependent, with higher doses leading to more intense visual and sensory changes. Overdoses can cause anxiety, confusion, and physical discomfort. It is a potent 5-HT2A receptor agonist.",
            "subjective_effects": [
                "Visual enhancement and distortions",
                "Altered tactile sensations",
                "Euphoria",
                "Empathy and emotional openness",
                "Increased libido",
                "Mild stimulation",
                "Altered thought patterns",
                "Synesthesia at higher doses",
                "Possible anxiety or confusion at high doses"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (within days)",
                "half_tolerance": "~3\u20137 days",
                "zero_tolerance": "~1\u20132 weeks",
                "cross_tolerances": ["Other psychedelics (LSD, psilocybin)"]
            },
            "half_life": "~4 hours (estimates vary)",
            "citations": [
                {
                    "name": "Drug Users Bible: 2C-B",
                    "reference": "https://drugusersbible.org/content/chemscape/psychedelics/2c-b/index.html"
                },
                {
                    "name": "DrugBank: 2C-B",
                    "reference": "https://go.drugbank.com/articles/A27247"
                },
                {
                    "name": "Erowid: 2C-B",
                    "reference": "https://www.erowid.org/archive/rhodium/pdf/2c-b.review.pdf"
                },
                {
                    "name": "DrugWise: Pink Cocaine",
                    "reference": "https://www.drugwise.org.uk/pink-cocaine/"
                }
            ],
            "categories": ["psychedelic", "research-chemical", "hallucinogen"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "2C-B",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Based on multiple experience reports and pharmacological summaries (2022).",
                        "units": "hours",
                        "total_duration": {
                            "min": 5,
                            "max": 7,
                            "iso": ["PT5H", "PT7H"],
                            "note": "Averages ~6 hours, with effect durations varying by dose and individual."
                        },
                        "onset": {
                            "start": 0.05,
                            "end": 0.5,
                            "iso_start": ["PT3M"],
                            "iso_end": ["PT30M"]
                        },
                        "peak": {
                            "start": 0.5,
                            "end": 2.5,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT2H30M"]
                        },
                        "offset": {
                            "start": 2.5,
                            "end": 5,
                            "iso_start": ["PT2H30M"],
                            "iso_end": ["PT5H"]
                        },
                        "after_effects": {
                            "start": 5,
                            "end": 10,
                            "iso_start": ["PT5H"],
                            "iso_end": ["PT10H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 108,
        "title": "Tiletamine",
        "content": "",
        "drug_info": {
            "drug_name": "Tiletamine",
            "search_url": "https://pubchem.ncbi.nlm.nih.gov/compound/Tiletamine",
            "chemical_class": "Arylcyclohexylamine (thiophene-substituted ketamine analog)",
            "psychoactive_class": "Dissociative NMDA-receptor antagonist",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "5\u201315 mg",
                            "common": "15\u201340 mg",
                            "strong": "40\u201380 mg",
                            "heavy": "80 mg+"
                        }
                    },
                    {
                        "route": "rectal",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "5\u201315 mg",
                            "common": "15\u201330 mg",
                            "strong": "30\u201350 mg",
                            "heavy": "50 mg+"
                        }
                    },
                    {
                        "route": "IM",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "5\u201310 mg",
                            "common": "10\u201325 mg",
                            "strong": "25\u201340 mg",
                            "heavy": "40 mg+"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 15
                            },
                            "common": {
                                "min": 15,
                                "max": 40
                            },
                            "strong": {
                                "min": 40,
                                "max": 80
                            },
                            "heavy": {
                                "min": 80,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "rectal",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 15
                            },
                            "common": {
                                "min": 15,
                                "max": 30
                            },
                            "strong": {
                                "min": 30,
                                "max": 50
                            },
                            "heavy": {
                                "min": 50,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "intramuscular",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 15
                            },
                            "common": {
                                "min": 15,
                                "max": 30
                            },
                            "strong": {
                                "min": 30,
                                "max": 40
                            },
                            "heavy": {
                                "min": 40,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4\u20136 h",
                "onset": "5\u201310 min (insufflated) / 1\u20133 min (IM)",
                "peak": "30\u2013120 min",
                "offset": "2\u20133 h gradual decline",
                "after_effects": "1\u20133 h residual grogginess"
            },
            "addiction_potential": "Moderate; produces ketamine-like reward and rapid tolerance, but physical dependence is uncommon.",
            "interactions": {
                "dangerous": [
                    "Alcohol",
                    "Opioids (e.g., morphine, fentanyl)",
                    "Barbiturates"
                ],
                "unsafe": [
                    "Benzodiazepines",
                    "Gabapentinoids",
                    "Other dissociatives"
                ],
                "caution": [
                    "Stimulants (tachycardia)",
                    "MAOIs",
                    "Tramadol (seizure risk)"
                ]
            },
            "notes": "Sold illicitly both as pure base and as mis-labelled ketamine; users describe a more \u2018industrial\u2019, longer-lasting dissociation with vivid closed-eye visuals. Veterinary formulations contain equal zolazepam, complicating dosing if powder is extracted from vials.",
            "subjective_effects": [
                "Profound dissociation",
                "Floating or weightlessness",
                "Visual drifting and kaleidoscopic CEVs",
                "Time dilation",
                "Analgesia / numbness",
                "Euphoria at moderate doses",
                "Motor incoordination",
                "Amnesia at high doses"
            ],
            "tolerance": {
                "full_tolerance": "After 2\u20133 consecutive days of heavy use",
                "half_tolerance": "1\u20132 weeks",
                "zero_tolerance": "1\u20132 months",
                "cross_tolerances": ["ketamine", "PCP", "MXE", "O-PCE"]
            },
            "half_life": "\u22480.9 h (dog), 1.8 h (polar bear), 2\u20134 h (cat); human estimate \u22481.5\u20133 h",
            "citations": [
                {
                    "name": "PubChem CID 26533",
                    "reference": "turn13search0"
                },
                {
                    "name": "Zoetis Telazol\u00ae Prescribing Info",
                    "reference": "turn0search9"
                },
                {
                    "name": "ScienceDirect Topics: Tiletamine (cat plasma t\u00bd)",
                    "reference": "turn13search5"
                },
                {
                    "name": "Bluelight Trip Report (30 mg nasal)",
                    "reference": "turn16view0"
                },
                {
                    "name": "Bluelight Thread (2007 Telazol Q&A)",
                    "reference": "turn14view0"
                },
                {
                    "name": "Virbac Zoletil dosing sheet",
                    "reference": "turn6search0"
                },
                {
                    "name": "ScienceDirect polar-bear PK",
                    "reference": "turn13search3"
                },
                {
                    "name": "Fatal injection case report",
                    "reference": "turn0search4"
                },
                {
                    "name": "Rodent behavioural comparison study",
                    "reference": "turn0search5"
                },
                {
                    "name": "Drugs.com diazepam\u2013ketamine interaction",
                    "reference": "turn12search2"
                },
                {
                    "name": "AddictionCenter CNS-depressant cautions",
                    "reference": "turn12search7"
                },
                {
                    "name": "Rabbit intranasal ZT study",
                    "reference": "turn6search4"
                },
                {
                    "name": "Nervewing blog on arylcyclohexylamines",
                    "reference": "turn3search1"
                },
                {
                    "name": "ScienceDirect dog/cat dosage overview",
                    "reference": "turn6search2"
                },
                {
                    "name": "Wikipedia Tiletamine page (regulatory status)",
                    "reference": "turn13search6"
                }
            ],
            "categories": ["dissociative", "research-chemical", "hallucinogen"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Tiletamine",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Based on clinical literature (animal anesthesia), human anecdotal reports, and comparative studies with dissociatives such as ketamine and PCP.",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 6,
                            "iso": ["PT4H", "PT6H"],
                            "note": "Main effects subside by 4\u20136 hours post-dose."
                        },
                        "onset": {
                            "start": 0.08,
                            "end": 0.17,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT10M"]
                        },
                        "peak": {
                            "start": 0.5,
                            "end": 2,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 2,
                            "end": 3,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT3H"]
                        },
                        "after_effects": {
                            "start": 4,
                            "end": 9,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT9H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 114,
        "title": "BZP (Benzylpiperazine)",
        "content": "",
        "drug_info": {
            "drug_name": "BZP (Benzylpiperazine)",
            "search_url": "https://www.erowid.org/chemicals/bzp/bzp_basics.shtml",
            "chemical_class": "Piperazine",
            "psychoactive_class": "Stimulant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "10 mg",
                            "light": "20-50 mg",
                            "common": "50-100 mg",
                            "strong": "100-150 mg",
                            "heavy": "150+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 10,
                                "max": 20
                            },
                            "light": {
                                "min": 20,
                                "max": 50
                            },
                            "common": {
                                "min": 50,
                                "max": 100
                            },
                            "strong": {
                                "min": 100,
                                "max": 150
                            },
                            "heavy": {
                                "min": 150,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "6-8 hours",
                "onset": "30-90 minutes",
                "peak": "2-4 hours",
                "offset": "2-4 hours",
                "after_effects": "up to 24 hours (residual stimulation, insomnia)"
            },
            "addiction_potential": "Limited to moderate abuse potential, with some risk of psychological dependence, especially with frequent use.",
            "interactions": {
                "dangerous": ["MAOIs", "other strong stimulants"],
                "unsafe": ["SSRIs", "tricyclic antidepressants"],
                "caution": ["alcohol", "cannabis", "other stimulants"]
            },
            "notes": "BZP was marketed as a 'legal high' and alternative to amphetamines and MDMA in the early 2000s. It is now illegal in many countries. Side effects can include anxiety, insomnia, nausea, headaches, and, at high doses, seizures. It has legitimate veterinary uses as an anti-parasitic in cattle.",
            "subjective_effects": [
                "Euphoria",
                "Wakefulness",
                "Improved vigilance",
                "Increased energy",
                "Hyperactivity",
                "Reduced reaction time",
                "Mild empathogenic effects",
                "Anxiety (at high doses)",
                "Insomnia",
                "Headache",
                "Nausea"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (within days)",
                "half_tolerance": "3-7 days",
                "zero_tolerance": "1-2 weeks",
                "cross_tolerances": ["Other stimulants (e.g., amphetamines)"]
            },
            "half_life": "Several hours (estimates range from 3 to 6 hours)",
            "citations": [
                {
                    "name": "Erowid BZP Basics",
                    "reference": "https://www.erowid.org/chemicals/bzp/bzp_basics.shtml"
                },
                {
                    "name": "DrugWise BZP",
                    "reference": "https://www.drugwise.org.uk/bzp/"
                },
                {
                    "name": "Erowid Piperazines Info",
                    "reference": "https://www.erowid.org/chemicals/piperazines/piperazines_info1.shtml"
                },
                {
                    "name": "Erowid BZP Article 1",
                    "reference": "https://www.erowid.org/chemicals/bzp/bzp_article1.shtml"
                }
            ],
            "categories": ["stimulant", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "BZP (Benzylpiperazine)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Based on published pharmacology literature, clinical reports, and user experiences (up to 2024).",
                        "units": "hours",
                        "total_duration": {
                            "min": 6,
                            "max": 8,
                            "iso": ["PT6H", "PT8H"],
                            "note": "Main effects typically last from 6 to 8 hours after insufflation."
                        },
                        "onset": {
                            "start": 0.5,
                            "end": 1.5,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT90M"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "offset": {
                            "start": 4,
                            "end": 8,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT8H"]
                        },
                        "after_effects": {
                            "start": 8,
                            "end": 24,
                            "iso_start": ["PT8H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 115,
        "title": "Dizocilpine (MK-801)",
        "content": "",
        "drug_info": {
            "drug_name": "Dizocilpine (MK-801)",
            "search_url": "https://go.drugbank.com/drugs/DB06182",
            "chemical_class": "Arylcyclohexylamine (specifically, a diarylcycloheptenimine)",
            "psychoactive_class": "Dissociative (NMDA receptor antagonist)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "0.05 mg",
                            "light": "0.1\u20130.2 mg",
                            "common": "0.2\u20130.5 mg",
                            "strong": "0.5\u20131 mg",
                            "heavy": "1+ mg"
                        }
                    },
                    {
                        "route": "intramuscular",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "0.02 mg",
                            "light": "0.05\u20130.1 mg",
                            "common": "0.1\u20130.3 mg",
                            "strong": "0.3\u20130.5 mg",
                            "heavy": "0.5+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.05,
                                "max": 0.1
                            },
                            "light": {
                                "min": 0.1,
                                "max": 0.2
                            },
                            "common": {
                                "min": 0.2,
                                "max": 0.5
                            },
                            "strong": {
                                "min": 0.5,
                                "max": 1
                            },
                            "heavy": {
                                "min": 1,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "intramuscular",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.02,
                                "max": 0.05
                            },
                            "light": {
                                "min": 0.05,
                                "max": 0.1
                            },
                            "common": {
                                "min": 0.1,
                                "max": 0.3
                            },
                            "strong": {
                                "min": 0.3,
                                "max": 0.5
                            },
                            "heavy": {
                                "min": 0.5,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "6\u201312 hours",
                "onset": "15\u201360 minutes (oral)",
                "peak": "2\u20136 hours",
                "offset": "4\u20138 hours",
                "after_effects": "12\u201324 hours (residual cognitive/psychomotor effects possible)"
            },
            "addiction_potential": "Low to moderate; not typically considered habit-forming in humans, but can be reinforcing in animal studies. Abuse potential exists due to dissociative and stimulant-like effects.",
            "interactions": {
                "dangerous": [
                    "Other dissociatives (e.g., ketamine, PCP)",
                    "Alcohol (increased CNS depression, risk of respiratory depression)"
                ],
                "unsafe": [
                    "Stimulants (risk of psychosis, cardiovascular strain)",
                    "MAOIs (unknown, but potentially dangerous)"
                ],
                "caution": [
                    "Antipsychotics (may attenuate or alter effects)",
                    "Benzodiazepines (may reduce agitation or anxiety, but increase CNS depression)"
                ]
            },
            "notes": "Dizocilpine (MK-801) is a potent, non-competitive NMDA receptor antagonist with strong dissociative and neurotoxic properties. It is primarily used in research and is not approved for human use due to its neurotoxicity and potential for causing psychosis, memory impairment, and motor disturbances. It is not controlled in some jurisdictions (e.g., Canada), but is scheduled in others (e.g., US). Extreme caution is advised due to its high potency and risk profile.",
            "subjective_effects": [
                "Dissociation",
                "Hallucinations (visual and auditory)",
                "Cognitive impairment",
                "Motor incoordination",
                "Euphoria",
                "Anxiety",
                "Paranoia",
                "Amnesia",
                "Agitation",
                "Sedation (at higher doses)",
                "Perceptual distortions"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (within days)",
                "half_tolerance": "~1\u20132 weeks",
                "zero_tolerance": "2\u20134 weeks (after cessation)",
                "cross_tolerances": [
                    "Other NMDA antagonists (e.g., ketamine, PCP)"
                ]
            },
            "half_life": "2\u20134 hours (elimination half-life); effects may persist longer due to active metabolites and CNS redistribution.",
            "citations": [
                {
                    "name": "DrugBank: Dizocilpine",
                    "reference": "https://go.drugbank.com/drugs/DB06182"
                },
                {
                    "name": "Isomerdesign: Drug Status Report (Canada)",
                    "reference": "https://isomerdesign.com/Cdsa/HC/StatusDecisions/A-2013-00235%20-%20PDFs/NC-Dizocilpine%20maleate%202006-08-21.pdf"
                },
                {
                    "name": "DrugBank Article: NMDA antagonist effects",
                    "reference": "https://go.drugbank.com/articles/A6789"
                }
            ],
            "categories": ["dissociative", "research-chemical", "hallucinogen"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Dizocilpine (MK-801)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Academic literature on nonhuman and rare human use cases, along with structure-activity relation extrapolations from known NMDA antagonists (e.g., ketamine, PCP); human reports rare and primarily anecdotal for this ROA.",
                        "units": "hours",
                        "total_duration": {
                            "min": 6,
                            "max": 12,
                            "iso": ["PT6H", "PT12H"],
                            "note": "Total subjective psychoactive effects"
                        },
                        "onset": {
                            "start": 0.25,
                            "end": 1,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 6,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT6H"]
                        },
                        "offset": {
                            "start": 4,
                            "end": 8,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT8H"]
                        },
                        "after_effects": {
                            "start": 12,
                            "end": 24,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 116,
        "title": "Diphenidine",
        "content": "",
        "drug_info": {
            "drug_name": "Diphenidine",
            "search_url": "https://drugusersbible.org/content/chemscape/dissociatives/diphenidine/",
            "chemical_class": "Diarylethylamine",
            "psychoactive_class": "Dissociative anesthetic (NMDA receptor antagonist)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "50+",
                            "light": "70+",
                            "common": "85+",
                            "strong": "110+",
                            "heavy": "\u2014"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 25,
                                "max": 50
                            },
                            "light": {
                                "min": 50,
                                "max": 75
                            },
                            "common": {
                                "min": 75,
                                "max": 110
                            },
                            "strong": {
                                "min": 110,
                                "max": 150
                            },
                            "heavy": {
                                "min": 150,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "~5 hours",
                "onset": "~60 minutes",
                "peak": "\u2014",
                "offset": "\u2014",
                "after_effects": "\u2014"
            },
            "addiction_potential": "Potential for psychological dependence, with some reports of compulsive redosing and amnesia. Use caution, especially with frequent or high doses.",
            "interactions": {
                "dangerous": ["Other dissociatives", "Alcohol"],
                "unsafe": ["Benzodiazepines (increased CNS depression)"],
                "caution": ["Stimulants (may increase cardiovascular risk)"]
            },
            "notes": "Diphenidine is a novel dissociative with a significant amnestic component and mild stimulant effects. It is less smooth than its cousin ephenidine and has been associated with some adverse outcomes, including reports of tragedy at high or reckless doses. It is not scheduled in the US or Canada as of the latest reports, but legal status may vary. Use caution due to unpredictable effects and potential for amnesia or compulsive redosing.",
            "subjective_effects": [
                "Dissociation",
                "Amnesia",
                "Mild stimulation",
                "Altered perception of time and space",
                "Euphoria",
                "Confusion",
                "Impaired motor control"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (days)",
                "half_tolerance": "~1-2 weeks",
                "zero_tolerance": "~2-4 weeks",
                "cross_tolerances": [
                    "Other NMDA antagonists (e.g., ketamine, MXE, PCP)"
                ]
            },
            "half_life": "Not well established; likely several hours based on duration of effects.",
            "citations": [
                {
                    "name": "Drug Users Bible - Diphenidine",
                    "reference": "https://drugusersbible.org/content/chemscape/dissociatives/diphenidine/"
                },
                {
                    "name": "Bluelight - The Big & Dandy Diphenidine Thread",
                    "reference": "https://www.bluelight.org/community/threads/the-big-dandy-diphenidine-thread.668291/"
                },
                {
                    "name": "Isomerdesign - Diphenidine Drug Status Report",
                    "reference": "https://isomerdesign.com/Cdsa/HC/StatusDecisions/A-2013-01404%20-%20PDFs/NC-diphenidine-2014-01-27.pdf"
                }
            ],
            "categories": ["dissociative", "research-chemical", "hallucinogen"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Diphenidine",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Academic literature, user experience reports (2023 synthesis)",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 6,
                            "iso": ["PT4H", "PT6H"],
                            "note": "Total duration after intranasal use typically ranges 4\u20136 hours."
                        },
                        "onset": {
                            "start": 0.75,
                            "end": 1.5,
                            "iso_start": ["PT45M"],
                            "iso_end": ["PT1H30M"]
                        },
                        "peak": {
                            "start": 1.5,
                            "end": 3,
                            "iso_start": ["PT1H30M"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 3,
                            "end": 5,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT5H"]
                        },
                        "after_effects": {
                            "start": 5,
                            "end": 8,
                            "iso_start": ["PT5H"],
                            "iso_end": ["PT8H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 117,
        "title": "2C-B-FLY",
        "content": "",
        "drug_info": {
            "drug_name": "2C-B-FLY",
            "search_url": "https://drugusersbible.org/content/chemscape/psychedelics/2c-b-fly/index.html",
            "chemical_class": "Phenethylamine (dihydrodifuran analog of 2C-B)",
            "psychoactive_class": "Psychedelic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2 mg",
                            "light": "5 mg",
                            "common": "10 mg",
                            "strong": "18 mg",
                            "heavy": "25 mg"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2 mg",
                            "light": "5 mg",
                            "common": "10 mg",
                            "strong": "18 mg",
                            "heavy": "25 mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 1,
                                "max": 3
                            },
                            "light": {
                                "min": 3,
                                "max": 7
                            },
                            "common": {
                                "min": 7,
                                "max": 14
                            },
                            "strong": {
                                "min": 14,
                                "max": 20
                            },
                            "heavy": {
                                "min": 20,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 1,
                                "max": 3
                            },
                            "light": {
                                "min": 3,
                                "max": 7
                            },
                            "common": {
                                "min": 7,
                                "max": 13
                            },
                            "strong": {
                                "min": 13,
                                "max": 20
                            },
                            "heavy": {
                                "min": 20,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "~7 hours",
                "onset": "~1 hour",
                "peak": "Varies (typically 2-4 hours after onset)",
                "offset": "Several hours (gradual taper)",
                "after_effects": "Mild, may include residual stimulation or lethargy"
            },
            "addiction_potential": "Low; not habit-forming, with little evidence of compulsive use or dependence.",
            "interactions": {
                "dangerous": [
                    "MAOIs (risk of hypertensive crisis or serotonin syndrome)"
                ],
                "unsafe": ["Other stimulants or strong serotonergic drugs"],
                "caution": [
                    "Other psychedelics, SSRIs, SNRIs, tricyclic antidepressants"
                ]
            },
            "notes": "2C-B-FLY is a synthetic psychedelic with effects similar to 2C-B but with a longer duration and a slightly different character. It was first synthesized in 1996 by Aaron P. Monte. It is sometimes confused with Bromo-DragonFLY, a much more toxic compound. 2C-B-FLY is not widely used and has a short history of human consumption. It is not specifically scheduled in many countries but may be prosecuted under analogue laws. Most reports indicate a positive mood lift, mild stimulation, and visual effects, but lethargy or a 'stoned' feeling is also possible. Deaths attributed to 2C-B-FLY were actually due to mislabelled Bromo-DragonFLY.",
            "subjective_effects": [
                "Positive mood push",
                "Mild stimulation",
                "Visual distortions/enhancements",
                "Altered thought patterns",
                "Euphoria",
                "Lethargy or 'stoned' feeling (in some cases)",
                "Enhanced sensory perception"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (within days)",
                "half_tolerance": "~1 week",
                "zero_tolerance": "2 weeks or more",
                "cross_tolerances": [
                    "Other psychedelics (especially phenethylamines and tryptamines)"
                ]
            },
            "half_life": "Not well established; effects last ~7 hours, suggesting moderate duration of action.",
            "citations": [
                {
                    "name": "Erowid 2C-B-FLY Vault",
                    "reference": "https://erowid.org/chemicals/2cb_fly/2cb_fly.shtml"
                },
                {
                    "name": "TripSit Factsheet: 2C-B-FLY",
                    "reference": "https://tripsit.me/factsheets/2c-b-fly"
                },
                {
                    "name": "Drug Users Bible: 2C-B-FLY",
                    "reference": "https://drugusersbible.org/content/chemscape/psychedelics/2c-b-fly/"
                },
                {
                    "name": "Isomer Design: 2C-B-FLY Drug Status Report",
                    "reference": "https://isomerdesign.com/Cdsa/HC/StatusDecisions/A-2013-00235%20-%20PDFs/NC-2C-B-FLY-2011-08-03.pdf"
                }
            ],
            "categories": ["psychedelic", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "2C-B-FLY",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Academic literature and user reports (2024), excluding PsychonautWiki.",
                        "units": "hours",
                        "total_duration": {
                            "min": 6,
                            "max": 8,
                            "iso": ["PT6H", "PT8H"],
                            "note": "Actual total duration may vary due to batch purity, dose, and individual sensitivity."
                        },
                        "onset": {
                            "start": 0.15,
                            "end": 1,
                            "iso_start": ["PT9M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 1.5,
                            "end": 4,
                            "iso_start": ["PT1H30M"],
                            "iso_end": ["PT4H"]
                        },
                        "offset": {
                            "start": 4,
                            "end": 7,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT7H"]
                        },
                        "after_effects": {
                            "start": 7,
                            "end": 10,
                            "iso_start": ["PT7H"],
                            "iso_end": ["PT10H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 118,
        "title": "1P-LSD",
        "content": "",
        "drug_info": {
            "drug_name": "1P-LSD",
            "search_url": "https://drugusersbible.org/content/chemscape/psychedelics/1p-lsd/index.html",
            "chemical_class": "Lysergamide",
            "psychoactive_class": "Psychedelic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "\u00b5g",
                        "dose_ranges": {
                            "threshold": "20 \u00b5g+",
                            "light": "25\u201350 \u00b5g",
                            "common": "100 \u00b5g",
                            "strong": "150 \u00b5g",
                            "heavy": "150 \u00b5g+"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "ug",
                        "dose_ranges": {
                            "threshold": {
                                "min": 10,
                                "max": 20
                            },
                            "light": {
                                "min": 20,
                                "max": 50
                            },
                            "common": {
                                "min": 50,
                                "max": 125
                            },
                            "strong": {
                                "min": 125,
                                "max": 175
                            },
                            "heavy": {
                                "min": 175,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "8\u201312 hours",
                "onset": "~1 hour",
                "peak": "2\u20136 hours",
                "offset": "2\u20134 hours",
                "after_effects": "Up to 24 hours (residual)"
            },
            "addiction_potential": "Low; not considered physically addictive, but psychological habituation is possible with frequent use.",
            "interactions": {
                "dangerous": ["MAOIs (theoretical risk of serotonin syndrome)"],
                "unsafe": ["Tramadol (seizure risk)"],
                "caution": [
                    "Other serotonergic substances (risk of serotonin syndrome)"
                ]
            },
            "notes": "1P-LSD is a research chemical and a novel analogue of LSD, first appearing on the market around 2014. It is believed to act as a prodrug for LSD, meaning it is metabolized into LSD in the body. Effects are reported to be nearly indistinguishable from LSD, with some users noting slightly less intensity dose-for-dose. Sold primarily on blotter paper and typically administered orally. Legal status varies by country. Use caution due to limited long-term safety data.",
            "subjective_effects": [
                "Visual enhancement",
                "Color enhancement",
                "Pattern recognition",
                "Euphoria",
                "Altered thought patterns",
                "Time distortion",
                "Music enhancement",
                "Synesthesia (at higher doses)",
                "Mild stimulation",
                "Emotional enhancement",
                "Introspection"
            ],
            "tolerance": {
                "full_tolerance": "After 3\u20137 days of repeated use",
                "half_tolerance": "~7 days",
                "zero_tolerance": "2 weeks or more",
                "cross_tolerances": ["LSD", "other lysergamides"]
            },
            "half_life": "Unknown (likely similar to LSD: 3\u20135 hours)",
            "citations": [
                {
                    "name": "Drug Users Bible: 1P-LSD",
                    "reference": "https://drugusersbible.org/content/chemscape/psychedelics/1p-lsd/"
                },
                {
                    "name": "TripSit Factsheet: 1P-LSD",
                    "reference": "https://tripsit.me/factsheets/1p-lsd"
                },
                {
                    "name": "Bluelight: The Big & Dandy 1P-LSD Thread",
                    "reference": "https://www.bluelight.org/community/threads/the-big-dandy-1p-lsd-thread-volume-2.767154/"
                }
            ],
            "categories": ["psychedelic", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "1P-LSD",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Scientific literature and user reports (2020s); typical for lysergamides when insufflated.",
                        "units": "hours",
                        "total_duration": {
                            "min": 8,
                            "max": 12,
                            "iso": ["PT8H", "PT12H"],
                            "note": "1P-LSD is less commonly insufflated, but reports indicate somewhat faster onset than oral, with similar duration."
                        },
                        "onset": {
                            "start": 0.25,
                            "end": 1,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 6,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT6H"]
                        },
                        "offset": {
                            "start": 6,
                            "end": 12,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT12H"]
                        },
                        "after_effects": {
                            "start": 12,
                            "end": 24,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 119,
        "title": "1cP-LSD",
        "content": "",
        "drug_info": {
            "drug_name": "1cP-LSD",
            "search_url": "https://drugusersbible.org/content/chemscape/psychedelics/1cp-lsd/index.html",
            "chemical_class": "Lysergamide",
            "psychoactive_class": "Psychedelic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "\u00b5g",
                        "dose_ranges": {
                            "threshold": "~20-25 \u00b5g",
                            "light": "25 \u00b5g+",
                            "common": "50 \u00b5g+",
                            "strong": "100 \u00b5g+",
                            "heavy": "N/A"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "ug",
                        "dose_ranges": {
                            "threshold": {
                                "min": 10,
                                "max": 20
                            },
                            "light": {
                                "min": 20,
                                "max": 50
                            },
                            "common": {
                                "min": 50,
                                "max": 100
                            },
                            "strong": {
                                "min": 100,
                                "max": 150
                            },
                            "heavy": {
                                "min": 150,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "~8 hours",
                "onset": "~40 minutes",
                "peak": "Varies (not specified)",
                "offset": "Varies (not specified)",
                "after_effects": "Not specified"
            },
            "addiction_potential": "Very low; similar to other classical psychedelics, not considered habit-forming.",
            "interactions": {
                "dangerous": [
                    "MAOIs (potentially dangerous with all psychedelics)"
                ],
                "unsafe": [],
                "caution": [
                    "Other serotonergic substances (risk of serotonin syndrome)"
                ]
            },
            "notes": "1cP-LSD is a novel lysergamide and research chemical, closely related to 1P-LSD and LSD itself. It is typically found on blotter paper and is orally active. Subjective reports suggest it is slightly stronger and shorter in duration than 1P-LSD, with a calmer onset and greater head clarity. Effects are described as vibrant, energetic, and clear-headed, with a strong connection between visuals and thought. As a research chemical, long-term safety is not well established.",
            "subjective_effects": [
                "Visual enhancement",
                "Altered thought patterns",
                "Increased clarity of thought",
                "Energetic visuals",
                "Emotional enhancement",
                "Connection between visuals and thoughts",
                "Headspace clarity"
            ],
            "tolerance": {
                "full_tolerance": "After repeated use over several days (typical of psychedelics)",
                "half_tolerance": "~3-7 days",
                "zero_tolerance": "~2 weeks",
                "cross_tolerances": ["LSD", "1P-LSD", "Other lysergamides"]
            },
            "half_life": "Not precisely established; likely similar to LSD (3-5 hours)",
            "citations": [
                {
                    "name": "Drug Users Bible: 1cP-LSD",
                    "reference": "https://drugusersbible.org/content/chemscape/psychedelics/1cp-lsd/"
                },
                {
                    "name": "Bluelight: 1cP-LSD thread",
                    "reference": "https://www.bluelight.org/community/threads/the-small-handy-1cp-lsd-thread.877264/"
                }
            ],
            "categories": ["psychedelic", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "1cP-LSD",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Based on aggregated user reports, limited published sources, and comparison to similar lysergamides with intranasal use.",
                        "units": "hours",
                        "total_duration": {
                            "min": 7,
                            "max": 9,
                            "iso": ["PT7H", "PT9H"],
                            "note": "Reported durations cluster around 8 hours for insufflated 1cP-LSD, with some variation depending on dose and individual sensitivity."
                        },
                        "onset": {
                            "start": 0.33,
                            "end": 1,
                            "iso_start": ["PT20M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 1.5,
                            "end": 4,
                            "iso_start": ["PT1H30M"],
                            "iso_end": ["PT4H"]
                        },
                        "offset": {
                            "start": 4,
                            "end": 7,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT7H"]
                        },
                        "after_effects": {
                            "start": 7,
                            "end": 10,
                            "iso_start": ["PT7H"],
                            "iso_end": ["PT10H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 270,
        "title": "MAL",
        "content": "# Methallylescaline (MAL)\n## Phenethylamine (substituted phenethylamine, mescaline analogue) | Psychedelic\n      \nMethallylescaline (MAL) is a psychedelic phenethylamine first synthesized by Alexander Shulgin. It is structurally related to mescaline and allylescaline, but is less potent than allylescaline. Effects are long-lasting and can include strong visual and mental alterations. There is limited research on its toxicity and long-term health effects. Start with low doses due to individual variability in response. Not much is known about its safety profile, so caution is advised.",
        "drug_info": {
            "drug_name": "Methallylescaline (MAL)",
            "search_url": "https://c0c59da34f7608d6.ngrok.app/pihkal?name=MAL",
            "chemical_class": "Phenethylamine (substituted phenethylamine, mescaline analogue)",
            "psychoactive_class": "Psychedelic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "10 mg",
                            "light": "20-40 mg",
                            "common": "40-65 mg",
                            "strong": "65-80 mg",
                            "heavy": "80+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 10,
                                "max": 20
                            },
                            "light": {
                                "min": 20,
                                "max": 40
                            },
                            "common": {
                                "min": 40,
                                "max": 65
                            },
                            "strong": {
                                "min": 65,
                                "max": 80
                            },
                            "heavy": {
                                "min": 80,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "10-16 hours",
                "onset": "1-2 hours",
                "peak": "4-8 hours",
                "offset": "2-4 hours",
                "after_effects": "Up to 24 hours (residual)"
            },
            "addiction_potential": "Very low; not reported to be habit-forming or addictive.",
            "interactions": {
                "dangerous": ["MAOIs"],
                "unsafe": ["Tramadol"],
                "caution": ["Other serotonergic substances", "Stimulants"]
            },
            "notes": "Methallylescaline (MAL) is a psychedelic phenethylamine first synthesized by Alexander Shulgin. It is structurally related to mescaline and allylescaline, but is less potent than allylescaline. Effects are long-lasting and can include strong visual and mental alterations. There is limited research on its toxicity and long-term health effects. Start with low doses due to individual variability in response. Not much is known about its safety profile, so caution is advised.",
            "subjective_effects": [
                "Visual enhancement",
                "Color enhancement",
                "Euphoria",
                "Altered thought patterns",
                "Time distortion",
                "Increased appreciation of music",
                "Mild stimulation",
                "Empathy",
                "Body load (sometimes)",
                "Mild nausea (sometimes)"
            ],
            "tolerance": {
                "full_tolerance": "After 3-7 days of repeated use",
                "half_tolerance": "~7 days",
                "zero_tolerance": "2 weeks or more",
                "cross_tolerances": [
                    "Other psychedelics (e.g., mescaline, LSD, 2C-x)"
                ]
            },
            "half_life": "Unknown (estimated 8-12 hours based on duration)",
            "citations": [
                {
                    "name": "Erowid Methallylescaline Experience Reports",
                    "reference": "https://erowid.org/experiences/subs/exp_Methallylescaline.shtml"
                },
                {
                    "name": "PIHKAL Entry for Methallylescaline",
                    "reference": "https://isomerdesign.com/pihkal/explore/99"
                },
                {
                    "name": "Bluelight Big & Dandy Methallylescaline Thread",
                    "reference": "https://www.bluelight.org/community/threads/the-big-dandy-methallylescaline-mal-thread.630226/page-3"
                },
                {
                    "name": "TripSit Factsheet: Methallylescaline",
                    "reference": "https://tripsit.me/factsheets/methallylescaline"
                }
            ],
            "categories": ["psychedelic", "research-chemical", "hallucinogen"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Methallylescaline (MAL)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Based on published user reports and available literature on methallylescaline and related phenethylamines.",
                        "units": "hours",
                        "total_duration": {
                            "min": 10,
                            "max": 16,
                            "iso": ["PT10H", "PT16H"],
                            "note": "Insufflated phenethylamines tend to have a somewhat shorter and more intense duration than oral, but similar to oral durations in this case."
                        },
                        "onset": {
                            "start": 0.25,
                            "end": 2,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT2H"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 8,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT8H"]
                        },
                        "offset": {
                            "start": 8,
                            "end": 16,
                            "iso_start": ["PT8H"],
                            "iso_end": ["PT16H"]
                        },
                        "after_effects": {
                            "start": 16,
                            "end": 40,
                            "iso_start": ["PT16H"],
                            "iso_end": ["PT40H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 120,
        "title": "1P-ETH-LAD",
        "content": "",
        "drug_info": {
            "drug_name": "1P-ETH-LAD",
            "search_url": "https://drugusersbible.org/content/chemscape/psychedelics/1p-eth-lad/index.html",
            "chemical_class": "Lysergamide",
            "psychoactive_class": "Psychedelic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "\u00b5g",
                        "dose_ranges": {
                            "threshold": "30 \u00b5g",
                            "light": "30\u201360 \u00b5g",
                            "common": "60\u2013100 \u00b5g",
                            "strong": "100+ \u00b5g",
                            "heavy": "100+ \u00b5g"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "ug",
                        "dose_ranges": {
                            "threshold": {
                                "min": 20,
                                "max": 30
                            },
                            "light": {
                                "min": 30,
                                "max": 60
                            },
                            "common": {
                                "min": 60,
                                "max": 100
                            },
                            "strong": {
                                "min": 100,
                                "max": 150
                            },
                            "heavy": {
                                "min": 150,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "8\u201312 hours",
                "onset": "~1 hour",
                "peak": "2\u20136 hours",
                "offset": "6\u201310 hours",
                "after_effects": "Mild afterglow possible for several hours"
            },
            "addiction_potential": "Not considered physically addictive; psychological dependence is rare but possible with frequent use.",
            "interactions": {
                "dangerous": ["MAOIs", "Tramadol"],
                "unsafe": ["Tricyclic antidepressants", "Lithium"],
                "caution": ["Other psychedelics", "Stimulants", "Cannabis"]
            },
            "notes": "1P-ETH-LAD is a lysergamide and a structural analogue of LSD and ETH-LAD. It is believed to act as a prodrug for ETH-LAD, similar to how 1P-LSD acts as a prodrug for LSD. Effects are considered nearly indistinguishable from ETH-LAD, which itself is a potent, shorter-acting LSD analogue. Use caution with dosage due to high potency. Sold primarily on blotter and intended for research purposes only. Legal status varies by country.",
            "subjective_effects": [
                "Visual enhancement",
                "Altered thought processes",
                "Increased clarity and awareness",
                "Euphoria",
                "Time distortion",
                "Synesthesia (at higher doses)",
                "Mild stimulation",
                "Emotional enhancement"
            ],
            "tolerance": {
                "full_tolerance": "Develops after 3\u20137 days of repeated use",
                "half_tolerance": "~7 days",
                "zero_tolerance": "~14 days",
                "cross_tolerances": ["LSD", "ETH-LAD", "AL-LAD"]
            },
            "half_life": "Not well established; likely similar to ETH-LAD (estimated 6\u20138 hours)",
            "citations": [
                {
                    "name": "Drug Users Bible \u2013 1P-ETH-LAD",
                    "reference": "https://drugusersbible.org/content/chemscape/psychedelics/1p-eth-lad/"
                },
                {
                    "name": "IsomerDesign \u2013 1P-ETH-LAD",
                    "reference": "https://isomerdesign.com/pihkal/explore/5917"
                },
                {
                    "name": "TripSit \u2013 ETH-LAD",
                    "reference": "https://tripsit.me/factsheets/ETH-LAD"
                }
            ],
            "categories": ["psychedelic", "research-chemical", "hallucinogen"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "1P-ETH-LAD",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Based on synthesis of anecdotal reports and general lysergamide pharmacology literature (2023).",
                        "units": "hours",
                        "total_duration": {
                            "min": 8,
                            "max": 12,
                            "iso": ["PT8H", "PT12H"],
                            "note": "Full effects, including residual fading of core effects."
                        },
                        "onset": {
                            "start": 0.5,
                            "end": 1.5,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT1H30M"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 6,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT6H"]
                        },
                        "offset": {
                            "start": 6,
                            "end": 10,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT10H"]
                        },
                        "after_effects": {
                            "start": 10,
                            "end": 16,
                            "iso_start": ["PT10H"],
                            "iso_end": ["PT16H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 121,
        "title": "2C-B-AN",
        "content": "",
        "drug_info": {
            "drug_name": "2C-B-AN",
            "search_url": "https://drugusersbible.org/content/chemscape/psychedelics/2c-b-an/index.html",
            "chemical_class": "Phenethylamine (2C family, prodrug of 2C-B)",
            "psychoactive_class": "Psychedelic (prodrug)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "50 mg",
                            "light": "100 mg",
                            "common": "150 mg",
                            "strong": "N/A",
                            "heavy": "N/A"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 25,
                                "max": 50
                            },
                            "light": {
                                "min": 50,
                                "max": 75
                            },
                            "common": {
                                "min": 75,
                                "max": 125
                            },
                            "strong": {
                                "min": 125,
                                "max": 200
                            },
                            "heavy": {
                                "min": 200,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "Likely similar to 2C-B (approx. 4-8 hours)",
                "onset": "Likely 45-90 minutes (as a prodrug)",
                "peak": "Likely 2-4 hours",
                "offset": "Likely 2-4 hours",
                "after_effects": "Mild, several hours"
            },
            "addiction_potential": "Low; similar to 2C-B, not considered habit-forming or addictive.",
            "interactions": {
                "dangerous": ["MAOIs", "Tramadol"],
                "unsafe": ["Other serotonergic drugs"],
                "caution": ["Stimulants", "Other psychedelics"]
            },
            "notes": "2C-B-AN is a novel prodrug for 2C-B, meaning it is metabolized in the body to produce 2C-B. Limited research and user reports exist, so caution is advised. Effects are presumed to be similar to 2C-B but may have a delayed onset and altered potency due to prodrug metabolism. Start with low doses due to variability in individual metabolism.",
            "subjective_effects": [
                "Empathy enhancement",
                "Visual alterations",
                "Euphoria",
                "Stimulation",
                "Altered perception of time",
                "Increased tactile sensation"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (days)",
                "half_tolerance": "~3-7 days",
                "zero_tolerance": "~2 weeks",
                "cross_tolerances": [
                    "Other 2C compounds",
                    "Psychedelic phenethylamines"
                ]
            },
            "half_life": "Unknown (likely similar to 2C-B: 3-6 hours)",
            "citations": [
                {
                    "name": "TripSit Factsheet: 2C-B-AN",
                    "reference": "https://tripsit.me/factsheets/2c-b-an"
                }
            ],
            "categories": ["psychedelic", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "2C-B-AN",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Expert synthesis based on 2C-B-AN's prodrug status and analogy to 2C-B, incorporating user reports and published literature on 2C-B-AN and closely related phenethylamines (2022-2024).",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 8,
                            "iso": ["PT4H", "PT8H"],
                            "note": "Estimated duration based on similarity to 2C-B and user reports indicating a comparable time course when insufflated."
                        },
                        "onset": {
                            "start": 0.75,
                            "end": 1.5,
                            "iso_start": ["PT45M"],
                            "iso_end": ["PT1H30M"]
                        },
                        "peak": {
                            "start": 1.5,
                            "end": 5.5,
                            "iso_start": ["PT1H30M"],
                            "iso_end": ["PT5H30M"]
                        },
                        "offset": {
                            "start": 5.5,
                            "end": 8,
                            "iso_start": ["PT5H30M"],
                            "iso_end": ["PT8H"]
                        },
                        "after_effects": {
                            "start": 8,
                            "end": 12,
                            "iso_start": ["PT8H"],
                            "iso_end": ["PT12H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 122,
        "title": "2C-E",
        "content": "",
        "drug_info": {
            "drug_name": "2C-E",
            "search_url": "https://drugusersbible.org/content/chemscape/psychedelics/2c-e/index.html",
            "chemical_class": "Phenethylamine (2C-x series)",
            "psychoactive_class": "Psychedelic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2 mg",
                            "light": "5 mg",
                            "common": "10 mg",
                            "strong": "15 mg",
                            "heavy": "25 mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 1,
                                "max": 3
                            },
                            "light": {
                                "min": 3,
                                "max": 7
                            },
                            "common": {
                                "min": 7,
                                "max": 15
                            },
                            "strong": {
                                "min": 15,
                                "max": 20
                            },
                            "heavy": {
                                "min": 20,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "6-10 hours",
                "onset": "20-60 minutes",
                "peak": "2-6 hours",
                "offset": "2-4 hours",
                "after_effects": "up to 24 hours (afterglow, residual stimulation)"
            },
            "addiction_potential": "Low; not considered habit-forming, but psychological dependence is possible with frequent use.",
            "interactions": {
                "dangerous": ["MAOIs", "Tramadol"],
                "unsafe": [
                    "Other stimulants",
                    "Other psychedelics (high dose)"
                ],
                "caution": ["SSRIs", "Alcohol", "Cannabis"]
            },
            "notes": "2C-E is known for its intense visuals and heavy body load compared to other 2C-x compounds. It is extremely dose-sensitive, with significant variation in effects between individuals. Negative effects and body discomfort increase with higher doses. Harm reduction practices are strongly advised. 2C-E is illegal in many jurisdictions.",
            "subjective_effects": [
                "Intense visual distortions",
                "Altered thought patterns",
                "Euphoria",
                "Enhanced sensory perception",
                "Body load (discomfort)",
                "Time distortion",
                "Emotional lability",
                "Occasional anxiety or confusion"
            ],
            "tolerance": {
                "full_tolerance": "After 3-7 days of repeated use",
                "half_tolerance": "~7 days",
                "zero_tolerance": "2-4 weeks",
                "cross_tolerances": [
                    "Other psychedelics (e.g., LSD, psilocybin, other 2C-x)"
                ]
            },
            "half_life": "~6-8 hours (estimated, not well-studied)",
            "citations": [
                {
                    "name": "TripSit 2C-E Factsheet",
                    "reference": "https://tripsit.me/factsheets/2c-e"
                },
                {
                    "name": "Erowid 2C-E Vault",
                    "reference": "https://www.erowid.org/chemicals/2ce/"
                },
                {
                    "name": "Drug Users Bible: 2C-E",
                    "reference": "https://drugusersbible.org/content/chemscape/psychedelics/2c-e/"
                },
                {
                    "name": "TripSit Wiki: 2C-E",
                    "reference": "https://wiki.tripsit.me/index.php?title=2C-E&mobileaction=toggle_view_desktop"
                }
            ],
            "categories": ["psychedelic", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "2C-E",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Shulgin, A., & Shulgin, A. (1991). PiHKAL: A Chemical Love Story. Experience reports from Erowid.org, peer-reviewed articles on psychedelic phenethylamines.",
                        "units": "hours",
                        "total_duration": {
                            "min": 6,
                            "max": 10,
                            "iso": ["PT6H", "PT10H"],
                            "note": "Subjective duration may be shorter or longer depending on dose, user tolerance, and body weight."
                        },
                        "onset": {
                            "start": 0.33,
                            "end": 1,
                            "iso_start": ["PT20M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 6,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT6H"]
                        },
                        "offset": {
                            "start": 6,
                            "end": 10,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT10H"]
                        },
                        "after_effects": {
                            "start": 10,
                            "end": 34,
                            "iso_start": ["PT10H"],
                            "iso_end": ["PT34H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 123,
        "title": "Brazepam",
        "content": "",
        "drug_info": {
            "drug_name": "Bromazepam",
            "search_url": "https://www.drug-do.se/benzos?name_like=brazepam",
            "chemical_class": "Benzodiazepine",
            "psychoactive_class": "Depressant, Anxiolytic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "1 mg",
                            "light": "1-3 mg",
                            "common": "3-6 mg",
                            "strong": "6-12 mg",
                            "heavy": "12+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 1,
                                "max": 1.5
                            },
                            "light": {
                                "min": 1.5,
                                "max": 3
                            },
                            "common": {
                                "min": 3,
                                "max": 6
                            },
                            "strong": {
                                "min": 6,
                                "max": 12
                            },
                            "heavy": {
                                "min": 12,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "8-12 hours",
                "onset": "30-60 minutes",
                "peak": "1-4 hours",
                "offset": "6-12 hours",
                "after_effects": "Residual sedation may last up to 24 hours"
            },
            "addiction_potential": "Moderate to high. Like other benzodiazepines, bromazepam carries a risk of dependence, tolerance, and withdrawal symptoms with prolonged or excessive use.",
            "interactions": {
                "dangerous": [
                    "Alcohol",
                    "Opioids",
                    "Other benzodiazepines",
                    "Barbiturates"
                ],
                "unsafe": ["Antipsychotics", "Sedative antihistamines"],
                "caution": ["Other CNS depressants", "Certain antidepressants"]
            },
            "notes": "Bromazepam is primarily used for its anxiolytic (anti-anxiety) properties and is prescribed for panic disorders and severe anxiety. It is not recommended for long-term use due to the risk of dependence and withdrawal. Abrupt discontinuation after prolonged use can result in severe withdrawal symptoms, including seizures. Use with caution in elderly patients and those with a history of substance abuse.",
            "subjective_effects": [
                "Anxiolysis (reduced anxiety)",
                "Sedation",
                "Muscle relaxation",
                "Mild euphoria",
                "Impaired coordination",
                "Cognitive impairment",
                "Drowsiness"
            ],
            "tolerance": {
                "full_tolerance": "Develops within weeks of regular use",
                "half_tolerance": "1-2 weeks after cessation",
                "zero_tolerance": "4-8 weeks after cessation",
                "cross_tolerances": ["Other benzodiazepines"]
            },
            "half_life": "10-20 hours",
            "citations": [
                {
                    "name": "TripSit Factsheet: Bromazepam",
                    "reference": "https://tripsit.me/factsheets/bromazepam"
                },
                {
                    "name": "DrugBank: Bromazepam (DB01558)",
                    "reference": "https://go.drugbank.com/drugs/DB01558"
                }
            ],
            "categories": ["depressant", "benzodiazepine", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Bromazepam",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Based on clinical and case report literature on bromazepam pharmacokinetics and user reports regarding intranasal benzodiazepines. See: Busto UE et al, 1979, and general benzodiazepine effect profiles.",
                        "units": "hours",
                        "total_duration": {
                            "min": 8,
                            "max": 12,
                            "iso": ["PT8H", "PT12H"],
                            "note": "Comparable to or somewhat shorter than oral route; inter-individual variation exists."
                        },
                        "onset": {
                            "start": 0.5,
                            "end": 1,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 4,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT4H"]
                        },
                        "offset": {
                            "start": 6,
                            "end": 12,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT12H"]
                        },
                        "after_effects": {
                            "start": 12,
                            "end": 24,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 279,
        "title": "Phendimetrazine",
        "content": "# Phendimetrazine\n## Phenylmorpholine (related to amphetamines) | Stimulant, Sympathomimetic amine\n      \nPhendimetrazine is used as a short-term adjunct in the management of exogenous obesity. It is chemically related to amphetamines and acts as an appetite suppressant. It should not be used in patients with a history of cardiovascular disease, hyperthyroidism, glaucoma, or substance abuse. Tolerance can develop rapidly, and abrupt cessation after prolonged use may result in withdrawal symptoms.",
        "drug_info": {
            "drug_name": "Phendimetrazine",
            "search_url": "https://go.drugbank.com/drugs/DB01579",
            "chemical_class": "Phenylmorpholine (related to amphetamines)",
            "psychoactive_class": "Stimulant, Sympathomimetic amine",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "Not well established",
                            "light": "17.5-35 mg",
                            "common": "35-70 mg",
                            "strong": "70-105 mg",
                            "heavy": "105+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 8.75,
                                "max": 17.5
                            },
                            "light": {
                                "min": 17.5,
                                "max": 35
                            },
                            "common": {
                                "min": 35,
                                "max": 70
                            },
                            "strong": {
                                "min": 70,
                                "max": 105
                            },
                            "heavy": {
                                "min": 105,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4-6 hours (immediate-release); 8-12 hours (extended-release)",
                "onset": "30-60 minutes",
                "peak": "1-3 hours",
                "offset": "2-4 hours",
                "after_effects": "Mild, up to several hours"
            },
            "addiction_potential": "Moderate. As a stimulant related to amphetamines, phendimetrazine has potential for misuse and dependence, though less than amphetamines. It is classified as a Schedule III controlled substance.",
            "interactions": {
                "dangerous": ["MAOIs (monoamine oxidase inhibitors)"],
                "unsafe": [
                    "Other stimulants (e.g., amphetamines, methylphenidate)"
                ],
                "caution": [
                    "Antihypertensives, tricyclic antidepressants, SSRIs, alcohol"
                ]
            },
            "notes": "Phendimetrazine is used as a short-term adjunct in the management of exogenous obesity. It is chemically related to amphetamines and acts as an appetite suppressant. It should not be used in patients with a history of cardiovascular disease, hyperthyroidism, glaucoma, or substance abuse. Tolerance can develop rapidly, and abrupt cessation after prolonged use may result in withdrawal symptoms.",
            "subjective_effects": [
                "Appetite suppression",
                "Increased energy",
                "Mild euphoria",
                "Insomnia",
                "Increased heart rate",
                "Dry mouth",
                "Anxiety"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with regular use (days to weeks)",
                "half_tolerance": "Several days to a week after cessation",
                "zero_tolerance": "1-2 weeks after cessation",
                "cross_tolerances": ["Amphetamines", "Other stimulants"]
            },
            "half_life": "~3.8-4.6 hours (immediate-release); extended-release forms may have longer apparent half-life",
            "citations": [
                {
                    "name": "DrugBank: Phendimetrazine",
                    "reference": "https://go.drugbank.com/drugs/DB01579"
                },
                {
                    "name": "DrugBank: Phendimetrazine Interactions",
                    "reference": "https://go.drugbank.com/drugs/DB01579/biointeractions"
                },
                {
                    "name": "DrugBank: Phendimetrazine Pharmacology",
                    "reference": "https://go.drugbank.com/articles/A5709"
                }
            ],
            "categories": ["stimulant", "habit-forming", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Phendimetrazine",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Phendimetrazine product labeling and clinical reference texts (e.g., Lexicomp, FDA label, Goodman & Gilman). Insufflation is less studied, but expected to accelerate onset and potentially shorten duration compared to oral administration.",
                        "units": "hours",
                        "total_duration": {
                            "min": 3,
                            "max": 5,
                            "iso": ["PT3H", "PT5H"],
                            "note": "Insufflation likely produces a shorter duration than oral; immediate-release oral range adjusted for ROA."
                        },
                        "onset": {
                            "start": 0.08,
                            "end": 0.33,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT20M"]
                        },
                        "peak": {
                            "start": 0.5,
                            "end": 2,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "after_effects": {
                            "start": 4,
                            "end": 8,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT8H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 125,
        "title": "Midazolam",
        "content": "",
        "drug_info": {
            "drug_name": "Midazolam",
            "search_url": "https://www.drug-do.se/benzos?name=midazolam",
            "chemical_class": "Benzodiazepine",
            "psychoactive_class": "Depressant, Sedative-Hypnotic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "0.5 mg",
                            "light": "1-2 mg",
                            "common": "2-5 mg",
                            "strong": "5-10 mg",
                            "heavy": "10+ mg"
                        }
                    },
                    {
                        "route": "IV",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "0.5 mg",
                            "light": "1-2 mg",
                            "common": "2-5 mg",
                            "strong": "5-10 mg",
                            "heavy": "10+ mg"
                        }
                    },
                    {
                        "route": "IM",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "0.5 mg",
                            "light": "1-2 mg",
                            "common": "2-5 mg",
                            "strong": "5-10 mg",
                            "heavy": "10+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.25,
                                "max": 1
                            },
                            "light": {
                                "min": 1,
                                "max": 2
                            },
                            "common": {
                                "min": 2,
                                "max": 5
                            },
                            "strong": {
                                "min": 5,
                                "max": 10
                            },
                            "heavy": {
                                "min": 10,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "intravenous",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.5,
                                "max": 1
                            },
                            "light": {
                                "min": 1,
                                "max": 2
                            },
                            "common": {
                                "min": 2,
                                "max": 5
                            },
                            "strong": {
                                "min": 5,
                                "max": 10
                            },
                            "heavy": {
                                "min": 10,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "intramuscular",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.5,
                                "max": 1
                            },
                            "light": {
                                "min": 1,
                                "max": 2
                            },
                            "common": {
                                "min": 2,
                                "max": 5
                            },
                            "strong": {
                                "min": 5,
                                "max": 10
                            },
                            "heavy": {
                                "min": 10,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "1-6 hours (route-dependent)",
                "onset": "1-15 minutes (IV: 1-5 min, oral: 10-20 min)",
                "peak": "20-60 minutes",
                "offset": "1-2 hours",
                "after_effects": "Residual sedation up to 6 hours"
            },
            "addiction_potential": "Moderate to high; benzodiazepines can cause physical and psychological dependence, especially with prolonged or high-dose use.",
            "interactions": {
                "dangerous": ["Opioids", "Alcohol", "Other CNS depressants"],
                "unsafe": ["Barbiturates", "Other benzodiazepines"],
                "caution": [
                    "Antidepressants",
                    "Antipsychotics",
                    "Certain antifungals (CYP3A4 inhibitors)"
                ]
            },
            "notes": "Midazolam is a short-acting benzodiazepine with strong sedative, anxiolytic, muscle relaxant, anticonvulsant, and amnesic properties. It is commonly used for procedural sedation, anesthesia induction, and acute seizure management. Overdose can cause respiratory depression and death, especially when combined with other depressants.",
            "subjective_effects": [
                "Sedation",
                "Anxiolysis",
                "Muscle relaxation",
                "Amnesia",
                "Euphoria (rare)",
                "Drowsiness",
                "Impaired coordination",
                "Confusion"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with regular use (days to weeks)",
                "half_tolerance": "~7-14 days after cessation",
                "zero_tolerance": "~2-4 weeks after cessation",
                "cross_tolerances": ["Other benzodiazepines", "Barbiturates"]
            },
            "half_life": "1.5\u20133 hours (may be longer in elderly or hepatic impairment)",
            "citations": [
                {
                    "name": "DrugBank: Midazolam",
                    "reference": "https://go.drugbank.com/drugs/DB00683"
                },
                {
                    "name": "DrugBank: Midazolam Salt",
                    "reference": "https://go.drugbank.com/salts/DBSALT000118"
                }
            ],
            "categories": [
                "depressant",
                "sedative",
                "benzodiazepine",
                "habit-forming"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Midazolam",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Clinical pharmacokinetics texts and benzodiazepine drug monographs, adjusted for insufflation route based on onset and duration reported in clinical/case studies.",
                        "units": "hours",
                        "total_duration": {
                            "min": 1.5,
                            "max": 4,
                            "iso": ["PT1H30M", "PT4H"],
                            "note": "Insufflated duration is typically shorter than oral but slightly longer than IV, and usually does not exceed 4 hours."
                        },
                        "onset": {
                            "start": 0.083,
                            "end": 0.25,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT15M"]
                        },
                        "peak": {
                            "start": 0.33,
                            "end": 1,
                            "iso_start": ["PT20M"],
                            "iso_end": ["PT1H"]
                        },
                        "offset": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        },
                        "after_effects": {
                            "start": 2,
                            "end": 6,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT6H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 126,
        "title": "Etizolam",
        "content": "",
        "drug_info": {
            "drug_name": "Etizolam",
            "search_url": "https://www.drug-do.se/benzos?name=etizolam",
            "chemical_class": "Thienodiazepine (benzodiazepine analogue)",
            "psychoactive_class": "Depressant (anxiolytic, sedative-hypnotic)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "0.25 mg",
                            "light": "0.25-0.5 mg",
                            "common": "0.5-2 mg",
                            "strong": "2-3 mg",
                            "heavy": "3+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.125,
                                "max": 0.25
                            },
                            "light": {
                                "min": 0.25,
                                "max": 0.5
                            },
                            "common": {
                                "min": 0.5,
                                "max": 2
                            },
                            "strong": {
                                "min": 2,
                                "max": 3
                            },
                            "heavy": {
                                "min": 3,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "5-8 hours",
                "onset": "15-45 minutes",
                "peak": "1-3 hours",
                "offset": "3-6 hours",
                "after_effects": "Up to 24 hours (residual sedation possible)"
            },
            "addiction_potential": "Moderate to high. Etizolam, like other benzodiazepine analogues, can cause dependence, tolerance, and withdrawal symptoms with regular use.",
            "interactions": {
                "dangerous": [
                    "Alcohol",
                    "Opioids",
                    "Other benzodiazepines",
                    "Barbiturates"
                ],
                "unsafe": ["Antihistamines (sedating)", "Muscle relaxants"],
                "caution": ["Other CNS depressants", "Certain antidepressants"]
            },
            "notes": "Etizolam is not approved for medical use in many countries but is prescribed in some (e.g., Japan, India) for anxiety and insomnia. It is considered more potent than diazepam milligram for milligram. Overdose risk increases significantly when combined with other depressants. Sudden discontinuation after prolonged use can cause severe withdrawal symptoms, including seizures.",
            "subjective_effects": [
                "Anxiolysis (anxiety relief)",
                "Sedation",
                "Muscle relaxation",
                "Mild euphoria",
                "Impaired coordination",
                "Memory impairment",
                "Drowsiness"
            ],
            "tolerance": {
                "full_tolerance": "Develops within 1-2 weeks of regular use",
                "half_tolerance": "~7 days after cessation",
                "zero_tolerance": "2-4 weeks after cessation",
                "cross_tolerances": [
                    "Benzodiazepines",
                    "Other thienodiazepines"
                ]
            },
            "half_life": "3.4-15 hours (varies by individual and metabolite)",
            "citations": [
                {
                    "name": "DrugBank: Etizolam",
                    "reference": "https://go.drugbank.com/drugs/DB09166"
                },
                {
                    "name": "DrugWise: Etizolam Factsheet",
                    "reference": "https://www.drugwise.org.uk/wp-content/uploads/Factsheet-etizolam.pdf"
                },
                {
                    "name": "TripSit Factsheet: Etizolam",
                    "reference": "https://tripsit.me/factsheets/etizolam"
                }
            ],
            "categories": [
                "depressant",
                "benzodiazepine",
                "research-chemical",
                "sedative"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Etizolam",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "General clinical literature and user reports on insufflated etizolam, excluding PsychonautWiki. See sources such as PubChem, Erowid, and relevant harm reduction sites.",
                        "units": "hours",
                        "total_duration": {
                            "min": 5,
                            "max": 8,
                            "iso": ["PT5H", "PT8H"],
                            "note": "Insufflation may cause a slightly faster onset and similar duration to oral use."
                        },
                        "onset": {
                            "start": 0.25,
                            "end": 0.75,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT45M"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 3,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 3,
                            "end": 6,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT6H"]
                        },
                        "after_effects": {
                            "start": 6,
                            "end": 24,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 127,
        "title": "Prazepam",
        "content": "",
        "drug_info": {
            "drug_name": "Prazepam",
            "search_url": "https://www.drug-do.se/benzos?name=prazepam",
            "chemical_class": "Benzodiazepine",
            "psychoactive_class": "Depressant (anxiolytic, sedative)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "5-10 mg",
                            "common": "10-30 mg",
                            "strong": "30-60 mg",
                            "heavy": "60+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 10
                            },
                            "common": {
                                "min": 10,
                                "max": 30
                            },
                            "strong": {
                                "min": 30,
                                "max": 60
                            },
                            "heavy": {
                                "min": 60,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "8-24 hours (due to active metabolites)",
                "onset": "30-90 minutes",
                "peak": "2-6 hours",
                "offset": "12-24 hours",
                "after_effects": "Residual sedation may last up to 24 hours"
            },
            "addiction_potential": "Moderate to high, similar to other benzodiazepines. Risk increases with prolonged use or high doses.",
            "interactions": {
                "dangerous": ["Alcohol", "Opioids", "Barbiturates"],
                "unsafe": ["Other CNS depressants"],
                "caution": [
                    "Antidepressants",
                    "Antipsychotics",
                    "Anticonvulsants"
                ]
            },
            "notes": "Prazepam is a long-acting benzodiazepine used primarily for the treatment of anxiety disorders. It is metabolized to desmethyldiazepam (nordazepam), which has a long half-life and contributes to its prolonged effects. Tolerance, dependence, and withdrawal are significant risks with long-term use. Not recommended for individuals with a history of substance abuse or respiratory depression.",
            "subjective_effects": [
                "Anxiolysis",
                "Sedation",
                "Muscle relaxation",
                "Impaired coordination",
                "Cognitive impairment",
                "Drowsiness",
                "Amnesia (at higher doses)"
            ],
            "tolerance": {
                "full_tolerance": "Develops within 2-4 weeks of regular use",
                "half_tolerance": "1-2 weeks after cessation",
                "zero_tolerance": "4-8 weeks after cessation",
                "cross_tolerances": ["Other benzodiazepines", "Barbiturates"]
            },
            "half_life": "30-150 hours (including active metabolites)",
            "citations": [
                {
                    "name": "DrugBank: Prazepam",
                    "reference": "https://go.drugbank.com/drugs/DB01588"
                },
                {
                    "name": "DrugBank: Prazepam Biointeractions",
                    "reference": "https://go.drugbank.com/drugs/DB01588/biointeractions"
                },
                {
                    "name": "DrugBank: Benzodiazepine Category",
                    "reference": "https://go.drugbank.com/categories/DBCAT000450"
                },
                {
                    "name": "DrugBank: Article on Prazepam Metabolism",
                    "reference": "https://go.drugbank.com/articles/A26165"
                }
            ],
            "categories": ["depressant", "benzodiazepine", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Prazepam",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Prazepam is a benzodiazepine prodrug with a long duration, mainly due to its active metabolite (desmethyldiazepam). Insufflation is not a typical route, but clinical pharmacology suggests similar oral timing with possibly faster onset and somewhat shorter duration due to bypassed first-pass metabolism. See: Goodman & Gilman's The Pharmacological Basis of Therapeutics (13th ed), RxList, and clinical reviews.",
                        "units": "hours",
                        "total_duration": {
                            "min": 8,
                            "max": 24,
                            "iso": ["PT8H", "PT24H"],
                            "note": "Long total duration; effects may persist due to active metabolites, especially desmethyldiazepam."
                        },
                        "onset": {
                            "start": 0.5,
                            "end": 1.5,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT1H30M"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 6,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT6H"]
                        },
                        "offset": {
                            "start": 12,
                            "end": 24,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT24H"]
                        },
                        "after_effects": {
                            "start": 12,
                            "end": 24,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 128,
        "title": "Diclazepam",
        "content": "",
        "drug_info": {
            "drug_name": "Diclazepam",
            "search_url": "https://www.drug-do.se/benzos?name=diclazepam",
            "chemical_class": "Benzodiazepine",
            "psychoactive_class": "Depressant, Anxiolytic, Sedative-Hypnotic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "0.5 mg",
                            "light": "0.5 - 1 mg",
                            "common": "1 - 2 mg",
                            "strong": "2 - 4 mg",
                            "heavy": "4+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.25,
                                "max": 0.5
                            },
                            "light": {
                                "min": 0.5,
                                "max": 1
                            },
                            "common": {
                                "min": 1,
                                "max": 2
                            },
                            "strong": {
                                "min": 2,
                                "max": 4
                            },
                            "heavy": {
                                "min": 4,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "12 - 24 hours",
                "onset": "30 - 90 minutes",
                "peak": "2 - 6 hours",
                "offset": "6 - 24 hours",
                "after_effects": "Up to 48 hours (due to long half-life and active metabolites)"
            },
            "addiction_potential": "High. Diclazepam, like other benzodiazepines, carries a significant risk of dependence, tolerance, and withdrawal symptoms with repeated use.",
            "interactions": {
                "dangerous": [
                    "Alcohol",
                    "Opioids",
                    "Other benzodiazepines",
                    "Barbiturates"
                ],
                "unsafe": ["GABAergic depressants"],
                "caution": [
                    "Antidepressants",
                    "Antipsychotics",
                    "Muscle relaxants"
                ]
            },
            "notes": "Diclazepam is a research chemical benzodiazepine not approved for medical use in most countries. It is structurally related to diazepam but is estimated to be about 10 times more potent. Its long half-life and active metabolites can lead to accumulation and increased risk of next-day sedation or impairment. Overdose can be fatal, especially in combination with other CNS depressants.",
            "subjective_effects": [
                "Sedation",
                "Anxiolysis (anxiety reduction)",
                "Muscle relaxation",
                "Amnesia",
                "Impaired coordination",
                "Drowsiness",
                "Mild euphoria",
                "Cognitive impairment"
            ],
            "tolerance": {
                "full_tolerance": "Develops within days to weeks of regular use",
                "half_tolerance": "1 - 2 weeks after cessation",
                "zero_tolerance": "2 - 4 weeks after cessation",
                "cross_tolerances": ["Other benzodiazepines", "Barbiturates"]
            },
            "half_life": "~42 hours (parent compound); active metabolites may extend effects up to 80+ hours",
            "citations": [
                {
                    "name": "TripSit Factsheet: Diclazepam",
                    "reference": "https://tripsit.me/factsheets/diclazepam"
                },
                {
                    "name": "Drug Users Bible: Diclazepam",
                    "reference": "https://drugusersbible.org/content/chemscape/anxiolytics_and_sedatives/others/"
                },
                {
                    "name": "TripSit Wiki: Benzodiazepines",
                    "reference": "https://wiki.tripsit.me/index.php?title=Benzodiazepines&oldid=&mobileaction=toggle_view_desktop"
                }
            ],
            "categories": [
                "depressant",
                "sedative",
                "benzodiazepine",
                "research-chemical"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Diclazepam",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Clinical literature and user reports up to 2024 (including Ashton Manual and benzodiazepine pharmacology reviews), considering the slow absorption and extended half-life of diclazepam and its metabolites.",
                        "units": "hours",
                        "total_duration": {
                            "min": 12,
                            "max": 24,
                            "iso": ["P12H", "P1D"],
                            "note": "Diclazepam is a long-acting benzodiazepine; total duration varies by individual metabolism."
                        },
                        "onset": {
                            "start": 0.5,
                            "end": 1.5,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT1H30M"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 6,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT6H"]
                        },
                        "offset": {
                            "start": 6,
                            "end": 24,
                            "iso_start": ["PT6H"],
                            "iso_end": ["P1D"]
                        },
                        "after_effects": {
                            "start": 24,
                            "end": 48,
                            "iso_start": ["P1D"],
                            "iso_end": ["P2D"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 129,
        "title": "Phenazepam",
        "content": "",
        "drug_info": {
            "drug_name": "Phenazepam",
            "search_url": "https://www.drug-do.se/benzos?name=phenazepam",
            "chemical_class": "Benzodiazepine",
            "psychoactive_class": "Depressant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "0.1 mg",
                            "light": "0.25-0.5 mg",
                            "common": "0.5-2 mg",
                            "strong": "2-5 mg",
                            "heavy": "5+ mg"
                        }
                    },
                    {
                        "route": "sublingual",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "0.1 mg",
                            "light": "0.25-0.5 mg",
                            "common": "0.5-2 mg",
                            "strong": "2-5 mg",
                            "heavy": "5+ mg"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "0.1 mg",
                            "light": "0.25-0.5 mg",
                            "common": "0.5-2 mg",
                            "strong": "2-5 mg",
                            "heavy": "5+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.1,
                                "max": 0.24
                            },
                            "light": {
                                "min": 0.25,
                                "max": 0.49
                            },
                            "common": {
                                "min": 0.5,
                                "max": 2
                            },
                            "strong": {
                                "min": 2,
                                "max": 5
                            },
                            "heavy": {
                                "min": 5,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "sublingual",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.1,
                                "max": 0.25
                            },
                            "light": {
                                "min": 0.25,
                                "max": 0.5
                            },
                            "common": {
                                "min": 0.5,
                                "max": 2
                            },
                            "strong": {
                                "min": 2,
                                "max": 5
                            },
                            "heavy": {
                                "min": 5,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.05,
                                "max": 0.1
                            },
                            "light": {
                                "min": 0.1,
                                "max": 0.5
                            },
                            "common": {
                                "min": 0.5,
                                "max": 2
                            },
                            "strong": {
                                "min": 2,
                                "max": 5
                            },
                            "heavy": {
                                "min": 5,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "12-72 hours (can be longer)",
                "onset": "20-60 minutes (oral)",
                "peak": "2-4 hours",
                "offset": "24-72 hours",
                "after_effects": "Residual sedation and cognitive impairment may persist for several days"
            },
            "addiction_potential": "High. Phenazepam, like other benzodiazepines, carries a significant risk of dependence, tolerance, and withdrawal symptoms, especially with prolonged or high-dose use.",
            "interactions": {
                "dangerous": [
                    "Alcohol",
                    "Other benzodiazepines",
                    "Barbiturates",
                    "Opioids",
                    "GABAergic depressants"
                ],
                "unsafe": ["Antihistamines", "Muscle relaxants"],
                "caution": ["Antidepressants", "Antipsychotics"]
            },
            "notes": "Phenazepam is a powerful, long-acting benzodiazepine, reportedly up to five times stronger than diazepam (Valium). It was developed in the Soviet Union in the 1970s and is still produced in Russia and some CIS countries for medical use, but is not approved in most Western countries. It is sometimes sold online as a 'legal high' and has been found in counterfeit 'Valium' tablets. Overdose risk is high due to its potency and long duration. Effects can last several days, increasing the risk of unintentional redosing and accumulation. Withdrawal can be severe and potentially life-threatening.",
            "subjective_effects": [
                "Sedation",
                "Muscle relaxation",
                "Anxiolysis (anxiety reduction)",
                "Amnesia",
                "Cognitive impairment",
                "Motor impairment",
                "Euphoria (rare)",
                "Disinhibition",
                "Respiratory depression (at high doses or with other depressants)"
            ],
            "tolerance": {
                "full_tolerance": "Develops within weeks of regular use",
                "half_tolerance": "7-14 days after cessation",
                "zero_tolerance": "2-4 weeks after cessation",
                "cross_tolerances": ["Other benzodiazepines", "Barbiturates"]
            },
            "half_life": "60 hours (range: 40-200 hours, depending on individual metabolism)",
            "citations": [
                {
                    "name": "DrugWise - Phenazepam",
                    "reference": "https://www.drugwise.org.uk/phenazepam/"
                },
                {
                    "name": "IsomerDesign ACMD Advice on Phenazepam",
                    "reference": "https://isomerdesign.com/Cdsa/ACMD/acmd-advice-phenazepam.pdf"
                },
                {
                    "name": "Erowid - Phenazepam Law",
                    "reference": "https://www.erowid.org/pharms/phenazepam/phenazepam_law.shtml"
                }
            ],
            "categories": ["depressant", "benzodiazepine", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Phenazepam",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "General clinical reviews and case studies on phenazepam in forensic and toxicological literature (e.g., 'Phenazepam: a review of a controversial benzodiazepine' in Forensic Toxicology, 2017)",
                        "units": "hours",
                        "total_duration": {
                            "min": 12,
                            "max": 72,
                            "iso": ["PT12H", "PT72H"],
                            "note": "Some effects may persist even longer in sensitive individuals or high doses."
                        },
                        "onset": {
                            "start": 0.33,
                            "end": 1,
                            "iso_start": ["PT20M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "offset": {
                            "start": 24,
                            "end": 72,
                            "iso_start": ["PT24H"],
                            "iso_end": ["PT72H"]
                        },
                        "after_effects": {
                            "start": 48,
                            "end": 96,
                            "iso_start": ["PT48H"],
                            "iso_end": ["PT96H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 131,
        "title": "Clobazam",
        "content": "",
        "drug_info": {
            "drug_name": "Clobazam",
            "search_url": "https://www.drug-do.se/benzos?name=clobazam",
            "chemical_class": "Benzodiazepine (1,5-benzodiazepine)",
            "psychoactive_class": "Depressant, Anticonvulsant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "5-10 mg",
                            "common": "10-30 mg",
                            "strong": "30-60 mg",
                            "heavy": "60+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2.5,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 10
                            },
                            "common": {
                                "min": 10,
                                "max": 30
                            },
                            "strong": {
                                "min": 30,
                                "max": 60
                            },
                            "heavy": {
                                "min": 60,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "8-12 hours (therapeutic); psychoactive effects may be shorter",
                "onset": "30-60 minutes",
                "peak": "1-4 hours",
                "offset": "6-12 hours",
                "after_effects": "Residual sedation may persist for up to 24 hours"
            },
            "addiction_potential": "Moderate to high. As with other benzodiazepines, clobazam carries a risk of dependence and withdrawal symptoms with prolonged or high-dose use.",
            "interactions": {
                "dangerous": [
                    "Other CNS depressants (e.g., opioids, alcohol, barbiturates)"
                ],
                "unsafe": [
                    "Strong CYP3A4 inhibitors (may increase clobazam levels)"
                ],
                "caution": [
                    "Other benzodiazepines, antiepileptic drugs, CYP2C19 inhibitors"
                ]
            },
            "notes": "Clobazam is primarily used as an adjunctive treatment for seizures associated with Lennox-Gastaut syndrome, but is sometimes used off-label for other types of epilepsy and anxiety. It is considered to have a slightly different structure from classic benzodiazepines (1,5- vs. 1,4-benzodiazepines), which may affect its side effect profile. Tolerance, dependence, and withdrawal are significant risks with long-term use. Sudden discontinuation can result in withdrawal symptoms, including seizures.",
            "subjective_effects": [
                "Sedation",
                "Anxiolysis",
                "Muscle relaxation",
                "Anticonvulsant effects",
                "Mild euphoria (at higher doses)",
                "Cognitive and memory impairment",
                "Drowsiness"
            ],
            "tolerance": {
                "full_tolerance": "Develops within 2-4 weeks of regular use",
                "half_tolerance": "1-2 weeks after cessation",
                "zero_tolerance": "4-8 weeks after cessation",
                "cross_tolerances": ["Other benzodiazepines", "Barbiturates"]
            },
            "half_life": "36-42 hours (parent drug); active metabolite (N-desmethylclobazam) 40-50 hours",
            "citations": [
                {
                    "name": "DrugBank: Clobazam",
                    "reference": "https://go.drugbank.com/drugs/DB00349"
                },
                {
                    "name": "DrugBank Article: Clobazam for Lennox-Gastaut syndrome",
                    "reference": "https://go.drugbank.com/articles/A256938"
                },
                {
                    "name": "DrugBank Article: Clobazam pharmacology",
                    "reference": "https://go.drugbank.com/articles/A256968"
                }
            ],
            "categories": [
                "depressant",
                "benzodiazepine",
                "antidepressant",
                "sedative"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Clobazam",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Clobazam prescribing information, case reports, and review articles (e.g., PubChem, RxList; note: insufflation is rare and not recommended due to irritation and erratic absorption).",
                        "units": "hours",
                        "total_duration": {
                            "min": 8,
                            "max": 12,
                            "iso": ["PT8H", "PT12H"],
                            "note": "Therapeutic effects may last 8-12h; psychoactive effects (anxiolytic, sedative) may be subjectively shorter, 6-10h. Insufflation is not standard and may result in faster\u2014but potentially erratic\u2014onset and duration."
                        },
                        "onset": {
                            "start": 0.5,
                            "end": 1,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 4,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT4H"]
                        },
                        "offset": {
                            "start": 6,
                            "end": 12,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT12H"]
                        },
                        "after_effects": {
                            "start": 12,
                            "end": 24,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 132,
        "title": "Brotizolam",
        "content": "",
        "drug_info": {
            "drug_name": "Brotizolam",
            "search_url": "https://www.drug-do.se/benzos?name_like=brotizolam",
            "chemical_class": "Thienodiazepine (benzodiazepine analogue)",
            "psychoactive_class": "Depressant (sedative-hypnotic, anxiolytic)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "0.0625 mg",
                            "light": "0.125 mg",
                            "common": "0.125\u20130.25 mg",
                            "strong": "0.25\u20130.5 mg",
                            "heavy": "0.5 mg+"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.0625,
                                "max": 0.125
                            },
                            "light": {
                                "min": 0.125,
                                "max": 0.25
                            },
                            "common": {
                                "min": 0.25,
                                "max": 0.5
                            },
                            "strong": {
                                "min": 0.5,
                                "max": 1.0
                            },
                            "heavy": {
                                "min": 1.0,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "6\u20138 hours",
                "onset": "15\u201330 minutes",
                "peak": "1\u20132 hours",
                "offset": "4\u20136 hours",
                "after_effects": "Residual sedation may last up to 12 hours, especially in elderly or sensitive individuals."
            },
            "addiction_potential": "Brotizolam, like other benzodiazepine analogues, has a moderate to high risk of dependence and addiction, especially with prolonged or high-dose use.",
            "interactions": {
                "dangerous": [
                    "Alcohol",
                    "Opioids",
                    "Other benzodiazepines",
                    "Barbiturates"
                ],
                "unsafe": ["CNS depressants"],
                "caution": [
                    "Antidepressants",
                    "Antipsychotics",
                    "Antihistamines"
                ]
            },
            "notes": "Brotizolam is a short-acting benzodiazepine analogue primarily prescribed for the short-term treatment of severe or debilitating insomnia. It should be used with caution in elderly patients and those with a history of substance abuse. Abrupt discontinuation after prolonged use may result in withdrawal symptoms, including rebound insomnia, anxiety, and seizures.",
            "subjective_effects": [
                "Sedation",
                "Anxiolysis",
                "Muscle relaxation",
                "Hypnotic (sleep-inducing) effects",
                "Impaired coordination",
                "Amnesia (at higher doses)",
                "Reduced alertness"
            ],
            "tolerance": {
                "full_tolerance": "Develops within 2\u20134 weeks of regular use",
                "half_tolerance": "1\u20132 weeks after cessation",
                "zero_tolerance": "4\u20138 weeks after cessation",
                "cross_tolerances": ["Other benzodiazepines", "Z-drugs"]
            },
            "half_life": "3\u20136 hours",
            "citations": [
                {
                    "name": "DrugBank: Brotizolam",
                    "reference": "https://go.drugbank.com/drugs/DB09017"
                },
                {
                    "name": "DrugBank: Benzodiazepine category",
                    "reference": "https://go.drugbank.com/categories/DBCAT003883"
                }
            ],
            "categories": [
                "depressant",
                "benzodiazepine",
                "sedative",
                "habit-forming"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Brotizolam",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Brotizolam is a thienotriazolodiazepine hypnotic used for its sedative and anxiolytic effects. Its oral route is better characterized, but limited data and analogues suggest a faster onset with insufflation. See: 'Brotizolam', Lexicomp, 2024; general benzodiazepine clinical resources.",
                        "units": "hours",
                        "total_duration": {
                            "min": 6,
                            "max": 8,
                            "iso": ["PT6H", "PT8H"],
                            "note": "Total subjective duration of noticeable effects (hypnosis, anxiolysis, sedation)."
                        },
                        "onset": {
                            "start": 0.25,
                            "end": 0.5,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT30M"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 4,
                            "end": 6,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT6H"]
                        },
                        "after_effects": {
                            "start": 8,
                            "end": 12,
                            "iso_start": ["PT8H"],
                            "iso_end": ["PT12H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 133,
        "title": "Cocaine",
        "content": "",
        "drug_info": {
            "drug_name": "Cocaine",
            "search_url": "https://go.drugbank.com/drugs/DB00907",
            "chemical_class": "Tropane alkaloid",
            "psychoactive_class": "Stimulant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5-10 mg",
                            "light": "10-30 mg",
                            "common": "30-60 mg",
                            "strong": "60-100 mg",
                            "heavy": "100+ mg"
                        }
                    },
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "10-20 mg",
                            "light": "20-50 mg",
                            "common": "50-100 mg",
                            "strong": "100-150 mg",
                            "heavy": "150+ mg"
                        }
                    },
                    {
                        "route": "IV",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5-10 mg",
                            "light": "10-30 mg",
                            "common": "30-60 mg",
                            "strong": "60-100 mg",
                            "heavy": "100+ mg"
                        }
                    },
                    {
                        "route": "smoked",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5-10 mg",
                            "light": "10-20 mg",
                            "common": "20-50 mg",
                            "strong": "50-100 mg",
                            "heavy": "100+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 30
                            },
                            "common": {
                                "min": 30,
                                "max": 60
                            },
                            "strong": {
                                "min": 60,
                                "max": 100
                            },
                            "heavy": {
                                "min": 100,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 10,
                                "max": 20
                            },
                            "light": {
                                "min": 20,
                                "max": 50
                            },
                            "common": {
                                "min": 50,
                                "max": 100
                            },
                            "strong": {
                                "min": 100,
                                "max": 150
                            },
                            "heavy": {
                                "min": 150,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "intravenous",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 30
                            },
                            "common": {
                                "min": 30,
                                "max": 60
                            },
                            "strong": {
                                "min": 60,
                                "max": 100
                            },
                            "heavy": {
                                "min": 100,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "smoked",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 20
                            },
                            "common": {
                                "min": 20,
                                "max": 50
                            },
                            "strong": {
                                "min": 50,
                                "max": 100
                            },
                            "heavy": {
                                "min": 100,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "30-90 minutes (insufflated)",
                "onset": "1-3 minutes (insufflated), seconds (smoked/IV)",
                "peak": "15-30 minutes (insufflated)",
                "offset": "30-60 minutes",
                "after_effects": "1-3 hours (comedown, afterglow)"
            },
            "addiction_potential": "High. Cocaine is well-known for its strong potential for psychological addiction and compulsive use, with rapid tolerance development and significant withdrawal symptoms.",
            "interactions": {
                "dangerous": [
                    "MAOIs",
                    "other stimulants (e.g., amphetamines, methamphetamine)",
                    "alcohol (increases risk of cocaethylene formation, cardiac toxicity)"
                ],
                "unsafe": [
                    "SSRIs",
                    "tricyclic antidepressants",
                    "antipsychotics"
                ],
                "caution": [
                    "opioids (risk of respiratory depression when mixed)",
                    "benzodiazepines (may mask toxicity)"
                ]
            },
            "notes": "Cocaine is a powerful central nervous system stimulant with significant abuse potential. It acts as a local anesthetic and vasoconstrictor. Overdose can result in seizures, cardiac arrest, and death. Chronic use is associated with cardiovascular issues, nasal septum damage (when insufflated), and psychiatric symptoms. Mixing with alcohol forms cocaethylene, which is more cardiotoxic.",
            "subjective_effects": [
                "Euphoria",
                "Increased energy",
                "Increased confidence",
                "Alertness",
                "Decreased appetite",
                "Increased heart rate",
                "Anxiety",
                "Paranoia",
                "Agitation",
                "Compulsive redosing",
                "Insomnia"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (within hours to days)",
                "half_tolerance": "3-7 days",
                "zero_tolerance": "1-2 weeks",
                "cross_tolerances": ["Other stimulants (partial)"]
            },
            "half_life": "0.7\u20131.5 hours",
            "citations": [
                {
                    "name": "DrugWise Cocaine Infographic",
                    "reference": "https://www.drugwise.org.uk/wp-content/uploads/CocaineInfographic-1.pdf"
                },
                {
                    "name": "DrugBank: Cocaine",
                    "reference": "https://go.drugbank.com/drugs/DB00907"
                }
            ],
            "categories": ["stimulant", "habit-forming", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Cocaine",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Mayo Clinic; DrugFacts: Cocaine, National Institute on Drug Abuse (2023); Julien's Primer of Drug Action, 14th Ed.",
                        "units": "minutes",
                        "total_duration": {
                            "min": 30,
                            "max": 90,
                            "iso": ["PT30M", "PT1H30M"],
                            "note": "Total period of notable psychoactive effect after a typical single dose."
                        },
                        "onset": {
                            "start": 1,
                            "end": 3,
                            "iso_start": ["PT1M"],
                            "iso_end": ["PT3M"]
                        },
                        "peak": {
                            "start": 15,
                            "end": 30,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT30M"]
                        },
                        "offset": {
                            "start": 30,
                            "end": 60,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT1H"]
                        },
                        "after_effects": {
                            "start": 60,
                            "end": 180,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT3H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 135,
        "title": "Chlordiazepoxide",
        "content": "",
        "drug_info": {
            "drug_name": "Chlordiazepoxide",
            "search_url": "https://www.drug-do.se/benzos?name=chlordiazepoxide",
            "chemical_class": "Benzodiazepine",
            "psychoactive_class": "Depressant, Anxiolytic, Sedative",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2 mg",
                            "light": "5-10 mg",
                            "common": "10-25 mg",
                            "strong": "25-50 mg",
                            "heavy": "50+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 10
                            },
                            "common": {
                                "min": 10,
                                "max": 25
                            },
                            "strong": {
                                "min": 25,
                                "max": 50
                            },
                            "heavy": {
                                "min": 50,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "6-48 hours (varies by dose and individual)",
                "onset": "30-60 minutes",
                "peak": "1-4 hours",
                "offset": "6-48 hours",
                "after_effects": "Residual sedation may last up to 24 hours"
            },
            "addiction_potential": "Moderate to high with regular use; risk of dependence and withdrawal symptoms, especially with long-term or high-dose use.",
            "interactions": {
                "dangerous": ["Alcohol", "Opioids", "Barbiturates"],
                "unsafe": ["Other CNS depressants"],
                "caution": ["Antidepressants", "Antipsychotics"]
            },
            "notes": "Chlordiazepoxide is primarily prescribed for anxiety, panic disorders, and acute alcohol withdrawal. It has sedative, hypnotic, anticonvulsant, and amnesic properties. Long-term use can lead to tolerance, dependence, and withdrawal symptoms. Use caution when combining with other CNS depressants due to risk of respiratory depression and overdose.",
            "subjective_effects": [
                "Sedation",
                "Anxiolysis (reduced anxiety)",
                "Muscle relaxation",
                "Amnesia",
                "Lowered inhibitions",
                "Drowsiness",
                "Impaired coordination"
            ],
            "tolerance": {
                "full_tolerance": "Develops within 2-4 weeks of regular use",
                "half_tolerance": "1-2 weeks after cessation",
                "zero_tolerance": "4-8 weeks after cessation",
                "cross_tolerances": ["Other benzodiazepines", "Barbiturates"]
            },
            "half_life": "5-30 hours (parent compound); active metabolites may prolong effects up to 100 hours",
            "citations": [
                {
                    "name": "Erowid Chlordiazepoxide Vault",
                    "reference": "https://erowid.org/pharms/chlordiazepoxide/"
                },
                {
                    "name": "DrugBank: Chlordiazepoxide",
                    "reference": "https://go.drugbank.com/drugs/DB00475"
                },
                {
                    "name": "TripSit Factsheet: Librium",
                    "reference": "https://tripsit.me/factsheets/librium"
                }
            ],
            "categories": [
                "depressant",
                "benzodiazepine",
                "habit-forming",
                "sedative"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Chlordiazepoxide",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th Edition; clinical literature on benzodiazepines.",
                        "units": "hours",
                        "total_duration": {
                            "min": 6,
                            "max": 48,
                            "iso": ["PT6H", "PT48H"],
                            "note": "Duration varies widely due to long half-life and active metabolites. Individual differences, dose, and prior tolerance all affect range."
                        },
                        "onset": {
                            "start": 0.5,
                            "end": 1,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 4,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT4H"]
                        },
                        "offset": {
                            "start": 6,
                            "end": 48,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT48H"]
                        },
                        "after_effects": {
                            "start": 6,
                            "end": 24,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 136,
        "title": "Flubromazepam",
        "content": "",
        "drug_info": {
            "drug_name": "Flubromazepam",
            "search_url": "https://www.drug-do.se/benzos?name=flubromazepam",
            "chemical_class": "Benzodiazepine",
            "psychoactive_class": "Depressant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "0.5 mg",
                            "light": "0.5-1 mg",
                            "common": "1-4 mg",
                            "strong": "4-8 mg",
                            "heavy": "8+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.5,
                                "max": 1
                            },
                            "light": {
                                "min": 1,
                                "max": 2
                            },
                            "common": {
                                "min": 2,
                                "max": 6
                            },
                            "strong": {
                                "min": 6,
                                "max": 10
                            },
                            "heavy": {
                                "min": 10,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "18-36 hours (can be longer at high doses)",
                "onset": "20-60 minutes",
                "peak": "2-6 hours",
                "offset": "12-24 hours",
                "after_effects": "Residual sedation can last up to 3 days"
            },
            "addiction_potential": "High; similar to other benzodiazepines, flubromazepam carries a significant risk of dependence and withdrawal symptoms with repeated use.",
            "interactions": {
                "dangerous": [
                    "Alcohol",
                    "Opioids",
                    "Other benzodiazepines",
                    "Barbiturates"
                ],
                "unsafe": ["Antipsychotics", "Sedative antihistamines"],
                "caution": ["Other CNS depressants"]
            },
            "notes": "Flubromazepam is known for its extremely long duration, with effects sometimes lasting up to three days, especially at higher doses. Overdose risk is significant due to delayed onset and long half-life. It is associated with strong sedative, hypnotic, and anxiolytic effects. Users report amnesia and motor impairment at higher doses. It is a 'research chemical' benzodiazepine and not approved for medical use. Use with caution due to risk of overdose and severe withdrawal.",
            "subjective_effects": [
                "Sedation",
                "Anxiolysis",
                "Muscle relaxation",
                "Hypnotic effects",
                "Amnesia",
                "Motor impairment",
                "Euphoria (occasionally reported)"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (days to weeks)",
                "half_tolerance": "1-2 weeks after cessation",
                "zero_tolerance": "4-8 weeks after cessation",
                "cross_tolerances": ["Other benzodiazepines"]
            },
            "half_life": "~105 hours (very long, may vary by individual)",
            "citations": [
                {
                    "name": "TripSit Factsheet: Flubromazepam",
                    "reference": "https://tripsit.me/factsheets/flubromazepam"
                },
                {
                    "name": "Bluelight Drug Info: Flubromazepam",
                    "reference": "https://www.bluelight.org/community/threads/drug-info-flubromazepam.699828/"
                }
            ],
            "categories": [
                "depressant",
                "benzodiazepine",
                "research-chemical",
                "habit-forming"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Flubromazepam",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Relevant literature on long-acting benzodiazepines and user reports, e.g., 'The Pharmacology and Abuse of Flubromazepam,' academic review articles, and typical pharmacokinetic durations for similar compounds.",
                        "units": "hours",
                        "total_duration": {
                            "min": 18,
                            "max": 36,
                            "iso": ["PT18H", "PT36H"],
                            "note": "Can be longer with high doses"
                        },
                        "onset": {
                            "start": 0.33,
                            "end": 1,
                            "iso_start": ["PT20M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 6,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT6H"]
                        },
                        "offset": {
                            "start": 12,
                            "end": 24,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT24H"]
                        },
                        "after_effects": {
                            "start": 24,
                            "end": 72,
                            "iso_start": ["PT24H"],
                            "iso_end": ["PT72H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 137,
        "title": "Amphetamine",
        "content": "",
        "drug_info": {
            "drug_name": "Amphetamine",
            "search_url": "https://go.drugbank.com/drugs/DB00182",
            "chemical_class": "Phenethylamine",
            "psychoactive_class": "Stimulant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2.5 mg",
                            "light": "5-10 mg",
                            "common": "10-30 mg",
                            "strong": "30-60 mg",
                            "heavy": "60+ mg"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2 mg",
                            "light": "5-10 mg",
                            "common": "10-25 mg",
                            "strong": "25-50 mg",
                            "heavy": "50+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2.5,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 10
                            },
                            "common": {
                                "min": 10,
                                "max": 30
                            },
                            "strong": {
                                "min": 30,
                                "max": 60
                            },
                            "heavy": {
                                "min": 60,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 10
                            },
                            "common": {
                                "min": 10,
                                "max": 25
                            },
                            "strong": {
                                "min": 25,
                                "max": 50
                            },
                            "heavy": {
                                "min": 50,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4-8 hours (oral)",
                "onset": "20-60 minutes (oral)",
                "peak": "2-4 hours (oral)",
                "offset": "2-4 hours (oral)",
                "after_effects": "up to 24 hours (residual stimulation, insomnia)"
            },
            "addiction_potential": "High. Amphetamine has a significant risk of psychological dependence and abuse, especially with frequent or high-dose use.",
            "interactions": {
                "dangerous": ["MAOIs", "other stimulants"],
                "unsafe": [
                    "tricyclic antidepressants",
                    "SSRIs",
                    "antihypertensives"
                ],
                "caution": ["alcohol", "caffeine", "antipsychotics"]
            },
            "notes": "Amphetamine is a controlled substance with a high potential for abuse. It is used medically for ADHD, narcolepsy, and, less commonly, obesity. Overdose can cause severe cardiovascular and psychiatric symptoms. Chronic use may lead to neurotoxicity, cardiovascular issues, and mental health problems. Use caution with other stimulants or medications affecting serotonin and dopamine.",
            "subjective_effects": [
                "increased energy",
                "euphoria",
                "increased focus",
                "appetite suppression",
                "increased heart rate",
                "insomnia",
                "anxiety",
                "paranoia (at high doses)",
                "jaw clenching",
                "increased sociability"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (days to weeks)",
                "half_tolerance": "Several weeks",
                "zero_tolerance": "1-3 months",
                "cross_tolerances": ["other amphetamines", "methamphetamine"]
            },
            "half_life": "9-14 hours (varies by individual and pH)",
            "citations": [
                {
                    "name": "DrugBank: Amphetamine",
                    "reference": "https://go.drugbank.com/drugs/DB00182"
                },
                {
                    "name": "DrugWise: Amphetamines",
                    "reference": "https://www.drugwise.org.uk/amphetamines/"
                }
            ],
            "categories": ["stimulant", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Amphetamine",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "General clinical pharmacology texts (e.g., Goodman & Gilman's) and harm reduction sources; tailored for insufflation route.",
                        "units": "hours",
                        "total_duration": {
                            "min": 3,
                            "max": 6,
                            "iso": ["PT3H", "PT6H"],
                            "note": "Shorter than oral due to rapid onset and offset; typical for insufflated stimulants."
                        },
                        "onset": {
                            "start": 0.05,
                            "end": 0.5,
                            "iso_start": ["PT3M"],
                            "iso_end": ["PT30M"]
                        },
                        "peak": {
                            "start": 0.25,
                            "end": 2,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 2,
                            "end": 6,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT6H"]
                        },
                        "after_effects": {
                            "start": 6,
                            "end": 24,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 139,
        "title": "DOM",
        "content": "",
        "drug_info": {
            "drug_name": "DOM (2,5-Dimethoxy-4-methylamphetamine)",
            "search_url": "https://drugusersbible.org/content/chemscape/psychedelics/dom/index.html",
            "chemical_class": "Phenethylamine (substituted amphetamine)",
            "psychoactive_class": "Psychedelic (hallucinogen)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "0.5-1mg",
                            "light": "1-2.5mg",
                            "common": "2.5-5mg",
                            "strong": "5-7.5mg",
                            "heavy": "7.5mg+"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.5,
                                "max": 1
                            },
                            "light": {
                                "min": 1,
                                "max": 2.5
                            },
                            "common": {
                                "min": 2.5,
                                "max": 5
                            },
                            "strong": {
                                "min": 5,
                                "max": 7.5
                            },
                            "heavy": {
                                "min": 7.5,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "14-24 hours (dose dependent)",
                "onset": "1-2 hours",
                "peak": "2-3 hours",
                "offset": "4-12 hours (coming down)",
                "after_effects": "4-16 hours"
            },
            "addiction_potential": "DOM is not considered physically addictive, but psychological dependence is possible with frequent use, as with most psychedelics.",
            "interactions": {
                "dangerous": ["MAOIs", "Tramadol"],
                "unsafe": [
                    "Other stimulants",
                    "Other psychedelics (high dose)"
                ],
                "caution": ["SSRIs", "Benzodiazepines (may dull effects)"]
            },
            "notes": "DOM has a very slow onset and extremely long duration, making redosing risky. Overdoses in the 1960s were due to high doses and delayed onset. It is a potent psychedelic with effects similar to LSD but longer lasting. It can cause positive amphetamine drug tests for up to a week after use.",
            "subjective_effects": [
                "Visual hallucinations",
                "Altered perception of time",
                "Euphoria",
                "Stimulation",
                "Enhanced colors",
                "Synesthesia",
                "Anxiety (at high doses)",
                "Confusion (at high doses)"
            ],
            "tolerance": {
                "full_tolerance": "After 3-7 days of repeated use",
                "half_tolerance": "~7 days",
                "zero_tolerance": "2 weeks or more",
                "cross_tolerances": ["Other psychedelics (LSD, 2C-x, etc.)"]
            },
            "half_life": "Unknown (very long-acting, effects may last up to 24 hours)",
            "citations": [
                {
                    "name": "TripSit DOM Wiki",
                    "reference": "https://wiki.tripsit.me/wiki/DOM"
                },
                {
                    "name": "Erowid DOM Vault",
                    "reference": "https://erowid.org/chemicals/dom/"
                },
                {
                    "name": "DrugWise DOM",
                    "reference": "https://www.drugwise.org.uk/dom/"
                },
                {
                    "name": "DrugBank DOM",
                    "reference": "https://go.drugbank.com/drugs/DB01528"
                }
            ],
            "categories": ["psychedelic", "hallucinogen", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "DOM (2,5-Dimethoxy-4-methylamphetamine)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Shulgin, A., & Shulgin, A. (1991). PiHKAL: A Chemical Love Story. Experience reports and limited research literature on DOM indicate long duration, particularly via insufflation.",
                        "units": "hours",
                        "total_duration": {
                            "min": 14,
                            "max": 24,
                            "iso": ["PT14H", "PT24H"],
                            "note": "Highly dose dependent and subject to individual variation. Some reports note shorter or longer durations."
                        },
                        "onset": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 5,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT5H"]
                        },
                        "offset": {
                            "start": 5,
                            "end": 14,
                            "iso_start": ["PT5H"],
                            "iso_end": ["PT14H"]
                        },
                        "after_effects": {
                            "start": 14,
                            "end": 24,
                            "iso_start": ["PT14H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 141,
        "title": "2C-I",
        "content": "",
        "drug_info": {
            "drug_name": "2C-I",
            "search_url": "https://drugusersbible.org/content/chemscape/psychedelics/2c-i/index.html",
            "chemical_class": "Phenethylamine",
            "psychoactive_class": "Psychedelic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2-4 mg",
                            "light": "5-10 mg",
                            "common": "10-20 mg",
                            "strong": "20-25 mg",
                            "heavy": "25+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2,
                                "max": 4
                            },
                            "light": {
                                "min": 5,
                                "max": 10
                            },
                            "common": {
                                "min": 10,
                                "max": 20
                            },
                            "strong": {
                                "min": 20,
                                "max": 25
                            },
                            "heavy": {
                                "min": 25,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "6-10 hours",
                "onset": "30-90 minutes",
                "peak": "2-4 hours",
                "offset": "2-4 hours",
                "after_effects": "up to 24 hours (residual)"
            },
            "addiction_potential": "Low; 2C-I is not considered physically addictive, though psychological habituation is possible with frequent use.",
            "interactions": {
                "dangerous": ["MAOIs"],
                "unsafe": ["Tramadol"],
                "caution": ["Other stimulants", "Other psychedelics"]
            },
            "notes": "2C-I is a Schedule I controlled substance in the United States, making possession, distribution, or manufacture illegal. It is not the same as 2C-I-NBOMe, which is more potent and riskier. 2C-I is not detected in standard drug tests. Effects are similar to 2C-B, with vivid visuals and stimulation. Use caution with unknown substances, as misrepresentation is possible.",
            "subjective_effects": [
                "Vivid open-eye visuals",
                "Mild closed-eye visuals",
                "Stimulation",
                "Enhanced colors",
                "Euphoria",
                "Altered thought patterns",
                "Increased sociability"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (within days)",
                "half_tolerance": "~3-7 days",
                "zero_tolerance": "~1-2 weeks",
                "cross_tolerances": [
                    "Other psychedelics (especially phenethylamines)"
                ]
            },
            "half_life": "~4-6 hours (estimated)",
            "citations": [
                {
                    "name": "Erowid 2C-I Basics",
                    "reference": "https://erowid.org/chemicals/2ci/2ci_basics.shtml"
                },
                {
                    "name": "Erowid 2C-I Experience Reports",
                    "reference": "https://erowid.org/chemicals/2ci/2ci.shtml"
                },
                {
                    "name": "TripSit Factsheet: 2C-I",
                    "reference": "https://tripsit.me/factsheets/2C-I"
                },
                {
                    "name": "Erowid 2C-I Dosage",
                    "reference": "https://www.erowid.org/chemicals/2ci/2ci_dose.shtml"
                }
            ],
            "categories": ["psychedelic", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "2C-I",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Shulgin, A., & Shulgin, A. (1991). PIHKAL: A Chemical Love Story. User reports and published literature, 2C-I insufflated.",
                        "units": "hours",
                        "total_duration": {
                            "min": 6,
                            "max": 10,
                            "iso": ["PT6H", "PT10H"],
                            "note": "Duration can vary with dosage and individual sensitivity; the upper limit may be longer with higher doses or sensitive individuals."
                        },
                        "onset": {
                            "start": 0.5,
                            "end": 1.5,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT1H30M"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "offset": {
                            "start": 4,
                            "end": 8,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT8H"]
                        },
                        "after_effects": {
                            "start": 10,
                            "end": 24,
                            "iso_start": ["PT10H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 164,
        "title": "Tapentadol",
        "content": "# Tapentadol\n## Phenylpropylamine | Opioid\n      \nTapentadol is a centrally acting opioid analgesic with dual mechanisms of action: mu-opioid receptor agonism and norepinephrine reuptake inhibition. It is used for the management of moderate to severe pain and is available in immediate-release and extended-release formulations.",
        "drug_info": {
            "drug_name": "Tapentadol",
            "search_url": "https://www.drugs.com/tapentadol.html",
            "chemical_class": "Phenylpropylamine",
            "psychoactive_class": "Opioid",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "12.5 mg",
                            "light": "25 - 50 mg",
                            "common": "50 - 100 mg",
                            "strong": "100 - 150 mg",
                            "heavy": "150 - 300 mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 12.5,
                                "max": 25
                            },
                            "light": {
                                "min": 25,
                                "max": 50
                            },
                            "common": {
                                "min": 50,
                                "max": 100
                            },
                            "strong": {
                                "min": 100,
                                "max": 150
                            },
                            "heavy": {
                                "min": 150,
                                "max": 300
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4 - 6 hours",
                "onset": "30 - 60 minutes",
                "peak": "1 - 2 hours",
                "offset": "2 - 4 hours",
                "after_effects": "Up to 24 hours"
            },
            "addiction_potential": "Moderate to high potential for addiction and abuse, similar to other opioids.",
            "interactions": {
                "dangerous": ["Alcohol", "Benzodiazepines", "Other opioids"],
                "unsafe": ["MAOIs", "SSRIs"],
                "caution": ["Antihistamines", "Antidepressants"]
            },
            "notes": "Tapentadol is a centrally acting opioid analgesic with dual mechanisms of action: mu-opioid receptor agonism and norepinephrine reuptake inhibition. It is used for the management of moderate to severe pain and is available in immediate-release and extended-release formulations.",
            "subjective_effects": [
                "Euphoria",
                "Sedation",
                "Pain relief",
                "Drowsiness",
                "Nausea",
                "Dizziness"
            ],
            "tolerance": {
                "full_tolerance": "Develops with prolonged use",
                "half_tolerance": "Approximately 1 week",
                "zero_tolerance": "Approximately 10 days",
                "cross_tolerances": ["Other opioids"]
            },
            "half_life": "4 hours",
            "citations": [
                {
                    "name": "Drugs.com - Tapentadol",
                    "reference": "https://www.drugs.com/tapentadol.html"
                },
                {
                    "name": "DrugBank Overview of Tapentadol",
                    "reference": "https://go.drugbank.com/drugs/DB06204"
                },
                {
                    "name": "DrugBank Biointeractions for Tapentadol",
                    "reference": "https://go.drugbank.com/drugs/DB06204/biointeractions"
                }
            ],
            "categories": ["opioid", "depressant"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Tapentadol",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Tapentadol, a centrally acting analgesic, is occasionally insufflated recreationally, although it is intended for oral administration. Insufflation typically shortens the onset and may slightly alter peak effects but doesn't drastically extend or shorten duration versus oral. Data from published pharmacokinetic studies and user reports have been considered. Example references: 'Tapentadol\u2014Pharmacology, Mechanism of Action, and Tolerability', Drugs (2010), and anecdotal user reports (e.g. Erowid).",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 6,
                            "iso": ["PT4H", "PT6H"],
                            "note": "Insufflated duration is similar but may trend toward lower end of oral duration; maximum values reflect edge cases."
                        },
                        "onset": {
                            "start": 0.25,
                            "end": 1,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "after_effects": {
                            "start": 6,
                            "end": 24,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 280,
        "title": "DOB",
        "content": "# DOB (2,5-Dimethoxy-4-bromoamphetamine)\n## Phenethylamine (specifically, substituted amphetamine) | Psychedelic (hallucinogen)\n      \nDOB is a potent and long-lasting psychedelic amphetamine, notable for its low active dose and extended duration. It is less common than other psychedelics like LSD or 2C-B and can be physically stimulating. Overdoses can be dangerous due to vasoconstriction and cardiovascular effects. The onset is slow, and the experience can be intense and physically taxing. Caution is advised due to its potency and duration.",
        "drug_info": {
            "drug_name": "DOB (2,5-Dimethoxy-4-bromoamphetamine)",
            "search_url": "https://c0c59da34f7608d6.ngrok.app/pihkal?name=DOB",
            "chemical_class": "Phenethylamine (specifically, substituted amphetamine)",
            "psychoactive_class": "Psychedelic (hallucinogen)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "0.5 mg",
                            "light": "1.0-1.5 mg",
                            "common": "1.5-3.0 mg",
                            "strong": "3.0-5.0 mg",
                            "heavy": "5.0+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.25,
                                "max": 0.5
                            },
                            "light": {
                                "min": 0.5,
                                "max": 1.5
                            },
                            "common": {
                                "min": 1.5,
                                "max": 3.0
                            },
                            "strong": {
                                "min": 3.0,
                                "max": 5.0
                            },
                            "heavy": {
                                "min": 5.0,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "18-30 hours",
                "onset": "1-3 hours",
                "peak": "4-8 hours",
                "offset": "8-18 hours",
                "after_effects": "Up to 48 hours (residual stimulation, afterglow)"
            },
            "addiction_potential": "Low. DOB is not considered physically addictive, but psychological habituation is possible with frequent use.",
            "interactions": {
                "dangerous": [
                    "MAOIs (risk of hypertensive crisis or serotonin syndrome)"
                ],
                "unsafe": ["Other stimulants (increased cardiovascular risk)"],
                "caution": [
                    "Other psychedelics (potentiation and unpredictable effects)",
                    "SSRIs (may alter effects)"
                ]
            },
            "notes": "DOB is a potent and long-lasting psychedelic amphetamine, notable for its low active dose and extended duration. It is less common than other psychedelics like LSD or 2C-B and can be physically stimulating. Overdoses can be dangerous due to vasoconstriction and cardiovascular effects. The onset is slow, and the experience can be intense and physically taxing. Caution is advised due to its potency and duration.",
            "subjective_effects": [
                "Visual hallucinations (colorful, geometric patterns)",
                "Enhanced colors",
                "Euphoria",
                "Stimulation",
                "Altered thought patterns",
                "Time distortion",
                "Vasoconstriction (cold extremities)",
                "Insomnia",
                "Anxiety (at high doses)",
                "Nausea"
            ],
            "tolerance": {
                "full_tolerance": "Develops after 3-4 days of repeated use",
                "half_tolerance": "~7 days",
                "zero_tolerance": "2-3 weeks",
                "cross_tolerances": ["Other psychedelics (e.g., LSD, 2C-B)"]
            },
            "half_life": "13-20 hours (estimates vary)",
            "citations": [
                {
                    "name": "Erowid DOB Vault",
                    "reference": "https://www.erowid.org/chemicals/dob/dob.shtml"
                },
                {
                    "name": "Erowid 2C-B FAQ (DOB section)",
                    "reference": "https://www.erowid.org/chemicals/2cb/2cb_faq.shtml"
                },
                {
                    "name": "Isomerdesign: PiHKAL entry for DOB",
                    "reference": "https://isomerdesign.com/pihkal/read/pk/62"
                },
                {
                    "name": "Erowid Reference: Effective Dose",
                    "reference": "https://erowid.org/references/refs_view.php?ID=6864"
                }
            ],
            "categories": ["psychedelic", "research-chemical", "hallucinogen"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "DOB (2,5-Dimethoxy-4-bromoamphetamine)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Academic literature on psychedelic amphetamines and numerous user reports (see 'PiHKAL', medical case reviews).",
                        "units": "hours",
                        "total_duration": {
                            "min": 18,
                            "max": 30,
                            "iso": ["PT18H", "PT30H"],
                            "note": "Insufflated DOB onset is somewhat faster than oral, but total duration is comparable; some users report a slightly shorter tail phase."
                        },
                        "onset": {
                            "start": 1,
                            "end": 3,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT3H"]
                        },
                        "peak": {
                            "start": 4,
                            "end": 8,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT8H"]
                        },
                        "offset": {
                            "start": 8,
                            "end": 18,
                            "iso_start": ["PT8H"],
                            "iso_end": ["PT18H"]
                        },
                        "after_effects": {
                            "start": 18,
                            "end": 48,
                            "iso_start": ["PT18H"],
                            "iso_end": ["PT48H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 142,
        "title": "Flutoprazepam",
        "content": "",
        "drug_info": {
            "drug_name": "Flutoprazepam",
            "search_url": "https://www.drug-do.se/benzos?name=flutoprazepam",
            "chemical_class": "Benzodiazepine",
            "psychoactive_class": "Depressant (Benzodiazepine)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "0.5 mg",
                            "light": "0.5-1 mg",
                            "common": "1-2.5 mg",
                            "strong": "2.5-5 mg",
                            "heavy": "5+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.5,
                                "max": 1
                            },
                            "light": {
                                "min": 1,
                                "max": 2
                            },
                            "common": {
                                "min": 2,
                                "max": 3.5
                            },
                            "strong": {
                                "min": 3.5,
                                "max": 6
                            },
                            "heavy": {
                                "min": 6,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "60-90 hours (very long-acting)",
                "onset": "30-60 minutes",
                "peak": "1-3 hours",
                "offset": "Several days (due to long half-life)",
                "after_effects": "May persist for several days due to accumulation"
            },
            "addiction_potential": "High; similar to other benzodiazepines, with risk of dependence and withdrawal symptoms after prolonged use.",
            "interactions": {
                "dangerous": ["Alcohol", "Opioids", "Other CNS depressants"],
                "unsafe": ["Barbiturates", "Other benzodiazepines"],
                "caution": [
                    "Antidepressants",
                    "Antipsychotics",
                    "Antihistamines"
                ]
            },
            "notes": "Flutoprazepam is a long-acting benzodiazepine, primarily prescribed for serious insomnia and as an anticonvulsant. It has powerful hypnotic, sedative, anxiolytic, and muscle relaxant properties. Due to its long half-life, accumulation and next-day sedation are significant risks. It is sometimes misused and has been reported as a date rape drug. Not approved in many countries, mainly used in Japan.",
            "subjective_effects": [
                "Anxiolysis",
                "Sedation",
                "Muscle relaxation",
                "Hypnotic effects (sleep induction)",
                "Motor impairment",
                "Amnesia",
                "Calmness"
            ],
            "tolerance": {
                "full_tolerance": "Within weeks of regular use",
                "half_tolerance": "7-14 days after cessation",
                "zero_tolerance": "2-4 weeks after cessation",
                "cross_tolerances": ["Other benzodiazepines", "Barbiturates"]
            },
            "half_life": "60-90 hours",
            "citations": [
                {
                    "name": "DrugBank: Flutoprazepam",
                    "reference": "https://go.drugbank.com/drugs/DB01544"
                },
                {
                    "name": "Bluelight: Flutoprazepam or Restas",
                    "reference": "https://www.bluelight.org/community/threads/flutoprazepam-or-restas-the-longest-lasting-benzo-and-japan-exclusive.476124/"
                },
                {
                    "name": "Erowid Experience: Flutoprazepam",
                    "reference": "https://erowid.org/experiences/exp.php?ID=111431"
                },
                {
                    "name": "TripSit Factsheet: Norflurazepam",
                    "reference": "https://tripsit.me/factsheets/norflurazepam"
                },
                {
                    "name": "TripSit Wiki: Benzodiazepines",
                    "reference": "https://wiki.tripsit.me/index.php?title=Benzodiazepines&oldid=&mobileaction=toggle_view_desktop"
                }
            ],
            "categories": ["depressant", "benzodiazepine", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Flutoprazepam",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Flutoprazepam is a long-acting benzodiazepine. While oral duration is more documented, insufflation is rarely described; however, absorption would still result in an extensive duration due to its long half-life. See: PubChem, various benzodiazepine pharmacokinetics reviews (e.g. PubMed: PMID 16951778).",
                        "units": "hours",
                        "total_duration": {
                            "min": 60,
                            "max": 90,
                            "iso": ["P2DT12H", "P3DT18H"],
                            "note": "Duration is long due to extensive half-life and active metabolites."
                        },
                        "onset": {
                            "start": 0.5,
                            "end": 1,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 3,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 24,
                            "end": 90,
                            "iso_start": ["P1D"],
                            "iso_end": ["P3DT18H"]
                        },
                        "after_effects": {
                            "start": 48,
                            "end": 120,
                            "iso_start": ["P2D"],
                            "iso_end": ["P5D"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 145,
        "title": "Selegiline",
        "content": "",
        "drug_info": {
            "drug_name": "Selegiline",
            "search_url": "https://go.drugbank.com/drugs/DB01037",
            "chemical_class": "Phenethylamine (substituted amphetamine derivative), Propargylamine",
            "psychoactive_class": "Monoamine oxidase inhibitor (MAOI), specifically selective MAO-B inhibitor at therapeutic doses",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "1 mg",
                            "light": "2.5-5 mg",
                            "common": "5-10 mg",
                            "strong": "10-15 mg",
                            "heavy": "20 mg+"
                        }
                    },
                    {
                        "route": "transdermal",
                        "units": "mg/24h",
                        "dose_ranges": {
                            "threshold": "2 mg/24h",
                            "light": "3-6 mg/24h",
                            "common": "6-12 mg/24h",
                            "strong": "12-18 mg/24h",
                            "heavy": "18 mg+/24h"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 1,
                                "max": 2.5
                            },
                            "light": {
                                "min": 2.5,
                                "max": 5
                            },
                            "common": {
                                "min": 5,
                                "max": 10
                            },
                            "strong": {
                                "min": 10,
                                "max": 15
                            },
                            "heavy": {
                                "min": 15,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "transdermal",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2,
                                "max": 3
                            },
                            "light": {
                                "min": 3,
                                "max": 6
                            },
                            "common": {
                                "min": 6,
                                "max": 12
                            },
                            "strong": {
                                "min": 12,
                                "max": 18
                            },
                            "heavy": {
                                "min": 18,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "24-48 hours (due to irreversible MAO-B inhibition)",
                "onset": "Within 1 hour (oral); several hours (transdermal)",
                "peak": "1-2 hours (oral); 6-12 hours (transdermal)",
                "offset": "Several days (enzyme recovery required)",
                "after_effects": "MAO-B inhibition persists for up to 2 weeks after discontinuation"
            },
            "addiction_potential": "Low; not habit-forming at therapeutic doses. Some stimulant-like effects at high doses due to amphetamine metabolites, but not generally considered addictive.",
            "interactions": {
                "dangerous": [
                    "Other MAOIs",
                    "SSRIs",
                    "SNRIs",
                    "TCAs",
                    "Meperidine",
                    "Tramadol",
                    "Dextromethorphan"
                ],
                "unsafe": [
                    "Sympathomimetics (risk of hypertensive crisis)",
                    "Levodopa (dose adjustment required)"
                ],
                "caution": [
                    "Tyramine-rich foods (at high doses or non-selective inhibition)",
                    "Other dopaminergic drugs"
                ]
            },
            "notes": "Selegiline is a selective, irreversible MAO-B inhibitor at therapeutic doses (\u226410 mg/day oral), used for Parkinson's disease and major depressive disorder. At higher doses, selectivity is lost, and it inhibits both MAO-A and MAO-B, increasing risk of hypertensive crisis with tyramine. Its transdermal form (EMSAM) is used for depression and has less dietary restriction at lower doses. Metabolized to L-methamphetamine and L-amphetamine, which may cause mild stimulant effects. Dangerous interactions with serotonergic and sympathomimetic drugs. Enzyme recovery after discontinuation takes up to 2 weeks.",
            "subjective_effects": [
                "Mood elevation (in depression)",
                "Increased energy",
                "Mild stimulation (high doses)",
                "Improved motor function (in Parkinson's)",
                "Possible insomnia",
                "Rarely, agitation or anxiety"
            ],
            "tolerance": {
                "full_tolerance": "Develops slowly, if at all, with chronic use",
                "half_tolerance": "Not well established",
                "zero_tolerance": "Several weeks after discontinuation",
                "cross_tolerances": ["Other MAO inhibitors"]
            },
            "half_life": "10 hours (parent drug); MAO-B inhibition lasts much longer (up to 2 weeks)",
            "citations": [
                {
                    "name": "DrugBank: Selegiline",
                    "reference": "https://go.drugbank.com/drugs/DB01037"
                },
                {
                    "name": "DrugBank: Selegiline (deprenyl) selective MAO-B inhibitor",
                    "reference": "https://go.drugbank.com/articles/A13519"
                },
                {
                    "name": "DrugBank: Selegiline for Parkinson's disease",
                    "reference": "https://go.drugbank.com/salts/DBSALT000260"
                },
                {
                    "name": "DrugBank: Selegiline clinical trials",
                    "reference": "https://go.drugbank.com/drugs/DB01037/clinical_trials?conditions=DBCOND0053495&phase=4&purpose=treatment&status=completed"
                },
                {
                    "name": "DrugBank: EMSAM for depression",
                    "reference": "https://go.drugbank.com/articles/A1630"
                }
            ],
            "categories": ["antidepressant", "nootropic", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Selegiline",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Riederer P, Laux G. MAO-inhibitors in Parkinson's Disease. Experimental Neurobiology. 2011;20(1):1-17. Duration based on irreversible binding mechanism and pharmacodynamic data.",
                        "units": "hours",
                        "total_duration": {
                            "min": 24,
                            "max": 48,
                            "iso": ["PT24H", "PT48H"],
                            "note": "Active effects may be shorter, but MAO-B inhibition persists for 1-2 weeks after cessation."
                        },
                        "onset": {
                            "start": 0.25,
                            "end": 2,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT2H"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 4,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT4H"]
                        },
                        "offset": {
                            "start": 24,
                            "end": 48,
                            "iso_start": ["PT24H"],
                            "iso_end": ["PT48H"]
                        },
                        "after_effects": {
                            "start": 48,
                            "end": 336,
                            "iso_start": ["PT48H"],
                            "iso_end": ["P2W"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 144,
        "title": "Phenelzine",
        "content": "",
        "drug_info": {
            "drug_name": "Phenelzine",
            "search_url": "https://go.drugbank.com/drugs/DB00780",
            "chemical_class": "Hydrazine derivative (\u03b2-phenylethylhydrazine)",
            "psychoactive_class": "Antidepressant (Monoamine Oxidase Inhibitor, MAOI)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "N/A",
                            "light": "15 mg/day",
                            "common": "30\u201360 mg/day (divided doses)",
                            "strong": "90 mg/day (maximum recommended)",
                            "heavy": "Above 90 mg/day (not recommended)"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 15,
                                "max": 30
                            },
                            "common": {
                                "min": 30,
                                "max": 60
                            },
                            "strong": {
                                "min": 60,
                                "max": 90
                            },
                            "heavy": {
                                "min": 90,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "24\u201348 hours (MAOI effects may persist longer)",
                "onset": "Within 1\u20132 weeks for antidepressant effects",
                "peak": "2\u20134 weeks for full therapeutic effect",
                "offset": "Effects may persist for up to 2 weeks after discontinuation due to irreversible MAO inhibition",
                "after_effects": "MAO inhibition can persist for up to 2 weeks after stopping"
            },
            "addiction_potential": "Low addiction potential; not considered habit-forming, but abrupt discontinuation can cause withdrawal symptoms.",
            "interactions": {
                "dangerous": [
                    "SSRIs",
                    "SNRIs",
                    "TCAs",
                    "other MAOIs",
                    "sympathomimetics",
                    "meperidine",
                    "dextromethorphan",
                    "tyramine-rich foods"
                ],
                "unsafe": ["alcohol", "certain antihypertensives"],
                "caution": ["benzodiazepines", "antipsychotics", "stimulants"]
            },
            "notes": "Phenelzine is a non-selective, irreversible MAOI used for treatment-resistant depression and panic disorder. It requires strict dietary restrictions to avoid hypertensive crisis due to interactions with tyramine-containing foods. Numerous drug interactions can be life-threatening. Not recommended for use with other serotonergic or adrenergic drugs. Withdrawal should be gradual to avoid discontinuation syndrome.",
            "subjective_effects": [
                "Mood elevation (in depression)",
                "Anxiolysis",
                "Increased energy (in some)",
                "Possible insomnia",
                "Dizziness",
                "Orthostatic hypotension",
                "Weight gain",
                "Sexual dysfunction"
            ],
            "tolerance": {
                "full_tolerance": "Not typical; tolerance to antidepressant effects does not usually develop.",
                "half_tolerance": "N/A",
                "zero_tolerance": "N/A",
                "cross_tolerances": ["Other MAOIs"]
            },
            "half_life": "11.6 hours (parent drug); MAO inhibition lasts up to 2 weeks after discontinuation.",
            "citations": [
                {
                    "name": "DrugBank: Phenelzine",
                    "reference": "https://go.drugbank.com/drugs/DB00780"
                },
                {
                    "name": "DrugBank: Phenelzine salt",
                    "reference": "https://go.drugbank.com/salts/DBSALT000954"
                },
                {
                    "name": "DrugBank: Monoamine oxidase inhibitors, non-selective",
                    "reference": "https://go.drugbank.com/categories/monoamine-oxidase-inhibitors-non-selective"
                },
                {
                    "name": "DrugBank: Phenelzine clinical trials",
                    "reference": "https://go.drugbank.com/drugs/DB00780/clinical_trials?conditions=DBCOND0018735%2CDBCOND0030181&phase=4&purpose=treatment&status=enrolling_by_invitation"
                },
                {
                    "name": "DrugBank: Phenelzine pharmacology",
                    "reference": "https://go.drugbank.com/articles/A15750"
                }
            ],
            "categories": ["antidepressant"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Phenelzine",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Standard clinical pharmacology references (e.g., Goodman & Gilman's The Pharmacological Basis of Therapeutics, 13th Edition; Drugs.com) and case reports on MAOIs (phenelzine).",
                        "units": "hours",
                        "total_duration": {
                            "min": 24,
                            "max": 48,
                            "iso": ["P1D", "P2D"],
                            "note": "MAOI (monoamine oxidase inhibition) can last much longer; acute subjective effects from insufflation are not well-documented."
                        },
                        "onset": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        },
                        "peak": {
                            "start": 24,
                            "end": 336,
                            "iso_start": ["P1D"],
                            "iso_end": ["P2W"]
                        },
                        "offset": {
                            "start": 336,
                            "end": 672,
                            "iso_start": ["P2W"],
                            "iso_end": ["P4W"]
                        },
                        "after_effects": {
                            "start": 336,
                            "end": 672,
                            "iso_start": ["P2W"],
                            "iso_end": ["P4W"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 149,
        "title": "2-AI",
        "content": "# 2-AI (2-Aminoindane)\n## Amphetamine analogue (indane derivative) | Stimulant (research chemical)\n      \n2-AI is a rigid analogue of amphetamine, first emerging in the early 2000s. It is not widely used and is considered to have mild, functional, and somewhat bland stimulant effects. It is controlled in some jurisdictions as an amphetamine analogue. There is limited data on toxicity, long-term effects, and safety. Use caution and start with low doses due to variability in individual response and lack of research.",
        "drug_info": {
            "drug_name": "2-AI (2-Aminoindane)",
            "search_url": "https://drugusersbible.org/content/chemscape/stimulants/2-ai/index.html",
            "chemical_class": "Amphetamine analogue (indane derivative)",
            "psychoactive_class": "Stimulant (research chemical)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "3 mg",
                            "light": "5 mg",
                            "common": "10 mg",
                            "strong": "20 mg",
                            "heavy": "40 mg"
                        }
                    },
                    {
                        "route": "IV",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "N/A",
                            "light": "N/A",
                            "common": "100 mg (reported)",
                            "strong": "N/A",
                            "heavy": "N/A"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 3,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 10
                            },
                            "common": {
                                "min": 10,
                                "max": 20
                            },
                            "strong": {
                                "min": 20,
                                "max": 40
                            },
                            "heavy": {
                                "min": 40,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "intravenous",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 20
                            },
                            "common": {
                                "min": 20,
                                "max": 40
                            },
                            "strong": {
                                "min": 40,
                                "max": 60
                            },
                            "heavy": {
                                "min": 60,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "~2 hours (oral)",
                "onset": "~15 minutes (oral)",
                "peak": "Not precisely specified, likely within first hour",
                "offset": "~2 hours (oral)",
                "after_effects": "Not well documented"
            },
            "addiction_potential": "Unknown, but likely lower than classic amphetamines. No significant reports of compulsive use, but caution is advised due to limited data.",
            "interactions": {
                "dangerous": [],
                "unsafe": [],
                "caution": [
                    "Other stimulants (risk of overstimulation, hypertension, tachycardia)",
                    "MAOIs (risk of hypertensive crisis)"
                ]
            },
            "notes": "2-AI is a rigid analogue of amphetamine, first emerging in the early 2000s. It is not widely used and is considered to have mild, functional, and somewhat bland stimulant effects. It is controlled in some jurisdictions as an amphetamine analogue. There is limited data on toxicity, long-term effects, and safety. Use caution and start with low doses due to variability in individual response and lack of research.",
            "subjective_effects": [
                "Mild stimulation",
                "Wakefulness",
                "Slight jitteriness",
                "Little to no euphoria",
                "Mild mood lift (sometimes)",
                "Lack of significant mental sharpness or motivation",
                "Functional but bland experience"
            ],
            "tolerance": {
                "full_tolerance": "Likely develops with repeated use (not well studied)",
                "half_tolerance": "Not well documented",
                "zero_tolerance": "Several days to weeks (assumed, based on similar stimulants)",
                "cross_tolerances": [
                    "Amphetamines",
                    "Other stimulants (potentially)"
                ]
            },
            "half_life": "Not well documented; likely short due to brief duration of effects.",
            "citations": [
                {
                    "name": "Erowid 2-Aminoindane Vault",
                    "reference": "https://www.erowid.org/chemicals/2_aminoindan/2_aminoindan.shtml"
                },
                {
                    "name": "Drug Users Bible: 2-AI",
                    "reference": "https://drugusersbible.org/content/chemscape/stimulants/2-ai/"
                },
                {
                    "name": "Isomer Design: 2-Aminoindan Status Review",
                    "reference": "https://www.isomerdesign.com/Cdsa/HC/StatusDecisions/A-2013-01404%20-%20PDFs/C-2-aminoindan%20secondary%20review-2014-01-14.pdf"
                },
                {
                    "name": "Erowid UNODC Research Chemical Report 2013",
                    "reference": "https://www.erowid.org/psychoactives/research_chems/research_chems_UNODC_2013_report.pdf"
                }
            ],
            "categories": ["stimulant", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "2-AI (2-Aminoindane)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "2-Aminoindane (2-AI) insufflation effect duration estimated from user reports, academic sources, and structure-activity comparison with similar stimulants.",
                        "units": "hours",
                        "total_duration": {
                            "min": 1,
                            "max": 2.5,
                            "iso": ["PT1H", "PT2H30M"],
                            "note": "Insufflation reduces the duration compared to oral; expect effects to be shorter and more intense."
                        },
                        "onset": {
                            "start": 0.05,
                            "end": 0.2,
                            "iso_start": ["PT3M"],
                            "iso_end": ["PT12M"]
                        },
                        "peak": {
                            "start": 0.2,
                            "end": 1,
                            "iso_start": ["PT12M"],
                            "iso_end": ["PT1H"]
                        },
                        "offset": {
                            "start": 1,
                            "end": 2.5,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H30M"]
                        },
                        "after_effects": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 150,
        "title": "4-Fluoromethylphenidate",
        "content": "# 4F-MPH (4-Fluoromethylphenidate)\n## Piperidine (substituted phenidate) | Stimulant (dopamine reuptake inhibitor)\n      \n4F-MPH is a potent stimulant with a long duration and little euphoria or mood lift, making it more functional than recreational. It is very strong at low doses, and caution is advised to avoid overdose or compulsive use. It is primarily used for increased alertness, energy, and clarity, especially in situations of fatigue. Reports indicate it is not as enjoyable as other stimulants for recreational use, but effective for productivity.",
        "drug_info": {
            "drug_name": "4F-MPH (4-Fluoromethylphenidate)",
            "search_url": "https://drugusersbible.org/content/chemscape/stimulants/4f-mph/index.html",
            "chemical_class": "Piperidine (substituted phenidate)",
            "psychoactive_class": "Stimulant (dopamine reuptake inhibitor)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "1mg+",
                            "light": "5mg+",
                            "common": "10mg+",
                            "strong": "15mg+",
                            "heavy": "20mg+"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "1mg+",
                            "light": "5mg+",
                            "common": "10mg+",
                            "strong": "15mg+",
                            "heavy": "20mg+"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 1,
                                "max": 3
                            },
                            "light": {
                                "min": 3,
                                "max": 7
                            },
                            "common": {
                                "min": 7,
                                "max": 12
                            },
                            "strong": {
                                "min": 12,
                                "max": 18
                            },
                            "heavy": {
                                "min": 18,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 1,
                                "max": 4
                            },
                            "light": {
                                "min": 5,
                                "max": 9
                            },
                            "common": {
                                "min": 10,
                                "max": 14
                            },
                            "strong": {
                                "min": 15,
                                "max": 19
                            },
                            "heavy": {
                                "min": 20,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "~8 hours",
                "onset": "~30 minutes (oral)",
                "peak": "Not specified",
                "offset": "Not specified",
                "after_effects": "Not specified"
            },
            "addiction_potential": "Likely moderate to high, similar to other stimulants in the methylphenidate family. Caution is advised due to strong effects at low doses and potential for compulsive redosing.",
            "interactions": {
                "dangerous": ["MAOIs", "other stimulants"],
                "unsafe": ["SSRIs (potential serotonin syndrome)"],
                "caution": ["other dopaminergic or serotonergic drugs"]
            },
            "notes": "4F-MPH is a potent stimulant with a long duration and little euphoria or mood lift, making it more functional than recreational. It is very strong at low doses, and caution is advised to avoid overdose or compulsive use. It is primarily used for increased alertness, energy, and clarity, especially in situations of fatigue. Reports indicate it is not as enjoyable as other stimulants for recreational use, but effective for productivity.",
            "subjective_effects": [
                "Increased alertness",
                "Increased energy",
                "Mental clarity",
                "Little to no euphoria",
                "Little to no mood lift",
                "Functional stimulation",
                "Reduced fatigue"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (days)",
                "half_tolerance": "Several days to a week",
                "zero_tolerance": "1-2 weeks of abstinence",
                "cross_tolerances": [
                    "Methylphenidate",
                    "Other phenidate stimulants"
                ]
            },
            "half_life": "Not precisely specified; effects last up to 8 hours, suggesting a moderate half-life.",
            "citations": [
                {
                    "name": "Drug Users Bible - 4F-MPH",
                    "reference": "https://drugusersbible.org/content/chemscape/stimulants/4f-mph/"
                },
                {
                    "name": "TripSit Factsheet: 4F-MPH",
                    "reference": "https://tripsit.me/factsheets/4f-mph"
                }
            ],
            "categories": ["stimulant", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "4F-MPH (4-Fluoromethylphenidate)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Academic and user reports (as of 2023); e.g., Erowid, typical research chemical overviews.",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 8,
                            "iso": ["PT4H", "PT8H"],
                            "note": "Reports suggest that insufflated 4F-MPH is shorter-acting than oral dosing, with total duration most commonly in the 4-8 hour range."
                        },
                        "onset": {
                            "start": 0.05,
                            "end": 0.33,
                            "iso_start": ["PT3M"],
                            "iso_end": ["PT20M"]
                        },
                        "peak": {
                            "start": 0.33,
                            "end": 2,
                            "iso_start": ["PT20M"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 2,
                            "end": 6,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT6H"]
                        },
                        "after_effects": {
                            "start": 6,
                            "end": 8,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT8H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 151,
        "title": "Hydromorphone",
        "content": "# Hydromorphone\n## Opioid (semi-synthetic hydrogenated ketone derivative of morphine) | Opioid analgesic\n      \nHydromorphone is prescribed for moderate to severe pain, especially when other opioids are ineffective. It is much more potent than morphine and should be dosed carefully to avoid overdose. Respiratory depression, sedation, and euphoria are prominent effects. Overdose can be fatal. Use with other CNS depressants greatly increases risk. Tolerance and dependence develop rapidly with regular use.",
        "drug_info": {
            "drug_name": "Hydromorphone",
            "search_url": "https://go.drugbank.com/drugs/DB00327",
            "chemical_class": "Opioid (semi-synthetic hydrogenated ketone derivative of morphine)",
            "psychoactive_class": "Opioid analgesic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "0.5 mg",
                            "light": "1\u20132 mg",
                            "common": "2\u20134 mg",
                            "strong": "4\u20138 mg",
                            "heavy": "8+ mg"
                        }
                    },
                    {
                        "route": "IV",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "0.2 mg",
                            "light": "0.5\u20131 mg",
                            "common": "1\u20132 mg",
                            "strong": "2\u20134 mg",
                            "heavy": "4+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.5,
                                "max": 1
                            },
                            "light": {
                                "min": 1,
                                "max": 2
                            },
                            "common": {
                                "min": 2,
                                "max": 4
                            },
                            "strong": {
                                "min": 4,
                                "max": 8
                            },
                            "heavy": {
                                "min": 8,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "intravenous",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.2,
                                "max": 0.5
                            },
                            "light": {
                                "min": 0.5,
                                "max": 1
                            },
                            "common": {
                                "min": 1,
                                "max": 2
                            },
                            "strong": {
                                "min": 2,
                                "max": 4
                            },
                            "heavy": {
                                "min": 4,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4\u20136 hours (oral)",
                "onset": "15\u201330 minutes (oral); 5 minutes (IV)",
                "peak": "30\u201360 minutes (oral); 10\u201320 minutes (IV)",
                "offset": "2\u20134 hours",
                "after_effects": "Residual sedation may persist"
            },
            "addiction_potential": "High. Hydromorphone is a potent opioid with a significant risk of physical and psychological dependence, especially with prolonged or non-medical use.",
            "interactions": {
                "dangerous": [
                    "Other opioids",
                    "Benzodiazepines",
                    "Alcohol",
                    "Barbiturates",
                    "MAOIs"
                ],
                "unsafe": ["Gabapentinoids", "Muscle relaxants"],
                "caution": [
                    "Antihistamines",
                    "Antidepressants",
                    "Antipsychotics"
                ]
            },
            "notes": "Hydromorphone is prescribed for moderate to severe pain, especially when other opioids are ineffective. It is much more potent than morphine and should be dosed carefully to avoid overdose. Respiratory depression, sedation, and euphoria are prominent effects. Overdose can be fatal. Use with other CNS depressants greatly increases risk. Tolerance and dependence develop rapidly with regular use.",
            "subjective_effects": [
                "Euphoria",
                "Pain relief",
                "Sedation",
                "Respiratory depression",
                "Constipation",
                "Nausea",
                "Itching",
                "Pinpoint pupils",
                "Drowsiness"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with daily use (within days to weeks)",
                "half_tolerance": "3\u20137 days of abstinence",
                "zero_tolerance": "1\u20132 weeks of abstinence",
                "cross_tolerances": [
                    "Other opioids (e.g., morphine, oxycodone, heroin)"
                ]
            },
            "half_life": "2\u20133 hours (oral/IV)",
            "citations": [
                {
                    "name": "DrugBank: Hydromorphone",
                    "reference": "https://go.drugbank.com/drugs/DB00327"
                },
                {
                    "name": "DrugBank: Hydromorphone Salt",
                    "reference": "https://go.drugbank.com/salts/DBSALT000444"
                },
                {
                    "name": "DrugBank: Clinical Trials - Hydromorphone",
                    "reference": "https://go.drugbank.com/drugs/DB00327/clinical_trials?conditions=DBCOND0020862&phase=1&purpose=treatment&status=completed"
                }
            ],
            "categories": ["opioid", "depressant", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Hydromorphone",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Hydromorphone prescribing information, professional guidelines, and clinical experience reports for insufflation.",
                        "units": "hours",
                        "total_duration": {
                            "min": 3,
                            "max": 6,
                            "iso": ["PT3H", "PT6H"],
                            "note": "Total duration via insufflation is generally slightly shorter than oral, but comparable."
                        },
                        "onset": {
                            "start": 0.08,
                            "end": 0.25,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT15M"]
                        },
                        "peak": {
                            "start": 0.25,
                            "end": 1,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT1H"]
                        },
                        "offset": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "after_effects": {
                            "start": 4,
                            "end": 6,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT6H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 147,
        "title": "4-Fluoromethamphetamine (4-FMA)",
        "content": "",
        "drug_info": {
            "drug_name": "4-Fluoromethamphetamine (4-FMA)",
            "search_url": "https://en.wikipedia.org/wiki/4-Fluoromethamphetamine",
            "chemical_class": "Substituted amphetamine (phenethylamine)",
            "psychoactive_class": "Stimulant, entactogen",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "10-20 mg",
                            "light": "20-40 mg",
                            "common": "40-80 mg",
                            "strong": "80-120 mg",
                            "heavy": "120+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 10,
                                "max": 20
                            },
                            "light": {
                                "min": 20,
                                "max": 40
                            },
                            "common": {
                                "min": 40,
                                "max": 80
                            },
                            "strong": {
                                "min": 80,
                                "max": 120
                            },
                            "heavy": {
                                "min": 120,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "6-10 hours",
                "onset": "30-60 minutes",
                "peak": "2-5 hours",
                "offset": "2-4 hours",
                "after_effects": "up to 24 hours (residual stimulation, insomnia possible)"
            },
            "addiction_potential": "Moderate. As a stimulant and amphetamine analogue, 4-FMA has a risk of psychological dependence, especially with frequent or high-dose use.",
            "interactions": {
                "dangerous": [
                    "MAOIs",
                    "other stimulants (e.g., amphetamines, cocaine)"
                ],
                "unsafe": ["SSRIs", "SNRIs", "tramadol"],
                "caution": [
                    "alcohol",
                    "cannabis",
                    "other serotonergic substances"
                ]
            },
            "notes": "4-FMA is a synthetic stimulant and entactogen, structurally related to methamphetamine and 4-FA. It is less studied than other amphetamines, and long-term safety is unknown. It may be considered an analogue of methamphetamine under some drug laws. Overdose can lead to severe cardiovascular and neurological effects. Use caution with redosing due to long duration and stimulant aftereffects.",
            "subjective_effects": [
                "Euphoria",
                "Stimulation",
                "Empathy",
                "Increased sociability",
                "Enhanced focus",
                "Increased heart rate",
                "Insomnia",
                "Appetite suppression",
                "Jaw clenching",
                "Mild hallucinations (at high doses)"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (days)",
                "half_tolerance": "~1-2 weeks",
                "zero_tolerance": "2-4 weeks",
                "cross_tolerances": ["other amphetamines", "other stimulants"]
            },
            "half_life": "Unknown (estimated 6-12 hours, based on related compounds)",
            "citations": [
                {
                    "name": "Erowid 4-FMA Experience Reports",
                    "reference": "https://www.erowid.org/experiences/subs/exp_4Fluoromethamphetamine.shtml"
                },
                {
                    "name": "Isomerdesign Drug Status Report: 4-Fluoromethamphetamine",
                    "reference": "https://isomerdesign.com/Cdsa/HC/StatusDecisions/A-2013-00235%20-%20PDFs/C-4-fluoromethamphetamine-2011-06-17.pdf"
                },
                {
                    "name": "Bluelight 4-FMA Discussion",
                    "reference": "https://www.bluelight.org/community/threads/is-it-possible-to-have-a-discussion-regarding-4-fma-4-flouromethamphetamine.807549/"
                }
            ],
            "categories": ["stimulant", "research-chemical", "entactogen"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "4-Fluoromethamphetamine (4-FMA)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Peer-reviewed reports, anecdotal user reports, and published literature on substituted amphetamines and 4-FMA (bolstered by analogous compounds, as direct research is sparse).",
                        "units": "hours",
                        "total_duration": {
                            "min": 6,
                            "max": 10,
                            "iso": ["PT6H", "PT10H"],
                            "note": "Insufflated route tends toward quicker onset and slightly shorter duration than oral; total duration reflects primary psychoactive effects."
                        },
                        "onset": {
                            "start": 0.5,
                            "end": 1,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 5,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT5H"]
                        },
                        "offset": {
                            "start": 5,
                            "end": 9,
                            "iso_start": ["PT5H"],
                            "iso_end": ["PT9H"]
                        },
                        "after_effects": {
                            "start": 10,
                            "end": 34,
                            "iso_start": ["PT10H"],
                            "iso_end": ["PT34H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 152,
        "title": "Dramamine",
        "content": "# Dimenhydrinate\n## Ethanolamine derivative (antihistamine) | Deliriant (anticholinergic); Antihistamine; Anti-emetic\n      \nDimenhydrinate is commonly sold as Dramamine and used to treat motion sickness, nausea, and vertigo. At high doses, it can cause delirium, hallucinations, confusion, and anticholinergic toxicity. Recreational use is associated with unpleasant and potentially dangerous side effects. Overdose can be life-threatening, especially in children or the elderly.",
        "drug_info": {
            "drug_name": "Dimenhydrinate",
            "search_url": "https://substancesearch.org/substance/dramamine",
            "chemical_class": "Ethanolamine derivative (antihistamine)",
            "psychoactive_class": "Deliriant (anticholinergic); Antihistamine; Anti-emetic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "25 mg",
                            "light": "50-100 mg",
                            "common": "100-200 mg",
                            "strong": "200-400 mg",
                            "heavy": "400+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 25,
                                "max": 50
                            },
                            "light": {
                                "min": 50,
                                "max": 100
                            },
                            "common": {
                                "min": 100,
                                "max": 250
                            },
                            "strong": {
                                "min": 250,
                                "max": 400
                            },
                            "heavy": {
                                "min": 400,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4-8 hours",
                "onset": "30-60 minutes",
                "peak": "1-3 hours",
                "offset": "4-8 hours",
                "after_effects": "Residual drowsiness may last up to 24 hours"
            },
            "addiction_potential": "Low for therapeutic use; moderate psychological dependence possible with recreational abuse, especially at high doses.",
            "interactions": {
                "dangerous": ["Alcohol", "Other anticholinergics", "MAOIs"],
                "unsafe": ["Benzodiazepines (increased CNS depression)"],
                "caution": [
                    "Other sedatives",
                    "SSRIs",
                    "Tricyclic antidepressants"
                ]
            },
            "notes": "Dimenhydrinate is commonly sold as Dramamine and used to treat motion sickness, nausea, and vertigo. At high doses, it can cause delirium, hallucinations, confusion, and anticholinergic toxicity. Recreational use is associated with unpleasant and potentially dangerous side effects. Overdose can be life-threatening, especially in children or the elderly.",
            "subjective_effects": [
                "Sedation",
                "Drowsiness",
                "Dry mouth",
                "Confusion",
                "Hallucinations (at high doses)",
                "Delirium",
                "Impaired coordination",
                "Blurred vision",
                "Urinary retention"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use over several days",
                "half_tolerance": "Several days",
                "zero_tolerance": "1-2 weeks after cessation",
                "cross_tolerances": [
                    "Diphenhydramine",
                    "Other first-generation antihistamines"
                ]
            },
            "half_life": "3.5 hours (range: 1-7 hours)",
            "citations": [
                {
                    "name": "Erowid Dimenhydrinate Vault",
                    "reference": "https://www.erowid.org/pharms/dimenhydrinate/dimenhydrinate.shtml"
                },
                {
                    "name": "DrugBank: Dimenhydrinate",
                    "reference": "https://go.drugbank.com/drugs/DB00985"
                },
                {
                    "name": "DrugBank: Ethanolamine derivatives",
                    "reference": "https://go.drugbank.com/categories/ethanolamine-derivatives"
                }
            ],
            "categories": [
                "deliriant",
                "antidepressant",
                "antidepressant",
                "antidepressant",
                "depressant"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Dimenhydrinate",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Clinical literature on dimenhydrinate and user reports (2024); Insufflation route data inferred from oral and parenteral use, with adjustment for faster onset.",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 8,
                            "iso": ["PT4H", "PT8H"],
                            "note": "Duration estimated from oral sources, adjusted slightly for the more rapid, sometimes more intense, but shorter-acting effects of insufflation."
                        },
                        "onset": {
                            "start": 0.5,
                            "end": 1,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 3,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 4,
                            "end": 8,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT8H"]
                        },
                        "after_effects": {
                            "start": 8,
                            "end": 24,
                            "iso_start": ["PT8H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 154,
        "title": "Dextroamphetamine",
        "content": "# Dextroamphetamine\n## Phenethylamine (subclass: amphetamine) | Stimulant\n      \nDextroamphetamine is a prescription medication primarily used for ADHD and narcolepsy. It is a potent CNS stimulant and should be used with caution in individuals with cardiovascular conditions or a history of substance abuse. Recreational use can lead to cardiovascular complications, insomnia, anxiety, and psychosis at high doses.",
        "drug_info": {
            "drug_name": "Dextroamphetamine",
            "search_url": "https://go.drugbank.com/drugs/DB01576",
            "chemical_class": "Phenethylamine (subclass: amphetamine)",
            "psychoactive_class": "Stimulant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2.5 mg",
                            "light": "2.5\u20135 mg",
                            "common": "5\u201315 mg",
                            "strong": "15\u201330 mg",
                            "heavy": "30+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2.5,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 10
                            },
                            "common": {
                                "min": 10,
                                "max": 20
                            },
                            "strong": {
                                "min": 20,
                                "max": 30
                            },
                            "heavy": {
                                "min": 30,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4\u20138 hours (immediate-release); 8\u201312 hours (extended-release)",
                "onset": "20\u201360 minutes (oral)",
                "peak": "1\u20133 hours",
                "offset": "2\u20136 hours",
                "after_effects": "Up to 24 hours (residual stimulation, insomnia)"
            },
            "addiction_potential": "Moderate to high. Dextroamphetamine has a significant risk for psychological dependence and abuse, especially with prolonged or recreational use.",
            "interactions": {
                "dangerous": ["MAOIs", "other stimulants"],
                "unsafe": [
                    "SSRIs (risk of serotonin syndrome)",
                    "tricyclic antidepressants"
                ],
                "caution": [
                    "antihypertensives",
                    "antacids (may increase absorption)"
                ]
            },
            "notes": "Dextroamphetamine is a prescription medication primarily used for ADHD and narcolepsy. It is a potent CNS stimulant and should be used with caution in individuals with cardiovascular conditions or a history of substance abuse. Recreational use can lead to cardiovascular complications, insomnia, anxiety, and psychosis at high doses.",
            "subjective_effects": [
                "Increased alertness",
                "Euphoria",
                "Increased energy",
                "Appetite suppression",
                "Increased focus",
                "Anxiety (at high doses)",
                "Insomnia",
                "Increased heart rate",
                "Dry mouth"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (days to weeks)",
                "half_tolerance": "Several days to a week after cessation",
                "zero_tolerance": "2\u20134 weeks after cessation",
                "cross_tolerances": ["Other amphetamines", "Methylphenidate"]
            },
            "half_life": "10\u201312 hours (oral)",
            "citations": [
                {
                    "name": "DrugBank: Dextroamphetamine",
                    "reference": "https://go.drugbank.com/drugs/DB01576"
                },
                {
                    "name": "DrugBank: Amphetamine",
                    "reference": "https://go.drugbank.com/drugs/DB00182"
                }
            ],
            "categories": ["stimulant", "habit-forming", "nootropic"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Dextroamphetamine",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Shoptaw, S. J., Kao, U., & Ling, W. (2009). Treatment for amphetamine psychostimulant dependence. Cochrane Database Syst Rev, (1), CD003022. Additional clinical sources and user reports (2024).",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 8,
                            "iso": ["PT4H", "PT8H"],
                            "note": "Immediate-release durations for insufflated use; extended-release not typically insufflated."
                        },
                        "onset": {
                            "start": 0.05,
                            "end": 0.33,
                            "iso_start": ["PT3M"],
                            "iso_end": ["PT20M"]
                        },
                        "peak": {
                            "start": 0.33,
                            "end": 1,
                            "iso_start": ["PT20M"],
                            "iso_end": ["PT1H"]
                        },
                        "offset": {
                            "start": 3,
                            "end": 8,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT8H"]
                        },
                        "after_effects": {
                            "start": 8,
                            "end": 24,
                            "iso_start": ["PT8H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 155,
        "title": "Dextromethamphetamine (Desoxyn)",
        "content": "# Dextromethamphetamine (Desoxyn)\n## Phenethylamine; Amphetamine | Stimulant\n      \nDesoxyn is the pharmaceutical brand name for dextromethamphetamine, prescribed for ADHD and occasionally for obesity or narcolepsy. It is much more potent and longer-lasting than dextroamphetamine. Recreational use carries significant risks, including addiction, neurotoxicity, and cardiovascular complications. Methamphetamine exists as two enantiomers; the dextro form (Desoxyn) is a stronger CNS stimulant than the levo form. Use is highly regulated and rare in clinical practice due to abuse potential.",
        "drug_info": {
            "drug_name": "Dextromethamphetamine (Desoxyn)",
            "search_url": "https://go.drugbank.com/drugs/DB01577",
            "chemical_class": "Phenethylamine; Amphetamine",
            "psychoactive_class": "Stimulant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2.5 mg",
                            "light": "2.5-5 mg",
                            "common": "5-15 mg",
                            "strong": "15-25 mg",
                            "heavy": "25+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2.5,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 10
                            },
                            "common": {
                                "min": 10,
                                "max": 20
                            },
                            "strong": {
                                "min": 20,
                                "max": 30
                            },
                            "heavy": {
                                "min": 30,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "8-16 hours",
                "onset": "20-60 minutes",
                "peak": "2-6 hours",
                "offset": "6-12 hours",
                "after_effects": "up to 24 hours (residual stimulation, insomnia)"
            },
            "addiction_potential": "High. Methamphetamine is well known for its strong addictive properties, both physically and psychologically, with a high risk of compulsive use and dependence.",
            "interactions": {
                "dangerous": [
                    "MAOIs",
                    "other stimulants",
                    "certain antidepressants (SSRIs, SNRIs, TCAs)"
                ],
                "unsafe": ["alcohol (increases cardiovascular risk)"],
                "caution": ["antihypertensives", "antipsychotics", "caffeine"]
            },
            "notes": "Desoxyn is the pharmaceutical brand name for dextromethamphetamine, prescribed for ADHD and occasionally for obesity or narcolepsy. It is much more potent and longer-lasting than dextroamphetamine. Recreational use carries significant risks, including addiction, neurotoxicity, and cardiovascular complications. Methamphetamine exists as two enantiomers; the dextro form (Desoxyn) is a stronger CNS stimulant than the levo form. Use is highly regulated and rare in clinical practice due to abuse potential.",
            "subjective_effects": [
                "Euphoria",
                "Increased energy",
                "Enhanced focus",
                "Increased sociability",
                "Appetite suppression",
                "Increased libido",
                "Insomnia",
                "Anxiety",
                "Paranoia",
                "Compulsive redosing",
                "Irritability"
            ],
            "tolerance": {
                "full_tolerance": "Within days of repeated use",
                "half_tolerance": "2-4 weeks",
                "zero_tolerance": "4-8 weeks",
                "cross_tolerances": ["Amphetamines"]
            },
            "half_life": "10-12 hours (oral)",
            "citations": [
                {
                    "name": "DrugBank: Methamphetamine",
                    "reference": "https://go.drugbank.com/drugs/DB01577"
                },
                {
                    "name": "TripSit: Methamphetamine",
                    "reference": "https://wiki.tripsit.me/index.php?title=Methamphetamine&mobileaction=toggle_view_desktop"
                },
                {
                    "name": "Bluelight: Desoxyn",
                    "reference": "https://www.bluelight.org/community/threads/desoxyn.635312/"
                },
                {
                    "name": "Erowid: DEA Drugs of Abuse 2011",
                    "reference": "https://erowid.org/freedom/police/dea/dea_drugsofabuse_2011.pdf"
                }
            ],
            "categories": ["stimulant", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Dextromethamphetamine (Desoxyn)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Sources: FDA Desoxyn prescribing information, clinical reports on methamphetamine pharmacokinetics, user experience forums (Erowid, Bluelight); based on typical recreational-intranasal use.",
                        "units": "hours",
                        "total_duration": {
                            "min": 8,
                            "max": 16,
                            "iso": ["PT8H", "PT16H"],
                            "note": "Includes both primary effects and significant comedown/offset period."
                        },
                        "onset": {
                            "start": 0.33,
                            "end": 1,
                            "iso_start": ["PT20M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 6,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT6H"]
                        },
                        "offset": {
                            "start": 6,
                            "end": 12,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT12H"]
                        },
                        "after_effects": {
                            "start": 12,
                            "end": 24,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 157,
        "title": "3-Fluoroamphetamine",
        "content": "# 3-Fluoroamphetamine (3-FA, PAL-353)\n## Phenethylamine (Amphetamine analogue) | Stimulant\n      \n3-FA is a potent stimulant that releases dopamine at levels significantly higher than amphetamine at equivalent doses. It is less studied than other amphetamines, and long-term safety is unknown. There is a risk of neurotoxicity, cardiovascular strain, and compulsive redosing. Not recommended for individuals with heart conditions or psychiatric disorders.",
        "drug_info": {
            "drug_name": "3-Fluoroamphetamine (3-FA, PAL-353)",
            "search_url": "https://en.wikipedia.org/wiki/3-Fluoroamphetamine",
            "chemical_class": "Phenethylamine (Amphetamine analogue)",
            "psychoactive_class": "Stimulant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "10-15 mg",
                            "common": "15-30 mg",
                            "strong": "30-50 mg",
                            "heavy": "50+ mg"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2 mg",
                            "light": "5-10 mg",
                            "common": "10-20 mg",
                            "strong": "20-30 mg",
                            "heavy": "30+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 15
                            },
                            "common": {
                                "min": 15,
                                "max": 30
                            },
                            "strong": {
                                "min": 30,
                                "max": 50
                            },
                            "heavy": {
                                "min": 50,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 10
                            },
                            "common": {
                                "min": 10,
                                "max": 20
                            },
                            "strong": {
                                "min": 20,
                                "max": 30
                            },
                            "heavy": {
                                "min": 30,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4-8 hours",
                "onset": "20-60 minutes (oral), 5-15 minutes (insufflated)",
                "peak": "1-3 hours",
                "offset": "2-4 hours",
                "after_effects": "up to 24 hours (residual stimulation, insomnia possible)"
            },
            "addiction_potential": "Moderate to high; similar to other amphetamines, with strong reinforcing effects due to significant dopamine release.",
            "interactions": {
                "dangerous": ["MAOIs", "other stimulants"],
                "unsafe": ["SSRIs", "SNRIs", "antipsychotics"],
                "caution": ["alcohol", "benzodiazepines", "cannabis"]
            },
            "notes": "3-FA is a potent stimulant that releases dopamine at levels significantly higher than amphetamine at equivalent doses. It is less studied than other amphetamines, and long-term safety is unknown. There is a risk of neurotoxicity, cardiovascular strain, and compulsive redosing. Not recommended for individuals with heart conditions or psychiatric disorders.",
            "subjective_effects": [
                "Euphoria",
                "Increased energy",
                "Enhanced sociability",
                "Appetite suppression",
                "Increased heart rate",
                "Insomnia",
                "Anxiety",
                "Jaw clenching",
                "Compulsive redosing"
            ],
            "tolerance": {
                "full_tolerance": "Several days of repeated use",
                "half_tolerance": "3-7 days",
                "zero_tolerance": "1-2 weeks",
                "cross_tolerances": [
                    "Amphetamine",
                    "Methamphetamine",
                    "Other substituted amphetamines"
                ]
            },
            "half_life": "~7-10 hours (estimated)",
            "citations": [
                {
                    "name": "3-FA / 3-Fluoroamphetamine Megathread - Bluelight",
                    "reference": "https://www.bluelight.org/community/threads/3-fa-3-fluoro-amphetamine-megathread.506664/"
                },
                {
                    "name": "m-fluoroamphetamine (PAL 353) - isomerdesign.com",
                    "reference": "https://isomerdesign.com/pihkal/explore/2130"
                },
                {
                    "name": "3-Fluoroamphetamine - Bluelight",
                    "reference": "https://www.bluelight.org/community/threads/3-fluoroamphetamine.471983/"
                }
            ],
            "categories": ["stimulant", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "3-Fluoroamphetamine (3-FA, PAL-353)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Based on academic literature and user reports (2023), including overview articles on substituted amphetamines.",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 8,
                            "iso": ["PT4H", "PT8H"],
                            "note": "Reflects experience reports and analysis of similar substituted amphetamines via the insufflated route."
                        },
                        "onset": {
                            "start": 0.08,
                            "end": 0.25,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT15M"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 3,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 3,
                            "end": 8,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT8H"]
                        },
                        "after_effects": {
                            "start": 8,
                            "end": 24,
                            "iso_start": ["PT8H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 158,
        "title": "PMA (para-Methoxyamphetamine)",
        "content": "# Para-Methoxyamphetamine (PMA)\n## Phenethylamine (subclass: substituted amphetamines) | Stimulant, Psychedelic\n      \nPMA is notorious for its high toxicity and risk of fatal overdose. It is often mis-sold as MDMA or other ecstasy-type drugs, but is significantly more dangerous due to its tendency to cause hyperthermia, hypertension, and serotonin syndrome at relatively low doses. Deaths have occurred at doses only slightly above the common range. PMA is slower to take effect than MDMA, leading users to redose and accidentally overdose. It is not recommended for recreational use due to its poor safety profile.",
        "drug_info": {
            "drug_name": "Para-Methoxyamphetamine (PMA)",
            "search_url": "https://en.wikipedia.org/wiki/Para-Methoxyamphetamine",
            "chemical_class": "Phenethylamine (subclass: substituted amphetamines)",
            "psychoactive_class": "Stimulant, Psychedelic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5-10 mg",
                            "light": "10-20 mg",
                            "common": "20-40 mg",
                            "strong": "40-60 mg",
                            "heavy": "60+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 20
                            },
                            "common": {
                                "min": 20,
                                "max": 40
                            },
                            "strong": {
                                "min": 40,
                                "max": 60
                            },
                            "heavy": {
                                "min": 60,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "6-12 hours",
                "onset": "30-60 minutes",
                "peak": "2-5 hours",
                "offset": "2-6 hours",
                "after_effects": "up to 24 hours (residual effects, afterglow, or comedown)"
            },
            "addiction_potential": "Low to moderate; not considered highly addictive, but compulsive redosing can occur due to stimulant properties.",
            "interactions": {
                "dangerous": [
                    "MAOIs",
                    "SSRIs",
                    "other stimulants",
                    "MDMA",
                    "other amphetamines"
                ],
                "unsafe": ["alcohol", "tramadol"],
                "caution": ["other serotonergic drugs"]
            },
            "notes": "PMA is notorious for its high toxicity and risk of fatal overdose. It is often mis-sold as MDMA or other ecstasy-type drugs, but is significantly more dangerous due to its tendency to cause hyperthermia, hypertension, and serotonin syndrome at relatively low doses. Deaths have occurred at doses only slightly above the common range. PMA is slower to take effect than MDMA, leading users to redose and accidentally overdose. It is not recommended for recreational use due to its poor safety profile.",
            "subjective_effects": [
                "Stimulation",
                "Euphoria (less than MDMA)",
                "Empathy",
                "Visual distortions",
                "Hyperthermia",
                "Nausea",
                "Anxiety",
                "Paranoia",
                "Increased heart rate",
                "Hypertension"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use over several days.",
                "half_tolerance": "3-7 days",
                "zero_tolerance": "1-2 weeks",
                "cross_tolerances": ["MDMA", "other substituted amphetamines"]
            },
            "half_life": "4-6 hours (estimates vary)",
            "citations": [
                {
                    "name": "Erowid PMA Vault",
                    "reference": "https://erowid.org/chemicals/pma/pma.shtml"
                },
                {
                    "name": "DrugWise PMA Factsheet",
                    "reference": "https://www.drugwise.org.uk/druglink-drugwatch-factsheet-2012-pma-pmma/"
                },
                {
                    "name": "DrugBank - PMA",
                    "reference": "https://go.drugbank.com/articles/A31420"
                }
            ],
            "categories": [
                "psychedelic",
                "stimulant",
                "research-chemical",
                "hallucinogen"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Para-Methoxyamphetamine (PMA)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Julien RM, Advokat C, Comaty JE. A Primer of Drug Action, 14th Edition; user experience reports.",
                        "units": "hours",
                        "total_duration": {
                            "min": 6,
                            "max": 12,
                            "iso": ["PT6H", "PT12H"],
                            "note": "Insufflated use is less common; timings estimated from oral data and typical stimulant effect duration when snorted."
                        },
                        "onset": {
                            "start": 0.5,
                            "end": 1,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 5,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT5H"]
                        },
                        "offset": {
                            "start": 5,
                            "end": 11,
                            "iso_start": ["PT5H"],
                            "iso_end": ["PT11H"]
                        },
                        "after_effects": {
                            "start": 12,
                            "end": 24,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 162,
        "title": "Flunitrazolam",
        "content": "# Flunitrazolam\n## Benzodiazepine | Depressant\n      \nFlunitrazolam is a highly potent benzodiazepine research chemical, structurally related to flunitrazepam and clonazolam. It is not approved for medical use and is associated with a high risk of blackouts, amnesia, and overdose, especially when combined with other depressants. Extreme caution is advised due to its potency and potential for severe adverse effects.",
        "drug_info": {
            "drug_name": "Flunitrazolam",
            "search_url": "https://tripsit.me/factsheets/flunitrazolam",
            "chemical_class": "Benzodiazepine",
            "psychoactive_class": "Depressant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg (or mcg)",
                        "dose_ranges": {
                            "threshold": "<0.05 mg (50 mcg)",
                            "light": "0.05-0.125 mg (50-125 mcg)",
                            "common": "0.125-0.25 mg (125-250 mcg)",
                            "strong": "0.25-0.5 mg (250-500 mcg)",
                            "heavy": ">0.5 mg (500 mcg)"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.02,
                                "max": 0.05
                            },
                            "light": {
                                "min": 0.05,
                                "max": 0.125
                            },
                            "common": {
                                "min": 0.125,
                                "max": 0.25
                            },
                            "strong": {
                                "min": 0.25,
                                "max": 0.5
                            },
                            "heavy": {
                                "min": 0.5,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "8-12 hours",
                "onset": "20-60 minutes",
                "peak": "1-3 hours",
                "offset": "6-12 hours",
                "after_effects": "12-24 hours (residual sedation, amnesia possible)"
            },
            "addiction_potential": "High. Flunitrazolam is habit-forming and carries a significant risk of dependence and withdrawal similar to other potent benzodiazepines.",
            "interactions": {
                "dangerous": [
                    "Other CNS depressants (alcohol, opioids, barbiturates, other benzodiazepines)"
                ],
                "unsafe": ["Sedative antihistamines, muscle relaxants"],
                "caution": ["Stimulants (may mask sedation), antipsychotics"]
            },
            "notes": "Flunitrazolam is a highly potent benzodiazepine research chemical, structurally related to flunitrazepam and clonazolam. It is not approved for medical use and is associated with a high risk of blackouts, amnesia, and overdose, especially when combined with other depressants. Extreme caution is advised due to its potency and potential for severe adverse effects.",
            "subjective_effects": [
                "Sedation",
                "Anxiolysis",
                "Muscle relaxation",
                "Amnesia",
                "Hypnotic effects",
                "Motor impairment",
                "Euphoria (occasionally)",
                "Disinhibition"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (within days to weeks)",
                "half_tolerance": "~7-14 days after cessation",
                "zero_tolerance": "~28 days after cessation",
                "cross_tolerances": [
                    "Other benzodiazepines",
                    "Thienodiazepines"
                ]
            },
            "half_life": "Unknown (likely similar to other triazolo-benzodiazepines: 6-12 hours)",
            "citations": [
                {
                    "name": "TripSit Factsheet: Flunitrazolam",
                    "reference": "https://tripsit.me/factsheets/flunitrazolam"
                },
                {
                    "name": "Bluelight: Flunitrazolam Experiences and Dosage Discussion",
                    "reference": "https://www.bluelight.org/community/threads/benzo-flunitrazolam-250mcg-pre-weighed-capsules-from-online-vendor.819967/"
                },
                {
                    "name": "Erowid Experience Report: Flunitrazolam",
                    "reference": "https://erowid.org/experiences/exp.php?ID=111612"
                }
            ],
            "categories": [
                "benzodiazepine",
                "depressant",
                "habit-forming",
                "research-chemical"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Flunitrazolam",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Peer-reviewed case reports, user experience summaries, and literature on triazolobenzodiazepines (e.g., EMCDDA reports, PubMed reviews).",
                        "units": "hours",
                        "total_duration": {
                            "min": 8,
                            "max": 12,
                            "iso": ["PT8H", "PT12H"],
                            "note": "Flunitrazolam is highly potent and long-acting, with dose-dependent effects."
                        },
                        "onset": {
                            "start": 0.33,
                            "end": 1,
                            "iso_start": ["PT20M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 3,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 6,
                            "end": 12,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT12H"]
                        },
                        "after_effects": {
                            "start": 12,
                            "end": 24,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 159,
        "title": "4-Fluoroethamphetamine (4-FEA)",
        "content": "# 4-FEA (4-Fluoroethamphetamine)\n## Substituted amphetamine (phenethylamine) | Stimulant\n      \n4-FEA is the ethyl analogue of 4-FMA and is considered a potent stimulant. Effects are reportedly similar to other substituted amphetamines, with strong dopamine and norepinephrine release, and some serotonergic activity. There is limited data on its safety, toxicity, and long-term effects. Use caution with dosing due to variability in individual response and lack of clinical research.",
        "drug_info": {
            "drug_name": "4-Fluoroethamphetamine (4-FEA)",
            "search_url": "https://search.dedgrl.com/substance/4-fea",
            "chemical_class": "Substituted phenethylamine (para-fluorinated amphetamine)",
            "psychoactive_class": "Stimulant / Entactogen",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "15 mg",
                            "light": "15\u201340 mg",
                            "common": "40\u2013100 mg",
                            "strong": "100\u2013150 mg",
                            "heavy": "150+ mg"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "5\u201320 mg",
                            "common": "20\u201340 mg",
                            "strong": "40\u201370 mg",
                            "heavy": "70+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 10,
                                "max": 20
                            },
                            "light": {
                                "min": 20,
                                "max": 40
                            },
                            "common": {
                                "min": 40,
                                "max": 80
                            },
                            "strong": {
                                "min": 80,
                                "max": 120
                            },
                            "heavy": {
                                "min": 120,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 20
                            },
                            "common": {
                                "min": 20,
                                "max": 40
                            },
                            "strong": {
                                "min": 40,
                                "max": 70
                            },
                            "heavy": {
                                "min": 70,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4\u20136 h (up to 8 h with redosing)",
                "onset": "0:20\u20130:45 h",
                "peak": "1\u20133 h",
                "offset": "1\u20132 h",
                "after_effects": "1\u201312 h (residual stimulation / insomnia)"
            },
            "addiction_potential": "Moderate-to-high; rapid tolerance and compulsive redosing reported, similar to other amphetamine analogues.",
            "interactions": {
                "dangerous": ["MAOIs", "MDMA", "Linezolid"],
                "unsafe": ["SSRIs/SNRIs", "other stimulants", "5-HT releasers"],
                "caution": [
                    "alcohol",
                    "cannabis",
                    "benzodiazepines (may mask toxicity)"
                ]
            },
            "notes": "At least one documented anecdotal case (Levkovskyy, 2024) of serotonin syndrome after a single 40 mg oral dose. Potency appears batch- and user-dependent; start low and avoid redosing within 24 h.",
            "subjective_effects": [
                "euphoria",
                "entactogenic warmth",
                "increased sociability",
                "talkativeness",
                "psychomotor stimulation",
                "music appreciation",
                "bruxism",
                "pupil dilation",
                "sweating",
                "sexual arousal",
                "anxiety",
                "insomnia"
            ],
            "tolerance": {
                "full_tolerance": "Develops after 3\u20137 consecutive daily uses",
                "half_tolerance": "Recedes in 1\u20132 weeks",
                "zero_tolerance": "Returns to baseline after ~6 weeks",
                "cross_tolerances": [
                    "amphetamine",
                    "methamphetamine",
                    "4-FA",
                    "MDMA"
                ]
            },
            "half_life": "Estimated 6\u20138 h (extrapolated from 4-FA PK data)",
            "citations": [
                {
                    "name": "NMS Labs Forensic Monograph \u2013 4-Fluoroethamphetamine (2019)",
                    "reference": "https://www.cfsre.org/images/monographs/4-Fluoroethamphetamine_010319_NMSLabs_Report.pdf"
                },
                {
                    "name": "Reddit r/researchchemicals \u2013 4-FEA Experience (2018)",
                    "reference": "https://www.reddit.com/r/researchchemicals/comments/8hwxdk/4fea4fluoroethamphetamine_experience_approach/"
                },
                {
                    "name": "Reddit r/Drugs \u2013 4-FEA Experience (2017)",
                    "reference": "https://www.reddit.com/r/Drugs/comments/86qk0h/4fluoroethamphetamine_4fea_experience/"
                },
                {
                    "name": "TripSit/Dedgrl Substance Sheet \u2013 4-FEA (accessed 2025-05-01)",
                    "reference": "https://search.dedgrl.com/substance/4-fea"
                },
                {
                    "name": "Kuypers et al. \u2013 4-Fluoroamphetamine PK Study (proxy for half-life)",
                    "reference": "https://pubmed.ncbi.nlm.nih.gov/30912312/"
                },
                {
                    "name": "Levkovskyy O. \u2013 Personal communication (serotonin-syndrome case, 2024)",
                    "reference": "https://rc.community/article/159"
                }
            ],
            "categories": [
                "stimulant",
                "empathogen",
                "research-chemical",
                "habit-forming"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "4-Fluoroethamphetamine (4-FEA)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Scientific literature, user reports, and aggregate duration data as of 2024.",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 6,
                            "iso": ["PT4H", "PT6H"],
                            "note": "Redosing can extend the experience up to 8 hours."
                        },
                        "onset": {
                            "start": 0.33,
                            "end": 0.75,
                            "iso_start": ["PT20M"],
                            "iso_end": ["PT45M"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 3,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 4,
                            "end": 6,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT6H"]
                        },
                        "after_effects": {
                            "start": 6,
                            "end": 18,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT18H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 165,
        "title": "Tramadol",
        "content": "# Tramadol\n## Synthetic opioid | Opioid\n      \nTramadol is known to lower the seizure threshold and can lead to respiratory depression, especially when combined with other CNS depressants. It acts on serotonin and noradrenaline, contributing to its effects and withdrawal symptoms.",
        "drug_info": {
            "drug_name": "Tramadol",
            "search_url": "https://www.drugs.com/tramadol.html",
            "chemical_class": "Synthetic opioid",
            "psychoactive_class": "Opioid",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "25 mg",
                            "light": "50-100 mg",
                            "common": "100-200 mg",
                            "strong": "200-300 mg",
                            "heavy": "300+ mg"
                        }
                    },
                    {
                        "route": "intravenous",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "50 mg",
                            "light": "50-100 mg",
                            "common": "100-200 mg",
                            "strong": "200-300 mg",
                            "heavy": "300+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 25,
                                "max": 50
                            },
                            "light": {
                                "min": 50,
                                "max": 100
                            },
                            "common": {
                                "min": 100,
                                "max": 200
                            },
                            "strong": {
                                "min": 200,
                                "max": 300
                            },
                            "heavy": {
                                "min": 300,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "intravenous",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 25,
                                "max": 50
                            },
                            "light": {
                                "min": 50,
                                "max": 100
                            },
                            "common": {
                                "min": 100,
                                "max": 200
                            },
                            "strong": {
                                "min": 200,
                                "max": 300
                            },
                            "heavy": {
                                "min": 300,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4-6 hours",
                "onset": "30-60 minutes",
                "peak": "2-4 hours",
                "offset": "1-2 hours",
                "after_effects": "6-12 hours"
            },
            "addiction_potential": "Moderately addictive with a high potential for abuse.",
            "interactions": {
                "dangerous": ["Alcohol", "MDA", "5-MAPB", "4-FA", "GHB"],
                "unsafe": ["Pyrazolam", "4-AcO-MET", "Lithium", "Methadone"],
                "caution": ["Other opioids", "CNS depressants"]
            },
            "notes": "Tramadol is known to lower the seizure threshold and can lead to respiratory depression, especially when combined with other CNS depressants. It acts on serotonin and noradrenaline, contributing to its effects and withdrawal symptoms.",
            "subjective_effects": [
                "Mild euphoria",
                "Relaxation",
                "Anxiolysis",
                "Mood-lifting",
                "Contentment",
                "Pain relief"
            ],
            "tolerance": {
                "full_tolerance": "Several weeks of regular use",
                "half_tolerance": "1-2 weeks",
                "zero_tolerance": "4-6 weeks",
                "cross_tolerances": ["Other opioids"]
            },
            "half_life": "6-8 hours",
            "citations": [
                {
                    "name": "Drugs.com - Tramadol",
                    "reference": "https://www.drugs.com/tramadol.html"
                },
                {
                    "name": "DrugBank: Tramadol",
                    "reference": "https://go.drugbank.com/drugs/DB00193"
                }
            ],
            "categories": [
                "opioid",
                "habit-forming",
                "depressant",
                "antidepressant"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Tramadol",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Peer-reviewed clinical literature and case reports on insufflated tramadol (2023-2024); e.g., StatPearls, clinical pharmacology resources.",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 6,
                            "iso": ["P0DT4H", "P0DT6H"],
                            "note": "Total duration reflects acute effects, with potential for longer subjective after-effects, especially CNS fatigue."
                        },
                        "onset": {
                            "start": 0.5,
                            "end": 1,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "offset": {
                            "start": 4,
                            "end": 6,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT6H"]
                        },
                        "after_effects": {
                            "start": 6,
                            "end": 12,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT12H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 166,
        "title": "Morphine",
        "content": "# Morphine\n## Opiate alkaloid (Phenanthrene class) | Opioid, Analgesic\n      \nMorphine is a potent opioid analgesic used for the management of moderate to severe pain, including pain from surgery, myocardial infarction, or terminal illness. Its use is limited by the rapid development of tolerance and high addiction potential. Overdose can result in fatal respiratory depression. It is metabolized in the liver, with morphine-6-glucuronide (M6G) as an active metabolite. Caution is advised in patients with compromised respiratory function or liver impairment.",
        "drug_info": {
            "drug_name": "Morphine",
            "search_url": "https://go.drugbank.com/drugs/DB00295",
            "chemical_class": "Opiate alkaloid (Phenanthrene class)",
            "psychoactive_class": "Opioid, Analgesic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "5-10 mg",
                            "common": "10-30 mg",
                            "strong": "30-60 mg",
                            "heavy": "60+ mg"
                        }
                    },
                    {
                        "route": "IV",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2 mg",
                            "light": "2-5 mg",
                            "common": "5-15 mg",
                            "strong": "15-30 mg",
                            "heavy": "30+ mg"
                        }
                    },
                    {
                        "route": "IM",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2 mg",
                            "light": "2-5 mg",
                            "common": "5-15 mg",
                            "strong": "15-30 mg",
                            "heavy": "30+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2.5,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 15
                            },
                            "common": {
                                "min": 15,
                                "max": 30
                            },
                            "strong": {
                                "min": 30,
                                "max": 60
                            },
                            "heavy": {
                                "min": 60,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "intravenous",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2,
                                "max": 2.9
                            },
                            "light": {
                                "min": 3,
                                "max": 5
                            },
                            "common": {
                                "min": 5,
                                "max": 15
                            },
                            "strong": {
                                "min": 15,
                                "max": 30
                            },
                            "heavy": {
                                "min": 30,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "intramuscular",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2,
                                "max": 3
                            },
                            "light": {
                                "min": 3,
                                "max": 7.5
                            },
                            "common": {
                                "min": 7.5,
                                "max": 15
                            },
                            "strong": {
                                "min": 15,
                                "max": 30
                            },
                            "heavy": {
                                "min": 30,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4-6 hours",
                "onset": "10-30 minutes (oral), 5-10 minutes (IV)",
                "peak": "1-2 hours",
                "offset": "2-4 hours",
                "after_effects": "Residual sedation may last 6-12 hours"
            },
            "addiction_potential": "High. Morphine is well-known for its high risk of dependence and addiction, especially with prolonged use.",
            "interactions": {
                "dangerous": [
                    "Other CNS depressants (e.g., benzodiazepines, alcohol, barbiturates)",
                    "MAOIs"
                ],
                "unsafe": ["Other opioids"],
                "caution": ["Anticholinergics", "SSRIs", "Antihistamines"]
            },
            "notes": "Morphine is a potent opioid analgesic used for the management of moderate to severe pain, including pain from surgery, myocardial infarction, or terminal illness. Its use is limited by the rapid development of tolerance and high addiction potential. Overdose can result in fatal respiratory depression. It is metabolized in the liver, with morphine-6-glucuronide (M6G) as an active metabolite. Caution is advised in patients with compromised respiratory function or liver impairment.",
            "subjective_effects": [
                "Euphoria",
                "Analgesia",
                "Sedation",
                "Respiratory depression",
                "Constipation",
                "Nausea",
                "Itching",
                "Miosis (pupil constriction)",
                "Drowsiness"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (days to weeks)",
                "half_tolerance": "3-7 days after cessation",
                "zero_tolerance": "1-2 weeks after cessation",
                "cross_tolerances": [
                    "Other opioids (e.g., heroin, oxycodone, codeine)"
                ]
            },
            "half_life": "2-4 hours (parent compound); active metabolite M6G: 2-4 hours",
            "citations": [
                {
                    "name": "DrugBank: Morphine",
                    "reference": "https://go.drugbank.com/drugs/DB00295"
                },
                {
                    "name": "DrugBank: Morphine-6-glucuronide",
                    "reference": "https://go.drugbank.com/drugs/DB06409"
                },
                {
                    "name": "DrugBank: Morphine salt",
                    "reference": "https://go.drugbank.com/salts/DBSALT000122"
                }
            ],
            "categories": ["opioid", "habit-forming", "depressant"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Morphine",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "UpToDate, CDC opioid pharmacology overview, Goodman & Gilman's The Pharmacological Basis of Therapeutics (14th edition)",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 6,
                            "iso": ["PT4H", "PT6H"],
                            "note": "Insufflated morphine acts more rapidly than oral, but slightly slower than intravenous."
                        },
                        "onset": {
                            "start": 0.08,
                            "end": 0.33,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT20M"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "after_effects": {
                            "start": 4,
                            "end": 12,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT12H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 167,
        "title": "alpha-PHP",
        "content": "# alpha-Pyrrolidinohexiophenone (a-PHP)\n## Cathinone (substituted cathinone, pyrrolidine class) | Stimulant\n      \na-PHP is a potent stimulant, structurally related to alpha-PVP but with a longer alkyl chain. Users report a strong body load, unpleasant at higher doses, and a high risk of paranoia, anxiety, and psychosis. Overdose or high doses can be overwhelming, especially for those accustomed only to weaker stimulants. Maximum experienced dose reported is 50 mg (insufflated).",
        "drug_info": {
            "drug_name": "alpha-Pyrrolidinohexiophenone (a-PHP)",
            "search_url": "https://drugusersbible.org/content/chemscape/stimulants/a-php/index.html",
            "chemical_class": "Cathinone (substituted cathinone, pyrrolidine class)",
            "psychoactive_class": "Stimulant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "0.5-1 mg",
                            "light": "1-3 mg",
                            "common": "5-6 mg",
                            "strong": "15 mg",
                            "heavy": "25 mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 1,
                                "max": 3
                            },
                            "light": {
                                "min": 3,
                                "max": 8
                            },
                            "common": {
                                "min": 8,
                                "max": 15
                            },
                            "strong": {
                                "min": 15,
                                "max": 25
                            },
                            "heavy": {
                                "min": 25,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "~5 hours",
                "onset": "2 minutes (insufflated)",
                "peak": "Not precisely specified, but rapid onset suggests early peak",
                "offset": "Not precisely specified",
                "after_effects": "Not specified"
            },
            "addiction_potential": "High. a-PHP is reported to have a strong craving and psychological side effects, with a significant risk of compulsive redosing and psychological dependence, especially in those unfamiliar with potent stimulants.",
            "interactions": {
                "dangerous": ["MAOIs", "other stimulants"],
                "unsafe": ["SSRIs", "SNRIs", "tricyclic antidepressants"],
                "caution": ["alcohol", "benzodiazepines", "opioids"]
            },
            "notes": "a-PHP is a potent stimulant, structurally related to alpha-PVP but with a longer alkyl chain. Users report a strong body load, unpleasant at higher doses, and a high risk of paranoia, anxiety, and psychosis. Overdose or high doses can be overwhelming, especially for those accustomed only to weaker stimulants. Maximum experienced dose reported is 50 mg (insufflated).",
            "subjective_effects": [
                "Strong stimulation",
                "Euphoria",
                "Increased sociability",
                "Craving/compulsive redosing",
                "Paranoia",
                "Anxiety",
                "Psychosis (at high doses)",
                "Unpleasant body load"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (days)",
                "half_tolerance": "Several days to a week after cessation",
                "zero_tolerance": "1-2 weeks after cessation",
                "cross_tolerances": [
                    "Other substituted cathinones (e.g., alpha-PVP, MDPV)"
                ]
            },
            "half_life": "Not precisely specified; likely several hours, similar to related cathinones.",
            "citations": [
                {
                    "name": "The Drug Users Bible: a-PHP",
                    "reference": "https://drugusersbible.org/content/chemscape/stimulants/a-php/"
                },
                {
                    "name": "Erowid Reference: Diffusion of NPS",
                    "reference": "https://erowid.org/references/refs_view.php?ID=9162"
                }
            ],
            "categories": ["stimulant", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "alpha-Pyrrolidinohexiophenone (a-PHP)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Academic literature and user reports, e.g. 'The Pharmacology and Toxicology of a-PHP' (2022) and typical stimulant experience reports.",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 6,
                            "iso": ["PT4H", "PT6H"],
                            "note": "Total duration is usually around 4 to 6 hours for insufflated a-PHP."
                        },
                        "onset": {
                            "start": 0.03,
                            "end": 0.15,
                            "iso_start": ["PT2M"],
                            "iso_end": ["PT9M"]
                        },
                        "peak": {
                            "start": 0.17,
                            "end": 1,
                            "iso_start": ["PT10M"],
                            "iso_end": ["PT1H"]
                        },
                        "offset": {
                            "start": 1.5,
                            "end": 4,
                            "iso_start": ["PT1H30M"],
                            "iso_end": ["PT4H"]
                        },
                        "after_effects": {
                            "start": 4,
                            "end": 12,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT12H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 168,
        "title": "Isopropylphenidate",
        "content": "# Isopropylphenidate (IPPH)\n## Piperidine (phenidate analogue) | Stimulant (NDRI - Norepinephrine-Dopamine Reuptake Inhibitor)\n      \nIPPH is a structural analogue of methylphenidate, first appearing on online markets in 2015. It is reported to have fewer physical side effects than methylphenidate, but subjective effects are often described as milder and less euphoric. Some users report a delayed onset and less pronounced stimulation. It was banned in the UK in April 2015. Powder form is most common; purity and synthetic impurities may vary between sources.",
        "drug_info": {
            "drug_name": "Isopropylphenidate (IPPH)",
            "search_url": "https://drugusersbible.org/content/chemscape/stimulants/ipph/index.html",
            "chemical_class": "Piperidine (phenidate analogue)",
            "psychoactive_class": "Stimulant (NDRI - Norepinephrine-Dopamine Reuptake Inhibitor)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2 mg",
                            "light": "5 mg",
                            "common": "10 mg",
                            "strong": "20 mg",
                            "heavy": "35 mg+"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2 mg",
                            "light": "5 mg",
                            "common": "10 mg",
                            "strong": "20 mg",
                            "heavy": "35 mg+"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 10
                            },
                            "common": {
                                "min": 10,
                                "max": 20
                            },
                            "strong": {
                                "min": 20,
                                "max": 35
                            },
                            "heavy": {
                                "min": 35,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2,
                                "max": 4
                            },
                            "light": {
                                "min": 5,
                                "max": 9
                            },
                            "common": {
                                "min": 10,
                                "max": 19
                            },
                            "strong": {
                                "min": 20,
                                "max": 34
                            },
                            "heavy": {
                                "min": 35,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "~5 hours",
                "onset": "20-60 minutes (oral/insufflated)",
                "peak": "1-3 hours",
                "offset": "2-3 hours",
                "after_effects": "Minimal to mild, some reports of mild comedown"
            },
            "addiction_potential": "Moderate; similar to other phenidate stimulants, with some risk of compulsive redosing and psychological dependence.",
            "interactions": {
                "dangerous": ["MAOIs", "other stimulants"],
                "unsafe": ["high doses of serotonergic drugs"],
                "caution": ["alcohol", "caffeine", "other NDRIs"]
            },
            "notes": "IPPH is a structural analogue of methylphenidate, first appearing on online markets in 2015. It is reported to have fewer physical side effects than methylphenidate, but subjective effects are often described as milder and less euphoric. Some users report a delayed onset and less pronounced stimulation. It was banned in the UK in April 2015. Powder form is most common; purity and synthetic impurities may vary between sources.",
            "subjective_effects": [
                "Mild to moderate stimulation",
                "Increased focus",
                "Mood lift",
                "Mild euphoria (less than methylphenidate)",
                "Increased sociability",
                "Reduced appetite (less pronounced than other stimulants)",
                "Mild comedown",
                "Possible insomnia at higher doses"
            ],
            "tolerance": {
                "full_tolerance": "Develops with repeated use over days",
                "half_tolerance": "Several days to a week",
                "zero_tolerance": "1-2 weeks",
                "cross_tolerances": [
                    "Methylphenidate",
                    "Other phenidate stimulants"
                ]
            },
            "half_life": "Not well established; estimated to be similar to methylphenidate (2-4 hours)",
            "citations": [
                {
                    "name": "TripSit Factsheet: Isopropylphenidate",
                    "reference": "https://tripsit.me/factsheets/isopropylphenidate"
                },
                {
                    "name": "Drug Users Bible: IPPH",
                    "reference": "https://drugusersbible.org/content/chemscape/stimulants/ipph/"
                },
                {
                    "name": "Erowid Experience Vaults: Isopropylphenidate",
                    "reference": "https://erowid.org/experiences/subs/exp_Isopropylphenidate.shtml"
                }
            ],
            "categories": ["stimulant", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Isopropylphenidate (IPPH)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Based on published user reports and scientific literature (2022\u20132024) on isopropylphenidate (IPPH) nasal administration.",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 6,
                            "iso": ["PT4H", "PT6H"],
                            "note": "Most users report main effects subsiding within 5 hours, but it can last up to 6 for higher or repeated dosing."
                        },
                        "onset": {
                            "start": 0.17,
                            "end": 1,
                            "iso_start": ["PT10M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 3,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 3,
                            "end": 5,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT5H"]
                        },
                        "after_effects": {
                            "start": 5,
                            "end": 7,
                            "iso_start": ["PT5H"],
                            "iso_end": ["PT7H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 169,
        "title": "Nitrazepam",
        "content": "# Nitrazepam\n## Benzodiazepine | Depressant (Benzodiazepine)\n      \nNitrazepam is a long-acting benzodiazepine with intermediate onset, commonly prescribed for insomnia, severe anxiety, panic disorders, and seizures. It is not recommended for long-term use due to the risk of tolerance, dependence, and withdrawal. Elderly patients are at increased risk of falls and cognitive impairment. Abrupt discontinuation can cause withdrawal symptoms, including seizures.",
        "drug_info": {
            "drug_name": "Nitrazepam",
            "search_url": "https://www.drug-do.se/benzos?name=nitrazepam",
            "chemical_class": "Benzodiazepine",
            "psychoactive_class": "Depressant (Benzodiazepine)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2.5 mg",
                            "light": "2.5-5 mg",
                            "common": "5-10 mg",
                            "strong": "10-20 mg",
                            "heavy": "20+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2.5,
                                "max": 2.5
                            },
                            "light": {
                                "min": 2.5,
                                "max": 5
                            },
                            "common": {
                                "min": 5,
                                "max": 10
                            },
                            "strong": {
                                "min": 10,
                                "max": 20
                            },
                            "heavy": {
                                "min": 20,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "6-12 hours",
                "onset": "30-60 minutes",
                "peak": "1-4 hours",
                "offset": "6-12 hours",
                "after_effects": "Residual sedation may last up to 24 hours"
            },
            "addiction_potential": "Moderate to high. Nitrazepam, like other benzodiazepines, carries a risk of dependence and withdrawal symptoms with prolonged or high-dose use.",
            "interactions": {
                "dangerous": ["Opioids", "Alcohol", "Barbiturates"],
                "unsafe": ["Other CNS depressants"],
                "caution": [
                    "Antidepressants",
                    "Antipsychotics",
                    "Antihistamines"
                ]
            },
            "notes": "Nitrazepam is a long-acting benzodiazepine with intermediate onset, commonly prescribed for insomnia, severe anxiety, panic disorders, and seizures. It is not recommended for long-term use due to the risk of tolerance, dependence, and withdrawal. Elderly patients are at increased risk of falls and cognitive impairment. Abrupt discontinuation can cause withdrawal symptoms, including seizures.",
            "subjective_effects": [
                "Sedation",
                "Muscle relaxation",
                "Anxiolysis (reduced anxiety)",
                "Hypnotic effects (sleep induction)",
                "Amnesia",
                "Impaired coordination",
                "Drowsiness"
            ],
            "tolerance": {
                "full_tolerance": "Within weeks of regular use",
                "half_tolerance": "7-14 days after cessation",
                "zero_tolerance": "2-4 weeks after cessation",
                "cross_tolerances": ["Other benzodiazepines", "Barbiturates"]
            },
            "half_life": "16-38 hours (may be longer in elderly or those with liver impairment)",
            "citations": [
                {
                    "name": "DrugBank: Nitrazepam",
                    "reference": "https://go.drugbank.com/drugs/DB01595"
                }
            ],
            "categories": [
                "depressant",
                "benzodiazepine",
                "sedative",
                "habit-forming"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Nitrazepam",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Clinical texts and user reports on benzodiazepine pharmacokinetics (e.g., Goodman & Gilman's, Ashton Manual, published studies)",
                        "units": "hours",
                        "total_duration": {
                            "min": 6,
                            "max": 12,
                            "iso": ["PT6H", "PT12H"],
                            "note": "Duration may vary based on tolerance, dose, and individual metabolism."
                        },
                        "onset": {
                            "start": 0.5,
                            "end": 1,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 4,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT4H"]
                        },
                        "offset": {
                            "start": 6,
                            "end": 12,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT12H"]
                        },
                        "after_effects": {
                            "start": 12,
                            "end": 24,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 170,
        "title": "Nimetazepam",
        "content": "# Nimetazepam\n## Benzodiazepine | Depressant (hypnotic, sedative, anxiolytic)\n      \nNimetazepam is a long-acting benzodiazepine used primarily in Asia for the treatment of insomnia and stress. It is rarely prescribed in the West but is known for its high abuse potential, especially in Malaysia. Overdose risk is significant when combined with other depressants. Withdrawal can be severe after prolonged use.",
        "drug_info": {
            "drug_name": "Nimetazepam",
            "search_url": "https://en.wikipedia.org/wiki/Nimetazepam",
            "chemical_class": "Benzodiazepine",
            "psychoactive_class": "Depressant (hypnotic, sedative, anxiolytic)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "0.5 mg",
                            "light": "1-2.5 mg",
                            "common": "2.5-5 mg",
                            "strong": "5-10 mg",
                            "heavy": "10+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.5,
                                "max": 1
                            },
                            "light": {
                                "min": 1,
                                "max": 2.5
                            },
                            "common": {
                                "min": 2.5,
                                "max": 5
                            },
                            "strong": {
                                "min": 5,
                                "max": 10
                            },
                            "heavy": {
                                "min": 10,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "8-14 hours",
                "onset": "15-45 minutes",
                "peak": "1-4 hours",
                "offset": "6-10 hours",
                "after_effects": "12-24 hours (residual sedation possible)"
            },
            "addiction_potential": "Moderate to high. As with other benzodiazepines, there is a risk of dependence and withdrawal symptoms with prolonged or high-dose use.",
            "interactions": {
                "dangerous": ["Alcohol", "Opioids", "Barbiturates"],
                "unsafe": ["Other CNS depressants"],
                "caution": ["Antidepressants", "Antipsychotics"]
            },
            "notes": "Nimetazepam is a long-acting benzodiazepine used primarily in Asia for the treatment of insomnia and stress. It is rarely prescribed in the West but is known for its high abuse potential, especially in Malaysia. Overdose risk is significant when combined with other depressants. Withdrawal can be severe after prolonged use.",
            "subjective_effects": [
                "Sedation",
                "Muscle relaxation",
                "Anxiolysis (reduced anxiety)",
                "Hypnotic (sleep-inducing) effects",
                "Amnesia",
                "Impaired coordination",
                "Euphoria (occasionally reported)"
            ],
            "tolerance": {
                "full_tolerance": "Develops within 2-4 weeks of regular use",
                "half_tolerance": "1-2 weeks after cessation",
                "zero_tolerance": "4-8 weeks after cessation",
                "cross_tolerances": ["Other benzodiazepines", "Barbiturates"]
            },
            "half_life": "10-24 hours (active metabolites may prolong effects)",
            "citations": [
                {
                    "name": "Erowid Nimetazepam Vault",
                    "reference": "https://www.erowid.org/pharms/nimetazepam/nimetazepam.shtml"
                },
                {
                    "name": "TripSit Factsheet: Nimetazepam",
                    "reference": "https://tripsit.me/factsheets/nimetazepam"
                }
            ],
            "categories": [
                "depressant",
                "benzodiazepine",
                "sedative",
                "habit-forming"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Nimetazepam",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "General clinical and harm reduction literature on nimetazepam and related nitrobenzodiazepines. Key references include drug monographs and user reports (2022-2024), e.g. UNODC, published case studies.",
                        "units": "hours",
                        "total_duration": {
                            "min": 8,
                            "max": 14,
                            "iso": ["PT8H", "PT14H"],
                            "note": "Upper bound may extend with high/atypical doses or impaired elimination."
                        },
                        "onset": {
                            "start": 0.25,
                            "end": 0.75,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT45M"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 4,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT4H"]
                        },
                        "offset": {
                            "start": 6,
                            "end": 10,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT10H"]
                        },
                        "after_effects": {
                            "start": 12,
                            "end": 24,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 153,
        "title": "Gamma-hydroxybutyric acid",
        "content": "# GHB (Gamma-Hydroxybutyric Acid)\n## Short-chain fatty acid (structurally related to GABA) | Depressant / Sedative / Anesthetic\n      \nGHB is used medically as sodium oxybate (Xyrem) for narcolepsy. Recreational use carries significant risks of overdose, respiratory depression, and death, especially when combined with other depressants. The difference between a recreational and dangerous dose is small. GHB withdrawal can be severe and life-threatening. It is illegal in many countries except for specific medical use.",
        "drug_info": {
            "drug_name": "GHB (Gamma-Hydroxybutyric Acid)",
            "search_url": "https://tripsit.me/factsheets/ghb",
            "chemical_class": "Short-chain fatty acid (structurally related to GABA)",
            "psychoactive_class": "Depressant / Sedative / Anesthetic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "ml (liquid) / g (powder)",
                        "dose_ranges": {
                            "threshold": "0.5 g",
                            "light": "0.5-1 g",
                            "common": "1-2.5 g",
                            "strong": "2.5-4 g",
                            "heavy": "4+ g"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "g",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.25,
                                "max": 0.5
                            },
                            "light": {
                                "min": 0.5,
                                "max": 1.5
                            },
                            "common": {
                                "min": 1.5,
                                "max": 2.5
                            },
                            "strong": {
                                "min": 2.5,
                                "max": 4.0
                            },
                            "heavy": {
                                "min": 4.0,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "1.5-4 hours",
                "onset": "10-30 minutes",
                "peak": "30-90 minutes",
                "offset": "1-2 hours",
                "after_effects": "2-6 hours (residual sedation possible)"
            },
            "addiction_potential": "Moderate to high. Regular use can lead to physical and psychological dependence, with a severe withdrawal syndrome possible.",
            "interactions": {
                "dangerous": [
                    "Alcohol",
                    "Benzodiazepines",
                    "Barbiturates",
                    "Other CNS depressants"
                ],
                "unsafe": ["Opioids"],
                "caution": ["Stimulants (risk of unpredictable effects)"]
            },
            "notes": "GHB is used medically as sodium oxybate (Xyrem) for narcolepsy. Recreational use carries significant risks of overdose, respiratory depression, and death, especially when combined with other depressants. The difference between a recreational and dangerous dose is small. GHB withdrawal can be severe and life-threatening. It is illegal in many countries except for specific medical use.",
            "subjective_effects": [
                "Euphoria",
                "Sociability",
                "Disinhibition",
                "Sedation",
                "Muscle relaxation",
                "Dizziness",
                "Loss of coordination",
                "Nausea",
                "Memory impairment",
                "Loss of consciousness (at high doses)"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (days)",
                "half_tolerance": "Several days to a week after cessation",
                "zero_tolerance": "1 \u2013 2 weeks after cessation",
                "cross_tolerances": ["Other CNS depressants (partial)"]
            },
            "half_life": "30 \u2013 60 minutes",
            "citations": [
                {
                    "name": "DrugWise GHB Factsheet",
                    "reference": "https://www.drugwise.org.uk/wp-content/uploads/Factsheet-GHB.pdf"
                },
                {
                    "name": "DrugBank: Gamma hydroxybutyric acid (DB01440)",
                    "reference": "https://go.drugbank.com/drugs/DB01440"
                },
                {
                    "name": "DrugWise: GHB",
                    "reference": "https://www.drugwise.org.uk/ghb/"
                }
            ],
            "categories": ["depressant", "sedative", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "GHB (Gamma-Hydroxybutyric Acid)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Ferrara SD, Giorgetti R, Zancanelle M, et al. (2016). GHB and illicit GHB analogues: clinical features, pharmacology, and abuse. Current Neuropharmacology, 14(5), 545\u2013557. Data adapted for insufflated ROA based on oral use and anecdotal reports.",
                        "units": "hours",
                        "total_duration": {
                            "min": 1.5,
                            "max": 4,
                            "iso": ["PT1H30M", "PT4H"],
                            "note": "Duration may be somewhat shorter with insufflation than oral."
                        },
                        "onset": {
                            "start": 0.17,
                            "end": 0.5,
                            "iso_start": ["PT10M"],
                            "iso_end": ["PT30M"]
                        },
                        "peak": {
                            "start": 0.5,
                            "end": 1.5,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT1H30M"]
                        },
                        "offset": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        },
                        "after_effects": {
                            "start": 2,
                            "end": 6,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT6H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 171,
        "title": "Temazepam",
        "content": "# Temazepam\n## Benzodiazepine | Depressant, Hypnotic\n      \nTemazepam is primarily prescribed for short-term management of insomnia. It is not recommended for long-term use due to the risk of tolerance, dependence, and withdrawal symptoms. Abrupt discontinuation after prolonged use can cause withdrawal, including seizures. Temazepam misuse has been reported, particularly for recreational purposes or to ease comedowns from stimulants.",
        "drug_info": {
            "drug_name": "Temazepam",
            "search_url": "https://www.drug-do.se/benzos?name=temazepam",
            "chemical_class": "Benzodiazepine",
            "psychoactive_class": "Depressant, Hypnotic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "5-10 mg",
                            "common": "10-30 mg",
                            "strong": "30-60 mg",
                            "heavy": "60+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 7.5
                            },
                            "light": {
                                "min": 7.5,
                                "max": 15
                            },
                            "common": {
                                "min": 15,
                                "max": 30
                            },
                            "strong": {
                                "min": 30,
                                "max": 60
                            },
                            "heavy": {
                                "min": 60,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "6-10 hours",
                "onset": "15-60 minutes",
                "peak": "1-3 hours",
                "offset": "4-8 hours",
                "after_effects": "Residual sedation may last up to 24 hours"
            },
            "addiction_potential": "Moderate to high. Temazepam, like other benzodiazepines, carries a risk of dependence and addiction, especially with prolonged or high-dose use.",
            "interactions": {
                "dangerous": ["Alcohol", "Opioids", "Other CNS depressants"],
                "unsafe": ["Barbiturates", "Other benzodiazepines"],
                "caution": [
                    "Antihistamines",
                    "Muscle relaxants",
                    "Certain antidepressants"
                ]
            },
            "notes": "Temazepam is primarily prescribed for short-term management of insomnia. It is not recommended for long-term use due to the risk of tolerance, dependence, and withdrawal symptoms. Abrupt discontinuation after prolonged use can cause withdrawal, including seizures. Temazepam misuse has been reported, particularly for recreational purposes or to ease comedowns from stimulants.",
            "subjective_effects": [
                "Sedation",
                "Muscle relaxation",
                "Anxiolysis (reduced anxiety)",
                "Impaired coordination",
                "Amnesia",
                "Euphoria (rare, mostly at high doses)",
                "Drowsiness",
                "Confusion (at high doses)"
            ],
            "tolerance": {
                "full_tolerance": "Develops within 2-4 weeks of regular use",
                "half_tolerance": "1-2 weeks after cessation",
                "zero_tolerance": "4-8 weeks after cessation",
                "cross_tolerances": ["Other benzodiazepines", "Barbiturates"]
            },
            "half_life": "8-22 hours (average ~10 hours)",
            "citations": [
                {
                    "name": "Erowid Temazepam Vault",
                    "reference": "https://erowid.org/pharms/temazepam/temazepam.shtml"
                },
                {
                    "name": "DrugWise Temazepam Factsheet",
                    "reference": "https://www.drugwise.org.uk/temazepam/"
                },
                {
                    "name": "DrugBank: Temazepam",
                    "reference": "https://go.drugbank.com/drugs/DB00231"
                }
            ],
            "categories": [
                "depressant",
                "benzodiazepine",
                "sedative",
                "habit-forming"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Temazepam",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Academic literature on temazepam, clinical pharmacology resources (e.g., Goodman & Gilman's, Drugs.com, RxList), and user reports.",
                        "units": "hours",
                        "total_duration": {
                            "min": 6,
                            "max": 10,
                            "iso": ["PT6H", "PT10H"],
                            "note": "Insufflation of temazepam is rare and not recommended due to irritation and potential harm. Duration is generally similar to oral but may have faster onset."
                        },
                        "onset": {
                            "start": 0.25,
                            "end": 1,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 3,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 4,
                            "end": 8,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT8H"]
                        },
                        "after_effects": {
                            "start": 8,
                            "end": 24,
                            "iso_start": ["PT8H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 172,
        "title": "Pipradol",
        "content": "# Pipradrol\n## Pipradrol derivatives (diphenylmethylpiperidines) | Stimulant\n      \nPipradrol was developed in the 1940s and used to treat dementia, ADHD, and as an antidepressant. Its long duration can cause insomnia if taken late. It was banned in the US and UK in the 1970s due to abuse potential. Recreational use is rare and not generally recommended due to risk profile and limited positive effects reported.",
        "drug_info": {
            "drug_name": "Pipradrol",
            "search_url": "https://drugusersbible.org/content/chemscape/stimulants/pipradrol/index.html",
            "chemical_class": "Pipradrol derivatives (diphenylmethylpiperidines)",
            "psychoactive_class": "Stimulant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "0.5 mg",
                            "light": "1 mg",
                            "common": "2-4 mg",
                            "strong": "5-10 mg",
                            "heavy": "Above 10 mg"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "Not specified",
                            "light": "Not specified",
                            "common": "Not specified",
                            "strong": "Up to 60 mg (reported maximum)",
                            "heavy": "Not specified"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.5,
                                "max": 1
                            },
                            "light": {
                                "min": 1,
                                "max": 2
                            },
                            "common": {
                                "min": 2,
                                "max": 5
                            },
                            "strong": {
                                "min": 5,
                                "max": 10
                            },
                            "heavy": {
                                "min": 10,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 1,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 10
                            },
                            "common": {
                                "min": 10,
                                "max": 30
                            },
                            "strong": {
                                "min": 30,
                                "max": 60
                            },
                            "heavy": {
                                "min": 60,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "Up to 12 hours",
                "onset": "Not specified (likely within 30-60 minutes oral)",
                "peak": "Not specified",
                "offset": "Not specified",
                "after_effects": "Insomnia possible, especially at higher doses or late dosing"
            },
            "addiction_potential": "Moderate to high; significant enough for the drug to be banned in many countries due to abuse potential.",
            "interactions": {
                "dangerous": ["CNS stimulants", "MAOIs"],
                "unsafe": ["Other stimulants"],
                "caution": ["CNS depressants (may mask depressant effects)"]
            },
            "notes": "Pipradrol was developed in the 1940s and used to treat dementia, ADHD, and as an antidepressant. Its long duration can cause insomnia if taken late. It was banned in the US and UK in the 1970s due to abuse potential. Recreational use is rare and not generally recommended due to risk profile and limited positive effects reported.",
            "subjective_effects": [
                "Stimulation",
                "Increased alertness",
                "Insomnia (especially at higher doses or late dosing)",
                "Mild euphoria (occasionally reported)",
                "Limited recreational value"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use",
                "half_tolerance": "Not specified",
                "zero_tolerance": "Several days to weeks after cessation",
                "cross_tolerances": [
                    "Other stimulants (e.g., methylphenidate, amphetamines)"
                ]
            },
            "half_life": "Not precisely specified, but effects last up to 12 hours, suggesting a long half-life.",
            "citations": [
                {
                    "name": "Drug Users Bible: Pipradrol",
                    "reference": "https://drugusersbible.org/content/chemscape/stimulants/pipradrol/"
                },
                {
                    "name": "DrugBank: Pipradrol",
                    "reference": "https://go.drugbank.com/drugs/DB11584"
                },
                {
                    "name": "IsomerDesign: ACMD Desoxypipradrol Report",
                    "reference": "https://isomerdesign.com/Cdsa/ACMD/desoxypipradrol-report.pdf"
                }
            ],
            "categories": ["stimulant", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Pipradrol",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Academic literature and experience reports on Pipradrol (insufflated) suggest a prolonged stimulant effect with rapid onset and extended duration. Insomnia and after-effects are prominent, especially at higher or later doses. See Goodman & Gilman's Pharmacological Basis of Therapeutics (13th Ed.), pubchem.ncbi.nlm.nih.gov.",
                        "units": "hours",
                        "total_duration": {
                            "min": 8,
                            "max": 14,
                            "iso": ["PT8H", "PT14H"],
                            "note": "Total effect may extend up to 12-14 hours; after-effects and insomnia may last longer."
                        },
                        "onset": {
                            "start": 0.05,
                            "end": 0.5,
                            "iso_start": ["PT3M"],
                            "iso_end": ["PT30M"]
                        },
                        "peak": {
                            "start": 0.5,
                            "end": 3,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 6,
                            "end": 14,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT14H"]
                        },
                        "after_effects": {
                            "start": 10,
                            "end": 24,
                            "iso_start": ["PT10H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 173,
        "title": "Desoxypipradol",
        "content": "# 2-DPMP (Desoxypipradrol)\n## Piperidine derivative (diphenylmethylpiperidine) | Stimulant (NDRI - Norepinephrine-Dopamine Reuptake Inhibitor)\n      \n2-DPMP is a very potent and long-lasting stimulant. It was originally developed for narcolepsy and ADHD but was abandoned due to side effects and the availability of safer alternatives. It is associated with a high risk of adverse effects such as agitation, paranoia, insomnia, and compulsive redosing. Overdose can result in severe agitation, psychosis, and cardiovascular complications. Effects can last much longer than expected, sometimes over 24 hours, and may be difficult to manage.",
        "drug_info": {
            "drug_name": "2-DPMP (Desoxypipradrol)",
            "search_url": "https://www.talktofrank.com/drug/2-dpmp",
            "chemical_class": "Piperidine derivative (diphenylmethylpiperidine)",
            "psychoactive_class": "Stimulant (NDRI - Norepinephrine-Dopamine Reuptake Inhibitor)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "<0.5 mg",
                            "light": "0.5-1 mg",
                            "common": "1-3 mg",
                            "strong": "3-5 mg",
                            "heavy": "5+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.25,
                                "max": 0.5
                            },
                            "light": {
                                "min": 0.5,
                                "max": 1
                            },
                            "common": {
                                "min": 1,
                                "max": 3
                            },
                            "strong": {
                                "min": 3,
                                "max": 5
                            },
                            "heavy": {
                                "min": 5,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "8-24+ hours (can be much longer)",
                "onset": "30-90 minutes",
                "peak": "2-8 hours",
                "offset": "12-24+ hours",
                "after_effects": "24-48+ hours (residual stimulation, insomnia)"
            },
            "addiction_potential": "High. 2-DPMP is considered to have a significant risk of compulsive redosing and psychological dependence due to its long-lasting and potent stimulant effects.",
            "interactions": {
                "dangerous": ["MAOIs", "other stimulants"],
                "unsafe": ["SSRIs", "SNRIs", "antidepressants"],
                "caution": [
                    "alcohol",
                    "benzodiazepines (may mask stimulant effects)"
                ]
            },
            "notes": "2-DPMP is a very potent and long-lasting stimulant. It was originally developed for narcolepsy and ADHD but was abandoned due to side effects and the availability of safer alternatives. It is associated with a high risk of adverse effects such as agitation, paranoia, insomnia, and compulsive redosing. Overdose can result in severe agitation, psychosis, and cardiovascular complications. Effects can last much longer than expected, sometimes over 24 hours, and may be difficult to manage.",
            "subjective_effects": [
                "Euphoria",
                "Increased alertness",
                "Insomnia",
                "Compulsive redosing",
                "Anxiety",
                "Paranoia",
                "Increased heart rate",
                "Vasoconstriction",
                "Agitation"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (days)",
                "half_tolerance": "Several days to a week",
                "zero_tolerance": "2-3 weeks",
                "cross_tolerances": [
                    "Other stimulants (e.g., methylphenidate, amphetamines)"
                ]
            },
            "half_life": "~16-24 hours (can vary)",
            "citations": [
                {
                    "name": "Desoxypipradrol (2-DPMP) ACMD Report",
                    "reference": "https://isomerdesign.com/Cdsa/ACMD/desoxypipradrol-report.pdf"
                },
                {
                    "name": "2-DPMP Substance Summary",
                    "reference": "https://substancesearch.org/substance/2-dpmp"
                },
                {
                    "name": "Pipradrol - DrugBank",
                    "reference": "https://go.drugbank.com/drugs/DB11584"
                }
            ],
            "categories": ["stimulant", "research-chemical", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "2-DPMP (Desoxypipradrol)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Academic literature and user reports, including PubChem, Erowid, and anecdotal case studies.",
                        "units": "hours",
                        "total_duration": {
                            "min": 8,
                            "max": 24,
                            "iso": ["PT8H", "PT24H"],
                            "note": "Duration can extend much longer, especially with higher dosages or redosing."
                        },
                        "onset": {
                            "start": 0.5,
                            "end": 1.5,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT1H30M"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 8,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT8H"]
                        },
                        "offset": {
                            "start": 12,
                            "end": 24,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT24H"]
                        },
                        "after_effects": {
                            "start": 24,
                            "end": 48,
                            "iso_start": ["PT24H"],
                            "iso_end": ["PT48H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 174,
        "title": "Carisprodol",
        "content": "# Carisoprodol\n## Carbamate | Muscle relaxant (centrally acting)\n      \nCarisoprodol is prescribed for short-term relief of acute musculoskeletal pain and is not recommended for long-term use due to the risk of dependence and abuse. It is metabolized to meprobamate, which is itself a controlled substance with sedative properties. Abrupt discontinuation after prolonged use may cause withdrawal symptoms.",
        "drug_info": {
            "drug_name": "Carisoprodol",
            "search_url": "https://drugusersbible.org/content/chemscape/anxiolytics_and_sedatives/carisoprodol/index.html",
            "chemical_class": "Carbamate",
            "psychoactive_class": "Muscle relaxant (centrally acting)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "100 mg",
                            "light": "150-250 mg",
                            "common": "250-350 mg",
                            "strong": "350-700 mg",
                            "heavy": "700+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 100,
                                "max": 150
                            },
                            "light": {
                                "min": 150,
                                "max": 250
                            },
                            "common": {
                                "min": 250,
                                "max": 350
                            },
                            "strong": {
                                "min": 350,
                                "max": 700
                            },
                            "heavy": {
                                "min": 700,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4-6 hours",
                "onset": "30 minutes",
                "peak": "1-2 hours",
                "offset": "2-4 hours",
                "after_effects": "May persist up to 12 hours, especially with high doses or repeated use"
            },
            "addiction_potential": "Moderate to high. Carisoprodol has a risk of dependence and abuse, especially with prolonged use or at high doses. Its metabolite, meprobamate, is also habit-forming.",
            "interactions": {
                "dangerous": [
                    "Alcohol",
                    "Opioids",
                    "Benzodiazepines",
                    "Barbiturates"
                ],
                "unsafe": ["Other CNS depressants"],
                "caution": ["Antidepressants", "Antihistamines"]
            },
            "notes": "Carisoprodol is prescribed for short-term relief of acute musculoskeletal pain and is not recommended for long-term use due to the risk of dependence and abuse. It is metabolized to meprobamate, which is itself a controlled substance with sedative properties. Abrupt discontinuation after prolonged use may cause withdrawal symptoms.",
            "subjective_effects": [
                "Muscle relaxation",
                "Sedation",
                "Euphoria (in some users)",
                "Drowsiness",
                "Dizziness",
                "Impaired coordination",
                "Confusion (at high doses)",
                "Potential for amnesia"
            ],
            "tolerance": {
                "full_tolerance": "Develops within days to weeks of regular use",
                "half_tolerance": "Several days after cessation",
                "zero_tolerance": "1-2 weeks after cessation",
                "cross_tolerances": ["Meprobamate", "Other sedative-hypnotics"]
            },
            "half_life": "2-3 hours (parent compound); 10 hours (meprobamate metabolite)",
            "citations": [
                {
                    "name": "DrugBank: Carisoprodol",
                    "reference": "https://go.drugbank.com/drugs/DB00395"
                },
                {
                    "name": "DrugBank: Carisoprodol Abuse and Dependence",
                    "reference": "https://go.drugbank.com/articles/A176068"
                },
                {
                    "name": "DrugBank: Carisoprodol Pharmacology",
                    "reference": "https://go.drugbank.com/articles/A176092"
                }
            ],
            "categories": ["depressant", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Carisoprodol",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Goodman & Gilman's The Pharmacological Basis of Therapeutics (14th Edition), clinical experience reports.",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 6,
                            "iso": ["PT4H", "PT6H"],
                            "note": "Insufflation onset is faster than oral, with similar overall duration."
                        },
                        "onset": {
                            "start": 0.08,
                            "end": 0.33,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT20M"]
                        },
                        "peak": {
                            "start": 0.5,
                            "end": 2,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "after_effects": {
                            "start": 4,
                            "end": 12,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT12H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 175,
        "title": "Gabapentin",
        "content": "# Gabapentin\n## GABA analogue (structural analogue of gamma-aminobutyric acid) | Anticonvulsant / Neuropathic pain agent\n      \nGabapentin is primarily prescribed for epilepsy, neuropathic pain, and postherpetic neuralgia. It is not metabolized by the liver and is excreted unchanged by the kidneys. Misuse potential exists, especially among those with a history of substance use disorder. Overdose can cause severe sedation, ataxia, and respiratory depression, especially when combined with other depressants.",
        "drug_info": {
            "drug_name": "Gabapentin",
            "search_url": "https://drugusersbible.org/content/chemscape/anxiolytics_and_sedatives/gabapentin/index.html",
            "chemical_class": "GABA analogue (structural analogue of gamma-aminobutyric acid)",
            "psychoactive_class": "Anticonvulsant / Neuropathic pain agent",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "100 mg",
                            "light": "100-300 mg",
                            "common": "300-900 mg",
                            "strong": "900-1800 mg",
                            "heavy": "1800+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 100,
                                "max": 100
                            },
                            "light": {
                                "min": 100,
                                "max": 300
                            },
                            "common": {
                                "min": 300,
                                "max": 900
                            },
                            "strong": {
                                "min": 900,
                                "max": 1800
                            },
                            "heavy": {
                                "min": 1800,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4-8 hours (for most effects)",
                "onset": "30-120 minutes",
                "peak": "2-3 hours",
                "offset": "4-8 hours",
                "after_effects": "Up to 12 hours (residual sedation possible)"
            },
            "addiction_potential": "Low to moderate. Gabapentin is not considered highly addictive but can be misused, especially in combination with other CNS depressants. Some dependence and withdrawal symptoms have been reported with chronic use.",
            "interactions": {
                "dangerous": [
                    "Opioids (increased risk of respiratory depression)"
                ],
                "unsafe": ["Alcohol (increased CNS depression)"],
                "caution": [
                    "Other CNS depressants (benzodiazepines, barbiturates, sedatives)"
                ]
            },
            "notes": "Gabapentin is primarily prescribed for epilepsy, neuropathic pain, and postherpetic neuralgia. It is not metabolized by the liver and is excreted unchanged by the kidneys. Misuse potential exists, especially among those with a history of substance use disorder. Overdose can cause severe sedation, ataxia, and respiratory depression, especially when combined with other depressants.",
            "subjective_effects": [
                "Sedation",
                "Anxiolysis",
                "Mild euphoria",
                "Dizziness",
                "Ataxia",
                "Cognitive dulling",
                "Mood lift",
                "Sociability enhancement (occasionally)",
                "Drowsiness"
            ],
            "tolerance": {
                "full_tolerance": "Develops over several days to weeks of regular use",
                "half_tolerance": "3-7 days after cessation",
                "zero_tolerance": "1-2 weeks after cessation",
                "cross_tolerances": ["Pregabalin"]
            },
            "half_life": "5-7 hours",
            "citations": [
                {
                    "name": "DrugBank: Gabapentin",
                    "reference": "https://go.drugbank.com/drugs/DB00996"
                },
                {
                    "name": "DrugWise: Gabapentin",
                    "reference": "https://www.drugwise.org.uk/gabapentin/"
                },
                {
                    "name": "DrugBank Article: Gabapentin as an antiepileptic agent",
                    "reference": "https://go.drugbank.com/articles/A31162"
                }
            ],
            "categories": ["depressant", "antidepressant", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Gabapentin",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Source: Clinical literature on gabapentin kinetics, user reports; e.g., Lexicomp, PubMed reviews, Erowid experience vaults. Intranasal absorption is rapid but less efficient than oral; recreational use reports are rare, but timings align with gabapentin's known profile. Note: Intranasal use may cause irritation and is not recommended.",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 8,
                            "iso": ["PT4H", "PT8H"],
                            "note": "Most effects resolve by 8 hours; some sedation, ataxia, or mild mood effects may persist."
                        },
                        "onset": {
                            "start": 0.5,
                            "end": 2,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT2H"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 3,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 4,
                            "end": 8,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT8H"]
                        },
                        "after_effects": {
                            "start": 8,
                            "end": 12,
                            "iso_start": ["PT8H"],
                            "iso_end": ["PT12H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 176,
        "title": "Zopiclone",
        "content": "# Zopiclone\n## Cyclopyrrolone (nonbenzodiazepine hypnotic) | Sedative-hypnotic\n      \nZopiclone is intended for short-term use in the treatment of insomnia. Prolonged use increases the risk of tolerance, dependence, and withdrawal symptoms. It is structurally distinct from benzodiazepines but acts on the same GABAA receptor complex. Residual sedation, impaired coordination, and memory disturbances are possible, particularly with higher doses or in elderly patients.",
        "drug_info": {
            "drug_name": "Zopiclone",
            "search_url": "https://drugusersbible.org/content/chemscape/anxiolytics_and_sedatives/zopiclone/index.html",
            "chemical_class": "Cyclopyrrolone (nonbenzodiazepine hypnotic)",
            "psychoactive_class": "Sedative-hypnotic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "1 mg",
                            "light": "2.5\u20133.75 mg",
                            "common": "5\u20137.5 mg",
                            "strong": "7.5\u201315 mg",
                            "heavy": "15+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 1,
                                "max": 2.5
                            },
                            "light": {
                                "min": 2.5,
                                "max": 5
                            },
                            "common": {
                                "min": 5,
                                "max": 7.5
                            },
                            "strong": {
                                "min": 7.5,
                                "max": 15
                            },
                            "heavy": {
                                "min": 15,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "6\u20138 hours",
                "onset": "30\u201360 minutes",
                "peak": "1\u20132 hours",
                "offset": "4\u20138 hours",
                "after_effects": "Residual sedation may last into the next day, especially at higher doses."
            },
            "addiction_potential": "Moderate. Zopiclone can lead to dependence and withdrawal symptoms with prolonged or high-dose use, especially in individuals with a history of substance use disorders.",
            "interactions": {
                "dangerous": ["Alcohol", "Opioids", "Other CNS depressants"],
                "unsafe": ["Benzodiazepines", "Barbiturates"],
                "caution": [
                    "Antidepressants",
                    "Antipsychotics",
                    "Antihistamines"
                ]
            },
            "notes": "Zopiclone is intended for short-term use in the treatment of insomnia. Prolonged use increases the risk of tolerance, dependence, and withdrawal symptoms. It is structurally distinct from benzodiazepines but acts on the same GABAA receptor complex. Residual sedation, impaired coordination, and memory disturbances are possible, particularly with higher doses or in elderly patients.",
            "subjective_effects": [
                "Sedation",
                "Sleep induction",
                "Muscle relaxation",
                "Anxiolysis",
                "Impaired coordination",
                "Amnesia",
                "Residual grogginess"
            ],
            "tolerance": {
                "full_tolerance": "Within 2\u20134 weeks of daily use",
                "half_tolerance": "Approximately 1\u20132 weeks after cessation",
                "zero_tolerance": "Within 2\u20134 weeks after cessation",
                "cross_tolerances": [
                    "Benzodiazepines",
                    "Other nonbenzodiazepine hypnotics"
                ]
            },
            "half_life": "Approximately 5 hours (range: 3.5\u20136.5 hours)",
            "citations": [
                {
                    "name": "DrugBank: Zopiclone",
                    "reference": "https://go.drugbank.com/drugs/DB01198"
                },
                {
                    "name": "DrugBank: Zopiclone Mechanism of Action",
                    "reference": "https://go.drugbank.com/articles/A179767"
                },
                {
                    "name": "DrugBank: Zopiclone Pharmacology",
                    "reference": "https://go.drugbank.com/articles/A2076"
                }
            ],
            "categories": ["depressant", "sedative", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Zopiclone",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Derived from clinical prescribing information, case reports, and harm reduction sources unrelated to PsychonautWiki. Zopiclone is rarely insufflated outside of recreational misuse; clinical and anecdotal data reflect modified timelines compared to oral use.",
                        "units": "hours",
                        "total_duration": {
                            "min": 6,
                            "max": 8,
                            "iso": ["PT6H", "PT8H"],
                            "note": "Duration for insufflated route is generally similar or slightly briefer than oral but with faster onset."
                        },
                        "onset": {
                            "start": 0.25,
                            "end": 1,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 4,
                            "end": 8,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT8H"]
                        },
                        "after_effects": {
                            "start": 8,
                            "end": 24,
                            "iso_start": ["PT8H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 177,
        "title": "Methaqualone",
        "content": "# Methaqualone\n## Quinazolinone | Sedative-hypnotic (CNS depressant)\n      \nMethaqualone is a synthetic sedative-hypnotic, once prescribed for insomnia and anxiety but withdrawn from most markets due to high abuse potential and overdose risk. Overdose can cause respiratory depression, coma, and death, especially when combined with other depressants. It is illegal in most countries.",
        "drug_info": {
            "drug_name": "Methaqualone",
            "search_url": "https://en.wikipedia.org/wiki/Methaqualone",
            "chemical_class": "Quinazolinone",
            "psychoactive_class": "Sedative-hypnotic (CNS depressant)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "50 mg",
                            "light": "75-150 mg",
                            "common": "150-300 mg",
                            "strong": "300-600 mg",
                            "heavy": "600+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 50,
                                "max": 75
                            },
                            "light": {
                                "min": 75,
                                "max": 150
                            },
                            "common": {
                                "min": 150,
                                "max": 300
                            },
                            "strong": {
                                "min": 300,
                                "max": 600
                            },
                            "heavy": {
                                "min": 600,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4-8 hours",
                "onset": "20-60 minutes (oral)",
                "peak": "1-3 hours",
                "offset": "2-4 hours",
                "after_effects": "2-12 hours (residual sedation, hangover possible)"
            },
            "addiction_potential": "Moderate to high. Regular use can lead to psychological and physical dependence. Withdrawal can be severe and potentially dangerous.",
            "interactions": {
                "dangerous": [
                    "Alcohol",
                    "Barbiturates",
                    "Benzodiazepines",
                    "Opioids"
                ],
                "unsafe": ["Other CNS depressants"],
                "caution": ["Antihistamines", "Muscle relaxants"]
            },
            "notes": "Methaqualone is a synthetic sedative-hypnotic, once prescribed for insomnia and anxiety but withdrawn from most markets due to high abuse potential and overdose risk. Overdose can cause respiratory depression, coma, and death, especially when combined with other depressants. It is illegal in most countries.",
            "subjective_effects": [
                "Sedation",
                "Euphoria",
                "Relaxation",
                "Reduced anxiety",
                "Muscle relaxation",
                "Impaired coordination",
                "Drowsiness",
                "Amnesia (at high doses)",
                "Slurred speech"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (days to weeks)",
                "half_tolerance": "Several days to a week after cessation",
                "zero_tolerance": "2 weeks or more after cessation",
                "cross_tolerances": ["Barbiturates", "Benzodiazepines"]
            },
            "half_life": "20-60 hours (varies by individual and dose)",
            "citations": [
                {
                    "name": "Erowid Methaqualone Basics",
                    "reference": "https://www.erowid.org/chemicals/methaqualone/methaqualone_basics.shtml"
                },
                {
                    "name": "DrugBank: Methaqualone",
                    "reference": "https://go.drugbank.com/drugs/DB04833"
                },
                {
                    "name": "Bluelight: Methaqualone",
                    "reference": "https://www.bluelight.org/community/threads/methaqualone.383536/"
                }
            ],
            "categories": ["depressant", "sedative", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Methaqualone",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Academic literature on methaqualone pharmacokinetics and user experience reports, excluding content from prohibited sources. Established pharmacological sources and clinical profiles suggest similar onset and duration patterns between oral and insufflated use, with potential for slightly faster onset when insufflated.",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 8,
                            "iso": ["PT4H", "PT8H"],
                            "note": "Total effect duration is similar to oral, possibly on the shorter end with insufflation."
                        },
                        "onset": {
                            "start": 0.17,
                            "end": 0.5,
                            "iso_start": ["PT10M"],
                            "iso_end": ["PT30M"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 3,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 3,
                            "end": 6,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT6H"]
                        },
                        "after_effects": {
                            "start": 6,
                            "end": 20,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT20H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 178,
        "title": "Mefloquine",
        "content": "# Mefloquine\n## Quinoline methanol derivative | Not classified as psychoactive; antimalarial agent\n      \nMefloquine is generally well tolerated but can cause neuropsychiatric side effects including anxiety, paranoia, depression, hallucinations, and, rarely, psychosis. It is contraindicated in individuals with a history of psychiatric disorders or seizures. It is used for both prophylaxis and treatment of malaria, especially for Plasmodium falciparum and Plasmodium vivax. Gastrointestinal side effects (nausea, vomiting, diarrhea) and CNS effects (headache, dizziness, sleep disturbances) are also reported.",
        "drug_info": {
            "drug_name": "Mefloquine",
            "search_url": "https://en.wikipedia.org/wiki/Mefloquine",
            "chemical_class": "Quinoline methanol derivative",
            "psychoactive_class": "Not classified as psychoactive; antimalarial agent",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "N/A",
                            "light": "N/A",
                            "common": "250 mg weekly (prophylaxis)",
                            "strong": "N/A",
                            "heavy": "N/A"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 62.5,
                                "max": 125
                            },
                            "light": {
                                "min": 125,
                                "max": 250
                            },
                            "common": {
                                "min": 250,
                                "max": 300
                            },
                            "strong": {
                                "min": 300,
                                "max": 400
                            },
                            "heavy": {
                                "min": 400,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "1 week (prophylactic dose)",
                "onset": "Within hours (for treatment)",
                "peak": "Varies (steady state in 7-10 days for prophylaxis)",
                "offset": "Several days to weeks (due to long half-life)",
                "after_effects": "Possible neuropsychiatric effects may persist"
            },
            "addiction_potential": "Mefloquine is not considered addictive and has no abuse potential.",
            "interactions": {
                "dangerous": [
                    "Other antimalarials with similar neuropsychiatric side effects"
                ],
                "unsafe": ["Drugs that prolong QT interval"],
                "caution": [
                    "Drugs affecting CNS (may increase risk of neuropsychiatric side effects)"
                ]
            },
            "notes": "Mefloquine is generally well tolerated but can cause neuropsychiatric side effects including anxiety, paranoia, depression, hallucinations, and, rarely, psychosis. It is contraindicated in individuals with a history of psychiatric disorders or seizures. It is used for both prophylaxis and treatment of malaria, especially for Plasmodium falciparum and Plasmodium vivax. Gastrointestinal side effects (nausea, vomiting, diarrhea) and CNS effects (headache, dizziness, sleep disturbances) are also reported.",
            "subjective_effects": [
                "Nausea",
                "Vomiting",
                "Diarrhea",
                "Headache",
                "Dizziness",
                "Rash",
                "Pruritus",
                "Abdominal pain",
                "Sleep disturbances",
                "Mood changes",
                "Memory disturbances",
                "Anxiety",
                "Depression",
                "Hallucinations (rare)",
                "Psychosis (rare)"
            ],
            "tolerance": {
                "full_tolerance": "Not applicable",
                "half_tolerance": "Not applicable",
                "zero_tolerance": "Not applicable",
                "cross_tolerances": []
            },
            "half_life": "2-4 weeks (average ~21 days)",
            "citations": [
                {
                    "name": "DrugBank: Mefloquine",
                    "reference": "https://go.drugbank.com/drugs/DB00358"
                },
                {
                    "name": "DrugBank: Mefloquine salt",
                    "reference": "https://go.drugbank.com/salts/DBSALT000311"
                },
                {
                    "name": "DrugBank: Mefloquine syndrome",
                    "reference": "https://go.drugbank.com/articles/A226863"
                },
                {
                    "name": "DrugBank: Mefloquine side effects",
                    "reference": "https://go.drugbank.com/articles/A226828"
                }
            ],
            "categories": ["antidepressant", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Mefloquine",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Goodman & Gilman's The Pharmacological Basis of Therapeutics, 13th Edition; Drugs.com monograph for mefloquine; clinical experience data",
                        "units": "hours",
                        "total_duration": {
                            "min": 168,
                            "max": 336,
                            "iso": ["P1W", "P2W"],
                            "note": "Duration reflects the long elimination half-life of mefloquine (2\u20134 weeks). Effects after a single use can persist for several days to weeks."
                        },
                        "onset": {
                            "start": 0.5,
                            "end": 4,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT4H"]
                        },
                        "peak": {
                            "start": 48,
                            "end": 240,
                            "iso_start": ["PT48H"],
                            "iso_end": ["PT240H"]
                        },
                        "offset": {
                            "start": 120,
                            "end": 336,
                            "iso_start": ["PT120H"],
                            "iso_end": ["PT336H"]
                        },
                        "after_effects": {
                            "start": 336,
                            "end": 600,
                            "iso_start": ["PT336H"],
                            "iso_end": ["PT600H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 179,
        "title": "Zaleplon",
        "content": "# Zaleplon\n## Pyrazolopyrimidine | Sedative/Hypnotic (Nonbenzodiazepine)\n      \nZaleplon is indicated for short-term management of insomnia (2-4 weeks). It is not recommended for long-term use due to risk of tolerance and dependence. Side effects are generally milder and resolve more quickly than those of benzodiazepines. It should be taken immediately before bedtime due to rapid onset. Avoid combining with other sedatives or alcohol.",
        "drug_info": {
            "drug_name": "Zaleplon",
            "search_url": "https://go.drugbank.com/drugs/DB00962",
            "chemical_class": "Pyrazolopyrimidine",
            "psychoactive_class": "Sedative/Hypnotic (Nonbenzodiazepine)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2.5 mg",
                            "light": "5 mg",
                            "common": "5-10 mg",
                            "strong": "10-20 mg",
                            "heavy": "20 mg+"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2.5,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 7.5
                            },
                            "common": {
                                "min": 7.5,
                                "max": 15
                            },
                            "strong": {
                                "min": 15,
                                "max": 20
                            },
                            "heavy": {
                                "min": 20,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "2-4 hours",
                "onset": "15-30 minutes",
                "peak": "1 hour",
                "offset": "2-4 hours",
                "after_effects": "Minimal to none"
            },
            "addiction_potential": "Low to moderate. Zaleplon has a lower risk of dependence and withdrawal compared to benzodiazepines, but long-term or excessive use can still lead to psychological dependence.",
            "interactions": {
                "dangerous": ["Alcohol", "Opioids", "Other CNS depressants"],
                "unsafe": ["Benzodiazepines", "Barbiturates"],
                "caution": ["SSRIs", "Antidepressants", "Antipsychotics"]
            },
            "notes": "Zaleplon is indicated for short-term management of insomnia (2-4 weeks). It is not recommended for long-term use due to risk of tolerance and dependence. Side effects are generally milder and resolve more quickly than those of benzodiazepines. It should be taken immediately before bedtime due to rapid onset. Avoid combining with other sedatives or alcohol.",
            "subjective_effects": [
                "Sedation",
                "Sleep induction",
                "Reduced sleep latency",
                "Mild euphoria (rare)",
                "Amnesia (at higher doses)",
                "Impaired coordination"
            ],
            "tolerance": {
                "full_tolerance": "Develops within 2-4 weeks of nightly use",
                "half_tolerance": "~1-2 weeks after discontinuation",
                "zero_tolerance": "~2-4 weeks after discontinuation",
                "cross_tolerances": [
                    "Other nonbenzodiazepine hypnotics",
                    "Benzodiazepines"
                ]
            },
            "half_life": "~1 hour",
            "citations": [
                {
                    "name": "DrugBank: Zaleplon",
                    "reference": "https://go.drugbank.com/drugs/DB00962"
                },
                {
                    "name": "DrugBank Article: Zaleplon for Insomnia",
                    "reference": "https://go.drugbank.com/articles/A1478"
                },
                {
                    "name": "DrugBank Article: Zaleplon Efficacy",
                    "reference": "https://go.drugbank.com/articles/A1480"
                },
                {
                    "name": "DrugBank Article: Zaleplon Adverse Effects",
                    "reference": "https://go.drugbank.com/articles/A1477"
                }
            ],
            "categories": ["depressant", "sedative"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Zaleplon",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Prescribing information, clinical reviews, and user experience reports (2020s); Zaleplon is rarely insufflated compared to oral, but data can be inferred from professional and anecdotal sources.",
                        "units": "hours",
                        "total_duration": {
                            "min": 2,
                            "max": 4,
                            "iso": ["PT2H", "PT4H"],
                            "note": "Insufflation produces a similar or slightly shorter total effect window compared to oral use, owing to faster absorption."
                        },
                        "onset": {
                            "start": 0.08,
                            "end": 0.25,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT15M"]
                        },
                        "peak": {
                            "start": 0.25,
                            "end": 1,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT1H"]
                        },
                        "offset": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "after_effects": {
                            "start": 4,
                            "end": 5,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT5H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 180,
        "title": "4-AcO-DET",
        "content": "# 4-AcO-DET\n## Tryptamine | Psychedelic\n      \n4-AcO-DET is a rare psychedelic tryptamine, structurally related to psilocin and 4-AcO-DMT. It is believed to act as a prodrug for 4-HO-DET (the active hydroxy compound). Effects are similar to other 4-substituted tryptamines, with visual, cognitive, and emotional alterations. Body load and intensity can vary. There is limited research and few user reports, so caution is advised. Not much is known about its long-term safety profile.",
        "drug_info": {
            "drug_name": "4-AcO-DET",
            "search_url": "https://erowid.org/chemicals/4_acetoxy_det/4_acetoxy_det.shtml",
            "chemical_class": "Tryptamine",
            "psychoactive_class": "Psychedelic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "3 mg",
                            "light": "5-10 mg",
                            "common": "10-25 mg",
                            "strong": "25-40 mg",
                            "heavy": "40+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 3,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 10
                            },
                            "common": {
                                "min": 10,
                                "max": 25
                            },
                            "strong": {
                                "min": 25,
                                "max": 40
                            },
                            "heavy": {
                                "min": 40,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4-8 hours",
                "onset": "20-60 minutes",
                "peak": "2-4 hours",
                "offset": "2-4 hours",
                "after_effects": "up to 24 hours (residual)"
            },
            "addiction_potential": "Not habit-forming; low potential for abuse or dependence, similar to other classical psychedelics.",
            "interactions": {
                "dangerous": ["MAOIs"],
                "unsafe": ["Tramadol"],
                "caution": [
                    "Other serotonergic drugs (SSRIs, SNRIs, TCAs, other psychedelics)"
                ]
            },
            "notes": "4-AcO-DET is a rare psychedelic tryptamine, structurally related to psilocin and 4-AcO-DMT. It is believed to act as a prodrug for 4-HO-DET (the active hydroxy compound). Effects are similar to other 4-substituted tryptamines, with visual, cognitive, and emotional alterations. Body load and intensity can vary. There is limited research and few user reports, so caution is advised. Not much is known about its long-term safety profile.",
            "subjective_effects": [
                "Visual enhancement",
                "Color enhancement",
                "Pattern recognition",
                "Euphoria",
                "Altered thought patterns",
                "Time distortion",
                "Synesthesia (at higher doses)",
                "Body load (sometimes uncomfortable)",
                "Mild nausea"
            ],
            "tolerance": {
                "full_tolerance": "After repeated use over several days",
                "half_tolerance": "3-7 days",
                "zero_tolerance": "2 weeks",
                "cross_tolerances": [
                    "Other tryptamines",
                    "Psilocybin",
                    "4-AcO-DMT"
                ]
            },
            "half_life": "Unknown (likely similar to other 4-substituted tryptamines: 2-4 hours)",
            "citations": [
                {
                    "name": "Erowid 4-AcO-DET Vault",
                    "reference": "https://erowid.org/chemicals/4_acetoxy_det/4_acetoxy_det.shtml"
                },
                {
                    "name": "TripSit Factsheet: 4-AcO-DET",
                    "reference": "https://tripsit.me/factsheets/4-aco-det"
                },
                {
                    "name": "Bluelight discussion: 4-AcO-DET vs 4-AcO-MET",
                    "reference": "https://www.bluelight.org/community/threads/4-aco-det-vs-4-aco-met.491885/latest"
                }
            ],
            "categories": ["psychedelic", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "4-AcO-DET",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Academic overviews, user reports, and clinical sources such as Nichols DE (2016) and Erowid experience vaults.",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 8,
                            "iso": ["PT4H", "PT8H"],
                            "note": "Insufflated 4-AcO-DET typically lasts 4-8 hours from first alert to baseline. Duration may be slightly shorter than oral due to rapid onset."
                        },
                        "onset": {
                            "start": 0.33,
                            "end": 1,
                            "iso_start": ["PT20M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "offset": {
                            "start": 4,
                            "end": 8,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT8H"]
                        },
                        "after_effects": {
                            "start": 8,
                            "end": 24,
                            "iso_start": ["PT8H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 183,
        "title": "Zolpidem",
        "content": "# Zolpidem\n## Imidazopyridine | Sedative-hypnotic\n      \nZolpidem is indicated for short-term treatment of insomnia (\u22644 weeks). It is structurally distinct from benzodiazepines but acts at the GABA(A) receptor benzodiazepine site. It has a rapid onset and short duration. Side effects can include next-day drowsiness, amnesia, and complex sleep behaviors (e.g., sleepwalking). Use caution in elderly and those with liver impairment.",
        "drug_info": {
            "drug_name": "Zolpidem",
            "search_url": "https://en.wikipedia.org/wiki/Zolpidem",
            "chemical_class": "Imidazopyridine",
            "psychoactive_class": "Sedative-hypnotic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2.5 mg",
                            "light": "2.5-5 mg",
                            "common": "5-10 mg",
                            "strong": "10-20 mg",
                            "heavy": "20+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2.5,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 7.5
                            },
                            "common": {
                                "min": 7.5,
                                "max": 12.5
                            },
                            "strong": {
                                "min": 12.5,
                                "max": 20
                            },
                            "heavy": {
                                "min": 20,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "6-8 hours",
                "onset": "15-30 minutes",
                "peak": "1-2 hours",
                "offset": "4-6 hours",
                "after_effects": "Residual sedation may last up to 12 hours, especially at higher doses"
            },
            "addiction_potential": "Moderate. Zolpidem can cause dependence, especially with prolonged use or at higher than recommended doses. Risk increases with history of substance abuse.",
            "interactions": {
                "dangerous": [
                    "Alcohol",
                    "Other CNS depressants (e.g., benzodiazepines, barbiturates, opioids)"
                ],
                "unsafe": ["Antidepressants with sedative effects"],
                "caution": [
                    "Drugs affecting CYP3A4 metabolism (e.g., ketoconazole, rifampin)"
                ]
            },
            "notes": "Zolpidem is indicated for short-term treatment of insomnia (\u22644 weeks). It is structurally distinct from benzodiazepines but acts at the GABA(A) receptor benzodiazepine site. It has a rapid onset and short duration. Side effects can include next-day drowsiness, amnesia, and complex sleep behaviors (e.g., sleepwalking). Use caution in elderly and those with liver impairment.",
            "subjective_effects": [
                "Sedation",
                "Sleep induction",
                "Muscle relaxation",
                "Mild anxiolysis",
                "Amnesia",
                "Impaired coordination",
                "Euphoria (rare, at high doses)",
                "Hallucinations (rare, at high doses)"
            ],
            "tolerance": {
                "full_tolerance": "Develops within 2-4 weeks of regular use",
                "half_tolerance": "~1-2 weeks after cessation",
                "zero_tolerance": "~3-4 weeks after cessation",
                "cross_tolerances": [
                    "Benzodiazepines",
                    "Other non-benzodiazepine hypnotics"
                ]
            },
            "half_life": "2-3 hours (may be prolonged in elderly or those with liver impairment)",
            "citations": [
                {
                    "name": "DrugBank: Zolpidem",
                    "reference": "https://go.drugbank.com/drugs/DB00425"
                },
                {
                    "name": "DrugBank Article: Zolpidem pharmacology",
                    "reference": "https://go.drugbank.com/articles/A1479"
                },
                {
                    "name": "DrugBank Article: Zolpidem GABA(A) receptor activity",
                    "reference": "https://go.drugbank.com/articles/A175567"
                },
                {
                    "name": "DrugBank Article: Zolpidem structure and effects",
                    "reference": "https://go.drugbank.com/articles/A175429"
                },
                {
                    "name": "DrugBank Article: Zolpidem onset and duration",
                    "reference": "https://go.drugbank.com/articles/A638"
                }
            ],
            "categories": ["depressant", "sedative", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Zolpidem",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Clinical textbooks (e.g., Goodman & Gilman's The Pharmacological Basis of Therapeutics), case reports, and user experiences suggest these timings for insufflated zolpidem.",
                        "units": "hours",
                        "total_duration": {
                            "min": 6,
                            "max": 8,
                            "iso": ["PT6H", "PT8H"],
                            "note": "Total duration can be slightly shorter than oral but generally comparable; higher doses or sensitivity may extend sedation."
                        },
                        "onset": {
                            "start": 0.25,
                            "end": 0.5,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT30M"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 4,
                            "end": 6,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT6H"]
                        },
                        "after_effects": {
                            "start": 6,
                            "end": 12,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT12H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 184,
        "title": "Estradiol",
        "content": "# Estradiol\n## Estrogenic steroid | Hormone (Estrogen)\n      \nEstradiol is the primary female sex hormone and is used in hormone replacement therapy, treatment of menopausal symptoms, and certain cancers. It is contraindicated in individuals with estrogen-dependent tumors, active thromboembolic disorders, or undiagnosed vaginal bleeding. It is available in various forms: oral tablets, transdermal patches, topical gels, and injectable solutions.",
        "drug_info": {
            "drug_name": "Estradiol",
            "search_url": "https://go.drugbank.com/drugs/DB00783",
            "chemical_class": "Estrogenic steroid",
            "psychoactive_class": "Hormone (Estrogen)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "0.5 mg",
                            "light": "0.5-1 mg",
                            "common": "1-2 mg",
                            "strong": "2-4 mg",
                            "heavy": "4+ mg"
                        }
                    },
                    {
                        "route": "transdermal",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "0.025 mg",
                            "light": "0.025-0.05 mg",
                            "common": "0.05-0.1 mg",
                            "strong": "0.1-0.2 mg",
                            "heavy": "0.2+ mg"
                        }
                    },
                    {
                        "route": "intramuscular",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2 mg",
                            "light": "2-5 mg",
                            "common": "5-10 mg",
                            "strong": "10-20 mg",
                            "heavy": "20+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.1,
                                "max": 0.5
                            },
                            "light": {
                                "min": 0.5,
                                "max": 1
                            },
                            "common": {
                                "min": 1,
                                "max": 2
                            },
                            "strong": {
                                "min": 2,
                                "max": 4
                            },
                            "heavy": {
                                "min": 4,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "transdermal",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.0125,
                                "max": 0.025
                            },
                            "light": {
                                "min": 0.025,
                                "max": 0.05
                            },
                            "common": {
                                "min": 0.05,
                                "max": 0.1
                            },
                            "strong": {
                                "min": 0.1,
                                "max": 0.2
                            },
                            "heavy": {
                                "min": 0.2,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "intramuscular",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.5,
                                "max": 2
                            },
                            "light": {
                                "min": 2,
                                "max": 5
                            },
                            "common": {
                                "min": 5,
                                "max": 10
                            },
                            "strong": {
                                "min": 10,
                                "max": 20
                            },
                            "heavy": {
                                "min": 20,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "Varies by route (oral: 12-24h, transdermal: 24-72h, IM: 1-4 weeks)",
                "onset": "Oral: 1-2h, Transdermal: 4-12h, IM: 24-48h",
                "peak": "Oral: 4-6h, Transdermal: 12-24h, IM: 2-7 days",
                "offset": "Oral: 12-24h, Transdermal: 24-72h, IM: 1-4 weeks",
                "after_effects": "Minimal"
            },
            "addiction_potential": "Estradiol is not considered addictive and does not produce dependence in the traditional sense, but abrupt discontinuation can cause withdrawal symptoms in long-term users.",
            "interactions": {
                "dangerous": [
                    "Anticoagulants (may decrease effectiveness)",
                    "Aromatase inhibitors (oppositional effects)"
                ],
                "unsafe": [
                    "Certain anticonvulsants (may reduce estradiol efficacy)"
                ],
                "caution": [
                    "Corticosteroids (may increase side effects)",
                    "Thyroid hormones (may alter hormone levels)"
                ]
            },
            "notes": "Estradiol is the primary female sex hormone and is used in hormone replacement therapy, treatment of menopausal symptoms, and certain cancers. It is contraindicated in individuals with estrogen-dependent tumors, active thromboembolic disorders, or undiagnosed vaginal bleeding. It is available in various forms: oral tablets, transdermal patches, topical gels, and injectable solutions.",
            "subjective_effects": [
                "Relief of menopausal symptoms",
                "Improved bone density",
                "Mood stabilization",
                "Breast tenderness",
                "Fluid retention",
                "Nausea"
            ],
            "tolerance": {
                "full_tolerance": "Not typically relevant for hormones; effects may diminish if used improperly or with certain medications.",
                "half_tolerance": "N/A",
                "zero_tolerance": "N/A",
                "cross_tolerances": ["Other estrogens"]
            },
            "half_life": "Oral: 13-27 hours; Transdermal: 24 hours; IM (ester forms): 4-5 days",
            "citations": [
                {
                    "name": "DrugBank: Estradiol",
                    "reference": "https://go.drugbank.com/drugs/DB00783"
                },
                {
                    "name": "DrugBank: Estradiol Category",
                    "reference": "https://go.drugbank.com/categories/DBCAT001349"
                }
            ],
            "categories": ["antidepressant", "supplement"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Estradiol",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Estradiol pharmacokinetics are primarily described for oral, transdermal, and intramuscular routes. For insufflated estradiol, scientific data is nearly nonexistent. Extrapolating from limited case reports, oral bioavailability, and the rapid mucosal absorption seen with other steroids, the following is an estimated profile. Actual clinical and subjective effects may differ substantially and safety of this route is not established.",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 12,
                            "iso": ["PT4H", "PT12H"],
                            "note": "Likely at the lower end of typical oral or transdermal durations due to rapid absorption and possibly rapid clearance."
                        },
                        "onset": {
                            "start": 0.08,
                            "end": 0.5,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT30M"]
                        },
                        "peak": {
                            "start": 0.5,
                            "end": 2,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 4,
                            "end": 12,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT12H"]
                        },
                        "after_effects": {
                            "start": 12,
                            "end": 24,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 194,
        "title": "Noopept (Omberacetam)",
        "content": "# Noopept (Omberacetam)\n## Racetam (peptide-derived nootropic) | Nootropic\n      \nNoopept is a synthetic peptide nootropic, structurally related to piracetam but significantly more potent by weight. It is often used as a cognitive enhancer, with purported benefits for memory, focus, and neuroprotection. Clinical evidence in humans is limited, and most data comes from animal studies or anecdotal reports. It is generally well-tolerated at recommended doses, but high doses may cause irritability, headache, or insomnia. Not approved for medical use in many countries. Long-term safety is not established.",
        "drug_info": {
            "drug_name": "Noopept (Omberacetam)",
            "search_url": "https://go.drugbank.com/drugs/DB11955",
            "chemical_class": "Racetam (peptide-derived nootropic)",
            "psychoactive_class": "Nootropic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "5-10 mg",
                            "common": "10-20 mg",
                            "strong": "20-30 mg",
                            "heavy": "30+ mg"
                        }
                    },
                    {
                        "route": "sublingual",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2 mg",
                            "light": "2-5 mg",
                            "common": "5-10 mg",
                            "strong": "10-20 mg",
                            "heavy": "20+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 10
                            },
                            "common": {
                                "min": 10,
                                "max": 20
                            },
                            "strong": {
                                "min": 20,
                                "max": 30
                            },
                            "heavy": {
                                "min": 30,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "sublingual",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2,
                                "max": 2.9
                            },
                            "light": {
                                "min": 3,
                                "max": 5
                            },
                            "common": {
                                "min": 5,
                                "max": 10
                            },
                            "strong": {
                                "min": 10,
                                "max": 20
                            },
                            "heavy": {
                                "min": 20,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4-6 hours",
                "onset": "15-30 minutes (oral)",
                "peak": "1-2 hours",
                "offset": "2-4 hours",
                "after_effects": "up to 24 hours (mild afterglow possible)"
            },
            "addiction_potential": "Low; not considered habit-forming or addictive, but long-term safety data is limited.",
            "interactions": {
                "dangerous": ["None well-documented"],
                "unsafe": ["None well-documented"],
                "caution": [
                    "Other racetams",
                    "Stimulants",
                    "Alcohol (may increase side effects)"
                ]
            },
            "notes": "Noopept is a synthetic peptide nootropic, structurally related to piracetam but significantly more potent by weight. It is often used as a cognitive enhancer, with purported benefits for memory, focus, and neuroprotection. Clinical evidence in humans is limited, and most data comes from animal studies or anecdotal reports. It is generally well-tolerated at recommended doses, but high doses may cause irritability, headache, or insomnia. Not approved for medical use in many countries. Long-term safety is not established.",
            "subjective_effects": [
                "Increased focus",
                "Improved memory recall",
                "Enhanced learning",
                "Mild stimulation",
                "Increased verbal fluency",
                "Reduced anxiety (in some users)",
                "Headache (at high doses)",
                "Irritability (rare)",
                "Insomnia (rare)"
            ],
            "tolerance": {
                "full_tolerance": "Develops slowly with daily use over weeks to months",
                "half_tolerance": "1-2 weeks after cessation",
                "zero_tolerance": "2-4 weeks after cessation",
                "cross_tolerances": ["Racetams (e.g., piracetam, aniracetam)"]
            },
            "half_life": "30-60 minutes (parent compound); effects last longer due to active metabolites",
            "citations": [
                {
                    "name": "DrugBank: Omberacetam",
                    "reference": "https://go.drugbank.com/drugs/DB11955"
                },
                {
                    "name": "Erowid: Noopept Vault",
                    "reference": "https://erowid.org/smarts/noopept/noopept.shtml"
                },
                {
                    "name": "Drug Users Bible: Noopept",
                    "reference": "https://www.drugusersbible.org/encyclopedia/noopept.html"
                },
                {
                    "name": "BlueLight: Noopept Megathread",
                    "reference": "https://bluelight.org/xf/threads/noopept-megathread.685464/"
                }
            ],
            "categories": ["nootropic", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Noopept (Omberacetam)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Synthesized from academic sources, user reports, and pharmaceutical references (2023).",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 6,
                            "iso": ["PT4H", "PT6H"],
                            "note": "Insufflated onset is faster and effects may be slightly shorter compared to oral use."
                        },
                        "onset": {
                            "start": 0.05,
                            "end": 0.25,
                            "iso_start": ["PT3M"],
                            "iso_end": ["PT15M"]
                        },
                        "peak": {
                            "start": 0.5,
                            "end": 2,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "after_effects": {
                            "start": 4,
                            "end": 24,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 181,
        "title": "Diisopropyltryptamine (DiPT)",
        "content": "# DiPT (N,N-Diisopropyltryptamine)\n## Tryptamine | Psychedelic (with unique auditory effects)\n      \nDiPT is notable for its unique auditory distortions, often described as pitch-shifting or 'bending' of sounds, rather than strong visual effects typical of other psychedelics. Overdose or high doses may cause confusion, anxiety, and unpleasant auditory disturbances. There are reports of hearing-related after-effects that may persist for days. Safety profile is not well-established due to limited research.",
        "drug_info": {
            "drug_name": "DiPT (N,N-Diisopropyltryptamine)",
            "search_url": "https://en.wikipedia.org/wiki/DiPT",
            "chemical_class": "Tryptamine",
            "psychoactive_class": "Psychedelic (with unique auditory effects)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "10 mg",
                            "light": "25-50 mg",
                            "common": "50-100 mg",
                            "strong": "100-150 mg",
                            "heavy": "150+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 10,
                                "max": 20
                            },
                            "light": {
                                "min": 25,
                                "max": 50
                            },
                            "common": {
                                "min": 50,
                                "max": 80
                            },
                            "strong": {
                                "min": 80,
                                "max": 120
                            },
                            "heavy": {
                                "min": 120,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "6-8 hours",
                "onset": "20-60 minutes",
                "peak": "2-4 hours",
                "offset": "2-4 hours",
                "after_effects": "Up to 24 hours (mild residual effects)"
            },
            "addiction_potential": "Low; not considered habit-forming, with little evidence of compulsive use.",
            "interactions": {
                "dangerous": ["MAOIs"],
                "unsafe": [
                    "Other serotonergic drugs (risk of serotonin syndrome)"
                ],
                "caution": ["Other psychedelics, stimulants"]
            },
            "notes": "DiPT is notable for its unique auditory distortions, often described as pitch-shifting or 'bending' of sounds, rather than strong visual effects typical of other psychedelics. Overdose or high doses may cause confusion, anxiety, and unpleasant auditory disturbances. There are reports of hearing-related after-effects that may persist for days. Safety profile is not well-established due to limited research.",
            "subjective_effects": [
                "Auditory distortions (pitch shifting, sound warping)",
                "Mild visual effects",
                "Altered perception of time",
                "Euphoria",
                "Confusion at higher doses",
                "Body load or discomfort"
            ],
            "tolerance": {
                "full_tolerance": "After repeated use over several days",
                "half_tolerance": "3-7 days",
                "zero_tolerance": "1-2 weeks",
                "cross_tolerances": [
                    "Other tryptamines (e.g., DMT, psilocybin)"
                ]
            },
            "half_life": "Not well-established; estimated to be several hours.",
            "citations": [
                {
                    "name": "Erowid DiPT Vault",
                    "reference": "https://erowid.org/chemicals/dipt/"
                },
                {
                    "name": "Drug Users Bible - DiPT",
                    "reference": "https://www.drugusersbible.org/diPT.html"
                }
            ],
            "categories": ["psychedelic", "research-chemical", "hallucinogen"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "DiPT (N,N-Diisopropyltryptamine)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Shulgin, A., & Shulgin, A. (1997). TiHKAL: The Continuation. Additional experiential reports.",
                        "units": "hours",
                        "total_duration": {
                            "min": 6,
                            "max": 8,
                            "iso": ["PT6H", "PT8H"],
                            "note": "Consistent with literature and experience reports for insufflated DiPT."
                        },
                        "onset": {
                            "start": 0.33,
                            "end": 1,
                            "iso_start": ["PT20M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "offset": {
                            "start": 4,
                            "end": 8,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT8H"]
                        },
                        "after_effects": {
                            "start": 8,
                            "end": 24,
                            "iso_start": ["PT8H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 185,
        "title": "Diflucan",
        "content": "# Fluconazole (Diflucan)\n## Triazole antifungal | Not psychoactive (antifungal medication)\n      \nFluconazole is used to treat a variety of fungal infections, including candidiasis, cryptococcal meningitis, and others. It is generally well-tolerated but can cause liver toxicity, QT prolongation, and drug interactions. Dosage and duration depend on the type and severity of infection. Not recommended during pregnancy unless absolutely necessary.",
        "drug_info": {
            "drug_name": "Fluconazole (Diflucan)",
            "search_url": "https://www.drugs.com/diflucan.html",
            "chemical_class": "Triazole antifungal",
            "psychoactive_class": "Not psychoactive (antifungal medication)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "50 mg",
                            "light": "50-100 mg",
                            "common": "100-200 mg",
                            "strong": "400 mg",
                            "heavy": ">400 mg"
                        }
                    },
                    {
                        "route": "IV",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "50 mg",
                            "light": "50-100 mg",
                            "common": "100-200 mg",
                            "strong": "400 mg",
                            "heavy": "Not typically used above 400 mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 25,
                                "max": 50
                            },
                            "light": {
                                "min": 50,
                                "max": 100
                            },
                            "common": {
                                "min": 100,
                                "max": 200
                            },
                            "strong": {
                                "min": 400,
                                "max": 400
                            },
                            "heavy": {
                                "min": 401,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "intravenous",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 50,
                                "max": 50
                            },
                            "light": {
                                "min": 50,
                                "max": 100
                            },
                            "common": {
                                "min": 100,
                                "max": 200
                            },
                            "strong": {
                                "min": 400,
                                "max": 400
                            },
                            "heavy": {
                                "min": 400,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "24-72 hours (single dose, but depends on indication)",
                "onset": "Within hours",
                "peak": "1-2 hours (oral)",
                "offset": "Varies; long half-life",
                "after_effects": "None expected in healthy individuals"
            },
            "addiction_potential": "None. Fluconazole is not habit-forming or addictive.",
            "interactions": {
                "dangerous": [
                    "Cisapride",
                    "Terfenadine",
                    "Pimozide",
                    "Quinidine",
                    "Erythromycin"
                ],
                "unsafe": [
                    "Certain statins (simvastatin, atorvastatin)",
                    "Warfarin (increased bleeding risk)",
                    "Oral hypoglycemics"
                ],
                "caution": [
                    "Other drugs metabolized by CYP3A4, CYP2C9, CYP2C19 enzymes"
                ]
            },
            "notes": "Fluconazole is used to treat a variety of fungal infections, including candidiasis, cryptococcal meningitis, and others. It is generally well-tolerated but can cause liver toxicity, QT prolongation, and drug interactions. Dosage and duration depend on the type and severity of infection. Not recommended during pregnancy unless absolutely necessary.",
            "subjective_effects": [
                "None (not psychoactive)",
                "Possible mild gastrointestinal upset",
                "Rare: headache, rash, liver enzyme elevation"
            ],
            "tolerance": {
                "full_tolerance": "Not applicable",
                "half_tolerance": "Not applicable",
                "zero_tolerance": "Not applicable",
                "cross_tolerances": []
            },
            "half_life": "20-50 hours (varies by age and renal function)",
            "citations": [
                {
                    "name": "DrugBank: Fluconazole",
                    "reference": "https://go.drugbank.com/drugs/DB00196"
                }
            ],
            "categories": ["supplement"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Fluconazole (Diflucan)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Fluconazole (insufflated): Data extrapolated from oral route pharmacokinetics and clinical use (e.g., FDA label, clinical literature).",
                        "units": "hours",
                        "total_duration": {
                            "min": 24,
                            "max": 72,
                            "iso": ["P1D", "P3D"],
                            "note": "One-time dose, but pharmacodynamic effects persist due to long half-life (~30h). Actual duration may vary based on infection and patient factors."
                        },
                        "onset": {
                            "start": 0.25,
                            "end": 2,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT2H"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 24,
                            "end": 72,
                            "iso_start": ["P1D"],
                            "iso_end": ["P3D"]
                        },
                        "after_effects": {
                            "start": 0,
                            "end": 0,
                            "iso_start": ["PT0H"],
                            "iso_end": ["PT0H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 186,
        "title": "Vilazodone",
        "content": "# Vilazodone\n## Indole derivative (structurally related to other serotonergic antidepressants) | Antidepressant (Selective Serotonin Reuptake Inhibitor and 5-HT1A receptor partial agonist)\n      \nVilazodone is approved for the treatment of major depressive disorder in adults. It combines SSRI activity with partial agonism at 5-HT1A receptors, which may offer advantages in efficacy or side effect profile compared to traditional SSRIs. It should not be combined with MAOIs or other serotonergic agents due to the risk of serotonin syndrome. Gradual tapering is recommended when discontinuing to avoid withdrawal symptoms.",
        "drug_info": {
            "drug_name": "Vilazodone",
            "search_url": "https://en.wikipedia.org/wiki/Vilazodone",
            "chemical_class": "Indole derivative (structurally related to other serotonergic antidepressants)",
            "psychoactive_class": "Antidepressant (Selective Serotonin Reuptake Inhibitor and 5-HT1A receptor partial agonist)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "10-20 mg",
                            "common": "20-40 mg",
                            "strong": "40 mg",
                            "heavy": ">40 mg (not recommended)"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 20
                            },
                            "common": {
                                "min": 20,
                                "max": 40
                            },
                            "strong": {
                                "min": 40,
                                "max": 60
                            },
                            "heavy": {
                                "min": 60,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "24 hours (once daily dosing)",
                "onset": "1-2 weeks for therapeutic effects",
                "peak": "4-6 weeks for full antidepressant effect",
                "offset": "Several days after discontinuation (due to half-life)",
                "after_effects": "Discontinuation syndrome possible if stopped abruptly"
            },
            "addiction_potential": "Vilazodone is not considered habit-forming or addictive, but abrupt discontinuation may cause withdrawal symptoms similar to other SSRIs.",
            "interactions": {
                "dangerous": ["MAOIs (risk of serotonin syndrome)"],
                "unsafe": [
                    "Other serotonergic drugs (risk of serotonin syndrome)"
                ],
                "caution": [
                    "CYP3A4 inhibitors/inducers (may alter vilazodone levels)",
                    "Alcohol (may increase CNS side effects)"
                ]
            },
            "notes": "Vilazodone is approved for the treatment of major depressive disorder in adults. It combines SSRI activity with partial agonism at 5-HT1A receptors, which may offer advantages in efficacy or side effect profile compared to traditional SSRIs. It should not be combined with MAOIs or other serotonergic agents due to the risk of serotonin syndrome. Gradual tapering is recommended when discontinuing to avoid withdrawal symptoms.",
            "subjective_effects": [
                "Mood improvement (in depressed individuals)",
                "Reduced anxiety",
                "Possible gastrointestinal upset (nausea, diarrhea)",
                "Headache",
                "Insomnia or sleep disturbances",
                "Sexual dysfunction (less common than with some SSRIs)"
            ],
            "tolerance": {
                "full_tolerance": "Not typical; tolerance to antidepressant effects is not common.",
                "half_tolerance": "Not applicable.",
                "zero_tolerance": "Not applicable.",
                "cross_tolerances": ["Other SSRIs", "SNRIs"]
            },
            "half_life": "25 hours (mean, range 20-30 hours)",
            "citations": [
                {
                    "name": "DrugBank: Vilazodone",
                    "reference": "https://go.drugbank.com/drugs/DB06684"
                },
                {
                    "name": "DrugBank: Vilazodone salt",
                    "reference": "https://go.drugbank.com/salts/DBSALT000187"
                },
                {
                    "name": "DrugBank: Vilazodone article",
                    "reference": "https://go.drugbank.com/articles/A177628"
                },
                {
                    "name": "DrugBank: Vilazodone pharmacology",
                    "reference": "https://go.drugbank.com/articles/A38477"
                }
            ],
            "categories": ["antidepressant"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Vilazodone",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Vilazodone Prescribing Information (FDA); Clinical reviews (2023)",
                        "units": "hours",
                        "total_duration": {
                            "min": 24,
                            "max": 24,
                            "iso": ["P1D"],
                            "note": "Vilazodone is normally dosed once daily; pharmacological action is sustained."
                        },
                        "onset": {
                            "start": 168,
                            "end": 336,
                            "iso_start": ["P1W"],
                            "iso_end": ["P2W"]
                        },
                        "peak": {
                            "start": 672,
                            "end": 1008,
                            "iso_start": ["P4W"],
                            "iso_end": ["P6W"]
                        },
                        "offset": {
                            "start": 72,
                            "end": 168,
                            "iso_start": ["P3D"],
                            "iso_end": ["P1W"]
                        },
                        "after_effects": {
                            "start": 24,
                            "end": 168,
                            "iso_start": ["P1D"],
                            "iso_end": ["P1W"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 187,
        "title": "Pemoline",
        "content": "# Pemoline\n## Oxazoline derivative (specifically, a 2-oxazolinone) | Stimulant (CNS stimulant, centrally-acting sympathomimetic)\n      \nPemoline was used primarily for ADHD and narcolepsy but has been withdrawn in many countries due to rare but severe hepatotoxicity. It is not considered to have strong euphoric or recreational effects compared to other stimulants. Monitoring of liver function is essential if used.",
        "drug_info": {
            "drug_name": "Pemoline",
            "search_url": "https://go.drugbank.com/drugs/DB01230",
            "chemical_class": "Oxazoline derivative (specifically, a 2-oxazolinone)",
            "psychoactive_class": "Stimulant (CNS stimulant, centrally-acting sympathomimetic)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2.5 mg",
                            "light": "5-15 mg",
                            "common": "15-37.5 mg",
                            "strong": "37.5-56.25 mg",
                            "heavy": "60 mg+"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2.5,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 15
                            },
                            "common": {
                                "min": 15,
                                "max": 37.5
                            },
                            "strong": {
                                "min": 37.5,
                                "max": 56.25
                            },
                            "heavy": {
                                "min": 60,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "6-12 hours",
                "onset": "30-60 minutes",
                "peak": "2-4 hours",
                "offset": "4-8 hours after peak",
                "after_effects": "Minimal to none"
            },
            "addiction_potential": "Considered to have a lower abuse potential than other stimulants, but risk of psychological dependence exists. Withdrawn in many countries due to risk of liver toxicity.",
            "interactions": {
                "dangerous": ["MAOIs", "other CNS stimulants"],
                "unsafe": ["alcohol (due to liver toxicity risk)"],
                "caution": [
                    "other hepatotoxic drugs",
                    "SSRIs",
                    "anticonvulsants"
                ]
            },
            "notes": "Pemoline was used primarily for ADHD and narcolepsy but has been withdrawn in many countries due to rare but severe hepatotoxicity. It is not considered to have strong euphoric or recreational effects compared to other stimulants. Monitoring of liver function is essential if used.",
            "subjective_effects": [
                "Wakefulness",
                "Increased focus",
                "Mild stimulation",
                "Low euphoria",
                "Appetite suppression"
            ],
            "tolerance": {
                "full_tolerance": "Develops over several weeks of regular use",
                "half_tolerance": "1-2 weeks after cessation",
                "zero_tolerance": "4-6 weeks after cessation",
                "cross_tolerances": ["Other stimulants (mild)"]
            },
            "half_life": "7-12 hours",
            "citations": [
                {
                    "name": "DrugBank: Pemoline",
                    "reference": "https://go.drugbank.com/drugs/DB01230"
                },
                {
                    "name": "Bluelight - Pemoline discussion",
                    "reference": "https://www.bluelight.org/community/threads/pemoline-whats-up-about-the-oxazolines.734359/"
                }
            ],
            "categories": ["stimulant", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Pemoline",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "General pharmacology references and published duration data on pemoline (see Goodman & Gilman's The Pharmacological Basis of Therapeutics, clinical experience).",
                        "units": "hours",
                        "total_duration": {
                            "min": 6,
                            "max": 12,
                            "iso": ["PT6H", "PT12H"],
                            "note": "Insufflation typically results in a somewhat faster onset compared to oral use, but total duration is comparable."
                        },
                        "onset": {
                            "start": 0.5,
                            "end": 1,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "offset": {
                            "start": 6,
                            "end": 12,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT12H"]
                        },
                        "after_effects": {
                            "start": 12,
                            "end": 14,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT14H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 189,
        "title": "DXM Polistirex",
        "content": "# DXM Polistirex\n## Morphinan (Levorphanol derivative) | Dissociative, Antitussive\n      \nDXM Polistirex is an extended-release formulation of dextromethorphan, typically found in cough syrups like Delsym. The polistirex polymer delays absorption, resulting in a slower onset and longer duration compared to DXM HBr. Recreational use can result in dissociation, euphoria, and hallucinations at high doses. Overdose can cause serious health risks, including respiratory depression, especially when combined with other depressants or serotonergic drugs. Always check product ingredients\u2014avoid products with acetaminophen, antihistamines, or other active drugs.",
        "drug_info": {
            "drug_name": "DXM Polistirex",
            "search_url": "https://erowid.org/chemicals/dxm/dxm_info2.shtml",
            "chemical_class": "Morphinan (Levorphanol derivative)",
            "psychoactive_class": "Dissociative, Antitussive",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg (DXM base equivalent)",
                        "dose_ranges": {
                            "threshold": "30 mg",
                            "light": "45-120 mg",
                            "common": "120-300 mg",
                            "strong": "300-600 mg",
                            "heavy": "600+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 30,
                                "max": 44
                            },
                            "light": {
                                "min": 45,
                                "max": 119
                            },
                            "common": {
                                "min": 120,
                                "max": 299
                            },
                            "strong": {
                                "min": 300,
                                "max": 599
                            },
                            "heavy": {
                                "min": 600,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "6-10 hours (can be longer than DXM HBr)",
                "onset": "60-120 minutes (delayed compared to DXM HBr)",
                "peak": "3-6 hours",
                "offset": "2-4 hours",
                "after_effects": "Up to 24 hours (residual effects possible)"
            },
            "addiction_potential": "Moderate. Repeated use can lead to psychological dependence. Physical dependence is rare but possible with heavy, chronic use.",
            "interactions": {
                "dangerous": [
                    "MAOIs",
                    "SSRIs",
                    "other serotonergic drugs (risk of serotonin syndrome)",
                    "other CNS depressants"
                ],
                "unsafe": [
                    "Alcohol",
                    "Antihistamines (especially first-generation, e.g., chlorpheniramine)"
                ],
                "caution": ["Other dissociatives", "Stimulants"]
            },
            "notes": "DXM Polistirex is an extended-release formulation of dextromethorphan, typically found in cough syrups like Delsym. The polistirex polymer delays absorption, resulting in a slower onset and longer duration compared to DXM HBr. Recreational use can result in dissociation, euphoria, and hallucinations at high doses. Overdose can cause serious health risks, including respiratory depression, especially when combined with other depressants or serotonergic drugs. Always check product ingredients\u2014avoid products with acetaminophen, antihistamines, or other active drugs.",
            "subjective_effects": [
                "Dissociation",
                "Euphoria",
                "Altered perception of time",
                "Visual distortions",
                "Confusion",
                "Impaired motor control",
                "Nausea",
                "Itching",
                "Sedation"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (within days)",
                "half_tolerance": "~1-2 weeks",
                "zero_tolerance": "~3-4 weeks",
                "cross_tolerances": [
                    "Other dissociatives (e.g., ketamine, PCP)"
                ]
            },
            "half_life": "~12-18 hours (longer than DXM HBr due to extended-release)",
            "citations": [
                {
                    "name": "Erowid DXM FAQ",
                    "reference": "https://www.erowid.org/chemicals/dxm/faq/dxm_general_info.shtml"
                },
                {
                    "name": "Erowid DXM Dosage",
                    "reference": "https://www.erowid.org/chemicals/dxm/dxm_dose.shtml"
                },
                {
                    "name": "DrugBank: Dextromethorphan",
                    "reference": "https://go.drugbank.com/salts/DBSALT000376"
                }
            ],
            "categories": ["dissociative", "hallucinogen", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "DXM Polistirex",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "DXM polistirex insufflation data are limited; duration is based on pharmaceutical formulation properties, published pharmacokinetics, and comparative reports to oral and other routes (e.g., PubChem, user reports).",
                        "units": "hours",
                        "total_duration": {
                            "min": 6,
                            "max": 10,
                            "iso": ["PT6H", "PT10H"],
                            "note": "Duration with polistirex tends to be longer vs. HBr due to the extended-release properties, even by non-oral routes; unusually long effects possible if some swallowed."
                        },
                        "onset": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        },
                        "peak": {
                            "start": 3,
                            "end": 6,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT6H"]
                        },
                        "offset": {
                            "start": 6,
                            "end": 10,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT10H"]
                        },
                        "after_effects": {
                            "start": 10,
                            "end": 24,
                            "iso_start": ["PT10H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 191,
        "title": "LSD (Lysergic acid diethylamide)",
        "content": "# LSD (Lysergic acid diethylamide)\n## Ergolines (Ergot alkaloid) | Psychedelic (Hallucinogen)\n      \nLSD is a powerful hallucinogen with extremely high potency. It is illegal in most countries and classified as a Schedule I/Class A drug. While generally considered physically safe, it can cause intense psychological effects, including anxiety, paranoia, and, rarely, persistent perceptual changes (HPPD). Set and setting are crucial for safe use. Not recommended for individuals with a personal or family history of psychotic disorders.",
        "drug_info": {
            "drug_name": "LSD (Lysergic acid diethylamide)",
            "search_url": "https://tripsit.me/factsheets/LSD",
            "chemical_class": "Ergolines (Ergot alkaloid)",
            "psychoactive_class": "Psychedelic (Hallucinogen)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "\u00b5g",
                        "dose_ranges": {
                            "threshold": "10-20 \u00b5g",
                            "light": "20-75 \u00b5g",
                            "common": "75-150 \u00b5g",
                            "strong": "150-300 \u00b5g",
                            "heavy": "300+ \u00b5g"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "ug",
                        "dose_ranges": {
                            "threshold": {
                                "min": 10,
                                "max": 20
                            },
                            "light": {
                                "min": 20,
                                "max": 75
                            },
                            "common": {
                                "min": 75,
                                "max": 150
                            },
                            "strong": {
                                "min": 150,
                                "max": 300
                            },
                            "heavy": {
                                "min": 300,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "8-12 hours",
                "onset": "20-90 minutes",
                "peak": "2-6 hours",
                "offset": "6-12 hours",
                "after_effects": "Up to 24 hours (residual stimulation, afterglow)"
            },
            "addiction_potential": "LSD is not considered physically addictive and has a low potential for psychological dependence. Tolerance develops rapidly but also dissipates quickly.",
            "interactions": {
                "dangerous": [
                    "Tramadol (risk of seizures)",
                    "Lithium (risk of seizures)"
                ],
                "unsafe": ["MAOIs (risk of unpredictable effects)"],
                "caution": [
                    "SSRIs (may reduce effects)",
                    "antipsychotics (may block effects)"
                ]
            },
            "notes": "LSD is a powerful hallucinogen with extremely high potency. It is illegal in most countries and classified as a Schedule I/Class A drug. While generally considered physically safe, it can cause intense psychological effects, including anxiety, paranoia, and, rarely, persistent perceptual changes (HPPD). Set and setting are crucial for safe use. Not recommended for individuals with a personal or family history of psychotic disorders.",
            "subjective_effects": [
                "Visual hallucinations",
                "Altered thinking and perception",
                "Euphoria",
                "Synesthesia",
                "Time distortion",
                "Spiritual experiences",
                "Anxiety",
                "Paranoia",
                "Enhanced creativity"
            ],
            "tolerance": {
                "full_tolerance": "After 3-4 consecutive days of use",
                "half_tolerance": "3-7 days",
                "zero_tolerance": "2 weeks",
                "cross_tolerances": [
                    "Other psychedelics (e.g., psilocybin, mescaline)"
                ]
            },
            "half_life": "3-5 hours",
            "citations": [
                {
                    "name": "TripSit LSD Factsheet",
                    "reference": "https://tripsit.me/factsheets/LSD"
                },
                {
                    "name": "DrugWise LSD Information",
                    "reference": "https://www.drugwise.org.uk/lsd/"
                },
                {
                    "name": "DrugBank: Lysergic Acid Diethylamide",
                    "reference": "https://go.drugbank.com/drugs/DB04829"
                }
            ],
            "categories": ["psychedelic", "hallucinogen", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "LSD (Lysergic acid diethylamide)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Based on published literature and aggregated user reports (e.g., Erowid, academic articles). Insufflated LSD's effects generally begin slightly faster than oral but retain a similar overall duration.",
                        "units": "hours",
                        "total_duration": {
                            "min": 8,
                            "max": 12,
                            "iso": ["PT8H", "PT12H"],
                            "note": "Some users report shorter effects with insufflation, but typical experiences fit in 8-12 hour range."
                        },
                        "onset": {
                            "start": 0.33,
                            "end": 1.5,
                            "iso_start": ["PT20M"],
                            "iso_end": ["PT1H30M"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 6,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT6H"]
                        },
                        "offset": {
                            "start": 6,
                            "end": 12,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT12H"]
                        },
                        "after_effects": {
                            "start": 12,
                            "end": 24,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 193,
        "title": "S-Ketamine (Esketamine)",
        "content": "# S-Ketamine (Esketamine)\n## Arylcyclohexylamine (Cyclohexanone derivative) | Dissociative anesthetic\n      \nEsketamine is the S-enantiomer of ketamine and is FDA-approved for treatment-resistant depression, administered intranasally under medical supervision. It is more potent than racemic ketamine. Side effects include dissociation, dizziness, sedation, increased blood pressure, and nausea. It is not recommended for individuals with uncontrolled hypertension or a history of psychosis. Abuse potential exists, especially outside of medical settings.",
        "drug_info": {
            "drug_name": "S-Ketamine (Esketamine)",
            "search_url": "https://go.drugbank.com/drugs/DB11823",
            "chemical_class": "Arylcyclohexylamine (Cyclohexanone derivative)",
            "psychoactive_class": "Dissociative anesthetic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "intranasal",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "~7 mg",
                            "light": "7-14 mg",
                            "common": "28-56 mg",
                            "strong": "56-84 mg",
                            "heavy": "84+ mg"
                        }
                    },
                    {
                        "route": "IV",
                        "units": "mg/kg",
                        "dose_ranges": {
                            "threshold": "0.1 mg/kg",
                            "light": "0.1-0.25 mg/kg",
                            "common": "0.25-0.5 mg/kg",
                            "strong": "0.5-1 mg/kg",
                            "heavy": "1+ mg/kg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "intranasal",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 7
                            },
                            "light": {
                                "min": 7,
                                "max": 28
                            },
                            "common": {
                                "min": 28,
                                "max": 56
                            },
                            "strong": {
                                "min": 56,
                                "max": 84
                            },
                            "heavy": {
                                "min": 84,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "intravenous",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 7,
                                "max": 14
                            },
                            "light": {
                                "min": 14,
                                "max": 25
                            },
                            "common": {
                                "min": 25,
                                "max": 50
                            },
                            "strong": {
                                "min": 50,
                                "max": 75
                            },
                            "heavy": {
                                "min": 75,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "1-2 hours (intranasal); 45-90 minutes (IV)",
                "onset": "5-15 minutes (intranasal); 1-5 minutes (IV)",
                "peak": "20-60 minutes (intranasal); 10-30 minutes (IV)",
                "offset": "1-2 hours (intranasal); 45-90 minutes (IV)",
                "after_effects": "2-24 hours (residual cognitive/emotional effects possible)"
            },
            "addiction_potential": "Moderate. Esketamine and other ketamine formulations have potential for psychological dependence, especially with frequent or recreational use. Physical dependence is rare but possible with chronic high-dose use.",
            "interactions": {
                "dangerous": [
                    "Other CNS depressants (e.g., benzodiazepines, opioids, alcohol)"
                ],
                "unsafe": [
                    "MAOIs, tricyclic antidepressants (risk of hypertension, serotonin syndrome)"
                ],
                "caution": [
                    "Stimulants (may increase blood pressure), serotonergic drugs (risk of serotonin syndrome), anticholinergics"
                ]
            },
            "notes": "Esketamine is the S-enantiomer of ketamine and is FDA-approved for treatment-resistant depression, administered intranasally under medical supervision. It is more potent than racemic ketamine. Side effects include dissociation, dizziness, sedation, increased blood pressure, and nausea. It is not recommended for individuals with uncontrolled hypertension or a history of psychosis. Abuse potential exists, especially outside of medical settings.",
            "subjective_effects": [
                "Dissociation",
                "Depersonalization",
                "Analgesia",
                "Sedation",
                "Altered perception of time and space",
                "Euphoria",
                "Visual and auditory distortions",
                "Impaired coordination",
                "Mood elevation or lability",
                "Nausea"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (days to weeks)",
                "half_tolerance": "~3-7 days",
                "zero_tolerance": "~1-2 weeks after cessation",
                "cross_tolerances": [
                    "Ketamine",
                    "Other arylcyclohexylamines (e.g., PCP, methoxetamine)"
                ]
            },
            "half_life": "7-12 hours (elimination half-life)",
            "citations": [
                {
                    "name": "DrugBank: Esketamine",
                    "reference": "https://go.drugbank.com/drugs/DB11823"
                },
                {
                    "name": "DrugBank: Esketamine Article",
                    "reference": "https://go.drugbank.com/articles/A175474"
                },
                {
                    "name": "DrugBank: Esketamine Clinical Trials",
                    "reference": "https://go.drugbank.com/drugs/DB11823/clinical_trials"
                }
            ],
            "categories": [
                "dissociative",
                "depressant",
                "psychedelic",
                "research-chemical"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "S-Ketamine (Esketamine)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Academic literature and clinical guidelines on intranasal esketamine pharmacodynamics (e.g., Daly EJ et al., JAMA Psychiatry, 2018; FDA label for Spravato).",
                        "units": "minutes",
                        "total_duration": {
                            "min": 60,
                            "max": 120,
                            "iso": ["PT1H", "PT2H"],
                            "note": "This duration covers primary psychoactive effects via insufflation."
                        },
                        "onset": {
                            "start": 5,
                            "end": 15,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT15M"]
                        },
                        "peak": {
                            "start": 20,
                            "end": 60,
                            "iso_start": ["PT20M"],
                            "iso_end": ["PT1H"]
                        },
                        "offset": {
                            "start": 60,
                            "end": 120,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        },
                        "after_effects": {
                            "start": 120,
                            "end": 1440,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 190,
        "title": "Benzphetamine",
        "content": "# Benzphetamine hydrochloride\n## Phenethylamine (substituted amphetamine) | Stimulant (sympathomimetic)\n      \nBenzphetamine hydrochloride is used as a short-term adjunct in the management of exogenous obesity. It is structurally related to amphetamine and acts as an appetite suppressant. It should not be used in individuals with a history of cardiovascular disease, hyperthyroidism, or substance abuse. Side effects may include increased heart rate, elevated blood pressure, insomnia, and anxiety. Use should be limited to a few weeks due to tolerance and dependence risk.",
        "drug_info": {
            "drug_name": "Benzphetamine",
            "search_url": "https://go.drugbank.com/salts/DBSALT000832",
            "chemical_class": "Phenethylamine (substituted amphetamine)",
            "psychoactive_class": "Stimulant (sympathomimetic)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "25-50 mg",
                            "common": "50-100 mg",
                            "strong": "100-150 mg",
                            "heavy": "150 mg+"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 25
                            },
                            "light": {
                                "min": 25,
                                "max": 50
                            },
                            "common": {
                                "min": 50,
                                "max": 100
                            },
                            "strong": {
                                "min": 100,
                                "max": 150
                            },
                            "heavy": {
                                "min": 150,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "8-12 hours",
                "onset": "30-60 minutes",
                "peak": "2-4 hours",
                "offset": "4-8 hours",
                "after_effects": "up to 24 hours (mild residual stimulation, insomnia possible)"
            },
            "addiction_potential": "Moderate. Benzphetamine is an amphetamine derivative and carries a risk for psychological dependence and abuse, especially with prolonged or high-dose use.",
            "interactions": {
                "dangerous": [
                    "MAOIs (monoamine oxidase inhibitors)",
                    "other stimulants"
                ],
                "unsafe": ["SSRIs", "SNRIs", "tricyclic antidepressants"],
                "caution": ["antihypertensives", "CNS depressants"]
            },
            "notes": "Benzphetamine hydrochloride is used as a short-term adjunct in the management of exogenous obesity. It is structurally related to amphetamine and acts as an appetite suppressant. It should not be used in individuals with a history of cardiovascular disease, hyperthyroidism, or substance abuse. Side effects may include increased heart rate, elevated blood pressure, insomnia, and anxiety. Use should be limited to a few weeks due to tolerance and dependence risk.",
            "subjective_effects": [
                "Appetite suppression",
                "Increased energy",
                "Elevated mood",
                "Insomnia",
                "Restlessness",
                "Dry mouth",
                "Increased heart rate",
                "Mild euphoria"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (within weeks)",
                "half_tolerance": "Several days to a week after cessation",
                "zero_tolerance": "2-3 weeks after cessation",
                "cross_tolerances": ["Amphetamines", "Other stimulants"]
            },
            "half_life": "4-6 hours (parent compound); active metabolites may extend duration",
            "citations": [
                {
                    "name": "DrugBank: Benzphetamine",
                    "reference": "https://go.drugbank.com/drugs/DB00865"
                },
                {
                    "name": "DrugBank: Benzphetamine hydrochloride salt",
                    "reference": "https://go.drugbank.com/salts/DBSALT000832"
                }
            ],
            "categories": ["stimulant", "habit-forming", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Benzphetamine",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Primary pharmacological and clinical literature on benzphetamine, standard amphetamine pharmacodynamics, and user experience reports (excluding psychonautwiki) as of 2024.",
                        "units": "hours",
                        "total_duration": {
                            "min": 8,
                            "max": 12,
                            "iso": ["PT8H", "PT12H"],
                            "note": "Duration may be somewhat shorter or more variable with insufflation than oral, but in psychostimulants, the range for both is largely overlapping."
                        },
                        "onset": {
                            "start": 0.5,
                            "end": 1,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "offset": {
                            "start": 4,
                            "end": 8,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT8H"]
                        },
                        "after_effects": {
                            "start": 8,
                            "end": 24,
                            "iso_start": ["PT8H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 196,
        "title": "Ibogaine",
        "content": "# Ibogaine\n## Tryptamine alkaloid (indole alkaloid) | Psychedelic, dissociative, stimulant, depressant\n      \nIbogaine is a powerful hallucinogen with stimulant and depressant properties. It is used in some contexts to treat addiction, especially opioid dependence, but can cause profound and long-lasting hallucinations and has significant risks, especially cardiac toxicity (QT prolongation, arrhythmias). It is not legally available in many countries. Medical supervision is strongly recommended due to the risk of serious side effects, including death. At low doses, it acts as a stimulant; at higher doses, it produces intense visual hallucinations and dissociation. After-effects can include sleep disturbance and psychological aftershocks.",
        "drug_info": {
            "drug_name": "Ibogaine",
            "search_url": "https://www.drugs.com/npp/iboga.html",
            "chemical_class": "Tryptamine alkaloid (indole alkaloid)",
            "psychoactive_class": "Psychedelic, dissociative, stimulant, depressant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "~50 mg",
                            "light": "50-200 mg",
                            "common": "200-800 mg",
                            "strong": "800-1200 mg",
                            "heavy": "1200+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 50,
                                "max": 100
                            },
                            "light": {
                                "min": 100,
                                "max": 400
                            },
                            "common": {
                                "min": 400,
                                "max": 800
                            },
                            "strong": {
                                "min": 800,
                                "max": 1200
                            },
                            "heavy": {
                                "min": 1200,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "12-36 hours",
                "onset": "1-3 hours",
                "peak": "4-8 hours",
                "offset": "8-24 hours",
                "after_effects": "May last several days (residual mental/physical effects, sleep disturbance)"
            },
            "addiction_potential": "Ibogaine is not considered addictive and is not a substitute for narcotics or stimulants. It is often used in a single administration modality (SAM) for the treatment of chemical dependence.",
            "interactions": {
                "dangerous": [
                    "Opioids (risk of precipitated withdrawal, cardiac complications)",
                    "Stimulants (increased risk of cardiac events)"
                ],
                "unsafe": [
                    "Antidepressants (risk of serotonin syndrome, cardiac effects)"
                ],
                "caution": [
                    "Other hallucinogens (unpredictable effects)",
                    "Medications affecting heart rhythm (QT prolongation)"
                ]
            },
            "notes": "Ibogaine is a powerful hallucinogen with stimulant and depressant properties. It is used in some contexts to treat addiction, especially opioid dependence, but can cause profound and long-lasting hallucinations and has significant risks, especially cardiac toxicity (QT prolongation, arrhythmias). It is not legally available in many countries. Medical supervision is strongly recommended due to the risk of serious side effects, including death. At low doses, it acts as a stimulant; at higher doses, it produces intense visual hallucinations and dissociation. After-effects can include sleep disturbance and psychological aftershocks.",
            "subjective_effects": [
                "Visual hallucinations",
                "Dissociation",
                "Increased alertness (low dose)",
                "Reduced fatigue and hunger (low dose)",
                "Profound introspection",
                "Spiritual experiences",
                "Nausea",
                "Ataxia",
                "Dry mouth",
                "Cardiac effects (palpitations, arrhythmias)",
                "Sleep disturbance"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly after one dose; repeated dosing is rare due to intensity and duration.",
                "half_tolerance": "Unknown, but likely several days to weeks.",
                "zero_tolerance": "Several weeks; repeated use is uncommon.",
                "cross_tolerances": ["Other psychedelics (partial)"]
            },
            "half_life": "4-7 hours (ibogaine); active metabolite noribogaine: 28-49 hours",
            "citations": [
                {
                    "name": "Erowid Ibogaine Basics",
                    "reference": "https://www.erowid.org/chemicals/ibogaine/ibogaine_basics.shtml"
                },
                {
                    "name": "Erowid Ibogaine FAQ",
                    "reference": "https://www.erowid.org/chemicals/ibogaine/ibogaine_faq.shtml"
                },
                {
                    "name": "DrugWise: Ibogaine",
                    "reference": "https://www.drugwise.org.uk/ibogaine/"
                },
                {
                    "name": "Erowid Ibogaine Article",
                    "reference": "https://www.erowid.org/chemicals/ibogaine/ibogaine_article3.shtml"
                }
            ],
            "categories": [
                "psychedelic",
                "dissociative",
                "stimulant",
                "depressant",
                "hallucinogen",
                "research-chemical"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Ibogaine",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Alper KR, Lotsof HS, Kaplan CD. The Ibogaine Medical Subculture. J Ethnopharmacol. 2008;115(1):9-24. DOI:10.1016/j.jep.2007.08.034; user provided note.",
                        "units": "hours",
                        "total_duration": {
                            "min": 12,
                            "max": 36,
                            "iso": ["PT12H", "PT36H"],
                            "note": "Insufflated routes may slightly shorten onset and duration vs oral, but large individual variability exists."
                        },
                        "onset": {
                            "start": 1,
                            "end": 3,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT3H"]
                        },
                        "peak": {
                            "start": 4,
                            "end": 8,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT8H"]
                        },
                        "offset": {
                            "start": 8,
                            "end": 24,
                            "iso_start": ["PT8H"],
                            "iso_end": ["PT24H"]
                        },
                        "after_effects": {
                            "start": 24,
                            "end": 72,
                            "iso_start": ["PT24H"],
                            "iso_end": ["PT72H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 199,
        "title": "Yopo",
        "content": "# Yopo (Anadenanthera peregrina)\n## Tryptamine (plant-derived) | Psychedelic, hallucinogen\n      \nYopo seeds contain primarily bufotenin as the active compound, with variable and usually trace amounts of DMT and 5-MeO-DMT. Effects can be intense and sometimes unpleasant (anxiety, panic, physical discomfort). Seeds are typically roasted, ground, and insufflated. Yopo is not controlled in many countries, but the active compounds may be regulated. There is a risk of serotonin toxicity if combined with MAO inhibitors. Indigenous use is traditional in South America. Seeds are sometimes confused with cebil (Anadenanthera colubrina), which has similar chemistry.",
        "drug_info": {
            "drug_name": "Yopo (Anadenanthera peregrina)",
            "search_url": "https://tripsitter.substack.com/p/yopo",
            "chemical_class": "Tryptamine (plant-derived)",
            "psychoactive_class": "Psychedelic, hallucinogen",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "insufflated",
                        "units": "mg (seeds)",
                        "dose_ranges": {
                            "threshold": "Varies (effects at low doses)",
                            "light": "~50-100 mg (seeds, pulverized)",
                            "common": "100-200 mg (seeds, pulverized)",
                            "strong": "200-300 mg (seeds, pulverized)",
                            "heavy": "300+ mg (seeds, pulverized)"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 10,
                                "max": 30
                            },
                            "light": {
                                "min": 30,
                                "max": 70
                            },
                            "common": {
                                "min": 70,
                                "max": 150
                            },
                            "strong": {
                                "min": 150,
                                "max": 250
                            },
                            "heavy": {
                                "min": 250,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "30-90 minutes (insufflated)",
                "onset": "5-15 minutes (insufflated)",
                "peak": "15-45 minutes",
                "offset": "45-90 minutes",
                "after_effects": "Several hours (mild afterglow, possible anxiety)"
            },
            "addiction_potential": "Low; no evidence of physical dependence, but psychological habituation is possible with frequent use.",
            "interactions": {
                "dangerous": [
                    "MAO-A inhibitors (risk of serotonin syndrome, especially with 5-MeO-DMT or DMT content)"
                ],
                "unsafe": ["Other strong serotonergic substances"],
                "caution": [
                    "Other psychedelics, stimulants, or substances affecting serotonin"
                ]
            },
            "notes": "Yopo seeds contain primarily bufotenin as the active compound, with variable and usually trace amounts of DMT and 5-MeO-DMT. Effects can be intense and sometimes unpleasant (anxiety, panic, physical discomfort). Seeds are typically roasted, ground, and insufflated. Yopo is not controlled in many countries, but the active compounds may be regulated. There is a risk of serotonin toxicity if combined with MAO inhibitors. Indigenous use is traditional in South America. Seeds are sometimes confused with cebil (Anadenanthera colubrina), which has similar chemistry.",
            "subjective_effects": [
                "Visual hallucinations",
                "Auditory distortions",
                "Altered body perception",
                "Strong physical sensations (tingling, pressure)",
                "Nausea",
                "Anxiety or panic (sometimes lasting days)",
                "Euphoria",
                "Dissociation",
                "Intense mental effects"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (days)",
                "half_tolerance": "Several days",
                "zero_tolerance": "1-2 weeks",
                "cross_tolerances": [
                    "Other tryptamines (e.g., DMT, psilocybin)"
                ]
            },
            "half_life": "Unknown (bufotenin: short, effects last <2 hours)",
            "citations": [
                {
                    "name": "Drug Users Bible: Yopo",
                    "reference": "https://drugusersbible.org/content/botscape/psychedelics/yopo/index.html"
                },
                {
                    "name": "Erowid: Anadenanthera",
                    "reference": "https://www.erowid.org/plants/anadenanthera/anadenanthera.shtml"
                },
                {
                    "name": "Health Canada Drug Status Report: Anadenanthera peregrina",
                    "reference": "https://isomerdesign.com/Cdsa/HC/StatusDecisions/A-2013-00235%20-%20PDFs/C-Anadenanthera%20peregina%20(Yopo)%20seeds-2012-11-13.pdf"
                }
            ],
            "categories": ["psychedelic", "hallucinogen", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Yopo (Anadenanthera peregrina)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Academic literature on Anadenanthera peregrina (Yopo) human use and ethnobotanical reports (e.g., Ott, 1996; Shulgin & Shulgin, 1997)",
                        "units": "minutes",
                        "total_duration": {
                            "min": 30,
                            "max": 90,
                            "iso": ["PT30M", "PT1H30M"],
                            "note": "Insufflated; total main effects persist around 1\u20131.5 hours."
                        },
                        "onset": {
                            "start": 5,
                            "end": 15,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT15M"]
                        },
                        "peak": {
                            "start": 15,
                            "end": 45,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT45M"]
                        },
                        "offset": {
                            "start": 45,
                            "end": 90,
                            "iso_start": ["PT45M"],
                            "iso_end": ["PT1H30M"]
                        },
                        "after_effects": {
                            "start": 90,
                            "end": 240,
                            "iso_start": ["PT1H30M"],
                            "iso_end": ["PT4H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 200,
        "title": "Penis Envy",
        "content": "# Penis Envy (Psilocybe cubensis, Penis Envy strain)\n## Tryptamine | Psychedelic\n      \nPenis Envy is a well-known strain of Psilocybe cubensis, notable for its higher potency compared to most other P. cubensis strains. Users report that 1 gram of Penis Envy can be as potent as 2 grams of a standard cubensis strain. Effects are highly dose-dependent and can include intense visual and cognitive changes. Set and setting are crucial for a safe experience. Potency can vary depending on cultivation and genetics.",
        "drug_info": {
            "drug_name": "Penis Envy (Psilocybe cubensis, Penis Envy strain)",
            "search_url": "https://tripsitter.substack.com/p/penis-envy-mushrooms?r=1da21z",
            "chemical_class": "Tryptamine",
            "psychoactive_class": "Psychedelic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "g (dried mushrooms)",
                        "dose_ranges": {
                            "threshold": "0.25 g",
                            "light": "0.5 - 1 g",
                            "common": "1 - 2.5 g",
                            "strong": "2.5 - 4 g",
                            "heavy": "4+ g"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "g",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.2,
                                "max": 0.4
                            },
                            "light": {
                                "min": 0.4,
                                "max": 1
                            },
                            "common": {
                                "min": 1,
                                "max": 2.5
                            },
                            "strong": {
                                "min": 2.5,
                                "max": 4
                            },
                            "heavy": {
                                "min": 4,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4 - 6 hours",
                "onset": "20 - 60 minutes",
                "peak": "2 - 3 hours",
                "offset": "1 - 2 hours",
                "after_effects": "Up to 24 hours (residual effects, afterglow)"
            },
            "addiction_potential": "Psilocybin mushrooms have a very low addiction potential. They are not considered habit-forming and tolerance develops rapidly, discouraging frequent use.",
            "interactions": {
                "dangerous": ["MAOIs (can dangerously potentiate effects)"],
                "unsafe": ["SSRIs (may blunt effects)"],
                "caution": [
                    "Other psychedelics (increased risk of overwhelming experience)"
                ]
            },
            "notes": "Penis Envy is a well-known strain of Psilocybe cubensis, notable for its higher potency compared to most other P. cubensis strains. Users report that 1 gram of Penis Envy can be as potent as 2 grams of a standard cubensis strain. Effects are highly dose-dependent and can include intense visual and cognitive changes. Set and setting are crucial for a safe experience. Potency can vary depending on cultivation and genetics.",
            "subjective_effects": [
                "Visual distortions",
                "Euphoria",
                "Altered thinking",
                "Time dilation",
                "Synesthesia",
                "Spiritual or mystical experiences",
                "Emotional lability",
                "Introspection",
                "Body high",
                "Nausea (sometimes)"
            ],
            "tolerance": {
                "full_tolerance": "After 2-3 consecutive days of use",
                "half_tolerance": "5-7 days",
                "zero_tolerance": "2 weeks",
                "cross_tolerances": [
                    "Other tryptamine psychedelics (e.g., LSD, DMT)"
                ]
            },
            "half_life": "1.5 - 3 hours (psilocybin); effects last longer due to active metabolite psilocin",
            "citations": [
                {
                    "name": "Erowid Psilocybin Mushroom Vault",
                    "reference": "https://erowid.org/plants/mushrooms/mushrooms.shtml"
                },
                {
                    "name": "Bluelight - Penis Envy Mushrooms Discussion",
                    "reference": "https://www.bluelight.org/community/threads/penis-envy-mushrooms.520747/post-11662949"
                },
                {
                    "name": "Bluelight - Getting the Most Out of Mushrooms",
                    "reference": "https://www.bluelight.org/community/threads/getting-the-most-out-of-mushrooms.555352/page-2"
                }
            ],
            "categories": ["psychedelic", "hallucinogen", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Penis Envy (Psilocybe cubensis, Penis Envy strain)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Academic journals on psilocybin pharmacokinetics, anecdotal reports of insufflated Psilocybe cubensis (Penis Envy) effects. Example references: Passie et al. (2002) 'The pharmacology of psilocybin', Erowid user experiences.",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 6,
                            "iso": ["PT4H", "PT6H"],
                            "note": "Insufflation of mushroom powder is uncommon and potentially dangerous, but reported effects duration is generally shorter than oral ingestion."
                        },
                        "onset": {
                            "start": 0.33,
                            "end": 1,
                            "iso_start": ["PT20M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 3,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 3,
                            "end": 5,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT5H"]
                        },
                        "after_effects": {
                            "start": 6,
                            "end": 24,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 201,
        "title": "Amanita Muscaria",
        "content": "# Amanita muscaria (Fly Agaric)\n## Isoxazole (containing ibotenic acid and muscimol) | Psychedelic, Deliriant (distinct from classical tryptamine/phenethylamine psychedelics)\n      \nAmanita muscaria is visually iconic with its red cap and white spots. Its main active compounds are ibotenic acid (a neurotoxin) and muscimol (the primary psychoactive agent). Effects are highly variable and can include delirium, confusion, euphoria, ataxia, and visual distortions. Toxicity risk increases with dose, and some individuals are more sensitive. Traditional preparation methods (drying, parboiling) reduce toxicity. Deaths are rare but possible, especially with misidentification or high doses. Some historical accounts describe psychoactive urine recycling due to muscimol excretion. Not a classical 'magic mushroom' (psilocybin) and effects are very different.",
        "drug_info": {
            "drug_name": "Amanita muscaria (Fly Agaric)",
            "search_url": "https://www.acslab.com/mushrooms/amanita-muscaria-dosage-guide-extracts-tinctures",
            "chemical_class": "Isoxazole (containing ibotenic acid and muscimol)",
            "psychoactive_class": "Psychedelic, Deliriant (distinct from classical tryptamine/phenethylamine psychedelics)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "g (dried cap)",
                        "dose_ranges": {
                            "threshold": "1 g",
                            "light": "1-3 g",
                            "common": "3-6 g",
                            "strong": "6-10 g",
                            "heavy": "10+ g"
                        }
                    },
                    {
                        "route": "smoked",
                        "units": "g (dried cap)",
                        "dose_ranges": {
                            "threshold": "<1 g",
                            "light": "1-2 g",
                            "common": "2-4 g",
                            "strong": "4-6 g",
                            "heavy": "6+ g"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "g",
                        "dose_ranges": {
                            "threshold": {
                                "min": 1,
                                "max": 2
                            },
                            "light": {
                                "min": 2,
                                "max": 5
                            },
                            "common": {
                                "min": 5,
                                "max": 10
                            },
                            "strong": {
                                "min": 10,
                                "max": 15
                            },
                            "heavy": {
                                "min": 15,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "smoked",
                        "units": "g",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.25,
                                "max": 1
                            },
                            "light": {
                                "min": 1,
                                "max": 2
                            },
                            "common": {
                                "min": 2,
                                "max": 4
                            },
                            "strong": {
                                "min": 4,
                                "max": 6
                            },
                            "heavy": {
                                "min": 6,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "6-8 hours (oral)",
                "onset": "30-120 minutes (oral)",
                "peak": "2-4 hours",
                "offset": "2-4 hours",
                "after_effects": "Up to 24 hours (residual effects, grogginess)"
            },
            "addiction_potential": "Very low; not considered habit-forming. Repeated use is rare due to unpredictable effects and unpleasant side effects.",
            "interactions": {
                "dangerous": [
                    "Alcohol (increased risk of delirium, vomiting, CNS depression)"
                ],
                "unsafe": ["Other deliriants (e.g., Datura, Diphenhydramine)"],
                "caution": [
                    "Psychedelics (unpredictable potentiation or confusion)"
                ]
            },
            "notes": "Amanita muscaria is visually iconic with its red cap and white spots. Its main active compounds are ibotenic acid (a neurotoxin) and muscimol (the primary psychoactive agent). Effects are highly variable and can include delirium, confusion, euphoria, ataxia, and visual distortions. Toxicity risk increases with dose, and some individuals are more sensitive. Traditional preparation methods (drying, parboiling) reduce toxicity. Deaths are rare but possible, especially with misidentification or high doses. Some historical accounts describe psychoactive urine recycling due to muscimol excretion. Not a classical 'magic mushroom' (psilocybin) and effects are very different.",
            "subjective_effects": [
                "Euphoria",
                "Sedation",
                "Delirium",
                "Ataxia (loss of coordination)",
                "Visual distortions",
                "Altered perception of time",
                "Confusion",
                "Muscle twitches",
                "Nausea",
                "Dream-like states",
                "Retrograde amnesia"
            ],
            "tolerance": {
                "full_tolerance": "Unknown; infrequent use reported",
                "half_tolerance": "Unknown",
                "zero_tolerance": "Likely within 1-2 weeks",
                "cross_tolerances": [
                    "Other isoxazoles (e.g., Amanita pantherina)"
                ]
            },
            "half_life": "Muscimol: ~6 hours (varies); Ibotenic acid: rapidly decarboxylated to muscimol",
            "citations": [
                {
                    "name": "Erowid Amanitas Vault",
                    "reference": "https://www.erowid.org/plants/amanitas/amanitas.shtml"
                },
                {
                    "name": "Drug Users Bible: Fly Agaric",
                    "reference": "https://drugusersbible.org/content/botscape/psychedelics/fly_agaric/"
                },
                {
                    "name": "DrugWise: Magic Mushrooms",
                    "reference": "https://www.drugwise.org.uk/magic-mushrooms/"
                },
                {
                    "name": "Erowid Amanita muscaria Dose",
                    "reference": "https://www.erowid.org/plants/amanitas/amanitas_dose.shtml"
                }
            ],
            "categories": [
                "psychedelic",
                "deliriant",
                "hallucinogen",
                "research-chemical"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Amanita muscaria (Fly Agaric)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Expert synthesis based on ethnobotanical and clinical literature (excluding PW and related sources) as of 2024.",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 8,
                            "iso": ["PT4H", "PT8H"],
                            "note": "Insufflation may speed onset but total duration is similar to oral, possibly shortened slightly due to less efficient absorption."
                        },
                        "onset": {
                            "start": 0.25,
                            "end": 1,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 3,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 3,
                            "end": 6,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT6H"]
                        },
                        "after_effects": {
                            "start": 6,
                            "end": 24,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 202,
        "title": "Bupropion",
        "content": "# Bupropion\n## Aminoketone (subclass of substituted cathinones) | Antidepressant, Stimulant (NDRI: norepinephrine-dopamine reuptake inhibitor)\n      \nBupropion is indicated for major depressive disorder (MDD), seasonal affective disorder (SAD), and as an aid to smoking cessation. It is sometimes used as an adjunct to SSRIs. It lowers the seizure threshold, especially at higher doses or with rapid dose escalation. It is contraindicated in individuals with a history of seizures or eating disorders. Bupropion is a negative allosteric modulator of serotonin 3A receptors, which may contribute to its unique profile among antidepressants.",
        "drug_info": {
            "drug_name": "Bupropion",
            "search_url": "https://go.drugbank.com/drugs/DB01156",
            "chemical_class": "Aminoketone (subclass of substituted cathinones)",
            "psychoactive_class": "Antidepressant, Stimulant (NDRI: norepinephrine-dopamine reuptake inhibitor)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "50 mg",
                            "light": "75-100 mg",
                            "common": "150-300 mg",
                            "strong": "300-400 mg",
                            "heavy": "400+ mg (not recommended due to seizure risk)"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 50,
                                "max": 75
                            },
                            "light": {
                                "min": 75,
                                "max": 150
                            },
                            "common": {
                                "min": 150,
                                "max": 300
                            },
                            "strong": {
                                "min": 300,
                                "max": 400
                            },
                            "heavy": {
                                "min": 400,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "12-24 hours (extended-release); 6-8 hours (immediate-release)",
                "onset": "1-2 hours",
                "peak": "2-4 hours",
                "offset": "6-24 hours (formulation dependent)",
                "after_effects": "Mild, may include insomnia or agitation"
            },
            "addiction_potential": "Low to moderate. Bupropion is considered to have a lower risk of abuse and dependence compared to other stimulants, but misuse has been reported, especially at high doses.",
            "interactions": {
                "dangerous": [
                    "MAOIs (monoamine oxidase inhibitors): risk of hypertensive crisis or serotonin syndrome",
                    "Other drugs that lower seizure threshold (e.g., antipsychotics, other stimulants, tramadol)"
                ],
                "unsafe": ["Alcohol (increases seizure risk)"],
                "caution": [
                    "SSRIs (may increase side effects)",
                    "Drugs metabolized by CYP2B6 (bupropion is a CYP2B6 substrate and inhibitor)"
                ]
            },
            "notes": "Bupropion is indicated for major depressive disorder (MDD), seasonal affective disorder (SAD), and as an aid to smoking cessation. It is sometimes used as an adjunct to SSRIs. It lowers the seizure threshold, especially at higher doses or with rapid dose escalation. It is contraindicated in individuals with a history of seizures or eating disorders. Bupropion is a negative allosteric modulator of serotonin 3A receptors, which may contribute to its unique profile among antidepressants.",
            "subjective_effects": [
                "Increased energy",
                "Improved mood",
                "Reduced cravings (for nicotine)",
                "Mild stimulation",
                "Insomnia",
                "Anxiety",
                "Dry mouth",
                "Sweating",
                "Tremor",
                "Agitation"
            ],
            "tolerance": {
                "full_tolerance": "Develops slowly with regular use (weeks to months)",
                "half_tolerance": "Not well established",
                "zero_tolerance": "Several weeks after discontinuation",
                "cross_tolerances": ["Other NDRIs"]
            },
            "half_life": "~21 hours (range: 11-25 hours; active metabolites may persist longer)",
            "citations": [
                {
                    "name": "DrugBank: Bupropion",
                    "reference": "https://go.drugbank.com/drugs/DB01156"
                },
                {
                    "name": "DrugBank: Bupropion category",
                    "reference": "https://go.drugbank.com/categories/DBCAT003624"
                },
                {
                    "name": "DrugBank: Bupropion as NDRI",
                    "reference": "https://go.drugbank.com/unearth/q?query=bupropin&searcher=drugs"
                },
                {
                    "name": "DrugBank: Bupropion and serotonin 3A receptors",
                    "reference": "https://go.drugbank.com/articles/A178840"
                }
            ],
            "categories": ["antidepressant", "stimulant"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Bupropion",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Bupropion's pharmacokinetics via insufflation are not well-documented in the clinical literature, but extrapolation from oral administration and user reports suggests a shorter and somewhat more abrupt profile than oral use. Typical onset is faster, with duration closer to the immediate-release profile.",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 8,
                            "iso": ["PT4H", "PT8H"],
                            "note": "Insufflation generally provides a rapid onset and a shorter, more intense duration than oral use. Effects rarely exceed 8 hours."
                        },
                        "onset": {
                            "start": 0.08,
                            "end": 0.5,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT30M"]
                        },
                        "peak": {
                            "start": 0.5,
                            "end": 2,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 2,
                            "end": 6,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT6H"]
                        },
                        "after_effects": {
                            "start": 6,
                            "end": 24,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 203,
        "title": "Viloxazine",
        "content": "# Viloxazine\n## Morpholine derivative | Antidepressant, Norepinephrine Reuptake Inhibitor (NRI)\n      \nViloxazine is a selective norepinephrine reuptake inhibitor (NRI) and also modulates serotonergic activity as a 5-HT2B antagonist and 5-HT2C agonist. It was historically used as an antidepressant in Europe and is now approved for ADHD in the US. It is generally well-tolerated, but may cause insomnia, irritability, or gastrointestinal upset. Caution is advised in patients with liver impairment or those taking CYP1A2 inhibitors.",
        "drug_info": {
            "drug_name": "Viloxazine",
            "search_url": "https://go.drugbank.com/drugs/DB09185",
            "chemical_class": "Morpholine derivative",
            "psychoactive_class": "Antidepressant, Norepinephrine Reuptake Inhibitor (NRI)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "Not established",
                            "light": "Not established",
                            "common": "100-400 mg/day (for ADHD and depression, divided doses)",
                            "strong": ">400 mg/day (not typically recommended)",
                            "heavy": "Not established"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 10,
                                "max": 20
                            },
                            "light": {
                                "min": 20,
                                "max": 50
                            },
                            "common": {
                                "min": 100,
                                "max": 400
                            },
                            "strong": {
                                "min": 400,
                                "max": 600
                            },
                            "heavy": {
                                "min": 600,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "12-24 hours (extended-release)",
                "onset": "Within 2 hours (oral)",
                "peak": "4-6 hours (oral)",
                "offset": "Varies, generally within 24 hours",
                "after_effects": "Minimal, some residual stimulation or insomnia possible"
            },
            "addiction_potential": "Viloxazine is considered to have a low addiction potential. It is not associated with euphoria or reinforcing effects typical of habit-forming drugs.",
            "interactions": {
                "dangerous": ["MAOIs (risk of hypertensive crisis)"],
                "unsafe": [
                    "Other serotonergic drugs (risk of serotonin syndrome)"
                ],
                "caution": [
                    "Other antidepressants",
                    "Stimulants",
                    "CYP1A2 inhibitors (may increase viloxazine levels)"
                ]
            },
            "notes": "Viloxazine is a selective norepinephrine reuptake inhibitor (NRI) and also modulates serotonergic activity as a 5-HT2B antagonist and 5-HT2C agonist. It was historically used as an antidepressant in Europe and is now approved for ADHD in the US. It is generally well-tolerated, but may cause insomnia, irritability, or gastrointestinal upset. Caution is advised in patients with liver impairment or those taking CYP1A2 inhibitors.",
            "subjective_effects": [
                "Improved attention",
                "Reduced hyperactivity",
                "Mild stimulation",
                "Possible insomnia",
                "Mild gastrointestinal upset"
            ],
            "tolerance": {
                "full_tolerance": "Not typically observed with therapeutic use",
                "half_tolerance": "Not applicable",
                "zero_tolerance": "Not applicable",
                "cross_tolerances": ["Other NRIs"]
            },
            "half_life": "7-8 hours (immediate-release); 10-13 hours (extended-release)",
            "citations": [
                {
                    "name": "DrugBank: Viloxazine",
                    "reference": "https://go.drugbank.com/drugs/DB09185"
                },
                {
                    "name": "DrugBank Article: Viloxazine for ADHD",
                    "reference": "https://go.drugbank.com/articles/A247110"
                },
                {
                    "name": "DrugBank Article: Viloxazine Clinical Use",
                    "reference": "https://go.drugbank.com/articles/A247985"
                }
            ],
            "categories": ["antidepressant", "stimulant", "nootropic"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Viloxazine",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Drug label literature; clinical pharmacokinetics studies (oral administration) extrapolated for insufflation.",
                        "units": "hours",
                        "total_duration": {
                            "min": 8,
                            "max": 16,
                            "iso": ["PT8H", "PT16H"],
                            "note": "Insufflation typically produces faster onset and shorter overall duration compared to oral extended-release formulations."
                        },
                        "onset": {
                            "start": 0.1,
                            "end": 0.5,
                            "iso_start": ["PT6M"],
                            "iso_end": ["PT30M"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 3,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 8,
                            "end": 16,
                            "iso_start": ["PT8H"],
                            "iso_end": ["PT16H"]
                        },
                        "after_effects": {
                            "start": 12,
                            "end": 24,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 205,
        "title": "Bromo-DragonFLY",
        "content": "# Bromo-DragonFLY\n## Phenethylamine (benzodifuran derivative) | Psychedelic (hallucinogen)\n      \nBromo-DragonFLY is extremely potent and long-lasting, with a high risk of overdose and severe vasoconstriction, which can lead to tissue necrosis or death. Multiple fatalities have been reported, especially in Scandinavia. Effects are unpredictable and can be physically dangerous. Not recommended for human consumption outside of controlled research settings.",
        "drug_info": {
            "drug_name": "Bromo-DragonFLY",
            "search_url": "https://en.wikipedia.org/wiki/Bromo-DragonFLY",
            "chemical_class": "Phenethylamine (benzodifuran derivative)",
            "psychoactive_class": "Psychedelic (hallucinogen)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "\u00b5g",
                        "dose_ranges": {
                            "threshold": "<100 \u00b5g",
                            "light": "100-500 \u00b5g",
                            "common": "500-1000 \u00b5g",
                            "strong": "1000-2000 \u00b5g",
                            "heavy": "2000+ \u00b5g"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "ug",
                        "dose_ranges": {
                            "threshold": {
                                "min": 20,
                                "max": 50
                            },
                            "light": {
                                "min": 50,
                                "max": 200
                            },
                            "common": {
                                "min": 200,
                                "max": 800
                            },
                            "strong": {
                                "min": 800,
                                "max": 1200
                            },
                            "heavy": {
                                "min": 1200,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "18-36 hours (can be longer)",
                "onset": "1-3 hours",
                "peak": "4-12 hours",
                "offset": "12-24 hours",
                "after_effects": "Up to several days (residual stimulation, sleep disturbance)"
            },
            "addiction_potential": "Low physical addiction potential, but psychological dependence is possible due to intense and long-lasting effects.",
            "interactions": {
                "dangerous": ["MAOIs", "vasoconstrictive drugs"],
                "unsafe": ["stimulants", "other psychedelics"],
                "caution": ["SSRIs", "antipsychotics"]
            },
            "notes": "Bromo-DragonFLY is extremely potent and long-lasting, with a high risk of overdose and severe vasoconstriction, which can lead to tissue necrosis or death. Multiple fatalities have been reported, especially in Scandinavia. Effects are unpredictable and can be physically dangerous. Not recommended for human consumption outside of controlled research settings.",
            "subjective_effects": [
                "Visual hallucinations",
                "Altered perception of time",
                "Euphoria",
                "Anxiety",
                "Vasoconstriction (cold extremities, numbness)",
                "Confusion",
                "Paranoia",
                "Insomnia",
                "Severe agitation (at high doses)"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (within days)",
                "half_tolerance": "~7 days",
                "zero_tolerance": "2-3 weeks",
                "cross_tolerances": [
                    "Other serotonergic psychedelics (e.g., LSD, DOB, DOI)"
                ]
            },
            "half_life": "20-30 hours (estimates vary)",
            "citations": [
                {
                    "name": "Erowid Bromo-Dragonfly Vault",
                    "reference": "https://www.erowid.org/chemicals/bromo_dragonfly/bromo_dragonfly.shtml"
                },
                {
                    "name": "UNODC 2013 Report on Research Chemicals",
                    "reference": "https://www.erowid.org/psychoactives/research_chems/research_chems_UNODC_2013_report.pdf"
                },
                {
                    "name": "Erowid Bromo-Dragonfly Effects",
                    "reference": "https://erowid.org/chemicals/bromo_dragonfly/bromo_dragonfly_effects.shtml"
                },
                {
                    "name": "Erowid Bromo-Dragonfly Dose",
                    "reference": "https://www.erowid.org/chemicals/bromo_dragonfly/bromo_dragonfly_dose.shtml"
                }
            ],
            "categories": ["psychedelic", "research-chemical", "hallucinogen"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Bromo-DragonFLY",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Academic papers, user reports (e.g., Erowid, drug research publications) on Bromo-DragonFLY insufflation pharmacology.",
                        "units": "hours",
                        "total_duration": {
                            "min": 18,
                            "max": 36,
                            "iso": ["P18H", "P1DT12H"],
                            "note": "Reported durations show wide variation; some experiences last even longer depending on dose and individual sensitivity."
                        },
                        "onset": {
                            "start": 1,
                            "end": 3,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT3H"]
                        },
                        "peak": {
                            "start": 4,
                            "end": 12,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT12H"]
                        },
                        "offset": {
                            "start": 12,
                            "end": 24,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT24H"]
                        },
                        "after_effects": {
                            "start": 24,
                            "end": 72,
                            "iso_start": ["PT24H"],
                            "iso_end": ["PT72H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 206,
        "title": "Kratom",
        "content": "# Kratom\n## Indole alkaloid (primarily mitragynine and 7-hydroxymitragynine) | Stimulant (low doses), Opioid-like (high doses)\n      \nKratom is a botanical derived from Mitragyna speciosa, native to Southeast Asia. It is used traditionally for its stimulant and opioid-like effects. Strains vary in effects, often indicated by vein color and region of origin. It is sometimes used to manage pain or opioid withdrawal, but can itself be addictive. Overuse may lead to nausea, constipation, liver toxicity, and withdrawal symptoms. Legal status varies by country and region. Use caution when combining with other CNS depressants or stimulants.",
        "drug_info": {
            "drug_name": "Kratom",
            "search_url": "https://www.erowid.org/plants/kratom/kratom.shtml",
            "chemical_class": "Indole alkaloid (primarily mitragynine and 7-hydroxymitragynine)",
            "psychoactive_class": "Stimulant (low doses), Opioid-like (high doses)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "g",
                        "dose_ranges": {
                            "threshold": "1 g",
                            "light": "1-2 g",
                            "common": "2-5 g",
                            "strong": "5-8 g",
                            "heavy": "8+ g"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "g",
                        "dose_ranges": {
                            "threshold": {
                                "min": 1,
                                "max": 2
                            },
                            "light": {
                                "min": 2,
                                "max": 4
                            },
                            "common": {
                                "min": 4,
                                "max": 6
                            },
                            "strong": {
                                "min": 6,
                                "max": 8
                            },
                            "heavy": {
                                "min": 8,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4-6 hours",
                "onset": "10-30 minutes",
                "peak": "1-2 hours",
                "offset": "2-4 hours",
                "after_effects": "Up to 24 hours (mild afterglow or residual sedation)"
            },
            "addiction_potential": "Moderate. Kratom can be habit-forming, especially with frequent or high-dose use. Dependence and withdrawal symptoms have been reported, particularly with daily use.",
            "interactions": {
                "dangerous": ["Other opioids (risk of respiratory depression)"],
                "unsafe": ["Alcohol (increased sedation, risk of overdose)"],
                "caution": [
                    "Benzodiazepines (increased sedation)",
                    "Stimulants (potential for unpredictable effects)"
                ]
            },
            "notes": "Kratom is a botanical derived from Mitragyna speciosa, native to Southeast Asia. It is used traditionally for its stimulant and opioid-like effects. Strains vary in effects, often indicated by vein color and region of origin. It is sometimes used to manage pain or opioid withdrawal, but can itself be addictive. Overuse may lead to nausea, constipation, liver toxicity, and withdrawal symptoms. Legal status varies by country and region. Use caution when combining with other CNS depressants or stimulants.",
            "subjective_effects": [
                "Stimulation (low doses)",
                "Euphoria",
                "Analgesia (pain relief)",
                "Sedation (high doses)",
                "Mood lift",
                "Sociability",
                "Relaxation",
                "Reduced anxiety",
                "Nausea (especially at high doses)",
                "Constipation",
                "Sweating"
            ],
            "tolerance": {
                "full_tolerance": "Several days of daily use",
                "half_tolerance": "3-7 days after cessation",
                "zero_tolerance": "1-2 weeks after cessation",
                "cross_tolerances": ["Opioids"]
            },
            "half_life": "Unknown (varies by alkaloid; mitragynine estimated 7-24 hours)",
            "citations": [
                {
                    "name": "Erowid Kratom Basics",
                    "reference": "https://www.erowid.org/plants/kratom/kratom_basics.shtml"
                },
                {
                    "name": "Erowid Kratom Dose",
                    "reference": "https://www.erowid.org/plants/kratom/kratom_dose.shtml"
                },
                {
                    "name": "Drug Users Bible: Kratom",
                    "reference": "https://drugusersbible.org/content/botscape/unclassified/kratom/"
                },
                {
                    "name": "TripSit Factsheet: Kratom",
                    "reference": "https://tripsit.me/factsheets/kratom"
                },
                {
                    "name": "Erowid Kratom Health",
                    "reference": "https://www.erowid.org/plants/kratom/kratom_health.shtml"
                }
            ],
            "categories": [
                "opioid",
                "research-chemical",
                "habit-forming",
                "hallucinogen"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Kratom",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Analysis based on user reports and clinical literature outside of PsychonautWiki, e.g., journal articles and case studies on intranasal kratom use.",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 6,
                            "iso": ["PT4H", "PT6H"],
                            "note": "Total subjective experience, may vary with dose and individual sensitivity."
                        },
                        "onset": {
                            "start": 0.16,
                            "end": 0.5,
                            "iso_start": ["PT10M"],
                            "iso_end": ["PT30M"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "after_effects": {
                            "start": 4,
                            "end": 24,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 208,
        "title": "Kava",
        "content": "# Kava (Piper methysticum)\n## Dihydropyranones (kavalactones) | Anxiolytic, sedative, relaxant\n      \nKava is associated with potential liver toxicity, especially with extracts or heavy, prolonged use. It is used traditionally in Pacific cultures for its relaxing and social effects. Some kavalactones act as reversible MAO-B inhibitors and norepinephrine reuptake inhibitors, which may contribute to its mood and focus effects. Not recommended for those with liver disease or those taking hepatotoxic medications.",
        "drug_info": {
            "drug_name": "Kava (Piper methysticum)",
            "search_url": "https://www.drugscience.org.uk/kava",
            "chemical_class": "Dihydropyranones (kavalactones)",
            "psychoactive_class": "Anxiolytic, sedative, relaxant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg (kavalactones)",
                        "dose_ranges": {
                            "threshold": "<50 mg",
                            "light": "50-70 mg",
                            "common": "70-150 mg",
                            "strong": "150-200 mg",
                            "heavy": "300 mg+"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 30,
                                "max": 50
                            },
                            "light": {
                                "min": 50,
                                "max": 100
                            },
                            "common": {
                                "min": 100,
                                "max": 250
                            },
                            "strong": {
                                "min": 250,
                                "max": 400
                            },
                            "heavy": {
                                "min": 400,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "3-6 hours",
                "onset": "20-30 minutes",
                "peak": "~3 hours",
                "offset": "Varies, typically after 6 hours",
                "after_effects": "9-18 hours"
            },
            "addiction_potential": "Low to moderate. Kava is not considered physically addictive, but regular use can lead to psychological dependence in some individuals.",
            "interactions": {
                "dangerous": ["Alcohol (increased risk of liver toxicity)"],
                "unsafe": ["Other hepatotoxic drugs"],
                "caution": [
                    "Benzodiazepines (additive sedative effects)",
                    "CNS depressants",
                    "MAO inhibitors (due to MAO-B inhibition by some kavalactones)"
                ]
            },
            "notes": "Kava is associated with potential liver toxicity, especially with extracts or heavy, prolonged use. It is used traditionally in Pacific cultures for its relaxing and social effects. Some kavalactones act as reversible MAO-B inhibitors and norepinephrine reuptake inhibitors, which may contribute to its mood and focus effects. Not recommended for those with liver disease or those taking hepatotoxic medications.",
            "subjective_effects": [
                "Relaxation",
                "Mild euphoria",
                "Sociability",
                "Anxiolysis (reduced anxiety)",
                "Mild sedation",
                "Numbness of mouth/tongue (when consumed as beverage)",
                "Enhanced focus (some users)",
                "Drowsiness (higher doses)"
            ],
            "tolerance": {
                "full_tolerance": "Develops with regular use (days to weeks)",
                "half_tolerance": "Several days after cessation",
                "zero_tolerance": "1-2 weeks after cessation",
                "cross_tolerances": ["Other GABAergic substances (mild)"]
            },
            "half_life": "Varies by kavalactone; generally 6-9 hours for major constituents.",
            "citations": [
                {
                    "name": "Erowid Kava Vault",
                    "reference": "https://www.erowid.org/plants/kava/kava.shtml"
                },
                {
                    "name": "TripSit Kava Wiki",
                    "reference": "https://wiki.tripsit.me/wiki/Kava"
                },
                {
                    "name": "DrugBank: Kava",
                    "reference": "https://go.drugbank.com/drugs/DB01322"
                },
                {
                    "name": "DrugBank Article: Liver toxicity of Kava",
                    "reference": "https://go.drugbank.com/articles/A2387"
                }
            ],
            "categories": [
                "depressant",
                "sedative",
                "psychedelic",
                "habit-forming"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Kava (Piper methysticum)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Kava's effects via insufflation are rarely documented in scientific or ethnobotanical literature, but extrapolation from oral use and anecdotal reports suggest a similar but potentially more rapid course. Sources: Sarris J et al., Phytotherapy Research (2011); anecdotal experiences from drug forums.",
                        "units": "hours",
                        "total_duration": {
                            "min": 3,
                            "max": 6,
                            "iso": ["PT3H", "PT6H"],
                            "note": "Duration may be shorter or less predictable than oral administration; adverse effects more likely with non-oral use."
                        },
                        "onset": {
                            "start": 0.33,
                            "end": 0.5,
                            "iso_start": ["PT20M"],
                            "iso_end": ["PT30M"]
                        },
                        "peak": {
                            "start": 0.5,
                            "end": 3.5,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT3H30M"]
                        },
                        "offset": {
                            "start": 3.5,
                            "end": 6,
                            "iso_start": ["PT3H30M"],
                            "iso_end": ["PT6H"]
                        },
                        "after_effects": {
                            "start": 9,
                            "end": 18,
                            "iso_start": ["PT9H"],
                            "iso_end": ["PT18H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 210,
        "title": "Buprenorphine",
        "content": "# Buprenorphine\n## Semi-synthetic opioid (thebaine derivative) | Opioid\n      \nBuprenorphine is used for pain management and as opioid substitution therapy (OST) for opioid dependence. It is a partial mu-opioid receptor agonist and kappa-opioid receptor antagonist, which gives it a ceiling effect for respiratory depression. It can precipitate withdrawal in opioid-dependent individuals if administered too soon after other opioids. Combination with naloxone (Suboxone) is common to deter misuse.",
        "drug_info": {
            "drug_name": "Buprenorphine",
            "search_url": "https://go.drugbank.com/drugs/DB00921",
            "chemical_class": "Semi-synthetic opioid (thebaine derivative)",
            "psychoactive_class": "Opioid",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "sublingual",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "0.2 mg",
                            "light": "0.2-0.5 mg",
                            "common": "0.5-2 mg",
                            "strong": "2-4 mg",
                            "heavy": "4+ mg"
                        }
                    },
                    {
                        "route": "transdermal",
                        "units": "mcg/hour",
                        "dose_ranges": {
                            "threshold": "5 mcg/h",
                            "light": "5-10 mcg/h",
                            "common": "10-20 mcg/h",
                            "strong": "20-40 mcg/h",
                            "heavy": "40+ mcg/h"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "sublingual",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.2,
                                "max": 0.2
                            },
                            "light": {
                                "min": 0.2,
                                "max": 0.5
                            },
                            "common": {
                                "min": 0.5,
                                "max": 2
                            },
                            "strong": {
                                "min": 2,
                                "max": 4
                            },
                            "heavy": {
                                "min": 4,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "transdermal",
                        "units": "ug",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 10
                            },
                            "common": {
                                "min": 10,
                                "max": 20
                            },
                            "strong": {
                                "min": 20,
                                "max": 40
                            },
                            "heavy": {
                                "min": 40,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "12-72 hours (formulation dependent)",
                "onset": "30-60 minutes (sublingual)",
                "peak": "1-4 hours (sublingual)",
                "offset": "varies, up to 72 hours (patch)",
                "after_effects": "Mild, may last up to 24 hours"
            },
            "addiction_potential": "Moderate to high. Buprenorphine has a lower risk of respiratory depression and overdose compared to full opioid agonists, but dependence and withdrawal can still occur.",
            "interactions": {
                "dangerous": [
                    "Other opioids (risk of overdose, precipitated withdrawal)",
                    "Benzodiazepines (increased risk of respiratory depression)"
                ],
                "unsafe": ["Alcohol (increased CNS depression)"],
                "caution": [
                    "CYP3A4 inhibitors/inducers (may alter buprenorphine levels)"
                ]
            },
            "notes": "Buprenorphine is used for pain management and as opioid substitution therapy (OST) for opioid dependence. It is a partial mu-opioid receptor agonist and kappa-opioid receptor antagonist, which gives it a ceiling effect for respiratory depression. It can precipitate withdrawal in opioid-dependent individuals if administered too soon after other opioids. Combination with naloxone (Suboxone) is common to deter misuse.",
            "subjective_effects": [
                "Analgesia",
                "Euphoria (mild, less than full agonists)",
                "Sedation",
                "Constipation",
                "Itching",
                "Nausea",
                "Sweating",
                "Mild respiratory depression"
            ],
            "tolerance": {
                "full_tolerance": "Develops within days to weeks of regular use",
                "half_tolerance": "~3-7 days after cessation",
                "zero_tolerance": "~1-2 weeks after cessation",
                "cross_tolerances": ["Other opioids"]
            },
            "half_life": "24-60 hours (formulation and individual dependent)",
            "citations": [
                {
                    "name": "DrugBank: Buprenorphine",
                    "reference": "https://go.drugbank.com/drugs/DB00921"
                },
                {
                    "name": "DrugWise: Buprenorphine",
                    "reference": "https://www.drugwise.org.uk/buprenorphine/"
                }
            ],
            "categories": ["opioid", "habit-forming", "depressant"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Buprenorphine",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Based on clinical studies and pharmacology references (see e.g., Prevodnik et al., 2019, and drug labeling information) describing insufflated buprenorphine.",
                        "units": "hours",
                        "total_duration": {
                            "min": 12,
                            "max": 48,
                            "iso": ["P12H", "P2DT"],
                            "note": "Duration may vary with dose and formulation; typically less than 72 hours for insufflated route."
                        },
                        "onset": {
                            "start": 0.25,
                            "end": 1,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 4,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT4H"]
                        },
                        "offset": {
                            "start": 8,
                            "end": 48,
                            "iso_start": ["PT8H"],
                            "iso_end": ["P2DT"]
                        },
                        "after_effects": {
                            "start": 12,
                            "end": 24,
                            "iso_start": ["P12H"],
                            "iso_end": ["P1DT"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 211,
        "title": "Phenethylamine",
        "content": "# Phenethylamine\n## Phenethylamine (PEA) | Stimulant, Trace Amine\n      \nPhenethylamine is rapidly metabolized by monoamine oxidase B (MAO-B) in the body, resulting in very low oral bioavailability unless combined with a MAO-B inhibitor (which can be dangerous). It acts as a central nervous system stimulant and is structurally related to amphetamine. High doses can cause overstimulation, anxiety, or cardiovascular effects. It is naturally found in the human body and in some foods (e.g., chocolate).",
        "drug_info": {
            "drug_name": "Phenethylamine",
            "search_url": "https://go.drugbank.com/bio_entities/BE0001831",
            "chemical_class": "Phenethylamine (PEA)",
            "psychoactive_class": "Stimulant, Trace Amine",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "10-20 mg",
                            "light": "20-50 mg",
                            "common": "50-100 mg",
                            "strong": "100-200 mg",
                            "heavy": "200+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 10,
                                "max": 20
                            },
                            "light": {
                                "min": 20,
                                "max": 50
                            },
                            "common": {
                                "min": 50,
                                "max": 100
                            },
                            "strong": {
                                "min": 100,
                                "max": 200
                            },
                            "heavy": {
                                "min": 200,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "~30-120 minutes (oral)",
                "onset": "10-30 minutes (oral)",
                "peak": "30-60 minutes",
                "offset": "60-120 minutes",
                "after_effects": "minimal"
            },
            "addiction_potential": "Low; phenethylamine is not considered to have significant addiction potential, though it may be habit-forming in some individuals due to its stimulant effects.",
            "interactions": {
                "dangerous": ["MAOIs (monoamine oxidase inhibitors)"],
                "unsafe": ["Other stimulants"],
                "caution": ["SSRIs", "SNRIs", "tricyclic antidepressants"]
            },
            "notes": "Phenethylamine is rapidly metabolized by monoamine oxidase B (MAO-B) in the body, resulting in very low oral bioavailability unless combined with a MAO-B inhibitor (which can be dangerous). It acts as a central nervous system stimulant and is structurally related to amphetamine. High doses can cause overstimulation, anxiety, or cardiovascular effects. It is naturally found in the human body and in some foods (e.g., chocolate).",
            "subjective_effects": [
                "Mild stimulation",
                "Mood lift",
                "Increased sociability",
                "Euphoria (at higher doses)",
                "Increased heart rate",
                "Anxiety (at high doses)",
                "Insomnia"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (days)",
                "half_tolerance": "~3-7 days",
                "zero_tolerance": "~1-2 weeks",
                "cross_tolerances": ["Other stimulants"]
            },
            "half_life": "~5-10 minutes (oral, due to rapid metabolism)",
            "citations": [
                {
                    "name": "DrugBank Phenethylamine BioEntity",
                    "reference": "https://go.drugbank.com/bio_entities/BE0001831"
                },
                {
                    "name": "Comparative effects of amphetamine, phenylethylamine and related drugs on dopamine efflux, dopamine uptake and mazindol binding.",
                    "reference": "https://go.drugbank.com/articles/A17103"
                }
            ],
            "categories": ["stimulant", "psychedelic", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Phenethylamine",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Julien's Primer of Drug Action, 14th Edition; user reports (Erowid, Bluelight); Goodman & Gilman's Pharmacological Basis of Therapeutics, 13th Edition.",
                        "units": "minutes",
                        "total_duration": {
                            "min": 15,
                            "max": 60,
                            "iso": ["PT15M", "PT1H"],
                            "note": "Insufflation produces a faster onset and shorter duration than oral use."
                        },
                        "onset": {
                            "start": 2,
                            "end": 10,
                            "iso_start": ["PT2M"],
                            "iso_end": ["PT10M"]
                        },
                        "peak": {
                            "start": 10,
                            "end": 25,
                            "iso_start": ["PT10M"],
                            "iso_end": ["PT25M"]
                        },
                        "offset": {
                            "start": 25,
                            "end": 60,
                            "iso_start": ["PT25M"],
                            "iso_end": ["PT1H"]
                        },
                        "after_effects": {
                            "start": 60,
                            "end": 90,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT1H30M"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 212,
        "title": "Ephedrine",
        "content": "# Ephedrine\n## Phenethylamine (Ephedra alkaloid) | Stimulant, Sympathomimetic\n      \nEphedrine is a naturally occurring alkaloid found in Ephedra species. It is used medically as a bronchodilator, decongestant, and to treat hypotension. It is structurally similar to amphetamines but is less potent. Ephedrine is regulated in many countries due to its use as a precursor in the illicit synthesis of methamphetamine and MDMA. Side effects include increased heart rate, hypertension, anxiety, and insomnia. Overdose can cause serious cardiovascular events.",
        "drug_info": {
            "drug_name": "Ephedrine",
            "search_url": "https://www.saferparty.ch/substanzen/ephedrin",
            "chemical_class": "Phenethylamine (Ephedra alkaloid)",
            "psychoactive_class": "Stimulant, Sympathomimetic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5-10 mg",
                            "light": "10-25 mg",
                            "common": "25-50 mg",
                            "strong": "50-75 mg",
                            "heavy": "75+ mg"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "10-20 mg",
                            "common": "20-40 mg",
                            "strong": "40-60 mg",
                            "heavy": "60+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 25
                            },
                            "common": {
                                "min": 25,
                                "max": 50
                            },
                            "strong": {
                                "min": 50,
                                "max": 75
                            },
                            "heavy": {
                                "min": 75,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 20
                            },
                            "common": {
                                "min": 20,
                                "max": 40
                            },
                            "strong": {
                                "min": 40,
                                "max": 60
                            },
                            "heavy": {
                                "min": 60,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "3-6 hours (oral)",
                "onset": "20-60 minutes (oral)",
                "peak": "1-2 hours (oral)",
                "offset": "2-4 hours (oral)",
                "after_effects": "May persist for several hours as mild stimulation or insomnia"
            },
            "addiction_potential": "Moderate. Ephedrine can be habit-forming with repeated use, especially for its stimulant effects. Psychological dependence is more common than physical dependence.",
            "interactions": {
                "dangerous": ["MAOIs (risk of hypertensive crisis)"],
                "unsafe": ["Other stimulants (increased cardiovascular risk)"],
                "caution": [
                    "Antihypertensives, beta-blockers, certain antidepressants, caffeine"
                ]
            },
            "notes": "Ephedrine is a naturally occurring alkaloid found in Ephedra species. It is used medically as a bronchodilator, decongestant, and to treat hypotension. It is structurally similar to amphetamines but is less potent. Ephedrine is regulated in many countries due to its use as a precursor in the illicit synthesis of methamphetamine and MDMA. Side effects include increased heart rate, hypertension, anxiety, and insomnia. Overdose can cause serious cardiovascular events.",
            "subjective_effects": [
                "Increased alertness",
                "Stimulation",
                "Elevated heart rate",
                "Increased blood pressure",
                "Reduced appetite",
                "Anxiety",
                "Insomnia",
                "Sweating",
                "Restlessness"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (days)",
                "half_tolerance": "Several days after cessation",
                "zero_tolerance": "1-2 weeks after cessation",
                "cross_tolerances": ["Amphetamines", "Other stimulants"]
            },
            "half_life": "3-6 hours",
            "citations": [
                {
                    "name": "Erowid Ephedrine Vault",
                    "reference": "https://www.erowid.org/chemicals/ephedrine/ephedrine_info1.shtml"
                },
                {
                    "name": "DrugBank: Ephedrine",
                    "reference": "https://go.drugbank.com/drugs/DB01364"
                },
                {
                    "name": "TripSit: Ephedrine",
                    "reference": "https://wiki.tripsit.me/index.php?title=Ephedrine"
                }
            ],
            "categories": ["stimulant", "research-chemical", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Ephedrine",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Ephedrine pharmacology textbooks; clinical studies on ephedrine insufflation.",
                        "units": "hours",
                        "total_duration": {
                            "min": 2,
                            "max": 4,
                            "iso": ["PT2H", "PT4H"],
                            "note": "Insufflation results in a somewhat shorter and more abrupt effect than oral use."
                        },
                        "onset": {
                            "start": 0.08,
                            "end": 0.25,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT15M"]
                        },
                        "peak": {
                            "start": 0.25,
                            "end": 1,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT1H"]
                        },
                        "offset": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        },
                        "after_effects": {
                            "start": 2,
                            "end": 6,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT6H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 207,
        "title": "N-Ethylpentedrone (NEP)",
        "content": "# N-Ethylpentedrone (NEP)\n## Cathinone | Stimulant, Entactogen\n      \nVery little is known about the long-term risks, toxicity, or safe dosage range of N-Ethylpentedrone. User reports indicate stimulating, euphoric, and mildly entactogenic effects, but also unpleasant comedown symptoms. Health risks are largely unknown and may be significant. Use with caution, especially due to the unknowns regarding toxicity and long-term effects.",
        "drug_info": {
            "drug_name": "N-Ethylpentedrone",
            "search_url": "https://pubchem.ncbi.nlm.nih.gov/compound/132886199",
            "chemical_class": "Synthetic cathinone (\u03b2-keto amphetamine)",
            "psychoactive_class": "Stimulant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "~10 mg",
                            "light": "10\u201325 mg",
                            "common": "25\u201340 mg",
                            "strong": "40\u201360 mg",
                            "heavy": "60 mg+"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "~5 mg",
                            "light": "5\u201315 mg",
                            "common": "15\u201330 mg",
                            "strong": "30\u201350 mg",
                            "heavy": "50 mg+"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 25
                            },
                            "common": {
                                "min": 25,
                                "max": 40
                            },
                            "strong": {
                                "min": 40,
                                "max": 60
                            },
                            "heavy": {
                                "min": 60,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 3,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 15
                            },
                            "common": {
                                "min": 15,
                                "max": 30
                            },
                            "strong": {
                                "min": 30,
                                "max": 50
                            },
                            "heavy": {
                                "min": 50,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "3\u20136 hours",
                "onset": "10\u201330 minutes (route-dependent)",
                "peak": "1\u20132 hours",
                "offset": "1\u20132 hours",
                "after_effects": "1\u20133 hours residual stimulation / crash"
            },
            "addiction_potential": "Moderate to high; strong compulsive redosing and binge patterns similar to other cathinones have been documented in user forums and case reports.",
            "interactions": {
                "dangerous": [
                    "MAOIs",
                    "Other potent stimulants (cocaine, methamphetamine, MDMA)",
                    "Bupropion"
                ],
                "unsafe": [
                    "Alcohol (exacerbates tachycardia/dehydration)",
                    "Tramadol (lowers seizure threshold)",
                    "DXM"
                ],
                "caution": [
                    "Cannabis (may amplify anxiety)",
                    "Benzodiazepines (mask warning signs)",
                    "SSRIs/SNRIs"
                ]
            },
            "notes": "NEP produces significant cardiovascular strain and can trigger anxiety, paranoia, and compulsive redosing. Fatalities have been linked to tachyarrhythmia and hyperthermia. Drug-checking is advised due to frequent cathinone mislabeling. Use meticulous hydration and cooling; avoid consecutive-day use.",
            "subjective_effects": [
                "Euphoria",
                "Stimulation",
                "Increased sociability",
                "Mild empathy",
                "Enhanced tactile sensation",
                "Increased libido",
                "Jaw clenching",
                "Sweating",
                "Vasoconstriction",
                "Elevated heart rate",
                "Insomnia",
                "Anxiety",
                "Paranoia (high dose)",
                "Crash dysphoria"
            ],
            "tolerance": {
                "full_tolerance": "Builds rapidly after 1\u20132 days of heavy use",
                "half_tolerance": "3\u20137 days of abstinence",
                "zero_tolerance": "14\u201321 days of abstinence",
                "cross_tolerances": [
                    "Other synthetic cathinones",
                    "Amphetamine-type stimulants"
                ]
            },
            "half_life": "Approx. 6\u20138 hours (in-vitro human hepatocyte t\u00bd \u2248 770 min)",
            "citations": [
                {
                    "name": "Bluelight NEP discussion (2016)",
                    "reference": "https://www.bluelight.org/community/threads/n-ethylpentedrone-nep-or-nepd.807193/"
                },
                {
                    "name": "Reddit NEP tips & facts (2018)",
                    "reference": "https://www.reddit.com/r/researchchemicals/comments/9s42bi/nethylpentedrone_nep_tips_and_facts/"
                },
                {
                    "name": "Reddit NEP experience report (2019)",
                    "reference": "https://www.reddit.com/r/researchchemicals/comments/dw638y/nethylpentedrone_experience/"
                },
                {
                    "name": "Drug Classroom \u2013 NEP video overview",
                    "reference": "https://thedrugclassroom.com/video/n-ethylpentedrone-nep/"
                },
                {
                    "name": "TripSit Ethyl-pentedrone factsheet",
                    "reference": "https://tripsit.me/factsheets/ethyl-pentedrone"
                },
                {
                    "name": "Drug Intelligence Bulletin \u2013 Rising Trend of NEP (2023)",
                    "reference": "https://www.drugintelligencebulletin.com/p/the-rising-trend-of-n-ethylpentedrone"
                },
                {
                    "name": "Metabolic profile NEH/NEP/4-CMC (2024)",
                    "reference": "https://www.sciencedirect.com/science/article/pii/S0731708524000347"
                },
                {
                    "name": "Human hepatocyte t\u00bd study (PubMed 38399311)",
                    "reference": "https://pubmed.ncbi.nlm.nih.gov/38399311/"
                },
                {
                    "name": "Forensic fatal cases (2025)",
                    "reference": "https://www.sciencedirect.com/science/article/pii/S2352007825000204"
                },
                {
                    "name": "Journal of Analytical Toxicology case series",
                    "reference": "https://academic.oup.com/jat/advance-article-abstract/doi/10.1093/jat/bkac092/6855747"
                },
                {
                    "name": "CFSRE NEP monograph",
                    "reference": "https://www.cfsre.org/images/monographs/N-ethyl_Pentedrone_022420_ToxicologyAnalyticalReport.pdf"
                },
                {
                    "name": "UNODC Early Warning Advisory on NPS",
                    "reference": "https://www.unodc.org/nps"
                },
                {
                    "name": "UNODC ICE 2024/1 Summary \u2013 N-Ethylpentedrone listings",
                    "reference": "https://www.unodc.org/documents/scientific/Summary_report_2024-1_SM.pdf"
                },
                {
                    "name": "Oral-fluid pharmacokinetics table",
                    "reference": "https://www.researchgate.net/figure/Pharmacokinetic-parameters-of-4-CMC-NEP-and-NEH-in-oral-fluid_tbl3_371114455"
                },
                {
                    "name": "Review: Toxicological analysis of cathinone intoxications",
                    "reference": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9375235/"
                }
            ],
            "categories": ["stimulant", "research-chemical", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "N-Ethylpentedrone",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Peer-reviewed articles, user experience reports, and general psychostimulant onset/duration literature.",
                        "units": "hours",
                        "total_duration": {
                            "min": 3,
                            "max": 6,
                            "iso": ["PT3H", "PT6H"],
                            "note": "Reported range for total effect window; upper bound can extend with higher doses or repeated use."
                        },
                        "onset": {
                            "start": 0.17,
                            "end": 0.5,
                            "iso_start": ["PT10M"],
                            "iso_end": ["PT30M"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "after_effects": {
                            "start": 3,
                            "end": 9,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT9H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 214,
        "title": "Caffeine",
        "content": "# Caffeine\n## Methylxanthine | Stimulant\n      \nCaffeine is the most widely used psychoactive substance in the world. It is legal and unregulated in most countries. Overuse can lead to anxiety, insomnia, and increased heart rate. Toxicity is rare but possible at very high doses (over 1 gram).",
        "drug_info": {
            "drug_name": "Caffeine",
            "search_url": "https://www.drugscience.org.uk/caffeine",
            "chemical_class": "Methylxanthine",
            "psychoactive_class": "Stimulant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "10-20 mg",
                            "light": "20-50 mg",
                            "common": "50-200 mg",
                            "strong": "200-400 mg",
                            "heavy": "400+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 10,
                                "max": 20
                            },
                            "light": {
                                "min": 20,
                                "max": 50
                            },
                            "common": {
                                "min": 50,
                                "max": 200
                            },
                            "strong": {
                                "min": 200,
                                "max": 400
                            },
                            "heavy": {
                                "min": 400,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "3-6 hours",
                "onset": "15-45 minutes",
                "peak": "30-75 minutes",
                "offset": "2-4 hours",
                "after_effects": "Up to 12 hours (residual stimulation, insomnia)"
            },
            "addiction_potential": "Moderate. Habit-forming with regular use; withdrawal symptoms (headache, irritability, fatigue) are common.",
            "interactions": {
                "dangerous": ["None commonly noted at typical doses"],
                "unsafe": [
                    "High doses with other stimulants (e.g., amphetamines)"
                ],
                "caution": [
                    "MAOIs, certain psychiatric medications, alcohol (may mask intoxication), some antibiotics (e.g., ciprofloxacin)"
                ]
            },
            "notes": "Caffeine is the most widely used psychoactive substance in the world. It is legal and unregulated in most countries. Overuse can lead to anxiety, insomnia, and increased heart rate. Toxicity is rare but possible at very high doses (over 1 gram).",
            "subjective_effects": [
                "Increased alertness",
                "Wakefulness",
                "Improved concentration",
                "Mild euphoria",
                "Increased heart rate",
                "Jitteriness",
                "Anxiety (at high doses)",
                "Insomnia"
            ],
            "tolerance": {
                "full_tolerance": "Develops within days of regular use",
                "half_tolerance": "3-7 days after cessation",
                "zero_tolerance": "1-2 weeks after cessation",
                "cross_tolerances": [
                    "Other methylxanthines (theobromine, theophylline)"
                ]
            },
            "half_life": "3-7 hours (varies by individual, liver function, and other factors)",
            "citations": [
                {
                    "name": "Erowid Caffeine Vault",
                    "reference": "https://www.erowid.org/chemicals/caffeine/caffeine.shtml"
                },
                {
                    "name": "DrugWise: Caffeine",
                    "reference": "https://www.drugwise.org.uk/caffeine/"
                },
                {
                    "name": "TripSit Factsheet: Caffeine",
                    "reference": "https://tripsit.me/factsheets/caffeine"
                },
                {
                    "name": "DrugBank: Caffeine",
                    "reference": "https://go.drugbank.com/drugs/DB00201"
                }
            ],
            "categories": ["stimulant", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Caffeine",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Literature on caffeine pharmacokinetics and anecdotal insufflation reports.",
                        "units": "hours",
                        "total_duration": {
                            "min": 3,
                            "max": 6,
                            "iso": ["PT3H", "PT6H"],
                            "note": "Duration reflects active stimulation and noticeable effects from insufflated caffeine, which may be shorter but often is similar to oral due to rapid absorption offset by shorter subjective peak."
                        },
                        "onset": {
                            "start": 0.25,
                            "end": 0.75,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT45M"]
                        },
                        "peak": {
                            "start": 0.5,
                            "end": 1.25,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT1H15M"]
                        },
                        "offset": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "after_effects": {
                            "start": 4,
                            "end": 12,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT12H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 215,
        "title": "Ibotenic acid",
        "content": "# Ibotenic acid\n## Isoxazole | Dissociative/Deliriant (neurotoxin, glutamate agonist)\n      \nIbotenic acid is a neurotoxin and a prodrug to muscimol, which is primarily responsible for the psychoactive effects of Amanita muscaria. It acts as a glutamate agonist and can cause neurotoxicity at high doses. It is not a controlled substance in the US, Canada, or under international law. Most recreational effects attributed to Amanita muscaria are due to muscimol, not ibotenic acid itself. Ibotenic acid is used in research to study neurotoxicity and GABA/glutamate systems.",
        "drug_info": {
            "drug_name": "Ibotenic acid",
            "search_url": "https://en.m.wikipedia.org/wiki/Ibotenic_acid",
            "chemical_class": "Isoxazole",
            "psychoactive_class": "Dissociative/Deliriant (neurotoxin, glutamate agonist)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "~30 mg",
                            "light": "30-50 mg",
                            "common": "50-100 mg",
                            "strong": "100-150 mg",
                            "heavy": "150+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 20,
                                "max": 30
                            },
                            "light": {
                                "min": 30,
                                "max": 50
                            },
                            "common": {
                                "min": 50,
                                "max": 100
                            },
                            "strong": {
                                "min": 100,
                                "max": 150
                            },
                            "heavy": {
                                "min": 150,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "6-8 hours (when ingested as part of Amanita muscaria)",
                "onset": "30-120 minutes",
                "peak": "2-4 hours",
                "offset": "2-4 hours",
                "after_effects": "Residual effects may last up to 24 hours, including confusion or lethargy."
            },
            "addiction_potential": "Low; not considered habit-forming. No evidence of physical dependence or addiction in literature.",
            "interactions": {
                "dangerous": ["Other deliriants", "CNS depressants"],
                "unsafe": ["Alcohol"],
                "caution": [
                    "Other psychoactive mushrooms (potentiation or unpredictable effects)"
                ]
            },
            "notes": "Ibotenic acid is a neurotoxin and a prodrug to muscimol, which is primarily responsible for the psychoactive effects of Amanita muscaria. It acts as a glutamate agonist and can cause neurotoxicity at high doses. It is not a controlled substance in the US, Canada, or under international law. Most recreational effects attributed to Amanita muscaria are due to muscimol, not ibotenic acid itself. Ibotenic acid is used in research to study neurotoxicity and GABA/glutamate systems.",
            "subjective_effects": [
                "Confusion",
                "Delirium",
                "Sedation",
                "Dizziness",
                "Visual distortions",
                "Nausea",
                "Ataxia",
                "Muscle twitching",
                "Drowsiness",
                "Disorientation"
            ],
            "tolerance": {
                "full_tolerance": "Unknown; likely develops slowly with repeated use.",
                "half_tolerance": "Unknown",
                "zero_tolerance": "Unknown",
                "cross_tolerances": ["Muscimol"]
            },
            "half_life": "Unknown (rapidly decarboxylated to muscimol in vivo)",
            "citations": [
                {
                    "name": "Erowid Amanitas Chemistry",
                    "reference": "https://www.erowid.org/plants/amanitas/amanitas_chemistry.shtml"
                },
                {
                    "name": "Erowid Amanitas Info (Ott)",
                    "reference": "https://www.erowid.org/plants/amanitas/amanitas_info_ott.shtml"
                },
                {
                    "name": "IsomerDesign Drug Status Report",
                    "reference": "https://isomerdesign.com/Cdsa/HC/StatusDecisions/A-2013-00235%20-%20PDFs/NC-Ibotenic%20acid-2008-05-14.pdf"
                }
            ],
            "categories": ["dissociative", "deliriant", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Ibotenic acid",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Based on pharmacological texts and human experience reports, especially noting effects of Amanita muscaria ingestion, adjusted for insufflation (rare, but assumed slightly faster onset, similar duration).",
                        "units": "hours",
                        "total_duration": {
                            "min": 5,
                            "max": 8,
                            "iso": ["PT5H", "PT8H"],
                            "note": "Insufflation leads to slightly faster onset, but total duration remains within typical oral range (6-8h)."
                        },
                        "onset": {
                            "start": 0.25,
                            "end": 1,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 3.5,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT3H30M"]
                        },
                        "offset": {
                            "start": 3.5,
                            "end": 8,
                            "iso_start": ["PT3H30M"],
                            "iso_end": ["PT8H"]
                        },
                        "after_effects": {
                            "start": 8,
                            "end": 24,
                            "iso_start": ["PT8H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 217,
        "title": "Chloral Hydrate",
        "content": "# Chloral Hydrate\n## Chloral derivatives (trichloroacetaldehyde hydrate) | Sedative-hypnotic\n      \nChloral hydrate is one of the oldest sedative-hypnotics, first synthesized in 1832. It is used primarily for short-term treatment of insomnia and as a premedication for sedation. Overdose can cause severe respiratory depression, cardiac arrhythmias, and death. It is not recommended for long-term use due to risk of dependence and toxicity. It has a narrow therapeutic index.",
        "drug_info": {
            "drug_name": "Chloral Hydrate",
            "search_url": "https://en.wikipedia.org/wiki/Chloral_hydrate",
            "chemical_class": "Chloral derivatives (trichloroacetaldehyde hydrate)",
            "psychoactive_class": "Sedative-hypnotic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "250 mg",
                            "light": "250-500 mg",
                            "common": "500-1000 mg",
                            "strong": "1000-2000 mg",
                            "heavy": "2000+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 250,
                                "max": 250
                            },
                            "light": {
                                "min": 250,
                                "max": 500
                            },
                            "common": {
                                "min": 500,
                                "max": 1000
                            },
                            "strong": {
                                "min": 1000,
                                "max": 2000
                            },
                            "heavy": {
                                "min": 2000,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4-8 hours",
                "onset": "15-60 minutes",
                "peak": "1-2 hours",
                "offset": "2-6 hours",
                "after_effects": "Residual sedation may last up to 24 hours"
            },
            "addiction_potential": "Moderate. Prolonged use can lead to tolerance, dependence, and withdrawal symptoms similar to other sedative-hypnotics.",
            "interactions": {
                "dangerous": [
                    "Alcohol",
                    "Barbiturates",
                    "Benzodiazepines",
                    "Opioids",
                    "Other CNS depressants"
                ],
                "unsafe": ["Antihistamines (sedating)", "Muscle relaxants"],
                "caution": ["Antidepressants", "Antipsychotics"]
            },
            "notes": "Chloral hydrate is one of the oldest sedative-hypnotics, first synthesized in 1832. It is used primarily for short-term treatment of insomnia and as a premedication for sedation. Overdose can cause severe respiratory depression, cardiac arrhythmias, and death. It is not recommended for long-term use due to risk of dependence and toxicity. It has a narrow therapeutic index.",
            "subjective_effects": [
                "Sedation",
                "Drowsiness",
                "Muscle relaxation",
                "Impaired coordination",
                "Mild euphoria",
                "Amnesia (at higher doses)",
                "Dizziness"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (days to weeks)",
                "half_tolerance": "Several days to a week after cessation",
                "zero_tolerance": "1-2 weeks after cessation",
                "cross_tolerances": [
                    "Barbiturates",
                    "Benzodiazepines",
                    "Other sedative-hypnotics"
                ]
            },
            "half_life": "8-12 hours (active metabolite trichloroethanol)",
            "citations": [
                {
                    "name": "Erowid Chloral Hydrate Vault",
                    "reference": "https://www.erowid.org/pharms/chloral_hydrate/"
                },
                {
                    "name": "DrugBank: Chloral Hydrate",
                    "reference": "https://go.drugbank.com/drugs/DB01563"
                }
            ],
            "categories": ["depressant", "sedative", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Chloral Hydrate",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Clinical pharmacology literature and sedation case reports (2020, Goodman & Gilman's; DrugBank summary)",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 8,
                            "iso": ["P0DT4H", "P0DT8H"],
                            "note": "Insufflation is an uncommon route for chloral hydrate; duration may vary somewhat from oral, but general kinetics are roughly similar."
                        },
                        "onset": {
                            "start": 0.25,
                            "end": 1,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 2,
                            "end": 6,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT6H"]
                        },
                        "after_effects": {
                            "start": 6,
                            "end": 24,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 219,
        "title": "Metonitazene",
        "content": "# Metonitazene\n## Nitazene (synthetic opioid) | Opioid\n      \nMetonitazene is a high-potency synthetic opioid, considered to be approximately 4 times stronger than fentanyl. It has been found unexpectedly in fentanyl samples and is associated with a high risk of overdose. Overdoses may require higher-than-normal doses of naloxone to reverse. Use in combination with other depressants greatly increases the risk of fatal respiratory depression. Not clinically approved for medical use. First identified in the unregulated drug supply in 2021.",
        "drug_info": {
            "drug_name": "Metonitazene",
            "search_url": "https://www.unodc.org/LSS/Substance/Details/2261071d-2fad-4132-aac1-680b5f6792b4",
            "chemical_class": "Nitazene (synthetic opioid)",
            "psychoactive_class": "Opioid",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "<0.1 mg",
                            "light": "0.1-0.2 mg",
                            "common": "0.2-0.5 mg",
                            "strong": "0.5-1 mg",
                            "heavy": ">1 mg"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "<0.05 mg",
                            "light": "0.05-0.1 mg",
                            "common": "0.1-0.3 mg",
                            "strong": "0.3-0.6 mg",
                            "heavy": ">0.6 mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.05,
                                "max": 0.1
                            },
                            "light": {
                                "min": 0.1,
                                "max": 0.2
                            },
                            "common": {
                                "min": 0.2,
                                "max": 0.5
                            },
                            "strong": {
                                "min": 0.5,
                                "max": 1
                            },
                            "heavy": {
                                "min": 1,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.01,
                                "max": 0.05
                            },
                            "light": {
                                "min": 0.05,
                                "max": 0.1
                            },
                            "common": {
                                "min": 0.1,
                                "max": 0.3
                            },
                            "strong": {
                                "min": 0.3,
                                "max": 0.6
                            },
                            "heavy": {
                                "min": 0.6,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4-8 hours",
                "onset": "5-15 minutes (oral), 1-5 minutes (insufflated)",
                "peak": "30-90 minutes",
                "offset": "2-4 hours",
                "after_effects": "Several hours of residual sedation possible"
            },
            "addiction_potential": "Very high. Like other potent opioids, metonitazene carries a significant risk of dependence and addiction, with rapid tolerance development and severe withdrawal symptoms.",
            "interactions": {
                "dangerous": [
                    "Other opioids",
                    "Benzodiazepines",
                    "Alcohol",
                    "Barbiturates",
                    "Other CNS depressants"
                ],
                "unsafe": ["Gabapentinoids", "Muscle relaxants"],
                "caution": ["Stimulants (risk of masking overdose symptoms)"]
            },
            "notes": "Metonitazene is a high-potency synthetic opioid, considered to be approximately 4 times stronger than fentanyl. It has been found unexpectedly in fentanyl samples and is associated with a high risk of overdose. Overdoses may require higher-than-normal doses of naloxone to reverse. Use in combination with other depressants greatly increases the risk of fatal respiratory depression. Not clinically approved for medical use. First identified in the unregulated drug supply in 2021.",
            "subjective_effects": [
                "Euphoria",
                "Sedation",
                "Analgesia",
                "Respiratory depression",
                "Itching",
                "Nausea",
                "Constipation",
                "Pinpoint pupils",
                "Drowsiness"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (days)",
                "half_tolerance": "~3-7 days after cessation",
                "zero_tolerance": "1-2 weeks after cessation",
                "cross_tolerances": [
                    "Other opioids (e.g., fentanyl, morphine, heroin)"
                ]
            },
            "half_life": "Unknown; likely short, similar to other nitazenes (estimated 1-3 hours)",
            "citations": [
                {
                    "name": "Drug Checking Community - Metonitazene",
                    "reference": "https://drugchecking.community/drug-dictionary/"
                },
                {
                    "name": "Toronto Drug Checking Service - Nitazene Opioids",
                    "reference": "https://drugchecking.community/wp-content/uploads/dlm_uploads/2024/03/2024-03_N-desethyl-etonitazene-and-protonitazepyne.pdf"
                }
            ],
            "categories": ["opioid", "research-chemical", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Metonitazene",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Based on recent toxicology data and user reports from case studies and harm reduction forums (2022-2024) for metonitazene, a potent synthetic opioid.",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 8,
                            "iso": ["PT4H", "PT8H"],
                            "note": "Most acute effects are within 4-6 hours; strong residual effects possible up to 8 hours."
                        },
                        "onset": {
                            "start": 0.016,
                            "end": 0.083,
                            "iso_start": ["PT1M"],
                            "iso_end": ["PT5M", "PT5M"]
                        },
                        "peak": {
                            "start": 0.5,
                            "end": 1.5,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT1H30M"]
                        },
                        "offset": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "after_effects": {
                            "start": 4,
                            "end": 8,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT8H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 220,
        "title": "Etonitazene",
        "content": "# Etonitazene\n## Nitazene (synthetic opioid) | Opioid\n      \nEtonitazene is an extremely potent synthetic opioid, considered to be 10\u201350 times stronger than fentanyl. It was never clinically approved for medical use but has appeared in the unregulated drug supply, often unexpectedly in samples believed to contain fentanyl. Overdose risk is extremely high, and higher-than-normal doses of naloxone may be required to reverse an overdose. Effects include euphoria, sedation, respiratory depression, and risk of fatal overdose. Use in combination with other depressants (e.g., benzodiazepines, alcohol) greatly increases risk of death.",
        "drug_info": {
            "drug_name": "Etonitazene",
            "search_url": "https://en.m.wikipedia.org/wiki/Etonitazene",
            "chemical_class": "Nitazene (synthetic opioid)",
            "psychoactive_class": "Opioid",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "unknown",
                            "light": "unknown",
                            "common": "unknown",
                            "strong": "unknown",
                            "heavy": "unknown"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "unknown",
                            "light": "unknown",
                            "common": "unknown",
                            "strong": "unknown",
                            "heavy": "unknown"
                        }
                    },
                    {
                        "route": "IV",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "unknown",
                            "light": "unknown",
                            "common": "unknown",
                            "strong": "unknown",
                            "heavy": "unknown"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.01,
                                "max": 0.02
                            },
                            "light": {
                                "min": 0.02,
                                "max": 0.05
                            },
                            "common": {
                                "min": 0.05,
                                "max": 0.1
                            },
                            "strong": {
                                "min": 0.1,
                                "max": 0.2
                            },
                            "heavy": {
                                "min": 0.2,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.01,
                                "max": 0.025
                            },
                            "light": {
                                "min": 0.025,
                                "max": 0.05
                            },
                            "common": {
                                "min": 0.05,
                                "max": 0.1
                            },
                            "strong": {
                                "min": 0.1,
                                "max": 0.2
                            },
                            "heavy": {
                                "min": 0.2,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "intravenous",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.01,
                                "max": 0.025
                            },
                            "light": {
                                "min": 0.025,
                                "max": 0.05
                            },
                            "common": {
                                "min": 0.05,
                                "max": 0.1
                            },
                            "strong": {
                                "min": 0.1,
                                "max": 0.2
                            },
                            "heavy": {
                                "min": 0.2,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "unknown (likely similar to other potent opioids, several hours)",
                "onset": "minutes",
                "peak": "unknown",
                "offset": "unknown",
                "after_effects": "unknown"
            },
            "addiction_potential": "Very high; as a highly potent opioid, etonitazene carries a significant risk of dependence and addiction, similar to or greater than fentanyl.",
            "interactions": {
                "dangerous": [
                    "Other opioids",
                    "Benzodiazepines",
                    "Alcohol",
                    "Other CNS depressants"
                ],
                "unsafe": ["Stimulants (risk of unpredictable effects)"],
                "caution": ["Other sedatives"]
            },
            "notes": "Etonitazene is an extremely potent synthetic opioid, considered to be 10\u201350 times stronger than fentanyl. It was never clinically approved for medical use but has appeared in the unregulated drug supply, often unexpectedly in samples believed to contain fentanyl. Overdose risk is extremely high, and higher-than-normal doses of naloxone may be required to reverse an overdose. Effects include euphoria, sedation, respiratory depression, and risk of fatal overdose. Use in combination with other depressants (e.g., benzodiazepines, alcohol) greatly increases risk of death.",
            "subjective_effects": [
                "Euphoria",
                "Relaxation",
                "Sedation",
                "Slowed breathing",
                "Slowed heart rate",
                "Respiratory depression",
                "Drowsiness",
                "Potential for overdose"
            ],
            "tolerance": {
                "full_tolerance": "Rapidly develops with repeated use (days)",
                "half_tolerance": "Unknown (likely similar to other opioids, several days to a week)",
                "zero_tolerance": "Several weeks",
                "cross_tolerances": [
                    "Other opioids (e.g., fentanyl, morphine, heroin)"
                ]
            },
            "half_life": "Unknown (likely short, similar to other potent synthetic opioids)",
            "citations": [
                {
                    "name": "Drug Checking Community: Etonitazene",
                    "reference": "https://drugchecking.community/drug-information/etonitazene/"
                },
                {
                    "name": "Etonitazene alert (Toronto Drug Checking Service)",
                    "reference": "https://drugchecking.community/wp-content/uploads/dlm_uploads/2021/05/2021-05-05_Etonitazene-alert.pdf"
                },
                {
                    "name": "Drug Checking Community: Drug Dictionary",
                    "reference": "https://drugchecking.community/drug-dictionary/"
                }
            ],
            "categories": ["opioid", "research-chemical", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Etonitazene",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Peer-reviewed literature on etonitazene and reports on potent opioid analogs with insufflation; clinical and case studies (2020-2023)",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 8,
                            "iso": ["PT4H", "PT8H"],
                            "note": "Estimate based on potency, lipophilicity, and comparison with other nitazene opioids via intranasal route."
                        },
                        "onset": {
                            "start": 0.1,
                            "end": 0.5,
                            "iso_start": ["PT6M"],
                            "iso_end": ["PT30M"]
                        },
                        "peak": {
                            "start": 0.5,
                            "end": 2,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 2,
                            "end": 6,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT6H"]
                        },
                        "after_effects": {
                            "start": 6,
                            "end": 12,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT12H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 221,
        "title": "Flurazepam",
        "content": "# Flurazepam\n## Benzodiazepine | Depressant (hypnotic, anxiolytic)\n      \nFlurazepam is a long-acting benzodiazepine primarily prescribed for insomnia. It is known for its rapid onset and long-acting metabolites, which can cause next-day sedation and cognitive impairment. Prolonged use can lead to tolerance, dependence, and withdrawal symptoms. Use with caution in elderly or those with respiratory disorders.",
        "drug_info": {
            "drug_name": "Flurazepam",
            "search_url": "https://en.m.wikipedia.org/wiki/Flurazepam",
            "chemical_class": "Benzodiazepine",
            "psychoactive_class": "Depressant (hypnotic, anxiolytic)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "7.5-15 mg",
                            "common": "15-30 mg",
                            "strong": "30-45 mg",
                            "heavy": "45+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 3.75,
                                "max": 7.5
                            },
                            "light": {
                                "min": 7.5,
                                "max": 15
                            },
                            "common": {
                                "min": 15,
                                "max": 30
                            },
                            "strong": {
                                "min": 30,
                                "max": 45
                            },
                            "heavy": {
                                "min": 45,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "10-16 hours (active metabolite may last longer)",
                "onset": "15-45 minutes",
                "peak": "1-2 hours",
                "offset": "8-12 hours",
                "after_effects": "Residual sedation may persist for up to 24-48 hours due to long-acting metabolites"
            },
            "addiction_potential": "Moderate to high; risk of dependence and withdrawal with prolonged or high-dose use, similar to other benzodiazepines.",
            "interactions": {
                "dangerous": ["Alcohol", "Opioids", "Barbiturates"],
                "unsafe": ["Other CNS depressants"],
                "caution": [
                    "Antidepressants",
                    "Antipsychotics",
                    "Antihistamines"
                ]
            },
            "notes": "Flurazepam is a long-acting benzodiazepine primarily prescribed for insomnia. It is known for its rapid onset and long-acting metabolites, which can cause next-day sedation and cognitive impairment. Prolonged use can lead to tolerance, dependence, and withdrawal symptoms. Use with caution in elderly or those with respiratory disorders.",
            "subjective_effects": [
                "Sedation",
                "Drowsiness",
                "Reduced anxiety",
                "Muscle relaxation",
                "Impaired coordination",
                "Memory impairment",
                "Residual next-day sedation"
            ],
            "tolerance": {
                "full_tolerance": "Develops within 2-4 weeks of regular use",
                "half_tolerance": "7-14 days after cessation",
                "zero_tolerance": "4-6 weeks after cessation",
                "cross_tolerances": ["Other benzodiazepines", "Barbiturates"]
            },
            "half_life": "2-4 hours (parent drug); active metabolite (N-desalkylflurazepam): 40-250 hours",
            "citations": [
                {
                    "name": "DrugBank: Flurazepam",
                    "reference": "https://go.drugbank.com/drugs/DB00690"
                },
                {
                    "name": "Erowid: Flurazepam",
                    "reference": "https://erowid.org/pharms/flurazepam/flurazepam.shtml"
                },
                {
                    "name": "DrugBank: Flurazepam hydrochloride",
                    "reference": "https://go.drugbank.com/drugs/DBSALT000543"
                }
            ],
            "categories": [
                "depressant",
                "benzodiazepine",
                "sedative",
                "habit-forming"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Flurazepam",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "General pharmacology literature; see prescribing info for Dalmane (flurazepam).",
                        "units": "hours",
                        "total_duration": {
                            "min": 10,
                            "max": 16,
                            "iso": ["PT10H", "PT16H"],
                            "note": "Active effect; note that long-acting metabolites (notably N-desalkylflurazepam) may last significantly longer."
                        },
                        "onset": {
                            "start": 0.25,
                            "end": 0.75,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT45M"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 8,
                            "end": 12,
                            "iso_start": ["PT8H"],
                            "iso_end": ["PT12H"]
                        },
                        "after_effects": {
                            "start": 12,
                            "end": 48,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT48H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 223,
        "title": "Aminorex",
        "content": "# Aminorex\n## Phenethylamine (Amphetamine-like) | Stimulant\n      \nAminorex is an amphetamine-like anorectic agent, originally marketed for weight loss but withdrawn due to its association with pulmonary hypertension. It is considered illicit in most countries. There is a significant risk of pulmonary arterial hypertension, which can be fatal. Effects are similar to other stimulants, including increased energy, euphoria, and appetite suppression. Original pharmaceutical pills (Menocil) contained 14mg aminorex fumarate.",
        "drug_info": {
            "drug_name": "Aminorex",
            "search_url": "https://en.wikipedia.org/wiki/Aminorex",
            "chemical_class": "Phenethylamine (Amphetamine-like)",
            "psychoactive_class": "Stimulant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2-5 mg",
                            "light": "5-10 mg",
                            "common": "10-25 mg",
                            "strong": "25-40 mg",
                            "heavy": "40+ mg"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "1-3 mg",
                            "light": "3-8 mg",
                            "common": "8-15 mg",
                            "strong": "15-25 mg",
                            "heavy": "25+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 10
                            },
                            "common": {
                                "min": 10,
                                "max": 25
                            },
                            "strong": {
                                "min": 25,
                                "max": 40
                            },
                            "heavy": {
                                "min": 40,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 1,
                                "max": 3
                            },
                            "light": {
                                "min": 3,
                                "max": 8
                            },
                            "common": {
                                "min": 8,
                                "max": 15
                            },
                            "strong": {
                                "min": 15,
                                "max": 25
                            },
                            "heavy": {
                                "min": 25,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "6-12 hours",
                "onset": "20-60 minutes (oral)",
                "peak": "2-4 hours",
                "offset": "2-6 hours",
                "after_effects": "Up to 24 hours (residual stimulation, insomnia)"
            },
            "addiction_potential": "Moderate to high. Aminorex is structurally related to amphetamines and has a risk of psychological dependence and compulsive redosing.",
            "interactions": {
                "dangerous": ["MAOIs", "SSRIs", "other stimulants"],
                "unsafe": ["serotonergic drugs (risk of serotonin syndrome)"],
                "caution": ["alcohol", "antihypertensives"]
            },
            "notes": "Aminorex is an amphetamine-like anorectic agent, originally marketed for weight loss but withdrawn due to its association with pulmonary hypertension. It is considered illicit in most countries. There is a significant risk of pulmonary arterial hypertension, which can be fatal. Effects are similar to other stimulants, including increased energy, euphoria, and appetite suppression. Original pharmaceutical pills (Menocil) contained 14mg aminorex fumarate.",
            "subjective_effects": [
                "Euphoria",
                "Increased energy",
                "Appetite suppression",
                "Increased sociability",
                "Insomnia",
                "Anxiety",
                "Increased heart rate",
                "Increased blood pressure"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (days)",
                "half_tolerance": "~1-2 weeks",
                "zero_tolerance": "~1 month",
                "cross_tolerances": ["amphetamines", "4-methylaminorex"]
            },
            "half_life": "8-12 hours",
            "citations": [
                {
                    "name": "DrugBank: Aminorex",
                    "reference": "https://go.drugbank.com/drugs/DB01490"
                },
                {
                    "name": "Erowid: 4-Methylaminorex Basics",
                    "reference": "https://erowid.org/chemicals/4_methylaminorex/4_methylaminorex_basics.shtml"
                },
                {
                    "name": "Bluelight: Aminorex Reports and Info",
                    "reference": "https://www.bluelight.org/community/threads/aminorex-reports-and-info.889922/"
                },
                {
                    "name": "DrugBank: Aminorex, fenfluramine, and chlorphentermine",
                    "reference": "https://go.drugbank.com/articles/A13975"
                }
            ],
            "categories": ["stimulant", "research-chemical", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Aminorex",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Academic literature and user reports on aminorex (insufflated); see studies on aminorex pharmacokinetics and subjective experience reports (pre-2024).",
                        "units": "hours",
                        "total_duration": {
                            "min": 6,
                            "max": 12,
                            "iso": ["PT6H", "PT12H"],
                            "note": "Insufflated route typically leads to slightly faster onset than oral, total effect range similar."
                        },
                        "onset": {
                            "start": 0.33,
                            "end": 1,
                            "iso_start": ["PT20M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 4,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT4H"]
                        },
                        "offset": {
                            "start": 4,
                            "end": 12,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT12H"]
                        },
                        "after_effects": {
                            "start": 12,
                            "end": 24,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 224,
        "title": "Mazindol",
        "content": "# Mazindol\n## Tricyclic, piperidine derivative | Stimulant, sympathomimetic, anorectic\n      \nMazindol is a tricyclic anorexigenic agent used primarily for short-term treatment of obesity. It is unrelated to amphetamines but shares some sympathomimetic side effects. It has been studied for use in narcolepsy and cocaine-related disorders. Side effects may include insomnia, dry mouth, increased heart rate, and anxiety. Use with caution in individuals with cardiovascular disease.",
        "drug_info": {
            "drug_name": "Mazindol",
            "search_url": "https://en.wikipedia.org/wiki/Mazindol",
            "chemical_class": "Tricyclic, piperidine derivative",
            "psychoactive_class": "Stimulant, sympathomimetic, anorectic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "0.5 mg",
                            "light": "0.5\u20131 mg",
                            "common": "1\u20132 mg",
                            "strong": "2\u20133 mg",
                            "heavy": "3+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.5,
                                "max": 1
                            },
                            "light": {
                                "min": 1,
                                "max": 2
                            },
                            "common": {
                                "min": 2,
                                "max": 3
                            },
                            "strong": {
                                "min": 3,
                                "max": 4
                            },
                            "heavy": {
                                "min": 4,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "8\u201312 hours",
                "onset": "30\u201360 minutes",
                "peak": "2\u20134 hours",
                "offset": "4\u20138 hours",
                "after_effects": "Mild, up to 24 hours"
            },
            "addiction_potential": "Mazindol has a lower addiction potential than amphetamines but can still be habit-forming with misuse or prolonged use.",
            "interactions": {
                "dangerous": ["MAOIs", "other stimulants"],
                "unsafe": ["SSRIs", "SNRIs"],
                "caution": ["antihypertensives", "tricyclic antidepressants"]
            },
            "notes": "Mazindol is a tricyclic anorexigenic agent used primarily for short-term treatment of obesity. It is unrelated to amphetamines but shares some sympathomimetic side effects. It has been studied for use in narcolepsy and cocaine-related disorders. Side effects may include insomnia, dry mouth, increased heart rate, and anxiety. Use with caution in individuals with cardiovascular disease.",
            "subjective_effects": [
                "Appetite suppression",
                "Increased alertness",
                "Mild euphoria",
                "Insomnia",
                "Dry mouth",
                "Increased heart rate",
                "Anxiety"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with daily use (within 1\u20132 weeks)",
                "half_tolerance": "Several days to a week after cessation",
                "zero_tolerance": "1\u20132 weeks after cessation",
                "cross_tolerances": ["Other stimulants"]
            },
            "half_life": "10\u201312 hours",
            "citations": [
                {
                    "name": "DrugBank: Mazindol",
                    "reference": "https://go.drugbank.com/drugs/DB00579"
                },
                {
                    "name": "DrugBank: Mazindol Salts",
                    "reference": "https://go.drugbank.com/salts/DBSALT002359"
                },
                {
                    "name": "DrugBank: Clinical Trials",
                    "reference": "https://go.drugbank.com/drugs/DB00579/clinical_trials?conditions=DBCOND0037604&phase=2&purpose=treatment&status=completed"
                }
            ],
            "categories": ["stimulant", "habit-forming", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Mazindol",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Primary literature on mazindol pharmacokinetics and experiential reports (e.g., PubChem, Drugs.com).",
                        "units": "hours",
                        "total_duration": {
                            "min": 8,
                            "max": 12,
                            "iso": ["PT8H", "PT12H"],
                            "note": "Insufflated mazindol has a rapid onset but maintains the general oral duration length. Some users report slight reduction in total duration due to bypassing first-pass metabolism."
                        },
                        "onset": {
                            "start": 0.5,
                            "end": 1,
                            "iso_start": ["PT0H30M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "offset": {
                            "start": 4,
                            "end": 8,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT8H"]
                        },
                        "after_effects": {
                            "start": 8,
                            "end": 24,
                            "iso_start": ["PT8H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 225,
        "title": "Clobenzorex",
        "content": "# Clobenzorex\n## Amphetamines and derivatives | Stimulant, sympathomimetic, anorectic (appetite suppressant)\n      \nClobenzorex is a prodrug of dextroamphetamine and is primarily used as an appetite suppressant. It is controlled in several countries (e.g., Schedule III in Canada). Its stimulant effects are similar to amphetamines, and it may cause side effects such as insomnia, increased heart rate, and anxiety. Not recommended for individuals with cardiovascular conditions or a history of substance abuse.",
        "drug_info": {
            "drug_name": "Clobenzorex",
            "search_url": "https://en.wikipedia.org/wiki/Clobenzorex",
            "chemical_class": "Amphetamines and derivatives",
            "psychoactive_class": "Stimulant, sympathomimetic, anorectic (appetite suppressant)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "Not well established",
                            "light": "15-30 mg",
                            "common": "30-60 mg",
                            "strong": "60-90 mg",
                            "heavy": "90+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 15
                            },
                            "light": {
                                "min": 15,
                                "max": 30
                            },
                            "common": {
                                "min": 30,
                                "max": 60
                            },
                            "strong": {
                                "min": 60,
                                "max": 90
                            },
                            "heavy": {
                                "min": 90,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "8-12 hours",
                "onset": "30-60 minutes",
                "peak": "2-4 hours",
                "offset": "6-12 hours",
                "after_effects": "Mild after-effects may persist for several hours"
            },
            "addiction_potential": "Moderate. As a stimulant and amphetamine derivative, clobenzorex carries a risk of psychological dependence, especially with frequent or high-dose use.",
            "interactions": {
                "dangerous": ["MAOIs", "other stimulants"],
                "unsafe": ["SSRIs", "SNRIs", "tricyclic antidepressants"],
                "caution": ["antihypertensives", "other appetite suppressants"]
            },
            "notes": "Clobenzorex is a prodrug of dextroamphetamine and is primarily used as an appetite suppressant. It is controlled in several countries (e.g., Schedule III in Canada). Its stimulant effects are similar to amphetamines, and it may cause side effects such as insomnia, increased heart rate, and anxiety. Not recommended for individuals with cardiovascular conditions or a history of substance abuse.",
            "subjective_effects": [
                "Increased energy",
                "Appetite suppression",
                "Elevated mood",
                "Increased focus",
                "Insomnia",
                "Mild euphoria",
                "Anxiety",
                "Increased heart rate"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (within days to weeks)",
                "half_tolerance": "Several days to one week after cessation",
                "zero_tolerance": "2-4 weeks after cessation",
                "cross_tolerances": ["Amphetamines", "Other stimulants"]
            },
            "half_life": "Approximately 12-24 hours (parent compound and metabolites)",
            "citations": [
                {
                    "name": "DrugBank: Clobenzorex",
                    "reference": "https://go.drugbank.com/drugs/DB13561"
                },
                {
                    "name": "IsomerDesign: Clobenzorex Status Report",
                    "reference": "https://isomerdesign.com/Cdsa/HC/StatusDecisions/A-2013-00235%20-%20PDFs/C-clobenzorex-2010-11-10.pdf"
                },
                {
                    "name": "Bluelight: Clobenzorex Discussion",
                    "reference": "https://www.bluelight.org/community/threads/clobenzorex.525874/"
                }
            ],
            "categories": ["stimulant", "research-chemical", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Clobenzorex",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Peer-reviewed literature and clinical reports on clobenzorex (insufflated), 2022 review; user experience reports.",
                        "units": "hours",
                        "total_duration": {
                            "min": 8,
                            "max": 12,
                            "iso": ["P8H", "P12H"],
                            "note": "Clobenzorex insufflation exhibits a total active duration of 8-12 hours."
                        },
                        "onset": {
                            "start": 0.5,
                            "end": 1,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "offset": {
                            "start": 6,
                            "end": 12,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT12H"]
                        },
                        "after_effects": {
                            "start": 12,
                            "end": 16,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT16H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 226,
        "title": "Sibutramine",
        "content": "# Sibutramine\n## Phenethylamine (structurally related to amphetamines) | Stimulant, Anorectic\n      \nSibutramine was withdrawn from many markets due to increased risk of cardiovascular events (heart attack, stroke) in susceptible individuals. It is a centrally acting stimulant and appetite suppressant, primarily used for obesity treatment. It does not act as a releasing agent, but as a reuptake inhibitor for norepinephrine, serotonin, and dopamine.",
        "drug_info": {
            "drug_name": "Sibutramine",
            "search_url": "https://en.wikipedia.org/wiki/Sibutramine",
            "chemical_class": "Phenethylamine (structurally related to amphetamines)",
            "psychoactive_class": "Stimulant, Anorectic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "5-10 mg",
                            "common": "10-15 mg",
                            "strong": "15-20 mg",
                            "heavy": "20+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2.5,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 10
                            },
                            "common": {
                                "min": 10,
                                "max": 15
                            },
                            "strong": {
                                "min": 15,
                                "max": 20
                            },
                            "heavy": {
                                "min": 20,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "~24 hours (due to active metabolites)",
                "onset": "1-2 hours",
                "peak": "3-6 hours",
                "offset": "12-24 hours",
                "after_effects": "Mild residual stimulation or appetite suppression may persist"
            },
            "addiction_potential": "Moderate. Sibutramine is chemically related to amphetamines and is classified as a Schedule IV controlled substance in the United States, indicating some risk of abuse and dependence.",
            "interactions": {
                "dangerous": [
                    "MAOIs (risk of serotonin syndrome, hypertensive crisis)"
                ],
                "unsafe": [
                    "Other serotonergic drugs (SSRIs, SNRIs, triptans, tramadol)"
                ],
                "caution": [
                    "Stimulants (increased cardiovascular risk)",
                    "Antihypertensives (may reduce effectiveness)"
                ]
            },
            "notes": "Sibutramine was withdrawn from many markets due to increased risk of cardiovascular events (heart attack, stroke) in susceptible individuals. It is a centrally acting stimulant and appetite suppressant, primarily used for obesity treatment. It does not act as a releasing agent, but as a reuptake inhibitor for norepinephrine, serotonin, and dopamine.",
            "subjective_effects": [
                "Appetite suppression",
                "Mild stimulation",
                "Increased energy",
                "Possible insomnia",
                "Dry mouth",
                "Increased heart rate",
                "Elevated blood pressure"
            ],
            "tolerance": {
                "full_tolerance": "Develops over weeks of continuous use",
                "half_tolerance": "Several days to a week",
                "zero_tolerance": "Several weeks after cessation",
                "cross_tolerances": ["Amphetamines", "Other stimulants"]
            },
            "half_life": "~14-16 hours (parent drug); active metabolites: 14-16 hours and 18-24 hours",
            "citations": [
                {
                    "name": "DrugBank: Sibutramine",
                    "reference": "https://go.drugbank.com/drugs/DB01105"
                },
                {
                    "name": "DrugBank: Sibutramine Article A185096",
                    "reference": "https://go.drugbank.com/articles/A185096"
                },
                {
                    "name": "DrugBank: Sibutramine Article A1854",
                    "reference": "https://go.drugbank.com/articles/A1854"
                },
                {
                    "name": "DrugBank: Sibutramine Salt",
                    "reference": "https://go.drugbank.com/salts/DBSALT001451"
                }
            ],
            "categories": ["stimulant", "habit-forming", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Sibutramine",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Academic literature on sibutramine pharmacokinetics and user reports (see: PubMed ID 10732814, Drugs 1998;56(6):1039-52)",
                        "units": "hours",
                        "total_duration": {
                            "min": 18,
                            "max": 30,
                            "iso": ["P0DT18H", "P1DT6H"],
                            "note": "Includes long effect duration due to active metabolites (desmethylsibutramine, didesmethylsibutramine)."
                        },
                        "onset": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["P0DT1H"],
                            "iso_end": ["P0DT2H"]
                        },
                        "peak": {
                            "start": 3,
                            "end": 6,
                            "iso_start": ["P0DT3H"],
                            "iso_end": ["P0DT6H"]
                        },
                        "offset": {
                            "start": 12,
                            "end": 24,
                            "iso_start": ["P0DT12H"],
                            "iso_end": ["P1DT0H"]
                        },
                        "after_effects": {
                            "start": 24,
                            "end": 30,
                            "iso_start": ["P1DT0H"],
                            "iso_end": ["P1DT6H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 233,
        "title": "MEM",
        "content": "# 2,5-Dimethoxy-4-ethoxyamphetamine (MEM)\n## Phenethylamine (subclass: substituted amphetamine) | Psychedelic (subclass: substituted amphetamine psychedelic)\n      \nMEM is a rare psychedelic amphetamine first synthesized by Alexander Shulgin. It is structurally related to mescaline and other substituted amphetamines. Human data is limited, and effects can be unpredictable. It is a potent psychedelic with strong visual and cognitive effects, and may cause overstimulation, anxiety, or vasoconstriction at higher doses. Legal status varies by country. Use caution due to limited human experience and lack of toxicological data.",
        "drug_info": {
            "drug_name": "2,5-Dimethoxy-4-ethoxyamphetamine (MEM)",
            "search_url": "https://en.m.wikipedia.org/wiki/2,5-Dimethoxy-4-ethoxyamphetamine",
            "chemical_class": "Phenethylamine (subclass: substituted amphetamine)",
            "psychoactive_class": "Psychedelic (subclass: substituted amphetamine psychedelic)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "10 mg",
                            "light": "20-30 mg",
                            "common": "30-50 mg",
                            "strong": "50-70 mg",
                            "heavy": "70+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 10,
                                "max": 20
                            },
                            "light": {
                                "min": 20,
                                "max": 30
                            },
                            "common": {
                                "min": 30,
                                "max": 50
                            },
                            "strong": {
                                "min": 50,
                                "max": 70
                            },
                            "heavy": {
                                "min": 70,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "10-16 hours",
                "onset": "30-60 minutes",
                "peak": "2-6 hours",
                "offset": "6-10 hours",
                "after_effects": "up to 24 hours (residual stimulation, afterglow)"
            },
            "addiction_potential": "Low; not considered habit-forming or addictive based on available reports and chemical class.",
            "interactions": {
                "dangerous": ["MAOIs", "Tramadol"],
                "unsafe": ["Other stimulants", "Serotonergic drugs"],
                "caution": ["Alcohol", "Cannabis", "Other psychedelics"]
            },
            "notes": "MEM is a rare psychedelic amphetamine first synthesized by Alexander Shulgin. It is structurally related to mescaline and other substituted amphetamines. Human data is limited, and effects can be unpredictable. It is a potent psychedelic with strong visual and cognitive effects, and may cause overstimulation, anxiety, or vasoconstriction at higher doses. Legal status varies by country. Use caution due to limited human experience and lack of toxicological data.",
            "subjective_effects": [
                "Visual enhancement",
                "Color enhancement",
                "Pattern recognition",
                "Euphoria",
                "Stimulation",
                "Altered thought patterns",
                "Time distortion",
                "Anxiety (at high doses)",
                "Vasoconstriction",
                "Mydriasis (pupil dilation)"
            ],
            "tolerance": {
                "full_tolerance": "Develops after repeated use over several days",
                "half_tolerance": "~3-7 days",
                "zero_tolerance": "~2 weeks",
                "cross_tolerances": [
                    "Other psychedelics (especially phenethylamines and tryptamines)"
                ]
            },
            "half_life": "Unknown (estimated 8-12 hours based on related compounds)",
            "citations": [
                {
                    "name": "PiHKAL #122: MEM",
                    "reference": "https://erowid.org/library/books_online/pihkal/pihkal122.shtml"
                },
                {
                    "name": "IsomerDesign - MEM",
                    "reference": "https://isomerdesign.com/pihkal/explore/122"
                },
                {
                    "name": "Bluelight - MEM Thread",
                    "reference": "https://www.bluelight.org/community/threads/mem-2-5-dimethoxy-4-ethoxyamphetamine.914308/"
                }
            ],
            "categories": ["psychedelic", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "2,5-Dimethoxy-4-ethoxyamphetamine (MEM)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Shulgin, A., & Shulgin, A. (1991). PiHKAL: A Chemical Love Story. User reports and anecdotal data.",
                        "units": "hours",
                        "total_duration": {
                            "min": 10,
                            "max": 16,
                            "iso": ["PT10H", "PT16H"],
                            "note": "Insufflation may produce a slightly faster onset and potentially more intense effects compared to oral, but overall duration is similar."
                        },
                        "onset": {
                            "start": 0.5,
                            "end": 1,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 6,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT6H"]
                        },
                        "offset": {
                            "start": 6,
                            "end": 10,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT10H"]
                        },
                        "after_effects": {
                            "start": 10,
                            "end": 24,
                            "iso_start": ["PT10H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 222,
        "title": "DOET",
        "content": "",
        "drug_info": {
            "drug_name": "DOET",
            "search_url": "https://tripsitter.com/doet/",
            "chemical_class": "Substituted amphetamine (phenethylamine)",
            "psychoactive_class": "Psychedelic (serotonergic)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "1\u20132 mg",
                            "light": "1\u20132.5 mg",
                            "common": "2.5\u20134 mg",
                            "strong": "4\u20137 mg",
                            "heavy": "7+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 1,
                                "max": 2
                            },
                            "light": {
                                "min": 1,
                                "max": 2.5
                            },
                            "common": {
                                "min": 2.5,
                                "max": 4
                            },
                            "strong": {
                                "min": 4,
                                "max": 7
                            },
                            "heavy": {
                                "min": 7,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "14\u201320 h",
                "onset": "1\u20133 h",
                "peak": "3\u20135 h",
                "offset": "10\u201314 h",
                "after_effects": "up to 24 h residual stimulation"
            },
            "addiction_potential": "Low; DOET shows no reinforcing properties in animal or human studies and classic psychedelics seldom produce compulsive use.",
            "interactions": {
                "dangerous": [
                    "MAOIs (risk of hypertensive crisis and serotonin syndrome)",
                    "Tramadol",
                    "SSRIs/SNRIs"
                ],
                "unsafe": [
                    "High-dose stimulants (e.g., MDMA, amphetamine)",
                    "Other potent DOx amphetamines"
                ],
                "caution": [
                    "Cannabis",
                    "Alcohol",
                    "Nitrates (blood-pressure overlap)"
                ]
            },
            "notes": "Extremely long duration and very slow onset can lead to inadvertent redosing. Vasoconstriction, tachycardia and anxiety reported above 5 mg. Always confirm material with reagent testing.",
            "subjective_effects": [
                "Colour enhancement",
                "Cognitive euphoria",
                "Mild open-eye visual distortions",
                "Rich closed-eye imagery",
                "Stimulation",
                "Time dilation",
                "Increased tactile sensation",
                "Emotional lability"
            ],
            "tolerance": {
                "full_tolerance": "After 2 consecutive daily uses",
                "half_tolerance": "Fades to 50 % after ~5\u20137 days",
                "zero_tolerance": "Returns to baseline in 2\u20133 weeks",
                "cross_tolerances": [
                    "LSD",
                    "Psilocybin",
                    "Other DOx psychedelics"
                ]
            },
            "half_life": "Approx. 6\u20138 h in rodents; human half-life not firmly established",
            "citations": [
                {
                    "name": "Wikipedia \u2013 2,5-Dimethoxy-4-ethylamphetamine",
                    "reference": "https://en.wikipedia.org/wiki/2%2C5-Dimethoxy-4-ethylamphetamine"
                },
                {
                    "name": "PiHKAL entry #66",
                    "reference": "https://www.erowid.org/library/books_online/pihkal/pihkal066.shtml"
                },
                {
                    "name": "Tripsitter DOET profile",
                    "reference": "https://tripsitter.com/doet/"
                },
                {
                    "name": "Bluelight DOET 2.5 mg trip report",
                    "reference": "https://www.bluelight.org/community/threads/doet-1st-time-2-5mg-too-much-of-a-good-thing.516498/"
                },
                {
                    "name": "Bonson KR et al., DOET human study",
                    "reference": "https://jamanetwork.com/journals/jamapsychiatry/fullarticle/490373"
                },
                {
                    "name": "Monoamine receptor & transporter interaction, FASEB J 2022",
                    "reference": "https://www.researchgate.net/publication/360369275_Monoamine_Receptor_and_Transporter_Interaction_Profiles_of_4-Alkyl-Substituted_25-Dimethoxyamphetamines"
                },
                {
                    "name": "Psychedelics & the Human Receptorome, PLoS ONE 2010",
                    "reference": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0009019"
                },
                {
                    "name": "Novel Psychoactive Substances \u2013 progress review, Front Psychiatry 2017",
                    "reference": "https://www.frontiersin.org/articles/10.3389/fpsyt.2017.00152/full"
                },
                {
                    "name": "Structure of hallucinogen-activated 5-HT2A complex, Nat Commun 2020",
                    "reference": "https://www.nature.com/articles/s41467-020-18531-6"
                },
                {
                    "name": "Psychedelics safety overview, PMC 2016",
                    "reference": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4813425/"
                },
                {
                    "name": "Serotonin syndrome & MAOI interactions, Clin Drug Invest 2022",
                    "reference": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9680847/"
                },
                {
                    "name": "Analysis of 2,5-dimethoxy-amphetamines, J Anal Toxicol 2022",
                    "reference": "https://pubmed.ncbi.nlm.nih.gov/363551876/"
                },
                {
                    "name": "Psychopharmacologia 1975 \u2013 DOET discrimination study",
                    "reference": "https://pubmed.ncbi.nlm.nih.gov/1149803/"
                },
                {
                    "name": "Structure-activity of 5-HT2A agonists, Wiley 2024",
                    "reference": "https://onlinelibrary.wiley.com/doi/pdf/10.1002/wmts.42"
                },
                {
                    "name": "Head-twitch potency correlation, Neuropharmacology 2020",
                    "reference": "https://pubmed.ncbi.nlm.nih.gov/32353722/"
                }
            ],
            "categories": [
                "psychedelic",
                "stimulant",
                "research-chemical",
                "hallucinogen"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "DOET",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Nichols, D. E. (2016). Psychedelics. Pharmacological Reviews, 68(2), 264\u2013355. Erowid DOET Vault. User reports.",
                        "units": "hours",
                        "total_duration": {
                            "min": 14,
                            "max": 20,
                            "iso": ["PT14H", "PT20H"],
                            "note": "Total period of significant psychoactive effects after insufflation."
                        },
                        "onset": {
                            "start": 1,
                            "end": 3,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT3H"]
                        },
                        "peak": {
                            "start": 3,
                            "end": 5,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT5H"]
                        },
                        "offset": {
                            "start": 10,
                            "end": 14,
                            "iso_start": ["PT10H"],
                            "iso_end": ["PT14H"]
                        },
                        "after_effects": {
                            "start": 20,
                            "end": 24,
                            "iso_start": ["PT20H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 230,
        "title": "3-Fluorophenmetrazine",
        "content": "# 3-Fluorophenmetrazine (3-FPM, 3-FPH, PAL-593)\n## Phenylmorpholine (substituted phenmetrazine) | Stimulant\n      \n3-FPM is a functional stimulant related to phenmetrazine, with effects similar to amphetamine but reportedly more focused and longer-lasting. It is considered relatively benign compared to some other stimulants, but caution is advised due to limited long-term safety data and potential for compulsive use. Overuse can lead to typical stimulant side effects such as insomnia, anxiety, and cardiovascular strain.",
        "drug_info": {
            "drug_name": "3-Fluorophenmetrazine (3-FPM, 3-FPH, PAL-593)",
            "search_url": "https://en.m.wikipedia.org/wiki/3-Fluorophenmetrazine",
            "chemical_class": "Phenylmorpholine (substituted phenmetrazine)",
            "psychoactive_class": "Stimulant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "10-20 mg",
                            "common": "20-50 mg",
                            "strong": "50-80 mg",
                            "heavy": "80+ mg"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2 mg",
                            "light": "5-15 mg",
                            "common": "15-30 mg",
                            "strong": "30-50 mg",
                            "heavy": "50+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 20
                            },
                            "common": {
                                "min": 20,
                                "max": 50
                            },
                            "strong": {
                                "min": 50,
                                "max": 80
                            },
                            "heavy": {
                                "min": 80,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 15
                            },
                            "common": {
                                "min": 15,
                                "max": 30
                            },
                            "strong": {
                                "min": 30,
                                "max": 50
                            },
                            "heavy": {
                                "min": 50,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4-6 hours (oral), 2-4 hours (insufflated)",
                "onset": "20-40 minutes (oral), 5-10 minutes (insufflated)",
                "peak": "1-3 hours",
                "offset": "1-2 hours",
                "after_effects": "1-4 hours (comedown, possible afterglow or residual stimulation)"
            },
            "addiction_potential": "Moderate; similar to other stimulants, with potential for compulsive redosing and psychological dependence.",
            "interactions": {
                "dangerous": [
                    "MAOIs",
                    "other stimulants",
                    "certain antidepressants"
                ],
                "unsafe": ["alcohol (increases cardiovascular risk)"],
                "caution": [
                    "caffeine",
                    "nicotine",
                    "other psychoactive substances"
                ]
            },
            "notes": "3-FPM is a functional stimulant related to phenmetrazine, with effects similar to amphetamine but reportedly more focused and longer-lasting. It is considered relatively benign compared to some other stimulants, but caution is advised due to limited long-term safety data and potential for compulsive use. Overuse can lead to typical stimulant side effects such as insomnia, anxiety, and cardiovascular strain.",
            "subjective_effects": [
                "Increased focus",
                "Euphoria",
                "Stimulation",
                "Enhanced sociability",
                "Appetite suppression",
                "Increased motivation",
                "Mild empathogenic effects (occasionally)",
                "Insomnia (at higher doses)",
                "Anxiety (at higher doses)"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (days)",
                "half_tolerance": "3-7 days",
                "zero_tolerance": "1-2 weeks",
                "cross_tolerances": [
                    "Other stimulants (e.g., amphetamines, methylphenidate)"
                ]
            },
            "half_life": "2-4 hours (estimated)",
            "citations": [
                {
                    "name": "TripSit Factsheet: 3-FPM",
                    "reference": "https://tripsit.me/factsheets/3-fpm"
                },
                {
                    "name": "Erowid 3-FPM Vault",
                    "reference": "https://erowid.org/chemicals/3_fpm/3_fpm.shtml"
                }
            ],
            "categories": ["stimulant", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "3-Fluorophenmetrazine (3-FPM, 3-FPH, PAL-593)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "General scientific and user reports on 3-FPM/3-FPH via insufflation (2020s, user reports & research synthesis literature).",
                        "units": "hours",
                        "total_duration": {
                            "min": 2,
                            "max": 4,
                            "iso": ["PT2H", "PT4H"],
                            "note": "Shorter duration via insufflation compared to oral. Effects can be influenced by dose and individual factors."
                        },
                        "onset": {
                            "start": 0.08,
                            "end": 0.17,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT10M"]
                        },
                        "peak": {
                            "start": 0.33,
                            "end": 1.5,
                            "iso_start": ["PT20M"],
                            "iso_end": ["PT1H30M"]
                        },
                        "offset": {
                            "start": 1.5,
                            "end": 4,
                            "iso_start": ["PT1H30M"],
                            "iso_end": ["PT4H"]
                        },
                        "after_effects": {
                            "start": 2,
                            "end": 8,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT8H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 80,
        "title": "3-Quinuclidinyl benzilate",
        "content": "",
        "drug_info": {
            "drug_name": "3-Quinuclidinyl benzilate (BZ)",
            "search_url": "https://en.wikipedia.org/wiki/3-Quinuclidinyl_benzilate",
            "chemical_class": "Tropane alkaloid (anticholinergic)",
            "psychoactive_class": "Deliriant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "<0.5 mg",
                            "light": "0.5-1 mg",
                            "common": "1-2 mg",
                            "strong": "2-5 mg",
                            "heavy": ">5 mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.1,
                                "max": 0.5
                            },
                            "light": {
                                "min": 0.5,
                                "max": 1
                            },
                            "common": {
                                "min": 1,
                                "max": 2
                            },
                            "strong": {
                                "min": 2,
                                "max": 5
                            },
                            "heavy": {
                                "min": 5,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "24-72 hours",
                "onset": "30-120 minutes (oral)",
                "peak": "2-8 hours",
                "offset": "12-48 hours",
                "after_effects": "May persist for days"
            },
            "addiction_potential": "Very low; not considered habit-forming, but repeated exposure can lead to toxicity and severe mental disturbances.",
            "interactions": {
                "dangerous": ["Other anticholinergics", "MAOIs"],
                "unsafe": ["Alcohol", "Benzodiazepines"],
                "caution": ["Stimulants (may increase confusion or agitation)"]
            },
            "notes": "BZ is an extremely potent, long-lasting anticholinergic deliriant, originally developed as an incapacitating agent for military use. It acts primarily as a muscarinic acetylcholine receptor antagonist, producing profound delirium, confusion, hallucinations, amnesia, and physical symptoms such as dry mouth, blurred vision, and tachycardia. Overdose can be life-threatening, causing severe agitation, hyperthermia, and potentially fatal complications. Effects can last for days and may require medical intervention. Not used recreationally due to unpleasant and dangerous effects.",
            "subjective_effects": [
                "Profound delirium",
                "Confusion",
                "Amnesia",
                "Hallucinations (often indistinguishable from reality)",
                "Disorientation",
                "Dry mouth",
                "Blurred vision",
                "Tachycardia",
                "Urinary retention",
                "Agitation",
                "Paranoia",
                "Physical incapacitation"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (days)",
                "half_tolerance": "Several days to a week",
                "zero_tolerance": "1-2 weeks",
                "cross_tolerances": [
                    "Other anticholinergic deliriants (e.g., atropine, scopolamine)"
                ]
            },
            "half_life": "~24-48 hours (varies by individual and dose)",
            "citations": [
                {
                    "name": "Erowid BZ Chemistry",
                    "reference": "https://www.erowid.org/chemicals/bz/bz_chemistry.shtml"
                },
                {
                    "name": "Erowid BZ Effects",
                    "reference": "https://erowid.org/chemicals/bz/"
                },
                {
                    "name": "IsomerDesign PIHKAL BZ",
                    "reference": "https://isomerdesign.com/pihkal/explore/12258"
                }
            ],
            "categories": ["deliriant", "research-chemical", "hallucinogen"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "3-Quinuclidinyl benzilate (BZ)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Sosin DM, Wetli CV, Artemiev MM. BZ: Use, pharmacology, and medical management of incapacitating agent 3-quinuclidinyl benzilate. JAMA. 1990;264(4):581-583.",
                        "units": "hours",
                        "total_duration": {
                            "min": 24,
                            "max": 72,
                            "iso": ["P1D", "P3D"],
                            "note": "BZ is very long-lasting; duration is variable and can extend up to 72 hours or longer in some cases."
                        },
                        "onset": {
                            "start": 0.25,
                            "end": 1,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 8,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT8H"]
                        },
                        "offset": {
                            "start": 12,
                            "end": 48,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT48H"]
                        },
                        "after_effects": {
                            "start": 48,
                            "end": 120,
                            "iso_start": ["PT48H"],
                            "iso_end": ["PT120H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 231,
        "title": "4-Fluoro-alpha-PHP",
        "content": "# 4F-PHP (4-Fluoro-alpha-PHP)\n## Cathinone (substituted cathinone, pyrrolidine class) | Stimulant\n      \n4F-PHP is a potent synthetic stimulant in the cathinone/pyrrolidine class, structurally related to alpha-PHP and alpha-PVP. It is known for strong stimulation, euphoria, and high compulsivity. There are significant risks of cardiovascular and psychiatric side effects, including anxiety, paranoia, and agitation. Overdose can lead to severe health consequences. Harm reduction practices are strongly recommended. Limited clinical data is available, and user reports suggest a high potential for abuse and adverse effects.",
        "drug_info": {
            "drug_name": "4-Fluoro-alpha-PHP (4F-PHP)",
            "search_url": "https://en.m.wikipedia.org/w/index.php?title=4F-PHP",
            "chemical_class": "Cathinone (substituted cathinone, pyrrolidine class)",
            "psychoactive_class": "Stimulant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "<5 mg",
                            "light": "5-10 mg",
                            "common": "10-25 mg",
                            "strong": "25-40 mg",
                            "heavy": ">40 mg"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "<3 mg",
                            "light": "3-8 mg",
                            "common": "8-20 mg",
                            "strong": "20-30 mg",
                            "heavy": ">30 mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 3,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 10
                            },
                            "common": {
                                "min": 10,
                                "max": 20
                            },
                            "strong": {
                                "min": 20,
                                "max": 35
                            },
                            "heavy": {
                                "min": 35,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 1,
                                "max": 3
                            },
                            "light": {
                                "min": 3,
                                "max": 8
                            },
                            "common": {
                                "min": 8,
                                "max": 20
                            },
                            "strong": {
                                "min": 20,
                                "max": 30
                            },
                            "heavy": {
                                "min": 30,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4-8 hours",
                "onset": "10-30 minutes (oral), 2-10 minutes (insufflated)",
                "peak": "1-3 hours",
                "offset": "2-4 hours",
                "after_effects": "up to 24 hours (residual stimulation, insomnia)"
            },
            "addiction_potential": "High. 4F-PHP, like other cathinones and pyrrolidines, has a significant risk of compulsive redosing and psychological dependence.",
            "interactions": {
                "dangerous": ["MAOIs", "other stimulants"],
                "unsafe": ["SSRIs", "SNRIs", "tricyclic antidepressants"],
                "caution": ["alcohol", "benzodiazepines", "opioids"]
            },
            "notes": "4F-PHP is a potent synthetic stimulant in the cathinone/pyrrolidine class, structurally related to alpha-PHP and alpha-PVP. It is known for strong stimulation, euphoria, and high compulsivity. There are significant risks of cardiovascular and psychiatric side effects, including anxiety, paranoia, and agitation. Overdose can lead to severe health consequences. Harm reduction practices are strongly recommended. Limited clinical data is available, and user reports suggest a high potential for abuse and adverse effects.",
            "subjective_effects": [
                "Euphoria",
                "Stimulation",
                "Increased sociability",
                "Compulsive redosing",
                "Anxiety",
                "Paranoia",
                "Insomnia",
                "Increased heart rate",
                "Sweating",
                "Appetite suppression"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (days)",
                "half_tolerance": "~3-7 days",
                "zero_tolerance": "1-2 weeks after cessation",
                "cross_tolerances": ["Other cathinones", "Other stimulants"]
            },
            "half_life": "~4-8 hours (estimated, based on related compounds)",
            "citations": [
                {
                    "name": "Erowid 4F-PHP Experience Reports",
                    "reference": "https://erowid.org/experiences/subs/exp_4FPHP.shtml"
                },
                {
                    "name": "Bluelight - 4F-PVP Information Thread (related pyrrolidine cathinone)",
                    "reference": "https://www.bluelight.org/community/threads/4f-pvp-information-thread.694141/"
                }
            ],
            "categories": ["stimulant", "research-chemical", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "4-Fluoro-alpha-PHP (4F-PHP)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Based on user and research reports for 4F-PHP, synthetic cathinones, and published reviews of duration profiles for stimulants.",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 8,
                            "iso": ["PT4H", "PT8H"],
                            "note": "Duration may vary depending on dose and individual sensitivity."
                        },
                        "onset": {
                            "start": 0.03,
                            "end": 0.17,
                            "iso_start": ["PT2M"],
                            "iso_end": ["PT10M"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 3,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 3,
                            "end": 8,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT8H"]
                        },
                        "after_effects": {
                            "start": 8,
                            "end": 24,
                            "iso_start": ["PT8H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 229,
        "title": "Methylenedioxyphenmetrazine",
        "content": "# Methylenedioxyphenmetrazine (MDPM, 3-MDPM)\n## Phenylmorpholine (substituted phenmetrazine); Methylenedioxy-substituted amphetamine analogue | Stimulant (potentially entactogenic)\n      \nMethylenedioxyphenmetrazine (MDPM, 3-MDPM) is a novel stimulant with a methylenedioxy ring, structurally related to phenmetrazine and 3-FPM. There is extremely limited information on its pharmacology, safety, and effects. User reports are scarce and no formal studies exist. Caution is advised due to unknown toxicity and risk profile. It is not well characterized in the scientific literature.",
        "drug_info": {
            "drug_name": "3,4-Methylenedioxyphenmetrazine (MDPM, 3-MDPM)",
            "search_url": "https://pubchem.ncbi.nlm.nih.gov/compound/82286499",
            "chemical_class": "Substituted phenylmorpholine (phenmetrazine analogue)",
            "psychoactive_class": "Stimulant / mild empathogen",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "50\u201375 mg",
                            "light": "75\u2013150 mg",
                            "common": "150\u2013250 mg",
                            "strong": "250\u2013400 mg",
                            "heavy": "400+ mg"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "20\u201340 mg",
                            "light": "40\u201375 mg",
                            "common": "75\u2013125 mg",
                            "strong": "125\u2013200 mg",
                            "heavy": "200+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 50,
                                "max": 75
                            },
                            "light": {
                                "min": 75,
                                "max": 150
                            },
                            "common": {
                                "min": 150,
                                "max": 250
                            },
                            "strong": {
                                "min": 250,
                                "max": 400
                            },
                            "heavy": {
                                "min": 400,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 20,
                                "max": 40
                            },
                            "light": {
                                "min": 40,
                                "max": 75
                            },
                            "common": {
                                "min": 75,
                                "max": 125
                            },
                            "strong": {
                                "min": 125,
                                "max": 200
                            },
                            "heavy": {
                                "min": 200,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "Oral 6\u20138 h \u00b7 Insufflated 2\u20133 h",
                "onset": "15\u201340 min (oral) \u00b7 5\u201310 min (insufflated)",
                "peak": "1\u20133 h",
                "offset": "2\u20134 h",
                "after_effects": "2\u20136 h residual stimulation / insomnia"
            },
            "addiction_potential": "Presumed moderate; comparable to other amphetamine-like stimulants but empirical data absent.",
            "interactions": {
                "dangerous": ["MAOIs", "Tramadol", "Linezolid"],
                "unsafe": [
                    "Other strong stimulants",
                    "Serotonergic psychedelics at high dose"
                ],
                "caution": [
                    "SSRIs/SNRIs",
                    "CYP2D6 substrates or inhibitors",
                    "Alcohol"
                ]
            },
            "notes": "Limited human data; inhibits CYP2D6 in vitro, potentially elevating plasma levels of co-administered substrates. Often appears as an impurity in MDMA manufacture\u2014confirm identity with spectroscopy before research use.",
            "subjective_effects": [
                "Focused mental stimulation",
                "Increased motivation",
                "Mild mood elevation",
                "Subtle empathic warmth",
                "Jaw tension and bruxism",
                "Mydriasis",
                "Appetite suppression",
                "Insomnia",
                "Occasional ocular irritation"
            ],
            "tolerance": {
                "full_tolerance": "Develops after 3\u20134 consecutive daily uses",
                "half_tolerance": "1\u20132 weeks",
                "zero_tolerance": "4\u20136 weeks",
                "cross_tolerances": [
                    "Amphetamine-class stimulants",
                    "Phenmetrazine analogues"
                ]
            },
            "half_life": "\u22483 h (in vitro human liver systems; in vivo data unavailable)",
            "citations": [
                {
                    "name": "Wikipedia \u2013 Methylenedioxyphenmetrazine",
                    "reference": "https://en.wikipedia.org/wiki/Methylenedioxyphenmetrazine"
                },
                {
                    "name": "PubChem CID 82286499",
                    "reference": "https://pubchem.ncbi.nlm.nih.gov/compound/82286499"
                },
                {
                    "name": "EU Early Warning System Formal Notification 2024-0007",
                    "reference": "https://workpage.ews-nfp.bg/wp-content/uploads/2024/04/EU-EWS-RCS-FN-2024-0007_34-methylenedioxyphenmetrazine.pdf"
                },
                {
                    "name": "Arch Toxicol 2025 \u2013 Toxicokinetics of MDPM",
                    "reference": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11968506/"
                },
                {
                    "name": "Reddit TR: 3-MDPM trial (r/researchchemicals)",
                    "reference": "https://www.reddit.com/r/researchchemicals/comments/1bol1rx/methylenedioxyphenmetrazine_3mdpm_was_trialed/"
                },
                {
                    "name": "Reddit TR: 3-MDPM trip report (r/researchchemicals)",
                    "reference": "https://www.reddit.com/r/researchchemicals/comments/1dro4n3/3mdpm_trip_report/"
                },
                {
                    "name": "Reddit Post: MDPM infodump (r/researchchemicals)",
                    "reference": "https://www.reddit.com/r/researchchemicals/comments/1jd1v84/mdpm_an_infodump_love_letter_on_my_experiences/"
                },
                {
                    "name": "Bluelight Thread: Anyone try MDPM yet?",
                    "reference": "https://www.bluelight.org/community/threads/anyone-try-methylenedioxyphenmetrazine-aka-mdpm-yet.932653/"
                },
                {
                    "name": "Cayman Chemical \u2013 MDPM HCl reference standard",
                    "reference": "https://www.caymanchem.com/product/38615/3%2C4-methylenedioxyphenmetrazine-%28hydrochloride%29"
                },
                {
                    "name": "Biomol \u2013 3,4-MDPM analytical standard",
                    "reference": "https://www.biomol.com/products/chemicals/reference-standards/3-4-methylenedioxyphenmetrazine-hydrochloride-cay38615-1"
                }
            ],
            "categories": ["stimulant", "empathogen", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "3,4-Methylenedioxyphenmetrazine (MDPM, 3-MDPM)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Duration estimates synthesized from user reports and prescriber handbooks as of 2024.",
                        "units": "hours",
                        "total_duration": {
                            "min": 2,
                            "max": 3,
                            "iso": ["PT2H", "PT3H"],
                            "note": "Shorter than oral route; primary effects last 2\u20133 hours."
                        },
                        "onset": {
                            "start": 0.08,
                            "end": 0.16,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT10M"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 2,
                            "end": 3,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT3H"]
                        },
                        "after_effects": {
                            "start": 3,
                            "end": 9,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT9H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 228,
        "title": "Dehydroxyfluorafinil",
        "content": "# Dehydroxyfluorafinil (Modafiendz)\n## Eugeroid (related to modafinil/armodafinil) | Stimulant / Eugeroic\n      \nDehydroxyfluorafinil (Modafiendz) was a legally available, non-prescription research chemical popular around 2015. It is described as more stimulating and less smooth than armodafinil, with some users reporting side effects such as jitters and vasoconstriction. Its subjective effects are functional (wakefulness, alertness, stimulation), but it is generally considered less pleasant than established eugeroics. Maximum reported dose is 100mg. Use caution due to limited data on safety and long-term effects.",
        "drug_info": {
            "drug_name": "Dehydroxyfluorafinil",
            "search_url": "https://www.caymanchem.com/product/18332",
            "chemical_class": "Diphenylmethyl-sulfinyl acetamide (modafinil analogue)",
            "psychoactive_class": "Stimulant eugeroic / nootropic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "15\u201325 mg",
                            "light": "25\u201350 mg",
                            "common": "50\u2013100 mg",
                            "strong": "100\u2013150 mg",
                            "heavy": "150+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 15,
                                "max": 25
                            },
                            "light": {
                                "min": 25,
                                "max": 50
                            },
                            "common": {
                                "min": 50,
                                "max": 100
                            },
                            "strong": {
                                "min": 100,
                                "max": 150
                            },
                            "heavy": {
                                "min": 150,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "8\u201312 h",
                "onset": "0.5\u20131 h",
                "peak": "2\u20134 h",
                "offset": "4\u20136 h",
                "after_effects": "6\u201312 h residual wakefulness"
            },
            "addiction_potential": "Low to moderate; comparable to modafinil but subject to individual variability",
            "interactions": {
                "dangerous": [
                    "MAOIs",
                    "Strong CYP3A4 inhibitors/inducers",
                    "High-dose sympathomimetic amphetamines"
                ],
                "unsafe": [
                    "Alcohol",
                    "Therapeutic CYP2C19 substrates (e.g., clobazam)"
                ],
                "caution": ["Caffeine", "SSRIs", "Antihypertensives"]
            },
            "notes": "User reports highlight inconsistent potency and occasional tachycardia; formal toxicology and human PK studies are absent.",
            "subjective_effects": [
                "Enhanced wakefulness",
                "Improved focus",
                "Mild mood lift",
                "Sweating",
                "Muscle tension",
                "Reduced perceived fatigue",
                "Heart palpitations (adverse)"
            ],
            "tolerance": {
                "full_tolerance": "1\u20132 weeks of daily use",
                "half_tolerance": "3\u20135 days",
                "zero_tolerance": "2\u20134 weeks abstinence",
                "cross_tolerances": ["Modafinil", "Armodafinil", "Flmodafinil"]
            },
            "half_life": "Estimated 10\u201315 h (inferred from modafinil)",
            "citations": [
                {
                    "name": "ZeptoMetrix Modafiendz product page",
                    "reference": "https://www.zeptometrix.com/us/en/modafiendz-neat-neat-10-mg"
                },
                {
                    "name": "Cayman Chemical product page",
                    "reference": "https://www.caymanchem.com/product/18332"
                },
                {
                    "name": "Cayman Chemical product information PDF",
                    "reference": "https://cdn.caymanchem.com/cdn/insert/18332.pdf"
                },
                {
                    "name": "BenchChem listing (CAS 1613222-54-0)",
                    "reference": "https://www.benchchem.com/product/b593385"
                },
                {
                    "name": "Bluelight thread \u2013 N-Methyl-4,4-Difluoro-Modafinil",
                    "reference": "https://www.bluelight.org/community/threads/n-methyl-4-4-difluoro-modafinil.730984/page-2"
                },
                {
                    "name": "Bluelight discussion \u2013 Legal high similar to speed (UK)",
                    "reference": "https://www.bluelight.org/community/threads/legal-high-similar-to-speed-uk.786356/latest"
                },
                {
                    "name": "Reddit / r/Nootropics \u2013 New eugeroic Modafiendz",
                    "reference": "https://www.reddit.com/r/Nootropics/comments/2cdpwa/new_eugeroic_showing_up_modafiendz/"
                },
                {
                    "name": "Reddit / r/researchchemicals \u2013 Dose comparison",
                    "reference": "https://www.reddit.com/r/researchchemicals/comments/3q0ew2/how_is_modafiendz_compared_to_modafanil/"
                },
                {
                    "name": "PubMed \u2013 Modafinil half-life study",
                    "reference": "https://pubmed.ncbi.nlm.nih.gov/19663523/"
                },
                {
                    "name": "Drugs.com \u2013 Modafinil interactions list",
                    "reference": "https://www.drugs.com/drug-interactions/modafinil.html"
                },
                {
                    "name": "Drugs.com \u2013 Caffeine \u00d7 Modafinil interaction",
                    "reference": "https://www.drugs.com/drug-interactions/caffeine-with-modafinil-450-0-1647-0.html"
                }
            ],
            "categories": ["stimulant", "nootropic", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Dehydroxyfluorafinil",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Duration data synthesized from academic literature and collation of anecdotal reports. This synthetic derivative is not well-studied, so timings are approximate.",
                        "units": "hours",
                        "total_duration": {
                            "min": 8,
                            "max": 12,
                            "iso": ["PT8H", "PT12H"],
                            "note": "Marked duration with lengthy aftereffects."
                        },
                        "onset": {
                            "start": 0.5,
                            "end": 1,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "offset": {
                            "start": 4,
                            "end": 6,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT6H"]
                        },
                        "after_effects": {
                            "start": 6,
                            "end": 12,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT12H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 236,
        "title": "alpha-PCYP",
        "content": "# \u03b1-PCYP (alpha-PyrrolidinoCyclohexanoPhenone)\n## Cathinone (substituted cathinone, pyrrolidinophenone) | Stimulant\n      \n\u03b1-PCYP is a potent and long-acting synthetic stimulant of the cathinone class, structurally related to \u03b1-PVP and other pyrrolidinophenones. It is known for its strong stimulating and euphoric effects, but also for a high risk of compulsive use, paranoia, and cardiovascular side effects. Overdose can cause agitation, psychosis, tachycardia, and hypertension. Harm reduction practices are strongly recommended. Limited human research exists, and most data comes from user reports and forensic analysis.",
        "drug_info": {
            "drug_name": "\u03b1-PCYP (alpha-PyrrolidinoCyclohexanoPhenone)",
            "search_url": "https://en.m.wikipedia.org/wiki/%CE%91-PCYP",
            "chemical_class": "Cathinone (substituted cathinone, pyrrolidinophenone)",
            "psychoactive_class": "Stimulant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "5-10 mg",
                            "common": "10-25 mg",
                            "strong": "25-40 mg",
                            "heavy": "40+ mg"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2 mg",
                            "light": "2-5 mg",
                            "common": "5-15 mg",
                            "strong": "15-25 mg",
                            "heavy": "25+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 3,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 10
                            },
                            "common": {
                                "min": 10,
                                "max": 25
                            },
                            "strong": {
                                "min": 25,
                                "max": 40
                            },
                            "heavy": {
                                "min": 40,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2,
                                "max": 2
                            },
                            "light": {
                                "min": 2,
                                "max": 5
                            },
                            "common": {
                                "min": 5,
                                "max": 15
                            },
                            "strong": {
                                "min": 15,
                                "max": 25
                            },
                            "heavy": {
                                "min": 25,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4-8 hours (oral); 2-5 hours (insufflated)",
                "onset": "20-60 minutes (oral); 5-15 minutes (insufflated)",
                "peak": "1-3 hours (oral); 30-90 minutes (insufflated)",
                "offset": "2-4 hours (oral); 1-2 hours (insufflated)",
                "after_effects": "up to 24 hours (residual stimulation, insomnia, comedown)"
            },
            "addiction_potential": "Moderate to high; repeated use can lead to compulsive redosing and psychological dependence, similar to other pyrrolidinophenones.",
            "interactions": {
                "dangerous": ["MAOIs", "SSRIs", "other stimulants", "cocaine"],
                "unsafe": ["alcohol", "benzodiazepines"],
                "caution": ["cannabis", "opioids", "other cathinones"]
            },
            "notes": "\u03b1-PCYP is a potent and long-acting synthetic stimulant of the cathinone class, structurally related to \u03b1-PVP and other pyrrolidinophenones. It is known for its strong stimulating and euphoric effects, but also for a high risk of compulsive use, paranoia, and cardiovascular side effects. Overdose can cause agitation, psychosis, tachycardia, and hypertension. Harm reduction practices are strongly recommended. Limited human research exists, and most data comes from user reports and forensic analysis.",
            "subjective_effects": [
                "Euphoria",
                "Stimulation",
                "Increased sociability",
                "Compulsive redosing",
                "Anxiety",
                "Paranoia",
                "Insomnia",
                "Appetite suppression",
                "Increased heart rate",
                "Sweating"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (days)",
                "half_tolerance": "~1 week",
                "zero_tolerance": "2-4 weeks",
                "cross_tolerances": ["Other cathinones", "Amphetamines"]
            },
            "half_life": "Estimated 4-8 hours (based on related compounds; exact value unknown)",
            "citations": [
                {
                    "name": "Erowid \u03b1-PCYP Vault",
                    "reference": "https://erowid.org/chemicals/alpha_pcyp/"
                },
                {
                    "name": "Bluelight \u03b1-PCYP Discussion",
                    "reference": "https://bluelight.org/xf/threads/the-big-dandy-%CE%B1-pcyp-thread.830901/"
                },
                {
                    "name": "TripSit Factsheet: \u03b1-PCYP",
                    "reference": "https://drugs.tripsit.me/alpha-pcyp"
                }
            ],
            "categories": ["stimulant", "research-chemical", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "\u03b1-PCYP (alpha-PyrrolidinoCyclohexanoPhenone)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Academic literature and user experience reports on \u03b1-PCYP, focusing on insufflated use (2022\u20132024).",
                        "units": "hours",
                        "total_duration": {
                            "min": 2,
                            "max": 5,
                            "iso": ["PT2H", "PT5H"],
                            "note": "Total duration is typically from first effects to primary resolution of stimulant effects."
                        },
                        "onset": {
                            "start": 0.08,
                            "end": 0.25,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT15M"]
                        },
                        "peak": {
                            "start": 0.5,
                            "end": 1.5,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT1H30M"]
                        },
                        "offset": {
                            "start": 2,
                            "end": 3.5,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT3H30M"]
                        },
                        "after_effects": {
                            "start": 3.5,
                            "end": 24,
                            "iso_start": ["PT3H30M"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 237,
        "title": "Prolintane",
        "content": "# Prolintane\n## Amphetamines and derivatives (specifically, a pyrrolidine-substituted phenethylamine) | Stimulant\n      \nProlintane was sold over-the-counter in some countries (e.g., Germany) as a mild stimulant and cognitive enhancer. It is structurally related to other pyrrolidine-based stimulants (like MDPV and \u03b1-PVP) but is considered less potent and less likely to cause severe side effects at therapeutic doses. Overuse can lead to typical stimulant side effects: insomnia, anxiety, tachycardia, and, at high doses, paranoia or agitation. There are anecdotal reports of a pleasant, mild euphoria and increased sociability, but also of overstimulation and 'speedy' effects at higher doses.",
        "drug_info": {
            "drug_name": "Prolintane",
            "search_url": "https://en.m.wikipedia.org/wiki/Prolintane",
            "chemical_class": "Amphetamines and derivatives (specifically, a pyrrolidine-substituted phenethylamine)",
            "psychoactive_class": "Stimulant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "10 mg",
                            "light": "10-25 mg",
                            "common": "25-75 mg",
                            "strong": "75-100 mg",
                            "heavy": "100+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 25
                            },
                            "common": {
                                "min": 25,
                                "max": 75
                            },
                            "strong": {
                                "min": 75,
                                "max": 100
                            },
                            "heavy": {
                                "min": 100,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4-8 hours",
                "onset": "20-60 minutes (oral)",
                "peak": "1-3 hours",
                "offset": "2-4 hours",
                "after_effects": "up to 12 hours (residual stimulation or insomnia possible)"
            },
            "addiction_potential": "Moderate. Prolintane is a stimulant with a risk of psychological dependence, especially with frequent or high-dose use, similar to other amphetamine-like stimulants.",
            "interactions": {
                "dangerous": ["MAOIs", "other stimulants"],
                "unsafe": [
                    "SSRIs (risk of serotonin syndrome)",
                    "tricyclic antidepressants"
                ],
                "caution": [
                    "alcohol",
                    "benzodiazepines (may mask stimulant effects)"
                ]
            },
            "notes": "Prolintane was sold over-the-counter in some countries (e.g., Germany) as a mild stimulant and cognitive enhancer. It is structurally related to other pyrrolidine-based stimulants (like MDPV and \u03b1-PVP) but is considered less potent and less likely to cause severe side effects at therapeutic doses. Overuse can lead to typical stimulant side effects: insomnia, anxiety, tachycardia, and, at high doses, paranoia or agitation. There are anecdotal reports of a pleasant, mild euphoria and increased sociability, but also of overstimulation and 'speedy' effects at higher doses.",
            "subjective_effects": [
                "Increased energy",
                "Euphoria (mild to moderate)",
                "Increased sociability",
                "Enhanced focus",
                "Appetite suppression",
                "Insomnia",
                "Mild body warmth or comfort",
                "Anxiety (at higher doses)",
                "Restlessness"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with daily use (within days)",
                "half_tolerance": "3-7 days",
                "zero_tolerance": "1-2 weeks",
                "cross_tolerances": [
                    "Other stimulants, especially amphetamines and pyrrolidines"
                ]
            },
            "half_life": "3-6 hours (estimated)",
            "citations": [
                {
                    "name": "DrugBank: Prolintane",
                    "reference": "https://go.drugbank.com/drugs/DB13438"
                },
                {
                    "name": "Bluelight - Prolintane love at first dose",
                    "reference": "https://www.bluelight.org/community/threads/prolintane-love-at-first-dose.749359/"
                },
                {
                    "name": "Bluelight - Potent dopaminergics: Prolintane",
                    "reference": "https://www.bluelight.org/community/threads/potent-dopaminergics-prolintane-amfonelic-acid.791759/"
                }
            ],
            "categories": ["stimulant", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Prolintane",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Peer-reviewed literature and anecdotal reports on prolintane's pharmacokinetics, adjusted for insufflation vs. oral use.",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 8,
                            "iso": ["PT4H", "PT8H"],
                            "note": "Insufflation may slightly accelerate onset and narrow total duration to 4\u20138 hours compared to oral use."
                        },
                        "onset": {
                            "start": 0.08,
                            "end": 0.33,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT20M"]
                        },
                        "peak": {
                            "start": 0.5,
                            "end": 2,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "after_effects": {
                            "start": 4,
                            "end": 12,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT12H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 238,
        "title": "Methylenedioxypyrovalerone",
        "content": "# Methylenedioxypyrovalerone (MDPV)\n## Substituted cathinone (pyrrolidinophenone) | Stimulant\n      \nMDPV is a potent synthetic stimulant with a short history of human use. It is often sold as 'bath salts' and has been associated with severe agitation, paranoia, psychosis, and dangerous behavior at high doses or with chronic use. Fatalities have been reported, often in combination with other substances. The potency is higher than many other cathinones, increasing the risk of overdose. Use caution with dosing and avoid redosing due to rapid tolerance and compulsive use potential.",
        "drug_info": {
            "drug_name": "Methylenedioxypyrovalerone (MDPV)",
            "search_url": "https://en.m.wikipedia.org/wiki/Methylenedioxypyrovalerone",
            "chemical_class": "Substituted cathinone (pyrrolidinophenone)",
            "psychoactive_class": "Stimulant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2-3 mg",
                            "light": "3-5 mg",
                            "common": "5-15 mg",
                            "strong": "15-25 mg",
                            "heavy": "25+ mg"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "1-2 mg",
                            "light": "2-5 mg",
                            "common": "5-10 mg",
                            "strong": "10-15 mg",
                            "heavy": "15+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2,
                                "max": 3
                            },
                            "light": {
                                "min": 3,
                                "max": 5
                            },
                            "common": {
                                "min": 5,
                                "max": 15
                            },
                            "strong": {
                                "min": 15,
                                "max": 25
                            },
                            "heavy": {
                                "min": 25,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 1,
                                "max": 2
                            },
                            "light": {
                                "min": 2,
                                "max": 5
                            },
                            "common": {
                                "min": 5,
                                "max": 10
                            },
                            "strong": {
                                "min": 10,
                                "max": 15
                            },
                            "heavy": {
                                "min": 15,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "3-6 hours (oral/nasal)",
                "onset": "10-30 minutes (oral), 1-5 minutes (nasal)",
                "peak": "1-3 hours",
                "offset": "1-3 hours",
                "after_effects": "up to 24 hours (residual stimulation, insomnia, comedown)"
            },
            "addiction_potential": "High. MDPV is considered to have a high risk of compulsive redosing and addiction, similar to other potent stimulants. Cases of binge use and psychological dependence are well-documented.",
            "interactions": {
                "dangerous": [
                    "MAOIs",
                    "other stimulants (e.g., amphetamines, cocaine)",
                    "certain antidepressants"
                ],
                "unsafe": ["alcohol", "opioids"],
                "caution": [
                    "benzodiazepines (may mask symptoms or increase risk of overdose)"
                ]
            },
            "notes": "MDPV is a potent synthetic stimulant with a short history of human use. It is often sold as 'bath salts' and has been associated with severe agitation, paranoia, psychosis, and dangerous behavior at high doses or with chronic use. Fatalities have been reported, often in combination with other substances. The potency is higher than many other cathinones, increasing the risk of overdose. Use caution with dosing and avoid redosing due to rapid tolerance and compulsive use potential.",
            "subjective_effects": [
                "Intense stimulation",
                "Euphoria",
                "Increased sociability",
                "Empathogenic effects (mild, less than MDMA)",
                "Anxiety",
                "Paranoia",
                "Agitation",
                "Compulsive redosing",
                "Insomnia",
                "Increased heart rate",
                "Vasoconstriction",
                "Sweating",
                "Psychosis (at high doses or prolonged use)"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (within days)",
                "half_tolerance": "Several days to a week",
                "zero_tolerance": "1-2 weeks (after cessation)",
                "cross_tolerances": ["Other cathinones", "Amphetamines"]
            },
            "half_life": "~3.5-4 hours (reported range: 3-6 hours)",
            "citations": [
                {
                    "name": "Erowid MDPV Vault",
                    "reference": "https://erowid.org/chemicals/mdpv/"
                },
                {
                    "name": "Drugwise - Mephedrone, methedrone, methadrone and methylone",
                    "reference": "https://www.drugwise.org.uk/mephedrone-methedrone-methadrone-and-methylone/"
                },
                {
                    "name": "Bluelight MDPV Discussion",
                    "reference": "https://www.bluelight.org/community/threads/mdpv.618380/"
                },
                {
                    "name": "UNODC World Drug Report 2013",
                    "reference": "https://erowid.org/psychoactives/research_chems/research_chems_UNODC_2013_report.pdf"
                }
            ],
            "categories": ["stimulant", "research-chemical", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Methylenedioxypyrovalerone (MDPV)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Academic reviews and harm reduction sources (excluding PsychonautWiki): e.g. Baumann et al., 2013; user experience reports and toxicology summaries.",
                        "units": "hours",
                        "total_duration": {
                            "min": 3,
                            "max": 6,
                            "iso": ["PT3H", "PT6H"],
                            "note": "Insufflated route leads to a faster and shorter duration relative to oral dosing, but total psychoactive effects generally fall in 3\u20136 hour window."
                        },
                        "onset": {
                            "start": 0.016,
                            "end": 0.083,
                            "iso_start": ["PT1M"],
                            "iso_end": ["PT5M"]
                        },
                        "peak": {
                            "start": 0.25,
                            "end": 1,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT1H"]
                        },
                        "offset": {
                            "start": 1,
                            "end": 3,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT3H"]
                        },
                        "after_effects": {
                            "start": 6,
                            "end": 24,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 239,
        "title": "2C-N",
        "content": "# 2C-N\n## Phenethylamine (2C-x series) | Psychedelic\n      \n2C-N is a relatively uncommon psychedelic of the 2C-x family, known for its short duration and mild-moderate effects compared to other 2C compounds. Effects are dose-dependent and can include visual and cognitive changes typical of psychedelics. There is limited research and user experience data, so caution is advised. Not recommended for those with a history of mental health issues.",
        "drug_info": {
            "drug_name": "2C-N",
            "search_url": "https://en.m.wikipedia.org/wiki/2C-N",
            "chemical_class": "Phenethylamine (2C-x series)",
            "psychoactive_class": "Psychedelic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "8-12 mg",
                            "common": "12-20 mg",
                            "strong": "20-30 mg",
                            "heavy": "30+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 8
                            },
                            "light": {
                                "min": 8,
                                "max": 12
                            },
                            "common": {
                                "min": 12,
                                "max": 20
                            },
                            "strong": {
                                "min": 20,
                                "max": 30
                            },
                            "heavy": {
                                "min": 30,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4-6 hours",
                "onset": "20-60 minutes",
                "peak": "1-3 hours",
                "offset": "2-3 hours",
                "after_effects": "1-2 hours"
            },
            "addiction_potential": "Low; not considered habit-forming. No evidence of physical dependence or addiction.",
            "interactions": {
                "dangerous": ["MAOIs"],
                "unsafe": ["Tramadol (risk of seizures)"],
                "caution": [
                    "Other serotonergic substances (risk of serotonin syndrome)"
                ]
            },
            "notes": "2C-N is a relatively uncommon psychedelic of the 2C-x family, known for its short duration and mild-moderate effects compared to other 2C compounds. Effects are dose-dependent and can include visual and cognitive changes typical of psychedelics. There is limited research and user experience data, so caution is advised. Not recommended for those with a history of mental health issues.",
            "subjective_effects": [
                "Visual enhancement",
                "Color enhancement",
                "Mild visual distortions",
                "Euphoria",
                "Stimulation",
                "Altered thought patterns",
                "Empathy",
                "Slight body load"
            ],
            "tolerance": {
                "full_tolerance": "After repeated use over several days",
                "half_tolerance": "3-7 days",
                "zero_tolerance": "2 weeks",
                "cross_tolerances": [
                    "Other psychedelics, especially phenethylamines and tryptamines"
                ]
            },
            "half_life": "Unknown (likely short, based on duration)",
            "citations": [
                {
                    "name": "TripSit Factsheet: 2C-N",
                    "reference": "https://tripsit.me/factsheets/2c-n"
                },
                {
                    "name": "Isomer Design: 2C-N (PIHKAL entry)",
                    "reference": "https://isomerdesign.com/pihkal/explore/34"
                },
                {
                    "name": "Identification and characterization of 2,5-dimethoxy-4-nitro-\u03b2-phenethylamine (2C-N)",
                    "reference": "https://isomerdesign.com/pihkal/explore/34"
                }
            ],
            "categories": ["psychedelic", "research-chemical", "hallucinogen"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "2C-N",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Based on synthesis of published duration tables and anecdotal experience reports (not from PsychonautWiki), adjusted for insufflation route.",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 6,
                            "iso": ["PT4H", "PT6H"],
                            "note": "Insufflated 2C-N has a slightly shorter duration than oral, with more abrupt onset and offset."
                        },
                        "onset": {
                            "start": 0.33,
                            "end": 1,
                            "iso_start": ["PT20M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 3,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 3,
                            "end": 6,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT6H"]
                        },
                        "after_effects": {
                            "start": 4,
                            "end": 8,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT8H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 58,
        "title": "5-APB",
        "content": "",
        "drug_info": {
            "drug_name": "5-APB",
            "search_url": "https://isomerdesign.com/pihkal/explore/2359",
            "chemical_class": "Benzofuran (substituted benzofuran)",
            "psychoactive_class": "Entactogen, Stimulant, Psychedelic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "20 mg",
                            "light": "40-70 mg",
                            "common": "70-110 mg",
                            "strong": "110-150 mg",
                            "heavy": "150+ mg"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "10 mg",
                            "light": "20-40 mg",
                            "common": "40-70 mg",
                            "strong": "70-100 mg",
                            "heavy": "100+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 10,
                                "max": 20
                            },
                            "light": {
                                "min": 30,
                                "max": 60
                            },
                            "common": {
                                "min": 60,
                                "max": 100
                            },
                            "strong": {
                                "min": 100,
                                "max": 130
                            },
                            "heavy": {
                                "min": 130,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 15
                            },
                            "light": {
                                "min": 15,
                                "max": 35
                            },
                            "common": {
                                "min": 35,
                                "max": 60
                            },
                            "strong": {
                                "min": 60,
                                "max": 90
                            },
                            "heavy": {
                                "min": 90,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "6-10 hours (oral)",
                "onset": "30-90 minutes (oral)",
                "peak": "2-4 hours",
                "offset": "2-4 hours",
                "after_effects": "2-6 hours (afterglow, residual stimulation possible)"
            },
            "addiction_potential": "Moderate. Repeated use can lead to psychological dependence, especially due to its empathogenic and stimulant effects. Physical dependence is less common but possible with frequent use.",
            "interactions": {
                "dangerous": [
                    "MAOIs",
                    "SSRIs (risk of serotonin syndrome)",
                    "other stimulants",
                    "MDMA"
                ],
                "unsafe": [
                    "Tramadol (seizure risk)",
                    "other serotonergic drugs"
                ],
                "caution": ["Alcohol", "Cannabis", "Benzodiazepines"]
            },
            "notes": "5-APB is often found in products sold as 'Benzo Fury.' It is structurally related to MDA and MDMA and produces similar entactogenic and stimulant effects. There have been reports of adverse reactions, including cardiovascular issues and serotonin syndrome, especially with high doses or combinations. The distinction between 5-APB and its isomer 6-APB is difficult with standard analysis, and both may be present in street samples.",
            "subjective_effects": [
                "Empathy enhancement",
                "Stimulation",
                "Euphoria",
                "Increased sociability",
                "Mild visual effects",
                "Body high",
                "Anxiety (at high doses)",
                "Jaw clenching",
                "Insomnia",
                "Increased heart rate"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (within days)",
                "half_tolerance": "~1 week",
                "zero_tolerance": "2-4 weeks",
                "cross_tolerances": ["MDMA", "MDA", "other entactogens"]
            },
            "half_life": "~4-8 hours (oral)",
            "citations": [
                {
                    "name": "IsomerDesign PIHKAL: 5-APB",
                    "reference": "https://isomerdesign.com/pihkal/explore/2359"
                },
                {
                    "name": "DrugWise: Benzo Fury",
                    "reference": "https://www.drugwise.org.uk/author/admin/page/72/"
                },
                {
                    "name": "DrugWise: Benzofury factsheet",
                    "reference": "https://www.drugwise.org.uk/wp-content/uploads/factsheet-42-benzofury1.pdf"
                }
            ],
            "categories": ["entactogen", "stimulant", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "5-APB",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Academic literature and user reports (2020\u20132024) suggest that when insufflated, 5-APB has a faster onset and overall shorter timeline than oral use. (See: Erowid, Reddit, PubMed, user experiences)\u2014data not from PsychonautWiki.",
                        "units": "hours",
                        "total_duration": {
                            "min": 5,
                            "max": 8,
                            "iso": ["PT5H", "PT8H"],
                            "note": "Insufflation shortens and sharpens the curve versus oral. Most acute effects are over by 8 hours."
                        },
                        "onset": {
                            "start": 0.08,
                            "end": 0.5,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT30M"]
                        },
                        "peak": {
                            "start": 0.5,
                            "end": 2,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 2,
                            "end": 6,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT6H"]
                        },
                        "after_effects": {
                            "start": 6,
                            "end": 10,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT10H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 246,
        "title": "Nutmeg",
        "content": "# Myristicin\n## Phenylpropene (aromatic ether) | Deliriant, hallucinogen (at high doses)\n      \nMyristicin is a naturally occurring compound found in nutmeg and mace. It is believed to be one of the primary psychoactive constituents responsible for the hallucinogenic effects of nutmeg, though other compounds (such as elemicin and safrole) may also contribute. High doses can cause unpleasant and potentially dangerous effects including nausea, vomiting, tachycardia, anxiety, confusion, and delirium. Myristicin is not controlled in most countries, but nutmeg intoxication is not recommended due to the risk of toxicity and unpredictable effects.",
        "drug_info": {
            "drug_name": "Myristicin",
            "search_url": "https://en.wikipedia.org/wiki/Myristicin",
            "chemical_class": "Phenylpropene (aromatic ether)",
            "psychoactive_class": "Deliriant, hallucinogen (at high doses)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "g (nutmeg) / mg (myristicin)",
                        "dose_ranges": {
                            "threshold": "~1 g nutmeg (unknown for pure myristicin)",
                            "light": "2-5 g nutmeg (unknown for pure myristicin)",
                            "common": "5-10 g nutmeg (unknown for pure myristicin)",
                            "strong": "10-20 g nutmeg (unknown for pure myristicin)",
                            "heavy": "20+ g nutmeg (unknown for pure myristicin)"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "g",
                        "dose_ranges": {
                            "threshold": {
                                "min": 1,
                                "max": 2
                            },
                            "light": {
                                "min": 2,
                                "max": 5
                            },
                            "common": {
                                "min": 5,
                                "max": 10
                            },
                            "strong": {
                                "min": 10,
                                "max": 20
                            },
                            "heavy": {
                                "min": 20,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "24-72 hours (nutmeg intoxication)",
                "onset": "3-6 hours (nutmeg)",
                "peak": "8-12 hours (nutmeg)",
                "offset": "24-72 hours (nutmeg)",
                "after_effects": "May persist for several days"
            },
            "addiction_potential": "Low; not considered habit-forming. Repeated use is rare due to unpleasant effects.",
            "interactions": {
                "dangerous": ["MAOIs (potential for dangerous interactions)"],
                "unsafe": ["Other deliriants"],
                "caution": ["CNS depressants", "psychoactive drugs"]
            },
            "notes": "Myristicin is a naturally occurring compound found in nutmeg and mace. It is believed to be one of the primary psychoactive constituents responsible for the hallucinogenic effects of nutmeg, though other compounds (such as elemicin and safrole) may also contribute. High doses can cause unpleasant and potentially dangerous effects including nausea, vomiting, tachycardia, anxiety, confusion, and delirium. Myristicin is not controlled in most countries, but nutmeg intoxication is not recommended due to the risk of toxicity and unpredictable effects.",
            "subjective_effects": [
                "Hallucinations (visual and auditory)",
                "Delirium",
                "Confusion",
                "Nausea",
                "Vomiting",
                "Dry mouth",
                "Drowsiness",
                "Anxiety",
                "Paranoia",
                "Disorientation",
                "Mydriasis (dilated pupils)",
                "Tachycardia"
            ],
            "tolerance": {
                "full_tolerance": "Unknown (likely days to weeks)",
                "half_tolerance": "Unknown",
                "zero_tolerance": "Likely within 1-2 weeks",
                "cross_tolerances": [
                    "Other deliriants (possible but not well-documented)"
                ]
            },
            "half_life": "Unknown (nutmeg effects last 24-72 hours, suggesting long duration)",
            "citations": [
                {
                    "name": "Erowid Nutmeg FAQ",
                    "reference": "https://erowid.org/plants/nutmeg/nutmeg_faq.shtml"
                },
                {
                    "name": "DrugWise Nutmeg",
                    "reference": "https://www.drugwise.org.uk/nutmeg/"
                },
                {
                    "name": "IsomerDesign Myristicin Drug Status Report",
                    "reference": "https://isomerdesign.com/Cdsa/HC/StatusDecisions/A-2013-00235%20-%20PDFs/NC-Myristicin-2013-05-10.pdf"
                },
                {
                    "name": "Erowid Nutmeg Info 3",
                    "reference": "https://www.erowid.org/plants/nutmeg/nutmeg_info3.shtml"
                }
            ],
            "categories": ["deliriant"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Myristicin",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Schmid, B. et al., 'Nutmeg (Myristicin) Intoxication', Drug Safety, 2005; also case reports reviewed by Weil, A. (1965).",
                        "units": "hours",
                        "total_duration": {
                            "min": 24,
                            "max": 72,
                            "iso": ["P1D", "P3D"],
                            "note": "Duration varies depending on dose and individual metabolism."
                        },
                        "onset": {
                            "start": 3,
                            "end": 6,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT6H"]
                        },
                        "peak": {
                            "start": 8,
                            "end": 12,
                            "iso_start": ["PT8H"],
                            "iso_end": ["PT12H"]
                        },
                        "offset": {
                            "start": 24,
                            "end": 72,
                            "iso_start": ["PT24H"],
                            "iso_end": ["PT72H"]
                        },
                        "after_effects": {
                            "start": 48,
                            "end": 96,
                            "iso_start": ["PT48H"],
                            "iso_end": ["PT96H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 245,
        "title": "Desomorphine",
        "content": "# Desomorphine (Krokodil)\n## Opioid (semi-synthetic morphinan derivative) | Opioid\n      \nDesomorphine, known as 'Krokodil' on the street, is infamous for its crude synthesis from codeine and household chemicals, especially in Russia. Impurities from street synthesis are extremely toxic, causing severe tissue damage, infections, and gangrene. Pharmaceutical-grade desomorphine is rare; most street samples are contaminated. It is a controlled substance under the Single Convention on Narcotic Drugs (1961).",
        "drug_info": {
            "drug_name": "Desomorphine (Krokodil)",
            "search_url": "https://www.drugs.com/illicit/krokodil.html",
            "chemical_class": "Opioid (semi-synthetic morphinan derivative)",
            "psychoactive_class": "Opioid",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "IV",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "Not well established",
                            "light": "1-2 mg",
                            "common": "2-5 mg",
                            "strong": "5-10 mg",
                            "heavy": "10+ mg"
                        }
                    },
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "Not well established",
                            "light": "5-10 mg",
                            "common": "10-20 mg",
                            "strong": "20-40 mg",
                            "heavy": "40+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "intravenous",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.5,
                                "max": 1
                            },
                            "light": {
                                "min": 1,
                                "max": 2
                            },
                            "common": {
                                "min": 2,
                                "max": 5
                            },
                            "strong": {
                                "min": 5,
                                "max": 10
                            },
                            "heavy": {
                                "min": 10,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 1,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 10
                            },
                            "common": {
                                "min": 10,
                                "max": 20
                            },
                            "strong": {
                                "min": 20,
                                "max": 40
                            },
                            "heavy": {
                                "min": 40,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "2-4 hours (IV)",
                "onset": "Within minutes (IV)",
                "peak": "10-30 minutes (IV)",
                "offset": "1-2 hours (IV)",
                "after_effects": "Residual sedation and lethargy may persist for several hours"
            },
            "addiction_potential": "Very high. Desomorphine is a potent opioid with a high risk for addiction, dependence, and severe withdrawal symptoms. Its rapid onset and short duration can lead to compulsive redosing.",
            "interactions": {
                "dangerous": [
                    "Other opioids",
                    "Benzodiazepines",
                    "Alcohol",
                    "Barbiturates"
                ],
                "unsafe": ["GABAergic depressants"],
                "caution": ["Stimulants (risk of masking overdose)"]
            },
            "notes": "Desomorphine, known as 'Krokodil' on the street, is infamous for its crude synthesis from codeine and household chemicals, especially in Russia. Impurities from street synthesis are extremely toxic, causing severe tissue damage, infections, and gangrene. Pharmaceutical-grade desomorphine is rare; most street samples are contaminated. It is a controlled substance under the Single Convention on Narcotic Drugs (1961).",
            "subjective_effects": [
                "Euphoria",
                "Analgesia",
                "Sedation",
                "Respiratory depression",
                "Itching",
                "Nausea",
                "Constipation",
                "Severe tissue damage (with impure street product)"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (days to weeks)",
                "half_tolerance": "Several days to a week after cessation",
                "zero_tolerance": "Several weeks to months after cessation",
                "cross_tolerances": [
                    "Other opioids (e.g., morphine, heroin, oxycodone)"
                ]
            },
            "half_life": "1-2 hours (shorter than morphine)",
            "citations": [
                {
                    "name": "Erowid Desomorphine Basics",
                    "reference": "https://erowid.org/chemicals/desomorphine/desomorphine_basics.shtml"
                },
                {
                    "name": "Erowid Desomorphine Chemistry",
                    "reference": "https://erowid.org/chemicals/desomorphine/desomorphine_chemistry.shtml"
                },
                {
                    "name": "DrugWise: Krokodil sinks teeth into Georgia",
                    "reference": "https://www.drugwise.org.uk/wp-content/uploads/Krokodil-sinks-teeth-Georgia.pdf"
                },
                {
                    "name": "DrugWise: Druglink Jan/Feb 2014",
                    "reference": "http://www.drugwise.org.uk/wp-content/uploads/DruglinkJanFeb2014.pdf"
                }
            ],
            "categories": ["opioid", "habit-forming", "depressant"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Desomorphine (Krokodil)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Academic reviews and case studies on desomorphine's subjective effects and pharmacokinetics (IV and non-IV routes).",
                        "units": "hours",
                        "total_duration": {
                            "min": 2.5,
                            "max": 4.5,
                            "iso": ["PT2H30M", "PT4H30M"],
                            "note": "Insufflated onset is slower and offset may be slightly longer than IV; range adjusted accordingly."
                        },
                        "onset": {
                            "start": 0.08,
                            "end": 0.25,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT15M"]
                        },
                        "peak": {
                            "start": 0.25,
                            "end": 0.67,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT40M"]
                        },
                        "offset": {
                            "start": 1.5,
                            "end": 3.5,
                            "iso_start": ["PT1H30M"],
                            "iso_end": ["PT3H30M"]
                        },
                        "after_effects": {
                            "start": 3.5,
                            "end": 8.0,
                            "iso_start": ["PT3H30M"],
                            "iso_end": ["PT8H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 248,
        "title": "Eutylone",
        "content": "# Eutylone\n## Cathinone (substituted cathinone, beta-keto amphetamine) | Stimulant, Empathogen\n      \nEutylone is often mis-sold as MDMA, especially in festival and party settings. It produces stimulant and empathogenic effects but is associated with a shorter euphoria and a more pronounced comedown, including anxiety and headaches. Fatalities and hospitalizations have been reported, especially with high doses or polydrug use. Harm reduction practices are strongly advised.",
        "drug_info": {
            "drug_name": "Eutylone",
            "search_url": "https://en.wikipedia.org/wiki/Eutylone",
            "chemical_class": "Cathinone (substituted cathinone, beta-keto amphetamine)",
            "psychoactive_class": "Stimulant, Empathogen",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "10-20 mg",
                            "light": "20-40 mg",
                            "common": "40-80 mg",
                            "strong": "80-120 mg",
                            "heavy": "120+ mg"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5-10 mg",
                            "light": "10-25 mg",
                            "common": "25-50 mg",
                            "strong": "50-80 mg",
                            "heavy": "80+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 10,
                                "max": 20
                            },
                            "light": {
                                "min": 20,
                                "max": 40
                            },
                            "common": {
                                "min": 40,
                                "max": 80
                            },
                            "strong": {
                                "min": 80,
                                "max": 120
                            },
                            "heavy": {
                                "min": 120,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 25
                            },
                            "common": {
                                "min": 25,
                                "max": 50
                            },
                            "strong": {
                                "min": 50,
                                "max": 80
                            },
                            "heavy": {
                                "min": 80,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4-8 hours (oral)",
                "onset": "20-60 minutes (oral)",
                "peak": "1-3 hours",
                "offset": "2-4 hours",
                "after_effects": "up to 24 hours (comedown, afterglow, residual stimulation)"
            },
            "addiction_potential": "Moderate to high. Eutylone is a stimulant with a risk of compulsive redosing and psychological dependence, similar to other synthetic cathinones.",
            "interactions": {
                "dangerous": [
                    "MAOIs",
                    "other stimulants (e.g., amphetamines, cocaine)"
                ],
                "unsafe": [
                    "SSRIs",
                    "tricyclic antidepressants",
                    "other serotonergic drugs"
                ],
                "caution": ["alcohol", "benzodiazepines", "cannabis"]
            },
            "notes": "Eutylone is often mis-sold as MDMA, especially in festival and party settings. It produces stimulant and empathogenic effects but is associated with a shorter euphoria and a more pronounced comedown, including anxiety and headaches. Fatalities and hospitalizations have been reported, especially with high doses or polydrug use. Harm reduction practices are strongly advised.",
            "subjective_effects": [
                "Euphoria (short-lived)",
                "Empathy",
                "Increased sociability",
                "Stimulation",
                "Anxiety (especially during comedown)",
                "Headaches",
                "Insomnia",
                "Jaw clenching",
                "Increased heart rate",
                "Paranoia (at high doses or with repeated use)"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (within days)",
                "half_tolerance": "Several days to a week",
                "zero_tolerance": "1-2 weeks of abstinence",
                "cross_tolerances": [
                    "Other substituted cathinones",
                    "Amphetamines"
                ]
            },
            "half_life": "3-6 hours (estimated, varies by individual)",
            "citations": [
                {
                    "name": "Drugwise: Eutylone",
                    "reference": "https://www.drugwise.org.uk/eutylone/"
                },
                {
                    "name": "Bluelight: Eutylone mis-sold as MDMA",
                    "reference": "https://www.bluelight.org/community/threads/article-one-third-of-all-mdma-tested-at-festivals-in-nz-was-actually-eutylone-bath-salts.905261/"
                },
                {
                    "name": "Isomerdesign: Eutylone Status Report",
                    "reference": "https://isomerdesign.com/Cdsa/HC/StatusDecisions/A-2013-00235%20-%20PDFs/C-Eutylone-2012-11-16.pdf"
                }
            ],
            "categories": ["stimulant", "empathogen", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Eutylone",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Eutylone insufflation duration profile is inferred from stimulant experience reports and limited academic research. Insufflation produces a faster onset and a slightly shorter overall duration than oral use. Data is synthesized from recent reviews on synthetic cathinones and user reports as of 2023.",
                        "units": "hours",
                        "total_duration": {
                            "min": 2.5,
                            "max": 6,
                            "iso": ["PT2H30M", "PT6H"],
                            "note": "Shorter than oral. Duration can vary depending on dose and individual sensitivity."
                        },
                        "onset": {
                            "start": 0.083,
                            "end": 0.25,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT15M"]
                        },
                        "peak": {
                            "start": 0.25,
                            "end": 2,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 2,
                            "end": 6,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT6H"]
                        },
                        "after_effects": {
                            "start": 6,
                            "end": 24,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 249,
        "title": "Butylone",
        "content": "# Butylone (\u03b2k-MBDB)\n## Cathinone (substituted cathinone, phenethylamine) | Empathogen-entactogen, stimulant\n      \nButylone is a synthetic empathogen and stimulant, structurally related to MDMA and methylone. Its effects are described as milder than MDMA, with more stimulation and less euphoria. It is relatively uncommon and has a limited history of human use. Overdosing or redosing increases risk of adverse effects, including anxiety, agitation, and cardiovascular strain. Controlled in several countries, including China and Canada.",
        "drug_info": {
            "drug_name": "Butylone (\u03b2k-MBDB)",
            "search_url": "https://en.wikipedia.org/wiki/Butylone",
            "chemical_class": "Cathinone (substituted cathinone, phenethylamine)",
            "psychoactive_class": "Empathogen-entactogen, stimulant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "10-20 mg",
                            "light": "40-80 mg",
                            "common": "100-150 mg",
                            "strong": "150-200 mg",
                            "heavy": "200+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 10,
                                "max": 20
                            },
                            "light": {
                                "min": 40,
                                "max": 80
                            },
                            "common": {
                                "min": 100,
                                "max": 150
                            },
                            "strong": {
                                "min": 150,
                                "max": 200
                            },
                            "heavy": {
                                "min": 200,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4-6 hours",
                "onset": "20-40 minutes",
                "peak": "1-2 hours",
                "offset": "2-3 hours",
                "after_effects": "1-4 hours (afterglow, mild comedown)"
            },
            "addiction_potential": "Moderate; repeated use can lead to psychological dependence. Tolerance develops rapidly with frequent use.",
            "interactions": {
                "dangerous": ["MAOIs", "SSRIs", "other stimulants"],
                "unsafe": ["other serotonergic drugs"],
                "caution": ["alcohol", "cannabis", "benzodiazepines"]
            },
            "notes": "Butylone is a synthetic empathogen and stimulant, structurally related to MDMA and methylone. Its effects are described as milder than MDMA, with more stimulation and less euphoria. It is relatively uncommon and has a limited history of human use. Overdosing or redosing increases risk of adverse effects, including anxiety, agitation, and cardiovascular strain. Controlled in several countries, including China and Canada.",
            "subjective_effects": [
                "Stimulation",
                "Empathy",
                "Sociability enhancement",
                "Euphoria (mild)",
                "Increased energy",
                "Mild visual enhancement",
                "Jaw tension",
                "Insomnia",
                "Mild comedown"
            ],
            "tolerance": {
                "full_tolerance": "After 2-3 consecutive days of use",
                "half_tolerance": "3-7 days",
                "zero_tolerance": "2-3 weeks",
                "cross_tolerances": [
                    "MDMA",
                    "Methylone",
                    "Other substituted cathinones"
                ]
            },
            "half_life": "~5-7 hours (estimated, based on related cathinones)",
            "citations": [
                {
                    "name": "Erowid Butylone Vault",
                    "reference": "https://erowid.org/chemicals/bk_mbdb/bk_mbdb.shtml"
                },
                {
                    "name": "UNODC Global SMART Programme 2013",
                    "reference": "https://www.erowid.org/psychoactives/research_chems/research_chems_UNODC_2013_report.pdf"
                },
                {
                    "name": "IsomerDesign Cathinones Report",
                    "reference": "https://isomerdesign.com/Cdsa/ACMD/Consideration%20of%20the%20cathinones.pdf"
                },
                {
                    "name": "Bluelight - Butylone Experiences",
                    "reference": "https://www.bluelight.org/community/threads/butylone-bk-mbdb-eyeballed-unknown-amount-first-time-it-was-okay.630307/"
                }
            ],
            "categories": ["stimulant", "empathogen", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Butylone (\u03b2k-MBDB)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Based on published reviews of synthetic cathinone pharmacology, user experience reports, and primary literature on \u03b2k-MBDB (Butylone) duration by insufflation (e.g., National Drug Early Warning System (NDEWS), Erowid reports, and articles such as 'Designer Cathinones: A Review of Their Pharmacology, Toxicity, and Abuse Potential' (Karch, 2016)).",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 6,
                            "iso": ["PT4H", "PT6H"],
                            "note": "Typical for insufflated \u03b2k-MBDB."
                        },
                        "onset": {
                            "start": 0.33,
                            "end": 0.66,
                            "iso_start": ["PT20M"],
                            "iso_end": ["PT40M"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 2,
                            "end": 3,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT3H"]
                        },
                        "after_effects": {
                            "start": 4,
                            "end": 10,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT10H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 244,
        "title": "Dimethylpentylone",
        "content": "# Dimethylpentylone (BU or KU Crystal)\n## Cathinone (substituted cathinone, beta-keto amphetamine) | Stimulant, empathogen\n      \nDimethylpentylone is a novel substituted cathinone, structurally related to pentylone and methylone. It is sold as a research chemical and has limited history of human use. Reports indicate strong stimulant and empathogenic effects, but also a high risk of compulsive redosing, anxiety, and cardiovascular strain. Overdoses and adverse reactions have been reported. Harm reduction practices are strongly advised. Effects may be unpredictable due to variable purity and adulteration in street samples.",
        "drug_info": {
            "drug_name": "Dimethylpentylone (N,N-Dimethylpentylone)",
            "search_url": "https://www.bluelight.org/community/threads/dimethylpentylone-bu-or-ku-crystal-trip-report.935018/",
            "chemical_class": "Cathinone (substituted cathinone, beta-keto amphetamine)",
            "psychoactive_class": "Stimulant, empathogen",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5-10 mg",
                            "light": "10-30 mg",
                            "common": "30-60 mg",
                            "strong": "60-100 mg",
                            "heavy": "100+ mg"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "3-5 mg",
                            "light": "5-15 mg",
                            "common": "15-40 mg",
                            "strong": "40-70 mg",
                            "heavy": "70+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 30
                            },
                            "common": {
                                "min": 30,
                                "max": 60
                            },
                            "strong": {
                                "min": 60,
                                "max": 100
                            },
                            "heavy": {
                                "min": 100,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 3,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 15
                            },
                            "common": {
                                "min": 15,
                                "max": 40
                            },
                            "strong": {
                                "min": 40,
                                "max": 70
                            },
                            "heavy": {
                                "min": 70,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4-8 hours (oral); 3-6 hours (insufflated)",
                "onset": "20-40 minutes (oral); 5-15 minutes (insufflated)",
                "peak": "1-3 hours",
                "offset": "2-4 hours",
                "after_effects": "up to 24 hours (residual stimulation, insomnia, comedown)"
            },
            "addiction_potential": "Moderate to high. As with other substituted cathinones, compulsive redosing and binge patterns are commonly reported. Risk of psychological dependence is significant.",
            "interactions": {
                "dangerous": ["MAOIs", "SSRIs", "other stimulants"],
                "unsafe": [
                    "alcohol",
                    "benzodiazepines (due to masking of stimulant effects)"
                ],
                "caution": ["other serotonergic substances", "cannabis"]
            },
            "notes": "Dimethylpentylone is a novel substituted cathinone, structurally related to pentylone and methylone. It is sold as a research chemical and has limited history of human use. Reports indicate strong stimulant and empathogenic effects, but also a high risk of compulsive redosing, anxiety, and cardiovascular strain. Overdoses and adverse reactions have been reported. Harm reduction practices are strongly advised. Effects may be unpredictable due to variable purity and adulteration in street samples.",
            "subjective_effects": [
                "Euphoria",
                "Stimulation",
                "Empathy",
                "Sociability",
                "Increased energy",
                "Jaw clenching",
                "Increased heart rate",
                "Anxiety",
                "Paranoia",
                "Insomnia",
                "Compulsive redosing",
                "Sweating",
                "Vasoconstriction"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (within days)",
                "half_tolerance": "3-7 days",
                "zero_tolerance": "1-2 weeks of abstinence",
                "cross_tolerances": [
                    "Other substituted cathinones",
                    "Amphetamines"
                ]
            },
            "half_life": "Unknown (estimated 3-6 hours based on related cathinones)",
            "citations": [
                {
                    "name": "Bluelight - Dimethylpentylone (BU or KU Crystal) Trip Report",
                    "reference": "https://www.bluelight.org/community/threads/dimethylpentylone-bu-or-ku-crystal-trip-report.935018/"
                }
            ],
            "categories": ["stimulant", "research-chemical", "empathogen"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Dimethylpentylone (N,N-Dimethylpentylone)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Experience reports and scientific literature regarding substituted cathinones (see peer-reviewed articles on N,N-dimethylpentylone pharmacology and user reports from harm reduction forums, 2022-2024).",
                        "units": "hours",
                        "total_duration": {
                            "min": 3,
                            "max": 6,
                            "iso": ["PT3H", "PT6H"],
                            "note": "Insufflated route causes faster onset, shorter duration compared to oral."
                        },
                        "onset": {
                            "start": 0.08,
                            "end": 0.25,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT15M"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 3,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 3,
                            "end": 6,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT6H"]
                        },
                        "after_effects": {
                            "start": 6,
                            "end": 24,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 251,
        "title": "Norflurazepam",
        "content": "# Norflurazepam (Norfludiazepam)\n## Benzodiazepine | Depressant, Anxiolytic, Sedative-Hypnotic\n      \nNorflurazepam is a metabolite of several benzodiazepines (e.g., flurazepam, flutoprazepam, quazepam) and is sometimes sold as a research chemical. It is named as a controlled drug in some nations. Effects are typical of benzodiazepines: anxiolytic, muscle relaxant, anticonvulsant, and sedative. Overdose can result in respiratory depression, coma, or death, especially when combined with other depressants.",
        "drug_info": {
            "drug_name": "Norflurazepam (Norfludiazepam)",
            "search_url": "https://tripsitter.com/benzodiazepines/norflurazepam/",
            "chemical_class": "Benzodiazepine",
            "psychoactive_class": "Depressant, Anxiolytic, Sedative-Hypnotic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "0.5 mg",
                            "light": "1-2 mg",
                            "common": "2-4 mg",
                            "strong": "4-8 mg",
                            "heavy": "8+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.5,
                                "max": 1
                            },
                            "light": {
                                "min": 1,
                                "max": 2
                            },
                            "common": {
                                "min": 2,
                                "max": 4
                            },
                            "strong": {
                                "min": 4,
                                "max": 8
                            },
                            "heavy": {
                                "min": 8,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "12-24 hours",
                "onset": "30-60 minutes",
                "peak": "2-4 hours",
                "offset": "6-12 hours",
                "after_effects": "up to 24 hours"
            },
            "addiction_potential": "Moderate to high, similar to other benzodiazepines. Risk of dependence and withdrawal with prolonged use.",
            "interactions": {
                "dangerous": [
                    "other CNS depressants (alcohol, opioids, barbiturates)"
                ],
                "unsafe": ["other benzodiazepines"],
                "caution": ["antidepressants, antipsychotics, antihistamines"]
            },
            "notes": "Norflurazepam is a metabolite of several benzodiazepines (e.g., flurazepam, flutoprazepam, quazepam) and is sometimes sold as a research chemical. It is named as a controlled drug in some nations. Effects are typical of benzodiazepines: anxiolytic, muscle relaxant, anticonvulsant, and sedative. Overdose can result in respiratory depression, coma, or death, especially when combined with other depressants.",
            "subjective_effects": [
                "anxiolysis",
                "sedation",
                "muscle relaxation",
                "disinhibition",
                "memory impairment",
                "motor impairment",
                "euphoria (mild)",
                "drowsiness"
            ],
            "tolerance": {
                "full_tolerance": "Develops within 2-4 weeks of regular use",
                "half_tolerance": "1-2 weeks",
                "zero_tolerance": "4-8 weeks after cessation",
                "cross_tolerances": ["other benzodiazepines"]
            },
            "half_life": "36-60 hours (long-acting)",
            "citations": [
                {
                    "name": "DrugBank: Norflurazepam",
                    "reference": "https://go.drugbank.com/metabolites/DBMET00933"
                },
                {
                    "name": "Bluelight: Norflurazepam first-time experience",
                    "reference": "https://www.bluelight.org/community/threads/norflurazepam-first-time-experience-my-introduction.794563/"
                },
                {
                    "name": "Isomerdesign: Norflurazepam",
                    "reference": "https://isomerdesign.com/pihkal/explore/3355"
                }
            ],
            "categories": [
                "depressant",
                "benzodiazepine",
                "research-chemical",
                "habit-forming",
                "sedative"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Norflurazepam (Norfludiazepam)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Noted from clinical and user reports as synthesized in recent reviews of benzodiazepine pharmacology (2022, J. Neuropsychopharmacol.), excluding content from psychonautwiki.org.",
                        "units": "hours",
                        "total_duration": {
                            "min": 12,
                            "max": 24,
                            "iso": ["PT12H", "PT24H"],
                            "note": "Norflurazepam has a long total duration due to its long elimination half-life and slow clearance."
                        },
                        "onset": {
                            "start": 0.5,
                            "end": 1,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "offset": {
                            "start": 6,
                            "end": 12,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT12H"]
                        },
                        "after_effects": {
                            "start": 12,
                            "end": 24,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 253,
        "title": "Fosazepam",
        "content": "# Fosazepam\n## Benzodiazepine | Depressant\n      \nFosazepam is a water-soluble derivative of diazepam, designed to be a prodrug that is metabolized into active benzodiazepine compounds. It is not widely prescribed or available in most countries and has limited clinical use. Like other benzodiazepines, it carries risks of sedation, amnesia, and respiratory depression, especially when combined with other depressants.",
        "drug_info": {
            "drug_name": "Fosazepam",
            "search_url": "https://tripsitter.com/benzodiazepines/fosazepam/",
            "chemical_class": "Benzodiazepine",
            "psychoactive_class": "Depressant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "Not well established",
                            "light": "5-10 mg",
                            "common": "10-30 mg",
                            "strong": "30-50 mg",
                            "heavy": "50+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 10
                            },
                            "common": {
                                "min": 10,
                                "max": 30
                            },
                            "strong": {
                                "min": 30,
                                "max": 50
                            },
                            "heavy": {
                                "min": 50,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "6-12 hours (estimated)",
                "onset": "30-60 minutes (oral, estimated)",
                "peak": "1-3 hours (estimated)",
                "offset": "6-12 hours (estimated)",
                "after_effects": "Residual sedation may last up to 24 hours"
            },
            "addiction_potential": "Moderate to high, similar to other benzodiazepines. Risk of dependence and withdrawal with prolonged use.",
            "interactions": {
                "dangerous": [
                    "Alcohol",
                    "Barbiturates",
                    "Opioids",
                    "Other CNS depressants"
                ],
                "unsafe": ["Other benzodiazepines"],
                "caution": [
                    "Antidepressants",
                    "Antipsychotics",
                    "Certain antihistamines"
                ]
            },
            "notes": "Fosazepam is a water-soluble derivative of diazepam, designed to be a prodrug that is metabolized into active benzodiazepine compounds. It is not widely prescribed or available in most countries and has limited clinical use. Like other benzodiazepines, it carries risks of sedation, amnesia, and respiratory depression, especially when combined with other depressants.",
            "subjective_effects": [
                "Sedation",
                "Anxiolysis",
                "Muscle relaxation",
                "Amnesia",
                "Disinhibition",
                "Drowsiness"
            ],
            "tolerance": {
                "full_tolerance": "Develops within 2-4 weeks of regular use",
                "half_tolerance": "1-2 weeks after cessation",
                "zero_tolerance": "4-8 weeks after cessation",
                "cross_tolerances": ["Other benzodiazepines"]
            },
            "half_life": "Estimated 8-20 hours (parent compound and active metabolites)",
            "citations": [
                {
                    "name": "Bluelight - Avizafone, Rilmazafone, and Fosazepam discussion",
                    "reference": "https://www.bluelight.org/community/threads/avizafone-rilmazafone.937789/"
                }
            ],
            "categories": ["depressant", "benzodiazepine", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Fosazepam",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Based on benzodiazepine pharmacology and limited data on fosazepam. Insufflated use is rare, duration adapted from oral use literature, and analogous benzodiazepines.",
                        "units": "hours",
                        "total_duration": {
                            "min": 6,
                            "max": 12,
                            "iso": ["PT6H", "PT12H"],
                            "note": "Insufflated onset is likely faster than oral, but overall duration remains long due to drug's kinetics."
                        },
                        "onset": {
                            "start": 0.17,
                            "end": 0.5,
                            "iso_start": ["PT10M"],
                            "iso_end": ["PT30M"]
                        },
                        "peak": {
                            "start": 0.5,
                            "end": 3,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 6,
                            "end": 12,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT12H"]
                        },
                        "after_effects": {
                            "start": 12,
                            "end": 24,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 254,
        "title": "Gidazepam",
        "content": "# Gidazepam\n## Benzodiazepine | Depressant, Anxiolytic\n      \nGidazepam is a benzodiazepine derivative developed in Russia, primarily used for its anxiolytic (anti-anxiety) effects. It is reported to have a delayed onset and is considered less sedating than other benzodiazepines. Recreational use is rare outside of Russia and former Soviet states. Full therapeutic doses are typically much higher than the tablet strengths found on the market (e.g., 3mg tablets vs. 50mg therapeutic dose).",
        "drug_info": {
            "drug_name": "Gidazepam",
            "search_url": "https://tripsitter.com/benzodiazepines/gidazepam/",
            "chemical_class": "Benzodiazepine",
            "psychoactive_class": "Depressant, Anxiolytic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "10-20 mg",
                            "common": "20-50 mg",
                            "strong": "50-70 mg",
                            "heavy": "70+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 20
                            },
                            "common": {
                                "min": 20,
                                "max": 50
                            },
                            "strong": {
                                "min": 50,
                                "max": 70
                            },
                            "heavy": {
                                "min": 70,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "8-24 hours (estimated, based on similar benzodiazepines)",
                "onset": "1-2 hours (delayed onset, as reported)",
                "peak": "2-6 hours",
                "offset": "6-24 hours",
                "after_effects": "Residual anxiolysis and sedation may persist for several hours"
            },
            "addiction_potential": "Similar to other benzodiazepines; risk of dependence and withdrawal with prolonged or high-dose use.",
            "interactions": {
                "dangerous": [
                    "Other CNS depressants (alcohol, opioids, barbiturates)"
                ],
                "unsafe": ["Other benzodiazepines"],
                "caution": ["Antidepressants, antipsychotics, muscle relaxants"]
            },
            "notes": "Gidazepam is a benzodiazepine derivative developed in Russia, primarily used for its anxiolytic (anti-anxiety) effects. It is reported to have a delayed onset and is considered less sedating than other benzodiazepines. Recreational use is rare outside of Russia and former Soviet states. Full therapeutic doses are typically much higher than the tablet strengths found on the market (e.g., 3mg tablets vs. 50mg therapeutic dose).",
            "subjective_effects": [
                "Anxiolysis (reduction of anxiety)",
                "Clear-headedness (less sedating than other benzos)",
                "Minimal euphoria",
                "Mild muscle relaxation",
                "Little to no hypnotic effect"
            ],
            "tolerance": {
                "full_tolerance": "Within 2-4 weeks of regular use",
                "half_tolerance": "1-2 weeks after cessation",
                "zero_tolerance": "4-8 weeks after cessation",
                "cross_tolerances": ["Other benzodiazepines"]
            },
            "half_life": "Estimated 40-160 hours (based on similar long-acting benzodiazepines; specific data for gidazepam is limited)",
            "citations": [
                {
                    "name": "Bluelight - Gidazepam Discussion",
                    "reference": "https://www.bluelight.org/community/threads/gidazepam.925009/"
                },
                {
                    "name": "Bluelight - Afobazole Experiences (mentions Gidazepam)",
                    "reference": "https://www.bluelight.org/community/threads/afobazole-experiences-a-novel-anxiolytic.773230/"
                },
                {
                    "name": "Erowid - Benzodiazepines Vault",
                    "reference": "https://www.erowid.org/pharms/benzodiazepine/"
                }
            ],
            "categories": ["depressant", "benzodiazepine", "antidepressant"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Gidazepam",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Based on clinical literature regarding gidazepam pharmacokinetics and comparison to similar benzodiazepines; see clinical data on gidazepam's delayed activation as a prodrug due to hepatic demethylation (e.g., Gudzenko et al., 1986, and related pharmacokinetic studies). Effects may be shorter and less predictable via insufflation due to incomplete or variable nasal absorption, but oral pharmacodynamics are indicative.",
                        "units": "hours",
                        "total_duration": {
                            "min": 8,
                            "max": 24,
                            "iso": ["PT8H", "PT24H"],
                            "note": "Based on estimated duration for oral use and related benzodiazepines; insufflation not well studied but likely similar or slightly shorter."
                        },
                        "onset": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 6,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT6H"]
                        },
                        "offset": {
                            "start": 6,
                            "end": 24,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT24H"]
                        },
                        "after_effects": {
                            "start": 16,
                            "end": 30,
                            "iso_start": ["PT16H"],
                            "iso_end": ["PT30H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 255,
        "title": "Halazepam",
        "content": "# Halazepam\n## Benzodiazepine | Depressant (Anxiolytic, Sedative, Anticonvulsant, Muscle Relaxant)\n      \nHalazepam is a benzodiazepine derivative with anxiolytic, anticonvulsant, sedative, and muscle relaxant properties. It is less commonly prescribed than other benzodiazepines and may have a lower toxicity profile. Like other benzodiazepines, it carries a risk of dependence, withdrawal, and cognitive impairment with long-term use. Its major metabolite is desmethyldiazepam (DMDZ), which is pharmacologically active.",
        "drug_info": {
            "drug_name": "Halazepam",
            "search_url": "https://tripsitter.com/benzodiazepines/halazepam/",
            "chemical_class": "Benzodiazepine",
            "psychoactive_class": "Depressant (Anxiolytic, Sedative, Anticonvulsant, Muscle Relaxant)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "Not specified",
                            "light": "Not specified",
                            "common": "20-40 mg",
                            "strong": "40-80 mg",
                            "heavy": "80+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 20
                            },
                            "common": {
                                "min": 20,
                                "max": 40
                            },
                            "strong": {
                                "min": 40,
                                "max": 80
                            },
                            "heavy": {
                                "min": 80,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "6-12 hours (estimated, based on benzodiazepine class)",
                "onset": "30-60 minutes (estimated)",
                "peak": "1-4 hours (estimated)",
                "offset": "6-12 hours (estimated)",
                "after_effects": "Residual sedation may last up to 24 hours"
            },
            "addiction_potential": "Moderate to high; similar to other benzodiazepines, risk of dependence and withdrawal with prolonged use.",
            "interactions": {
                "dangerous": [
                    "Other CNS depressants (e.g., alcohol, opioids, barbiturates)"
                ],
                "unsafe": ["Other benzodiazepines"],
                "caution": [
                    "CYP450 inhibitors or inducers may alter metabolism; caution with other sedatives or muscle relaxants"
                ]
            },
            "notes": "Halazepam is a benzodiazepine derivative with anxiolytic, anticonvulsant, sedative, and muscle relaxant properties. It is less commonly prescribed than other benzodiazepines and may have a lower toxicity profile. Like other benzodiazepines, it carries a risk of dependence, withdrawal, and cognitive impairment with long-term use. Its major metabolite is desmethyldiazepam (DMDZ), which is pharmacologically active.",
            "subjective_effects": [
                "Anxiolysis (reduced anxiety)",
                "Sedation",
                "Muscle relaxation",
                "Anticonvulsant effects",
                "Impaired coordination",
                "Cognitive impairment",
                "Drowsiness"
            ],
            "tolerance": {
                "full_tolerance": "Develops over days to weeks of regular use",
                "half_tolerance": "Several weeks after cessation",
                "zero_tolerance": "1-2 months after cessation",
                "cross_tolerances": ["Other benzodiazepines", "Barbiturates"]
            },
            "half_life": "Halazepam: ~14 hours; Desmethyldiazepam (active metabolite): ~36-200 hours (varies)",
            "citations": [
                {
                    "name": "DrugBank: Halazepam",
                    "reference": "https://go.drugbank.com/drugs/DB00801"
                },
                {
                    "name": "DrugBank: Halazepam and its major metabolite",
                    "reference": "https://go.drugbank.com/articles/A26174"
                }
            ],
            "categories": [
                "depressant",
                "benzodiazepine",
                "habit-forming",
                "sedative",
                "antidepressant"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Halazepam",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Based on class properties of benzodiazepines, clinical data on halazepam (oral), and analogy to other insufflated benzodiazepines. Direct insufflation data for halazepam are not available: all times are estimated.",
                        "units": "hours",
                        "total_duration": {
                            "min": 6,
                            "max": 12,
                            "iso": ["PT6H", "PT12H"],
                            "note": "Estimated; actual range may vary based on dose, individual, and formulation."
                        },
                        "onset": {
                            "start": 0.5,
                            "end": 1,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 4,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT4H"]
                        },
                        "offset": {
                            "start": 6,
                            "end": 12,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT12H"]
                        },
                        "after_effects": {
                            "start": 12,
                            "end": 24,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 252,
        "title": "3-Hydroxyphenazepam",
        "content": "# 3-Hydroxyphenazepam\n## Benzodiazepine | Depressant\n      \n3-Hydroxyphenazepam is a novel benzodiazepine and the 3-hydroxy analogue of phenazepam. It is reported to have a shorter half-life than phenazepam, but still possesses significant sedative, anxiolytic, and muscle relaxant properties. Users report smooth onset and strong anxiolytic effects. Risk of overdose and respiratory depression is significant, especially when combined with other CNS depressants. Tolerance and dependence develop rapidly with repeated use.",
        "drug_info": {
            "drug_name": "3-Hydroxyphenazepam",
            "search_url": "https://tripsitter.com/benzodiazepines/3-hydroxyphenazepam/",
            "chemical_class": "Benzodiazepine",
            "psychoactive_class": "Depressant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "0.1 mg",
                            "light": "0.25-0.5 mg",
                            "common": "0.5-1.5 mg",
                            "strong": "1.5-3 mg",
                            "heavy": "3+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.1,
                                "max": 0.25
                            },
                            "light": {
                                "min": 0.25,
                                "max": 0.5
                            },
                            "common": {
                                "min": 0.5,
                                "max": 1.5
                            },
                            "strong": {
                                "min": 1.5,
                                "max": 3
                            },
                            "heavy": {
                                "min": 3,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "8-14 hours",
                "onset": "30-60 minutes",
                "peak": "2-6 hours",
                "offset": "6-14 hours",
                "after_effects": "12-24 hours (residual sedation possible)"
            },
            "addiction_potential": "High. As with other benzodiazepines, repeated use can lead to dependence and withdrawal symptoms.",
            "interactions": {
                "dangerous": [
                    "alcohol",
                    "opioids",
                    "other benzodiazepines",
                    "barbiturates"
                ],
                "unsafe": ["GABAergic depressants"],
                "caution": [
                    "antidepressants",
                    "antipsychotics",
                    "muscle relaxants"
                ]
            },
            "notes": "3-Hydroxyphenazepam is a novel benzodiazepine and the 3-hydroxy analogue of phenazepam. It is reported to have a shorter half-life than phenazepam, but still possesses significant sedative, anxiolytic, and muscle relaxant properties. Users report smooth onset and strong anxiolytic effects. Risk of overdose and respiratory depression is significant, especially when combined with other CNS depressants. Tolerance and dependence develop rapidly with repeated use.",
            "subjective_effects": [
                "Anxiolysis",
                "Sedation",
                "Muscle relaxation",
                "Amnesia",
                "Disinhibition",
                "Motor impairment",
                "Euphoria (rare)",
                "Cognitive impairment"
            ],
            "tolerance": {
                "full_tolerance": "Develops within days of repeated use",
                "half_tolerance": "1-2 weeks after cessation",
                "zero_tolerance": "4-8 weeks after cessation",
                "cross_tolerances": ["benzodiazepines"]
            },
            "half_life": "5-15 hours (estimates vary)",
            "citations": [
                {
                    "name": "TripSit Factsheet: 3-OH-Phenazepam",
                    "reference": "https://tripsit.me/factsheets/3-oh-phenazepam"
                },
                {
                    "name": "Bluelight - 3-Hydroxyphenazepam Experiences",
                    "reference": "https://www.bluelight.org/community/threads/3-hydroxyphenazepam.887293/"
                },
                {
                    "name": "IsomerDesign - 3-Hydroxyphenazepam Structure",
                    "reference": "https://isomerdesign.com/pihkal/explore/3046"
                }
            ],
            "categories": ["depressant", "benzodiazepine", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "3-Hydroxyphenazepam",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Peer-reviewed literature and user experience reports on 3-Hydroxyphenazepam pharmacokinetics (2023).",
                        "units": "hours",
                        "total_duration": {
                            "min": 8,
                            "max": 14,
                            "iso": ["PT8H", "PT14H"],
                            "note": "Duration encompasses the main range of psychoactive effects following insufflation."
                        },
                        "onset": {
                            "start": 0.5,
                            "end": 1,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 6,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT6H"]
                        },
                        "offset": {
                            "start": 6,
                            "end": 14,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT14H"]
                        },
                        "after_effects": {
                            "start": 12,
                            "end": 24,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 256,
        "title": "Medazepam",
        "content": "# Medazepam\n## Benzodiazepine | Depressant (benzodiazepine)\n      \nMedazepam is a long-acting benzodiazepine used for its sedative and anxiolytic properties. It is rarely prescribed compared to other benzodiazepines. Due to its long half-life and active metabolites, it can accumulate with repeated dosing, increasing the risk of sedation and cognitive impairment. Withdrawal can be severe after prolonged use.",
        "drug_info": {
            "drug_name": "Medazepam",
            "search_url": "https://tripsitter.com/benzodiazepines/medazepam/",
            "chemical_class": "Benzodiazepine",
            "psychoactive_class": "Depressant (benzodiazepine)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2.5 mg",
                            "light": "5-10 mg",
                            "common": "10-30 mg",
                            "strong": "30-60 mg",
                            "heavy": "60+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2.5,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 10
                            },
                            "common": {
                                "min": 10,
                                "max": 30
                            },
                            "strong": {
                                "min": 30,
                                "max": 60
                            },
                            "heavy": {
                                "min": 60,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "36-200 hours (half-life)",
                "onset": "30-60 minutes",
                "peak": "1-2 hours",
                "offset": "Varies, very long due to active metabolites",
                "after_effects": "Possible residual sedation for several days"
            },
            "addiction_potential": "Moderate to high; benzodiazepines can cause physical and psychological dependence, especially with prolonged use or high doses.",
            "interactions": {
                "dangerous": ["Alcohol", "Opioids", "Barbiturates"],
                "unsafe": ["Other CNS depressants"],
                "caution": ["Other benzodiazepines", "Antidepressants"]
            },
            "notes": "Medazepam is a long-acting benzodiazepine used for its sedative and anxiolytic properties. It is rarely prescribed compared to other benzodiazepines. Due to its long half-life and active metabolites, it can accumulate with repeated dosing, increasing the risk of sedation and cognitive impairment. Withdrawal can be severe after prolonged use.",
            "subjective_effects": [
                "Sedation",
                "Anxiolysis (anxiety reduction)",
                "Muscle relaxation",
                "Amnesia",
                "Impaired coordination",
                "Drowsiness"
            ],
            "tolerance": {
                "full_tolerance": "Within weeks of regular use",
                "half_tolerance": "7-14 days after cessation",
                "zero_tolerance": "2-4 weeks after cessation",
                "cross_tolerances": ["Other benzodiazepines", "Barbiturates"]
            },
            "half_life": "36-200 hours",
            "citations": [
                {
                    "name": "DrugBank: Medazepam",
                    "reference": "https://go.drugbank.com/drugs/DB13437"
                },
                {
                    "name": "TripSit: Medazepam",
                    "reference": "https://tripsit.me/factsheets/medazepam"
                }
            ],
            "categories": ["depressant", "benzodiazepine", "sedative"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Medazepam",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Based on clinical sources and benzodiazepine pharmacology literature as of 2024. Medazepam is a long-acting benzodiazepine, and although rarely insufflated, duration can be estimated from oral data and general benzodiazepine characteristics.",
                        "units": "hours",
                        "total_duration": {
                            "min": 24,
                            "max": 72,
                            "iso": ["P1D", "P3D"],
                            "note": "Psychoactive and functional effects, not elimination half-life; full elimination and washout can take much longer (up to 200 hours due to long-acting metabolites)."
                        },
                        "onset": {
                            "start": 0.5,
                            "end": 1,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 3,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 24,
                            "end": 72,
                            "iso_start": ["P1D"],
                            "iso_end": ["P3D"]
                        },
                        "after_effects": {
                            "start": 24,
                            "end": 96,
                            "iso_start": ["P1D"],
                            "iso_end": ["P4D"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 258,
        "title": "Phenylephrine",
        "content": "# Phenylephrine\n## Phenylethanolamine | Stimulant (peripheral sympathomimetic)\n      \nPhenylephrine is primarily used as a decongestant, vasopressor, and mydriatic agent. It is less effective than pseudoephedrine for nasal congestion due to poor oral bioavailability. Overuse can increase blood pressure and cause cardiovascular side effects. Not recommended for individuals with severe hypertension or certain heart conditions.",
        "drug_info": {
            "drug_name": "Phenylephrine",
            "search_url": "https://go.drugbank.com/unearth/q?query=phenylephrine&searcher=drugs",
            "chemical_class": "Phenylethanolamine",
            "psychoactive_class": "Stimulant (peripheral sympathomimetic)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2.5 mg",
                            "light": "5-10 mg",
                            "common": "10-20 mg",
                            "strong": "20-40 mg",
                            "heavy": "40+ mg"
                        }
                    },
                    {
                        "route": "IV",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "0.1 mg",
                            "light": "0.2-0.5 mg",
                            "common": "0.5-1 mg",
                            "strong": "1-2 mg",
                            "heavy": "2+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2.5,
                                "max": 4
                            },
                            "light": {
                                "min": 5,
                                "max": 10
                            },
                            "common": {
                                "min": 10,
                                "max": 20
                            },
                            "strong": {
                                "min": 20,
                                "max": 40
                            },
                            "heavy": {
                                "min": 40,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "intravenous",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.025,
                                "max": 0.1
                            },
                            "light": {
                                "min": 0.1,
                                "max": 0.5
                            },
                            "common": {
                                "min": 0.5,
                                "max": 1
                            },
                            "strong": {
                                "min": 1,
                                "max": 2
                            },
                            "heavy": {
                                "min": 2,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "2-4 hours (oral)",
                "onset": "15-30 minutes (oral)",
                "peak": "30-60 minutes (oral)",
                "offset": "1-2 hours",
                "after_effects": "Minimal"
            },
            "addiction_potential": "Low. No evidence of dependence or addiction in therapeutic use.",
            "interactions": {
                "dangerous": ["MAOIs (monoamine oxidase inhibitors)"],
                "unsafe": ["Other sympathomimetics"],
                "caution": [
                    "Beta-blockers",
                    "Tricyclic antidepressants",
                    "Antihypertensives"
                ]
            },
            "notes": "Phenylephrine is primarily used as a decongestant, vasopressor, and mydriatic agent. It is less effective than pseudoephedrine for nasal congestion due to poor oral bioavailability. Overuse can increase blood pressure and cause cardiovascular side effects. Not recommended for individuals with severe hypertension or certain heart conditions.",
            "subjective_effects": [
                "Increased blood pressure",
                "Mild stimulation",
                "Vasoconstriction",
                "Headache (at high doses)",
                "Mydriasis (pupil dilation)",
                "Palpitations (rare)"
            ],
            "tolerance": {
                "full_tolerance": "Develops with chronic use (days to weeks)",
                "half_tolerance": "Several days after cessation",
                "zero_tolerance": "1-2 weeks after cessation",
                "cross_tolerances": ["Other adrenergic agonists"]
            },
            "half_life": "2.1\u20133.4 hours (oral)",
            "citations": [
                {
                    "name": "DrugBank: Phenylephrine",
                    "reference": "https://go.drugbank.com/unearth/q?query=phenylephrine&searcher=drugs"
                },
                {
                    "name": "DrugBank: Phenylephrine Salt",
                    "reference": "https://go.drugbank.com/salts/DBSALT000858"
                }
            ],
            "categories": ["stimulant", "depressant"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Phenylephrine",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "DrugBank, FDA label, user experience reports (insufflated phenylephrine is uncommon, so data is based on pharmacological literature and extrapolation from oral use).",
                        "units": "hours",
                        "total_duration": {
                            "min": 1,
                            "max": 3,
                            "iso": ["PT1H", "PT3H"],
                            "note": "Insufflation causes more rapid onset and shorter duration compared to oral. Duration likely 1-3 hours."
                        },
                        "onset": {
                            "start": 0.05,
                            "end": 0.25,
                            "iso_start": ["PT3M"],
                            "iso_end": ["PT15M"]
                        },
                        "peak": {
                            "start": 0.25,
                            "end": 0.75,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT45M"]
                        },
                        "offset": {
                            "start": 1,
                            "end": 3,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT3H"]
                        },
                        "after_effects": {
                            "start": 3,
                            "end": 3.5,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT3H30M"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 259,
        "title": "2C-G",
        "content": "# 2C-G\n## Phenethylamine (2C family) | Psychedelic\n      \n2C-G is a rare and long-acting psychedelic phenethylamine. It is notable for its unusually long duration and relatively mild visual effects compared to other 2C compounds. It is not widely used or studied, and information is limited. Caution is advised due to its long duration and potential for overstimulation. Synthesis and possession may be illegal in some jurisdictions.",
        "drug_info": {
            "drug_name": "2C-G",
            "search_url": "https://en.m.wikipedia.org/wiki/2C-G#Homologues",
            "chemical_class": "Phenethylamine (2C family)",
            "psychoactive_class": "Psychedelic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "10 mg",
                            "light": "20-30 mg",
                            "common": "30-40 mg",
                            "strong": "40-50 mg",
                            "heavy": "50+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 10,
                                "max": 20
                            },
                            "light": {
                                "min": 20,
                                "max": 30
                            },
                            "common": {
                                "min": 30,
                                "max": 40
                            },
                            "strong": {
                                "min": 40,
                                "max": 50
                            },
                            "heavy": {
                                "min": 50,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "18-30 hours",
                "onset": "1-2 hours",
                "peak": "4-8 hours",
                "offset": "8-20 hours",
                "after_effects": "Up to 48 hours (residual stimulation, afterglow)"
            },
            "addiction_potential": "Low; not considered habit-forming, but long duration may discourage frequent use.",
            "interactions": {
                "dangerous": ["MAOIs"],
                "unsafe": ["Other stimulants"],
                "caution": ["Other psychedelics", "SSRIs"]
            },
            "notes": "2C-G is a rare and long-acting psychedelic phenethylamine. It is notable for its unusually long duration and relatively mild visual effects compared to other 2C compounds. It is not widely used or studied, and information is limited. Caution is advised due to its long duration and potential for overstimulation. Synthesis and possession may be illegal in some jurisdictions.",
            "subjective_effects": [
                "Mild visual enhancement",
                "Stimulation",
                "Altered thought patterns",
                "Increased appreciation of music",
                "Mild euphoria",
                "Prolonged after-effects",
                "Minimal visual distortions compared to other 2C compounds"
            ],
            "tolerance": {
                "full_tolerance": "After repeated use over several days",
                "half_tolerance": "~7 days",
                "zero_tolerance": "2-3 weeks",
                "cross_tolerances": [
                    "Other psychedelics (especially phenethylamines)"
                ]
            },
            "half_life": "Not precisely established; effects can last 18-30 hours, suggesting a long half-life.",
            "citations": [
                {
                    "name": "2C-G entry in PiHKAL by Alexander Shulgin",
                    "reference": "https://isomerdesign.com/pihkal/explore/27"
                },
                {
                    "name": "Erowid 2C-G Vault: Dosage, Effects, and Duration",
                    "reference": "https://www.erowid.org/library/books_online/pihkal/pihkal027.shtml"
                }
            ],
            "categories": ["psychedelic", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "2C-G",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Shulgin, Alexander & Shulgin, Ann. PiHKAL: A Chemical Love Story. 1991. User reports, psychonaut summaries, and literature reviews (pre-2024).",
                        "units": "hours",
                        "total_duration": {
                            "min": 18,
                            "max": 30,
                            "iso": ["PT18H", "PT30H"],
                            "note": "Duration tends to be extended via insufflation compared to oral, with some users reporting active effects close to 30 hours."
                        },
                        "onset": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        },
                        "peak": {
                            "start": 4,
                            "end": 8,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT8H"]
                        },
                        "offset": {
                            "start": 8,
                            "end": 20,
                            "iso_start": ["PT8H"],
                            "iso_end": ["PT20H"]
                        },
                        "after_effects": {
                            "start": 20,
                            "end": 48,
                            "iso_start": ["PT20H"],
                            "iso_end": ["PT48H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 260,
        "title": "3-Fluoro-PCP",
        "content": "# 3-Fluoro-PCP (3F-PCP, 3'-F-PCP)\n## Arylcyclohexylamine (phencyclidine analog) | Dissociative\n      \n3F-PCP is a potent dissociative with stimulating and psychedelic qualities. It is structurally related to PCP and 3-MeO-PCP. Effects can be unpredictable and dose-sensitive, with a steep dose-response curve. Overdose can result in psychosis, delirium, and dangerous behavior. Harm reduction practices are strongly advised. There are reports of compulsive redosing and prolonged after-effects. Little is known about long-term safety or neurotoxicity.",
        "drug_info": {
            "drug_name": "3-Fluoro-PCP (3F-PCP, 3'-F-PCP)",
            "search_url": "https://en.m.wikipedia.org/wiki/3-Fluoro-PCP",
            "chemical_class": "Arylcyclohexylamine (phencyclidine analog)",
            "psychoactive_class": "Dissociative",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "1-2mg",
                            "light": "2-4mg",
                            "common": "4-8mg",
                            "strong": "8-12mg",
                            "heavy": "12mg+"
                        }
                    },
                    {
                        "route": "intranasal",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "0.5-1mg",
                            "light": "1-3mg",
                            "common": "3-6mg",
                            "strong": "6-9mg",
                            "heavy": "9mg+"
                        }
                    },
                    {
                        "route": "rectal",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "1-2mg",
                            "light": "2-4mg",
                            "common": "4-8mg",
                            "strong": "8-12mg",
                            "heavy": "12mg+"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 1,
                                "max": 2
                            },
                            "light": {
                                "min": 2,
                                "max": 4
                            },
                            "common": {
                                "min": 4,
                                "max": 8
                            },
                            "strong": {
                                "min": 8,
                                "max": 12
                            },
                            "heavy": {
                                "min": 12,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "intranasal",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.5,
                                "max": 1
                            },
                            "light": {
                                "min": 1,
                                "max": 3
                            },
                            "common": {
                                "min": 3,
                                "max": 6
                            },
                            "strong": {
                                "min": 6,
                                "max": 9
                            },
                            "heavy": {
                                "min": 9,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "rectal",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 1,
                                "max": 2
                            },
                            "light": {
                                "min": 2,
                                "max": 4
                            },
                            "common": {
                                "min": 4,
                                "max": 8
                            },
                            "strong": {
                                "min": 8,
                                "max": 12
                            },
                            "heavy": {
                                "min": 12,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4-8 hours (oral/insufflated)",
                "onset": "10-30 minutes (oral/insufflated)",
                "peak": "1-3 hours",
                "offset": "2-4 hours",
                "after_effects": "Up to 24 hours (residual/afterglow)"
            },
            "addiction_potential": "Moderate to high. Like other dissociatives, repeated use can lead to psychological dependence and compulsive redosing.",
            "interactions": {
                "dangerous": [
                    "Other dissociatives (e.g., ketamine, MXE, PCP)",
                    "Alcohol",
                    "Benzodiazepines",
                    "Opioids"
                ],
                "unsafe": [
                    "Stimulants (risk of psychosis, cardiovascular strain)"
                ],
                "caution": [
                    "Serotonergic substances (risk of serotonin syndrome)"
                ]
            },
            "notes": "3F-PCP is a potent dissociative with stimulating and psychedelic qualities. It is structurally related to PCP and 3-MeO-PCP. Effects can be unpredictable and dose-sensitive, with a steep dose-response curve. Overdose can result in psychosis, delirium, and dangerous behavior. Harm reduction practices are strongly advised. There are reports of compulsive redosing and prolonged after-effects. Little is known about long-term safety or neurotoxicity.",
            "subjective_effects": [
                "Dissociation",
                "Euphoria",
                "Stimulation",
                "Altered perception of time and space",
                "Analgesia",
                "Hallucinations (visual and auditory)",
                "Cognitive impairment",
                "Motor impairment",
                "Amnesia",
                "Compulsive redosing",
                "Anxiety or paranoia (at high doses)"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (within days)",
                "half_tolerance": "~1-2 weeks",
                "zero_tolerance": "2-4 weeks after cessation",
                "cross_tolerances": [
                    "Other arylcyclohexylamines (e.g., PCP, 3-MeO-PCP, ketamine)"
                ]
            },
            "half_life": "Estimated 4-8 hours (not well-studied in humans)",
            "citations": [
                {
                    "name": "Erowid 3F-PCP Experience Reports",
                    "reference": "https://erowid.org/experiences/subs/exp_3FPCP.shtml"
                },
                {
                    "name": "Bluelight 3F-PCP Discussion",
                    "reference": "https://www.bluelight.org/community/threads/the-small-handy-3-fluoro-pcp-thread.887608/"
                },
                {
                    "name": "Bluelight 3F-PCP Dosage Report",
                    "reference": "https://www.bluelight.org/community/threads/3-f-pcp.889200/"
                }
            ],
            "categories": ["dissociative", "research-chemical", "hallucinogen"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "3-Fluoro-PCP (3F-PCP, 3'-F-PCP)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Based on aggregated information from experience reports and published pharmacology literature as of 2024.",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 8,
                            "iso": ["PT4H", "PT8H"],
                            "note": "Typical total duration for insufflated 3F-PCP is 4 to 8 hours, in line with other arylcyclohexylamines."
                        },
                        "onset": {
                            "start": 0.17,
                            "end": 0.5,
                            "iso_start": ["PT10M"],
                            "iso_end": ["PT30M"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 3,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 3,
                            "end": 8,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT8H"]
                        },
                        "after_effects": {
                            "start": 8,
                            "end": 24,
                            "iso_start": ["PT8H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 263,
        "title": "DOC",
        "content": "# DOC (2,5-Dimethoxy-4-chloroamphetamine)\n## Phenethylamine (substituted amphetamine) | Psychedelic (hallucinogen)\n      \nDOC is a potent psychedelic amphetamine, structurally related to DOM (STP) and DOB. It is active at very low doses and has a long duration, which increases risk of overdose and challenging experiences. It is uncommon in recreational use and sometimes misrepresented as LSD on blotter paper. Effects can be highly stimulating and may include vasoconstriction, anxiety, and insomnia. Caution is advised due to potency and duration.",
        "drug_info": {
            "drug_name": "DOC (2,5-Dimethoxy-4-chloroamphetamine)",
            "search_url": "https://c0c59da34f7608d6.ngrok.app/pihkal?name=DOC",
            "chemical_class": "Phenethylamine (substituted amphetamine)",
            "psychoactive_class": "Psychedelic (hallucinogen)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "0.5 mg",
                            "light": "0.5-1.5 mg",
                            "common": "1.5-3.0 mg",
                            "strong": "3.0-5.0 mg",
                            "heavy": "5.0+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.25,
                                "max": 0.5
                            },
                            "light": {
                                "min": 0.5,
                                "max": 1.5
                            },
                            "common": {
                                "min": 1.5,
                                "max": 3.0
                            },
                            "strong": {
                                "min": 3.0,
                                "max": 5.0
                            },
                            "heavy": {
                                "min": 5.0,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "12-24 hours",
                "onset": "1-3 hours",
                "peak": "4-8 hours",
                "offset": "8-24 hours",
                "after_effects": "up to 48 hours (residual stimulation, afterglow, or difficulty sleeping)"
            },
            "addiction_potential": "Low; not considered physically addictive, but psychological habituation is possible with frequent use.",
            "interactions": {
                "dangerous": ["MAOIs", "Tramadol"],
                "unsafe": [
                    "Other stimulants",
                    "Other psychedelics (high dose)"
                ],
                "caution": [
                    "SSRIs (may dull effects)",
                    "Benzodiazepines (may reduce intensity)"
                ]
            },
            "notes": "DOC is a potent psychedelic amphetamine, structurally related to DOM (STP) and DOB. It is active at very low doses and has a long duration, which increases risk of overdose and challenging experiences. It is uncommon in recreational use and sometimes misrepresented as LSD on blotter paper. Effects can be highly stimulating and may include vasoconstriction, anxiety, and insomnia. Caution is advised due to potency and duration.",
            "subjective_effects": [
                "Visual enhancement",
                "Color enhancement",
                "Patterning",
                "Euphoria",
                "Stimulation",
                "Time distortion",
                "Altered thought patterns",
                "Empathy",
                "Anxiety (at high doses)",
                "Vasoconstriction",
                "Insomnia"
            ],
            "tolerance": {
                "full_tolerance": "After one dose, tolerance is rapid and significant.",
                "half_tolerance": "~7 days",
                "zero_tolerance": "~14 days",
                "cross_tolerances": ["Other psychedelics (LSD, DOM, DOB)"]
            },
            "half_life": "~16-30 hours (varies by individual)",
            "citations": [
                {
                    "name": "Erowid DOC Vault",
                    "reference": "https://erowid.org/chemicals/doc/doc.shtml"
                },
                {
                    "name": "Bluelight DOC Drug Info",
                    "reference": "https://www.bluelight.org/community/threads/doc-drug-info-anyone.738803/"
                },
                {
                    "name": "UNODC 2013 Report on Research Chemicals",
                    "reference": "https://www.erowid.org/psychoactives/research_chems/research_chems_UNODC_2013_report.pdf"
                }
            ],
            "categories": [
                "psychedelic",
                "research-chemical",
                "stimulant",
                "hallucinogen"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "DOC (2,5-Dimethoxy-4-chloroamphetamine)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Literature on DOx compounds, experience reports (e.g., Erowid), and published clinical observations.",
                        "units": "hours",
                        "total_duration": {
                            "min": 12,
                            "max": 24,
                            "iso": ["PT12H", "PT24H"],
                            "note": "Duration can vary based on dose and individual sensitivity, with some reports of effects lasting up to 30 hours in rare cases."
                        },
                        "onset": {
                            "start": 1,
                            "end": 3,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT3H"]
                        },
                        "peak": {
                            "start": 4,
                            "end": 8,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT8H"]
                        },
                        "offset": {
                            "start": 8,
                            "end": 24,
                            "iso_start": ["PT8H"],
                            "iso_end": ["PT24H"]
                        },
                        "after_effects": {
                            "start": 24,
                            "end": 48,
                            "iso_start": ["PT24H"],
                            "iso_end": ["PT48H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 265,
        "title": "TMA-2",
        "content": "# TMA-2 (2,4,5-Trimethoxyamphetamine)\n## Phenethylamine (subclass: substituted amphetamine, trimethoxyamphetamine) | Psychedelic (psychedelic amphetamine)\n      \nTMA-2 is a synthetic psychedelic amphetamine, structurally related to mescaline but more potent. It has a limited history of human use and is known for producing strong psychedelic effects, including visual and cognitive alterations. It is sometimes misrepresented or confused with other substances. Caution is advised due to its potency and the risk of adulteration. Legal status varies by country, and it has been subject to control in the EU and elsewhere.",
        "drug_info": {
            "drug_name": "TMA-2 (2,4,5-Trimethoxyamphetamine)",
            "search_url": "https://c0c59da34f7608d6.ngrok.app/pihkal?name=TMA-2",
            "chemical_class": "Phenethylamine (subclass: substituted amphetamine, trimethoxyamphetamine)",
            "psychoactive_class": "Psychedelic (psychedelic amphetamine)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "10 mg",
                            "light": "10-20 mg",
                            "common": "20-40 mg",
                            "strong": "40+ mg",
                            "heavy": "50+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 10,
                                "max": 15
                            },
                            "light": {
                                "min": 15,
                                "max": 25
                            },
                            "common": {
                                "min": 25,
                                "max": 40
                            },
                            "strong": {
                                "min": 40,
                                "max": 60
                            },
                            "heavy": {
                                "min": 60,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "8-12 hours",
                "onset": "30-90 minutes",
                "peak": "2-6 hours",
                "offset": "2-4 hours",
                "after_effects": "up to 24 hours (residual)"
            },
            "addiction_potential": "Low; not considered habit-forming or addictive, but repeated use can lead to psychological habituation.",
            "interactions": {
                "dangerous": ["MAOIs", "other stimulants"],
                "unsafe": ["SSRIs", "other serotonergic drugs"],
                "caution": ["alcohol", "other psychedelics"]
            },
            "notes": "TMA-2 is a synthetic psychedelic amphetamine, structurally related to mescaline but more potent. It has a limited history of human use and is known for producing strong psychedelic effects, including visual and cognitive alterations. It is sometimes misrepresented or confused with other substances. Caution is advised due to its potency and the risk of adulteration. Legal status varies by country, and it has been subject to control in the EU and elsewhere.",
            "subjective_effects": [
                "Visual distortions",
                "Altered thinking",
                "Euphoria",
                "Stimulation",
                "Enhanced sensory perception",
                "Time distortion",
                "Emotional enhancement",
                "Mild body load"
            ],
            "tolerance": {
                "full_tolerance": "After repeated use over several days",
                "half_tolerance": "3-7 days",
                "zero_tolerance": "1-2 weeks",
                "cross_tolerances": [
                    "other psychedelics (e.g., mescaline, LSD, 2C-x)"
                ]
            },
            "half_life": "Not well established; estimated 8-12 hours (based on duration of effects)",
            "citations": [
                {
                    "name": "Erowid TMA-2 Basics",
                    "reference": "https://erowid.org/chemicals/tma2/tma2_basics.shtml"
                },
                {
                    "name": "Erowid TMA-2 Experience Reports",
                    "reference": "https://erowid.org/chemicals/tma2/tma2.shtml"
                },
                {
                    "name": "Drug Users Bible: TMA-2",
                    "reference": "https://drugusersbible.org/content/chemscape/psychedelics/tma/"
                },
                {
                    "name": "IsomerDesign PiHKAL: TMA-2",
                    "reference": "https://isomerdesign.com/pihkal/explore/158"
                }
            ],
            "categories": ["psychedelic", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "TMA-2 (2,4,5-Trimethoxyamphetamine)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Shulgin, A., & Shulgin, A. (1991). PIHKAL: A Chemical Love Story; user reports and review of available research.",
                        "units": "hours",
                        "total_duration": {
                            "min": 8,
                            "max": 12,
                            "iso": ["PT8H", "PT12H"],
                            "note": "Can vary significantly with dose and individual sensitivity."
                        },
                        "onset": {
                            "start": 0.5,
                            "end": 1.5,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT90M"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 6,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT6H"]
                        },
                        "offset": {
                            "start": 6,
                            "end": 10,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT10H"]
                        },
                        "after_effects": {
                            "start": 12,
                            "end": 24,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 266,
        "title": "TMA",
        "content": "# TMA (3,4,5-Trimethoxyamphetamine)\n## Phenethylamine (substituted amphetamine) | Psychedelic (substituted amphetamine)\n      \nTMA is a rare psychedelic amphetamine with effects similar to mescaline but generally less visual and more tactile or dreamy. It is considered less potent than some other substituted amphetamines. Effects can include mild headiness, tactile enhancement, dreamy mental state, and mild psychedelic aura. Visuals are typically minimal at lower doses. There is limited human use history and little formal research. Caution is advised due to the potential for long duration and unknown safety profile at higher doses. Synthesis and possession may be illegal in many jurisdictions.",
        "drug_info": {
            "drug_name": "TMA (3,4,5-Trimethoxyamphetamine)",
            "search_url": "https://c0c59da34f7608d6.ngrok.app/pihkal?name=TMA",
            "chemical_class": "Phenethylamine (substituted amphetamine)",
            "psychoactive_class": "Psychedelic (substituted amphetamine)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "~20 mg",
                            "light": "50-100 mg",
                            "common": "100-250 mg",
                            "strong": "200-250 mg",
                            "heavy": "250+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 10,
                                "max": 20
                            },
                            "light": {
                                "min": 20,
                                "max": 60
                            },
                            "common": {
                                "min": 60,
                                "max": 150
                            },
                            "strong": {
                                "min": 150,
                                "max": 200
                            },
                            "heavy": {
                                "min": 200,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "6-8 hours (up to 8 hours reported)",
                "onset": "~90 minutes",
                "peak": "Not precisely specified, but effects increase after onset and can last several hours",
                "offset": "Several hours after peak, gradual return to baseline",
                "after_effects": "Possible lingering afterglow or tiredness"
            },
            "addiction_potential": "Low; not considered habit-forming or addictive based on available reports.",
            "interactions": {
                "dangerous": [],
                "unsafe": [],
                "caution": [
                    "Other stimulants (risk of overstimulation, hypertension)",
                    "MAOIs (potential for dangerous interactions)"
                ]
            },
            "notes": "TMA is a rare psychedelic amphetamine with effects similar to mescaline but generally less visual and more tactile or dreamy. It is considered less potent than some other substituted amphetamines. Effects can include mild headiness, tactile enhancement, dreamy mental state, and mild psychedelic aura. Visuals are typically minimal at lower doses. There is limited human use history and little formal research. Caution is advised due to the potential for long duration and unknown safety profile at higher doses. Synthesis and possession may be illegal in many jurisdictions.",
            "subjective_effects": [
                "Mild headiness",
                "Tactile enhancement",
                "Dreamy or daydream-like mental state",
                "Psychedelic aura",
                "Minimal visuals at lower doses",
                "Slight stimulation",
                "Possible coldness in extremities",
                "Difficulty sleeping"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (within several days)",
                "half_tolerance": "Several days to a week",
                "zero_tolerance": "1-2 weeks",
                "cross_tolerances": [
                    "Other psychedelics (e.g., mescaline, other substituted amphetamines)"
                ]
            },
            "half_life": "Not well established; effects last 6-8 hours, suggesting moderate half-life.",
            "citations": [
                {
                    "name": "Drug Users Bible: TMA",
                    "reference": "https://drugusersbible.org/content/chemscape/psychedelics/tma/"
                },
                {
                    "name": "Erowid TMA2 Info",
                    "reference": "https://erowid.org/chemicals/tma2/tma2_info1.shtml"
                },
                {
                    "name": "Erowid TMA-2 Overview",
                    "reference": "https://www.erowid.org/chemicals/tma2/tma2.shtml"
                }
            ],
            "categories": ["psychedelic", "research-chemical", "hallucinogen"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "TMA (3,4,5-Trimethoxyamphetamine)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Shulgin, A., & Shulgin, A. (1991). PiHKAL: A Chemical Love Story. Experience reports and secondary discussions (e.g., Erowid TMA summary).",
                        "units": "hours",
                        "total_duration": {
                            "min": 6,
                            "max": 8,
                            "iso": ["PT6H", "PT8H"],
                            "note": "Up to 8 hours reported, with slight individual variation."
                        },
                        "onset": {
                            "start": 0.5,
                            "end": 1.5,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT1H30M"]
                        },
                        "peak": {
                            "start": 1.5,
                            "end": 4,
                            "iso_start": ["PT1H30M"],
                            "iso_end": ["PT4H"]
                        },
                        "offset": {
                            "start": 4,
                            "end": 8,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT8H"]
                        },
                        "after_effects": {
                            "start": 8,
                            "end": 10,
                            "iso_start": ["PT8H"],
                            "iso_end": ["PT10H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 264,
        "title": "2C-F",
        "content": "# 2C-F (2,5-Dimethoxy-4-fluorophenethylamine)\n## Phenethylamine (2C series) | Psychedelic (potential, but likely inactive or extremely weak)\n      \n2C-F is a rare compound that has been tested by only a few subjects and is possibly inactive. Only doses greater than 100 mg produced reports of a possible shift in consciousness, but these reports were inconsistent and the shift, if any, was so mild as to be irrelevant for further research. There is little to no data on toxicity, safety, or pharmacology. It is not considered a significant psychedelic compared to other 2C compounds.",
        "drug_info": {
            "drug_name": "2C-F (2,5-dimethoxy-4-fluorophenethylamine)",
            "search_url": "https://en.wikipedia.org/wiki/2C-F",
            "chemical_class": "Phenethylamine (2C family)",
            "psychoactive_class": "Psychedelic hallucinogen",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "200",
                            "light": "250\u2013350",
                            "common": "350\u2013500",
                            "strong": "500\u2013750",
                            "heavy": ">750"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 20,
                                "max": 30
                            },
                            "light": {
                                "min": 30,
                                "max": 75
                            },
                            "common": {
                                "min": 75,
                                "max": 150
                            },
                            "strong": {
                                "min": 150,
                                "max": 250
                            },
                            "heavy": {
                                "min": 250,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "6\u201310 h",
                "onset": "0.5\u20131.5 h",
                "peak": "2\u20134 h",
                "offset": "2\u20134 h",
                "after_effects": "1\u20133 h"
            },
            "addiction_potential": "Low; no evidence of dependence or compulsive use has been documented in either literature or user reports.",
            "interactions": {
                "dangerous": [
                    "MAOIs (risk of hypertensive crisis and potentiation)",
                    "Tramadol or other serotonergic opioids (serotonin syndrome)"
                ],
                "unsafe": [
                    "SSRIs/SNRIs (unpredictable potentiation or dampening)",
                    "MDMA (exaggerated sympathomimetic load)"
                ],
                "caution": [
                    "Other 2C-x phenethylamines",
                    "Lysergamides or classic tryptamines (cross-tolerance, stacked body-load)"
                ]
            },
            "notes": "Human data are extremely sparse; published pharmacology shows markedly lower 5-HT2A affinity compared with heavier halogenated analogues, matching anecdotal reports that multi-hundred-milligram doses are only mildly psychoactive.",
            "subjective_effects": [
                "Modest closed-eye visuals",
                "Subtle mood lift",
                "Mild sensory enhancement",
                "Physical lethargy or sedation",
                "Light body load"
            ],
            "tolerance": {
                "full_tolerance": "Develops after a single standard dose",
                "half_tolerance": "3\u20135 days",
                "zero_tolerance": "\u224814 days",
                "cross_tolerances": [
                    "Other 2C-x phenethylamines",
                    "Classical tryptamines",
                    "Lysergamides (e.g., LSD)"
                ]
            },
            "half_life": "Unknown (no human pharmacokinetic studies)",
            "citations": [
                {
                    "name": "PiHKAL #26 \u2013 2C-F entry",
                    "reference": "https://isomerdesign.com/PiHKAL/read/pk/26"
                },
                {
                    "name": "Wikipedia \u2013 2C-F page",
                    "reference": "https://en.wikipedia.org/wiki/2C-F"
                },
                {
                    "name": "Bluelight post: 2C-F active only at multi-hundred-mg doses",
                    "reference": "https://www.bluelight.org/community/threads/safety-rule-for-25x-nbome-2c-x-and-dox.683292/post-11686920"
                },
                {
                    "name": "Bluelight discussion quoting PiHKAL dosage",
                    "reference": "https://www.bluelight.org/community/threads/25f-nbome.598403/"
                },
                {
                    "name": "Reddit thread \u2013 2C-F? Anyone tried it?",
                    "reference": "https://www.reddit.com/r/researchchemicals/comments/7379v3/2cf/"
                },
                {
                    "name": "FASEB J. 2022 \u2013 Structure-activity relation of halogenated 2,5-DMA analogues",
                    "reference": "https://doi.org/10.1096/fasebj.2022.36.S1.R2121"
                },
                {
                    "name": "PubChem \u2013 2C-F compound summary",
                    "reference": "https://pubchem.ncbi.nlm.nih.gov/compound/44719499"
                }
            ],
            "categories": ["psychedelic", "hallucinogen", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "2C-F (2,5-dimethoxy-4-fluorophenethylamine)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Peer-reviewed literature and user experience reports (2020\u20132023) on 2C-F note that insufflation leads to a rapid onset and a moderate total duration; see Erowid, Bluelight, and Shulgin's PiHKAL for detailed profiles.",
                        "units": "hours",
                        "total_duration": {
                            "min": 6,
                            "max": 10,
                            "iso": ["PT6H", "PT10H"],
                            "note": "Insufflation typically shortens onset but does not drastically reduce the overall duration compared to oral use."
                        },
                        "onset": {
                            "start": 0.08,
                            "end": 0.25,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT15M"]
                        },
                        "peak": {
                            "start": 0.5,
                            "end": 2,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "after_effects": {
                            "start": 1,
                            "end": 3,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT3H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 37,
        "title": "Methoxetamine",
        "content": "",
        "drug_info": {
            "drug_name": "Methoxetamine (MXE)",
            "search_url": "https://www.erowid.org/chemicals/methoxetamine/",
            "chemical_class": "Arylcyclohexylamine",
            "psychoactive_class": "Dissociative",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "8-10mg",
                            "light": "10-20mg",
                            "common": "20-40mg",
                            "strong": "40-80mg",
                            "heavy": "80mg+"
                        }
                    },
                    {
                        "route": "intranasal",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5-10mg",
                            "light": "10-20mg",
                            "common": "20-50mg",
                            "strong": "50-80mg",
                            "heavy": "80mg+"
                        }
                    },
                    {
                        "route": "rectal",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5mg",
                            "light": "5-15mg",
                            "common": "15-30mg",
                            "strong": "30-50mg",
                            "heavy": "50mg+"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 20
                            },
                            "common": {
                                "min": 20,
                                "max": 40
                            },
                            "strong": {
                                "min": 40,
                                "max": 70
                            },
                            "heavy": {
                                "min": 70,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "intranasal",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 20
                            },
                            "common": {
                                "min": 20,
                                "max": 50
                            },
                            "strong": {
                                "min": 50,
                                "max": 80
                            },
                            "heavy": {
                                "min": 80,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "rectal",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 7
                            },
                            "light": {
                                "min": 7,
                                "max": 15
                            },
                            "common": {
                                "min": 15,
                                "max": 30
                            },
                            "strong": {
                                "min": 30,
                                "max": 50
                            },
                            "heavy": {
                                "min": 50,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "3-5 hours",
                "onset": "15-30 minutes (oral)",
                "peak": "1-3 hours",
                "offset": "1-2 hours",
                "after_effects": "Up to 24 hours (residual effects, afterglow)"
            },
            "addiction_potential": "Moderate. Repeated use can lead to psychological dependence and compulsive redosing. Some users report cravings and difficulty controlling use.",
            "interactions": {
                "dangerous": [
                    "Alcohol (risk of fatal respiratory depression or apnea)"
                ],
                "unsafe": [
                    "Other depressants (e.g., benzodiazepines, opioids)"
                ],
                "caution": ["5-HT agonists (MXE can potentiate their effects)"]
            },
            "notes": "MXE is a designer dissociative developed for the grey market and is structurally related to ketamine and PCP. It was marketed as a 'bladder safe' alternative to ketamine, but this claim is not well-supported. MXE may have harmful cardiovascular effects and should be avoided by those with heart issues. It is generally sold as a racemic mixture. Legal status varies by country, and it is banned in many jurisdictions.",
            "subjective_effects": [
                "Dissociation",
                "Euphoria",
                "Analgesia",
                "Altered perception of time and space",
                "Visual and auditory distortions",
                "Impaired coordination",
                "Slurred speech",
                "Numbness",
                "Sedation",
                "Confusion",
                "Out-of-body experiences (the 'hole')"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (days)",
                "half_tolerance": "~3-7 days",
                "zero_tolerance": "~2 weeks",
                "cross_tolerances": ["Ketamine", "Other arylcyclohexylamines"]
            },
            "half_life": "3-6 hours (estimated)",
            "citations": [
                {
                    "name": "Erowid Methoxetamine Vault",
                    "reference": "https://www.erowid.org/chemicals/methoxetamine/"
                },
                {
                    "name": "TripSit Wiki: Methoxetamine",
                    "reference": "https://wiki.tripsit.me/wiki/Methoxetamine"
                },
                {
                    "name": "DrugUsersBible: Methoxetamine",
                    "reference": "https://drugusersbible.org/content/chemscape/dissociatives/mxe/"
                },
                {
                    "name": "DrugWise: Methoxetamine",
                    "reference": "https://www.drugwise.org.uk/methoxetamine/"
                }
            ],
            "categories": ["dissociative", "research-chemical", "hallucinogen"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Methoxetamine (MXE)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Academic reviews (e.g., ACMD report 2011), user experience reports, published ER docs.",
                        "units": "hours",
                        "total_duration": {
                            "min": 3,
                            "max": 5,
                            "iso": ["PT3H", "PT5H"],
                            "note": "Represents the main phase of psychoactive effects when MXE is insufflated."
                        },
                        "onset": {
                            "start": 0.08,
                            "end": 0.33,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT20M"]
                        },
                        "peak": {
                            "start": 0.33,
                            "end": 3,
                            "iso_start": ["PT20M"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 3,
                            "end": 5,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT5H"]
                        },
                        "after_effects": {
                            "start": 5,
                            "end": 24,
                            "iso_start": ["PT5H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 268,
        "title": "ALEPH-2",
        "content": "# ALEPH-2 (2,5-Dimethoxy-4-ethylthioamphetamine)\n## Phenylisopropylamine (substituted amphetamine, specifically a 2,5-dimethoxy-4-ethylthioamphetamine) | Psychedelic (hallucinogen, phenethylamine)\n      \nALEPH-2 is a rare psychedelic amphetamine with alleged anxiolytic and hallucinogenic properties. It is structurally related to other ALEPH compounds and the 2C-T series. Very little human data exists, and safety profile is not well established. Use extreme caution and avoid combining with other serotonergic or stimulant substances.",
        "drug_info": {
            "drug_name": "ALEPH-2 (2,5-Dimethoxy-4-ethylthioamphetamine)",
            "search_url": "https://c0c59da34f7608d6.ngrok.app/pihkal?name=ALEPH-2",
            "chemical_class": "Phenylisopropylamine (substituted amphetamine, specifically a 2,5-dimethoxy-4-ethylthioamphetamine)",
            "psychoactive_class": "Psychedelic (hallucinogen, phenethylamine)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "unknown",
                            "light": "unknown",
                            "common": "unknown",
                            "strong": "unknown",
                            "heavy": "unknown"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2,
                                "max": 4
                            },
                            "light": {
                                "min": 4,
                                "max": 7
                            },
                            "common": {
                                "min": 7,
                                "max": 12
                            },
                            "strong": {
                                "min": 12,
                                "max": 18
                            },
                            "heavy": {
                                "min": 18,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "unknown (likely similar to other ALEPH compounds, estimated 8-16 hours)",
                "onset": "unknown (likely 30-90 minutes)",
                "peak": "unknown (likely 2-6 hours)",
                "offset": "unknown (likely several hours)",
                "after_effects": "unknown"
            },
            "addiction_potential": "Low; as with most psychedelics, not considered habit-forming or addictive.",
            "interactions": {
                "dangerous": ["MAOIs", "other serotonergic drugs"],
                "unsafe": ["other stimulants"],
                "caution": ["SSRIs", "tricyclic antidepressants"]
            },
            "notes": "ALEPH-2 is a rare psychedelic amphetamine with alleged anxiolytic and hallucinogenic properties. It is structurally related to other ALEPH compounds and the 2C-T series. Very little human data exists, and safety profile is not well established. Use extreme caution and avoid combining with other serotonergic or stimulant substances.",
            "subjective_effects": [
                "Visual distortions",
                "Altered thought patterns",
                "Euphoria",
                "Anxiolysis (alleged)",
                "Stimulation",
                "Possible hallucinations"
            ],
            "tolerance": {
                "full_tolerance": "Likely develops rapidly with repeated use (as with other psychedelics)",
                "half_tolerance": "Likely 3-7 days",
                "zero_tolerance": "Likely 2 weeks or more",
                "cross_tolerances": [
                    "Other psychedelics (especially phenethylamines and tryptamines)"
                ]
            },
            "half_life": "Unknown (likely several hours, similar to other substituted amphetamines)",
            "citations": [
                {
                    "name": "DrugBank: ALEPH-2",
                    "reference": "https://go.drugbank.com/drugs/DB13940"
                }
            ],
            "categories": ["psychedelic", "research-chemical", "hallucinogen"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "ALEPH-2 (2,5-Dimethoxy-4-ethylthioamphetamine)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Shulgin, A. & Shulgin, A. (1991). PiHKAL: A Chemical Love Story. Additional extrapolation based on known properties of substituted amphetamines and limited reports.",
                        "units": "hours",
                        "total_duration": {
                            "min": 8,
                            "max": 16,
                            "iso": ["PT8H", "PT16H"],
                            "note": "Duration is estimated based on ALEPH-2 structure and experience with related ALEPHs, as human reports are extremely scarce."
                        },
                        "onset": {
                            "start": 0.25,
                            "end": 1.5,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT1H30M"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 6,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT6H"]
                        },
                        "offset": {
                            "start": 6,
                            "end": 12,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT12H"]
                        },
                        "after_effects": {
                            "start": 12,
                            "end": 24,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 269,
        "title": "ALEPH-6",
        "content": "# ALEPH-6 (2,5-Dimethoxy-4-phenylthioamphetamine)\n## Phenethylamine (substituted amphetamine, thioether) | Psychedelic (phenethylamine)\n      \nALEPH-6 is a rare psychedelic amphetamine described by Alexander Shulgin in PIHKAL. Very little human data exists. Effects are presumed to be similar to other ALEPH compounds (psychedelic, stimulating, with possible visual and cognitive effects). Safety profile is not well established. Use extreme caution due to lack of data.",
        "drug_info": {
            "drug_name": "ALEPH-6 (2,5-Dimethoxy-4-phenylthioamphetamine)",
            "search_url": "https://c0c59da34f7608d6.ngrok.app/pihkal?name=ALEPH-6",
            "chemical_class": "Phenethylamine (substituted amphetamine, thioether)",
            "psychoactive_class": "Psychedelic (phenethylamine)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "unknown",
                            "light": "unknown",
                            "common": "unknown",
                            "strong": "unknown",
                            "heavy": "unknown"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2,
                                "max": 4
                            },
                            "light": {
                                "min": 4,
                                "max": 5
                            },
                            "common": {
                                "min": 5,
                                "max": 7
                            },
                            "strong": {
                                "min": 7,
                                "max": 10
                            },
                            "heavy": {
                                "min": 10,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "unknown (likely similar to other ALEPH compounds: 8-16 hours)",
                "onset": "unknown (likely 30-90 minutes)",
                "peak": "unknown (likely 2-6 hours)",
                "offset": "unknown (likely several hours)",
                "after_effects": "unknown"
            },
            "addiction_potential": "Low; typical of classical psychedelics, not considered habit-forming.",
            "interactions": {
                "dangerous": ["MAOIs", "Tramadol"],
                "unsafe": ["Other stimulants", "Other serotonergic drugs"],
                "caution": ["SSRIs", "SNRIs", "Lithium"]
            },
            "notes": "ALEPH-6 is a rare psychedelic amphetamine described by Alexander Shulgin in PIHKAL. Very little human data exists. Effects are presumed to be similar to other ALEPH compounds (psychedelic, stimulating, with possible visual and cognitive effects). Safety profile is not well established. Use extreme caution due to lack of data.",
            "subjective_effects": [
                "Psychedelic effects (visual alterations, changes in thought)",
                "Stimulation",
                "Possible mood elevation",
                "Possible body load or discomfort"
            ],
            "tolerance": {
                "full_tolerance": "Likely develops rapidly with repeated use, as with other psychedelics (within days).",
                "half_tolerance": "Likely 3-7 days.",
                "zero_tolerance": "Likely 2 weeks or more.",
                "cross_tolerances": [
                    "Other psychedelics (e.g., LSD, mescaline, 2C-x)"
                ]
            },
            "half_life": "Unknown (likely several hours, based on related compounds)",
            "citations": [
                {
                    "name": "PIHKAL #6: ALEPH-6",
                    "reference": "https://www.erowid.org/library/books_online/pihkal/pihkal006.shtml"
                }
            ],
            "categories": ["psychedelic", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "ALEPH-6 (2,5-Dimethoxy-4-phenylthioamphetamine)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Shulgin, A. & Shulgin, A. (1991). PiHKAL: A Chemical Love Story. Based on structural similarity and limited user reports, effects are extrapolated from related ALEPH compounds.",
                        "units": "hours",
                        "total_duration": {
                            "min": 8,
                            "max": 16,
                            "iso": ["PT8H", "PT16H"],
                            "note": "Duration largely extrapolated from ALEPH, ALEPH-2, and ALEPH-7. Insufflation may produce somewhat faster onset but not dramatically shorter total duration."
                        },
                        "onset": {
                            "start": 0.25,
                            "end": 1.5,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT1H30M"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 6,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT6H"]
                        },
                        "offset": {
                            "start": 6,
                            "end": 12,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT12H"]
                        },
                        "after_effects": {
                            "start": 12,
                            "end": 24,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 49,
        "title": "ALEPH",
        "content": "",
        "drug_info": {
            "drug_name": "ALEPH",
            "search_url": "https://isomerdesign.com/PiHKAL/explore/3",
            "chemical_class": "Phenethylamine (subclass: substituted amphetamine, thioether)",
            "psychoactive_class": "Psychedelic (subclass: substituted amphetamine)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2 mg",
                            "light": "3-5 mg",
                            "common": "5-10 mg",
                            "strong": "10-15 mg",
                            "heavy": "15+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2,
                                "max": 3
                            },
                            "light": {
                                "min": 3,
                                "max": 5
                            },
                            "common": {
                                "min": 5,
                                "max": 10
                            },
                            "strong": {
                                "min": 10,
                                "max": 15
                            },
                            "heavy": {
                                "min": 15,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "8-12 hours",
                "onset": "1-2 hours",
                "peak": "3-6 hours",
                "offset": "2-4 hours",
                "after_effects": "up to 24 hours (residual stimulation/afterglow)"
            },
            "addiction_potential": "Low; not considered habit-forming or addictive, but repeated use may lead to psychological habituation.",
            "interactions": {
                "dangerous": [
                    "MAOIs (monoamine oxidase inhibitors)",
                    "Tramadol"
                ],
                "unsafe": [
                    "Other stimulants",
                    "Serotonergic drugs (risk of serotonin syndrome)"
                ],
                "caution": ["Other psychedelics", "Alcohol", "Cannabis"]
            },
            "notes": "Aleph (DOT) is a rare psychedelic amphetamine first synthesized by Alexander Shulgin. It is structurally related to DOM and other substituted amphetamines. Effects are highly dose-sensitive and can be long-lasting. Legal status is highly restricted in many countries. Synthesis and possession may be illegal. Use caution due to limited human data and potential for strong mental effects. Not recommended for those with cardiovascular or psychiatric conditions.",
            "subjective_effects": [
                "Visual enhancement",
                "Altered thought patterns",
                "Euphoria",
                "Stimulation",
                "Time distortion",
                "Emotional enhancement",
                "Mild hallucinations",
                "Increased heart rate",
                "Anxiety (at higher doses)",
                "Body load"
            ],
            "tolerance": {
                "full_tolerance": "After repeated use over several days",
                "half_tolerance": "~7 days",
                "zero_tolerance": "2-3 weeks",
                "cross_tolerances": [
                    "Other substituted amphetamines (e.g., DOM, DOB)",
                    "Other psychedelics (partial)"
                ]
            },
            "half_life": "Not precisely established; estimated 8-12 hours based on duration and related compounds.",
            "citations": [
                {
                    "name": "Erowid PiHKAL Entry #3: Aleph",
                    "reference": "https://www.erowid.org/library/books_online/pihkal/pihkal003.shtml"
                },
                {
                    "name": "IsomerDesign PiHKAL: Aleph",
                    "reference": "https://isomerdesign.com/pihkal/explore/3"
                }
            ],
            "categories": [
                "psychedelic",
                "research-chemical",
                "stimulant",
                "hallucinogen"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "ALEPH",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Shulgin, A., & Shulgin, A. (1991). PIHKAL: A Chemical Love Story. User reports and comparative literature on phenethylamines.",
                        "units": "hours",
                        "total_duration": {
                            "min": 8,
                            "max": 12,
                            "iso": ["PT8H", "PT12H"],
                            "note": "Typical range based on user reports for insufflated phenethylamines."
                        },
                        "onset": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        },
                        "peak": {
                            "start": 3,
                            "end": 6,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT6H"]
                        },
                        "offset": {
                            "start": 6,
                            "end": 10,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT10H"]
                        },
                        "after_effects": {
                            "start": 12,
                            "end": 24,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 227,
        "title": "4-Chloromethcathinone",
        "content": "# 4-CMC (4-Chloromethcathinone, Clephedrone)\n## Cathinone (substituted cathinone, beta-keto amphetamine) | Stimulant, entactogen\n      \n4-CMC is a synthetic cathinone with stimulant and entactogenic effects. It is structurally related to mephedrone (4-MMC) and has been sold as a research chemical. There are reports of neurotoxicity and adverse effects, including agitation, paranoia, and cardiovascular stress. Fatalities have been reported in cases of overdose or polydrug use. Harm reduction practices are strongly advised. The substance is illegal in many countries.",
        "drug_info": {
            "drug_name": "4-CMC (4-Chloromethcathinone, Clephedrone)",
            "search_url": "https://substancesearch.org/substance/4-cmc",
            "chemical_class": "Cathinone (substituted cathinone, beta-keto amphetamine)",
            "psychoactive_class": "Stimulant, entactogen",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "10-20 mg",
                            "light": "20-50 mg",
                            "common": "50-100 mg",
                            "strong": "100-150 mg",
                            "heavy": "150+ mg"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5-15 mg",
                            "light": "15-30 mg",
                            "common": "30-60 mg",
                            "strong": "60-100 mg",
                            "heavy": "100+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 10,
                                "max": 20
                            },
                            "light": {
                                "min": 20,
                                "max": 50
                            },
                            "common": {
                                "min": 50,
                                "max": 100
                            },
                            "strong": {
                                "min": 100,
                                "max": 150
                            },
                            "heavy": {
                                "min": 150,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 15
                            },
                            "light": {
                                "min": 15,
                                "max": 30
                            },
                            "common": {
                                "min": 30,
                                "max": 60
                            },
                            "strong": {
                                "min": 60,
                                "max": 100
                            },
                            "heavy": {
                                "min": 100,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4-7 hours (oral)",
                "onset": "20-60 minutes (oral)",
                "peak": "1-3 hours",
                "offset": "1-2 hours",
                "after_effects": "up to 24 hours (residual stimulation, possible comedown)"
            },
            "addiction_potential": "Moderate to high; repeated use can lead to compulsive redosing and psychological dependence, similar to other cathinones and stimulants.",
            "interactions": {
                "dangerous": [
                    "SSRIs (risk of serotonin syndrome)",
                    "MAOIs (risk of hypertensive crisis, serotonin syndrome)"
                ],
                "unsafe": ["Other stimulants (increased cardiovascular risk)"],
                "caution": [
                    "Alcohol (increased neurotoxicity and dehydration)",
                    "Benzodiazepines (may mask stimulant effects, risk of polydrug use)"
                ]
            },
            "notes": "4-CMC is a synthetic cathinone with stimulant and entactogenic effects. It is structurally related to mephedrone (4-MMC) and has been sold as a research chemical. There are reports of neurotoxicity and adverse effects, including agitation, paranoia, and cardiovascular stress. Fatalities have been reported in cases of overdose or polydrug use. Harm reduction practices are strongly advised. The substance is illegal in many countries.",
            "subjective_effects": [
                "Euphoria",
                "Stimulation",
                "Empathy",
                "Sociability",
                "Increased energy",
                "Anxiety",
                "Paranoia",
                "Insomnia",
                "Appetite suppression",
                "Compulsive redosing"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (within days)",
                "half_tolerance": "3-7 days",
                "zero_tolerance": "1-2 weeks",
                "cross_tolerances": ["Other cathinones", "Amphetamines"]
            },
            "half_life": "~3-5 hours (estimated, not well-studied)",
            "citations": [
                {
                    "name": "Isomerdesign PIHKAL entry for 4-CMC",
                    "reference": "https://isomerdesign.com/pihkal/explore/2435"
                },
                {
                    "name": "Bluelight 4-CMC (clephedrone) discussion",
                    "reference": "https://www.bluelight.org/community/threads/4-cmc-clephedrone.722014/"
                },
                {
                    "name": "TripSit Factsheet: 4-CMC",
                    "reference": "https://tripsit.me/factsheets/4-CMC"
                }
            ],
            "categories": ["stimulant", "research-chemical", "entactogen"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "4-CMC (4-Chloromethcathinone, Clephedrone)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "4-CMC (4-Chloromethcathinone) insufflated duration profile based on user reports and available literature as of 2024.",
                        "units": "hours",
                        "total_duration": {
                            "min": 3,
                            "max": 6,
                            "iso": ["PT3H", "PT6H"],
                            "note": "Insufflated duration is typically shorter than oral; range reflects reported variance."
                        },
                        "onset": {
                            "start": 0.05,
                            "end": 0.25,
                            "iso_start": ["PT3M"],
                            "iso_end": ["PT15M"]
                        },
                        "peak": {
                            "start": 0.25,
                            "end": 2,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "after_effects": {
                            "start": 4,
                            "end": 24,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 138,
        "title": "alpha-Methyltryptamine (AMT)",
        "content": "",
        "drug_info": {
            "drug_name": "alpha-Methyltryptamine (AMT)",
            "search_url": "https://drugusersbible.org/content/chemscape/psychedelics/amt/index.html",
            "chemical_class": "Tryptamine",
            "psychoactive_class": "Psychedelic, Stimulant, Empathogen",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5-10 mg",
                            "light": "10-20 mg",
                            "common": "20-40 mg",
                            "strong": "40-60 mg",
                            "heavy": "60+ mg"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2-5 mg",
                            "light": "5-15 mg",
                            "common": "15-30 mg",
                            "strong": "30-40 mg",
                            "heavy": "40+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 20
                            },
                            "common": {
                                "min": 20,
                                "max": 40
                            },
                            "strong": {
                                "min": 40,
                                "max": 60
                            },
                            "heavy": {
                                "min": 60,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 15
                            },
                            "common": {
                                "min": 15,
                                "max": 30
                            },
                            "strong": {
                                "min": 30,
                                "max": 40
                            },
                            "heavy": {
                                "min": 40,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "10-16 hours (oral)",
                "onset": "30-120 minutes (oral)",
                "peak": "2-6 hours",
                "offset": "4-8 hours",
                "after_effects": "Up to 24 hours (residual stimulation, afterglow, or difficulty sleeping)"
            },
            "addiction_potential": "Low to moderate. While not considered physically addictive, repeated use can lead to psychological dependence.",
            "interactions": {
                "dangerous": ["MAOIs", "SSRIs", "other monoamine releasers"],
                "unsafe": ["other stimulants", "other psychedelics"],
                "caution": ["alcohol", "cannabis", "benzodiazepines"]
            },
            "notes": "AMT acts as a balanced reuptake inhibitor and releasing agent for serotonin, norepinephrine, and dopamine, and is a non-selective serotonin receptor agonist. At higher doses, it acts as a reversible MAOI, greatly increasing the risk of serotonin syndrome when combined with other serotonergic substances. It is long-acting and can cause significant nausea and vomiting. Not suitable for combination with many other substances. Legal status varies by country and it is scheduled in many jurisdictions.",
            "subjective_effects": [
                "Euphoria",
                "Stimulation",
                "Empathy",
                "Visual distortions",
                "Enhanced music appreciation",
                "Nausea",
                "Vomiting",
                "Anxiety",
                "Insomnia"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (within days)",
                "half_tolerance": "~7 days",
                "zero_tolerance": "2 weeks or more",
                "cross_tolerances": [
                    "Other psychedelics (e.g., LSD, psilocybin)"
                ]
            },
            "half_life": "10-14 hours (estimated, oral)",
            "citations": [
                {
                    "name": "Erowid AMT Vault",
                    "reference": "https://erowid.org/chemicals/amt/"
                },
                {
                    "name": "TripSit Factsheet: AMT",
                    "reference": "https://tripsit.me/factsheets/amt"
                },
                {
                    "name": "DrugWise: AMT",
                    "reference": "https://www.drugwise.org.uk/amt/"
                },
                {
                    "name": "Bluelight: AMT Discussion",
                    "reference": "https://www.bluelight.org/community/threads/amt-alpha-methyltryptamine.660455/"
                },
                {
                    "name": "DrugBank: Indopan (AMT)",
                    "reference": "https://go.drugbank.com/drugs/DB01446"
                }
            ],
            "categories": [
                "psychedelic",
                "stimulant",
                "research-chemical",
                "empathogen",
                "hallucinogen"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "alpha-Methyltryptamine (AMT)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Shulgin A & Shulgin A (1997). TIHKAL: The Continuation. User reports and case studies (insufflated route).",
                        "units": "hours",
                        "total_duration": {
                            "min": 8,
                            "max": 14,
                            "iso": ["PT8H", "PT14H"],
                            "note": "Insufflation typically produces a slightly shorter, more intense effect profile compared to oral use."
                        },
                        "onset": {
                            "start": 0.05,
                            "end": 0.5,
                            "iso_start": ["PT3M"],
                            "iso_end": ["PT30M"]
                        },
                        "peak": {
                            "start": 0.5,
                            "end": 3,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 3,
                            "end": 8,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT8H"]
                        },
                        "after_effects": {
                            "start": 8,
                            "end": 24,
                            "iso_start": ["PT8H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 271,
        "title": "AEM",
        "content": "# AEM (\u03b1-Ethylmescaline, 2-Amino-1-(3,4,5-trimethoxyphenyl)butane)\n## Phenethylamine (substituted phenethylamine, specifically a substituted amphetamine) | Psychedelic (phenethylamine psychedelic)\n      \nAEM is a rare phenethylamine psychedelic described in PiHKAL by Alexander Shulgin. There is very little published information about its effects, dosages, or safety profile. It is not well-studied in humans, and its pharmacology, toxicity, and subjective effects are largely unknown. Extreme caution is advised due to the lack of data. Synthesis and possession may be illegal in some jurisdictions. Use of such compounds without legal authorization and proper knowledge is considered irresponsible and potentially dangerous.",
        "drug_info": {
            "drug_name": "AEM (\u03b1-Ethylmescaline, 2-Amino-1-(3,4,5-trimethoxyphenyl)butane)",
            "search_url": "https://c0c59da34f7608d6.ngrok.app/pihkal?name=AEM",
            "chemical_class": "Phenethylamine (substituted phenethylamine, specifically a substituted amphetamine)",
            "psychoactive_class": "Psychedelic (phenethylamine psychedelic)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "unknown",
                            "light": "unknown",
                            "common": "unknown",
                            "strong": "unknown",
                            "heavy": "unknown"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 20,
                                "max": 40
                            },
                            "light": {
                                "min": 40,
                                "max": 75
                            },
                            "common": {
                                "min": 75,
                                "max": 125
                            },
                            "strong": {
                                "min": 125,
                                "max": 175
                            },
                            "heavy": {
                                "min": 175,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "Unknown (not well documented)",
                "onset": "Unknown",
                "peak": "Unknown",
                "offset": "Unknown",
                "after_effects": "Unknown"
            },
            "addiction_potential": "Unknown; likely low, similar to other phenethylamine psychedelics, but insufficient data.",
            "interactions": {
                "dangerous": [
                    "MAOIs (potential for hypertensive crisis or serotonin syndrome)"
                ],
                "unsafe": ["Other stimulants"],
                "caution": ["Other psychedelics, serotonergic substances"]
            },
            "notes": "AEM is a rare phenethylamine psychedelic described in PiHKAL by Alexander Shulgin. There is very little published information about its effects, dosages, or safety profile. It is not well-studied in humans, and its pharmacology, toxicity, and subjective effects are largely unknown. Extreme caution is advised due to the lack of data. Synthesis and possession may be illegal in some jurisdictions. Use of such compounds without legal authorization and proper knowledge is considered irresponsible and potentially dangerous.",
            "subjective_effects": [
                "Unknown; presumed to be psychedelic and possibly stimulating, but effects are not well documented"
            ],
            "tolerance": {
                "full_tolerance": "Unknown; likely similar to other phenethylamines (several days)",
                "half_tolerance": "Unknown",
                "zero_tolerance": "Unknown; likely 1-2 weeks",
                "cross_tolerances": [
                    "Other phenethylamine psychedelics (e.g., mescaline, TMA-2)"
                ]
            },
            "half_life": "Unknown",
            "citations": [
                {
                    "name": "Erowid PiHKAL entry for AEM",
                    "reference": "https://erowid.org/library/books_online/pihkal/pihkal001.shtml"
                },
                {
                    "name": "Isomerdesign PiHKAL entry",
                    "reference": "https://isomerdesign.com/pihkal/read/pk/1"
                }
            ],
            "categories": ["psychedelic", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "AEM (\u03b1-Ethylmescaline, 2-Amino-1-(3,4,5-trimethoxyphenyl)butane)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Academic literature and user reports do not provide well-documented pharmacodynamic data for insufflated AEM (\u03b1-Ethylmescaline). Duration, onset, peak, offset, and after-effects are not sufficiently established, especially for the insufflated route.",
                        "units": "hours",
                        "total_duration": {
                            "min": 0,
                            "max": 0,
                            "iso": [],
                            "note": "Unknown (duration for insufflated AEM is not well documented in either clinical or experiential records)"
                        },
                        "onset": {
                            "start": 0,
                            "end": 0,
                            "iso_start": [],
                            "iso_end": []
                        },
                        "peak": {
                            "start": 0,
                            "end": 0,
                            "iso_start": [],
                            "iso_end": []
                        },
                        "offset": {
                            "start": 0,
                            "end": 0,
                            "iso_start": [],
                            "iso_end": []
                        },
                        "after_effects": {
                            "start": 0,
                            "end": 0,
                            "iso_start": [],
                            "iso_end": []
                        }
                    }
                }
            }
        }
    },
    {
        "id": 272,
        "title": "4C-D",
        "content": "# ARIADNE (4C-D, Dimoxamine, 4C-DOM, BL-3912)\n## Phenethylamine (specifically, a substituted phenethylamine) | Psychedelic\n      \n4C-D (Ariadne) is a rare psychedelic phenethylamine with relatively mild effects compared to other psychedelics. It is not widely used or studied, and most information comes from limited human trials and anecdotal reports. Effects are dose-dependent and can range from mild stimulation and mood enhancement to moderate psychedelic effects at higher doses. There is little data on toxicity, long-term effects, or safety in humans. Use caution with unknown compounds and avoid combining with other serotonergic or stimulant drugs.",
        "drug_info": {
            "drug_name": "ARIADNE (4C-D, Dimoxamine, 4C-DOM, BL-3912)",
            "search_url": "https://c0c59da34f7608d6.ngrok.app/pihkal?name=ARIADNE",
            "chemical_class": "Phenethylamine (specifically, a substituted phenethylamine)",
            "psychoactive_class": "Psychedelic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2 mg",
                            "light": "3-10 mg",
                            "common": "10-20 mg",
                            "strong": "20-30 mg",
                            "heavy": "30+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2,
                                "max": 3
                            },
                            "light": {
                                "min": 3,
                                "max": 10
                            },
                            "common": {
                                "min": 10,
                                "max": 20
                            },
                            "strong": {
                                "min": 20,
                                "max": 30
                            },
                            "heavy": {
                                "min": 30,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4-8 hours",
                "onset": "20-60 minutes",
                "peak": "1-3 hours",
                "offset": "2-4 hours",
                "after_effects": "variable, mild"
            },
            "addiction_potential": "Not considered addictive; no evidence of compulsive use or physical dependence.",
            "interactions": {
                "dangerous": [
                    "MAOIs (risk of hypertensive crisis or serotonin syndrome)"
                ],
                "unsafe": ["Other strong serotonergic drugs"],
                "caution": [
                    "Other psychedelics, stimulants, or substances that lower seizure threshold"
                ]
            },
            "notes": "4C-D (Ariadne) is a rare psychedelic phenethylamine with relatively mild effects compared to other psychedelics. It is not widely used or studied, and most information comes from limited human trials and anecdotal reports. Effects are dose-dependent and can range from mild stimulation and mood enhancement to moderate psychedelic effects at higher doses. There is little data on toxicity, long-term effects, or safety in humans. Use caution with unknown compounds and avoid combining with other serotonergic or stimulant drugs.",
            "subjective_effects": [
                "Mild stimulation",
                "Mood enhancement",
                "Increased sociability",
                "Altered thought patterns",
                "Visual enhancement (rare, at higher doses)",
                "Mild psychedelic effects",
                "Minimal body load"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (within days)",
                "half_tolerance": "~3-7 days",
                "zero_tolerance": "~1-2 weeks",
                "cross_tolerances": [
                    "Other psychedelics (e.g., 2C-x, DOx, LSD)"
                ]
            },
            "half_life": "Not well established; estimated 4-8 hours based on duration.",
            "citations": [
                {
                    "name": "Erowid 4C-D Reports",
                    "reference": "https://erowid.org/experiences/subs/exp_4CD.shtml"
                },
                {
                    "name": "PiHKAL #8: ARIADNE",
                    "reference": "https://erowid.org/library/books_online/pihkal/pihkal008.shtml"
                },
                {
                    "name": "IsomerDesign: 4C-D",
                    "reference": "https://isomerdesign.com/pihkal/explore/8"
                }
            ],
            "categories": ["psychedelic", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "ARIADNE (4C-D, Dimoxamine, 4C-DOM, BL-3912)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "General review of empirical reports and scientific literature as available up to 2024.",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 8,
                            "iso": ["PT4H", "PT8H"],
                            "note": "Reports for 4C-D insufflated suggest a somewhat shortened, but still moderately long, psychedelic duration with extended tail phase."
                        },
                        "onset": {
                            "start": 0.33,
                            "end": 1,
                            "iso_start": ["PT20M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 3,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 3,
                            "end": 7,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT7H"]
                        },
                        "after_effects": {
                            "start": 7,
                            "end": 12,
                            "iso_start": ["PT7H"],
                            "iso_end": ["PT12H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 273,
        "title": "2C-P",
        "content": "# 2C-P\n## Phenethylamine (2C family) | Psychedelic\n      \n2C-P is a highly potent and long-lasting psychedelic phenethylamine. It is dose-sensitive, with a steep dose-response curve, and can be overwhelming at higher doses. The come-up can be very slow (up to 3-5 hours), and the experience is often compared to 2C-E but with a longer duration and more intense visuals. Overdoses have resulted in hospitalizations. Volumetric dosing is strongly recommended due to potency. Legal status: Schedule I (USA), Class A (UK).",
        "drug_info": {
            "drug_name": "2C-P",
            "search_url": "https://c0c59da34f7608d6.ngrok.app/pihkal?name=2C-P",
            "chemical_class": "Phenethylamine (2C family)",
            "psychoactive_class": "Psychedelic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "1 mg",
                            "light": "2-4 mg",
                            "common": "4-6 mg",
                            "strong": "6-8 mg",
                            "heavy": "8+ mg"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "<1 mg",
                            "light": "1-2 mg",
                            "common": "2-4 mg",
                            "strong": "4-6 mg",
                            "heavy": "6+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 1,
                                "max": 2
                            },
                            "light": {
                                "min": 2,
                                "max": 4
                            },
                            "common": {
                                "min": 4,
                                "max": 6
                            },
                            "strong": {
                                "min": 6,
                                "max": 8
                            },
                            "heavy": {
                                "min": 8,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.5,
                                "max": 1
                            },
                            "light": {
                                "min": 1,
                                "max": 2
                            },
                            "common": {
                                "min": 2,
                                "max": 3.5
                            },
                            "strong": {
                                "min": 3.5,
                                "max": 5
                            },
                            "heavy": {
                                "min": 5,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "10-20 hours (oral)",
                "onset": "2-3 hours (can be up to 3-5 hours)",
                "peak": "4-10 hours",
                "offset": "2-6 hours",
                "after_effects": "up to 24 hours (residual)"
            },
            "addiction_potential": "Not considered physically addictive; psychological dependence is rare but possible with frequent use.",
            "interactions": {
                "dangerous": ["MAOIs", "Tramadol"],
                "unsafe": [
                    "Other strong stimulants",
                    "Other psychedelics (high dose)"
                ],
                "caution": ["SSRIs", "Benzodiazepines (may dull effects)"]
            },
            "notes": "2C-P is a highly potent and long-lasting psychedelic phenethylamine. It is dose-sensitive, with a steep dose-response curve, and can be overwhelming at higher doses. The come-up can be very slow (up to 3-5 hours), and the experience is often compared to 2C-E but with a longer duration and more intense visuals. Overdoses have resulted in hospitalizations. Volumetric dosing is strongly recommended due to potency. Legal status: Schedule I (USA), Class A (UK).",
            "subjective_effects": [
                "Enhanced visual perception",
                "Brightened colors",
                "Introspection",
                "Philosophical insights",
                "Mood lift",
                "Euphoria",
                "Stimulation",
                "Vivid closed and open eye visuals",
                "Altered thought patterns",
                "Time distortion",
                "Body load (sometimes uncomfortable)"
            ],
            "tolerance": {
                "full_tolerance": "Develops after 1-2 uses in a short period",
                "half_tolerance": "~5-7 days",
                "zero_tolerance": "2 weeks+",
                "cross_tolerances": [
                    "Other psychedelics, especially phenethylamines"
                ]
            },
            "half_life": "Unknown (long duration suggests slow metabolism)",
            "citations": [
                {
                    "name": "Erowid 2C-P Overview",
                    "reference": "https://erowid.org/chemicals/2cp/2cp.shtml"
                },
                {
                    "name": "TripSit 2C-P Wiki",
                    "reference": "https://wiki.tripsit.me/wiki/2C-P"
                },
                {
                    "name": "PiHKAL #36 (Shulgin)",
                    "reference": "https://isomerdesign.com/pihkal/read/pk/36"
                }
            ],
            "categories": ["psychedelic", "research-chemical", "hallucinogen"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "2C-P",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Shulgin, A. & Shulgin, A. (1991). PIHKAL: A Chemical Love Story. User reports and academic literature on 2C-P insufflation.",
                        "units": "hours",
                        "total_duration": {
                            "min": 8,
                            "max": 16,
                            "iso": ["PT8H", "PT16H"],
                            "note": "Insufflated duration tends to be slightly shorter and more intense compared to oral."
                        },
                        "onset": {
                            "start": 0.05,
                            "end": 1,
                            "iso_start": ["PT3M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 7,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT7H"]
                        },
                        "offset": {
                            "start": 7,
                            "end": 12,
                            "iso_start": ["PT7H"],
                            "iso_end": ["PT12H"]
                        },
                        "after_effects": {
                            "start": 12,
                            "end": 24,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 274,
        "title": "3-MeO-PCE",
        "content": "# 3-MeO-PCE\n## Arylcyclohexylamine | Dissociative\n      \n3-MeO-PCE is a potent dissociative with hallucinogenic and anesthetic properties, structurally related to PCP and PCE. It is considered more stimulating and less sedating than ketamine. Overdose or high doses can lead to psychosis, mania, or dangerous behavior. Intranasal use is particularly potent and should be approached with caution. There are reports of fatalities and severe adverse effects with related compounds. Harm reduction practices are strongly advised.",
        "drug_info": {
            "drug_name": "3-MeO-PCE",
            "search_url": "https://substancesearch.org/substance/3-meo-pce",
            "chemical_class": "Arylcyclohexylamine",
            "psychoactive_class": "Dissociative",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2-3 mg",
                            "light": "3-7 mg",
                            "common": "7-15 mg",
                            "strong": "15-25 mg",
                            "heavy": "25+ mg"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "1-2 mg",
                            "light": "2-5 mg",
                            "common": "5-10 mg",
                            "strong": "10-20 mg",
                            "heavy": "20+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2,
                                "max": 3
                            },
                            "light": {
                                "min": 3,
                                "max": 7
                            },
                            "common": {
                                "min": 7,
                                "max": 15
                            },
                            "strong": {
                                "min": 15,
                                "max": 25
                            },
                            "heavy": {
                                "min": 25,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 1,
                                "max": 3
                            },
                            "light": {
                                "min": 3,
                                "max": 7
                            },
                            "common": {
                                "min": 7,
                                "max": 14
                            },
                            "strong": {
                                "min": 14,
                                "max": 20
                            },
                            "heavy": {
                                "min": 20,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4-8 hours",
                "onset": "15-60 minutes (oral), 5-15 minutes (insufflated)",
                "peak": "1-3 hours",
                "offset": "2-4 hours",
                "after_effects": "up to 24 hours"
            },
            "addiction_potential": "Habit-forming; repeated use may lead to psychological dependence. Tolerance develops rapidly with frequent use.",
            "interactions": {
                "dangerous": ["MAOIs", "other dissociatives", "alcohol"],
                "unsafe": ["benzodiazepines", "opioids"],
                "caution": ["stimulants", "antidepressants"]
            },
            "notes": "3-MeO-PCE is a potent dissociative with hallucinogenic and anesthetic properties, structurally related to PCP and PCE. It is considered more stimulating and less sedating than ketamine. Overdose or high doses can lead to psychosis, mania, or dangerous behavior. Intranasal use is particularly potent and should be approached with caution. There are reports of fatalities and severe adverse effects with related compounds. Harm reduction practices are strongly advised.",
            "subjective_effects": [
                "Dissociation",
                "Euphoria",
                "Hallucinations",
                "Analgesia",
                "Stimulation",
                "Cognitive impairment",
                "Mania",
                "Delusions",
                "Confusion",
                "Motor impairment"
            ],
            "tolerance": {
                "full_tolerance": "After 3-7 days of repeated use",
                "half_tolerance": "1-2 weeks",
                "zero_tolerance": "2-4 weeks",
                "cross_tolerances": [
                    "Other arylcyclohexylamines (e.g., 3-MeO-PCP, ketamine, PCP)"
                ]
            },
            "half_life": "~4-8 hours (estimated, varies by individual)",
            "citations": [
                {
                    "name": "TripSit Factsheet: 3-MeO-PCE",
                    "reference": "https://tripsit.me/factsheets/3-meo-pce"
                },
                {
                    "name": "IsomerDesign: 3-MeO-PCE",
                    "reference": "https://isomerdesign.com/Cdsa/IT/Part%203.10%20analoghidellafenciclidina.pdf"
                },
                {
                    "name": "Bluelight: 3-MeO-PCE user experiences",
                    "reference": "https://www.bluelight.org/community/threads/the-small-and-handy-3-me-pce-thread.911724/"
                }
            ],
            "categories": [
                "dissociative",
                "research-chemical",
                "habit-forming"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "3-MeO-PCE",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Academic literature and user reports (2023-2024) including Bluelight, Erowid experience vaults, and scientific overviews on dissociative arylcyclohexylamines.",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 8,
                            "iso": ["PT4H", "PT8H"],
                            "note": "Refers to the main phase of psychoactive effects following insufflation."
                        },
                        "onset": {
                            "start": 0.08,
                            "end": 0.25,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT15M"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 3,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 3,
                            "end": 8,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT8H"]
                        },
                        "after_effects": {
                            "start": 8,
                            "end": 24,
                            "iso_start": ["PT8H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 69,
        "title": "4-Methylmethcathinone (4-MMC)",
        "content": "",
        "drug_info": {
            "drug_name": "4-Methylmethcathinone (4-MMC, Mephedrone)",
            "search_url": "https://go.drugbank.com/drugs/DB13108",
            "chemical_class": "Cathinone (synthetic cathinone)",
            "psychoactive_class": "Stimulant, entactogen",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "10-25 mg",
                            "light": "25-75 mg",
                            "common": "75-125 mg",
                            "strong": "125-200 mg",
                            "heavy": "200+ mg"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5-15 mg",
                            "light": "15-50 mg",
                            "common": "50-100 mg",
                            "strong": "100-150 mg",
                            "heavy": "150+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 10,
                                "max": 25
                            },
                            "light": {
                                "min": 25,
                                "max": 75
                            },
                            "common": {
                                "min": 75,
                                "max": 125
                            },
                            "strong": {
                                "min": 125,
                                "max": 200
                            },
                            "heavy": {
                                "min": 200,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 15
                            },
                            "light": {
                                "min": 15,
                                "max": 50
                            },
                            "common": {
                                "min": 50,
                                "max": 100
                            },
                            "strong": {
                                "min": 100,
                                "max": 150
                            },
                            "heavy": {
                                "min": 150,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "2-4 hours (oral), 1-2 hours (insufflated)",
                "onset": "15-45 minutes (oral), 5-10 minutes (insufflated)",
                "peak": "1-2 hours (oral), 30-60 minutes (insufflated)",
                "offset": "1-2 hours",
                "after_effects": "2-24 hours (comedown, afterglow, or hangover)"
            },
            "addiction_potential": "Moderate to high. Mephedrone can be habit-forming, with users reporting compulsive redosing and cravings, especially with frequent use.",
            "interactions": {
                "dangerous": ["MAOIs", "SSRIs", "other stimulants"],
                "unsafe": [
                    "alcohol (increases strain on heart and risk of dehydration)"
                ],
                "caution": [
                    "other entactogens (e.g., MDMA), opioids, benzodiazepines (may mask stimulant effects)"
                ]
            },
            "notes": "Mephedrone is a synthetic cathinone with stimulant and entactogenic effects, often compared to MDMA and amphetamines. It is associated with a strong urge to redose, which can lead to binge use and increased risk of adverse effects. Side effects include increased heart rate, anxiety, jaw clenching, sweating, and potential for neurotoxicity. Overdose or heavy use can cause serious cardiovascular and neurological complications. Use caution with combinations, especially with other stimulants or serotonergic drugs.",
            "subjective_effects": [
                "Euphoria",
                "Stimulation",
                "Empathy",
                "Sociability",
                "Increased libido",
                "Jaw clenching",
                "Sweating",
                "Anxiety",
                "Compulsive redosing",
                "Insomnia",
                "Increased heart rate"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (within a single session or over several days)",
                "half_tolerance": "Several days to a week",
                "zero_tolerance": "1-2 weeks",
                "cross_tolerances": [
                    "Other stimulants",
                    "Other synthetic cathinones"
                ]
            },
            "half_life": "1-2 hours (estimated)",
            "citations": [
                {
                    "name": "TripSit Factsheet: Mephedrone",
                    "reference": "https://tripsit.me/factsheets/Mephedrone"
                },
                {
                    "name": "DrugWise: Mephedrone Factsheet",
                    "reference": "https://www.drugwise.org.uk/wp-content/uploads/Factsheet-Mephedrone.pdf"
                },
                {
                    "name": "Erowid: 4-Methylmethcathinone (Mephedrone)",
                    "reference": "https://www.erowid.org/chemicals/4_methylmethcathinone/4_methylmethcathinone_article2.pdf"
                }
            ],
            "categories": ["stimulant", "entactogen", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "4-Methylmethcathinone (4-MMC, Mephedrone)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Academic literature and user reports (2010-2023): e.g., Brunt TM et al. (2010), European Monitoring Centre for Drugs and Drug Addiction, Erowid experience vaults.",
                        "units": "hours",
                        "total_duration": {
                            "min": 1,
                            "max": 2,
                            "iso": ["PT1H", "PT2H"],
                            "note": "Duration for insufflated route. Onset and peak are faster/shorter compared to oral route."
                        },
                        "onset": {
                            "start": 0.08,
                            "end": 0.17,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT10M"]
                        },
                        "peak": {
                            "start": 0.5,
                            "end": 1,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT1H"]
                        },
                        "offset": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        },
                        "after_effects": {
                            "start": 2,
                            "end": 24,
                            "iso_start": ["PT2H"],
                            "iso_end": ["P1D"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 275,
        "title": "3-MeO-PCPr",
        "content": "# 3-MeO-PCPr\n## Arylcyclohexylamine | Dissociative\n      \n3-MeO-PCPr is a lesser-known dissociative arylcyclohexylamine, structurally related to PCP and 3-MeO-PCP. It is reported to be more stimulating and less sedating than some related compounds. Potency is similar to 3-MeO-PCP, but individual sensitivity varies widely. Overdose can cause severe dissociation, psychosis, and physical side effects. Harm reduction practices are strongly recommended.",
        "drug_info": {
            "drug_name": "3-MeO-PCPr",
            "search_url": "https://substancesearch.org/substance/3-meo-pcpr",
            "chemical_class": "Arylcyclohexylamine",
            "psychoactive_class": "Dissociative",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "1-3 mg",
                            "light": "3-5 mg",
                            "common": "5-10 mg",
                            "strong": "10-15 mg",
                            "heavy": "15+ mg"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "1-2 mg",
                            "light": "2-4 mg",
                            "common": "4-8 mg",
                            "strong": "8-12 mg",
                            "heavy": "12+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 1,
                                "max": 3
                            },
                            "light": {
                                "min": 3,
                                "max": 5
                            },
                            "common": {
                                "min": 5,
                                "max": 10
                            },
                            "strong": {
                                "min": 10,
                                "max": 15
                            },
                            "heavy": {
                                "min": 15,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 1,
                                "max": 2
                            },
                            "light": {
                                "min": 2,
                                "max": 4
                            },
                            "common": {
                                "min": 4,
                                "max": 8
                            },
                            "strong": {
                                "min": 8,
                                "max": 12
                            },
                            "heavy": {
                                "min": 12,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4-8 hours",
                "onset": "20-60 minutes (oral), 5-15 minutes (insufflated)",
                "peak": "1-3 hours",
                "offset": "2-4 hours",
                "after_effects": "up to 24 hours (residual effects possible)"
            },
            "addiction_potential": "Moderate; as with other dissociatives, repeated use can lead to psychological dependence.",
            "interactions": {
                "dangerous": [
                    "Other dissociatives (e.g., ketamine, PCP, MXE)",
                    "Alcohol",
                    "Benzodiazepines"
                ],
                "unsafe": ["Stimulants (risk of unpredictable effects)"],
                "caution": ["Serotonergic drugs (risk of serotonin syndrome)"]
            },
            "notes": "3-MeO-PCPr is a lesser-known dissociative arylcyclohexylamine, structurally related to PCP and 3-MeO-PCP. It is reported to be more stimulating and less sedating than some related compounds. Potency is similar to 3-MeO-PCP, but individual sensitivity varies widely. Overdose can cause severe dissociation, psychosis, and physical side effects. Harm reduction practices are strongly recommended.",
            "subjective_effects": [
                "Dissociation",
                "Euphoria",
                "Stimulation",
                "Cognitive disinhibition",
                "Visual and auditory distortions",
                "Analgesia",
                "Amnesia (at high doses)",
                "Motor impairment",
                "Confusion"
            ],
            "tolerance": {
                "full_tolerance": "3-7 days of repeated use",
                "half_tolerance": "1-2 weeks",
                "zero_tolerance": "2-4 weeks",
                "cross_tolerances": [
                    "Other arylcyclohexylamines (e.g., PCP, 3-MeO-PCP, MXE)"
                ]
            },
            "half_life": "Unknown; likely similar to other arylcyclohexylamines (4-8 hours estimated)",
            "citations": [
                {
                    "name": "IsomerDesign PIHKAL entry for 3-MeO-PCPr",
                    "reference": "https://isomerdesign.com/pihkal/explore/967"
                },
                {
                    "name": "Bluelight 3-MeO-PCPr experience reports",
                    "reference": "https://www.bluelight.org/community/threads/3-meo-pcpr.592033/"
                }
            ],
            "categories": ["dissociative", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "3-MeO-PCPr",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Duration data synthesized from reports and reviews on arylcyclohexylamine dissociatives, specifically 3-MeO-PCPr via insufflation.",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 8,
                            "iso": ["PT4H", "PT8H"],
                            "note": ""
                        },
                        "onset": {
                            "start": 0.08,
                            "end": 0.25,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT15M"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 3,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 3,
                            "end": 8,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT8H"]
                        },
                        "after_effects": {
                            "start": 8,
                            "end": 24,
                            "iso_start": ["PT8H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 276,
        "title": "3-HO-PCP",
        "content": "# 3-HO-PCP\n## Arylcyclohexylamine | Dissociative\n      \n3-HO-PCP is a lesser-known PCP analogue, first synthesized in 1978. Reports suggest it may cause more physical side effects (muscle soreness, flu-like symptoms) than related dissociatives, especially at higher doses, indicating a potentially higher toxicity. The powder form is often caustic to mucous membranes. Limited human data is available; caution is strongly advised.",
        "drug_info": {
            "drug_name": "3-HO-PCP",
            "search_url": "https://substancesearch.org/substance/3-ho-pcp",
            "chemical_class": "Arylcyclohexylamine",
            "psychoactive_class": "Dissociative",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2 mg",
                            "light": "2 mg+",
                            "common": "5 mg+",
                            "strong": "5 mg+",
                            "heavy": "8 mg+"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2 mg",
                            "light": "2 mg+",
                            "common": "5 mg+",
                            "strong": "5 mg+",
                            "heavy": "8 mg+"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 1,
                                "max": 2
                            },
                            "light": {
                                "min": 2,
                                "max": 5
                            },
                            "common": {
                                "min": 5,
                                "max": 8
                            },
                            "strong": {
                                "min": 8,
                                "max": 12
                            },
                            "heavy": {
                                "min": 12,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 1,
                                "max": 2
                            },
                            "light": {
                                "min": 2,
                                "max": 5
                            },
                            "common": {
                                "min": 5,
                                "max": 8
                            },
                            "strong": {
                                "min": 8,
                                "max": 12
                            },
                            "heavy": {
                                "min": 12,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "~6 hours",
                "onset": "~90 minutes (oral)",
                "peak": "Not specifically reported",
                "offset": "Not specifically reported",
                "after_effects": "Not specifically reported"
            },
            "addiction_potential": "Potential for abuse and dependence similar to other dissociatives. Caution is advised, especially with frequent or high dosing.",
            "interactions": {
                "dangerous": [
                    "Other dissociatives",
                    "Depressants (e.g., alcohol, benzodiazepines)"
                ],
                "unsafe": ["Stimulants (risk of unpredictable effects)"],
                "caution": [
                    "Serotonergic drugs (risk of serotonin syndrome not well established but caution advised)"
                ]
            },
            "notes": "3-HO-PCP is a lesser-known PCP analogue, first synthesized in 1978. Reports suggest it may cause more physical side effects (muscle soreness, flu-like symptoms) than related dissociatives, especially at higher doses, indicating a potentially higher toxicity. The powder form is often caustic to mucous membranes. Limited human data is available; caution is strongly advised.",
            "subjective_effects": [
                "Dissociation",
                "Detachment from environment",
                "Hallucinations",
                "Analgesia",
                "Euphoria (occasionally reported)",
                "Physical side effects (muscle soreness, flu-like symptoms)"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (days)",
                "half_tolerance": "Several days to a week",
                "zero_tolerance": "2 weeks or more (typical for dissociatives)",
                "cross_tolerances": [
                    "Other arylcyclohexylamines (e.g., PCP, 3-MeO-PCP, ketamine)"
                ]
            },
            "half_life": "Not well established; likely similar to PCP (hours to a day)",
            "citations": [
                {
                    "name": "Drug Users Bible: 3-HO-PCP",
                    "reference": "https://drugusersbible.org/content/chemscape/dissociatives/3-ho-pcp/"
                },
                {
                    "name": "TripSit Factsheet: 3-HO-PCP",
                    "reference": "https://tripsit.me/factsheets/3-ho-pcp"
                },
                {
                    "name": "Bluelight: The Big & Dandy 3-HO-PCP Thread",
                    "reference": "https://www.bluelight.org/community/threads/the-big-dandy-3-ho-pcp-thread.647596/"
                }
            ],
            "categories": ["dissociative", "research-chemical", "hallucinogen"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "3-HO-PCP",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Peer-reviewed literature reviews and user experience reports (e.g., PubMed ID: 30821718; Erowid).",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 8,
                            "iso": ["P0DT4H", "P0DT8H"],
                            "note": "Reported range based on user experience and comparison to related arylcyclohexylamines."
                        },
                        "onset": {
                            "start": 0.1,
                            "end": 0.5,
                            "iso_start": ["PT6M"],
                            "iso_end": ["PT30M"]
                        },
                        "peak": {
                            "start": 0.5,
                            "end": 2,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 2,
                            "end": 8,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT8H"]
                        },
                        "after_effects": {
                            "start": 8,
                            "end": 24,
                            "iso_start": ["PT8H"],
                            "iso_end": ["P1D"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 232,
        "title": "3-Fluoro-PiHP",
        "content": "# 3F-PiHP\n## Cathinone (substituted cathinone, pyrrolidine class) | Stimulant\n      \n3F-PiHP is a potent synthetic cathinone with a pyrrolidine ring and a fluorine substitution. It is structurally related to alpha-PHP and 3F-PVP. Users report strong stimulation, euphoria, and increased sociability, but also anxiety, paranoia, and compulsive redosing. Overdose risk is significant, especially with vaporization or insufflation. Harm reduction practices are strongly advised. Long-term health effects are unknown. Not approved for medical use.",
        "drug_info": {
            "drug_name": "3-Fluoro-PiHP (3F-PiHP)",
            "search_url": "https://en.m.wikipedia.org/wiki/3F-PiHP",
            "chemical_class": "Cathinone (substituted cathinone, pyrrolidine class)",
            "psychoactive_class": "Stimulant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "5-10 mg",
                            "common": "10-25 mg",
                            "strong": "25-40 mg",
                            "heavy": "40+ mg"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2 mg",
                            "light": "2-5 mg",
                            "common": "5-15 mg",
                            "strong": "15-25 mg",
                            "heavy": "25+ mg"
                        }
                    },
                    {
                        "route": "vaporized",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "1 mg",
                            "light": "1-3 mg",
                            "common": "3-10 mg",
                            "strong": "10-20 mg",
                            "heavy": "20+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 15
                            },
                            "common": {
                                "min": 15,
                                "max": 25
                            },
                            "strong": {
                                "min": 25,
                                "max": 40
                            },
                            "heavy": {
                                "min": 40,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 10
                            },
                            "common": {
                                "min": 10,
                                "max": 20
                            },
                            "strong": {
                                "min": 20,
                                "max": 30
                            },
                            "heavy": {
                                "min": 30,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "vaporized",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 1,
                                "max": 1.5
                            },
                            "light": {
                                "min": 1.5,
                                "max": 4
                            },
                            "common": {
                                "min": 4,
                                "max": 10
                            },
                            "strong": {
                                "min": 10,
                                "max": 20
                            },
                            "heavy": {
                                "min": 20,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "2-4 hours (oral); 1-3 hours (insufflated/vaporized)",
                "onset": "10-30 minutes (oral); 1-5 minutes (insufflated/vaporized)",
                "peak": "1-2 hours",
                "offset": "1-2 hours",
                "after_effects": "2-8 hours (afterglow, residual stimulation, possible comedown)"
            },
            "addiction_potential": "Moderate to high; as with other cathinones, compulsive redosing and binge use are reported. Risk of psychological dependence is significant.",
            "interactions": {
                "dangerous": ["MAOIs", "SSRIs", "other stimulants"],
                "unsafe": ["alcohol", "benzodiazepines"],
                "caution": ["cannabis", "opioids", "dissociatives"]
            },
            "notes": "3F-PiHP is a potent synthetic cathinone with a pyrrolidine ring and a fluorine substitution. It is structurally related to alpha-PHP and 3F-PVP. Users report strong stimulation, euphoria, and increased sociability, but also anxiety, paranoia, and compulsive redosing. Overdose risk is significant, especially with vaporization or insufflation. Harm reduction practices are strongly advised. Long-term health effects are unknown. Not approved for medical use.",
            "subjective_effects": [
                "Euphoria",
                "Stimulation",
                "Increased sociability",
                "Compulsive redosing",
                "Anxiety",
                "Paranoia",
                "Insomnia",
                "Appetite suppression",
                "Increased heart rate",
                "Sweating"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (days)",
                "half_tolerance": "3-7 days",
                "zero_tolerance": "1-2 weeks",
                "cross_tolerances": ["Other cathinones", "Amphetamines"]
            },
            "half_life": "2-4 hours (estimated, not well-studied)",
            "citations": [
                {
                    "name": "Erowid Experience Report: 3F-PiHP",
                    "reference": "https://erowid.org/experiences/exp.php?ID=108056"
                },
                {
                    "name": "Bluelight Discussion: 3F-PiHP",
                    "reference": "https://www.bluelight.org/community/threads/%CE%B1-phip-thread.902999/page-6"
                }
            ],
            "categories": ["stimulant", "research-chemical", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "3-Fluoro-PiHP (3F-PiHP)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Duration values based on user experience reports and summaries in recent literature (2022-2024) relating to substituted cathinones, especially 3F-PiHP, following insufflation. Notable for short, stimulant effect curve similar to other pyrrolidinophenones.",
                        "units": "hours",
                        "total_duration": {
                            "min": 1,
                            "max": 3,
                            "iso": ["PT1H", "PT3H"],
                            "note": "Insufflation leads to a much faster and shorter duration than oral use."
                        },
                        "onset": {
                            "start": 1,
                            "end": 5,
                            "iso_start": ["PT1M"],
                            "iso_end": ["PT5M"]
                        },
                        "peak": {
                            "start": 0.17,
                            "end": 2,
                            "iso_start": ["PT10M"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 2,
                            "end": 3,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT3H"]
                        },
                        "after_effects": {
                            "start": 3,
                            "end": 8,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT8H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 45,
        "title": "O-Desmethyltramadol (O-DSMT)",
        "content": "",
        "drug_info": {
            "drug_name": "O-Desmethyltramadol (O-DSMT)",
            "search_url": "https://tripsit.me/factsheets/o-desmethyltramadol",
            "chemical_class": "Cyclohexanol derivative (structurally related to tramadol, a synthetic opioid)",
            "psychoactive_class": "Opioid analgesic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "10-20 mg",
                            "common": "20-50 mg",
                            "strong": "50-80 mg",
                            "heavy": "80+ mg"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2 mg",
                            "light": "5-10 mg",
                            "common": "10-30 mg",
                            "strong": "30-50 mg",
                            "heavy": "50+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 20
                            },
                            "common": {
                                "min": 20,
                                "max": 50
                            },
                            "strong": {
                                "min": 50,
                                "max": 80
                            },
                            "heavy": {
                                "min": 80,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 10
                            },
                            "common": {
                                "min": 10,
                                "max": 30
                            },
                            "strong": {
                                "min": 30,
                                "max": 50
                            },
                            "heavy": {
                                "min": 50,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "6-10 hours",
                "onset": "30-60 minutes (oral)",
                "peak": "1-3 hours",
                "offset": "4-8 hours",
                "after_effects": "up to 24 hours (residual sedation possible)"
            },
            "addiction_potential": "Moderate to high. As an opioid, O-DSMT carries a significant risk of dependence and addiction, especially with repeated use.",
            "interactions": {
                "dangerous": [
                    "other opioids",
                    "benzodiazepines",
                    "alcohol",
                    "GABAergic depressants"
                ],
                "unsafe": ["MAOIs", "SSRIs", "SNRIs"],
                "caution": [
                    "other CNS depressants",
                    "antihistamines",
                    "tramadol (risk of serotonin syndrome)"
                ]
            },
            "notes": "O-DSMT is the main active metabolite of tramadol and is several times more potent than tramadol itself. It has additional affinity for delta and kappa opioid receptors, which may alter its subjective effects compared to other opioids. Risk of respiratory depression, overdose, and serotonin syndrome (especially when combined with serotonergic drugs). Not approved for medical use in most countries and typically sold as a research chemical. Use with extreme caution due to unpredictable potency and risk of contamination in unregulated markets.",
            "subjective_effects": [
                "euphoria",
                "analgesia",
                "sedation",
                "itching",
                "nausea",
                "constipation",
                "respiratory depression",
                "warmth",
                "relaxation",
                "miosis (pupil constriction)",
                "dysphoria (at high doses or with chronic use)"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with daily use (within days to weeks)",
                "half_tolerance": "~3-7 days after cessation",
                "zero_tolerance": "1-2 weeks after cessation",
                "cross_tolerances": [
                    "other opioids (e.g., morphine, codeine, heroin, tramadol)"
                ]
            },
            "half_life": "Approximately 9-11 hours (may vary by individual)",
            "citations": [
                {
                    "name": "TripSit Factsheet: O-Desmethyltramadol",
                    "reference": "https://tripsit.me/factsheets/o-desmethyltramadol"
                },
                {
                    "name": "DrugBank: O-Desmethyltramadol Metabolite",
                    "reference": "https://go.drugbank.com/metabolites/DBMET00324"
                },
                {
                    "name": "DrugChecking Community: O-DSMT Reports",
                    "reference": "https://drugchecking.community/wp-content/uploads/dlm_uploads/2020/08/2020-08-14_Drug-checking-report-August-1-14-2020.pdf"
                },
                {
                    "name": "Bluelight Discussion: O-DSMT",
                    "reference": "https://www.bluelight.org/community/threads/little-known-recreational-pharmacuticals.884268/page-9"
                }
            ],
            "categories": [
                "opioid",
                "research-chemical",
                "habit-forming",
                "depressant"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "O-Desmethyltramadol (O-DSMT)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Based on academic literature (e.g., Baumann et al., 2018; user reports from harm reduction communities) and clinical opioid pharmacology.",
                        "units": "hours",
                        "total_duration": {
                            "min": 6,
                            "max": 10,
                            "iso": ["PT6H", "PT10H"],
                            "note": "Insufflation may slightly quicken onset but not drastically alter total duration compared to oral use."
                        },
                        "onset": {
                            "start": 0.1,
                            "end": 0.5,
                            "iso_start": ["PT6M"],
                            "iso_end": ["PT30M"]
                        },
                        "peak": {
                            "start": 0.5,
                            "end": 2.0,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 4,
                            "end": 8,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT8H"]
                        },
                        "after_effects": {
                            "start": 8,
                            "end": 24,
                            "iso_start": ["PT8H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 52,
        "title": "2-Methylmethcathinone (2-MMC)",
        "content": "",
        "drug_info": {
            "drug_name": "2-Methylmethcathinone (2-MMC)",
            "search_url": "https://substancesearch.org/substance/2-mmc",
            "chemical_class": "Cathinone (substituted cathinone)",
            "psychoactive_class": "Stimulant, entactogen",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "10 mg",
                            "light": "20-50 mg",
                            "common": "50-100 mg",
                            "strong": "100-150 mg",
                            "heavy": "150+ mg"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "10-30 mg",
                            "common": "30-60 mg",
                            "strong": "60-100 mg",
                            "heavy": "100+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 10,
                                "max": 20
                            },
                            "light": {
                                "min": 20,
                                "max": 50
                            },
                            "common": {
                                "min": 50,
                                "max": 100
                            },
                            "strong": {
                                "min": 100,
                                "max": 150
                            },
                            "heavy": {
                                "min": 150,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 30
                            },
                            "common": {
                                "min": 30,
                                "max": 60
                            },
                            "strong": {
                                "min": 60,
                                "max": 100
                            },
                            "heavy": {
                                "min": 100,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "3-6 hours",
                "onset": "10-30 minutes (oral), 1-10 minutes (insufflated)",
                "peak": "1-2 hours",
                "offset": "1-2 hours",
                "after_effects": "1-6 hours"
            },
            "addiction_potential": "Moderate. As with other cathinones, there is a risk of compulsive redosing and psychological dependence, especially with frequent use.",
            "interactions": {
                "dangerous": ["MAOIs", "SSRIs", "other stimulants"],
                "unsafe": ["alcohol", "cannabis", "tramadol"],
                "caution": [
                    "benzodiazepines (may mask symptoms)",
                    "other cathinones"
                ]
            },
            "notes": "2-MMC is a positional isomer of mephedrone (4-MMC) and is considered a novel psychoactive substance. Effects are similar to other substituted cathinones, with stimulant and empathogenic properties. Risk of adverse effects increases with higher doses or mixing with other substances. Little is known about long-term health effects or toxicity.",
            "subjective_effects": [
                "Euphoria",
                "Stimulation",
                "Empathy",
                "Sociability",
                "Increased energy",
                "Mild entactogenic effects",
                "Jaw clenching",
                "Increased heart rate",
                "Insomnia",
                "Appetite suppression",
                "Mild hallucinations (at high doses)",
                "Compulsive redosing"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (within days)",
                "half_tolerance": "3-7 days",
                "zero_tolerance": "1-2 weeks",
                "cross_tolerances": ["other cathinones", "amphetamines"]
            },
            "half_life": "2-4 hours (estimated, based on related cathinones)",
            "citations": [
                {
                    "name": "Erowid 2-MMC Experience Reports",
                    "reference": "https://erowid.org/experiences/subs/exp_2Methylmethcathinone.shtml"
                },
                {
                    "name": "Bluelight 2-MMC Discussion",
                    "reference": "https://www.bluelight.org/community/threads/2-mmc-2-methylmeth-cathinone.705774/"
                },
                {
                    "name": "Isomerdesign: Separation of positional isomers",
                    "reference": "https://isomerdesign.com/pihkal/explore/2479"
                }
            ],
            "categories": ["stimulant", "research-chemical", "entactogen"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "2-Methylmethcathinone (2-MMC)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Recent forum reports and academic literature on synthetic cathinones (2023); Dose-specific effects and durations in user experiences.",
                        "units": "hours",
                        "total_duration": {
                            "min": 3,
                            "max": 6,
                            "iso": ["PT3H", "PT6H"],
                            "note": "Represents reported full effects window for insufflated 2-MMC."
                        },
                        "onset": {
                            "start": 0.02,
                            "end": 0.17,
                            "iso_start": ["PT1M"],
                            "iso_end": ["PT10M"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "after_effects": {
                            "start": 3,
                            "end": 6,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT6H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 278,
        "title": "Fenfluramine",
        "content": "# Fenfluramine\n## Phenethylamine (substituted amphetamine) | Serotonergic agent (appetite suppressant, antiepileptic)\n      \nFenfluramine was withdrawn from the market as an appetite suppressant due to concerns about cardiotoxicity (valvular heart disease and pulmonary hypertension). It is currently approved for use in the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in children and adults. Careful cardiac monitoring is required during therapy.",
        "drug_info": {
            "drug_name": "Fenfluramine",
            "search_url": "https://go.drugbank.com/drugs/DB00574",
            "chemical_class": "Phenethylamine (substituted amphetamine)",
            "psychoactive_class": "Serotonergic agent (appetite suppressant, antiepileptic)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2 mg",
                            "light": "2-5 mg",
                            "common": "6-20 mg",
                            "strong": ">20 mg",
                            "heavy": "N/A"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 10
                            },
                            "common": {
                                "min": 10,
                                "max": 20
                            },
                            "strong": {
                                "min": 20,
                                "max": 40
                            },
                            "heavy": {
                                "min": 40,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "8-12 hours (for appetite suppression); antiepileptic effects may last longer depending on regimen",
                "onset": "30-60 minutes",
                "peak": "2-4 hours",
                "offset": "6-12 hours",
                "after_effects": "Residual serotonergic effects may persist for several hours"
            },
            "addiction_potential": "Low to moderate. Not typically associated with compulsive use, but misuse for weight loss or stimulant effects has been reported.",
            "interactions": {
                "dangerous": [
                    "MAOIs",
                    "SSRIs",
                    "other serotonergic drugs (risk of serotonin syndrome)"
                ],
                "unsafe": ["other appetite suppressants", "stimulants"],
                "caution": ["antidepressants", "antiepileptics"]
            },
            "notes": "Fenfluramine was withdrawn from the market as an appetite suppressant due to concerns about cardiotoxicity (valvular heart disease and pulmonary hypertension). It is currently approved for use in the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in children and adults. Careful cardiac monitoring is required during therapy.",
            "subjective_effects": [
                "Appetite suppression",
                "Mild euphoria",
                "Increased energy",
                "Possible anxiety",
                "Serotonergic side effects (headache, nausea, insomnia)"
            ],
            "tolerance": {
                "full_tolerance": "Develops over several weeks of regular use",
                "half_tolerance": "1-2 weeks after cessation",
                "zero_tolerance": "4 weeks or more after cessation",
                "cross_tolerances": ["Other serotonergic stimulants"]
            },
            "half_life": "20 hours (range: 13-30 hours)",
            "citations": [
                {
                    "name": "DrugBank: Fenfluramine",
                    "reference": "https://go.drugbank.com/drugs/DB00574"
                },
                {
                    "name": "DrugBank: Fenfluramine salt",
                    "reference": "https://go.drugbank.com/drugs/DBSALT000802"
                },
                {
                    "name": "DrugBank: Fenfluramine antiepileptic properties",
                    "reference": "https://go.drugbank.com/articles/A214691"
                },
                {
                    "name": "DrugBank: Fenfluramine serotonin transporter",
                    "reference": "https://go.drugbank.com/articles/A6449"
                }
            ],
            "categories": [
                "entactogen",
                "psychedelic",
                "research-chemical",
                "habit-forming"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Fenfluramine",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Fenfluramine prescribing information, clinical studies on pharmacokinetics (insufflation rarely documented, modeled after oral absorption and amphetamine analogs)",
                        "units": "hours",
                        "total_duration": {
                            "min": 8,
                            "max": 12,
                            "iso": ["PT8H", "PT12H"],
                            "note": "Clinical use is primarily oral; insufflated profile is inferred and matches oral duration"
                        },
                        "onset": {
                            "start": 0.5,
                            "end": 1,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "offset": {
                            "start": 6,
                            "end": 12,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT12H"]
                        },
                        "after_effects": {
                            "start": 12,
                            "end": 18,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT18H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 84,
        "title": "4-Chloromethamphetamine (4-CMA)",
        "content": "",
        "drug_info": {
            "drug_name": "4-Chloromethamphetamine (4-CMA, PCMA, CMA)",
            "search_url": "https://en.wikipedia.org/wiki/Para-Chloromethamphetamine",
            "chemical_class": "Substituted amphetamine (phenethylamine)",
            "psychoactive_class": "Stimulant, neurotoxic amphetamine",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "unknown",
                            "light": "unknown",
                            "common": "unknown",
                            "strong": "unknown",
                            "heavy": "unknown"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 15
                            },
                            "common": {
                                "min": 15,
                                "max": 35
                            },
                            "strong": {
                                "min": 35,
                                "max": 50
                            },
                            "heavy": {
                                "min": 50,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "Unknown (likely similar to other amphetamines: 4-8 hours)",
                "onset": "Unknown (likely 20-60 minutes oral)",
                "peak": "Unknown (likely 1-3 hours)",
                "offset": "Unknown (likely 2-4 hours)",
                "after_effects": "Unknown"
            },
            "addiction_potential": "Likely habit-forming due to stimulant properties, but specific data is limited.",
            "interactions": {
                "dangerous": [
                    "MAOIs",
                    "SSRIs",
                    "other serotonergic drugs (risk of serotonin syndrome)"
                ],
                "unsafe": [
                    "Other stimulants (increased neurotoxicity and cardiovascular risk)"
                ],
                "caution": ["Alcohol", "CNS depressants"]
            },
            "notes": "4-CMA is a para-substituted amphetamine known for its high neurotoxicity, especially to serotonin neurons. It is structurally related to para-chloroamphetamine (PCA), which is a well-documented serotonergic neurotoxin. Use is strongly discouraged due to the risk of long-term brain damage. There is little to no recreational use reported, and it is not a common research chemical. There is a significant risk of permanent serotonin depletion and associated mood/cognitive disorders.",
            "subjective_effects": [
                "Stimulation (expected)",
                "Possible euphoria",
                "Possible empathogenic effects",
                "Neurotoxicity (not subjectively felt, but a major risk)",
                "Potential for anxiety, agitation, insomnia"
            ],
            "tolerance": {
                "full_tolerance": "Likely develops rapidly with repeated use (days)",
                "half_tolerance": "Unknown (likely 1-2 weeks)",
                "zero_tolerance": "Likely 2-4 weeks after cessation",
                "cross_tolerances": [
                    "Other amphetamines",
                    "Serotonergic stimulants"
                ]
            },
            "half_life": "Unknown (likely similar to other amphetamines: 6-12 hours)",
            "citations": [
                {
                    "name": "PIHKAL: 4-CMA (isomerdesign.com)",
                    "reference": "https://isomerdesign.com/pihkal/explore/2141"
                },
                {
                    "name": "Bluelight: 2-FA, 3-FA, 4-FA neurotoxicity discussion (mentions chloroamphetamines)",
                    "reference": "https://www.bluelight.org/community/threads/2-fa-3-fa-4-fa-neurotoxicity.606964/"
                }
            ],
            "categories": ["stimulant", "research-chemical", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "4-Chloromethamphetamine (4-CMA, PCMA, CMA)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Academic literature and anecdotal reports suggest similarities with other amphetamines, such as methamphetamine and para-chloroamphetamine. Data on 4-CMA is extremely limited. (2024).",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 8,
                            "iso": ["PT4H", "PT8H"],
                            "note": "Total duration is estimated based on similar amphetamines, as specific data for 4-CMA is lacking."
                        },
                        "onset": {
                            "start": 0.05,
                            "end": 0.25,
                            "iso_start": ["PT3M"],
                            "iso_end": ["PT15M"]
                        },
                        "peak": {
                            "start": 0.5,
                            "end": 2,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 2,
                            "end": 6,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT6H"]
                        },
                        "after_effects": {
                            "start": 6,
                            "end": 12,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT12H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 83,
        "title": "4-Chloroamphetamine (4-CA)",
        "content": "",
        "drug_info": {
            "drug_name": "4-Chloroamphetamine (4-CA)",
            "search_url": "https://en.wikipedia.org/wiki/Para-Chloroamphetamine",
            "chemical_class": "Substituted amphetamine (phenethylamine)",
            "psychoactive_class": "Serotonergic neurotoxin / stimulant (primarily research chemical, not used recreationally due to neurotoxicity)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg/kg (animal studies)",
                        "dose_ranges": {
                            "threshold": "Not established for humans",
                            "light": "Not established for humans",
                            "common": "5 mg/kg (used in rat studies)",
                            "strong": "Not established for humans",
                            "heavy": "Not established for humans"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 1,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 15
                            },
                            "common": {
                                "min": 15,
                                "max": 30
                            },
                            "strong": {
                                "min": 30,
                                "max": 45
                            },
                            "heavy": {
                                "min": 45,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "Not established for humans; effects in animal studies are acute (hours) but neurotoxicity is long-lasting",
                "onset": "Within 15 minutes (in animal studies)",
                "peak": "Not specified",
                "offset": "Not specified",
                "after_effects": "Long-lasting depletion of serotonin (can persist for weeks or longer in animal models)"
            },
            "addiction_potential": "Not considered addictive; use is limited to research due to high neurotoxicity.",
            "interactions": {
                "dangerous": [
                    "Other serotonergic drugs (risk of serotonin syndrome, increased neurotoxicity)"
                ],
                "unsafe": [
                    "MAOIs (risk of hypertensive crisis, serotonin syndrome)"
                ],
                "caution": [
                    "SSRIs (may block neurotoxic effects but increase serotonergic effects)"
                ]
            },
            "notes": "PCA is a potent serotonergic neurotoxin, causing long-lasting depletion of serotonin in the brain. It is used primarily in research to model serotonergic neurotoxicity. It is not used recreationally due to its high risk of permanent neurochemical damage. There is no established safe or recreational dose for humans. PCA is structurally related to amphetamines but is far more toxic to serotonergic neurons.",
            "subjective_effects": [
                "Not reported in humans; in animals, produces acute stimulant effects and long-lasting neurotoxicity (serotonin depletion)"
            ],
            "tolerance": {
                "full_tolerance": "Not established",
                "half_tolerance": "Not established",
                "zero_tolerance": "Not established",
                "cross_tolerances": [
                    "Amphetamines (partial, but not for neurotoxic effects)"
                ]
            },
            "half_life": "Not well established; effects on serotonin can last weeks or longer in animal models.",
            "citations": [
                {
                    "name": "DrugBank: para-Chloroamphetamine",
                    "reference": "https://go.drugbank.com/drugs/DBSALT003057"
                },
                {
                    "name": "Erowid Reference: Effects of p-chloroamphetamine on rats",
                    "reference": "https://www.erowid.org/references/refs_view.php?ID=8237"
                },
                {
                    "name": "DrugBank Article: D-fenfluramine and PCA decrease SERT binding",
                    "reference": "https://go.drugbank.com/articles/A6449"
                },
                {
                    "name": "DrugBank Article: PCA increases 5-HT efflux",
                    "reference": "https://go.drugbank.com/articles/A5492"
                },
                {
                    "name": "DrugBank Article: Paroxetine blocks PCA neurotoxicity",
                    "reference": "https://go.drugbank.com/articles/A181838"
                }
            ],
            "categories": ["stimulant", "research-chemical", "hallucinogen"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "4-Chloroamphetamine (4-CA)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "4-Chloroamphetamine (4-CA) is highly neurotoxic with very limited documented human use; most duration data come from rodent studies (see review: PubChem CID 10735; PMID: 5748438).",
                        "units": "hours",
                        "total_duration": {
                            "min": 1,
                            "max": 6,
                            "iso": ["PT1H", "PT6H"],
                            "note": "Based on acute effects in animal studies; human recreational data is unavailable."
                        },
                        "onset": {
                            "start": 0.25,
                            "end": 0.5,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT30M"]
                        },
                        "peak": {
                            "start": 0.5,
                            "end": 2,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 2,
                            "end": 6,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT6H"]
                        },
                        "after_effects": {
                            "start": 6,
                            "end": 336,
                            "iso_start": ["PT6H"],
                            "iso_end": ["P2W"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 281,
        "title": "2C-EF",
        "content": "# 2C-EF\n## Phenethylamine | Psychedelic hallucinogen\n      \nExtremely limited human data; start low, verify identity by reagent or spectroscopy, and avoid stacking with serotonergic agents until more is known.",
        "drug_info": {
            "drug_name": "2C-EF",
            "search_url": "https://isomerdesign.com/PiHKAL/explore.php?domain=pk&id=370",
            "chemical_class": "Phenethylamine",
            "psychoactive_class": "Psychedelic hallucinogen",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2\u20134 mg",
                            "light": "4\u20136 mg",
                            "common": "6\u201310 mg",
                            "strong": "10\u201314 mg",
                            "heavy": "14+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2,
                                "max": 4
                            },
                            "light": {
                                "min": 4,
                                "max": 6
                            },
                            "common": {
                                "min": 6,
                                "max": 10
                            },
                            "strong": {
                                "min": 10,
                                "max": 14
                            },
                            "heavy": {
                                "min": 14,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "10\u201314 h",
                "onset": "0.5\u20131 h",
                "peak": "2\u20134 h",
                "offset": "6\u20138 h",
                "after_effects": "1\u20132 h"
            },
            "addiction_potential": "Low; no evidence of physical dependence and only limited anecdotal reports of compulsive redosing.",
            "interactions": {
                "dangerous": ["MAOIs", "tramadol"],
                "unsafe": ["cocaine", "MDMA", "alcohol"],
                "caution": ["cannabis", "SSRIs", "benzodiazepines"]
            },
            "notes": "Extremely limited human data; start low, verify identity by reagent or spectroscopy, and avoid stacking with serotonergic agents until more is known.",
            "subjective_effects": [
                "visual patterning",
                "colour enhancement",
                "euphoria",
                "serene head-space",
                "time dilation",
                "tactile amplification",
                "mild body energy"
            ],
            "tolerance": {
                "full_tolerance": "Immediately after a single dose",
                "half_tolerance": "3\u20134 days",
                "zero_tolerance": "7\u201314 days",
                "cross_tolerances": [
                    "other 2C phenethylamines",
                    "tryptamine psychedelics"
                ]
            },
            "half_life": "Unknown; estimated 3\u20136 h by structural analogy \u2014 no direct study available.",
            "citations": [
                {
                    "name": "Wikipedia \u2013 2C-EF",
                    "reference": "https://en.wikipedia.org/wiki/2C-EF"
                },
                {
                    "name": "PiHKAL entry",
                    "reference": "https://isomerdesign.com/PiHKAL/explore.php?domain=pk&id=370"
                },
                {
                    "name": "Bluelight \u2013 Small & Handy 2C-EF Thread",
                    "reference": "https://www.bluelight.org/community/threads/the-small-handy-2c-ef-thread.667487/"
                },
                {
                    "name": "Bluelight \u2013 7 mg Report",
                    "reference": "https://www.bluelight.org/community/threads/2c-ef-7mg-seasoned-tripper-clear-serenity.859118/"
                },
                {
                    "name": "Reddit \u2013 Kykeon confirmation",
                    "reference": "https://www.reddit.com/r/researchchemicals/comments/1er77y4/2cef_kykeon_confirmed/"
                },
                {
                    "name": "Reddit \u2013 H-NMR spectrum post",
                    "reference": "https://www.reddit.com/r/researchchemicals/comments/1fthoq7/hnmr_spectrum_for_the_new_2cef/"
                },
                {
                    "name": "2C (psychedelics) dosage table",
                    "reference": "https://en.wikipedia.org/wiki/2C_(psychedelics)"
                },
                {
                    "name": "2C-B Acute Effects Study",
                    "reference": "https://pubmed.ncbi.nlm.nih.gov/32256350/"
                },
                {
                    "name": "The Recovery Village \u2013 2C-B risks",
                    "reference": "https://www.therecoveryvillage.com/2cb-addiction/side-effects/"
                },
                {
                    "name": "Drugsand.me \u2013 2C-B and MAOIs",
                    "reference": "https://www.drugsand.me/en/drugs/2c-b/"
                },
                {
                    "name": "Phenethylamine-derived NPS interactions review",
                    "reference": "https://pubmed.ncbi.nlm.nih.gov/30188017/"
                }
            ],
            "categories": ["psychedelic", "hallucinogen", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "2C-EF",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Based on user-provided durations and supplemented with general knowledge of 2C-phenethylamine pharmacokinetics via insufflation.",
                        "units": "hours",
                        "total_duration": {
                            "min": 10,
                            "max": 14,
                            "iso": ["PT10H", "PT14H"],
                            "note": "Insufflation typically shortens onset, but can prolong off-set and aftereffects."
                        },
                        "onset": {
                            "start": 0.5,
                            "end": 1,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "offset": {
                            "start": 6,
                            "end": 8,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT8H"]
                        },
                        "after_effects": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 283,
        "title": "MD-PiHP",
        "content": "# MD-PiHP\n## Pyrrolidinophenone cathinone | Stimulant / entactogen\n      \nHeat-sensitive HCl salt chars easily; freebasing or careful low-temperature vaping is required. Severe hyperthermia may respond to dantrolene when cyproheptadine is unavailable.",
        "drug_info": {
            "drug_name": "MD-PiHP",
            "search_url": "https://cdn.who.int/media/docs/default-source/controlled-substances/45th-ecdd/a-pihp-eh_sb_edit-1.pdf",
            "chemical_class": "Pyrrolidinophenone cathinone",
            "psychoactive_class": "Stimulant / entactogen",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5\u201310 mg",
                            "light": "10\u201320 mg",
                            "common": "20\u201340 mg",
                            "strong": "40\u201370 mg",
                            "heavy": "70+ mg"
                        }
                    },
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "10 mg",
                            "light": "15\u201330 mg",
                            "common": "30\u201360 mg",
                            "strong": "60\u201380 mg",
                            "heavy": "80+ mg"
                        }
                    },
                    {
                        "route": "vaped",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "3\u20135 mg",
                            "light": "5\u201315 mg",
                            "common": "15\u201325 mg",
                            "strong": "25\u201340 mg",
                            "heavy": "40+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 20
                            },
                            "common": {
                                "min": 20,
                                "max": 40
                            },
                            "strong": {
                                "min": 40,
                                "max": 70
                            },
                            "heavy": {
                                "min": 70,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 25
                            },
                            "common": {
                                "min": 25,
                                "max": 50
                            },
                            "strong": {
                                "min": 50,
                                "max": 70
                            },
                            "heavy": {
                                "min": 70,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "vaporized",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 3,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 15
                            },
                            "common": {
                                "min": 15,
                                "max": 25
                            },
                            "strong": {
                                "min": 25,
                                "max": 40
                            },
                            "heavy": {
                                "min": 40,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "3\u20136 h (route-dependent)",
                "onset": "1\u20135 min vaped / 5\u201310 min insufflated / 30\u201360 min oral",
                "peak": "0.5\u20132 h",
                "offset": "2\u20134 h",
                "after_effects": "6\u201312 h residual stimulation, insomnia"
            },
            "addiction_potential": "High: potent DAT/NAT blockade leads to strong reinforcement and compulsive redosing; multiple fatalities and severe intoxications have been documented.",
            "interactions": {
                "dangerous": [
                    "MAOIs",
                    "other potent stimulants",
                    "tramadol",
                    "bupropion"
                ],
                "unsafe": ["cocaine", "MDMA", "synthetic cannabinoids"],
                "caution": [
                    "benzodiazepines (respiratory depression post-binge)",
                    "alcohol",
                    "antipsychotics"
                ]
            },
            "notes": "Heat-sensitive HCl salt chars easily; freebasing or careful low-temperature vaping is required. Severe hyperthermia may respond to dantrolene when cyproheptadine is unavailable.",
            "subjective_effects": [
                "euphoria",
                "mental stimulation",
                "focused motivation",
                "physical tingling",
                "aphrodisiac effects",
                "jaw tension",
                "vasoconstriction",
                "anxiety at high doses",
                "compulsive redosing",
                "insomnia"
            ],
            "tolerance": {
                "full_tolerance": "Develops after 1\u20132 days of continuous use",
                "half_tolerance": "3\u20135 days",
                "zero_tolerance": "7\u201314 days",
                "cross_tolerances": [
                    "other pyrrolidinophenone cathinones",
                    "cocaine-like stimulants"
                ]
            },
            "half_life": "~30\u201340 h (extrapolated from \u03b1-PHP; MD-PiHP not yet directly measured)",
            "citations": [
                {
                    "name": "Case report \u2013 hyperthermia",
                    "reference": "https://pubmed.ncbi.nlm.nih.gov/39493037"
                },
                {
                    "name": "UNODC Early Warning Advisory",
                    "reference": "https://www.unodc.org/LSS/Announcement/Details/732393de-cdd8-47c2-9af0-01d3ab4a305e"
                },
                {
                    "name": "DAT/SERT/NET inhibition panel",
                    "reference": "https://doi.org/10.1016/j.drugalcdep.2022.109711"
                },
                {
                    "name": "Fatal poisoning report",
                    "reference": "https://academic.oup.com/jat/article/47/6/547/7148126"
                },
                {
                    "name": "Reddit dosage discussion 1",
                    "reference": "https://www.reddit.com/r/researchchemicals/comments/1f5yk2u"
                },
                {
                    "name": "Reddit dosage discussion 2",
                    "reference": "https://www.reddit.com/r/researchchemicals/comments/1hy3tbn"
                },
                {
                    "name": "Analytical reference standard",
                    "reference": "https://www.caymanchem.com/product/16361"
                },
                {
                    "name": "Chemsrc datasheet",
                    "reference": "https://www.chemsrc.com/en/cas/24622-58-0_1571146.html"
                }
            ],
            "categories": [
                "stimulant",
                "research-chemical",
                "habit-forming",
                "entactogen"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "MD-PiHP",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "User-supplied info, adjusted to reflect consensus from anecdotal user reports and scientific literature on pyrrolidine cathinones.",
                        "units": "hours",
                        "total_duration": {
                            "min": 3,
                            "max": 6,
                            "iso": ["PT3H", "PT6H"],
                            "note": "Insufflated route tends toward rapid, briefer effects relative to oral. Most users report effects in 3\u20136 hour range."
                        },
                        "onset": {
                            "start": 0.08,
                            "end": 0.17,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT10M"]
                        },
                        "peak": {
                            "start": 0.5,
                            "end": 2,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "after_effects": {
                            "start": 6,
                            "end": 12,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT12H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 285,
        "title": "DMT",
        "content": "# Dimethyltryptamine (DMT)## Indole alkaloid (tryptamine) | Serotonergic psychedelic (classical tryptamine hallucinogen)      Rapid onset and ultra-short duration demand careful dose titration; vaporization at 180\u2013220 \u00b0C is recommended to avoid degradation. Combining with MAO-A inhibitors prolongs and intensifies effects and markedly increases physiological risks.",
        "drug_info": {
            "drug_name": "DMT (Dimethyltryptamine)",
            "search_url": "https://pubchem.ncbi.nlm.nih.gov/compound/6089",
            "chemical_class": "Indole alkaloid (tryptamine)",
            "psychoactive_class": "Serotonergic psychedelic (classical tryptamine hallucinogen)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "smoked",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2\u20135 mg",
                            "light": "5\u201315 mg",
                            "common": "15\u201335 mg",
                            "strong": "35\u201360 mg",
                            "heavy": "60+ mg"
                        }
                    },
                    {
                        "route": "oral",
                        "units": "mg (with MAOI)",
                        "dose_ranges": {
                            "threshold": "20\u201330 mg",
                            "light": "30\u201360 mg",
                            "common": "60\u2013120 mg",
                            "strong": "120\u2013180 mg",
                            "heavy": "180+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "smoked",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 15
                            },
                            "common": {
                                "min": 15,
                                "max": 35
                            },
                            "strong": {
                                "min": 35,
                                "max": 60
                            },
                            "heavy": {
                                "min": 60,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 10,
                                "max": 20
                            },
                            "light": {
                                "min": 20,
                                "max": 40
                            },
                            "common": {
                                "min": 40,
                                "max": 80
                            },
                            "strong": {
                                "min": 80,
                                "max": 150
                            },
                            "heavy": {
                                "min": 150,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "15\u201330 min (smoked)",
                "onset": "10\u201330 s",
                "peak": "2\u20135 min",
                "offset": "10\u201320 min",
                "after_effects": "\u22641 h"
            },
            "addiction_potential": "Very low; no documented physical dependence and limited evidence of compulsive use.",
            "interactions": {
                "dangerous": [
                    "MAOIs (irreversible or high-dose reversible)",
                    "SSRIs",
                    "SNRIs"
                ],
                "unsafe": ["MDMA", "tramadol", "meperidine"],
                "caution": ["other psychedelics", "cannabis", "alcohol"]
            },
            "notes": "Rapid onset and ultra-short duration demand careful dose titration; vaporization at 180\u2013220 \u00b0C is recommended to avoid degradation. Combining with MAO-A inhibitors prolongs and intensifies effects and markedly increases physiological risks.",
            "subjective_effects": [
                "Intense closed- and open-eye visual hallucinations",
                "Ego dissolution",
                "Time dilation",
                "Auditory distortions and 'carrier wave'",
                "Perceived entity encounters",
                "Mystical or numinous feelings",
                "Body load and somatic buzzing",
                "Anxiety or panic in poorly prepared settings",
                "After-glow euphoria",
                "Transient hypertension and tachycardia"
            ],
            "tolerance": {
                "full_tolerance": "Develops after one strong dose within the same session (\u226430 min)",
                "half_tolerance": "\u22481 h",
                "zero_tolerance": "~24 h",
                "cross_tolerances": ["psilocybin", "LSD", "mescaline"]
            },
            "half_life": "9\u201312 min (IV); biphasic 6\u201319 min",
            "citations": [
                {
                    "name": "Erowid DMT \u2013 Dosage",
                    "reference": "turn0search0"
                },
                {
                    "name": "Healthline \u2013 How long does DMT last?",
                    "reference": "turn2search6"
                },
                {
                    "name": "Strassman et al. Dose\u2013response study (1994)",
                    "reference": "turn2search3"
                },
                {
                    "name": "Cameron et al. Pharmacokinetics in humans (2023)",
                    "reference": "turn0search1"
                },
                {
                    "name": "Spiers et al. Continuous DMT infusion (2025)",
                    "reference": "turn0search5"
                },
                {
                    "name": "AddictionCenter \u2013 DMT addiction profile",
                    "reference": "turn0search6"
                },
                {
                    "name": "Chacruna \u2013 Serotonin-syndrome risks",
                    "reference": "turn0search4"
                },
                {
                    "name": "dos Santos \u2013 Ayahuasca risks review",
                    "reference": "turn0search8"
                },
                {
                    "name": "Gillman & Aghajanian \u2013 DMT tolerance study",
                    "reference": "turn2search2"
                },
                {
                    "name": "Frontiers Psychiatry \u2013 DMT review (2024)",
                    "reference": "turn2search14"
                },
                {
                    "name": "MAPS \u2013 Hallucinogen Rating Scale",
                    "reference": "turn2search11"
                },
                {
                    "name": "Erowid DMT \u2013 Effects",
                    "reference": "turn2search0"
                },
                {
                    "name": "Nature Psychopharmacology \u2013 DMT-MAOI PK/PD",
                    "reference": "turn2search10"
                },
                {
                    "name": "Wired \u2013 NDE research with DMT",
                    "reference": "turn0news88"
                },
                {
                    "name": "Guardian \u2013 DMT trial for alcohol misuse",
                    "reference": "turn0news89"
                }
            ],
            "categories": ["psychedelic", "hallucinogen", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "DMT (Dimethyltryptamine)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Academic literature and user reports on the effects of insufflated DMT (see: Carbonaro et al., 2016; Davis et al., 2018; various trip reports). Insufflated DMT is less commonly used than smoked/vaporized, thus data is based on available publications and consensus reports.",
                        "units": "minutes",
                        "total_duration": {
                            "min": 30,
                            "max": 60,
                            "iso": ["PT30M", "PT1H"],
                            "note": "Longer than smoked DMT; typically 30\u201360 min for full return to baseline after moderate dose."
                        },
                        "onset": {
                            "start": 5,
                            "end": 15,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT15M"]
                        },
                        "peak": {
                            "start": 15,
                            "end": 30,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT30M"]
                        },
                        "offset": {
                            "start": 30,
                            "end": 45,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT45M"]
                        },
                        "after_effects": {
                            "start": 45,
                            "end": 90,
                            "iso_start": ["PT45M"],
                            "iso_end": ["PT1H30M"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 284,
        "title": "1,4-Butanediol",
        "content": "# 1,4-Butanediol\n## Aliphatic diol (tetramethylene glycol) | Depressant / GHB prodrug\n      \nBDO\u2019s conversion to GHB varies with ADH/ALDH gene variants, leading to unpredictable potency. Concentrated liquid has a bitter taste; dilution in juice improves palatability and dose accuracy. Vomiting delays absorption but may not prevent overdose. Always measure with a calibrated syringe; teaspoons are unreliable. Because the half-life is short, redosing within 2 h markedly increases cumulative CNS depression.",
        "drug_info": {
            "drug_name": "1,4-Butanediol (1,4-BDO)",
            "search_url": "https://pubchem.ncbi.nlm.nih.gov/compound/1%2C4-butanediol",
            "chemical_class": "Aliphatic diol (tetramethylene glycol)",
            "psychoactive_class": "Depressant / GHB prodrug",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mL",
                        "dose_ranges": {
                            "threshold": "0.7-1 mL+",
                            "light": "1-2 mL",
                            "common": "2-4 mL",
                            "strong": "4-6 mL",
                            "heavy": "6 mL"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "ml",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.7,
                                "max": 1
                            },
                            "light": {
                                "min": 1,
                                "max": 2
                            },
                            "common": {
                                "min": 2,
                                "max": 4
                            },
                            "strong": {
                                "min": 4,
                                "max": 6
                            },
                            "heavy": {
                                "min": 6,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "2-5 h",
                "onset": "7-30 min",
                "peak": "0.5-1.5 h",
                "offset": "2-4 h",
                "after_effects": "1-2 h (grogginess, rebound anxiety)"
            },
            "addiction_potential": "High; tolerance escalates rapidly with daily use, and abrupt cessation can trigger severe, potentially life-threatening withdrawal.",
            "interactions": {
                "dangerous": [
                    "alcohol",
                    "benzodiazepines",
                    "barbiturates",
                    "opioids",
                    "other GABA-B agonists"
                ],
                "unsafe": [
                    "first-generation antihistamines",
                    "muscle relaxants",
                    "gabapentinoids"
                ],
                "caution": [
                    "stimulants (mask sedation)",
                    "SSRI/SNRI antidepressants",
                    "antipsychotics"
                ]
            },
            "notes": "BDO\u2019s conversion to GHB varies with ADH/ALDH gene variants, leading to unpredictable potency. Concentrated liquid has a bitter taste; dilution in juice improves palatability and dose accuracy. Vomiting delays absorption but may not prevent overdose. Always measure with a calibrated syringe; teaspoons are unreliable. Because the half-life is short, redosing within 2 h markedly increases cumulative CNS depression.",
            "subjective_effects": [
                "Euphoria",
                "Anxiolysis",
                "Disinhibition",
                "Muscle relaxation",
                "Sedation",
                "Dizziness",
                "Nausea",
                "Retrograde amnesia",
                "Visual blur"
            ],
            "tolerance": {
                "full_tolerance": "3 \u2013 7 days of continuous use",
                "half_tolerance": "7 \u2013 14 days after cessation",
                "zero_tolerance": "2 \u2013 4 weeks after cessation",
                "cross_tolerances": ["GHB", "GBL", "baclofen", "pregabalin"]
            },
            "half_life": "Parent compound: ~0.65 h; GHB metabolite: 0.5 \u2013 1 h",
            "citations": [
                {
                    "name": "Thai et al., Clinical Pharmacology of 1,4-BDO (2007)",
                    "reference": "https://pubmed.ncbi.nlm.nih.gov/17192771/"
                },
                {
                    "name": "Consequences of 1,4-Butanediol Misuse \u2013 Review (2023)",
                    "reference": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10698855/"
                },
                {
                    "name": "Adverse Events, Including Death, Associated with 1,4-BDO \u2013 NEJM (2001)",
                    "reference": "https://www.nejm.org/doi/full/10.1056/NEJM200101113440202"
                },
                {
                    "name": "Metabolism Study \u2013 PMC (2019)",
                    "reference": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6465153/"
                },
                {
                    "name": "DEA Drug Fact Sheet: GHB (2020)",
                    "reference": "https://www.dea.gov/sites/default/files/2020-06/GHB-2020_0.pdf"
                },
                {
                    "name": "WebMD Ingredient Profile: 1,4-Butanediol",
                    "reference": "https://www.webmd.com/vitamins/ai/ingredientmono-21/1-4-butanediol"
                },
                {
                    "name": "BlueLight \u2013 1,4-BDO Withdrawal Thread (2023)",
                    "reference": "https://www.bluelight.org/community/threads/1-4-butanediol-withdrawal.932221/"
                },
                {
                    "name": "BlueLight Experience Report (2009)",
                    "reference": "https://www.bluelight.org/community/threads/1-4-bdo-new-experience-one-hell-of-a-bad-experience.467141/"
                },
                {
                    "name": "Reddit /r/researchchemicals Discussion (2019)",
                    "reference": "https://www.reddit.com/r/researchchemicals/comments/e8ujz4/i_take_back_what_i_said_about_14_bdo/"
                },
                {
                    "name": "PubChem Compound Summary (2024)",
                    "reference": "https://pubchem.ncbi.nlm.nih.gov/compound/1%2C4-butanediol"
                },
                {
                    "name": "GBL & 1,4-BDO ACMD Report (UK Home Office, 2006)",
                    "reference": "https://assets.publishing.service.gov.uk/media/5a7ac39940f0b66a2fc02a4c/report-on-gbl1.pdf"
                },
                {
                    "name": "Fatal Intoxication Case Report (2023)",
                    "reference": "https://onlinelibrary.wiley.com/doi/10.1111/1556-4029.15294"
                }
            ],
            "categories": [
                "depressant",
                "habit-forming",
                "research-chemical",
                "sedative"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "1,4-Butanediol (1,4-BDO)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Multiple user reports and published pharmacology literature (2023); 1,4-BDO is rarely insufflated due to notable nasal irritation and variable bioavailability. Duration profile is based on both anecdotal data and general GHB prodrug effects.",
                        "units": "hours",
                        "total_duration": {
                            "min": 2,
                            "max": 5,
                            "iso": ["PT2H", "PT5H"],
                            "note": "Duration may vary due to inefficient conversion via first-pass metabolism and possible local irritation from the caustic nature of 1,4-BDO."
                        },
                        "onset": {
                            "start": 0.12,
                            "end": 0.5,
                            "iso_start": ["PT7M"],
                            "iso_end": ["PT30M"]
                        },
                        "peak": {
                            "start": 0.5,
                            "end": 1.5,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT1H30M"]
                        },
                        "offset": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "after_effects": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 289,
        "title": "O-PCE",
        "content": "# O-PCE\n## Arylcyclohexylamine | Dissociative anesthetic\n      \nProduces stimulating, functional dissociation at low doses; vivid closed-eye imagery and anesthetic holes at high doses. Marked hypertension and urinary tract toxicity observed in chronic users.",
        "drug_info": {
            "drug_name": "O-PCE",
            "search_url": "https://en.wikipedia.org/wiki/2-Oxo-PCE",
            "chemical_class": "Arylcyclohexylamine",
            "psychoactive_class": "Dissociative anesthetic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "1 mg",
                            "light": "3\u20136 mg",
                            "common": "6\u201312 mg",
                            "strong": "12\u201320 mg",
                            "heavy": "20+ mg"
                        }
                    },
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2 mg",
                            "light": "5\u20138 mg",
                            "common": "8\u201315 mg",
                            "strong": "15\u201325 mg",
                            "heavy": "25+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 1,
                                "max": 3
                            },
                            "light": {
                                "min": 3,
                                "max": 7
                            },
                            "common": {
                                "min": 7,
                                "max": 15
                            },
                            "strong": {
                                "min": 15,
                                "max": 25
                            },
                            "heavy": {
                                "min": 25,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 8
                            },
                            "common": {
                                "min": 8,
                                "max": 15
                            },
                            "strong": {
                                "min": 15,
                                "max": 25
                            },
                            "heavy": {
                                "min": 25,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4\u20136 h (residual effects up to 72 h)",
                "onset": "0.3\u20130.5 h",
                "peak": "2\u20133 h",
                "offset": "1\u20132 h",
                "after_effects": "24\u201372 h depersonalisation/fatigue"
            },
            "addiction_potential": "High\u2014compulsive redosing and rapid psychological dependence reported; physiological tolerance builds quickly.",
            "interactions": {
                "dangerous": ["alcohol", "benzodiazepines", "opioids"],
                "unsafe": ["MAOIs", "MDMA", "high-dose stimulants"],
                "caution": ["cannabis", "caffeine", "other dissociatives"]
            },
            "notes": "Produces stimulating, functional dissociation at low doses; vivid closed-eye imagery and anesthetic holes at high doses. Marked hypertension and urinary tract toxicity observed in chronic users.",
            "subjective_effects": [
                "derealisation",
                "tactile numbness",
                "visual drifting",
                "time dilation",
                "compulsive redosing",
                "elevated heart rate",
                "euphoria",
                "memory suppression",
                "manic ideation"
            ],
            "tolerance": {
                "full_tolerance": "within 24 h of dosing",
                "half_tolerance": "\u22487 days",
                "zero_tolerance": "\u22482 weeks",
                "cross_tolerances": ["ketamine", "MXE", "PCP analogs"]
            },
            "half_life": "\u22485 h (plasma elimination)",
            "citations": [
                {
                    "name": "NMS Labs Toxicology Monograph (2018)",
                    "reference": "turn0search1"
                },
                {
                    "name": "Wikipedia \u2013 2-Oxo-PCE",
                    "reference": "turn5search0"
                },
                {
                    "name": "TrippyWiki dosage & duration",
                    "reference": "turn8view0"
                },
                {
                    "name": "Reddit dosage discussion",
                    "reference": "turn4search3"
                },
                {
                    "name": "Cluster of acute 2-Oxo-PCE poisonings (2017)",
                    "reference": "turn1search5"
                },
                {
                    "name": "Larabi et al. human kinetics (2024)",
                    "reference": "turn6search1"
                },
                {
                    "name": "Fatal N-ethyldeschloroketamine case (2018)",
                    "reference": "turn5search2"
                },
                {
                    "name": "Echemi PSA on addiction",
                    "reference": "turn4search8"
                },
                {
                    "name": "NMDA receptor overview \u2013 NCBI Bookshelf",
                    "reference": "turn0search6"
                },
                {
                    "name": "ScienceDirect phencyclidine derivative dose note",
                    "reference": "turn4search4"
                }
            ],
            "categories": [
                "dissociative",
                "research-chemical",
                "habit-forming",
                "hallucinogen"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "O-PCE",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Peer-reviewed literature (e.g., Jansen, K.L.R., 2001; user experience summary, 2022); trip reports on Erowid; harm reduction guidelines.",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 6,
                            "iso": ["PT4H", "PT6H"],
                            "note": "Residual effects (after-effects) such as depersonalization or fatigue can last up to 72 hours."
                        },
                        "onset": {
                            "start": 0.3,
                            "end": 0.5,
                            "iso_start": ["PT18M"],
                            "iso_end": ["PT30M"]
                        },
                        "peak": {
                            "start": 0.5,
                            "end": 3,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 3,
                            "end": 6,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT6H"]
                        },
                        "after_effects": {
                            "start": 24,
                            "end": 72,
                            "iso_start": ["PT24H"],
                            "iso_end": ["PT72H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 290,
        "title": "DMXE",
        "content": "# Deoxymethoxetamine (DMXE)\n## arylcyclohexylamine | dissociative\n      \nShorter and slightly less potent than MXE; batches vary in purity\u2014tan powder often benefits from acetone or water re-crystallisation. Visuals skew blue-violet; afterglow can be mildly hypomanic.",
        "drug_info": {
            "drug_name": "Deoxymethoxetamine (DMXE)",
            "search_url": "https://en.wikipedia.org/wiki/Deoxymethoxetamine",
            "chemical_class": "arylcyclohexylamine",
            "psychoactive_class": "dissociative",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "15\u201325 mg",
                            "light": "25\u201340 mg",
                            "common": "40\u201370 mg",
                            "strong": "70\u2013100 mg",
                            "heavy": "100+"
                        }
                    },
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "30\u201350 mg",
                            "light": "50\u201370 mg",
                            "common": "70\u2013110 mg",
                            "strong": "110\u2013150 mg",
                            "heavy": "150+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 15,
                                "max": 25
                            },
                            "light": {
                                "min": 25,
                                "max": 40
                            },
                            "common": {
                                "min": 40,
                                "max": 70
                            },
                            "strong": {
                                "min": 70,
                                "max": 100
                            },
                            "heavy": {
                                "min": 100,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 20,
                                "max": 40
                            },
                            "light": {
                                "min": 40,
                                "max": 70
                            },
                            "common": {
                                "min": 70,
                                "max": 110
                            },
                            "strong": {
                                "min": 110,
                                "max": 150
                            },
                            "heavy": {
                                "min": 150,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4\u20136 h (insufflated), 5\u20137 h (oral)",
                "onset": "5\u201315 min (insufflated); 20\u201340 min (oral)",
                "peak": "0.5\u20131.5 h",
                "offset": "2\u20133 h",
                "after_effects": "1\u20132 h residual afterglow"
            },
            "addiction_potential": "Moderate psychological dependence; rapid tolerance similar to MXE.",
            "interactions": {
                "dangerous": [
                    "alcohol (high dose)",
                    "GHB/GBL",
                    "other dissociatives"
                ],
                "unsafe": ["benzodiazepines"],
                "caution": ["stimulants", "SSRIs", "MAOIs", "opioids"]
            },
            "notes": "Shorter and slightly less potent than MXE; batches vary in purity\u2014tan powder often benefits from acetone or water re-crystallisation. Visuals skew blue-violet; afterglow can be mildly hypomanic.",
            "subjective_effects": [
                "euphoria",
                "dissociation",
                "visual geometry",
                "tactile anesthesia",
                "manic stimulation",
                "afterglow",
                "proprioceptive enhancement",
                "music appreciation",
                "warmth"
            ],
            "tolerance": {
                "full_tolerance": "3\u20137 days of daily use",
                "half_tolerance": "1\u20132 weeks",
                "zero_tolerance": "4\u20136 weeks",
                "cross_tolerances": [
                    "ketamine",
                    "methoxetamine",
                    "MXPr",
                    "other arylcyclohexylamines"
                ]
            },
            "half_life": "Estimated 3\u20136 h (inferred from analogues and user reports)",
            "citations": [
                {
                    "name": "PubChem CID 157010705",
                    "reference": "turn0search1"
                },
                {
                    "name": "Wikipedia \u2013 Deoxymethoxetamine",
                    "reference": "turn2search3"
                },
                {
                    "name": "Derivatives of MXE block NMDARs",
                    "reference": "turn2search1"
                },
                {
                    "name": "Metabolism study (3-DMXE, 2-DMXE)",
                    "reference": "turn4search4"
                },
                {
                    "name": "Identification in illegal products (Yakugaku Zasshi)",
                    "reference": "turn5search8"
                },
                {
                    "name": "Bluelight starter-dose post (30 mg)",
                    "reference": "turn10view0"
                },
                {
                    "name": "Bluelight 70 mg intranasal report",
                    "reference": "turn12view0"
                },
                {
                    "name": "Reddit 65\u201380 mg hole guidance",
                    "reference": "turn14search2"
                },
                {
                    "name": "Reddit oral 40 mg tablet discussion",
                    "reference": "turn14search0"
                },
                {
                    "name": "Reddit DMXE hangover thread",
                    "reference": "turn1search5"
                },
                {
                    "name": "Bluelight afterglow comparison post",
                    "reference": "turn1search6"
                },
                {
                    "name": "Bhoperehab \u2013 dissociative overview",
                    "reference": "turn0search5"
                },
                {
                    "name": "User assumption on half-life",
                    "reference": "turn4search5"
                },
                {
                    "name": "Bluelight benzo-DMXE caution",
                    "reference": "turn7view0"
                },
                {
                    "name": "DMXE Big & Dandy (general effects)",
                    "reference": "turn10view0"
                }
            ],
            "categories": ["dissociative", "research-chemical", "hallucinogen"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Deoxymethoxetamine (DMXE)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Published user reports, academic sources (e.g., Alexander Shulgin, Erowid, user forums, journal literature), as of 2024.",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 6,
                            "iso": ["PT4H", "PT6H"],
                            "note": "For insufflated DMXE. Oral route is longer, but not addressed here."
                        },
                        "onset": {
                            "start": 0.08,
                            "end": 0.25,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT15M"]
                        },
                        "peak": {
                            "start": 0.5,
                            "end": 1.5,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT1H30M"]
                        },
                        "offset": {
                            "start": 2,
                            "end": 3,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT3H"]
                        },
                        "after_effects": {
                            "start": 4,
                            "end": 8,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT8H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 291,
        "title": "MDMA",
        "content": "# MDMA\n## Substituted phenethylamine (methylenedioxyamphetamine family) | Entactogen / empathogen with stimulant and mild psychedelic properties\n      \nVerify identity with reagent and FT-IR tests; avoid redosing >1 x per session; maintain moderate ambient temperature; sip isotonic fluids (\u2264500 ml h\u207b\u00b9) to prevent hyponatremia; females are proportionally more susceptible to hyponatremia and hyperthermia.",
        "drug_info": {
            "drug_name": "MDMA",
            "search_url": "https://www.emcdda.europa.eu/publications/drug-profiles/mdma_en",
            "chemical_class": "Substituted phenethylamine (methylenedioxyamphetamine family)",
            "psychoactive_class": "Entactogen / empathogen with stimulant and mild psychedelic properties",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "30 mg",
                            "light": "40\u201375 mg",
                            "common": "75\u2013125 mg",
                            "strong": "125\u2013175 mg",
                            "heavy": "175+ mg"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "10\u201325 mg",
                            "common": "25\u201360 mg",
                            "strong": "60\u2013100 mg",
                            "heavy": "100+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 20,
                                "max": 40
                            },
                            "light": {
                                "min": 40,
                                "max": 75
                            },
                            "common": {
                                "min": 75,
                                "max": 125
                            },
                            "strong": {
                                "min": 125,
                                "max": 175
                            },
                            "heavy": {
                                "min": 175,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 25
                            },
                            "common": {
                                "min": 25,
                                "max": 60
                            },
                            "strong": {
                                "min": 60,
                                "max": 100
                            },
                            "heavy": {
                                "min": 100,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4\u20136 h",
                "onset": "20\u201360 min",
                "peak": "2\u20133 h",
                "offset": "2\u20134 h",
                "after_effects": "12\u201348 h (residual lethargy/low mood)"
            },
            "addiction_potential": "Moderate psychological reinforcement; minimal physical dependence. Compulsive redosing and short inter-dose intervals increase risk of habit formation.",
            "interactions": {
                "dangerous": [
                    "MAOIs (e.g., tranylcypromine, selegiline)",
                    "SSRIs / SNRIs",
                    "Linezolid",
                    "Tramadol",
                    "Dextromethorphan"
                ],
                "unsafe": [
                    "Alcohol (dehydration, hepatotoxicity)",
                    "Cocaine",
                    "Methamphetamine",
                    "MDA (serotonin overload)"
                ],
                "caution": [
                    "LSD",
                    "Psilocybin",
                    "Ketamine",
                    "Cannabis",
                    "Nitrous_oxide"
                ]
            },
            "notes": "Verify identity with reagent and FT-IR tests; avoid redosing >1 x per session; maintain moderate ambient temperature; sip isotonic fluids (\u2264500 ml h\u207b\u00b9) to prevent hyponatremia; females are proportionally more susceptible to hyponatremia and hyperthermia.",
            "subjective_effects": [
                "euphoria",
                "emotional openness",
                "empathy enhancement",
                "tactile amplification",
                "music appreciation",
                "visual brightness",
                "jaw clenching",
                "pupil dilation",
                "increased heart rate",
                "afterglow",
                "comedown dysphoria"
            ],
            "tolerance": {
                "full_tolerance": "Present after a single standard session",
                "half_tolerance": "\u22481 week",
                "zero_tolerance": "4\u20136 weeks",
                "cross_tolerances": ["MDA", "MDEA", "Serotonergic_amphetamines"]
            },
            "half_life": "Approx. 8\u20139 h (range 6\u201310 h)",
            "citations": [
                {
                    "name": "Erowid MDMA Dosage",
                    "reference": "https://www.erowid.org/chemicals/mdma/mdma_dose.shtml"
                },
                {
                    "name": "Pharmacology & Toxicology of Ecstasy \u2013 Kalant 1999",
                    "reference": "https://pmc.ncbi.nlm.nih.gov/articles/PMC81503/"
                },
                {
                    "name": "Non-linear Pharmacokinetics of MDMA \u2013 de la Torre 2000",
                    "reference": "https://pubmed.ncbi.nlm.nih.gov/10671903/"
                },
                {
                    "name": "DrugBank DB01454 (MDMA)",
                    "reference": "https://go.drugbank.com/drugs/DB01454"
                },
                {
                    "name": "MAPS Phase-III MDMA-Assisted Therapy 2021",
                    "reference": "https://maps.org/2021/05/03/maps-phase-3-trial-of-mdma-assisted-therapy-for-ptsd-achieves-successful-results-for-patients-with-severe-chronic-ptsd/"
                },
                {
                    "name": "Parrott AC 2013 Review \u2013 MDMA Neurotoxicity",
                    "reference": "https://pubmed.ncbi.nlm.nih.gov/23660456/"
                },
                {
                    "name": "Erowid Neurotoxicity Article \u2013 Baggott",
                    "reference": "https://erowid.org/chemicals/mdma/mdma_neurotoxicity1.shtml"
                },
                {
                    "name": "EMCDDA MDMA Drug Profile",
                    "reference": "https://www.emcdda.europa.eu/publications/drug-profiles/mdma_en"
                },
                {
                    "name": "Bluelight Thread: Threshold Dose for MDMA (2019)",
                    "reference": "https://www.bluelight.org/community/threads/threshold-dose-for-mdma.878731/"
                },
                {
                    "name": "Reddit r/researchchemicals MDMA Dosing Discussions",
                    "reference": "https://www.reddit.com/r/researchchemicals/"
                },
                {
                    "name": "Clinically Relevant Drug Interactions with MAOIs",
                    "reference": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9680847/"
                },
                {
                    "name": "Serotonin Syndrome Overview",
                    "reference": "https://www.healthline.com/health/serotonin-syndrome"
                },
                {
                    "name": "Serotonin Syndrome Case Series \u2013 FAERS 2022",
                    "reference": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8820588/"
                },
                {
                    "name": "RollSafe MDMA Wiki (Tolerance)",
                    "reference": "https://rollsafe.org/mdma-wiki/"
                },
                {
                    "name": "Healthline: MDMA & Bipolar Disorder Interaction",
                    "reference": "https://www.healthline.com/health/bipolar/mdma-treatment-for-bipolar"
                }
            ],
            "categories": [
                "empathogen",
                "entactogen",
                "stimulant",
                "psychedelic"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "MDMA",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Julien, R. M., Advokat, C. D., & Comaty, J. E. (2010). A Primer of Drug Action. McGraw-Hill; user experience reports.",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 6,
                            "iso": ["PT4H", "PT6H"],
                            "note": "Active MDMA effects from insufflation typically last between 4 and 6 hours."
                        },
                        "onset": {
                            "start": 0.33,
                            "end": 1,
                            "iso_start": ["PT20M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 3,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "after_effects": {
                            "start": 12,
                            "end": 48,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT48H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 257,
        "title": "DOEF",
        "content": "",
        "drug_info": {
            "drug_name": "DOEF",
            "search_url": "https://tripsitter.com/doef/",
            "chemical_class": "Substituted amphetamine; phenethylamine",
            "psychoactive_class": "Psychedelic (DOx series)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "1 mg",
                            "light": "1\u20132 mg",
                            "common": "2\u20133.5 mg",
                            "strong": "3.5\u20135 mg",
                            "heavy": "5+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 1,
                                "max": 1
                            },
                            "light": {
                                "min": 1,
                                "max": 2
                            },
                            "common": {
                                "min": 2,
                                "max": 3.5
                            },
                            "strong": {
                                "min": 3.5,
                                "max": 5
                            },
                            "heavy": {
                                "min": 5,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "12\u201316 h",
                "onset": "0.5\u20131.5 h",
                "peak": "3\u20136 h",
                "offset": "4\u20136 h",
                "after_effects": "2\u20134 h residual stimulation"
            },
            "addiction_potential": "Low; no evidence of compulsive use or withdrawal in the limited literature and user reports.",
            "interactions": {
                "dangerous": ["MAOIs", "Tramadol", "DXM"],
                "unsafe": ["SSRIs", "5-HTP", "MDMA"],
                "caution": ["cannabis", "caffeine", "alcohol"]
            },
            "notes": "Extremely limited human data. Verify identity\u2014DOEF has been mis-sold as DOI. Precise milligram scales and reagent tests are essential for harm reduction.",
            "subjective_effects": [
                "mild euphoria",
                "time dilation",
                "music and mood enhancement",
                "clear-headed stimulation",
                "minimal visuals",
                "body lightness",
                "subtle cognitive shift"
            ],
            "tolerance": {
                "full_tolerance": "After one dose; 3\u20137 days to baseline reduction",
                "half_tolerance": "\u22487 days",
                "zero_tolerance": "\u224814 days",
                "cross_tolerances": [
                    "other DOx psychedelics",
                    "classical psychedelics such as LSD or psilocybin"
                ]
            },
            "half_life": "Unknown; presumed >8 h by analogy with other DOx compounds.",
            "citations": [
                {
                    "name": "PubChem CID 14201982",
                    "reference": "https://pubchem.ncbi.nlm.nih.gov/compound/14201982"
                },
                {
                    "name": "CAS Common Chemistry (RN 121649-01-2)",
                    "reference": "https://commonchemistry.cas.org/detail?cas_rn=121649-01-2"
                },
                {
                    "name": "Wikipedia \u2013 DOEF",
                    "reference": "https://en.wikipedia.org/wiki/DOEF_%28drug%29"
                },
                {
                    "name": "PiHKAL entry (quoted by Tripsitter)",
                    "reference": "https://tripsitter.com/doef/"
                },
                {
                    "name": "Bluelight \u2013 Small & Handy DOEF thread",
                    "reference": "https://www.bluelight.org/community/threads/the-small-handy-doef-thread.441598/"
                },
                {
                    "name": "Bluelight \u2013 DOEF thread, page 3 (user trip synopsis)",
                    "reference": "https://bluelight.org/xf/threads/the-small-handy-doef-thread.441598/page-3"
                },
                {
                    "name": "Trachsel D. Fluorine in psychedelic phenethylamines (2012)",
                    "reference": "https://pubmed.ncbi.nlm.nih.gov/22374819/"
                },
                {
                    "name": "Gerdes JM et al. Synthesis related to 18F-labelled ligands (1988)",
                    "reference": "https://doi.org/10.1016/S0040-4039(00)82391-6"
                },
                {
                    "name": "Isomer Design \u2013 PiHKAL\u00b7info DOEF index",
                    "reference": "https://isomerdesign.com/pihkal/explore/65"
                },
                {
                    "name": "Infogalactic \u2013 2,5-Dimethoxy-4-(2-fluoroethyl)amphetamine",
                    "reference": "https://infogalactic.com/info/2,5-Dimethoxy-4-%282-fluoroethyl%29amphetamine"
                }
            ],
            "categories": ["psychedelic", "hallucinogen", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "DOEF",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Derived from qualitative and quantitative user reports and scientific literature on DOEF and similar substituted amphetamines.",
                        "units": "hours",
                        "total_duration": {
                            "min": 12,
                            "max": 16,
                            "iso": ["PT12H", "PT16H"],
                            "note": "Includes the main effects and lingering after-effects."
                        },
                        "onset": {
                            "start": 0.5,
                            "end": 1.5,
                            "iso_start": ["PT0H30M"],
                            "iso_end": ["PT1H30M"]
                        },
                        "peak": {
                            "start": 3,
                            "end": 6,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT6H"]
                        },
                        "offset": {
                            "start": 7,
                            "end": 12,
                            "iso_start": ["PT7H"],
                            "iso_end": ["PT12H"]
                        },
                        "after_effects": {
                            "start": 12,
                            "end": 16,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT16H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 292,
        "title": "25CN-NBOH",
        "content": "# 25CN-NBOH\n## N-benzyl phenethylamine (NBOMe/NBOH family) | psychedelic hallucinogen (5-HT2A selective agonist)\n      \n25CN-NBOH is the most 5-HT2A-selective agonist yet published; cyano substitution markedly reduces off-target 5-HT2B/2C activity.  Oral bioavailability appears higher than NBOMe analogues but is still poor; buccal or sublingual absorption is strongly preferred.  Users consistently report pronounced vasoconstriction and mouth numbness.  Visuals are dense and strobing, with cognitive disorganisation more acute than LSD at equivalent intensity.",
        "drug_info": {
            "drug_name": "25CN-NBOH",
            "search_url": "https://pubchem.ncbi.nlm.nih.gov/compound/90489020",
            "chemical_class": "N-benzyl phenethylamine (NBOMe/NBOH family)",
            "psychoactive_class": "psychedelic hallucinogen (5-HT2A selective agonist)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "buccal",
                        "units": "\u00b5g",
                        "dose_ranges": {
                            "threshold": "50-100 \u00b5g",
                            "light": "100-300 \u00b5g",
                            "common": "300-800 \u00b5g",
                            "strong": "800-1200 \u00b5g",
                            "heavy": "1200+ \u00b5g"
                        }
                    },
                    {
                        "route": "sublingual",
                        "units": "\u00b5g",
                        "dose_ranges": {
                            "threshold": "50-100 \u00b5g",
                            "light": "100-300 \u00b5g",
                            "common": "300-800 \u00b5g",
                            "strong": "800-1200 \u00b5g",
                            "heavy": "1200+ \u00b5g"
                        }
                    },
                    {
                        "route": "intranasal",
                        "units": "\u00b5g",
                        "dose_ranges": {
                            "threshold": "20-50 \u00b5g",
                            "light": "50-150 \u00b5g",
                            "common": "150-400 \u00b5g",
                            "strong": "400-700 \u00b5g",
                            "heavy": "700+ \u00b5g"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "buccal",
                        "units": "ug",
                        "dose_ranges": {
                            "threshold": {
                                "min": 50,
                                "max": 100
                            },
                            "light": {
                                "min": 100,
                                "max": 300
                            },
                            "common": {
                                "min": 300,
                                "max": 800
                            },
                            "strong": {
                                "min": 800,
                                "max": 1200
                            },
                            "heavy": {
                                "min": 1200,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "sublingual",
                        "units": "ug",
                        "dose_ranges": {
                            "threshold": {
                                "min": 50,
                                "max": 100
                            },
                            "light": {
                                "min": 100,
                                "max": 300
                            },
                            "common": {
                                "min": 300,
                                "max": 800
                            },
                            "strong": {
                                "min": 800,
                                "max": 1200
                            },
                            "heavy": {
                                "min": 1200,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "intranasal",
                        "units": "ug",
                        "dose_ranges": {
                            "threshold": {
                                "min": 20,
                                "max": 50
                            },
                            "light": {
                                "min": 50,
                                "max": 150
                            },
                            "common": {
                                "min": 150,
                                "max": 400
                            },
                            "strong": {
                                "min": 400,
                                "max": 700
                            },
                            "heavy": {
                                "min": 700,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "6 \u2013 10 h",
                "onset": "10 \u2013 30 min (buccal/sublingual); 2 \u2013 5 min (IN)",
                "peak": "1 \u2013 3 h",
                "offset": "3 \u2013 5 h",
                "after_effects": "up to 12 h residual stimulation / visual static"
            },
            "addiction_potential": "Very low; no compulsive redosing reported, tolerance develops rapidly after one session.",
            "interactions": {
                "dangerous": ["MAOIs", "Tramadol", "lithium"],
                "unsafe": [
                    "SSRIs / SNRIs (serotonin syndrome risk)",
                    "stimulants (hypertensive synergy)"
                ],
                "caution": [
                    "other psychedelics (cross-tolerance)",
                    "vasoconstrictors"
                ]
            },
            "notes": "25CN-NBOH is the most 5-HT2A-selective agonist yet published; cyano substitution markedly reduces off-target 5-HT2B/2C activity.  Oral bioavailability appears higher than NBOMe analogues but is still poor; buccal or sublingual absorption is strongly preferred.  Users consistently report pronounced vasoconstriction and mouth numbness.  Visuals are dense and strobing, with cognitive disorganisation more acute than LSD at equivalent intensity.",
            "subjective_effects": [
                "intense geometric open-eye visuals",
                "complex closed-eye scenes",
                "time dilation",
                "body-load vasoconstriction",
                "mouth and tongue numbness",
                "euphoria followed by emotional flattening",
                "confusion / language suppression",
                "after-image tracers",
                "mild tachycardia",
                "temperature sensitivity"
            ],
            "tolerance": {
                "full_tolerance": "after a single standard session",
                "half_tolerance": "3 \u2013 5 days",
                "zero_tolerance": "7 \u2013 14 days",
                "cross_tolerances": [
                    "psychedelic phenethylamines",
                    "tryptamines",
                    "lysergamides"
                ]
            },
            "half_life": "Human t\u00bd unknown; rat plasma t\u00bd \u2248 3 \u2013 5 h (extrapolated)",
            "citations": [
                {
                    "name": "25CN-NBOH structure\u2013activity and selectivity (Biochem Pharmacol 2020)",
                    "reference": "&#8203;:contentReference[oaicite:1]{index=1}"
                },
                {
                    "name": "Active-state 5-HT2A\u201325CN-NBOH cryo-EM structure (Cell 2020)",
                    "reference": "&#8203;:contentReference[oaicite:2]{index=2}"
                },
                {
                    "name": "Non-human primate PET occupancy vs. psilocybin (J Cereb Blood Flow 2024)",
                    "reference": "&#8203;:contentReference[oaicite:3]{index=3}"
                },
                {
                    "name": "\u03b2-Arrestin-biased analogues (J Med Chem 2022)",
                    "reference": "&#8203;:contentReference[oaicite:4]{index=4}"
                },
                {
                    "name": "Bluelight dosage discussion \u2013 500 \u00b5g strong (post #190)",
                    "reference": "&#8203;:contentReference[oaicite:5]{index=5}"
                },
                {
                    "name": "Bluelight oral-activity debate \u2013 lipophilicity note",
                    "reference": "&#8203;:contentReference[oaicite:6]{index=6}"
                },
                {
                    "name": "Bluelight PD Social \u2013 perceived lower toxicity of NBOHs",
                    "reference": "&#8203;:contentReference[oaicite:7]{index=7}"
                },
                {
                    "name": "Bluelight risk thread \u2013 conflicting dose advice",
                    "reference": "&#8203;:contentReference[oaicite:8]{index=8}"
                },
                {
                    "name": "Reddit r/researchchemicals \u2013 affinity & expected visuals",
                    "reference": "&#8203;:contentReference[oaicite:9]{index=9}"
                },
                {
                    "name": "Behavioural characterisation in mice (Psychopharmacology 2015)",
                    "reference": "&#8203;:contentReference[oaicite:10]{index=10}"
                }
            ],
            "categories": ["psychedelic", "hallucinogen", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "25CN-NBOH",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Duration values adapted from research chemical literature and user reports as of 2024. Insufflation has a more rapid onset and potentially a slightly shorter duration compared to oral/buccal routes.",
                        "units": "hours",
                        "total_duration": {
                            "min": 6,
                            "max": 10,
                            "iso": ["PT6H", "PT10H"],
                            "note": "Total duration may be slightly shorter compared to sublingual due to higher bioavailability via insufflation."
                        },
                        "onset": {
                            "start": 0.03,
                            "end": 0.08,
                            "iso_start": ["PT2M"],
                            "iso_end": ["PT5M"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 3,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 3,
                            "end": 5,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT5H"]
                        },
                        "after_effects": {
                            "start": 10,
                            "end": 22,
                            "iso_start": ["PT10H"],
                            "iso_end": ["PT22H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 192,
        "title": "Lisdexamfetamine",
        "content": "# Lisdexamfetamine\n## Phenethylamine (Amphetamine derivative) | Stimulant\n      \nLisdexamfetamine is a prodrug of dextroamphetamine, meaning it is inactive until metabolized in the body. It is primarily prescribed for ADHD and binge eating disorder. It has a lower abuse potential than immediate-release amphetamines due to its gradual onset, but misuse is still possible. It should not be combined with other stimulants or MAOIs due to risk of hypertensive crisis or serotonin syndrome.",
        "drug_info": {
            "drug_name": "Lisdexamfetamine (Vyvanse)",
            "search_url": "https://go.drugbank.com/drugs/DB01255",
            "chemical_class": "Phenethylamine (Amphetamine derivative)",
            "psychoactive_class": "Stimulant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "10-20 mg",
                            "common": "30-50 mg",
                            "strong": "60-70 mg",
                            "heavy": "80 mg+"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 20
                            },
                            "common": {
                                "min": 30,
                                "max": 50
                            },
                            "strong": {
                                "min": 60,
                                "max": 70
                            },
                            "heavy": {
                                "min": 80,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "10-14 hours",
                "onset": "0.5-2 hours",
                "peak": "3-6 hours",
                "offset": "2-4 hours",
                "after_effects": "up to 24 hours (residual stimulation, insomnia)"
            },
            "addiction_potential": "Moderate to high. As a prodrug of dextroamphetamine, it carries a risk of psychological and physical dependence, especially with prolonged or high-dose use.",
            "interactions": {
                "dangerous": [
                    "MAOIs (monoamine oxidase inhibitors)",
                    "other stimulants"
                ],
                "unsafe": [
                    "SSRIs (risk of serotonin syndrome)",
                    "SNRIs",
                    "tricyclic antidepressants"
                ],
                "caution": [
                    "antihypertensives",
                    "antacids (may alter absorption)"
                ]
            },
            "notes": "Lisdexamfetamine is a prodrug of dextroamphetamine, meaning it is inactive until metabolized in the body. It is primarily prescribed for ADHD and binge eating disorder. It has a lower abuse potential than immediate-release amphetamines due to its gradual onset, but misuse is still possible. It should not be combined with other stimulants or MAOIs due to risk of hypertensive crisis or serotonin syndrome.",
            "subjective_effects": [
                "Increased focus",
                "Euphoria",
                "Increased energy",
                "Appetite suppression",
                "Increased heart rate",
                "Insomnia",
                "Anxiety",
                "Dry mouth"
            ],
            "tolerance": {
                "full_tolerance": "Several weeks of daily use",
                "half_tolerance": "1-2 weeks",
                "zero_tolerance": "4-6 weeks",
                "cross_tolerances": ["Amphetamines", "Other stimulants"]
            },
            "half_life": "About 1 hour (lisdexamfetamine); active metabolite (dextroamphetamine): 10-13 hours",
            "citations": [
                {
                    "name": "DrugBank: Lisdexamfetamine",
                    "reference": "https://go.drugbank.com/drugs/DB01255"
                },
                {
                    "name": "DrugBank: Lisdexamfetamine salt info",
                    "reference": "https://go.drugbank.com/salts/DBSALT002824"
                },
                {
                    "name": "DrugBank: Lisdexamfetamine clinical trials",
                    "reference": "https://go.drugbank.com/drugs/DB01255/clinical_trials?conditions=DBCOND0041782&phase=4&purpose=treatment&status=completed"
                }
            ],
            "categories": ["stimulant", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Lisdexamfetamine (Vyvanse)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Lexicomp, Drugs.com, experience reports; Lisdexamfetamine is a prodrug of dextroamphetamine, which affects onset and duration.",
                        "units": "hours",
                        "total_duration": {
                            "min": 10,
                            "max": 14,
                            "iso": ["PT10H", "PT14H"],
                            "note": "Comparable to oral route due to prodrug conversion in blood; not significantly potentiated or shortened by insufflation."
                        },
                        "onset": {
                            "start": 0.5,
                            "end": 2,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT2H"]
                        },
                        "peak": {
                            "start": 3,
                            "end": 6,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT6H"]
                        },
                        "offset": {
                            "start": 8,
                            "end": 14,
                            "iso_start": ["PT8H"],
                            "iso_end": ["PT14H"]
                        },
                        "after_effects": {
                            "start": 14,
                            "end": 24,
                            "iso_start": ["PT14H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 288,
        "title": "MXiPr",
        "content": "# MXiPr\n## arylcyclohexylamine | dissociative hallucinogen\n      \nPotency is highly batch-variable. Accurate milligram-scale weighing and reagent testing are strongly recommended to avoid overdose or unidentified analogues. Users frequently report impaired motor control and derealisation; safe setting and sober supervision are advised.",
        "drug_info": {
            "drug_name": "MXiPr",
            "search_url": "https://tripsitter.com/mxipr/",
            "chemical_class": "arylcyclohexylamine",
            "psychoactive_class": "dissociative hallucinogen",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "10\u201320 mg",
                            "common": "20\u201340 mg",
                            "strong": "40\u201360 mg",
                            "heavy": "60+ mg"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "3 mg",
                            "light": "5\u201315 mg",
                            "common": "15\u201330 mg",
                            "strong": "30\u201345 mg",
                            "heavy": "45+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 20
                            },
                            "common": {
                                "min": 20,
                                "max": 40
                            },
                            "strong": {
                                "min": 40,
                                "max": 60
                            },
                            "heavy": {
                                "min": 60,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 3,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 15
                            },
                            "common": {
                                "min": 15,
                                "max": 30
                            },
                            "strong": {
                                "min": 30,
                                "max": 45
                            },
                            "heavy": {
                                "min": 45,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "2\u20135 h",
                "onset": "5\u201340 min (route-dependent)",
                "peak": "45\u2013120 min",
                "offset": "1\u20132 h",
                "after_effects": "1\u20133 h residual dissociation"
            },
            "addiction_potential": "Moderate; compulsive redosing and psychological dependence observed, similar to MXE and ketamine.",
            "interactions": {
                "dangerous": ["alcohol", "benzodiazepines", "opioids", "GHB"],
                "unsafe": [
                    "other NDMA-antagonist dissociatives",
                    "barbiturates"
                ],
                "caution": [
                    "strong stimulants",
                    "serotonergic psychedelics",
                    "cannabinoids"
                ]
            },
            "notes": "Potency is highly batch-variable. Accurate milligram-scale weighing and reagent testing are strongly recommended to avoid overdose or unidentified analogues. Users frequently report impaired motor control and derealisation; safe setting and sober supervision are advised.",
            "subjective_effects": [
                "euphoria",
                "depersonalisation",
                "time distortion",
                "tactile numbness",
                "body lightness",
                "visual blurring",
                "amnesia at high doses",
                "dream-like immersion",
                "increased music appreciation"
            ],
            "tolerance": {
                "full_tolerance": "Develops within 3\u20137 days of daily use",
                "half_tolerance": "Begins to subside after 7\u201314 days abstinence",
                "zero_tolerance": "Returns to baseline after 2\u20134 weeks abstinence",
                "cross_tolerances": [
                    "ketamine",
                    "MXE",
                    "other aryl-cyclohexylamines"
                ]
            },
            "half_life": "Unknown; estimated 2\u20134 h by user report and analogy to MXE",
            "citations": [
                {
                    "name": "Wikipedia \u2013 Methoxisopropamine",
                    "reference": "turn2search6"
                },
                {
                    "name": "Identification of MXiPr (PubMed)",
                    "reference": "turn2search2"
                },
                {
                    "name": "Salvum.love dosage table",
                    "reference": "turn5search0"
                },
                {
                    "name": "Tripsitter MXiPr profile",
                    "reference": "turn7view0"
                },
                {
                    "name": "TrippyWiki MXiPr guide",
                    "reference": "turn5search2"
                },
                {
                    "name": "Methoxetamine abuse-potential study",
                    "reference": "turn5search7"
                },
                {
                    "name": "Ketamine tolerance review (PMC)",
                    "reference": "turn11search0"
                },
                {
                    "name": "Bluelight trip report (Tiletamine + MXiPr)",
                    "reference": "turn0search2"
                },
                {
                    "name": "NIAAA \u2013 Alcohol & CNS-depressant synergy",
                    "reference": "turn8search2"
                },
                {
                    "name": "BenchChem \u2013 NMDA-blocker overview",
                    "reference": "turn5search9"
                }
            ],
            "categories": ["dissociative", "research-chemical", "psychedelic"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "MXiPr",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "General consensus from user experience reports and recent literature (as of 2023) on arylcyclohexylamine dissociatives including MXiPr.",
                        "units": "hours",
                        "total_duration": {
                            "min": 2,
                            "max": 5,
                            "iso": ["PT2H", "PT5H"],
                            "note": "Reports suggest most users return baseline within 5 hours post insufflation."
                        },
                        "onset": {
                            "start": 0.08,
                            "end": 0.66,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT40M"]
                        },
                        "peak": {
                            "start": 0.75,
                            "end": 2,
                            "iso_start": ["PT45M"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "after_effects": {
                            "start": 3,
                            "end": 8,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT8H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 113,
        "title": "alpha-PVP",
        "content": "",
        "drug_info": {
            "drug_name": "\u03b1-Pyrrolidinopentiophenone (\u03b1-PVP, Flakka, Gravel, A-PVP)",
            "search_url": "https://en.wikipedia.org/wiki/%CE%91-Pyrrolidinopentiophenone",
            "chemical_class": "Cathinone (substituted cathinone, pyrrolidinophenone)",
            "psychoactive_class": "Stimulant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "<5 mg",
                            "light": "5-10 mg",
                            "common": "10-25 mg",
                            "strong": "25-50 mg",
                            "heavy": ">50 mg"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "<3 mg",
                            "light": "3-8 mg",
                            "common": "8-15 mg",
                            "strong": "15-25 mg",
                            "heavy": ">25 mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 10
                            },
                            "common": {
                                "min": 10,
                                "max": 25
                            },
                            "strong": {
                                "min": 25,
                                "max": 40
                            },
                            "heavy": {
                                "min": 40,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 1,
                                "max": 3
                            },
                            "light": {
                                "min": 3,
                                "max": 8
                            },
                            "common": {
                                "min": 8,
                                "max": 15
                            },
                            "strong": {
                                "min": 15,
                                "max": 25
                            },
                            "heavy": {
                                "min": 25,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "2-5 hours",
                "onset": "5-30 minutes (oral), 1-5 minutes (insufflated)",
                "peak": "1-2 hours",
                "offset": "1-3 hours",
                "after_effects": "2-8 hours (afterglow, comedown)"
            },
            "addiction_potential": "High. \u03b1-PVP has a strong potential for compulsive redosing and psychological dependence, similar to other potent synthetic stimulants.",
            "interactions": {
                "dangerous": [
                    "MAOIs",
                    "other stimulants (e.g., amphetamines, cocaine)",
                    "serotonergic drugs (risk of serotonin syndrome)"
                ],
                "unsafe": [
                    "alcohol (increased toxicity)",
                    "opioids (increased risk of overdose)"
                ],
                "caution": [
                    "benzodiazepines (may mask stimulant effects, risk of polydrug use)"
                ]
            },
            "notes": "\u03b1-PVP is a potent synthetic stimulant with a short history of human use. It is structurally related to MDPV and is known for its strong euphoric and stimulating effects, but also for its high risk of compulsive use, paranoia, and psychosis at high or repeated doses. Overdose and severe agitation have been reported. Harm reduction practices are strongly advised.",
            "subjective_effects": [
                "Euphoria",
                "Stimulation",
                "Increased sociability",
                "Compulsive redosing",
                "Anxiety",
                "Paranoia",
                "Agitation",
                "Insomnia",
                "Increased heart rate",
                "Sweating",
                "Vasoconstriction"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (days)",
                "half_tolerance": "~3-7 days",
                "zero_tolerance": "1-2 weeks",
                "cross_tolerances": [
                    "Other cathinones",
                    "Stimulants (e.g., amphetamines, cocaine)"
                ]
            },
            "half_life": "4-6 hours (estimated)",
            "citations": [
                {
                    "name": "Erowid \u03b1-PVP Vault",
                    "reference": "https://www.erowid.org/chemicals/a-pvp/a-pvp.shtml"
                }
            ],
            "categories": ["stimulant", "research-chemical", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "\u03b1-Pyrrolidinopentiophenone (\u03b1-PVP, Flakka, Gravel, A-PVP)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Reports and clinical literature regarding \u03b1-Pyrrolidinopentiophenone (\u03b1-PVP, Flakka) insufflation (2014\u20132023)",
                        "units": "hours",
                        "total_duration": {
                            "min": 2,
                            "max": 5,
                            "iso": ["PT2H", "PT5H"],
                            "note": "Insufflated; total time from first perceptible effects to return to baseline."
                        },
                        "onset": {
                            "start": 0.02,
                            "end": 0.08,
                            "iso_start": ["PT1M", "PT5M"],
                            "iso_end": ["PT5M"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 2,
                            "end": 5,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT5H"]
                        },
                        "after_effects": {
                            "start": 2,
                            "end": 8,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT8H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 130,
        "title": "Pregabalin",
        "content": "",
        "drug_info": {
            "drug_name": "Pregabalin (Lyrica)",
            "search_url": "https://go.drugbank.com/drugs/DB00230",
            "chemical_class": "Gabapentinoid (structural analogue of GABA, but not a functional GABA agonist)",
            "psychoactive_class": "Anticonvulsant, anxiolytic, analgesic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "25 mg",
                            "light": "50-75 mg",
                            "common": "150-300 mg",
                            "strong": "300-450 mg",
                            "heavy": ">600 mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 25,
                                "max": 50
                            },
                            "light": {
                                "min": 50,
                                "max": 100
                            },
                            "common": {
                                "min": 150,
                                "max": 300
                            },
                            "strong": {
                                "min": 300,
                                "max": 450
                            },
                            "heavy": {
                                "min": 450,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "6-8 hours",
                "onset": "30-60 minutes",
                "peak": "1-2 hours",
                "offset": "4-8 hours",
                "after_effects": "up to 24 hours (residual sedation possible)"
            },
            "addiction_potential": "Moderate. Pregabalin can cause psychological and physical dependence, especially with prolonged or high-dose use. Abrupt discontinuation may result in withdrawal symptoms.",
            "interactions": {
                "dangerous": [
                    "Opioids (increased risk of respiratory depression)",
                    "Alcohol (increased CNS depression)"
                ],
                "unsafe": [
                    "Benzodiazepines (increased sedation and risk of overdose)"
                ],
                "caution": [
                    "Other CNS depressants",
                    "Gabapentin (similar mechanism, additive effects)"
                ]
            },
            "notes": "Pregabalin is approved for neuropathic pain, fibromyalgia, and as adjunct therapy for partial seizures. It is known to cause euphoria and sedation, and misuse is reported. Side effects include dizziness, somnolence, peripheral edema, and, less commonly, hallucinations. Tolerance and withdrawal can develop with regular use. Overdose can result in severe CNS depression.",
            "subjective_effects": [
                "Euphoria",
                "Sedation",
                "Anxiolysis",
                "Relaxation",
                "Dizziness",
                "Ataxia",
                "Mild hallucinations (rare)",
                "Cognitive impairment"
            ],
            "tolerance": {
                "full_tolerance": "Develops over several days to weeks of regular use",
                "half_tolerance": "~1-2 weeks after cessation",
                "zero_tolerance": "~2-4 weeks after cessation",
                "cross_tolerances": ["Gabapentin"]
            },
            "half_life": "~6.3 hours",
            "citations": [
                {
                    "name": "DrugBank: Pregabalin",
                    "reference": "https://go.drugbank.com/drugs/DB00230"
                },
                {
                    "name": "DrugWise: Pregabalin",
                    "reference": "https://www.drugwise.org.uk/pregabalin/"
                },
                {
                    "name": "DrugBank Article: Pregabalin Mechanism",
                    "reference": "https://go.drugbank.com/articles/A175879"
                }
            ],
            "categories": ["depressant", "antidepressant", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Pregabalin (Lyrica)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Based on case studies, user reports, and clinical data on pregabalin kinetics (e.g., PubMed ID: 17450342, and clinical pharmacology textbooks) \u2014 Pregabalin absorption is faster via insufflation than oral.",
                        "units": "hours",
                        "total_duration": {
                            "min": 6,
                            "max": 8,
                            "iso": ["PT6H", "PT8H"],
                            "note": "Insufflation route slightly shortens onset and possibly overall duration compared to oral."
                        },
                        "onset": {
                            "start": 0.5,
                            "end": 1,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 4,
                            "end": 8,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT8H"]
                        },
                        "after_effects": {
                            "start": 8,
                            "end": 24,
                            "iso_start": ["PT8H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 134,
        "title": "Flunitrazepam",
        "content": "",
        "drug_info": {
            "drug_name": "Flunitrazepam (Rohypnol)",
            "search_url": "https://www.drug-do.se/benzos?name=flunitrazepam",
            "chemical_class": "Benzodiazepine",
            "psychoactive_class": "Depressant (Benzodiazepine)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "0.25 mg",
                            "light": "0.5 - 1 mg",
                            "common": "1 - 2 mg",
                            "strong": "2 - 4 mg",
                            "heavy": "4+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.25,
                                "max": 0.5
                            },
                            "light": {
                                "min": 0.5,
                                "max": 1
                            },
                            "common": {
                                "min": 1,
                                "max": 2
                            },
                            "strong": {
                                "min": 2,
                                "max": 4
                            },
                            "heavy": {
                                "min": 4,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "12 - 24 hours",
                "onset": "15 - 30 minutes",
                "peak": "1 - 4 hours",
                "offset": "6 - 12 hours",
                "after_effects": "up to 24 hours (residual sedation, amnesia possible)"
            },
            "addiction_potential": "High. Flunitrazepam, like other benzodiazepines, carries a significant risk of dependence and addiction, especially with prolonged or high-dose use.",
            "interactions": {
                "dangerous": ["Alcohol", "Opioids", "Barbiturates"],
                "unsafe": ["Other benzodiazepines", "Sedative-hypnotics"],
                "caution": [
                    "Antidepressants",
                    "Antipsychotics",
                    "Muscle relaxants"
                ]
            },
            "notes": "Flunitrazepam is a potent hypnotic benzodiazepine with strong sedative, anxiolytic, muscle relaxant, and amnesic properties. It is infamous for its association with drug-facilitated sexual assault ('date rape drug'). Use is illegal or highly restricted in many countries. Overdose can cause severe respiratory depression, coma, or death, especially when combined with other CNS depressants.",
            "subjective_effects": [
                "Sedation",
                "Muscle relaxation",
                "Anxiolysis",
                "Amnesia",
                "Euphoria (in some cases)",
                "Impaired coordination",
                "Confusion",
                "Drowsiness"
            ],
            "tolerance": {
                "full_tolerance": "Develops within weeks of regular use",
                "half_tolerance": "7 - 14 days after cessation",
                "zero_tolerance": "2 - 4 weeks after cessation",
                "cross_tolerances": ["Other benzodiazepines", "Barbiturates"]
            },
            "half_life": "18 - 26 hours (active metabolites may prolong effects)",
            "citations": [
                {
                    "name": "DrugBank: Flunitrazepam",
                    "reference": "https://go.drugbank.com/drugs/DB01544"
                },
                {
                    "name": "TripSit Factsheet: Flunitrazepam",
                    "reference": "https://tripsit.me/factsheets/flunitrazepam"
                },
                {
                    "name": "DrugBank: Flunitrazepam Biointeractions",
                    "reference": "https://go.drugbank.com/drugs/DB01544/biointeractions"
                },
                {
                    "name": "DrugBank Article: Flunitrazepam",
                    "reference": "https://go.drugbank.com/articles/A185024"
                }
            ],
            "categories": [
                "depressant",
                "benzodiazepine",
                "sedative",
                "habit-forming"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Flunitrazepam (Rohypnol)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Academic literature on benzodiazepine pharmacology and clinical reports (e.g., Flunitrazepam prescribing information, published clinical guidelines).",
                        "units": "hours",
                        "total_duration": {
                            "min": 12,
                            "max": 24,
                            "iso": ["PT12H", "PT24H"],
                            "note": "Duration is somewhat longer than for oral use since insufflation provides a faster onset but does not drastically alter elimination half-life."
                        },
                        "onset": {
                            "start": 0.25,
                            "end": 0.5,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT30M"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 4,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT4H"]
                        },
                        "offset": {
                            "start": 6,
                            "end": 12,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT12H"]
                        },
                        "after_effects": {
                            "start": 12,
                            "end": 24,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 98,
        "title": "4-Fluorophenibut",
        "content": "",
        "drug_info": {
            "drug_name": "4-Fluorophenibut (F-Phenibut, 4-F-Phenibut, Fluorophenibut)",
            "search_url": "https://en.wikipedia.org/wiki/4-Fluorophenibut",
            "chemical_class": "Gabapentinoid (structurally related to phenibut and baclofen)",
            "psychoactive_class": "Depressant, Anxiolytic, Gabapentinoid",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "50 mg",
                            "light": "100-200 mg",
                            "common": "200-400 mg",
                            "strong": "400-600 mg",
                            "heavy": "600+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 50,
                                "max": 100
                            },
                            "light": {
                                "min": 100,
                                "max": 200
                            },
                            "common": {
                                "min": 200,
                                "max": 400
                            },
                            "strong": {
                                "min": 400,
                                "max": 600
                            },
                            "heavy": {
                                "min": 600,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "6-12 hours",
                "onset": "30-90 minutes",
                "peak": "2-5 hours",
                "offset": "4-8 hours",
                "after_effects": "up to 24 hours (residual sedation possible)"
            },
            "addiction_potential": "Moderate to high, similar to phenibut. Risk of dependence and withdrawal with frequent or high-dose use.",
            "interactions": {
                "dangerous": [
                    "Alcohol",
                    "Benzodiazepines",
                    "Other CNS depressants"
                ],
                "unsafe": ["Opioids", "Barbiturates"],
                "caution": [
                    "Other gabapentinoids (e.g., pregabalin, gabapentin)"
                ]
            },
            "notes": "4-Fluorophenibut is a fluorinated analog of phenibut, reported to be several times more potent. It acts primarily as a GABA-B receptor agonist, with possible additional gabapentinoid activity. Users report more pronounced physical effects than mental, and a higher risk of dependence and withdrawal compared to phenibut. Tolerance develops rapidly. Overdose can result in severe sedation, respiratory depression, and withdrawal can be dangerous.",
            "subjective_effects": [
                "Anxiolysis",
                "Sedation",
                "Muscle relaxation",
                "Euphoria (mild)",
                "Sociability enhancement",
                "Physical relaxation",
                "Reduced inhibition",
                "Mild cognitive impairment",
                "Drowsiness"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with daily use (within days)",
                "half_tolerance": "1-2 weeks after cessation",
                "zero_tolerance": "2-4 weeks after cessation",
                "cross_tolerances": ["Phenibut", "Baclofen"]
            },
            "half_life": "Likely similar to phenibut (5-6 hours), but may be longer due to increased potency.",
            "citations": [
                {
                    "name": "Bluelight - Novel Sedative: Fluorophenibut",
                    "reference": "https://www.bluelight.org/community/threads/novel-sedative-fluorophenibut.785636/"
                },
                {
                    "name": "Bluelight - F-Phenibut Megathread",
                    "reference": "https://www.bluelight.org/community/threads/f-phenibut-megathread.910510/page-3"
                },
                {
                    "name": "Erowid Experience Report - F-Phenibut",
                    "reference": "https://erowid.org/experiences/exp.php?ID=108165"
                },
                {
                    "name": "Bluelight - F-Phenibut, Fluorophenibut / 250mg First Time",
                    "reference": "https://www.bluelight.org/community/threads/f-phenibut-fluorophenibut-250mg-first-time-more-physical-than-mental.824688/"
                }
            ],
            "categories": ["depressant", "research-chemical", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "4-Fluorophenibut (F-Phenibut, 4-F-Phenibut, Fluorophenibut)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Literature on gabapentinoid duration and user reports; see JAMA. 2015;313(16):1671-1672.",
                        "units": "hours",
                        "total_duration": {
                            "min": 6,
                            "max": 12,
                            "iso": ["PT6H", "PT12H"],
                            "note": "Fluorophenibut's duration via insufflation is based on analogy to oral use with slightly faster onset and shorter peak; data are limited."
                        },
                        "onset": {
                            "start": 0.5,
                            "end": 1.5,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT90M"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 5,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT5H"]
                        },
                        "offset": {
                            "start": 4,
                            "end": 8,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT8H"]
                        },
                        "after_effects": {
                            "start": 8,
                            "end": 24,
                            "iso_start": ["PT8H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 293,
        "title": "HXE",
        "content": "# Hydroxetamine (HXE)\n## Arylcyclohexylamine | Dissociative anesthetic (NMDA receptor antagonist)\n      \nLow water solubility makes intranasal use harsh; oral dosing yields fuller effect. Historical mis-labelling issues mean reagent or GC/MS confirmation is prudent. May trigger false-positive PCP results on urine tests. Bladder toxicity risk parallels ketamine with heavy use.",
        "drug_info": {
            "drug_name": "Hydroxetamine (HXE)",
            "search_url": "https://pubchem.ncbi.nlm.nih.gov/compound/Hydroxetamine",
            "chemical_class": "Arylcyclohexylamine",
            "psychoactive_class": "Dissociative anesthetic (NMDA receptor antagonist)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "10\u201320 mg",
                            "light": "20\u201340 mg",
                            "common": "40\u201380 mg",
                            "strong": "80\u2013120 mg",
                            "heavy": "120+ mg"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5\u201310 mg",
                            "light": "15\u201330 mg",
                            "common": "30\u201360 mg",
                            "strong": "60\u2013100 mg",
                            "heavy": "100+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 10,
                                "max": 20
                            },
                            "light": {
                                "min": 20,
                                "max": 40
                            },
                            "common": {
                                "min": 40,
                                "max": 80
                            },
                            "strong": {
                                "min": 80,
                                "max": 120
                            },
                            "heavy": {
                                "min": 120,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 15,
                                "max": 30
                            },
                            "common": {
                                "min": 30,
                                "max": 60
                            },
                            "strong": {
                                "min": 60,
                                "max": 100
                            },
                            "heavy": {
                                "min": 100,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "2.5\u20134 h",
                "onset": "40\u201360 min (oral); 5\u201315 min (insufflated)",
                "peak": "60\u201390 min",
                "offset": "40\u201390 min",
                "after_effects": "Up to 8 h residual dissociation / sedation"
            },
            "addiction_potential": "Moderate; similar to ketamine\u2014rapid tolerance build-up and compulsive redosing are reported.",
            "interactions": {
                "dangerous": ["opioids", "alcohol", "GHB"],
                "unsafe": ["benzodiazepines", "barbiturates"],
                "caution": [
                    "stimulants",
                    "other dissociatives",
                    "serotonergic psychedelics",
                    "MAOIs"
                ]
            },
            "notes": "Low water solubility makes intranasal use harsh; oral dosing yields fuller effect. Historical mis-labelling issues mean reagent or GC/MS confirmation is prudent. May trigger false-positive PCP results on urine tests. Bladder toxicity risk parallels ketamine with heavy use.",
            "subjective_effects": [
                "warm sedation",
                "lucid dissociation",
                "body numbness",
                "mild euphoria",
                "time dilation",
                "closed-eye imagery",
                "impaired coordination",
                "nausea at higher doses"
            ],
            "tolerance": {
                "full_tolerance": "After 2\u20133 consecutive daily doses",
                "half_tolerance": "\u22481\u20132 weeks",
                "zero_tolerance": "\u22484\u20136 weeks",
                "cross_tolerances": [
                    "ketamine",
                    "methoxetamine",
                    "other arylcyclohexylamines"
                ]
            },
            "half_life": "Unknown; estimated 3\u20136 h by analogy with MXE and ketamine metabolites",
            "citations": [
                {
                    "name": "CFSRE Hydroxetamine Monograph (2022)",
                    "reference": "https://www.cfsre.org/nps-discovery/monographs/hydroxetamine"
                },
                {
                    "name": "Hydroxetamine Toxicology Report PDF (CFSRE 2022)",
                    "reference": "https://www.cfsre.org/images/monographs/Hydroxetamine-083122-CFSRE-Toxicology-Report.pdf"
                },
                {
                    "name": "PubChem CID 163192347",
                    "reference": "https://pubchem.ncbi.nlm.nih.gov/compound/Hydroxetamine"
                },
                {
                    "name": "Hydroxetamine \u2013 Wikipedia",
                    "reference": "https://en.wikipedia.org/wiki/Hydroxetamine"
                },
                {
                    "name": "Erowid HXE Experience Index",
                    "reference": "https://www.erowid.org/experiences/subs/exp_HXE.shtml"
                },
                {
                    "name": "Reddit r/dissociatives \u2013 'Some insight on dosage and effects of HXE' (2021)",
                    "reference": "https://www.reddit.com/r/dissociatives/comments/mfoxeo/some_insight_on_dosage_and_effects_of_hxe/"
                },
                {
                    "name": "Reddit r/researchchemicals \u2013 'My first trial with HXE' (2021)",
                    "reference": "https://www.reddit.com/r/researchchemicals/comments/lv8lzw/my_first_trial_with_hxe_promising_chem/"
                },
                {
                    "name": "Reddit r/researchchemicals \u2013 'HXE 100 mg IN + thoughts after the first gram' (2021)",
                    "reference": "https://www.reddit.com/r/researchchemicals/comments/m7ygaz/hxe_100mg_in_thoughts_after_the_first_gram/"
                },
                {
                    "name": "Reddit r/dissociatives \u2013 'HXE is the most sedating disso I tried' (2024)",
                    "reference": "https://www.reddit.com/r/dissociatives/comments/186oy6h/hxe_is_the_most_sedating_disso_i_tried/"
                },
                {
                    "name": "Detailed pharmacological evaluation of MXE (2016)",
                    "reference": "https://pubmed.ncbi.nlm.nih.gov/27155360/"
                },
                {
                    "name": "Cayman Chemical \u2013 Hydroxetamine analytical standard",
                    "reference": "https://www.caymanchem.com/product/33774/hydroxetamine"
                }
            ],
            "categories": ["dissociative", "research-chemical", "hallucinogen"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Hydroxetamine (HXE)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Original data, adjusted for known pharmacology of arylcyclohexylamines and published case reports (2022-2024) on HXE.",
                        "units": "hours",
                        "total_duration": {
                            "min": 2.5,
                            "max": 4,
                            "iso": ["PT2H30M", "PT4H"],
                            "note": "Refers to insufflated HXE effects."
                        },
                        "onset": {
                            "start": 0.08,
                            "end": 0.25,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT15M"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 1.5,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT1H30M"]
                        },
                        "offset": {
                            "start": 1.67,
                            "end": 2.5,
                            "iso_start": ["PT1H40M"],
                            "iso_end": ["PT2H30M"]
                        },
                        "after_effects": {
                            "start": 4,
                            "end": 8,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT8H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 303,
        "title": "Ondansetron",
        "content": "# Ondansetron\n## Carbazole derivative (specifically, a serotonin 5-HT3 receptor antagonist) | Antiemetic (not psychoactive in the traditional sense, but acts on the central nervous system to prevent nausea/vomiting)\n      \nOndansetron is primarily used to prevent nausea and vomiting associated with chemotherapy, radiation therapy, and surgery. It is generally well tolerated, but can rarely cause QT prolongation and serious cardiac arrhythmias. Use with caution in patients with electrolyte abnormalities or pre-existing heart conditions. Not recommended for routine use in pregnancy unless clearly needed.",
        "drug_info": {
            "drug_name": "Ondansetron",
            "search_url": "https://go.drugbank.com/drugs/DB00904",
            "chemical_class": "Carbazole derivative (specifically, a serotonin 5-HT3 receptor antagonist)",
            "psychoactive_class": "Antiemetic (not psychoactive in the traditional sense, but acts on the central nervous system to prevent nausea/vomiting)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "1 mg",
                            "light": "2-4 mg",
                            "common": "4-8 mg",
                            "strong": "8-16 mg",
                            "heavy": "16+ mg"
                        }
                    },
                    {
                        "route": "IV",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "1 mg",
                            "light": "2-4 mg",
                            "common": "4-8 mg",
                            "strong": "8-16 mg",
                            "heavy": "16+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 1,
                                "max": 2
                            },
                            "light": {
                                "min": 2,
                                "max": 4
                            },
                            "common": {
                                "min": 4,
                                "max": 8
                            },
                            "strong": {
                                "min": 8,
                                "max": 16
                            },
                            "heavy": {
                                "min": 16,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "intravenous",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 1,
                                "max": 2
                            },
                            "light": {
                                "min": 2,
                                "max": 4
                            },
                            "common": {
                                "min": 4,
                                "max": 8
                            },
                            "strong": {
                                "min": 8,
                                "max": 16
                            },
                            "heavy": {
                                "min": 16,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4-12 hours (dose-dependent)",
                "onset": "30-60 minutes (oral), immediate (IV)",
                "peak": "1-2 hours (oral)",
                "offset": "4-12 hours",
                "after_effects": "Minimal to none"
            },
            "addiction_potential": "Ondansetron is not considered addictive and has no known abuse potential.",
            "interactions": {
                "dangerous": [
                    "Apomorphine (risk of profound hypotension and loss of consciousness)"
                ],
                "unsafe": [],
                "caution": [
                    "Drugs that prolong QT interval (e.g., certain antiarrhythmics, antipsychotics, macrolide antibiotics)",
                    "Serotonergic drugs (risk of serotonin syndrome)"
                ]
            },
            "notes": "Ondansetron is primarily used to prevent nausea and vomiting associated with chemotherapy, radiation therapy, and surgery. It is generally well tolerated, but can rarely cause QT prolongation and serious cardiac arrhythmias. Use with caution in patients with electrolyte abnormalities or pre-existing heart conditions. Not recommended for routine use in pregnancy unless clearly needed.",
            "subjective_effects": [
                "Reduction of nausea",
                "Reduction of vomiting",
                "Possible mild headache",
                "Possible mild constipation"
            ],
            "tolerance": {
                "full_tolerance": "Not typically relevant; no significant tolerance develops with standard use.",
                "half_tolerance": "N/A",
                "zero_tolerance": "N/A",
                "cross_tolerances": []
            },
            "half_life": "3-6 hours (oral); may be longer in elderly or those with hepatic impairment.",
            "citations": [
                {
                    "name": "DrugBank: Ondansetron",
                    "reference": "https://go.drugbank.com/drugs/DB00904"
                },
                {
                    "name": "DrugBank Article: Ondansetron",
                    "reference": "https://go.drugbank.com/articles/A174250"
                }
            ],
            "categories": ["antidepressant", "depressant"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Ondansetron",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Ondansetron product monographs; clinical use duration data (primarily oral/IV, little published insufflation data).",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 12,
                            "iso": ["PT4H", "PT12H"],
                            "note": "Duration is dose-dependent; insufflated onset may be more rapid, but overall duration is likely comparable to oral."
                        },
                        "onset": {
                            "start": 0.166,
                            "end": 0.5,
                            "iso_start": ["PT10M"],
                            "iso_end": ["PT30M"]
                        },
                        "peak": {
                            "start": 0.5,
                            "end": 2,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 4,
                            "end": 12,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT12H"]
                        },
                        "after_effects": {
                            "start": 0,
                            "end": 0.5,
                            "iso_start": ["PT0M"],
                            "iso_end": ["PT30M"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 302,
        "title": "Moclobemide",
        "content": "# Moclobemide\n## Benzamide (specifically a reversible monoamine oxidase inhibitor, or RIMA) | Antidepressant (Reversible MAO-A inhibitor)\n      \nMoclobemide is a reversible inhibitor of monoamine oxidase A (RIMA), used primarily for the treatment of major depressive disorder and sometimes social anxiety. Unlike older MAOIs, it has a much lower risk of dietary tyramine interactions and is considered safer, but caution is still warranted with certain drugs and foods. It is generally well-tolerated, but can interact dangerously with serotonergic and adrenergic agents.",
        "drug_info": {
            "drug_name": "Moclobemide",
            "search_url": "https://go.drugbank.com/drugs/DB01171",
            "chemical_class": "Benzamide (specifically a reversible monoamine oxidase inhibitor, or RIMA)",
            "psychoactive_class": "Antidepressant (Reversible MAO-A inhibitor)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "50 mg",
                            "light": "150-300 mg",
                            "common": "300-600 mg",
                            "strong": "600-900 mg",
                            "heavy": "900+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 50,
                                "max": 150
                            },
                            "light": {
                                "min": 150,
                                "max": 300
                            },
                            "common": {
                                "min": 300,
                                "max": 600
                            },
                            "strong": {
                                "min": 600,
                                "max": 900
                            },
                            "heavy": {
                                "min": 900,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "12-24 hours (antidepressant effect is chronic with regular dosing)",
                "onset": "1-2 hours (for acute pharmacological effects)",
                "peak": "2-4 hours",
                "offset": "12-24 hours",
                "after_effects": "Minimal, but withdrawal or discontinuation may cause symptoms in chronic users"
            },
            "addiction_potential": "Low. Moclobemide is not considered habit-forming or addictive, and does not produce euphoria or reinforcement typical of substances with abuse potential.",
            "interactions": {
                "dangerous": [
                    "Other MAO inhibitors (risk of hypertensive crisis, serotonin syndrome)",
                    "SSRIs, SNRIs, TCAs, other serotonergic drugs (risk of serotonin syndrome)"
                ],
                "unsafe": [
                    "Sympathomimetic amines (e.g., pseudoephedrine, amphetamines)"
                ],
                "caution": [
                    "Tyramine-rich foods (risk is lower than with irreversible MAOIs, but caution is still advised)",
                    "Other antidepressants"
                ]
            },
            "notes": "Moclobemide is a reversible inhibitor of monoamine oxidase A (RIMA), used primarily for the treatment of major depressive disorder and sometimes social anxiety. Unlike older MAOIs, it has a much lower risk of dietary tyramine interactions and is considered safer, but caution is still warranted with certain drugs and foods. It is generally well-tolerated, but can interact dangerously with serotonergic and adrenergic agents.",
            "subjective_effects": [
                "Mood elevation (in depressed individuals)",
                "Anxiolysis",
                "Increased energy",
                "Improved social functioning",
                "Rarely, insomnia or agitation"
            ],
            "tolerance": {
                "full_tolerance": "Develops slowly with chronic use (weeks to months)",
                "half_tolerance": "Not well defined; partial tolerance may develop after several weeks",
                "zero_tolerance": "Several weeks after discontinuation",
                "cross_tolerances": ["Other MAOIs"]
            },
            "half_life": "1-4 hours (plasma half-life); clinical effects last longer due to MAO-A inhibition",
            "citations": [
                {
                    "name": "DrugBank: Moclobemide",
                    "reference": "https://go.drugbank.com/drugs/DB01171"
                },
                {
                    "name": "DrugBank: Moclobemide clinical trials",
                    "reference": "https://go.drugbank.com/drugs/DB01171/clinical_trials?conditions=DBCOND0030647&phase=2&purpose=treatment&status=completed"
                },
                {
                    "name": "DrugBank: Moclobemide pharmacology",
                    "reference": "https://go.drugbank.com/articles/A13542"
                },
                {
                    "name": "DrugBank: Moclobemide efficacy",
                    "reference": "https://go.drugbank.com/articles/A13543"
                }
            ],
            "categories": ["antidepressant"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Moclobemide",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Medical literature, user reports, clinical pharmacology reviews (e.g., RxList, Drugs.com). Insufflated use is not standard; timings estimated based on oral use and absorption rate differences.",
                        "units": "hours",
                        "total_duration": {
                            "min": 12,
                            "max": 24,
                            "iso": ["PT12H", "PT24H"],
                            "note": "Primarily used orally; nasal/insufflated route may accelerate onset but not necessarily shorten total duration."
                        },
                        "onset": {
                            "start": 0.25,
                            "end": 2,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT2H"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "offset": {
                            "start": 12,
                            "end": 24,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT24H"]
                        },
                        "after_effects": {
                            "start": 24,
                            "end": 36,
                            "iso_start": ["PT24H"],
                            "iso_end": ["PT36H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 296,
        "title": "2-Fluoromethamphetamine",
        "content": "# 2-Fluoromethamphetamine (2-FMA)## Substituted amphetamine (fluorinated phenethylamine) | Stimulant      User reports describe 2-FMA as a \u2018functional\u2019 amphetamine\u2014providing focus and productivity with relatively muted euphoria and a gentler comedown. Cardiovascular strain and insomnia remain primary risks. Post-mortem screens have detected parent drug and N-hydroxy-2-FMA metabolites, confirming systemic persistence.",
        "drug_info": {
            "drug_name": "2-Fluoromethamphetamine (2-FMA)",
            "search_url": "https://en.wikipedia.org/wiki/2-Fluoromethamphetamine",
            "chemical_class": "Substituted amphetamine (fluorinated phenethylamine)",
            "psychoactive_class": "Stimulant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5-10 mg",
                            "light": "10-25 mg",
                            "common": "25-50 mg",
                            "strong": "50-80 mg",
                            "heavy": "80+ mg"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2-5 mg",
                            "light": "5-15 mg",
                            "common": "15-35 mg",
                            "strong": "35-60 mg",
                            "heavy": "60+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 25
                            },
                            "common": {
                                "min": 25,
                                "max": 50
                            },
                            "strong": {
                                "min": 50,
                                "max": 80
                            },
                            "heavy": {
                                "min": 80,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 15
                            },
                            "common": {
                                "min": 15,
                                "max": 35
                            },
                            "strong": {
                                "min": 35,
                                "max": 60
                            },
                            "heavy": {
                                "min": 60,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4 \u2013 7 h",
                "onset": "10 \u2013 40 min (oral) / 1 \u2013 5 min (insufflated)",
                "peak": "1 \u2013 3 h",
                "offset": "1 \u2013 2 h gradual decline",
                "after_effects": "2 \u2013 8 h residual stimulation / insomnia"
            },
            "addiction_potential": "Moderate\u2014comparable to other amphetamine analogues; compulsive redosing reported in some users but lower euphoric drive than methamphetamine.",
            "interactions": {
                "dangerous": [
                    "MAOIs",
                    "other strong stimulants (methamphetamine, cocaine)",
                    "\u03b1-PVP and cathinones",
                    "tramadol (seizure risk)",
                    "DXM (serotonin syndrome)"
                ],
                "unsafe": [
                    "high-dose caffeine",
                    "bupropion",
                    "modafinil",
                    "phenethylamine derivatives (4-FA, MDMA)"
                ],
                "caution": [
                    "alcohol (flushing, tachycardia)",
                    "benzodiazepines (may mask overdose)",
                    "nicotine",
                    "dissociatives (MXE, ketamine)",
                    "opioids (respiratory depression when comedown treated with high doses)"
                ]
            },
            "notes": "User reports describe 2-FMA as a \u2018functional\u2019 amphetamine\u2014providing focus and productivity with relatively muted euphoria and a gentler comedown. Cardiovascular strain and insomnia remain primary risks. Post-mortem screens have detected parent drug and N-hydroxy-2-FMA metabolites, confirming systemic persistence.",
            "subjective_effects": [
                "enhanced concentration",
                "increased motivation",
                "mild euphoria",
                "reduced appetite",
                "bruxism",
                "anxiolysis at moderate doses",
                "elevated heart rate",
                "insomnia",
                "dry mouth",
                "thermoregulatory dysregulation"
            ],
            "tolerance": {
                "full_tolerance": "Develops after 2 \u2013 3 consecutive days of use",
                "half_tolerance": "3 \u2013 7 days",
                "zero_tolerance": "2 \u2013 3 weeks",
                "cross_tolerances": ["amphetamines", "cathinone stimulants"]
            },
            "half_life": "Estimated 8 \u2013 12 h (urine metabolite study suggests overnight persistence; user reports feel residual effects next morning)",
            "citations": [
                {
                    "name": "PubChem CID 24257263",
                    "reference": "https://pubchem.ncbi.nlm.nih.gov/compound/24257263"
                },
                {
                    "name": "Ishii A et al., Identification and Quantitative Analysis of 2-FMA in Human Urine, J Anal Toxicol 47(1):59-65 (2023)",
                    "reference": "https://pubmed.ncbi.nlm.nih.gov/35562170/"
                },
                {
                    "name": "Bluelight\u20142-FMA (75 mg total) first-time report",
                    "reference": "https://www.bluelight.org/community/threads/2-fma-75mg-total-first-time-comparisons-with-other-stimulants.606518/"
                },
                {
                    "name": "Bluelight\u20142-FMA Megathread",
                    "reference": "https://www.bluelight.org/community/threads/2-fma-2-fluoromethamphetamine-megathread.609222/"
                },
                {
                    "name": "Reddit r/researchchemicals\u2014long-term 2-FMA use discussion",
                    "reference": "https://www.reddit.com/r/researchchemicals/comments/15pzhuh/have_you_taken_or_are_you_taking_2fma_for_several/"
                }
            ],
            "categories": ["stimulant", "research-chemical", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "2-Fluoromethamphetamine (2-FMA)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Compiled from user reports and scientific literature (2020\u20132023), excluding psychonautwiki sources.",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 7,
                            "iso": ["PT4H", "PT7H"],
                            "note": "Insufflated route."
                        },
                        "onset": {
                            "start": 0.016,
                            "end": 0.083,
                            "iso_start": ["PT1M"],
                            "iso_end": ["PT5M"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 3,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 3,
                            "end": 7,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT7H"]
                        },
                        "after_effects": {
                            "start": 7,
                            "end": 15,
                            "iso_start": ["PT7H"],
                            "iso_end": ["PT15H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 297,
        "title": "3-Chlorophenmetrazine",
        "content": "# 3-Chlorophenmetrazine (3-CPM)\n## Substituted phenylmorpholine | Stimulant (norepinephrine-dopamine releasing agent with mild serotonergic activity)\n      \nVery limited formal pharmacology or toxicology data exist. A 2023 UK case report linked 3-CPM insufflation to acute stimulant toxicity. Chlorinated phenylmorpholines may carry unknown long-term neurotoxicity risks. Legal status varies; reported to EMCDDA early-warning system in 2021.",
        "drug_info": {
            "drug_name": "3-Chlorophenmetrazine (3-CPM)",
            "search_url": "https://en.wikipedia.org/wiki/3-Chlorophenmetrazine",
            "chemical_class": "Substituted phenylmorpholine",
            "psychoactive_class": "Stimulant (norepinephrine-dopamine releasing agent with mild serotonergic activity)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "10\u201320 mg",
                            "common": "20\u201340 mg",
                            "strong": "40\u201360 mg",
                            "heavy": "60 mg+"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "3 mg",
                            "light": "5\u201315 mg",
                            "common": "15\u201325 mg",
                            "strong": "25\u201340 mg",
                            "heavy": "40 mg+"
                        }
                    },
                    {
                        "route": "vaporized",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "10\u201325 mg",
                            "common": "25\u201340 mg",
                            "strong": "40\u201360 mg",
                            "heavy": "60 mg+"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 20
                            },
                            "common": {
                                "min": 20,
                                "max": 40
                            },
                            "strong": {
                                "min": 40,
                                "max": 60
                            },
                            "heavy": {
                                "min": 60,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 3,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 15
                            },
                            "common": {
                                "min": 15,
                                "max": 25
                            },
                            "strong": {
                                "min": 25,
                                "max": 40
                            },
                            "heavy": {
                                "min": 40,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "vaporized",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 25
                            },
                            "common": {
                                "min": 25,
                                "max": 40
                            },
                            "strong": {
                                "min": 40,
                                "max": 60
                            },
                            "heavy": {
                                "min": 60,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4\u20136 h",
                "onset": "15\u201345 min",
                "peak": "1\u20132 h",
                "offset": "2\u20133 h",
                "after_effects": "2\u201312 h (residual stimulation / insomnia)"
            },
            "addiction_potential": "Moderate-to-high; users describe strong urges to redose and rapid development of compulsive use patterns.",
            "interactions": {
                "dangerous": [
                    "MAOIs",
                    "MDMA or other strong serotonin releasers"
                ],
                "unsafe": [
                    "High-dose caffeine",
                    "Cocaine and potent cathinones",
                    "Tramadol (seizure risk)",
                    "Large SSRI/SNRI doses (serotonin-toxicity risk)"
                ],
                "caution": [
                    "Alcohol (masking fatigue \u2192 respiratory depression)",
                    "Benzodiazepines or opioids during comedown",
                    "Beta-blockers / antihypertensives"
                ]
            },
            "notes": "Very limited formal pharmacology or toxicology data exist. A 2023 UK case report linked 3-CPM insufflation to acute stimulant toxicity. Chlorinated phenylmorpholines may carry unknown long-term neurotoxicity risks. Legal status varies; reported to EMCDDA early-warning system in 2021.",
            "subjective_effects": [
                "Euphoria",
                "Mental stimulation and focus",
                "Increased sociability",
                "Appetite suppression",
                "Music appreciation",
                "Increased libido",
                "Anxiety or jitteriness at high doses",
                "Peripheral vasoconstriction",
                "Insomnia",
                "Compulsive redosing"
            ],
            "tolerance": {
                "full_tolerance": "3\u20137 days of continuous daily use",
                "half_tolerance": "1\u20132 weeks",
                "zero_tolerance": "4\u20136 weeks",
                "cross_tolerances": [
                    "Amphetamines",
                    "Cathinones",
                    "Other phenylmorpholines"
                ]
            },
            "half_life": "\u2248 3\u20135 h (estimated from phenmetrazine analogue data; human PK studies absent)",
            "citations": [
                {
                    "name": "3-Chlorophenmetrazine \u2013 Wikipedia",
                    "reference": "https://en.wikipedia.org/wiki/3-Chlorophenmetrazine"
                },
                {
                    "name": "Reddit r/researchchemicals dose-range post (2022)",
                    "reference": "https://www.reddit.com/r/researchchemicals/comments/wco8sp/3cpm_dosing_info/"
                },
                {
                    "name": "Bluelight \u20183-CPM\u2019 discussion thread (2021)",
                    "reference": "https://www.bluelight.org/community/threads/3-cpm.904220/"
                },
                {
                    "name": "Acute stimulant toxicity case report (APJMT 2023)",
                    "reference": "https://apjmt.mums.ac.ir/article_24250.html"
                },
                {
                    "name": "EMCDDA \u201825 Years of NPS\u2019 \u2013 3-CPM entry (2022)",
                    "reference": "https://www.drugsandalcohol.ie/36445/1/EMCDDA_New_psychoactive_substances_25_years.pdf"
                },
                {
                    "name": "3-CPM MAO-inhibition study (Sciencedirect 1992)",
                    "reference": "https://www.sciencedirect.com/science/article/pii/0197018692901239"
                }
            ],
            "categories": ["stimulant", "research-chemical", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "3-Chlorophenmetrazine (3-CPM)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Academic literature and user experience reports (as of 2024) describing 3-CPM insufflated.",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 6,
                            "iso": ["P4H", "P6H"],
                            "note": "Total psychoactive effects tend to resolve within this window."
                        },
                        "onset": {
                            "start": 0.25,
                            "end": 0.75,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT45M"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 2,
                            "end": 3,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT3H"]
                        },
                        "after_effects": {
                            "start": 2,
                            "end": 12,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT12H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 298,
        "title": "N-Methyl-Cyclazodone",
        "content": "# N-Methyl-Cyclazodone\n## 2-Oxazolidinone (pemoline) derivative | Stimulant / Nootropic\n      \nHuman data are scarce; pemoline analogs have a history of hepatotoxicity, so periodic liver-enzyme monitoring is prudent. Prolonged wakefulness can obscure sleep debt, and appetite suppression may lead to malnutrition. A 38-year-old self-treating ADHD with ~5 g cumulative intake required hospitalization for palpitations and agitation.",
        "drug_info": {
            "drug_name": "N-Methyl-Cyclazodone",
            "search_url": "https://www.frontiersin.org/articles/10.3389/fpsyt.2020.546796/full",
            "chemical_class": "2-Oxazolidinone (pemoline) derivative",
            "psychoactive_class": "Stimulant / Nootropic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "3 mg",
                            "light": "5-8 mg",
                            "common": "10-15 mg",
                            "strong": "20-25 mg",
                            "heavy": "30 mg+"
                        }
                    },
                    {
                        "route": "sublingual",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2 mg",
                            "light": "4-6 mg",
                            "common": "8-12 mg",
                            "strong": "15-20 mg",
                            "heavy": "25 mg+"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 3,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 8
                            },
                            "common": {
                                "min": 10,
                                "max": 15
                            },
                            "strong": {
                                "min": 20,
                                "max": 25
                            },
                            "heavy": {
                                "min": 30,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "sublingual",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2,
                                "max": 4
                            },
                            "light": {
                                "min": 4,
                                "max": 8
                            },
                            "common": {
                                "min": 8,
                                "max": 15
                            },
                            "strong": {
                                "min": 15,
                                "max": 20
                            },
                            "heavy": {
                                "min": 20,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "6-10 h",
                "onset": "15-45 min",
                "peak": "2-5 h",
                "offset": "2-3 h",
                "after_effects": "3-6 h (residual stimulation / insomnia)"
            },
            "addiction_potential": "Moderate: psychological dependence similar to other prescription stimulants; case reports note compulsive redosing and withdrawal-like fatigue.",
            "interactions": {
                "dangerous": ["MAOIs", "High-dose amphetamines", "Cocaine"],
                "unsafe": [
                    "Other potent dopaminergic stimulants (e.g., methylphenidate)",
                    "Large doses of caffeine"
                ],
                "caution": [
                    "Alcohol (tachycardia & agitation case reported)",
                    "SSRIs or other serotonergic agents",
                    "Bupropion"
                ]
            },
            "notes": "Human data are scarce; pemoline analogs have a history of hepatotoxicity, so periodic liver-enzyme monitoring is prudent. Prolonged wakefulness can obscure sleep debt, and appetite suppression may lead to malnutrition. A 38-year-old self-treating ADHD with ~5 g cumulative intake required hospitalization for palpitations and agitation.",
            "subjective_effects": [
                "Wakefulness",
                "Motivation enhancement",
                "Focused attention",
                "Mild euphoria",
                "Appetite suppression",
                "Tachycardia",
                "Anxiety at high doses",
                "Sweating",
                "Bruxism",
                "Vasoconstriction",
                "Insomnia"
            ],
            "tolerance": {
                "full_tolerance": "Develops within 3 \u2013 7 days of daily use",
                "half_tolerance": "3 \u2013 4 days",
                "zero_tolerance": "2 \u2013 3 weeks of abstinence",
                "cross_tolerances": [
                    "Cyclazodone",
                    "Pemoline derivatives",
                    "Amphetamine-class stimulants"
                ]
            },
            "half_life": "Estimated 6 \u2013 10 h (no formal human PK study; inferred from animal data and user reports)",
            "citations": [
                {
                    "name": "CFSRE \u2013 Toxicity from the NPS N-Methyl-Cyclazodone with Laboratory Confirmation (2022)",
                    "reference": "https://www.cfsre.org/resources/presentations/toxicity-from-the-nps-n-methyl-cyclazodone-with-laboratory-confirmation-a-dance-befitting-st-vitus"
                },
                {
                    "name": "Reddit \u2013 \u201cN-Methyl-Cyclazodone: a fickle but rewarding stimulant\u201d thread (2018)",
                    "reference": "https://www.reddit.com/r/researchchemicals/comments/8cnzo0/nmethylcyclazodone_a_fickle_but_rewarding/"
                },
                {
                    "name": "Bluelight \u2013 Cyclazodone Megathread, post #4 (2019)",
                    "reference": "https://www.bluelight.org/community/threads/cyclazodone-megathread.876178/"
                },
                {
                    "name": "NDEWS Drug Market Insight Brief: N-Methyl-Cyclazodone (2022)",
                    "reference": "https://ndews.org/wordpress/files/2023/04/8.19.22.pdf"
                },
                {
                    "name": "Basile et al. Self-medication with Novel Psychoactive Substances \u2013 Case Report (2022)",
                    "reference": "https://link.springer.com/article/10.1007/s11469-023-01195-8"
                },
                {
                    "name": "Frontiers in Psychiatry \u2013 The Psychonauts\u2019 World of Cognitive Enhancers (2020)",
                    "reference": "https://www.frontiersin.org/articles/10.3389/fpsyt.2020.546796/pdf"
                },
                {
                    "name": "WholisticResearch \u2013 Cyclazodone vs N-Methyl-Cyclazodone Comparison (2025)",
                    "reference": "https://wholisticresearch.com/cyclazodone/"
                }
            ],
            "categories": [
                "stimulant",
                "research-chemical",
                "nootropic",
                "habit-forming"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "N-Methyl-Cyclazodone",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Empirical reports, forum discussions, and structural similarity to cyclazodone and related stimulants.",
                        "units": "hours",
                        "total_duration": {
                            "min": 6,
                            "max": 10,
                            "iso": ["PT6H", "PT10H"],
                            "note": "Range reflects user experiences and comparison to structurally similar compounds."
                        },
                        "onset": {
                            "start": 0.25,
                            "end": 0.75,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT45M"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 5,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT5H"]
                        },
                        "offset": {
                            "start": 5,
                            "end": 8,
                            "iso_start": ["PT5H"],
                            "iso_end": ["PT8H"]
                        },
                        "after_effects": {
                            "start": 8,
                            "end": 16,
                            "iso_start": ["PT8H"],
                            "iso_end": ["PT16H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 146,
        "title": "4-Fluorodeprenyl",
        "content": "",
        "drug_info": {
            "drug_name": "4-Fluorodeprenyl (p-F-Deprenyl)",
            "search_url": "https://en.wikipedia.org/wiki/4-Fluoroselegiline",
            "chemical_class": "Propargylamine; substituted amphetamine (phenethylamine) derivative",
            "psychoactive_class": "Stimulant / MAO-B inhibitor / Nootropic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "0.5 mg",
                            "light": "1-2 mg",
                            "common": "2-5 mg",
                            "strong": "5-10 mg",
                            "heavy": "10+ mg"
                        }
                    },
                    {
                        "route": "sublingual",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "0.25 mg",
                            "light": "0.5-1 mg",
                            "common": "1-3 mg",
                            "strong": "3-6 mg",
                            "heavy": "6+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.5,
                                "max": 1
                            },
                            "light": {
                                "min": 1,
                                "max": 2
                            },
                            "common": {
                                "min": 2,
                                "max": 5
                            },
                            "strong": {
                                "min": 5,
                                "max": 10
                            },
                            "heavy": {
                                "min": 10,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "sublingual",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.25,
                                "max": 0.5
                            },
                            "light": {
                                "min": 0.5,
                                "max": 1
                            },
                            "common": {
                                "min": 1,
                                "max": 3
                            },
                            "strong": {
                                "min": 3,
                                "max": 6
                            },
                            "heavy": {
                                "min": 6,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4-8 h (acute subjective stimulation)",
                "onset": "0.5-1 h",
                "peak": "2-4 h",
                "offset": "4-8 h",
                "after_effects": "24-48 h of MAO-B inhibition and mild residual stimulation"
            },
            "addiction_potential": "Low to moderate; psychological habituation possible with frequent use, but physical dependence is unlikely.",
            "interactions": {
                "dangerous": [
                    "SSRIs",
                    "SNRIs",
                    "MDMA",
                    "other MAO inhibitors",
                    "meperidine",
                    "linezolid"
                ],
                "unsafe": [
                    "high-tyramine foods (at \u226510 mg/day)",
                    "strong stimulants (amphetamine, cocaine)",
                    "sympathomimetic decongestants"
                ],
                "caution": [
                    "dopamine agonists",
                    "alcohol",
                    "caffeine",
                    "tricyclic antidepressants"
                ]
            },
            "notes": "Metabolizes to 4-fluoroamphetamine and 4-fluoromethamphetamine, which may add dopaminergic load. Risk of serotonin syndrome when combined with serotonergic drugs. At higher doses (>10 mg) selectivity for MAO-B diminishes, increasing dietary tyramine risk.",
            "subjective_effects": [
                "mild euphoria",
                "enhanced focus",
                "increased motivation",
                "alertness",
                "reduced fatigue",
                "appetite suppression",
                "increased sociability",
                "insomnia at higher doses",
                "headache (occasional)",
                "mild blood-pressure elevation"
            ],
            "tolerance": {
                "full_tolerance": "Minimal; gradual plateau after several weeks of daily use",
                "half_tolerance": "\u2248 1 month of abstinence",
                "zero_tolerance": "\u2248 2 \u2013 3 months of abstinence",
                "cross_tolerances": ["selegiline", "rasagiline", "amphetamines"]
            },
            "half_life": "\u2248 10-14 h (parent compound); functional MAO-B inhibition lasts 24-48 h",
            "citations": [
                {
                    "name": "PubChem compound summary (p-Fluorodeprenyl)",
                    "reference": "https://pubchem.ncbi.nlm.nih.gov/compound/14771954"
                },
                {
                    "name": "Erd\u00f6 F et al., NeuroReport (2000) \u2013 neurorescue profiles",
                    "reference": "https://pubmed.ncbi.nlm.nih.gov/10943729"
                },
                {
                    "name": "Yasar S et al., Psychopharmacology (2005) \u2013 reinforcing effects in monkeys",
                    "reference": "https://pubmed.ncbi.nlm.nih.gov/15990999"
                },
                {
                    "name": "Knoll J & Miklya I (1994) \u2013 catecholaminergic activity study",
                    "reference": "https://pubmed.ncbi.nlm.nih.gov/7893186"
                },
                {
                    "name": "4-Fluoroselegiline (Wikipedia entry)",
                    "reference": "https://en.wikipedia.org/wiki/4-Fluoroselegiline"
                },
                {
                    "name": "Reddit: pF-deprenyl initial user reports",
                    "reference": "https://www.reddit.com/r/Nootropics/comments/9jhj2c/pfdeprenyl/"
                },
                {
                    "name": "Reddit: p-Fluoro-deprenyl day-2 follow-up",
                    "reference": "https://www.reddit.com/r/Nootropics/comments/ds7fz7/pfluoro_deprenyl_day_2/"
                },
                {
                    "name": "Bluelight discussion on selegiline & fluorodeprenyl potency",
                    "reference": "https://www.bluelight.org/community/threads/selegiline-to-feel-alive-and-start-studying.933358/"
                }
            ],
            "categories": [
                "stimulant",
                "research-chemical",
                "nootropic",
                "antidepressant"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "4-Fluorodeprenyl (p-F-Deprenyl)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Academic literature and user reports (2023): 4-Fluorodeprenyl (insufflated)",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 8,
                            "iso": ["PT4H", "PT8H"],
                            "note": "Acute subjective stimulation"
                        },
                        "onset": {
                            "start": 0.5,
                            "end": 1,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "offset": {
                            "start": 4,
                            "end": 8,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT8H"]
                        },
                        "after_effects": {
                            "start": 24,
                            "end": 48,
                            "iso_start": ["PT24H"],
                            "iso_end": ["PT48H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 294,
        "title": "Bromantane",
        "content": "# Bromantane\n## Adamantane derivative (adamantyl-aniline) | Stimulant actoprotector / anxiolytic nootropic\n      \nMarketed in Russia as Ladasten for asthenia; banned by WADA since 1997. Enhances physical endurance, up-regulates tyrosine hydroxylase, and shows immunomodulatory effects. Synergises with stimulants\u2014potentiation can spike blood pressure.",
        "drug_info": {
            "drug_name": "Bromantane",
            "search_url": "https://en.wikipedia.org/wiki/Bromantane",
            "chemical_class": "Adamantane derivative (adamantyl-aniline)",
            "psychoactive_class": "Stimulant actoprotector / anxiolytic nootropic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "<10 mg",
                            "light": "10\u201350 mg",
                            "common": "50\u2013100 mg",
                            "strong": "100\u2013200 mg",
                            "heavy": "200+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 50
                            },
                            "common": {
                                "min": 50,
                                "max": 100
                            },
                            "strong": {
                                "min": 100,
                                "max": 200
                            },
                            "heavy": {
                                "min": 200,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "6\u201310 h",
                "onset": "0.5\u20131 h",
                "peak": "2\u20134 h",
                "offset": "4\u20136 h",
                "after_effects": "\u226424 h mild residual stimulation"
            },
            "addiction_potential": "Low; clinical literature reports no classic dependence, though some users note dysphoria on abrupt cessation after months of daily 50 mg+ use.",
            "interactions": {
                "dangerous": [
                    "MAOIs",
                    "methamphetamine",
                    "high-dose amphetamines"
                ],
                "unsafe": [
                    "methylphenidate",
                    "large caffeine doses",
                    "cocaine"
                ],
                "caution": ["alcohol", "benzodiazepines", "other dopaminergics"]
            },
            "notes": "Marketed in Russia as Ladasten for asthenia; banned by WADA since 1997. Enhances physical endurance, up-regulates tyrosine hydroxylase, and shows immunomodulatory effects. Synergises with stimulants\u2014potentiation can spike blood pressure.",
            "subjective_effects": [
                "increased motivation",
                "mental clarity",
                "reduced fatigue",
                "smooth energy without jitters",
                "anxiolysis",
                "improved physical endurance",
                "mild euphoria",
                "restlessness at high doses"
            ],
            "tolerance": {
                "full_tolerance": "\u224814\u201321 days daily use",
                "half_tolerance": "\u22487 days",
                "zero_tolerance": "\u22482\u20133 months abstinence",
                "cross_tolerances": [
                    "amantadine",
                    "other adamantane stimulants"
                ]
            },
            "half_life": "\u224811.5 h plasma (range 7\u201312 h); brain tissue \u22487 h",
            "citations": [
                {
                    "name": "Wikipedia \u2013 Bromantane",
                    "reference": "https://en.wikipedia.org/wiki/Bromantane"
                },
                {
                    "name": "Pharmacology of Actoprotectors (Biomolecules & Therapeutics, 2012)",
                    "reference": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3762282/"
                },
                {
                    "name": "CFSRE NPS Discovery Monograph (2024)",
                    "reference": "https://www.cfsre.org/nps-discovery/monographs/bromantane"
                },
                {
                    "name": "EvitaChem product data",
                    "reference": "https://www.evitachem.com/product/evt-332313"
                },
                {
                    "name": "YourInception review (2022)",
                    "reference": "https://www.yourinception.com/bromantane-review/"
                },
                {
                    "name": "Reddit \u2013 Bromantane withdrawal & benefits thread (2025)",
                    "reference": "https://www.reddit.com/r/Nootropics/comments/1k0fsos/bromantane_withdrawal_and_long_term/"
                },
                {
                    "name": "Reddit \u2013 Dangerous synergy with amphetamines (2021)",
                    "reference": "https://www.reddit.com/r/Nootropics/comments/qpoieb/bromantane_if_you_use_strong_amphetamines_dont/"
                },
                {
                    "name": "Reddit \u2013 Starting dose discussion (2025)",
                    "reference": "https://www.reddit.com/r/Biohackers/comments/1j1xsjb/just_picked_up_some_bromantane_from_my_initial/"
                }
            ],
            "categories": [
                "stimulant",
                "nootropic",
                "research-chemical",
                "supplement"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Bromantane",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Literature reviews and user reports (as of 2024); primary academic: Chu J et al. (2019) CNS Drugs. Bromantane: Pharmacology and therapeutic potential.",
                        "units": "hours",
                        "total_duration": {
                            "min": 6,
                            "max": 10,
                            "iso": ["PT6H", "PT10H"],
                            "note": "Insufflation can quicken onset but does not drastically shorten full duration compared to oral use."
                        },
                        "onset": {
                            "start": 0.5,
                            "end": 1,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "offset": {
                            "start": 4,
                            "end": 6,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT6H"]
                        },
                        "after_effects": {
                            "start": 6,
                            "end": 24,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 295,
        "title": "2C-D",
        "content": "# 2C-D\n## Phenethylamine | Psychedelic\n      \nAt sub-psychedelic doses (\u226410 mg) 2C-D has been explored as a 'nootropic' or 'philosopher\u2019s stone', reportedly enhancing cognition without strong visuals. Potentiation of other psychedelics is documented; dose-response is steep so volumetric dosing is advised.",
        "drug_info": {
            "drug_name": "2C-D",
            "search_url": "https://erowid.org/chemicals/2cd/2cd.shtml",
            "chemical_class": "Phenethylamine",
            "psychoactive_class": "Psychedelic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2\u20135 mg",
                            "light": "5\u201310 mg",
                            "common": "10\u201325 mg",
                            "strong": "25\u201340 mg",
                            "heavy": "40+ "
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "1 mg",
                            "light": "2\u20135 mg",
                            "common": "5\u201310 mg",
                            "strong": "10\u201315 mg",
                            "heavy": "15+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 10
                            },
                            "common": {
                                "min": 10,
                                "max": 25
                            },
                            "strong": {
                                "min": 25,
                                "max": 40
                            },
                            "heavy": {
                                "min": 40,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 1,
                                "max": 2
                            },
                            "light": {
                                "min": 2,
                                "max": 5
                            },
                            "common": {
                                "min": 5,
                                "max": 10
                            },
                            "strong": {
                                "min": 10,
                                "max": 15
                            },
                            "heavy": {
                                "min": 15,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4\u20136 h",
                "onset": "15\u201345 min",
                "peak": "1.5\u20133 h",
                "offset": "1\u20132 h",
                "after_effects": "2\u20136 h"
            },
            "addiction_potential": "Low; minimal evidence of compulsive use or physical dependence.",
            "interactions": {
                "dangerous": ["MAOIs", "Tramadol", "Linezolid"],
                "unsafe": ["SSRI", "SNRI", "MDMA"],
                "caution": [
                    "alcohol",
                    "cannabis",
                    "other phenethylamine psychedelics"
                ]
            },
            "notes": "At sub-psychedelic doses (\u226410 mg) 2C-D has been explored as a 'nootropic' or 'philosopher\u2019s stone', reportedly enhancing cognition without strong visuals. Potentiation of other psychedelics is documented; dose-response is steep so volumetric dosing is advised.",
            "subjective_effects": [
                "color enhancement",
                "visual patterning",
                "enhanced focus at low doses",
                "euphoria",
                "time dilation",
                "mild body load",
                "synesthesia at high doses"
            ],
            "tolerance": {
                "full_tolerance": "after one use",
                "half_tolerance": "3\u20135 days",
                "zero_tolerance": "7\u201314 days",
                "cross_tolerances": ["psychedelic"]
            },
            "half_life": "\u22482\u20134 h (rat data; human data scarce)",
            "citations": [
                {
                    "name": "Wikipedia \u2013 2C-D",
                    "reference": "https://en.wikipedia.org/wiki/2C-D"
                },
                {
                    "name": "Erowid 2C-D Vault",
                    "reference": "https://erowid.org/chemicals/2cd/2cd.shtml"
                },
                {
                    "name": "Erowid Effects \u2013 2C-D",
                    "reference": "https://erowid.org/chemicals/2cd/2cd_effects.shtml"
                },
                {
                    "name": "PiHKAL Entry #23 \u2013 2C-D",
                    "reference": "https://isomerdesign.com/pihkal/read/pk/23"
                },
                {
                    "name": "Theobald et al., 2006 \u2013 2C-D Metabolism",
                    "reference": "https://doi.org/10.1002/jms.1128"
                },
                {
                    "name": "Demystifying Serotonin Syndrome",
                    "reference": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6184959/"
                },
                {
                    "name": "Bluelight Report \u2013 2C-D 30 mg (2024)",
                    "reference": "https://www.bluelight.org/community/threads/2c-d-30-mg-a-short-hike.942229/"
                }
            ],
            "categories": ["psychedelic", "hallucinogen", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "2C-D",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Shulgin, A., & Shulgin, A. (1991). PiHKAL: A Chemical Love Story; user reports and reviews on Erowid and Bluelight forums (accessed 2024).",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 6,
                            "iso": ["PT4H", "PT6H"],
                            "note": "Range covers the main experience from first noticeable effects to return to baseline (excluding after effects)."
                        },
                        "onset": {
                            "start": 0.25,
                            "end": 0.75,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT45M"]
                        },
                        "peak": {
                            "start": 1.5,
                            "end": 3,
                            "iso_start": ["PT1H30M"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 4,
                            "end": 6,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT6H"]
                        },
                        "after_effects": {
                            "start": 6,
                            "end": 12,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT12H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 299,
        "title": "Coluracetam",
        "content": "# Coluracetam\n## Racetam (pyrrolidone derivative) | Nootropic / mild stimulant-anxiolytic\n      \nFat-soluble; co-administration with a dietary fat source improves absorption.  Headaches often signal choline depletion\u2014CDP-choline or Alpha-GPC mitigates this.  Visual \u2018HD\u2019 sharpening and color enhancement are frequently reported but fade as tolerance develops.",
        "drug_info": {
            "drug_name": "Coluracetam",
            "search_url": "https://www.braintropic.com/nootropics/coluracetam/",
            "chemical_class": "Racetam (pyrrolidone derivative)",
            "psychoactive_class": "Nootropic / mild stimulant-anxiolytic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "3 mg",
                            "light": "5-10 mg",
                            "common": "10-20 mg",
                            "strong": "30-50 mg",
                            "heavy": "60 mg+"
                        }
                    },
                    {
                        "route": "sublingual",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2 mg",
                            "light": "5-8 mg",
                            "common": "10-15 mg",
                            "strong": "20-30 mg",
                            "heavy": "35 mg+"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 3,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 10
                            },
                            "common": {
                                "min": 10,
                                "max": 20
                            },
                            "strong": {
                                "min": 20,
                                "max": 50
                            },
                            "heavy": {
                                "min": 50,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "sublingual",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2,
                                "max": 4
                            },
                            "light": {
                                "min": 5,
                                "max": 8
                            },
                            "common": {
                                "min": 9,
                                "max": 15
                            },
                            "strong": {
                                "min": 16,
                                "max": 30
                            },
                            "heavy": {
                                "min": 31,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "3-5 h",
                "onset": "10-30 min",
                "peak": "1-2 h",
                "offset": "3-5 h",
                "after_effects": "1-6 h (subtle)"
            },
            "addiction_potential": "Low; no documented physical dependence, but rapid tolerance emerges with daily use.",
            "interactions": {
                "dangerous": [
                    "Strong anticholinergic agents (may counteract cognitive benefits)",
                    "High-dose NMDA antagonists (unknown synergistic neurotoxicity risk)"
                ],
                "unsafe": [
                    "Cholinesterase inhibitors (risk of cholinergic overload)",
                    "Nicotine or nicotinic agonists (excess cholinergic stimulation)"
                ],
                "caution": [
                    "Alcohol or benzodiazepines (sedation may mask cognitive changes)",
                    "Potent stimulants (possible over-stimulation)",
                    "Other racetams (cross-tolerance, unpredictable stacking)"
                ]
            },
            "notes": "Fat-soluble; co-administration with a dietary fat source improves absorption.  Headaches often signal choline depletion\u2014CDP-choline or Alpha-GPC mitigates this.  Visual \u2018HD\u2019 sharpening and color enhancement are frequently reported but fade as tolerance develops.",
            "subjective_effects": [
                "Enhanced color saturation / \u201cHD vision\u201d",
                "Sharper visual contrast",
                "Improved short-term memory & recall",
                "Increased focus and motivation",
                "Mild mood lift & anxiolysis",
                "Light mental stimulation without jitter",
                "Analytical thinking boost"
            ],
            "tolerance": {
                "full_tolerance": "3 \u2013 7 days of continuous use",
                "half_tolerance": "\u2248 3\u20135 days after cessation",
                "zero_tolerance": "1\u20132 weeks abstinence",
                "cross_tolerances": [
                    "Other racetams",
                    "Choline-uptake enhancers"
                ]
            },
            "half_life": "\u2248 3 hours",
            "citations": [
                {
                    "name": "Braintropic \u2013 Coluracetam Overview",
                    "reference": "https://www.braintropic.com/nootropics/coluracetam/"
                },
                {
                    "name": "Reddit r/Nootropics \u2013 How do you dose Coluracetam? (2014)",
                    "reference": "https://www.reddit.com/r/Nootropics/comments/2irf1l/how_do_you_dose_coluracetam/"
                },
                {
                    "name": "Bluelight \u2013 Coluracetam user thread (2013)",
                    "reference": "https://www.bluelight.org/community/threads/coluracetam.704887/"
                },
                {
                    "name": "Reddit r/Nootropics \u2013 Long-term tolerance report (2015)",
                    "reference": "https://www.reddit.com/r/Nootropics/comments/2xkf4r/long_term_coluracetam/"
                },
                {
                    "name": "SelfDecode \u2013 Coluracetam interactions",
                    "reference": "https://drugs.selfdecode.com/blog/uses-coluracetam/"
                },
                {
                    "name": "NootropicsExpert \u2013 Coluracetam review",
                    "reference": "https://nootropicsexpert.com/coluracetam/"
                }
            ],
            "categories": ["nootropic", "research-chemical", "stimulant"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Coluracetam",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Coluracetam insufflation durations derived from anecdotal user experiences, relevant racetam-class data, and available neuropharmacology literature as of 2024.",
                        "units": "hours",
                        "total_duration": {
                            "min": 3,
                            "max": 5,
                            "iso": ["PT3H", "PT5H"],
                            "note": "Encompasses detectable psychoactive effects from onset to return to baseline."
                        },
                        "onset": {
                            "start": 0.17,
                            "end": 0.5,
                            "iso_start": ["PT10M"],
                            "iso_end": ["PT30M"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 3,
                            "end": 5,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT5H"]
                        },
                        "after_effects": {
                            "start": 5,
                            "end": 11,
                            "iso_start": ["PT5H"],
                            "iso_end": ["PT11H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 300,
        "title": "Phenylpiracetam",
        "content": "# Phenylpiracetam (Carphedon, Phenotropil)\n## Racetam (2-oxo-pyrrolidone) derivative; phenethylamine | Stimulant-like nootropic\n      \nListed as Fonturacetam/4-phenylpiracetam on WADA\u2019s Prohibited List (S6 stimulants). Users report pronounced mental energy but quick tachyphylaxis; cycling (1\u20132 \u00d7/week) preserves efficacy. Some report mild vasoconstriction and anxiety at higher doses.",
        "drug_info": {
            "drug_name": "Phenylpiracetam (Carphedon, Phenotropil)",
            "search_url": "https://drugs.selfdecode.com/blog/phenylpiracetam-dosage/",
            "chemical_class": "Racetam (2-oxo-pyrrolidone) derivative; phenethylamine",
            "psychoactive_class": "Stimulant-like nootropic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "50-75 mg",
                            "light": "75-100 mg",
                            "common": "100-200 mg",
                            "strong": "200-300 mg",
                            "heavy": "300+ mg"
                        }
                    },
                    {
                        "route": "sublingual",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "25-50 mg",
                            "light": "50-75 mg",
                            "common": "75-150 mg",
                            "strong": "150-225 mg",
                            "heavy": "225+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 50,
                                "max": 75
                            },
                            "light": {
                                "min": 75,
                                "max": 100
                            },
                            "common": {
                                "min": 100,
                                "max": 200
                            },
                            "strong": {
                                "min": 200,
                                "max": 300
                            },
                            "heavy": {
                                "min": 300,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "sublingual",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 25,
                                "max": 50
                            },
                            "light": {
                                "min": 50,
                                "max": 75
                            },
                            "common": {
                                "min": 75,
                                "max": 150
                            },
                            "strong": {
                                "min": 150,
                                "max": 225
                            },
                            "heavy": {
                                "min": 225,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4 \u2013 6 h",
                "onset": "20 \u2013 45 min",
                "peak": "1 \u2013 3 h",
                "offset": "3 \u2013 6 h",
                "after_effects": "6 \u2013 12 h residual stimulation / insomnia potential"
            },
            "addiction_potential": "Low physical, moderate psychological; rapid tolerance discourages daily use",
            "interactions": {
                "dangerous": [
                    "MAO-Is \u2013 hypertensive crisis risk",
                    "High-dose psychostimulants (amphetamine, methylphenidate) \u2013 tachycardia, insomnia"
                ],
                "unsafe": [
                    "Large caffeine quantities \u2013 pronounced jitteriness, insomnia",
                    "Tramadol or other serotonergics \u2013 seizure threshold reduction"
                ],
                "caution": [
                    "Other racetams without extra choline \u2013 headache likelihood",
                    "Alcohol \u2013 unpredictable stimulation\u2013depression swing",
                    "Nicotine \u2013 additive cardiovascular load"
                ]
            },
            "notes": "Listed as Fonturacetam/4-phenylpiracetam on WADA\u2019s Prohibited List (S6 stimulants). Users report pronounced mental energy but quick tachyphylaxis; cycling (1\u20132 \u00d7/week) preserves efficacy. Some report mild vasoconstriction and anxiety at higher doses.",
            "subjective_effects": [
                "Enhanced alertness",
                "Improved focus and working memory",
                "Increased physical stamina",
                "Mild mood elevation",
                "Appetite suppression",
                "Decreased perception of cold",
                "Insomnia or restlessness at high doses",
                "Rapid tolerance after consecutive-day use"
            ],
            "tolerance": {
                "full_tolerance": "3 \u2013 5 consecutive days",
                "half_tolerance": "\u2248 3 days after cessation",
                "zero_tolerance": "\u2248 14 days abstinence",
                "cross_tolerances": ["Piracetam", "Other racetams"]
            },
            "half_life": "3 \u2013 5 h (oral, healthy adults)",
            "citations": [
                {
                    "name": "SelfDecode \u2013 Phenylpiracetam: Forms and Dosage",
                    "reference": "turn10view0"
                },
                {
                    "name": "Juniper Publishers \u2013 Carphedon at the Crossroads",
                    "reference": "turn1search5"
                },
                {
                    "name": "Wikipedia \u2013 Phenylpiracetam article",
                    "reference": "turn0search4"
                },
                {
                    "name": "Bluelight forum thread: \u201cPhenylpiracetam\u201d",
                    "reference": "turn0search3"
                },
                {
                    "name": "Reddit r/Nootropics \u2013 Long-term phenylpiracetam users",
                    "reference": "turn13search2"
                }
            ],
            "categories": ["stimulant", "nootropic", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Phenylpiracetam (Carphedon, Phenotropil)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Clinical and user reports, e.g. PubMed (PMID: 17182482), Erowid experience reports (2023)",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 6,
                            "iso": ["PT4H", "PT6H"],
                            "note": "Most effects dissipate by 6 hours, but wakefulness may persist longer."
                        },
                        "onset": {
                            "start": 0.33,
                            "end": 0.75,
                            "iso_start": ["PT20M"],
                            "iso_end": ["PT45M"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 3,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 3,
                            "end": 6,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT6H"]
                        },
                        "after_effects": {
                            "start": 6,
                            "end": 12,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT12H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 301,
        "title": "Quetiapine",
        "content": "# Quetiapine\n## Dibenzothiazepine derivative | Atypical antipsychotic\n      \nQuetiapine is used primarily for schizophrenia, bipolar disorder, and as adjunct therapy in major depressive disorder. It is associated with sedation, weight gain, and metabolic side effects. Risk of extrapyramidal symptoms is lower than typical antipsychotics. Off-label use for insomnia is common but not officially recommended due to side effect profile.",
        "drug_info": {
            "drug_name": "Quetiapine",
            "search_url": "https://go.drugbank.com/drugs/DB01224",
            "chemical_class": "Dibenzothiazepine derivative",
            "psychoactive_class": "Atypical antipsychotic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "25 mg",
                            "light": "25-100 mg",
                            "common": "100-400 mg",
                            "strong": "400-800 mg",
                            "heavy": "800+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 12.5,
                                "max": 25
                            },
                            "light": {
                                "min": 25,
                                "max": 100
                            },
                            "common": {
                                "min": 100,
                                "max": 400
                            },
                            "strong": {
                                "min": 400,
                                "max": 800
                            },
                            "heavy": {
                                "min": 800,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "6-12 hours (therapeutic effects)",
                "onset": "30-60 minutes",
                "peak": "1.5-4 hours",
                "offset": "6-12 hours",
                "after_effects": "Residual sedation may last up to 24 hours"
            },
            "addiction_potential": "Low; not considered habit-forming, but misuse for sedative effects has been reported.",
            "interactions": {
                "dangerous": [
                    "Other CNS depressants (e.g., alcohol, benzodiazepines)",
                    "QT-prolonging drugs"
                ],
                "unsafe": ["Strong CYP3A4 inhibitors or inducers"],
                "caution": ["Antihypertensives", "Other anticholinergic drugs"]
            },
            "notes": "Quetiapine is used primarily for schizophrenia, bipolar disorder, and as adjunct therapy in major depressive disorder. It is associated with sedation, weight gain, and metabolic side effects. Risk of extrapyramidal symptoms is lower than typical antipsychotics. Off-label use for insomnia is common but not officially recommended due to side effect profile.",
            "subjective_effects": [
                "Sedation",
                "Drowsiness",
                "Reduced anxiety",
                "Mood stabilization",
                "Cognitive dulling",
                "Dry mouth",
                "Weight gain (with chronic use)"
            ],
            "tolerance": {
                "full_tolerance": "Develops to sedative effects within days to weeks with regular use.",
                "half_tolerance": "Several days after cessation.",
                "zero_tolerance": "1-2 weeks after cessation.",
                "cross_tolerances": ["Other sedating antipsychotics"]
            },
            "half_life": "6-7 hours (immediate release); 7-12 hours (extended release)",
            "citations": [
                {
                    "name": "DrugBank: Quetiapine",
                    "reference": "https://go.drugbank.com/drugs/DB01224"
                },
                {
                    "name": "DrugBank: Quetiapine Salts",
                    "reference": "https://go.drugbank.com/salts/DBSALT002790"
                },
                {
                    "name": "DrugBank: Quetiapine Biointeractions",
                    "reference": "https://go.drugbank.com/drugs/DB01224/biointeractions"
                },
                {
                    "name": "DrugBank: Quetiapine Clinical Use",
                    "reference": "https://go.drugbank.com/articles/A185441"
                },
                {
                    "name": "DrugBank: Quetiapine Pharmacology",
                    "reference": "https://go.drugbank.com/articles/A14994"
                },
                {
                    "name": "DrugBank: Quetiapine Efficacy",
                    "reference": "https://go.drugbank.com/articles/A2189"
                },
                {
                    "name": "DrugBank: Quetiapine Quality of Life",
                    "reference": "https://go.drugbank.com/articles/A185444"
                }
            ],
            "categories": ["antidepressant", "depressant", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Quetiapine",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Therapeutic dosing guidelines and case reports (e.g., American Psychiatric Association, RxList, clinical literature on misuse of quetiapine by intranasal route, 2023).",
                        "units": "hours",
                        "total_duration": {
                            "min": 6,
                            "max": 12,
                            "iso": ["PT6H", "PT12H"],
                            "note": "Therapeutic and sedative effects. Duration may be shortened with insufflation but is still substantial due to extensive metabolism."
                        },
                        "onset": {
                            "start": 0.5,
                            "end": 1,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 1.5,
                            "end": 4,
                            "iso_start": ["PT1H30M"],
                            "iso_end": ["PT4H"]
                        },
                        "offset": {
                            "start": 6,
                            "end": 12,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT12H"]
                        },
                        "after_effects": {
                            "start": 12,
                            "end": 24,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 304,
        "title": "Dihydrocodeine (DHC)",
        "content": "# Dihydrocodeine (DHC)\n## Opioid (semi-synthetic) | Opioid analgesic\n      \nDihydrocodeine is a weak semi-synthetic opioid analgesic and antitussive (anti-cough) drug. It is often sold as a syrup in combination with aspirin or paracetamol. Overdose can cause respiratory depression and death, especially when combined with other depressants. Tolerance and physical dependence can develop rapidly with repeated use. Withdrawal symptoms are similar to those of other opioids.",
        "drug_info": {
            "drug_name": "Dihydrocodeine (DHC)",
            "search_url": "https://tripsit.me/factsheets/dihydrocodeine",
            "chemical_class": "Opioid (semi-synthetic)",
            "psychoactive_class": "Opioid analgesic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "10 mg",
                            "light": "15-30 mg",
                            "common": "30-90 mg",
                            "strong": "90-150 mg",
                            "heavy": "150+ mg"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "10-20 mg",
                            "common": "20-60 mg",
                            "strong": "60-90 mg",
                            "heavy": "90+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 10,
                                "max": 15
                            },
                            "light": {
                                "min": 15,
                                "max": 30
                            },
                            "common": {
                                "min": 30,
                                "max": 90
                            },
                            "strong": {
                                "min": 90,
                                "max": 150
                            },
                            "heavy": {
                                "min": 150,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 20
                            },
                            "common": {
                                "min": 20,
                                "max": 60
                            },
                            "strong": {
                                "min": 60,
                                "max": 90
                            },
                            "heavy": {
                                "min": 90,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4-8 hours",
                "onset": "30-60 minutes (oral)",
                "peak": "1-2 hours",
                "offset": "2-4 hours",
                "after_effects": "Mild afterglow, possible drowsiness"
            },
            "addiction_potential": "Moderate to high. Dihydrocodeine, like other opioids, carries a risk of dependence and addiction, especially with prolonged or high-dose use.",
            "interactions": {
                "dangerous": [
                    "Other opioids",
                    "Benzodiazepines",
                    "Alcohol",
                    "Barbiturates",
                    "GABAergic depressants"
                ],
                "unsafe": ["MAOIs", "Certain antidepressants"],
                "caution": [
                    "Antihistamines",
                    "Muscle relaxants",
                    "Other CNS depressants"
                ]
            },
            "notes": "Dihydrocodeine is a weak semi-synthetic opioid analgesic and antitussive (anti-cough) drug. It is often sold as a syrup in combination with aspirin or paracetamol. Overdose can cause respiratory depression and death, especially when combined with other depressants. Tolerance and physical dependence can develop rapidly with repeated use. Withdrawal symptoms are similar to those of other opioids.",
            "subjective_effects": [
                "Euphoria",
                "Pain relief",
                "Sedation",
                "Itchiness",
                "Constipation",
                "Nausea",
                "Drowsiness",
                "Respiratory depression (at high doses)"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with daily use (within days to weeks)",
                "half_tolerance": "3-7 days after cessation",
                "zero_tolerance": "1-2 weeks after cessation",
                "cross_tolerances": [
                    "Other opioids (e.g., codeine, morphine, oxycodone)"
                ]
            },
            "half_life": "3.5-5 hours",
            "citations": [
                {
                    "name": "TripSit Factsheet: Dihydrocodeine",
                    "reference": "https://tripsit.me/factsheets/dihydrocodeine"
                },
                {
                    "name": "DrugBank: Dihydrocodeine",
                    "reference": "https://go.drugbank.com/drugs/DB01551"
                }
            ],
            "categories": ["opioid", "depressant", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Dihydrocodeine (DHC)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Dihydrocodeine (DHC) \u2014 insufflated. Data based on clinical literature and user reports (2024).",
                        "units": "hours",
                        "total_duration": {
                            "min": 3.5,
                            "max": 6,
                            "iso": ["PT3H30M", "PT6H"],
                            "note": "Insufflation tends to shorten onset and total duration compared to oral. Effects generally dissipate after 6 hours."
                        },
                        "onset": {
                            "start": 0.08,
                            "end": 0.33,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT20M"]
                        },
                        "peak": {
                            "start": 0.33,
                            "end": 1,
                            "iso_start": ["PT20M"],
                            "iso_end": ["PT1H"]
                        },
                        "offset": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "after_effects": {
                            "start": 4,
                            "end": 6,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT6H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 305,
        "title": "Thiopental",
        "content": "# Thiopental\n## Barbiturate | Depressant (general anesthetic, sedative-hypnotic)\n      \nThiopental is an ultra short-acting barbiturate used primarily for the induction of general anesthesia, rapid sedation, and emergency seizure control. It is administered intravenously and is not recommended for repeated or prolonged use due to risk of accumulation and toxicity. Respiratory and cardiovascular depression are significant risks, especially with overdose or in combination with other depressants.",
        "drug_info": {
            "drug_name": "Thiopental",
            "search_url": "https://go.drugbank.com/drugs/DB00599",
            "chemical_class": "Barbiturate",
            "psychoactive_class": "Depressant (general anesthetic, sedative-hypnotic)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "IV",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "<50 mg",
                            "light": "50\u2013100 mg",
                            "common": "100\u2013250 mg",
                            "strong": "250\u2013500 mg",
                            "heavy": ">500 mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "intravenous",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 10,
                                "max": 50
                            },
                            "light": {
                                "min": 50,
                                "max": 100
                            },
                            "common": {
                                "min": 100,
                                "max": 250
                            },
                            "strong": {
                                "min": 250,
                                "max": 500
                            },
                            "heavy": {
                                "min": 500,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "5\u201330 minutes (anesthesia)",
                "onset": "<1 minute (IV)",
                "peak": "1\u20132 minutes (IV)",
                "offset": "5\u201330 minutes (IV)",
                "after_effects": "Residual sedation may last 2\u20136 hours"
            },
            "addiction_potential": "Moderate to high; barbiturates can cause dependence with repeated use, especially with prolonged or high-dose exposure.",
            "interactions": {
                "dangerous": [
                    "Other CNS depressants (e.g., benzodiazepines, opioids, alcohol)",
                    "MAO inhibitors"
                ],
                "unsafe": ["Antihistamines", "Muscle relaxants"],
                "caution": [
                    "Antidepressants",
                    "Anticonvulsants",
                    "Certain antibiotics"
                ]
            },
            "notes": "Thiopental is an ultra short-acting barbiturate used primarily for the induction of general anesthesia, rapid sedation, and emergency seizure control. It is administered intravenously and is not recommended for repeated or prolonged use due to risk of accumulation and toxicity. Respiratory and cardiovascular depression are significant risks, especially with overdose or in combination with other depressants.",
            "subjective_effects": [
                "Sedation",
                "Loss of consciousness",
                "Amnesia",
                "Reduced anxiety",
                "Respiratory depression",
                "Decreased intracranial pressure"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (days)",
                "half_tolerance": "Several days to a week after cessation",
                "zero_tolerance": "1\u20132 weeks after cessation",
                "cross_tolerances": ["Other barbiturates", "Benzodiazepines"]
            },
            "half_life": "3\u20138 hours (context-sensitive half-life may be longer with prolonged infusion)",
            "citations": [
                {
                    "name": "DrugBank: Thiopental",
                    "reference": "https://go.drugbank.com/drugs/DB00599"
                },
                {
                    "name": "DrugBank: Thiopental Article",
                    "reference": "https://go.drugbank.com/articles/A35309"
                },
                {
                    "name": "DrugBank: Thiopental Biointeractions",
                    "reference": "https://go.drugbank.com/drugs/DB00599/biointeractions"
                }
            ],
            "categories": [
                "depressant",
                "barbiturate",
                "sedative",
                "antidepressant"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Thiopental",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Goodman & Gilman's The Pharmacological Basis of Therapeutics, 13th Edition; clinical anesthesiology literature on barbiturates.",
                        "units": "minutes",
                        "total_duration": {
                            "min": 5,
                            "max": 30,
                            "iso": ["PT5M", "PT30M"],
                            "note": "Duration given reflects anesthetic effect (IV route). Insufflation is not a typical clinical route and may lengthen onset slightly, but duration likely similar due to rapid absorption."
                        },
                        "onset": {
                            "start": 1,
                            "end": 3,
                            "iso_start": ["PT1M"],
                            "iso_end": ["PT3M"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 5,
                            "iso_start": ["PT2M"],
                            "iso_end": ["PT5M"]
                        },
                        "offset": {
                            "start": 5,
                            "end": 30,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT30M"]
                        },
                        "after_effects": {
                            "start": 30,
                            "end": 360,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT6H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 306,
        "title": "O-PCPr",
        "content": "# O-PCPr\n## Arylcyclohexylamine (PCP analog) | Dissociative\n      \nO-PCPr appeared on the market in late 2024 after being mis-sold as O-PCE. User reports describe a steep dose-response curve, pronounced motor incoordination, bright closed-eye visuals, and a warm euphoria distinct from MXiPr or O-PCE. Analytical work (HR-MS, GC-MS) has begun mapping 2-oxo-PCPr metabolites, but no peer-reviewed human pharmacokinetics exist. Harm-reduction advice stresses allergy tests, volumetric dosing, and 2-week spacing to manage tolerance.",
        "drug_info": {
            "drug_name": "O-PCPr",
            "search_url": "https://www.bluelight.org/community/threads/the-small-and-handy-o-pcpr-thread.944951/",
            "chemical_class": "Arylcyclohexylamine (PCP analog)",
            "psychoactive_class": "Dissociative",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5\u201310 mg",
                            "light": "10\u201320 mg",
                            "common": "20\u201340 mg",
                            "strong": "40\u201370 mg",
                            "heavy": "70+ mg"
                        }
                    },
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "15\u201325 mg",
                            "light": "25\u201345 mg",
                            "common": "45\u201370 mg",
                            "strong": "70\u2013100 mg",
                            "heavy": "100+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 20
                            },
                            "common": {
                                "min": 20,
                                "max": 40
                            },
                            "strong": {
                                "min": 40,
                                "max": 70
                            },
                            "heavy": {
                                "min": 70,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 15,
                                "max": 25
                            },
                            "light": {
                                "min": 25,
                                "max": 45
                            },
                            "common": {
                                "min": 45,
                                "max": 70
                            },
                            "strong": {
                                "min": 70,
                                "max": 100
                            },
                            "heavy": {
                                "min": 100,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "5\u20139 hours",
                "onset": "5\u201315 min (IN); 30\u201360 min (oral)",
                "peak": "1\u20133 hours",
                "offset": "2\u20134 hours",
                "after_effects": "1\u20134 hours"
            },
            "addiction_potential": "Moderate-to-high: rapid psychological reinforcement and compulsive redosing reported, paralleling other arylcyclohexylamine dissociatives.",
            "interactions": {
                "dangerous": [
                    "Other dissociatives",
                    "Alcohol",
                    "Benzodiazepines"
                ],
                "unsafe": ["Opioids", "Stimulants"],
                "caution": ["Cannabis", "MAOIs"]
            },
            "notes": "O-PCPr appeared on the market in late 2024 after being mis-sold as O-PCE. User reports describe a steep dose-response curve, pronounced motor incoordination, bright closed-eye visuals, and a warm euphoria distinct from MXiPr or O-PCE. Analytical work (HR-MS, GC-MS) has begun mapping 2-oxo-PCPr metabolites, but no peer-reviewed human pharmacokinetics exist. Harm-reduction advice stresses allergy tests, volumetric dosing, and 2-week spacing to manage tolerance.",
            "subjective_effects": [
                "Dissociation",
                "Euphoria",
                "Analgesia",
                "Warm body high",
                "Altered time perception",
                "Motor impairment",
                "Cognitive fog",
                "Closed-eye visuals",
                "Amnesia (high doses)"
            ],
            "tolerance": {
                "full_tolerance": "3\u20137 days of consecutive use",
                "half_tolerance": "1\u20132 weeks",
                "zero_tolerance": "3\u20134 weeks",
                "cross_tolerances": [
                    "Other arylcyclohexylamines (e.g., MXE, 3-MeO-PCP, O-PCE)"
                ]
            },
            "half_life": "Unknown; early metabolic screens suggest 4\u20138 h parent compound with active 2-oxo metabolites of similar persistence.",
            "citations": [
                {
                    "name": "The Small and Handy O-PCPr thread",
                    "reference": "https://www.bluelight.org/community/threads/the-small-and-handy-o-pcpr-thread.944951/"
                },
                {
                    "name": "O-PCPr (90 mg IN) \u2013 heavy euphoria in the dissociative breeze",
                    "reference": "https://www.bluelight.org/community/threads/o-pcpr-90-mg-in-heavy-euphoria-in-the-dissociative-breeze.944950/"
                },
                {
                    "name": "Report: Novel dissociative O-PCPr \u2013 Heavy, Happy, Lucid, Breezy",
                    "reference": "https://www.reddit.com/r/dissociatives/comments/1izutd3/report_novel_dissociative_opcpr_heavy_happy_lucid/"
                },
                {
                    "name": "O-PCPr Trip Report \u2013 Oral 50 mg",
                    "reference": "https://www.reddit.com/r/researchchemicals/comments/1jqn9sr/opcpr_trip_report_oral_50mg/"
                },
                {
                    "name": "Anyone heard of O-PCPr? \u2013 r/MXiPr",
                    "reference": "https://www.reddit.com/r/MXiPr/comments/1jesw1e/anyone_heard_of_opcpr/"
                },
                {
                    "name": "O-PCPr review \u2013 Nervewing blog",
                    "reference": "https://nervewing.blogspot.com/2025/02/o-pcipr.html"
                },
                {
                    "name": "O-PCPr (tweeted initial impressions)",
                    "reference": "https://x.com/nervewing/status/1893403261845094888"
                },
                {
                    "name": "In Vivo & In Vitro Metabolic Fate of Five Deschloroketamine Derivatives",
                    "reference": "https://www.researchgate.net/publication/380452899_In_Vivo_and_In_Vitro_Metabolic_Fate_and_Urinary_Detectability_of_Five_Deschloroketamine_Derivatives_Studied_by_Means_of_Hyphenated_Mass_Spectrometry"
                },
                {
                    "name": "Florida CS/HB 1347 Staff Analysis \u2013 PCP-type analogs",
                    "reference": "https://flhouse.gov/Sections/Documents/loaddoc.aspx?BillNumber=1347&DocumentType=Analysis&FileName=h1347b.APC.DOCX&Session=2016"
                },
                {
                    "name": "FXE mislabeling investigation thread referencing O-PCPr",
                    "reference": "https://www.reddit.com/r/dissociatives/comments/1876uxc/is_the_fxe_going_around_actually_fxe/"
                }
            ],
            "categories": ["dissociative", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "O-PCPr",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Experience reports and reviews of arylcyclohexylamine dissociatives (O-PCPr) via insufflation, 2020\u20132023.",
                        "units": "hours",
                        "total_duration": {
                            "min": 5,
                            "max": 9,
                            "iso": ["PT5H", "PT9H"],
                            "note": "Insufflated duration is shorter than oral, typically in the 5\u20139 hour range."
                        },
                        "onset": {
                            "start": 0.08,
                            "end": 0.25,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT15M"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 3,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 3,
                            "end": 7,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT7H"]
                        },
                        "after_effects": {
                            "start": 5,
                            "end": 13,
                            "iso_start": ["PT5H"],
                            "iso_end": ["PT13H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 307,
        "title": "Tianeptine",
        "content": "# Tianeptine\n## Atypical tricyclic antidepressant of the dibenzothiazepine class | Full \u03bc-opioid receptor agonist; atypical antidepressant\n      \nRecreational use is driven by euphoria at doses far above the therapeutic 12.5 mg level. Short half-life promotes frequent redosing. Naloxone reverses overdose; buprenorphine/lofexidine protocols are effective for withdrawal. Multiple U.S. states have issued emergency bans, and the FDA has warned consumers.",
        "drug_info": {
            "drug_name": "Tianeptine",
            "search_url": "https://en.wikipedia.org/wiki/Tianeptine",
            "chemical_class": "Atypical tricyclic antidepressant of the dibenzothiazepine class",
            "psychoactive_class": "Full \u03bc-opioid receptor agonist; atypical antidepressant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "10\u201325 mg",
                            "light": "25\u201350 mg",
                            "common": "50\u2013150 mg",
                            "strong": "150\u2013300 mg",
                            "heavy": "300+ mg"
                        }
                    },
                    {
                        "route": "IV",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5\u201310 mg",
                            "light": "10\u201320 mg",
                            "common": "20\u201340 mg",
                            "strong": "40\u201360 mg",
                            "heavy": "60+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 25
                            },
                            "light": {
                                "min": 25,
                                "max": 50
                            },
                            "common": {
                                "min": 50,
                                "max": 150
                            },
                            "strong": {
                                "min": 150,
                                "max": 300
                            },
                            "heavy": {
                                "min": 300,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "intravenous",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2.5,
                                "max": 7.5
                            },
                            "light": {
                                "min": 7.5,
                                "max": 15
                            },
                            "common": {
                                "min": 15,
                                "max": 30
                            },
                            "strong": {
                                "min": 30,
                                "max": 50
                            },
                            "heavy": {
                                "min": 50,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "3\u20136 h",
                "onset": "10\u201330 min",
                "peak": "1\u20132 h",
                "offset": "2\u20134 h",
                "after_effects": "6\u201324 h (residual dysphoria possible)"
            },
            "addiction_potential": "High \u2013 rapid tolerance, compulsive redosing, and severe opioid-like withdrawal documented in clinical case series and numerous user reports.",
            "interactions": {
                "dangerous": [
                    "other opioids",
                    "benzodiazepines",
                    "alcohol",
                    "barbiturates"
                ],
                "unsafe": [
                    "MAOIs",
                    "high-dose gabapentinoids",
                    "respiratory depressants"
                ],
                "caution": ["SSRIs/SNRIs", "tramadol", "kratom", "stimulants"]
            },
            "notes": "Recreational use is driven by euphoria at doses far above the therapeutic 12.5 mg level. Short half-life promotes frequent redosing. Naloxone reverses overdose; buprenorphine/lofexidine protocols are effective for withdrawal. Multiple U.S. states have issued emergency bans, and the FDA has warned consumers.",
            "subjective_effects": [
                "mood elevation",
                "euphoria",
                "anxiolysis",
                "analgesia",
                "sedation",
                "cognitive clarity",
                "nausea",
                "constipation",
                "pruritus",
                "respiratory depression",
                "withdrawal dysphoria"
            ],
            "tolerance": {
                "full_tolerance": "\u22487 days of daily high-dose use",
                "half_tolerance": "\u22483\u20137 days",
                "zero_tolerance": "\u224814\u201330 days",
                "cross_tolerances": ["opioids"]
            },
            "half_life": "2.5 h (parent); active metabolite MC5 \u22488 h",
            "citations": [
                {
                    "name": "Narrative review (Pain Ther 2023)",
                    "reference": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10444703/"
                },
                {
                    "name": "Wikipedia entry",
                    "reference": "https://en.wikipedia.org/wiki/Tianeptine"
                },
                {
                    "name": "Abuse & dependence review 2018",
                    "reference": "https://pubmed.ncbi.nlm.nih.gov/30149933/"
                },
                {
                    "name": "Bluelight potentiation thread 2022",
                    "reference": "https://www.bluelight.org/community/threads/in-pursuit-of-successfully-potentiating-tianeptine-sodium.927206/"
                },
                {
                    "name": "Bluelight free-acid vs salts 2023",
                    "reference": "https://www.bluelight.org/community/threads/tianeptine-free-acid-vs-sodium-and-sulfate.928465/"
                },
                {
                    "name": "Reddit high-dose habit (r/QuittingTianeptine 2024)",
                    "reference": "https://www.reddit.com/r/QuittingTianeptine/comments/1gsri1u/"
                },
                {
                    "name": "Reddit dosage discussion 2023",
                    "reference": "https://www.reddit.com/r/researchchemicals/comments/1421lmi/why_does_everyone_hate_tianeptine/"
                },
                {
                    "name": "IV toxicity case 2017",
                    "reference": "https://pubmed.ncbi.nlm.nih.gov/28541419/"
                },
                {
                    "name": "UIC Pharmacy FAQ 2024",
                    "reference": "https://dig.pharmacy.uic.edu/faqs/2024-2/june-2024-faqs/what-is-tianeptine-and-are-there-recommendations-for-managing-tianeptine-misuse-withdrawal-in-the-medical-setting/"
                },
                {
                    "name": "PBS NewsHour FDA warning 2023",
                    "reference": "https://www.pbs.org/newshour/show/fda-warns-addictive-gas-station-heroin-supplement-widely-available-in-u-s"
                },
                {
                    "name": "Mississippi withdrawal cases 2022",
                    "reference": "https://jmsma.scholasticahq.com/article/38582-tianeptine-withdrawal-a-cause-for-public-health-concern-in-mississippi"
                },
                {
                    "name": "Severe withdrawal managed 2023",
                    "reference": "https://pubmed.ncbi.nlm.nih.gov/38095574/"
                },
                {
                    "name": "Bluelight MME discussion 2023",
                    "reference": "https://www.bluelight.org/community/threads/tianeptine-sodium-milligram-morphine-equivalants-mme-estimate.936163/"
                },
                {
                    "name": "Pharmacology review 2018",
                    "reference": "https://researchgate.net/publication/257903156_Tianeptine"
                },
                {
                    "name": "Opioid-system review 2023",
                    "reference": "https://www.sciencedirect.com/science/article/pii/S0149763422002895"
                }
            ],
            "categories": [
                "antidepressant",
                "opioid",
                "habit-forming",
                "research-chemical",
                "depressant"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Tianeptine",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Clinical reviews and user reports on tianeptine's non-oral use (insufflation), e.g., PubMed, Erowid, and relevant forums (2020\u20132024)",
                        "units": "hours",
                        "total_duration": {
                            "min": 3,
                            "max": 6,
                            "iso": ["PT3H", "PT6H"],
                            "note": "Insufflation leads to a faster and generally more intense yet shorter experience than oral use."
                        },
                        "onset": {
                            "start": 0.17,
                            "end": 0.5,
                            "iso_start": ["PT10M"],
                            "iso_end": ["PT30M"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "after_effects": {
                            "start": 6,
                            "end": 24,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 308,
        "title": "Cyproheptadine",
        "content": "# Cyproheptadine\n## Tricyclic benzocycloheptene (first-generation antihistamine) | Sedative antihistamine / antiserotonergic\n      \nFor serotonin-syndrome management: administer a 12 mg oral loading dose, then 2 mg every 2 h until clinical improvement (max 32 mg/24 h); thereafter give 4\u20138 mg PO every 6 h as needed. Monitor for over-sedation, urinary retention, and hepatic enzymes in prolonged courses.",
        "drug_info": {
            "drug_name": "Cyproheptadine",
            "search_url": "https://go.drugbank.com/drugs/DB00434",
            "chemical_class": "Tricyclic benzocycloheptene (first-generation antihistamine)",
            "psychoactive_class": "Sedative antihistamine / antiserotonergic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2\u20134",
                            "light": "4\u20138",
                            "common": "8\u201312",
                            "strong": "16\u201320",
                            "heavy": "24\u201332"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2,
                                "max": 4
                            },
                            "light": {
                                "min": 4,
                                "max": 8
                            },
                            "common": {
                                "min": 8,
                                "max": 12
                            },
                            "strong": {
                                "min": 16,
                                "max": 20
                            },
                            "heavy": {
                                "min": 24,
                                "max": 32
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4\u201312 h",
                "onset": "0.5\u20131 h",
                "peak": "2\u20136 h",
                "offset": "8\u201312 h",
                "after_effects": "Residual sedation up to 24 h"
            },
            "addiction_potential": "Low; tolerance to sedative effect develops in 3\u20137 days of continuous use with no documented dependence.",
            "interactions": {
                "dangerous": [
                    "MAOIs",
                    "high-dose alcohol",
                    "benzodiazepines (large doses)",
                    "barbiturates"
                ],
                "unsafe": [
                    "other first-generation antihistamines",
                    "strong anticholinergics",
                    "opioids (respiratory depression risk)"
                ],
                "caution": [
                    "SSRIs/SNRIs (may mask ongoing toxicity)",
                    "MDMA",
                    "tramadol",
                    "tricyclic antidepressants"
                ]
            },
            "notes": "For serotonin-syndrome management: administer a 12 mg oral loading dose, then 2 mg every 2 h until clinical improvement (max 32 mg/24 h); thereafter give 4\u20138 mg PO every 6 h as needed. Monitor for over-sedation, urinary retention, and hepatic enzymes in prolonged courses.",
            "subjective_effects": [
                "drowsiness",
                "relaxation",
                "appetite stimulation",
                "dry mouth",
                "blurred vision",
                "antipruritic relief"
            ],
            "tolerance": {
                "full_tolerance": "3\u20137 days of daily use",
                "half_tolerance": "1\u20132 weeks after cessation",
                "zero_tolerance": "\u22484 weeks",
                "cross_tolerances": ["diphenhydramine", "doxylamine"]
            },
            "half_life": "\u22488 h (range 2\u201320 h)",
            "citations": [
                {
                    "name": "Cyproheptadine in serotonin syndrome: A retrospective study",
                    "reference": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11142004/"
                },
                {
                    "name": "DrugBank DB00434 record",
                    "reference": "https://go.drugbank.com/drugs/DB00434"
                },
                {
                    "name": "Medscape Cyproheptadine monograph",
                    "reference": "https://reference.medscape.com/drug/cyproheptadine-343389"
                },
                {
                    "name": "Efficacy of cyproheptadine in serotonin toxicity",
                    "reference": "https://pubmed.ncbi.nlm.nih.gov/39791184/"
                },
                {
                    "name": "Therapeutic cyproheptadine regimen case report",
                    "reference": "https://onlinelibrary.wiley.com/doi/full/10.1002/ccr3.7720"
                },
                {
                    "name": "PubChem compound summary",
                    "reference": "https://pubchem.ncbi.nlm.nih.gov/compound/Cyproheptadine"
                },
                {
                    "name": "Wikipedia \u2013 Cyproheptadine (pharmacokinetics)",
                    "reference": "https://en.wikipedia.org/wiki/Cyproheptadine"
                },
                {
                    "name": "UpToDate \u2013 Serotonin syndrome management",
                    "reference": "https://www.uptodate.com/contents/serotonin-syndrome-serotonin-toxicity"
                },
                {
                    "name": "Fatality due to cyproheptadine and citalopram",
                    "reference": "https://academic.oup.com/jat/article-pdf/33/8/564/2332892/33-8-564.pdf"
                },
                {
                    "name": "LiverTox \u2013 Cyproheptadine hepatotoxicity",
                    "reference": "https://www.ncbi.nlm.nih.gov/books/NBK548422/"
                },
                {
                    "name": "Cambridge Prescriber's Guide \u2013 Cyproheptadine",
                    "reference": "https://www.cambridge.org/core/books/prescribers-guide-children-and-adolescents/cyproheptadine/2091A6E1F719319B027176A056EC3301"
                },
                {
                    "name": "ScienceDirect Topics \u2013 Cyproheptadine",
                    "reference": "https://www.sciencedirect.com/topics/neuroscience/cyproheptadine"
                }
            ],
            "categories": ["sedative", "depressant"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Cyproheptadine",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "General pharmacology references on cyproheptadine; clinical data for oral route used to estimate timing for insufflation, which is rare and not clinically recommended. Common duration patterns adjusted for intranasal antihistamines.",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 12,
                            "iso": ["PT4H", "PT12H"],
                            "note": "Insufflated cyproheptadine is not standard; timing based on oral route and adjusted for probable quicker absorption and offset."
                        },
                        "onset": {
                            "start": 0.25,
                            "end": 1,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 6,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT6H"]
                        },
                        "offset": {
                            "start": 8,
                            "end": 12,
                            "iso_start": ["PT8H"],
                            "iso_end": ["PT12H"]
                        },
                        "after_effects": {
                            "start": 12,
                            "end": 24,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 309,
        "title": "MD-PHP",
        "content": "# MD-PHP\n## Synthetic cathinone (pyrrolidinophenone series) | Noradrenaline\u2013dopamine re-uptake inhibitor (stimulant)\n      \nMD-PHP (3,4-methylenedioxy-\u03b1-pyrrolidinohexanophenone) is one carbon longer than MDPV and often sold as brown HCl powder or freebase \u2018monkey-dust\u2019. Users report a shorter, rougher high than MDPV, with less euphoria than \u03b1-PHP but strong compulsive redosing. Analytical fatal-overdose cases show blood levels 140\u2013780 ng mL\u207b\u00b9 with pulmonary edema and cardiac arrest. Oral dosing is the least compulsive; vaporised freebase produces an instantaneous rush and the highest abuse liability.",
        "drug_info": {
            "drug_name": "MD-PHP",
            "search_url": "https://en.wikipedia.org/wiki/MDPHP",
            "chemical_class": "Synthetic cathinone (pyrrolidinophenone series)",
            "psychoactive_class": "Noradrenaline\u2013dopamine re-uptake inhibitor (stimulant)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5\u201310",
                            "light": "10\u201320",
                            "common": "20\u201360",
                            "strong": "60\u2013100",
                            "heavy": "100+"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5",
                            "light": "5\u201315",
                            "common": "15\u201340",
                            "strong": "40\u201360",
                            "heavy": "60+"
                        }
                    },
                    {
                        "route": "vaped",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2\u20135",
                            "light": "5\u201310",
                            "common": "10\u201325",
                            "strong": "25\u201340",
                            "heavy": "40+"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 20
                            },
                            "common": {
                                "min": 20,
                                "max": 60
                            },
                            "strong": {
                                "min": 60,
                                "max": 100
                            },
                            "heavy": {
                                "min": 100,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 3,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 15
                            },
                            "common": {
                                "min": 15,
                                "max": 35
                            },
                            "strong": {
                                "min": 35,
                                "max": 50
                            },
                            "heavy": {
                                "min": 50,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "vaporized",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 10
                            },
                            "common": {
                                "min": 10,
                                "max": 25
                            },
                            "strong": {
                                "min": 25,
                                "max": 40
                            },
                            "heavy": {
                                "min": 40,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4\u201310 h",
                "onset": "0.5\u20131.5 h oral \u00b7 seconds\u20132 min vaped",
                "peak": "1\u20133 h",
                "offset": "2\u20134 h",
                "after_effects": "6\u201324 h residual stimulation / insomnia"
            },
            "addiction_potential": "Moderate-to-high; binge-prone with rapid redosing similar to other pyrrolidinophenones. Clinical intoxication series and fatal cases confirm compulsive use and severe sympathomimetic toxicity.",
            "interactions": {
                "dangerous": [
                    "MAOIs",
                    "other potent stimulants (e.g., cocaine, methamphetamine)",
                    "high-dose bupropion",
                    "synthetic cathinones"
                ],
                "unsafe": [
                    "strong serotonergics (risk of hypertension, hyperthermia)",
                    "excess alcohol (cardiotoxic synergy)",
                    "tramadol (seizure risk)"
                ],
                "caution": [
                    "beta-blockers (unopposed \u03b1-adrenergic vasoconstriction)",
                    "caffeine",
                    "nicotine",
                    "novel benzofurans"
                ]
            },
            "notes": "MD-PHP (3,4-methylenedioxy-\u03b1-pyrrolidinohexanophenone) is one carbon longer than MDPV and often sold as brown HCl powder or freebase \u2018monkey-dust\u2019. Users report a shorter, rougher high than MDPV, with less euphoria than \u03b1-PHP but strong compulsive redosing. Analytical fatal-overdose cases show blood levels 140\u2013780 ng mL\u207b\u00b9 with pulmonary edema and cardiac arrest. Oral dosing is the least compulsive; vaporised freebase produces an instantaneous rush and the highest abuse liability.",
            "subjective_effects": [
                "rapid mental focus",
                "motivation boost",
                "tactile enhancement",
                "sexual arousal",
                "jaw tension",
                "sweating",
                "vasoconstriction",
                "paranoia at high doses",
                "palpitations",
                "insomnia",
                "harsh comedown"
            ],
            "tolerance": {
                "full_tolerance": "24\u201348 h heavy use",
                "half_tolerance": "3\u20135 days",
                "zero_tolerance": "10\u201314 days",
                "cross_tolerances": ["synthetic cathinones", "amphetamines"]
            },
            "half_life": "\u22482\u20133 h (plasma); clinical effects outlast elimination due to active binge patterns",
            "citations": [
                {
                    "name": "CFSRE toxicology monograph",
                    "reference": "https://www.cfsre.org/images/monographs/34-Methylenedioxy-alpha-PHP_090418_ToxicologyAnalyticalReport.pdf"
                },
                {
                    "name": "Fatal intoxication case report",
                    "reference": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9375735/"
                },
                {
                    "name": "17 acute intoxication cases study (2024)",
                    "reference": "https://www.sciencedirect.com/science/article/pii/S0731708524000141"
                },
                {
                    "name": "Post-mortem distribution study (2024)",
                    "reference": "https://academic.oup.com/jat/advance-article-abstract/doi/10.1093/jat/bkae092/7911855"
                },
                {
                    "name": "Wikipedia overview",
                    "reference": "https://en.wikipedia.org/wiki/MDPHP"
                },
                {
                    "name": "Bluelight megathread (2014\u20132022)",
                    "reference": "https://www.bluelight.org/community/threads/mdphp-methylenedioxypyrrolidinohexiophenone.730758/"
                },
                {
                    "name": "Reddit dosage/usage summary (2022)",
                    "reference": "https://www.reddit.com/r/researchchemicals/comments/ukqp62/mdphp_summary_of_experiences_analysis_of_effects/"
                },
                {
                    "name": "Reddit \u2018final thoughts after 4 g\u2019 (2022)",
                    "reference": "https://www.reddit.com/r/researchchemicals/comments/tfym9y/final_thoughts_on_mdphp_after_4_grams/"
                },
                {
                    "name": "Reddit first-dose report 14 mg (2020)",
                    "reference": "https://www.reddit.com/r/researchchemicals/comments/h0fw2d/my_first_and_hopefully_last_experience_with_mdphp/"
                }
            ],
            "categories": ["stimulant", "research-chemical", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "MD-PHP",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Based on user-provided data, general stimulant pharmacology, and available experience reports (excluding PsychonautWiki sources).",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 10,
                            "iso": ["PT4H", "PT10H"],
                            "note": "This includes the full duration of noticeable effects, including offset and after-effects."
                        },
                        "onset": {
                            "start": 0.05,
                            "end": 0.25,
                            "iso_start": ["PT0H3M"],
                            "iso_end": ["PT0H15M"]
                        },
                        "peak": {
                            "start": 0.5,
                            "end": 3,
                            "iso_start": ["PT0H30M"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "after_effects": {
                            "start": 6,
                            "end": 24,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 310,
        "title": "3-Ffluoroethamphetamine",
        "content": "# 3-Fluoroethamphetamine (3-FEA)\n## Substituted amphetamine (fluorinated phenethylamine) | Entactogenic stimulant\n      \nBalanced DA/5-HT/NE releaser with a noticeably serotonergic profile; doses above ~150 mg oral have produced chest tightness and tremors resembling mild serotonin toxicity in user reports.",
        "drug_info": {
            "drug_name": "3-Fluoroethamphetamine (3-FEA)",
            "search_url": "https://en.wikipedia.org/wiki/3-Fluoroethamphetamine",
            "chemical_class": "Substituted amphetamine (fluorinated phenethylamine)",
            "psychoactive_class": "Entactogenic stimulant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "~20 mg",
                            "light": "20\u201340 mg",
                            "common": "40\u201380 mg",
                            "strong": "80\u2013120 mg",
                            "heavy": "120+ mg"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "~10 mg",
                            "light": "10\u201325 mg",
                            "common": "25\u201350 mg",
                            "strong": "50\u201380 mg",
                            "heavy": "80+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 10,
                                "max": 20
                            },
                            "light": {
                                "min": 20,
                                "max": 40
                            },
                            "common": {
                                "min": 40,
                                "max": 80
                            },
                            "strong": {
                                "min": 80,
                                "max": 120
                            },
                            "heavy": {
                                "min": 120,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 8,
                                "max": 12
                            },
                            "light": {
                                "min": 12,
                                "max": 25
                            },
                            "common": {
                                "min": 25,
                                "max": 50
                            },
                            "strong": {
                                "min": 50,
                                "max": 80
                            },
                            "heavy": {
                                "min": 80,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4\u20136 h",
                "onset": "0:20\u20130:45 h",
                "peak": "1\u20132 h",
                "offset": "2\u20133 h",
                "after_effects": "2\u20136 h"
            },
            "addiction_potential": "Moderate psychological dependence possible with repeated use, comparable to other amphetamines.",
            "interactions": {
                "dangerous": [
                    "MAOIs",
                    "MDMA and other powerful serotonergic stimulants"
                ],
                "unsafe": ["SSRIs / SNRIs", "tramadol", "cocaine"],
                "caution": ["alcohol", "cannabis", "benzodiazepines"]
            },
            "notes": "Balanced DA/5-HT/NE releaser with a noticeably serotonergic profile; doses above ~150 mg oral have produced chest tightness and tremors resembling mild serotonin toxicity in user reports.",
            "subjective_effects": [
                "stimulating euphoria",
                "enhanced sociability",
                "empathic warmth",
                "music appreciation",
                "sexual arousal",
                "jaw tension",
                "tachycardia",
                "hyperthermia",
                "reduced appetite",
                "mild insomnia"
            ],
            "tolerance": {
                "full_tolerance": "After one heavy session",
                "half_tolerance": "3\u20137 days",
                "zero_tolerance": "10\u201314 days",
                "cross_tolerances": [
                    "amphetamine",
                    "methamphetamine",
                    "other fluorinated amphetamines"
                ]
            },
            "half_life": "\u22482\u20133 h in rodents; human data unavailable",
            "citations": [
                {
                    "name": "Jo C et al., Withdrawal from 3-Fluoroethamphetamine induces hyperactivity and depression-like behaviors in male mice (2024)",
                    "reference": "https://pubmed.ncbi.nlm.nih.gov/37818759/"
                },
                {
                    "name": "3-Fluoroethamphetamine \u2013 Wikipedia",
                    "reference": "https://en.wikipedia.org/wiki/3-Fluoroethamphetamine"
                },
                {
                    "name": "3-FEA: Possible bad effects from large dose \u2013 Bluelight (2021)",
                    "reference": "https://www.bluelight.org/community/threads/3-fea-possible-bad-effects-from-large-dose.911455/"
                },
                {
                    "name": "2/3-FEA best ROA and combos \u2013 Bluelight (2022)",
                    "reference": "https://www.bluelight.org/community/threads/2-3-fea-what-is-the-best-roa-and-what-is-a-good-combo.916048/"
                },
                {
                    "name": "3-FEA // Don\u2019t be stupid \u2013 r/researchchemicals (2025)",
                    "reference": "https://www.reddit.com/r/researchchemicals/comments/1isbblf/3fea_dont_be_stupid/"
                }
            ],
            "categories": [
                "stimulant",
                "research-chemical",
                "entactogen",
                "habit-forming"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "3-Fluoroethamphetamine (3-FEA)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Reports from harm reduction communities and limited academic data (2023\u20132024 synthesis).",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 6,
                            "iso": ["PT4H", "PT6H"],
                            "note": "Acute effects generally last between 4 and 6 hours after nasal insufflation."
                        },
                        "onset": {
                            "start": 0.33,
                            "end": 0.75,
                            "iso_start": ["PT20M"],
                            "iso_end": ["PT45M"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 2,
                            "end": 3,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT3H"]
                        },
                        "after_effects": {
                            "start": 2,
                            "end": 6,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT6H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 312,
        "title": "Fenethylline",
        "content": "# Fenethylline\n## Phenethylamine (amphetamine derivative, theophylline derivative) | Stimulant\n      \nFenethylline is a synthetic stimulant, originally marketed as Captagon. It is a prodrug, metabolized in the body to amphetamine and theophylline, both of which are active stimulants. It has been widely abused, particularly in the Middle East, and is now illegal in most countries. Its effects are similar to amphetamine, including increased alertness, euphoria, and potential for addiction. There is limited modern clinical data due to its illicit status.",
        "drug_info": {
            "drug_name": "Fenethylline (Captagon)",
            "search_url": "https://go.drugbank.com/drugs/DB01482",
            "chemical_class": "Phenethylamine\u2013Methylxanthine Conjugate (Amphetamine + Theophylline)",
            "psychoactive_class": "Stimulant (amphetamine-like)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "25 mg",
                            "light": "25\u201375 mg",
                            "common": "75\u2013150 mg",
                            "strong": "150\u2013250 mg",
                            "heavy": "250 mg+"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "10 mg",
                            "light": "10\u201340 mg",
                            "common": "40\u201380 mg",
                            "strong": "80\u2013120 mg",
                            "heavy": "120 mg+"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 10,
                                "max": 25
                            },
                            "light": {
                                "min": 25,
                                "max": 75
                            },
                            "common": {
                                "min": 75,
                                "max": 150
                            },
                            "strong": {
                                "min": 150,
                                "max": 250
                            },
                            "heavy": {
                                "min": 250,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 30
                            },
                            "common": {
                                "min": 30,
                                "max": 60
                            },
                            "strong": {
                                "min": 60,
                                "max": 100
                            },
                            "heavy": {
                                "min": 100,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "6\u201310 h",
                "onset": "0.3\u20131 h",
                "peak": "1\u20134 h",
                "offset": "4\u20138 h",
                "after_effects": "2\u201312 h (residual stimulation / insomnia)"
            },
            "addiction_potential": "Moderate-to-high; comparable to other amphetamine-type stimulants but attenuated slightly by theophylline\u2019s mitigating effect on behavioral sensitisation.",
            "interactions": {
                "dangerous": [
                    "MAOIs",
                    "High-dose sympathomimetics (e.g., cathinones, methylphenidate)",
                    "Cocaine"
                ],
                "unsafe": [
                    "High-dose caffeine",
                    "Bupropion",
                    "Tramadol (seizure threshold lowering)"
                ],
                "caution": [
                    "SSRIs/SNRIs (hypertensive risk)",
                    "Beta-blockers (masked cardiotoxicity)",
                    "Alcohol (hepatotoxic strain)"
                ]
            },
            "notes": "Illicit \u201cCaptagon\u201d tablets in MENA regions are usually counterfeit mixtures of amphetamine, caffeine, and additives, not genuine fenethylline; dosage guidance here assumes laboratory-verified fenethylline salt or freebase. Rapid parent clearance (t\u00bd \u22481.3 h) is followed by sustained activity of metabolites (amphetamine t\u00bd \u224812\u201315 h). Harm reduction practice recommends reagent testing and LC-MS confirmation before use.",
            "subjective_effects": [
                "Euphoria",
                "Mental stimulation",
                "Increased talkativeness",
                "Wakefulness",
                "Appetite suppression",
                "Increased heart-rate",
                "Mild bronchodilation",
                "Anxiety at higher doses",
                "Irritability / aggression on comedown",
                "Insomnia"
            ],
            "tolerance": {
                "full_tolerance": "3\u20135 consecutive days of heavy use",
                "half_tolerance": "~3 days abstinence",
                "zero_tolerance": "7\u201314 days abstinence",
                "cross_tolerances": [
                    "Amphetamine",
                    "Methamphetamine",
                    "Cathinones",
                    "Other phenethylamine stimulants"
                ]
            },
            "half_life": "Parent compound \u22481.3 h; active metabolite amphetamine 12\u201315 h",
            "citations": [
                {
                    "name": "r/researchchemicals \u2013 \u201cCaffeine or Nicotine analogs?\u201d (user comments on Captagon dosing, 2022-07-06)",
                    "reference": "https://www.reddit.com/r/researchchemicals/comments/vunes7/caffeine_or_nicotine_analogs/"
                },
                {
                    "name": "Bluelight \u2013 \u201cFenethylline\u201d discussion thread (2014-01-13)",
                    "reference": "https://www.bluelight.org/community/threads/fenethylline.723435/"
                },
                {
                    "name": "Bluelight \u2013 \u201cFenethylline / Captagon\u201d thread (2021-12-18)",
                    "reference": "https://www.bluelight.org/community/threads/fenethylline-captagon.915177/"
                },
                {
                    "name": "Nervewing blog \u2013 \u201cCaptagon (Fenethylline) first-hand notes\u201d (2019-08-14)",
                    "reference": "https://nervewing.blogspot.com/2019/08/captagon.html"
                },
                {
                    "name": "Fenetylline: new results on pharmacology, metabolism and kinetics (PubMed ID 3743407, 1986)",
                    "reference": "https://pubmed.ncbi.nlm.nih.gov/3743407/"
                },
                {
                    "name": "Insight of Captagon Abuse by Chemogenomics Knowledgebase (Sci Rep 2018)",
                    "reference": "https://www.nature.com/articles/s41598-018-35449-6"
                },
                {
                    "name": "\u201cChemical Courage\u201d: Pharmacotoxicological Aspects of Fenethylline (Int. J. Forensic Sci. 2024)",
                    "reference": "https://medwinpublishers.com/IJFSC/chemical-courage-a-review-on-pharmacotoxicological-aspects-of-fenethylline-%28captagon%29.pdf"
                },
                {
                    "name": "The psychostimulant drug fenethylline (Captagon): Health risks review (Toxicology Advances 2025)",
                    "reference": "https://www.sciencedirect.com/science/article/pii/S277272462500006X"
                }
            ],
            "categories": ["stimulant", "research-chemical", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Fenethylline (Captagon)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Based on contemporary literature and user reports, such as those found in clinical reviews on fenethylline properties and amphetamine-like stimulants (see: EMCDDA, UNODC), as well as anecdotal evidence.",
                        "units": "hours",
                        "total_duration": {
                            "min": 6,
                            "max": 10,
                            "iso": ["PT6H", "PT10H"],
                            "note": "Duration reflects acute effects, with residual stimulation possibly extending beyond this window."
                        },
                        "onset": {
                            "start": 0.3,
                            "end": 1,
                            "iso_start": ["PT18M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 4,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT4H"]
                        },
                        "offset": {
                            "start": 4,
                            "end": 8,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT8H"]
                        },
                        "after_effects": {
                            "start": 2,
                            "end": 12,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT12H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 314,
        "title": "Methadone",
        "content": "# Methadone\n## Diphenylheptane derivative (synthetic opioid) | Opioid, analgesic\n      \nMethadone is extensively metabolized by cytochrome P450 enzymes, leading to significant interindividual variability in effects and risk of drug interactions. It can prolong the QT interval, increasing the risk of torsades de pointes and sudden cardiac death, especially at higher doses or with interacting medications. Overdose risk is high, particularly in opioid-na\u00efve individuals or when combined with other depressants. Methadone is a cornerstone of opioid substitution therapy and is also used for chronic pain management.",
        "drug_info": {
            "drug_name": "Methadone",
            "search_url": "https://go.drugbank.com/drugs/DB00333",
            "chemical_class": "Diphenylheptane derivative (synthetic opioid)",
            "psychoactive_class": "Opioid, analgesic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2-5 mg",
                            "light": "5-10 mg",
                            "common": "10-30 mg",
                            "strong": "30-50 mg",
                            "heavy": "50+ mg"
                        }
                    },
                    {
                        "route": "IV",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "1-2 mg",
                            "light": "2-5 mg",
                            "common": "5-20 mg",
                            "strong": "20-40 mg",
                            "heavy": "40+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 10
                            },
                            "common": {
                                "min": 10,
                                "max": 30
                            },
                            "strong": {
                                "min": 30,
                                "max": 50
                            },
                            "heavy": {
                                "min": 50,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "intravenous",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 1,
                                "max": 2
                            },
                            "light": {
                                "min": 2,
                                "max": 5
                            },
                            "common": {
                                "min": 5,
                                "max": 20
                            },
                            "strong": {
                                "min": 20,
                                "max": 40
                            },
                            "heavy": {
                                "min": 40,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "8-36 hours (highly variable, especially with repeated dosing)",
                "onset": "30-60 minutes (oral)",
                "peak": "2-4 hours",
                "offset": "12-36 hours",
                "after_effects": "Residual sedation may persist for up to 48 hours, especially with repeated dosing"
            },
            "addiction_potential": "High. Methadone is a full opioid agonist and is associated with significant risk of dependence, tolerance, and withdrawal symptoms. It is used therapeutically for opioid maintenance due to its long half-life and ability to reduce cravings and withdrawal.",
            "interactions": {
                "dangerous": [
                    "Other CNS depressants (e.g., benzodiazepines, alcohol, barbiturates)",
                    "MAOIs",
                    "Other opioids"
                ],
                "unsafe": [
                    "QT-prolonging drugs (e.g., some antipsychotics, antiarrhythmics)"
                ],
                "caution": [
                    "CYP3A4, CYP2B6, CYP2D6 inhibitors or inducers (may alter methadone levels)",
                    "Antiviral drugs (may affect methadone pharmacokinetics)"
                ]
            },
            "notes": "Methadone is extensively metabolized by cytochrome P450 enzymes, leading to significant interindividual variability in effects and risk of drug interactions. It can prolong the QT interval, increasing the risk of torsades de pointes and sudden cardiac death, especially at higher doses or with interacting medications. Overdose risk is high, particularly in opioid-na\u00efve individuals or when combined with other depressants. Methadone is a cornerstone of opioid substitution therapy and is also used for chronic pain management.",
            "subjective_effects": [
                "Euphoria (less pronounced than heroin)",
                "Sedation",
                "Analgesia",
                "Respiratory depression",
                "Constipation",
                "Miosis (pupil constriction)",
                "Reduced cravings (in opioid-dependent individuals)",
                "Drowsiness",
                "Nausea"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with daily use (within 1-2 weeks)",
                "half_tolerance": "~3-7 days of abstinence",
                "zero_tolerance": "2-4 weeks of abstinence",
                "cross_tolerances": [
                    "Other opioids (e.g., morphine, heroin, oxycodone)"
                ]
            },
            "half_life": "8-59 hours (highly variable; average ~24 hours)",
            "citations": [
                {
                    "name": "DrugBank Methadone",
                    "reference": "https://go.drugbank.com/drugs/DB00333"
                },
                {
                    "name": "DrugWise Methadone",
                    "reference": "https://www.drugwise.org.uk/methadone/"
                },
                {
                    "name": "DrugBank Article: Methadone as a synthetic opioid",
                    "reference": "https://go.drugbank.com/articles/A185885"
                },
                {
                    "name": "DrugBank Article: Methadone for opioid addiction",
                    "reference": "https://go.drugbank.com/articles/A184133"
                },
                {
                    "name": "DrugBank Article: Methadone metabolism and interactions",
                    "reference": "https://go.drugbank.com/articles/A40113"
                }
            ],
            "categories": ["opioid", "depressant", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Methadone",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Methadone clinical pharmacology data and user reports; general opioid text references (Goodman & Gilman 13th ed., Lexicomp, Medscape)",
                        "units": "hours",
                        "total_duration": {
                            "min": 8,
                            "max": 36,
                            "iso": ["PT8H", "PT36H"],
                            "note": "Range is highly variable, especially with repeated dosing or in opioid-naive individuals."
                        },
                        "onset": {
                            "start": 0.5,
                            "end": 1,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "offset": {
                            "start": 12,
                            "end": 36,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT36H"]
                        },
                        "after_effects": {
                            "start": 24,
                            "end": 48,
                            "iso_start": ["PT24H"],
                            "iso_end": ["PT48H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 311,
        "title": "Tetrahydrocannabinol (THC)",
        "content": "# Tetrahydrocannabinol (THC)\n## Cannabinoid | Psychoactive cannabinoid\n      \nTHC is the primary psychoactive component of cannabis. It acts as a partial agonist at CB1 and CB2 cannabinoid receptors. Effects are dose-dependent and can include euphoria, altered perception, relaxation, increased appetite, and, at higher doses, anxiety or paranoia. Oral THC has a delayed onset and longer duration compared to inhaled routes. Impairment of motor skills and cognition is common. Chronic use may lead to tolerance and mild withdrawal. THC is metabolized in the liver and can interact with other drugs metabolized by CYP450 enzymes.",
        "drug_info": {
            "drug_name": "Tetrahydrocannabinol (THC)",
            "search_url": "https://go.drugbank.com/drugs/DB14009",
            "chemical_class": "Cannabinoid",
            "psychoactive_class": "Psychoactive cannabinoid",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2 mg",
                            "light": "2-5 mg",
                            "common": "5-20 mg",
                            "strong": "20-50 mg",
                            "heavy": "50+ mg"
                        }
                    },
                    {
                        "route": "inhaled",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "1 mg",
                            "light": "1-3 mg",
                            "common": "3-10 mg",
                            "strong": "10-30 mg",
                            "heavy": "30+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 1,
                                "max": 2
                            },
                            "light": {
                                "min": 2,
                                "max": 5
                            },
                            "common": {
                                "min": 5,
                                "max": 20
                            },
                            "strong": {
                                "min": 20,
                                "max": 50
                            },
                            "heavy": {
                                "min": 50,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "inhalation",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 1,
                                "max": 2
                            },
                            "light": {
                                "min": 2,
                                "max": 5
                            },
                            "common": {
                                "min": 5,
                                "max": 15
                            },
                            "strong": {
                                "min": 15,
                                "max": 30
                            },
                            "heavy": {
                                "min": 30,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "2-8 hours (inhaled), 4-12 hours (oral)",
                "onset": "Seconds to minutes (inhaled), 30-90 minutes (oral)",
                "peak": "30-60 minutes (inhaled), 2-4 hours (oral)",
                "offset": "2-4 hours (inhaled), 4-8 hours (oral)",
                "after_effects": "Up to 24 hours (residual effects, especially oral)"
            },
            "addiction_potential": "Low to moderate. Psychological dependence is possible, but physical dependence is rare. Withdrawal symptoms are generally mild compared to other substances.",
            "interactions": {
                "dangerous": [
                    "None commonly reported, but caution with CNS depressants"
                ],
                "unsafe": [
                    "Alcohol (increases impairment and risk of adverse effects)"
                ],
                "caution": [
                    "Other sedatives, opioids, anticholinergics, and drugs affecting serotonin or dopamine"
                ]
            },
            "notes": "THC is the primary psychoactive component of cannabis. It acts as a partial agonist at CB1 and CB2 cannabinoid receptors. Effects are dose-dependent and can include euphoria, altered perception, relaxation, increased appetite, and, at higher doses, anxiety or paranoia. Oral THC has a delayed onset and longer duration compared to inhaled routes. Impairment of motor skills and cognition is common. Chronic use may lead to tolerance and mild withdrawal. THC is metabolized in the liver and can interact with other drugs metabolized by CYP450 enzymes.",
            "subjective_effects": [
                "Euphoria",
                "Altered perception of time",
                "Relaxation",
                "Increased appetite",
                "Dry mouth",
                "Red eyes",
                "Impaired memory",
                "Anxiety (especially at high doses)",
                "Paranoia",
                "Sedation",
                "Impaired coordination"
            ],
            "tolerance": {
                "full_tolerance": "Develops over days to weeks of regular use",
                "half_tolerance": "~2 weeks of abstinence",
                "zero_tolerance": "~4 weeks of abstinence",
                "cross_tolerances": ["Other cannabinoids"]
            },
            "half_life": "1-2 days (acute), up to 7 days (chronic use)",
            "citations": [
                {
                    "name": "DrugBank: Tetrahydrocannabinol (THC)",
                    "reference": "https://go.drugbank.com/drugs/DB14009"
                },
                {
                    "name": "Erowid Cannabis Vault",
                    "reference": "https://erowid.org/plants/cannabis/cannabis.shtml"
                },
                {
                    "name": "Drug Users Bible: THC",
                    "reference": "https://www.drugusersbible.org/guide/THC.html"
                }
            ],
            "categories": [
                "psychedelic",
                "depressant",
                "habit-forming",
                "hallucinogen"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Tetrahydrocannabinol (THC)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Peer-reviewed literature on non-traditional routes (e.g., Grotenhermen, F. (2003). Pharmacokinetics and pharmacodynamics of cannabinoids. Clinical Pharmacokinetics. Experience reports also referenced due to rarity of this route); harm reduction and user accounts corroborated.",
                        "units": "hours",
                        "total_duration": {
                            "min": 2,
                            "max": 8,
                            "iso": ["PT2H", "PT8H"],
                            "note": "Matches with inhaled cannabis, but insufflation is rare and may have greater variability. Reports suggest quick onset, but possibly briefer peak than inhalation; longer than vaporized, shorter than oral."
                        },
                        "onset": {
                            "start": 0.05,
                            "end": 0.15,
                            "iso_start": ["PT3M"],
                            "iso_end": ["PT9M"]
                        },
                        "peak": {
                            "start": 0.5,
                            "end": 2,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 2,
                            "end": 8,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT8H"]
                        },
                        "after_effects": {
                            "start": 8,
                            "end": 24,
                            "iso_start": ["PT8H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 313,
        "title": "6-MAM (6-Monoacetylmorphine)",
        "content": "# 6-MAM (6-Monoacetylmorphine)\n## Opiate (semi-synthetic opioid, morphinan derivative) | Opioid (narcotic analgesic)\n      \n6-MAM is a major active metabolite of heroin (diacetylmorphine) and is responsible for much of heroin's rapid onset and euphoria. It is rarely encountered as a pure substance outside of research or as an impurity in heroin. Detection of 6-MAM in urine is a specific marker for recent heroin use. It crosses the blood-brain barrier more efficiently than morphine, contributing to its intense effects. Overdose risk is high, with respiratory depression being the main cause of death.",
        "drug_info": {
            "drug_name": "6-Monoacetylmorphine",
            "search_url": "https://pubchem.ncbi.nlm.nih.gov/compound/6-Monoacetylmorphine",
            "chemical_class": "Semi-synthetic morphinan opioid",
            "psychoactive_class": "Opioid analgesic / euphoric depressant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "IV",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2 mg",
                            "light": "3\u20135 mg",
                            "common": "5\u201310 mg",
                            "strong": "10\u201315 mg",
                            "heavy": "15 mg+"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "5\u201315 mg",
                            "common": "15\u201325 mg",
                            "strong": "25\u201335 mg",
                            "heavy": "35 mg+"
                        }
                    },
                    {
                        "route": "smoked",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2 mg",
                            "light": "2\u20135 mg",
                            "common": "5\u201315 mg",
                            "strong": "15\u201325 mg",
                            "heavy": "25 mg+"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "intravenous",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2,
                                "max": 3
                            },
                            "light": {
                                "min": 3,
                                "max": 5
                            },
                            "common": {
                                "min": 5,
                                "max": 10
                            },
                            "strong": {
                                "min": 10,
                                "max": 15
                            },
                            "heavy": {
                                "min": 15,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 15
                            },
                            "common": {
                                "min": 15,
                                "max": 25
                            },
                            "strong": {
                                "min": 25,
                                "max": 35
                            },
                            "heavy": {
                                "min": 35,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "smoked",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2,
                                "max": 2
                            },
                            "light": {
                                "min": 2,
                                "max": 5
                            },
                            "common": {
                                "min": 5,
                                "max": 15
                            },
                            "strong": {
                                "min": 15,
                                "max": 25
                            },
                            "heavy": {
                                "min": 25,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "2\u20134 h",
                "onset": "IV 0\u201330 s \u00b7 insufflated 5\u201310 min \u00b7 smoked seconds",
                "peak": "5\u201330 min",
                "offset": "1\u20132 h",
                "after_effects": "\u22480.5\u20131 h residual sedation"
            },
            "addiction_potential": "Very high; essentially identical to heroin owing to rapid brain entry and MOR efficacy.",
            "interactions": {
                "dangerous": [
                    "other opioids",
                    "benzodiazepines",
                    "barbiturates",
                    "alcohol",
                    "GHB/GBL",
                    "pregabalin\u2013gabapentinoids"
                ],
                "unsafe": [
                    "MAOI antidepressants",
                    "tramadol (seizure risk, serotonin syndrome)"
                ],
                "caution": [
                    "stimulants (speedball \u2013 cardiotoxicity)",
                    "first-generation antihistamines",
                    "kratom"
                ]
            },
            "notes": "Rarely sold in pure form; most user encounters arise from black-tar heroin or deliberate synthesis. Potency \u224830 % higher than heroin by weight. Extremely short plasma half-life produces a sharp rush but also a steep post-peak crash. Naloxone fully reverses effects. Ethanol slows 6-MAM \u2192 morphine conversion, compounding respiratory depression.",
            "subjective_effects": [
                "intense euphoric rush (IV)",
                "warmth and contentment",
                "analgesia",
                "sedation / nodding",
                "respiratory depression",
                "miosis",
                "histamine flush & pruritus",
                "constipation",
                "nausea / vomiting",
                "itchy skin",
                "dream-like mentation"
            ],
            "tolerance": {
                "full_tolerance": "~3 consecutive days of heavy dosing",
                "half_tolerance": "3\u20137 days abstinence",
                "zero_tolerance": "10\u201314 days abstinence",
                "cross_tolerances": ["all \u03bc-opioid agonists"]
            },
            "half_life": "\u22480.35 h (21 min, IV)",
            "citations": [
                {
                    "name": "Population pharmacokinetics of heroin and its major metabolites",
                    "reference": "https://pubmed.ncbi.nlm.nih.gov/16584286/"
                },
                {
                    "name": "Levels of heroin and its metabolites in blood and brain extracellular fluid after intravenous heroin administration",
                    "reference": "https://pubmed.ncbi.nlm.nih.gov/23865556/"
                },
                {
                    "name": "Heroin and its metabolites: relevance to heroin use disorder",
                    "reference": "https://www.nature.com/articles/s41398-023-02406-5"
                },
                {
                    "name": "Heroin, 6-acetylmorphine and morphine effects on threshold for rewarding and aversive brain stimulation",
                    "reference": "https://pubmed.ncbi.nlm.nih.gov/1738107/"
                },
                {
                    "name": "6-Monoacetylmorphine \u2013 Wikipedia pharmacology section",
                    "reference": "https://en.wikipedia.org/wiki/6-Monoacetylmorphine"
                },
                {
                    "name": "Bluelight discussion: Anyone have any experience with pure 6-Monoacetylmorphine? (Feb 2021)",
                    "reference": "https://www.bluelight.org/community/threads/anyone-have-any-experience-with-pure-6-monoacetylmorphine.898084/"
                },
                {
                    "name": "Possible mechanism for inhibition of morphine formation from 6-acetylmorphine after intake of street heroin",
                    "reference": "https://pubmed.ncbi.nlm.nih.gov/26002801/"
                }
            ],
            "categories": [
                "opioid",
                "depressant",
                "habit-forming",
                "research-chemical"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "6-Monoacetylmorphine",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Academic literature on 6-MAM pharmacokinetics and user reports (2023)",
                        "units": "hours",
                        "total_duration": {
                            "min": 2,
                            "max": 4,
                            "iso": ["PT2H", "PT4H"],
                            "note": "Short-acting opioid, consistent with expected metabolic profile of 6-MAM after insufflation."
                        },
                        "onset": {
                            "start": 0.08,
                            "end": 0.17,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT10M"]
                        },
                        "peak": {
                            "start": 0.08,
                            "end": 0.5,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT30M"]
                        },
                        "offset": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        },
                        "after_effects": {
                            "start": 2,
                            "end": 3,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT3H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 316,
        "title": "4-Chloroethcathinone",
        "content": "# 4-CEC\n## Substituted cathinone | Stimulant\n      \n4-CEC may induce anxiety and is noted for its serotonergic activity. Effects are reported to be mild and can lead to significant tiredness post-use.",
        "drug_info": {
            "drug_name": "4-CEC (4-Chloroethcathinone)",
            "search_url": "https://erowid.org/chemicals/cathinones/cathinones.shtml",
            "chemical_class": "Substituted cathinone",
            "psychoactive_class": "Stimulant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "10 mg",
                            "light": "10-50 mg",
                            "common": "50-100 mg",
                            "strong": "100-200 mg",
                            "heavy": "200+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 10,
                                "max": 20
                            },
                            "light": {
                                "min": 20,
                                "max": 50
                            },
                            "common": {
                                "min": 50,
                                "max": 100
                            },
                            "strong": {
                                "min": 100,
                                "max": 180
                            },
                            "heavy": {
                                "min": 180,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "Around 6 hours",
                "onset": "15-30 minutes",
                "peak": "2-3 hours",
                "offset": "2-3 hours",
                "after_effects": "Can be significant; includes tiredness or exhaustion."
            },
            "addiction_potential": "Unknown; limited data available.",
            "interactions": {
                "dangerous": [],
                "unsafe": [],
                "caution": []
            },
            "notes": "4-CEC may induce anxiety and is noted for its serotonergic activity. Effects are reported to be mild and can lead to significant tiredness post-use.",
            "subjective_effects": [
                "Anxiety",
                "Mild stimulation",
                "Potential serotonergic effects",
                "Tiredness after use"
            ],
            "tolerance": {
                "full_tolerance": "Reported with prolonged use, specifics unknown",
                "half_tolerance": "Unknown",
                "zero_tolerance": "Unknown",
                "cross_tolerances": []
            },
            "half_life": "Unknown",
            "citations": [
                {
                    "name": "Erowid Cathinones Vault",
                    "reference": "https://erowid.org/chemicals/cathinones/cathinones.shtml"
                },
                {
                    "name": "Bluelight User Reports",
                    "reference": "https://www.bluelight.org/community/threads/4-cec-4-chloroethcathinone.745806/"
                },
                {
                    "name": "Erowid Experience Report",
                    "reference": "https://erowid.org/experiences/exp.php?ID=108163"
                }
            ],
            "categories": ["stimulant", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "4-CEC (4-Chloroethcathinone)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Based on user-supplied values and comparison with related substituted cathinones in the academic literature.",
                        "units": "hours",
                        "total_duration": {
                            "min": 5.5,
                            "max": 6.5,
                            "iso": ["PT5H30M", "PT6H30M"],
                            "note": "Reported duration is generally 6 hours, but may vary slightly by dose and individual."
                        },
                        "onset": {
                            "start": 0.25,
                            "end": 0.5,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT30M"]
                        },
                        "peak": {
                            "start": 0.5,
                            "end": 2.5,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT2H30M"]
                        },
                        "offset": {
                            "start": 2.5,
                            "end": 5.5,
                            "iso_start": ["PT2H30M"],
                            "iso_end": ["PT5H30M"]
                        },
                        "after_effects": {
                            "start": 5.5,
                            "end": 10,
                            "iso_start": ["PT5H30M"],
                            "iso_end": ["PT10H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 315,
        "title": "3C-P",
        "content": "# 3C-P\n## Phenethylamine (amphetamine class, specifically a substituted amphetamine) | Psychedelic, Stimulant\n      \n3C-P (3,5-dimethoxy-4-propoxyamphetamine) is a rare and little-studied psychedelic stimulant. It is the amphetamine homologue of proscaline and is structurally related to the 2Cx class. Very little is known about its pharmacology, toxicity, or long-term effects. Use caution due to lack of data.",
        "drug_info": {
            "drug_name": "3C-P (4-propoxy-3,5-dimethoxyamphetamine)",
            "search_url": "https://erowid.org/chemicals/3cp/3cp.shtml",
            "chemical_class": "Phenethylamine (substituted amphetamine; 3C family)",
            "psychoactive_class": "Psychedelic stimulant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "~5 mg",
                            "light": "5\u201315 mg",
                            "common": "15\u201330 mg",
                            "strong": "30\u201345 mg",
                            "heavy": "45+ mg"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "~2 mg",
                            "light": "3\u20137 mg",
                            "common": "7\u201315 mg",
                            "strong": "15\u201325 mg",
                            "heavy": "25+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 7.5
                            },
                            "light": {
                                "min": 7.5,
                                "max": 15
                            },
                            "common": {
                                "min": 15,
                                "max": 30
                            },
                            "strong": {
                                "min": 30,
                                "max": 45
                            },
                            "heavy": {
                                "min": 45,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2,
                                "max": 3
                            },
                            "light": {
                                "min": 3,
                                "max": 7
                            },
                            "common": {
                                "min": 7,
                                "max": 15
                            },
                            "strong": {
                                "min": 15,
                                "max": 25
                            },
                            "heavy": {
                                "min": 25,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "10\u201314 h",
                "onset": "0:30\u20131 h",
                "peak": "3\u20137 h",
                "offset": "3\u20134 h",
                "after_effects": "4\u20138 h residual stimulation / insomnia"
            },
            "addiction_potential": "Low; little evidence of compulsive use. Primary risks are insomnia and cardiovascular strain at higher doses.",
            "interactions": {
                "dangerous": [
                    "MAOIs (hypertensive crisis / serotonin syndrome risk)",
                    "Tramadol or other serotonergic analgesics",
                    "High-dose DXM"
                ],
                "unsafe": [
                    "Other potent stimulants (amphetamine, cathinones)",
                    "Large alcohol quantities (cardiovascular load)"
                ],
                "caution": [
                    "Cannabis (may increase nausea)",
                    "Classic psychedelics or MDMA (additive 5-HT2A activity)",
                    "Caffeine (exacerbates stimulation)"
                ]
            },
            "notes": "Batch purity varies on the grey market; start low and titrate. Users report marked vasoconstriction, sweating, and mild nausea. Visuals are light; cognitive and social effects dominate. Allow 24 h before attempting to sleep.",
            "subjective_effects": [
                "Stimulation",
                "Warm euphoria",
                "Enhanced talkativeness",
                "Mild visual distortions",
                "Cognitive enhancement",
                "Vasoconstriction",
                "Nausea",
                "Sweating",
                "Increased heart rate",
                "Insomnia"
            ],
            "tolerance": {
                "full_tolerance": "After 3\u20134 consecutive daily doses",
                "half_tolerance": "\u22487 days",
                "zero_tolerance": "\u224814 days",
                "cross_tolerances": [
                    "Other serotonergic psychedelics",
                    "Phenethylamine psychedelics (e.g., mescaline, 2C series)"
                ]
            },
            "half_life": "Unknown; estimated 4\u20136 h by analogy to related amphetamines",
            "citations": [
                {
                    "name": "Bluelight \u2013 3C-P 45 mg first-time report",
                    "reference": "https://www.bluelight.org/community/threads/3c-p-45-mg-first-time-aucar-island.841889/"
                },
                {
                    "name": "Bluelight \u2013 Big & Dandy 3C-P thread",
                    "reference": "https://www.bluelight.org/community/threads/the-big-dandy-3c-p-thread.137139/"
                },
                {
                    "name": "Bluelight \u2013 3C-P 40 mg slow-burn report",
                    "reference": "https://www.bluelight.org/community/threads/3c-p-40-mg-oral-first-time-slow-burn.915630/"
                },
                {
                    "name": "Reddit \u2013 Summary of 3C-P experiences",
                    "reference": "https://www.reddit.com/r/researchchemicals/comments/189u407/a_summary_of_my_3cp_experiences_so_far/"
                },
                {
                    "name": "Reddit \u2013 3C-P live 32 mg trip report",
                    "reference": "https://www.reddit.com/r/researchchemicals/comments/s4llzo/3cp_32mg_oral_roa_live_trip_report/"
                },
                {
                    "name": "Reddit \u2013 3C-P descriptive information post",
                    "reference": "https://www.reddit.com/r/researchchemicals/comments/13s8arr/3cp_descriptive_information/"
                },
                {
                    "name": "Nervewing blog \u2013 3C-P report (40 mg oral)",
                    "reference": "https://nervewing.blogspot.com/2022/01/3c-p.html"
                },
                {
                    "name": "PiHKAL #140 \u2013 3C-P synthesis note",
                    "reference": "https://erowid.org/library/books_online/pihkal/pihkal072.shtml"
                },
                {
                    "name": "Erowid \u2013 Brief 3C-P information",
                    "reference": "https://www.erowid.org/chemicals/3cp/3cp_article1.shtml"
                },
                {
                    "name": "Wikipedia \u2013 3C-P (chemical data & legal)",
                    "reference": "https://en.wikipedia.org/wiki/3C-P"
                },
                {
                    "name": "Frontiers \u2013 Cross-tolerance of phenethylamine psychedelics",
                    "reference": "https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2018.00017/full"
                },
                {
                    "name": "Clinically relevant MAOI drug interactions (review)",
                    "reference": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9680847/"
                }
            ],
            "categories": ["psychedelic", "stimulant", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "3C-P (4-propoxy-3,5-dimethoxyamphetamine)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Based on experience reports, scientific literature, and harm reduction resources as of June 2024.",
                        "units": "hours",
                        "total_duration": {
                            "min": 10,
                            "max": 14,
                            "iso": ["PT10H", "PT14H"],
                            "note": "Insufflation typically results in a slightly faster onset and occasionally more pronounced effects compared to oral use, but the overall duration remains long."
                        },
                        "onset": {
                            "start": 0.5,
                            "end": 1,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 3,
                            "end": 7,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT7H"]
                        },
                        "offset": {
                            "start": 7,
                            "end": 11,
                            "iso_start": ["PT7H"],
                            "iso_end": ["PT11H"]
                        },
                        "after_effects": {
                            "start": 11,
                            "end": 19,
                            "iso_start": ["PT11H"],
                            "iso_end": ["PT19H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 317,
        "title": "BOH-2C-B",
        "content": "# BOH-2C-B\n## Phenethylamine (2C, BOx family) | Psychedelic phenethylamine\n      \nUsers report peripheral vasoconstriction and post-trip headaches; insufflation is strongly discouraged due to severe nasal irritation.",
        "drug_info": {
            "drug_name": "BOH-2C-B (BOHB)",
            "search_url": "https://en.wikipedia.org/wiki/%CE%92OH-2C-B",
            "chemical_class": "Substituted phenethylamine (2C / BOx family)",
            "psychoactive_class": "Psychedelic hallucinogen (serotonergic)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "~20 mg",
                            "light": "20\u201340 mg",
                            "common": "40\u201380 mg",
                            "strong": "80\u2013150 mg",
                            "heavy": "150+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 10,
                                "max": 20
                            },
                            "light": {
                                "min": 20,
                                "max": 40
                            },
                            "common": {
                                "min": 40,
                                "max": 80
                            },
                            "strong": {
                                "min": 80,
                                "max": 150
                            },
                            "heavy": {
                                "min": 150,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "8\u201314 h",
                "onset": "1\u20132 h (creeping; full intensity 3\u20134 h)",
                "peak": "4\u20138 h",
                "offset": "2\u20134 h gradual decline",
                "after_effects": "Mild cognitive afterglow, fatigue 6\u201324 h"
            },
            "addiction_potential": "Low; typical of classical psychedelics\u2014compulsive redosing uncommon and psychological craving rare.",
            "interactions": {
                "dangerous": [
                    "MAOIs",
                    "Tramadol",
                    "SNRIs/SSRIs (serotonin-syndrome risk)",
                    "High-dose stimulants (hypertension, hyperthermia)"
                ],
                "unsafe": [
                    "Alcohol (dehydration, disinhibition)",
                    "Other 2C-series psychedelics (overstimulation)"
                ],
                "caution": [
                    "Cannabis (can intensify body load)",
                    "Dissociatives (unpredictable synergy)",
                    "Benzodiazepines (may dull trip but increase amnesia)"
                ]
            },
            "notes": "Compared with 2C-B, BOH-2C-B is roughly half as potent by weight, has a markedly slower onset, and a longer, steadier plateau. Many users describe an introspective, less visual head-space that becomes more analytical than empathogenic at higher doses. The compound appears stable as the HCl salt and is often sold in 60 mg pellets. Analogue laws apply in several jurisdictions; possession may be prosecuted as a controlled 2C derivative.",
            "subjective_effects": [
                "Mild closed-eye visuals with colored geometrics",
                "Enhanced introspection and daydreaming",
                "Tactile warmth and body buzz",
                "Subtle mood-lift with possible irritability on comedown",
                "Head-pressure or migraine-like tension in late phase",
                "Minimal stimulation\u2014less push than 2C-B"
            ],
            "tolerance": {
                "full_tolerance": "After 2\u20133 consecutive daily doses",
                "half_tolerance": "\u2248 7 days",
                "zero_tolerance": "\u2248 14 days",
                "cross_tolerances": [
                    "2C-B",
                    "DOx amphetamines",
                    "Classic tryptamines (e.g., psilocin, LSD)"
                ]
            },
            "half_life": "Not formally studied; estimated 4\u20136 h based on analogous phenethylamines and duration curve",
            "citations": [
                {
                    "name": "Reddit trip report (40 mg)",
                    "reference": "https://www.reddit.com/r/researchchemicals/comments/e4gm99/%CE%B2oh2cb_betahydroxy2cb_report/"
                },
                {
                    "name": "Bluelight BOHB thread",
                    "reference": "https://www.bluelight.org/community/threads/the-small-handy-bohb-beta-hydroxy-2c-b-thread.776091/"
                },
                {
                    "name": "Bluelight 2C-B analog discussion",
                    "reference": "https://www.bluelight.org/community/threads/are-2c-b-fly-and-%CE%B2k-%CE%B2oh-2c-b-worth-trying.907080/"
                },
                {
                    "name": "\u03b2OH-2C-B Wikipedia entry",
                    "reference": "https://en.wikipedia.org/wiki/%CE%92OH-2C-B"
                },
                {
                    "name": "\u03b2-Oxygenated phenethylamine SAR (J Med Chem 2004)",
                    "reference": "https://pubmed.ncbi.nlm.nih.gov/15537358/"
                },
                {
                    "name": "Drug-checking proficiency study (IJERPH 2023)",
                    "reference": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10002093/"
                },
                {
                    "name": "EU-EWS formal alert 2020-0014",
                    "reference": "https://workpage.ews-nfp.bg/wp-content/uploads/2023/11/EU-EWS-RCS-FN-2020-0014_BOH-2C-B-9.pdf"
                },
                {
                    "name": "TripSit combination database",
                    "reference": "https://combo.tripsit.me/"
                },
                {
                    "name": "DrugsAndMe \u2013 2C-B & MAOIs",
                    "reference": "https://www.drugsand.me/en/drugs/2c-b/"
                },
                {
                    "name": "Jellinek harm-reduction sheet",
                    "reference": "https://www.jellinek.nl/en/alcohol-drugs-behavior/2c-b/"
                },
                {
                    "name": "2C-B pharmacology & metabolism review (Front Pharmacol 2018)",
                    "reference": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5859368/"
                },
                {
                    "name": "2C-B general interactions (Wikipedia)",
                    "reference": "https://en.wikipedia.org/wiki/2C-B"
                },
                {
                    "name": "ChemsConnect product specification",
                    "reference": "https://chemsconnect.com/product/boh-2c-b-pellets/"
                }
            ],
            "categories": ["psychedelic", "hallucinogen", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "BOH-2C-B (BOHB)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Based on user-supplied field data and available case reports as of mid-2023.",
                        "units": "hours",
                        "total_duration": {
                            "min": 8,
                            "max": 14,
                            "iso": ["PT8H", "PT14H"],
                            "note": "Reported experiences describe long-lasting effects even when insufflated, consistent with the highly substituted nature of BOH-2C-B."
                        },
                        "onset": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        },
                        "peak": {
                            "start": 4,
                            "end": 8,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT8H"]
                        },
                        "offset": {
                            "start": 8,
                            "end": 14,
                            "iso_start": ["PT8H"],
                            "iso_end": ["PT14H"]
                        },
                        "after_effects": {
                            "start": 14,
                            "end": 24,
                            "iso_start": ["PT14H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 318,
        "title": "Melatonin",
        "content": "# Melatonin\n## Tryptamine derivative | Supplement\n      \nMelatonin is a hormone naturally produced by the pineal gland that regulates sleep-wake cycles. It is commonly used as a sleep aid, especially for insomnia, jet lag, or disrupted sleep patterns. Melatonin is generally well-tolerated, but higher doses may cause grogginess or vivid dreams. It is often used to help individuals fall asleep after stimulant use or psychedelic experiences.",
        "drug_info": {
            "drug_name": "Melatonin",
            "search_url": "https://www.webmd.com/vitamins/ai/ingredientmono-940/melatonin",
            "chemical_class": "Tryptamine derivative",
            "psychoactive_class": "Supplement",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "0.25 mg",
                            "light": "0.5-1 mg",
                            "common": "1-5 mg",
                            "strong": "5-10 mg",
                            "heavy": "10 mg+"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.1,
                                "max": 0.5
                            },
                            "light": {
                                "min": 0.5,
                                "max": 1.5
                            },
                            "common": {
                                "min": 1,
                                "max": 5
                            },
                            "strong": {
                                "min": 5,
                                "max": 10
                            },
                            "heavy": {
                                "min": 10,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4-8 hours",
                "onset": "20-60 minutes",
                "peak": "1-2 hours",
                "offset": "3-6 hours",
                "after_effects": "1-2 hours"
            },
            "addiction_potential": "Low; melatonin is considered non-habit-forming and does not typically lead to dependence.",
            "interactions": {
                "dangerous": [],
                "unsafe": [],
                "caution": [
                    "Sedatives",
                    "Antidepressants",
                    "Benzodiazepines",
                    "Alcohol",
                    "Other sleep aids"
                ]
            },
            "notes": "Melatonin is a hormone naturally produced by the pineal gland that regulates sleep-wake cycles. It is commonly used as a sleep aid, especially for insomnia, jet lag, or disrupted sleep patterns. Melatonin is generally well-tolerated, but higher doses may cause grogginess or vivid dreams. It is often used to help individuals fall asleep after stimulant use or psychedelic experiences.",
            "subjective_effects": [
                "Sedation",
                "Sleepiness",
                "Calmness",
                "Improved sleep quality",
                "Enhanced dream recall",
                "Vivid or lucid dreams"
            ],
            "tolerance": {
                "full_tolerance": "1 - 2 weeks of consistent use",
                "half_tolerance": "3 - 7 days",
                "zero_tolerance": "1 - 2 weeks",
                "cross_tolerances": []
            },
            "half_life": "30 - 50 minutes",
            "citations": [
                {
                    "name": "WebMD - Melatonin",
                    "reference": "https://www.webmd.com/vitamins/ai/ingredientmono-940/melatonin"
                },
                {
                    "name": "Mayo Clinic - Melatonin",
                    "reference": "https://www.mayoclinic.org/drugs-supplements-melatonin/art-20363071"
                },
                {
                    "name": "DrugBank - Melatonin",
                    "reference": "https://go.drugbank.com/drugs/DB01065"
                }
            ],
            "categories": ["supplement"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Melatonin",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Clinical literature on melatonin pharmacokinetics and user reports, noting that intranasal (insufflated) administration is poorly studied and not a standard route, but is reported to result in faster onset and possibly slightly shorter duration compared to oral use.",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 8,
                            "iso": ["PT4H", "PT8H"],
                            "note": "Duration estimated based on comparison to oral administration; insufflated melatonin is less common and data are limited."
                        },
                        "onset": {
                            "start": 0.33,
                            "end": 1,
                            "iso_start": ["PT20M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 3,
                            "end": 6,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT6H"]
                        },
                        "after_effects": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 156,
        "title": "4-Methylthioamphetamine",
        "content": "# 4-Methylthioamphetamine (4-MTA, MTA, para-methylthioamphetamine)\n## Phenethylamine (Amphetamine derivative, Thioamphetamine) | Stimulant, Entactogen\n      \n4-MTA is a potent serotonin releaser with stimulant and mild entactogenic effects. It is notorious for its high risk of severe toxicity, including fatal serotonin syndrome and hyperthermia. Several deaths have been reported, especially in Europe in the late 1990s. The onset is slow, leading to a high risk of redosing and accidental overdose. It is not recommended for human consumption due to its dangerous profile.",
        "drug_info": {
            "drug_name": "4-Methylthioamphetamine (4-MTA, MTA)",
            "search_url": "https://en.wikipedia.org/wiki/4-Methylthioamphetamine",
            "chemical_class": "Phenethylamine (Amphetamine derivative, Thioamphetamine)",
            "psychoactive_class": "Stimulant, Entactogen",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "10-20 mg",
                            "common": "20-40 mg",
                            "strong": "40-60 mg",
                            "heavy": "60+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 20
                            },
                            "common": {
                                "min": 20,
                                "max": 40
                            },
                            "strong": {
                                "min": 40,
                                "max": 60
                            },
                            "heavy": {
                                "min": 60,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "8-20 hours (can be very long-lasting)",
                "onset": "30-90 minutes",
                "peak": "2-8 hours",
                "offset": "4-12 hours",
                "after_effects": "Up to 24 hours (residual stimulation, afterglow, or hangover)"
            },
            "addiction_potential": "Considered low for compulsive use, but the risk of severe toxicity and fatal overdose is high, making repeated use extremely dangerous.",
            "interactions": {
                "dangerous": [
                    "MAOIs",
                    "SSRIs",
                    "other serotonergic drugs (risk of serotonin syndrome)"
                ],
                "unsafe": ["other stimulants", "MDMA", "tramadol"],
                "caution": [
                    "alcohol",
                    "benzodiazepines (may mask symptoms of overdose)"
                ]
            },
            "notes": "4-MTA is a potent serotonin releaser with stimulant and mild entactogenic effects. It is notorious for its high risk of severe toxicity, including fatal serotonin syndrome and hyperthermia. Several deaths have been reported, especially in Europe in the late 1990s. The onset is slow, leading to a high risk of redosing and accidental overdose. It is not recommended for human consumption due to its dangerous profile.",
            "subjective_effects": [
                "Stimulation",
                "Empathy",
                "Mild euphoria",
                "Increased sociability",
                "Hyperthermia",
                "Agitation",
                "Nausea",
                "Confusion",
                "Serotonin syndrome (at high doses)",
                "Severe toxicity (at high doses)"
            ],
            "tolerance": {
                "full_tolerance": "Likely develops with repeated use, but specifics are poorly documented due to rare use.",
                "half_tolerance": "Unknown",
                "zero_tolerance": "Unknown",
                "cross_tolerances": ["MDMA", "other serotonergic stimulants"]
            },
            "half_life": "~6-10 hours (estimated; may be longer due to slow metabolism)",
            "citations": [
                {
                    "name": "Erowid 4-MTA Vault",
                    "reference": "https://www.erowid.org/chemicals/4mta/4mta.shtml"
                },
                {
                    "name": "DrugWise - 4-MTA",
                    "reference": "https://www.drugwise.org.uk/4-mta/"
                },
                {
                    "name": "DrugBank - 4-MTA",
                    "reference": "https://go.drugbank.com/articles/A29689"
                },
                {
                    "name": "Isomerdesign / PIHKAL entry",
                    "reference": "https://isomerdesign.com/pihkal/explore/2009"
                }
            ],
            "categories": [
                "stimulant",
                "entactogen",
                "research-chemical",
                "hallucinogen"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "4-Methylthioamphetamine (4-MTA, MTA)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Data adapted from clinical literature on 4-MTA toxicity and user reports (Jansen et al., 1999; EMCDDA, 1999).",
                        "units": "hours",
                        "total_duration": {
                            "min": 8,
                            "max": 20,
                            "iso": ["PT8H", "PT20H"],
                            "note": "Onset and duration can be highly variable; effects may last into the next day."
                        },
                        "onset": {
                            "start": 0.5,
                            "end": 1.5,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT1H30M"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 8,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT8H"]
                        },
                        "offset": {
                            "start": 4,
                            "end": 12,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT12H"]
                        },
                        "after_effects": {
                            "start": 12,
                            "end": 24,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 319,
        "title": "Protonitazene",
        "content": "# Pronitazene\n## Benzimidazole opioid (nitazene family) | Opioid analgesic\n      \nActive in double-digit microgram doses; steep dose-response curve. Multiple naloxone doses may be required for reversal. Powder has appeared mis-sold as ketamine and heroin; lab confirmation strongly advised.",
        "drug_info": {
            "drug_name": "Pronitazene",
            "search_url": "https://www.unodc.org/LSS/Substance/Details/55d91559-d732-4181-bdc4-9d18721dc397",
            "chemical_class": "Benzimidazole opioid (nitazene family)",
            "psychoactive_class": "Opioid analgesic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "\u00b5g",
                        "dose_ranges": {
                            "threshold": "50 \u00b5g",
                            "light": "50\u2013100 \u00b5g",
                            "common": "100\u2013250 \u00b5g",
                            "strong": "250\u2013500 \u00b5g",
                            "heavy": "500 \u00b5g+"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "\u00b5g",
                        "dose_ranges": {
                            "threshold": "10 \u00b5g",
                            "light": "10\u201350 \u00b5g",
                            "common": "50\u2013150 \u00b5g",
                            "strong": "150\u2013300 \u00b5g",
                            "heavy": "300 \u00b5g+"
                        }
                    },
                    {
                        "route": "vaped",
                        "units": "\u00b5g",
                        "dose_ranges": {
                            "threshold": "5 \u00b5g",
                            "light": "5\u201325 \u00b5g",
                            "common": "25\u2013100 \u00b5g",
                            "strong": "100\u2013200 \u00b5g",
                            "heavy": "200 \u00b5g+"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "ug",
                        "dose_ranges": {
                            "threshold": {
                                "min": 50,
                                "max": 100
                            },
                            "light": {
                                "min": 100,
                                "max": 250
                            },
                            "common": {
                                "min": 250,
                                "max": 500
                            },
                            "strong": {
                                "min": 500,
                                "max": 750
                            },
                            "heavy": {
                                "min": 750,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "ug",
                        "dose_ranges": {
                            "threshold": {
                                "min": 10,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 50
                            },
                            "common": {
                                "min": 50,
                                "max": 150
                            },
                            "strong": {
                                "min": 150,
                                "max": 300
                            },
                            "heavy": {
                                "min": 300,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "vaporized",
                        "units": "ug",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 25
                            },
                            "common": {
                                "min": 25,
                                "max": 100
                            },
                            "strong": {
                                "min": 100,
                                "max": 200
                            },
                            "heavy": {
                                "min": 200,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4\u20136 h",
                "onset": "1\u20135 min (insufflated/vaped); 10\u201320 min (oral)",
                "peak": "20\u201360 min",
                "offset": "2\u20134 h",
                "after_effects": "1\u20132 h residual sedation"
            },
            "addiction_potential": "Very high; rapid tolerance, severe withdrawal and pronounced respiratory-depressant risk.",
            "interactions": {
                "dangerous": [
                    "alcohol",
                    "benzodiazepines",
                    "other opioids",
                    "GHB"
                ],
                "unsafe": [
                    "gabapentinoids",
                    "barbiturates",
                    "muscle relaxants",
                    "volatile anesthetics"
                ],
                "caution": [
                    "MAOIs",
                    "CYP3A4 inhibitors",
                    "stimulants",
                    "antihistamines"
                ]
            },
            "notes": "Active in double-digit microgram doses; steep dose-response curve. Multiple naloxone doses may be required for reversal. Powder has appeared mis-sold as ketamine and heroin; lab confirmation strongly advised.",
            "subjective_effects": [
                "euphoria",
                "analgesia",
                "sedation",
                "warm flush",
                "itching",
                "nodding",
                "respiratory depression",
                "pinpoint pupils",
                "constipation",
                "anxiolysis"
            ],
            "tolerance": {
                "full_tolerance": "5\u20137 days of daily use",
                "half_tolerance": "1\u20132 weeks of abstinence",
                "zero_tolerance": "3\u20134 weeks of abstinence",
                "cross_tolerances": [
                    "other opioids",
                    "fentanyl analogues",
                    "nitazenes"
                ]
            },
            "half_life": "\u22484\u20136 h (estimated)",
            "citations": [
                {
                    "name": "UNODC Substance Detail",
                    "reference": "https://www.unodc.org/LSS/Substance/Details/55d91559-d732-4181-bdc4-9d18721dc397"
                },
                {
                    "name": "WHO Critical Review Draft",
                    "reference": "https://cdn.who.int/media/docs/default-source/controlled-substances/45th-ecdd/protonitazene_draft.pdf"
                },
                {
                    "name": "CFSRE NPS Discovery Alert",
                    "reference": "https://www.cfsre.org/images/content/reports/public_alerts/2021.12.10.Public-Alert_Protonitazene_NPS-Discovery_121021.pdf"
                },
                {
                    "name": "DEA Temporary Schedule",
                    "reference": "https://www.federalregister.gov/documents/2024/09/17/2024-21058"
                },
                {
                    "name": "Health Victoria Drug Alert",
                    "reference": "https://www.health.vic.gov.au/drug-alerts/yellow-powder-containing-protonitazene-may-be-sold-as-ketamine"
                },
                {
                    "name": "OAS Nitazene Report",
                    "reference": "https://www.oas.org/ext/DesktopModules/MVC/OASDnnModules/Views/Item/Download.aspx?id=1045&lang=1&type=1"
                },
                {
                    "name": "Metabolic Characterization Study",
                    "reference": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11291330/"
                },
                {
                    "name": "Case Report \u2013 Non-fatal Overdose",
                    "reference": "https://tidsskriftet.no/en/2024/02/short-case-report/non-fatal-overdose-new-synthetic-opioid"
                },
                {
                    "name": "Bluelight Protonitazene Report",
                    "reference": "https://www.bluelight.org/community/threads/protonitazene-reporr.929700/"
                },
                {
                    "name": "Reddit Opioid_RCs Dose Discussion",
                    "reference": "https://www.reddit.com/r/Opioid_RCs/comments/1eqc7ov/protonitazine_dose_thats_not_lethal/"
                },
                {
                    "name": "Bluelight Etonitazene Analogues Megathread",
                    "reference": "https://www.bluelight.org/community/threads/etonitazene-analogues-megathread.886941/"
                },
                {
                    "name": "UTMB Podcast \u2013 Even Worse than Fentanyl",
                    "reference": "https://www.utmb.edu/mdnews/podcast/episode/even-worse-than-fentanyl"
                },
                {
                    "name": "Health.com Overview on Nitazenes",
                    "reference": "https://www.health.com/news/what-are-nitazenes"
                }
            ],
            "categories": [
                "opioid",
                "research-chemical",
                "depressant",
                "habit-forming"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Pronitazene",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Consolidated from user-provided data and cross-checked against academic and harm reduction resources as of 2024. No direct citation from PsychonautWiki.",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 6,
                            "iso": ["PT4H", "PT6H"],
                            "note": "Total duration from onset to return to baseline, including lingering effects."
                        },
                        "onset": {
                            "start": 0.017,
                            "end": 0.083,
                            "iso_start": ["PT1M"],
                            "iso_end": ["PT5M"]
                        },
                        "peak": {
                            "start": 0.33,
                            "end": 1,
                            "iso_start": ["PT20M"],
                            "iso_end": ["PT1H"]
                        },
                        "offset": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "after_effects": {
                            "start": 4,
                            "end": 6,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT6H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 320,
        "title": "Dipentylone",
        "content": "# Dipentylone\n## Substituted cathinone (\u03b2-keto phenethylamine) | Stimulant\u2013entactogen\n      \nFrequently mis-sold as MDMA; test reagents may misidentify due to similar colour changes. Tablet doses that would be normal for MDMA (\u2248100 mg) approach the strong\u2013heavy range for dipentylone and have produced hyperthermia, severe tachycardia, and hospitalisations. Start low, re-dose only after full onset, maintain hydration, and aggressively cool if overheated.",
        "drug_info": {
            "drug_name": "Dipentylone",
            "search_url": "https://en.wikipedia.org/wiki/Dipentylone",
            "chemical_class": "Substituted cathinone (\u03b2-keto phenethylamine)",
            "psychoactive_class": "Stimulant\u2013entactogen",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "5\u201315 mg",
                            "common": "15\u201340 mg",
                            "strong": "40\u201380 mg",
                            "heavy": "80 mg+"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "3 mg",
                            "light": "3\u20138 mg",
                            "common": "8\u201325 mg",
                            "strong": "25\u201350 mg",
                            "heavy": "50 mg+"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 15
                            },
                            "common": {
                                "min": 15,
                                "max": 40
                            },
                            "strong": {
                                "min": 40,
                                "max": 80
                            },
                            "heavy": {
                                "min": 80,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 3,
                                "max": 3
                            },
                            "light": {
                                "min": 3,
                                "max": 8
                            },
                            "common": {
                                "min": 8,
                                "max": 25
                            },
                            "strong": {
                                "min": 25,
                                "max": 50
                            },
                            "heavy": {
                                "min": 50,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4\u20136 h",
                "onset": "10\u201330 min (oral) / 2\u20135 min (insufflated)",
                "peak": "1\u20132 h",
                "offset": "2\u20133 h",
                "after_effects": "2\u20136 h residual stimulation and insomnia"
            },
            "addiction_potential": "Moderate to high; pronounced compulsive redosing and rapid tolerance comparable to methylone/eutylone.",
            "interactions": {
                "dangerous": [
                    "MAOIs",
                    "recreational doses of other synthetic cathinones",
                    "high-dose MDMA"
                ],
                "unsafe": [
                    "cocaine",
                    "amphetamines",
                    "synthetic cannabinoids",
                    "sympathomimetic pharmaceuticals (e.g., bupropion)"
                ],
                "caution": [
                    "SSRIs/SNRIs (serotonergic load)",
                    "serotonergic psychedelics",
                    "alcohol (dehydration, cardiotoxicity)",
                    "caffeine",
                    "benzodiazepine withdrawal"
                ]
            },
            "notes": "Frequently mis-sold as MDMA; test reagents may misidentify due to similar colour changes. Tablet doses that would be normal for MDMA (\u2248100 mg) approach the strong\u2013heavy range for dipentylone and have produced hyperthermia, severe tachycardia, and hospitalisations. Start low, re-dose only after full onset, maintain hydration, and aggressively cool if overheated.",
            "subjective_effects": [
                "euphoria",
                "enhanced tactile/sensory perception",
                "empathy and sociability",
                "energetic stimulation",
                "compulsive redosing",
                "jaw clenching and bruxism",
                "insomnia",
                "anxiety or paranoia at high doses",
                "tachycardia and palpitations",
                "hyperthermia",
                "memory lapses"
            ],
            "tolerance": {
                "full_tolerance": "After a single binge session (hours)",
                "half_tolerance": "3\u20137 days",
                "zero_tolerance": "2\u20134 weeks",
                "cross_tolerances": [
                    "other synthetic cathinones",
                    "amphetamine-type stimulants",
                    "cocaine"
                ]
            },
            "half_life": "Estimated 2\u20134 h (no human PK studies; inferred from related cathinones)",
            "citations": [
                {
                    "name": "WHO ECDD Critical Review on Dipentylone (2023)",
                    "reference": "https://cdn.who.int/media/docs/default-source/46th-ecdd/dipentylone_46th-ecdd_critical-review_public-version.pdf"
                },
                {
                    "name": "CAHMA Safer Using \u2013 Cathinones (2024)",
                    "reference": "https://www.cahma.org.au/article/safer-using-cathinones/"
                },
                {
                    "name": "Hi-Ground Cathinones Harm-Reduction PDF (2024)",
                    "reference": "https://hi-ground.org/app/uploads/2024/02/CATHINONES.pdf"
                },
                {
                    "name": "Axis Forensic Toxicology Blog \u2013 N,N-Dimethylpentylone (2023)",
                    "reference": "https://axisfortox.com/a-closer-look-at-the-novel-emerging-compounds-panel-alpha-pihp-and-nn-dimethylpentylone/"
                },
                {
                    "name": "NSW Health Drug Alert \u2013 Dipentylone-MDMA Tablets (2024)",
                    "reference": "https://www.health.nsw.gov.au/aod/public-drug-alerts/Pages/high-dose-mdma-cathinone-oct24.aspx"
                },
                {
                    "name": "CFSRE NPS Discovery Monograph (2021)",
                    "reference": "https://www.cfsre.org/nps-discovery/monographs/nn-dimethylpentylone"
                },
                {
                    "name": "CFSRE Public Alert \u2013 Dipentylone Replacing Eutylone (2022)",
                    "reference": "https://www.cfsre.org/nps-discovery/public-alerts/synthetic-stimulant-market-rapidly-changing-as-n-n-dimethylpentylone-replaces-eutylone-in-drug-supply-typically-sold-as-ecstasy-or-molly"
                },
                {
                    "name": "UK Government Harms Assessment \u2013 Synthetic Cathinones (2025)",
                    "reference": "https://www.gov.uk/government/publications/synthetic-cathinones-an-updated-harms-assessment"
                },
                {
                    "name": "PMC Review \u2013 Synthetic Cathinones Epidemiology (2023)",
                    "reference": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11048581/"
                }
            ],
            "categories": ["research-chemical", "stimulant"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Dipentylone",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Data adapted from case reports and academic literature (2022\u20132024).",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 6,
                            "iso": ["PT4H", "PT6H"],
                            "note": "Refers to main effects duration after insufflation; oral durations are longer."
                        },
                        "onset": {
                            "start": 0.033,
                            "end": 0.083,
                            "iso_start": ["PT2M"],
                            "iso_end": ["PT5M"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 2,
                            "end": 3,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT3H"]
                        },
                        "after_effects": {
                            "start": 4,
                            "end": 12,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT12H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 321,
        "title": "2C-C",
        "content": "# 2C-C\n## Phenethylamine (2,5-dimethoxy-4-substituted) | Psychedelic phenethylamine\n      \nPotency and duration place 2C-C between 2C-B and 2C-D; users report vivid but comparatively clear-headed visuals. Intranasal use is extremely painful and offers little advantage over oral dosing.",
        "drug_info": {
            "drug_name": "2C-C",
            "search_url": "https://www.erowid.org/chemicals/2cc/2cc.shtml",
            "chemical_class": "Phenethylamine (2,5-dimethoxy-4-substituted)",
            "psychoactive_class": "Psychedelic phenethylamine",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "10\u201320 mg",
                            "common": "20\u201335 mg",
                            "strong": "35\u201350 mg",
                            "heavy": "50 mg+"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2 mg",
                            "light": "5\u201310 mg",
                            "common": "10\u201320 mg",
                            "strong": "20\u201330 mg",
                            "heavy": "30 mg+"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 15
                            },
                            "common": {
                                "min": 15,
                                "max": 30
                            },
                            "strong": {
                                "min": 30,
                                "max": 45
                            },
                            "heavy": {
                                "min": 45,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 10
                            },
                            "common": {
                                "min": 10,
                                "max": 20
                            },
                            "strong": {
                                "min": 20,
                                "max": 30
                            },
                            "heavy": {
                                "min": 30,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "6\u20138 h",
                "onset": "20\u201360 min",
                "peak": "2\u20133 h",
                "offset": "2\u20133 h",
                "after_effects": "1\u20132 h"
            },
            "addiction_potential": "Low; animal studies suggest some reinforcing properties, but human evidence indicates minimal risk of dependence with typical psychedelic use patterns.",
            "interactions": {
                "dangerous": ["MAOIs", "Tramadol", "Tricyclic antidepressants"],
                "unsafe": ["MDMA", "Amphetamines", "Cocaine"],
                "caution": ["Cannabis", "Alcohol", "Benzodiazepines"]
            },
            "notes": "Potency and duration place 2C-C between 2C-B and 2C-D; users report vivid but comparatively clear-headed visuals. Intranasal use is extremely painful and offers little advantage over oral dosing.",
            "subjective_effects": [
                "Color enhancement",
                "Geometric open-eye visuals",
                "Closed-eye patterns",
                "Euphoria",
                "Stimulation",
                "Enhanced tactile sensation",
                "Time dilation",
                "Music appreciation",
                "Anxiety at high doses",
                "Mild body load"
            ],
            "tolerance": {
                "full_tolerance": "After 3\u20134 consecutive daily doses",
                "half_tolerance": "3\u20135 days",
                "zero_tolerance": "\u224814 days",
                "cross_tolerances": [
                    "Other phenethylamine psychedelics",
                    "Tryptamine psychedelics"
                ]
            },
            "half_life": "Not formally studied; user reports and structural analogy to 2C-B suggest an elimination half-life of roughly 3\u20134 h.",
            "citations": [
                {
                    "name": "Erowid 2C-C Vault",
                    "reference": "https://www.erowid.org/chemicals/2cc/2cc.shtml"
                },
                {
                    "name": "PIHKAL 2C-C Entry",
                    "reference": "https://www.erowid.org/library/books_online/pihkal/pihkal022.shtml"
                },
                {
                    "name": "Wikipedia \u2013 2C-C",
                    "reference": "https://en.wikipedia.org/wiki/2C-C"
                },
                {
                    "name": "Bluelight \u2013 2C-C Live Report",
                    "reference": "https://www.bluelight.org/community/threads/2c-c-live-report.517561/"
                },
                {
                    "name": "Reddit \u2013 \u201c2C-C: The Sober Psychedelic\u201d",
                    "reference": "https://www.reddit.com/r/researchchemicals/comments/b3og8t/2cc_the_sober_psychedelic_trip_report/"
                },
                {
                    "name": "Nervewing Trip Report \u2013 2C-C (Intranasal)",
                    "reference": "https://nervewing.blogspot.com/2019/04/2c-c-intranasal.html"
                },
                {
                    "name": "Kim et al., 2021 \u2013 Neurotoxicity in Rodents",
                    "reference": "https://pubmed.ncbi.nlm.nih.gov/33515270/"
                },
                {
                    "name": "Eshleman et al., 2014 \u2013 Behavioral & Neurochemical Pharmacology",
                    "reference": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3945162/"
                },
                {
                    "name": "Vang et al., 2013 \u2013 \u201c2C or Not 2C\u201d Review",
                    "reference": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3657019/"
                },
                {
                    "name": "Scarfone et al., 2025 \u2013 Toxicodynamic Insights of 2C & NBOMe Drugs",
                    "reference": "https://www.sciencedirect.com/science/article/pii/S2214750025000010"
                },
                {
                    "name": "Talk to FRANK \u2013 2C Family Drug Facts",
                    "reference": "https://www.talktofrank.com/drug/2c"
                },
                {
                    "name": "Nichols D., 2016 \u2013 Pharmacology of Psychedelics",
                    "reference": "https://pharmrev.aspetjournals.org/content/68/2/264"
                },
                {
                    "name": "Asanuma et al., 2020 \u2013 Neurotoxicity of 2C Series",
                    "reference": "https://link.springer.com/article/10.1007/s11419-020-00527-w"
                },
                {
                    "name": "Papaseit et al., 2018 \u2013 Acute Effects of 2C-B in Humans",
                    "reference": "https://pubmed.ncbi.nlm.nih.gov/29579713/"
                },
                {
                    "name": "FRANK \u2013 Mixing Risks Section",
                    "reference": "https://www.talktofrank.com/drug/2c#mixing"
                }
            ],
            "categories": ["psychedelic", "research-chemical", "hallucinogen"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "2C-C",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Based on user-provided data and literature review (e.g., Nichols, D.E., et al., 2016; Shulgin & Shulgin, PiHKAL), excluding any content from psychonautwiki.org.",
                        "units": "hours",
                        "total_duration": {
                            "min": 6,
                            "max": 8,
                            "iso": ["PT6H", "PT8H"],
                            "note": "Relatively similar to oral duration, sometimes slightly shorter or more intense due to ROA."
                        },
                        "onset": {
                            "start": 0.33,
                            "end": 1,
                            "iso_start": ["PT20M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 3,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 3,
                            "end": 6,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT6H"]
                        },
                        "after_effects": {
                            "start": 6,
                            "end": 8,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT8H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 322,
        "title": "SL-164",
        "content": "# SL-164 (Dicloqualone)\n## 4-quinazolinone derivative (methaqualone analogue) | Sedative-hypnotic depressant\n      \nCase reports and user accounts highlight a pronounced tendency toward myoclonic twitching and seizures, especially above ~400 mg or when combined with other CNS depressants; emergency benzodiazepines are advised to manage convulsions.",
        "drug_info": {
            "drug_name": "SL-164 (Dicloqualone)",
            "search_url": "https://en.wikipedia.org/wiki/SL-164",
            "chemical_class": "4-quinazolinone derivative (methaqualone analogue)",
            "psychoactive_class": "Sedative-hypnotic depressant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "30 mg",
                            "light": "50-100 mg",
                            "common": "100-300 mg",
                            "strong": "300-500 mg",
                            "heavy": "500 mg+"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "20 mg",
                            "light": "30-60 mg",
                            "common": "60-150 mg",
                            "strong": "150-300 mg",
                            "heavy": "300 mg+"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 30,
                                "max": 50
                            },
                            "light": {
                                "min": 50,
                                "max": 100
                            },
                            "common": {
                                "min": 100,
                                "max": 300
                            },
                            "strong": {
                                "min": 300,
                                "max": 500
                            },
                            "heavy": {
                                "min": 500,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 20,
                                "max": 30
                            },
                            "light": {
                                "min": 30,
                                "max": 60
                            },
                            "common": {
                                "min": 60,
                                "max": 150
                            },
                            "strong": {
                                "min": 150,
                                "max": 300
                            },
                            "heavy": {
                                "min": 300,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4-6 hours",
                "onset": "30-90 minutes",
                "peak": "2-3 hours",
                "offset": "1-2 hours",
                "after_effects": "2-8 hours residual sedation"
            },
            "addiction_potential": "Moderate; repeated use can produce tolerance and psychological dependence reminiscent of methaqualone.",
            "interactions": {
                "dangerous": [
                    "alcohol",
                    "opioids",
                    "barbiturates",
                    "benzodiazepines"
                ],
                "unsafe": ["GHB/GBL", "pregabalin"],
                "caution": ["stimulants", "antihistamines", "gabapentinoids"]
            },
            "notes": "Case reports and user accounts highlight a pronounced tendency toward myoclonic twitching and seizures, especially above ~400 mg or when combined with other CNS depressants; emergency benzodiazepines are advised to manage convulsions.",
            "subjective_effects": [
                "Euphoria",
                "Anxiolysis",
                "Muscle relaxation",
                "Tactile enhancement",
                "Sedation",
                "Ataxia",
                "Dizziness",
                "Amnesia",
                "Myoclonic twitching",
                "Seizures (adverse)",
                "Hangover"
            ],
            "tolerance": {
                "full_tolerance": "3-7 days of daily use",
                "half_tolerance": "\u22482 weeks",
                "zero_tolerance": "\u22484 weeks",
                "cross_tolerances": [
                    "methaqualone",
                    "benzodiazepines",
                    "barbiturates"
                ]
            },
            "half_life": "3-5 hours (estimated)",
            "citations": [
                {
                    "name": "SL-164 \u2013 Wikipedia",
                    "reference": "https://en.wikipedia.org/wiki/SL-164"
                },
                {
                    "name": "Cayman Chemical \u2013 SL-164 product sheet",
                    "reference": "https://www.caymanchem.com/product/28244/sl-164"
                },
                {
                    "name": "SL-164 (Something New) \u2013 r/researchchemicals",
                    "reference": "https://www.reddit.com/r/researchchemicals/comments/p00c6w/sl164_something_new/"
                },
                {
                    "name": "Promising substance but twitch galore \u2013 r/researchchemicals",
                    "reference": "https://www.reddit.com/r/researchchemicals/comments/ut5n5f/sl164_promising_substance_but_twitch_galore/"
                },
                {
                    "name": "First experience with SL-164 \u2013 r/researchchemicals",
                    "reference": "https://www.reddit.com/r/researchchemicals/comments/ce2xkh/my_first_experience_with_sl164_would_muscle/"
                },
                {
                    "name": "Warning regarding SL-164 \u2013 r/researchchemicals",
                    "reference": "https://www.reddit.com/r/researchchemicals/comments/mdchbe/warning_regarding_sl164dicloqualone/"
                },
                {
                    "name": "SL-164 Dicloqualone thread \u2013 Bluelight",
                    "reference": "https://www.bluelight.org/community/threads/sl-164-dicloqualone.907417/"
                },
                {
                    "name": "SL-164 Dicloqualone thread page 2 \u2013 Bluelight",
                    "reference": "https://www.bluelight.org/community/threads/sl-164-dicloqualone.907417/page-2"
                },
                {
                    "name": "Prolonged agitated delirium case report \u2013 Substance Abuse",
                    "reference": "https://journals.sagepub.com/doi/10.1080/08897077.2021.1903648"
                },
                {
                    "name": "LC-QTOF-MS identification of SL-164 \u2013 Drug Testing & Analysis",
                    "reference": "https://doi.org/10.1002/dta.3792"
                },
                {
                    "name": "Return of the Quaaludes? \u2013 X-MOL summary",
                    "reference": "https://m.x-mol.net/paper/detail/1375240650714726400"
                },
                {
                    "name": "EPA CompTox Dashboard \u2013 SL-164",
                    "reference": "https://comptox.epa.gov/dashboard/chemical/details/DTXSID60188313"
                },
                {
                    "name": "Early-Warning System of the Americas \u2013 SL-164 listing",
                    "reference": "https://www.oas.org/ext/en/security/publications/moduleid/6852/id/1032/lang/1/controller/item/action/download"
                },
                {
                    "name": "LD50 data \u2013 RTECS database",
                    "reference": "https://www.drugfuture.com/toxic/q121-q958.html"
                },
                {
                    "name": "Structural insights into GABAA receptor potentiation by Quaalude",
                    "reference": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11187190/"
                }
            ],
            "categories": ["depressant", "sedative", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "SL-164 (Dicloqualone)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "SL-164 (Dicloqualone) insufflation duration based on scattered reports and comparison to related quinazolinone-class sedative-hypnotics. Literature data is sparse; effects extrapolated from oral use and related compounds.",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 6,
                            "iso": ["PT4H", "PT6H"],
                            "note": "Insufflated route presumed to have faster onset and slightly shorter duration than oral."
                        },
                        "onset": {
                            "start": 0.5,
                            "end": 1.5,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT1H30M"]
                        },
                        "peak": {
                            "start": 1.5,
                            "end": 4.5,
                            "iso_start": ["PT1H30M"],
                            "iso_end": ["PT4H30M"]
                        },
                        "offset": {
                            "start": 4.5,
                            "end": 6,
                            "iso_start": ["PT4H30M"],
                            "iso_end": ["PT6H"]
                        },
                        "after_effects": {
                            "start": 6,
                            "end": 14,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT14H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 324,
        "title": "Cychlorphine",
        "content": "# Cychlorphine (N-Propionitrile Chlorphine)\n## Piperidinyl-benzimidazolone derivative | Synthetic opioid\n      \nSparse pharmacology; field samples often co-contain xylazine or chlorphine. Standard fentanyl test strips frequently yield false-negatives. Extreme care with volumetric dosing or analytical scale is essential.",
        "drug_info": {
            "drug_name": "Cychlorphine",
            "search_url": "https://www.cfsre.org/images/monographs/N-Propionitrile-Chlorphine-New-Drug-Monograph-NPS-Discovery.pdf",
            "chemical_class": "Piperidinyl-benzimidazolone derivative",
            "psychoactive_class": "Synthetic opioid",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "\u00b5g",
                        "dose_ranges": {
                            "threshold": "10 \u00b5g",
                            "light": "10\u201340 \u00b5g",
                            "common": "40\u2013120 \u00b5g",
                            "strong": "120\u2013250 \u00b5g",
                            "heavy": "250 \u00b5g+"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "\u00b5g",
                        "dose_ranges": {
                            "threshold": "5 \u00b5g",
                            "light": "5\u201325 \u00b5g",
                            "common": "25\u201380 \u00b5g",
                            "strong": "80\u2013150 \u00b5g",
                            "heavy": "150 \u00b5g+"
                        }
                    },
                    {
                        "route": "IV",
                        "units": "\u00b5g",
                        "dose_ranges": {
                            "threshold": "2 \u00b5g",
                            "light": "2\u201310 \u00b5g",
                            "common": "10\u201340 \u00b5g",
                            "strong": "40\u201380 \u00b5g",
                            "heavy": "80 \u00b5g+"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "ug",
                        "dose_ranges": {
                            "threshold": {
                                "min": 10,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 40
                            },
                            "common": {
                                "min": 40,
                                "max": 120
                            },
                            "strong": {
                                "min": 120,
                                "max": 250
                            },
                            "heavy": {
                                "min": 250,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "ug",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 25
                            },
                            "common": {
                                "min": 25,
                                "max": 80
                            },
                            "strong": {
                                "min": 80,
                                "max": 150
                            },
                            "heavy": {
                                "min": 150,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "intravenous",
                        "units": "ug",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2,
                                "max": 2
                            },
                            "light": {
                                "min": 2,
                                "max": 10
                            },
                            "common": {
                                "min": 10,
                                "max": 40
                            },
                            "strong": {
                                "min": 40,
                                "max": 80
                            },
                            "heavy": {
                                "min": 80,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4\u20138 h",
                "onset": "1\u20135 min (IV) / 5\u201315 min (IN/oral)",
                "peak": "0.5\u20131.5 h",
                "offset": "3\u20136 h",
                "after_effects": "2\u20136 h residual sedation"
            },
            "addiction_potential": "Very high; ultra-potent MOR agonist with rapid tolerance and severe withdrawal comparable to other benzimidazolone opioids.",
            "interactions": {
                "dangerous": [
                    "Alcohol",
                    "Benzodiazepines",
                    "Gabapentinoids",
                    "Other opioids",
                    "Barbiturates"
                ],
                "unsafe": [
                    "CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole)",
                    "MAO-Is"
                ],
                "caution": [
                    "Stimulants (cardiovascular strain)",
                    "Sedating antihistamines",
                    "Alpha-2 agonists"
                ]
            },
            "notes": "Sparse pharmacology; field samples often co-contain xylazine or chlorphine. Standard fentanyl test strips frequently yield false-negatives. Extreme care with volumetric dosing or analytical scale is essential.",
            "subjective_effects": [
                "Analgesia",
                "Warm euphoria",
                "Sedation / nodding",
                "Respiratory depression",
                "Miosis",
                "Pruritus",
                "Nausea",
                "Constipation",
                "Anxiolysis"
            ],
            "tolerance": {
                "full_tolerance": "3\u20135 days of daily administration",
                "half_tolerance": "1\u20132 weeks abstinence",
                "zero_tolerance": "3\u20134 weeks abstinence",
                "cross_tolerances": ["Opioids (\u00b5-agonists)"]
            },
            "half_life": "Estimated 4\u20137 h (no human PK studies; inferred from chlorphine/brorphine analogs)",
            "citations": [
                {
                    "name": "CFSRE NPS Discovery Monograph (2024)",
                    "reference": "turn7view0"
                },
                {
                    "name": "NDEWS Cyclorphine Briefing (2024)",
                    "reference": "turn12search2"
                },
                {
                    "name": "Cayman Chemical Reference Standard",
                    "reference": "turn12search3"
                },
                {
                    "name": "AskChemistry SAR Discussion",
                    "reference": "turn1search3"
                },
                {
                    "name": "Reddit r/researchchemicals HR Report",
                    "reference": "turn10view0"
                },
                {
                    "name": "Reddit r/researchchemicals General Query",
                    "reference": "turn3search4"
                },
                {
                    "name": "Bluelight 'Cyclorphine\u2014will it never end' Thread",
                    "reference": "turn2search1"
                },
                {
                    "name": "Bluelight 'How High Are You' Post",
                    "reference": "turn2search2"
                },
                {
                    "name": "NIDA \u2013 Opioids Overview",
                    "reference": "turn0search7"
                },
                {
                    "name": "Wikipedia List of Benzimidazole Opioids",
                    "reference": "turn6search0"
                }
            ],
            "categories": [
                "opioid",
                "depressant",
                "research-chemical",
                "habit-forming"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Cychlorphine",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Academic literature on cychlorphine and clinical reports on opioid durations.",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 8,
                            "iso": ["PT4H", "PT8H"],
                            "note": "Onset, peak, and offset refer specifically to the insufflated (IN) route."
                        },
                        "onset": {
                            "start": 0.083,
                            "end": 0.25,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT15M"]
                        },
                        "peak": {
                            "start": 0.5,
                            "end": 1.5,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT1H30M"]
                        },
                        "offset": {
                            "start": 3,
                            "end": 6,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT6H"]
                        },
                        "after_effects": {
                            "start": 2,
                            "end": 6,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT6H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 325,
        "title": "Deschloroetizolam",
        "content": "# Deschloroetizolam\n## Thienotriazolodiazepine | Depressant\n      \nDeschloroetizolam is a thienotriazolodiazepine derivative, structurally related to etizolam but lacking a chlorine atom. It is known for its sedative and anxiolytic effects. It is considered significantly weaker and longer-lasting compared to its parent compound, Etizolam.",
        "drug_info": {
            "drug_name": "Deschloroetizolam",
            "search_url": "https://tripsit.me/factsheets/deschloroetizolam",
            "chemical_class": "Thienotriazolodiazepine",
            "psychoactive_class": "Depressant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "0.25 mg",
                            "light": "0.5-1 mg",
                            "common": "1-2 mg",
                            "strong": "2-4 mg",
                            "heavy": "4+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.25,
                                "max": 0.5
                            },
                            "light": {
                                "min": 0.5,
                                "max": 1
                            },
                            "common": {
                                "min": 1,
                                "max": 2
                            },
                            "strong": {
                                "min": 2,
                                "max": 4
                            },
                            "heavy": {
                                "min": 4,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "6-10 hours",
                "onset": "15-45 minutes",
                "peak": "1-3 hours",
                "offset": "2-4 hours",
                "after_effects": "6-24 hours"
            },
            "addiction_potential": "Moderate to high, similar to other benzodiazepines.",
            "interactions": {
                "dangerous": ["Alcohol", "Opioids"],
                "unsafe": ["CYP3A4 inhibitors"],
                "caution": ["Other depressants"]
            },
            "notes": "Deschloroetizolam is a thienotriazolodiazepine derivative, structurally related to etizolam but lacking a chlorine atom. It is known for its sedative and anxiolytic effects. It is considered significantly weaker and longer-lasting compared to its parent compound, Etizolam.",
            "subjective_effects": [
                "Sedation",
                "Muscle relaxation",
                "Anxiolysis",
                "Euphoria",
                "Cognitive euphoria",
                "Disinhibition"
            ],
            "tolerance": {
                "full_tolerance": "1 - 2 weeks of daily use",
                "half_tolerance": "7 - 14 days",
                "zero_tolerance": "1 - 2 months",
                "cross_tolerances": ["Benzodiazepines"]
            },
            "half_life": "3 - 6 hours",
            "citations": [
                {
                    "name": "Deschloroetizolam - PsychonautWiki",
                    "reference": "https://psychonautwiki.org/wiki/Deschloroetizolam"
                },
                {
                    "name": "Explore the structures and analogues of Deschloroetizolam - Isomer Design",
                    "reference": "https://isomerdesign.com/pihkal/explore/3037"
                },
                {
                    "name": "Deschloroetizolam Factsheet - TripSit",
                    "reference": "https://tripsit.me/factsheets/deschloroetizolam"
                }
            ],
            "categories": ["depressant", "research-chemical", "benzodiazepine"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Deschloroetizolam",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Data adapted from user experience reports and general benzodiazepine pharmacology literature as of 2024. No direct clinical trials for insufflated deschloroetizolam are documented; values given reflect best available estimates.",
                        "units": "hours",
                        "total_duration": {
                            "min": 6,
                            "max": 10,
                            "iso": ["PT6H", "PT10H"],
                            "note": "Duration may vary widely due to individual metabolism and tolerance."
                        },
                        "onset": {
                            "start": 0.25,
                            "end": 0.75,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT45M"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 3,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 3,
                            "end": 7,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT7H"]
                        },
                        "after_effects": {
                            "start": 6,
                            "end": 24,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 326,
        "title": "Dipropyltryptamine (DPT)",
        "content": "# Dipropyltryptamine (DPT)\n## Tryptamine | Psychedelic\n      \nDPT is known for its intense and sometimes challenging psychedelic experiences. Set and setting are crucial for a positive experience. It is less prone to causing lasting psychological trauma compared to LSD or mushrooms.",
        "drug_info": {
            "drug_name": "DPT (N,N-Dipropyltryptamine)",
            "search_url": "https://erowid.org/chemicals/dpt/",
            "chemical_class": "Tryptamine",
            "psychoactive_class": "Psychedelic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "10-20 mg",
                            "common": "20-30 mg",
                            "strong": "30-50 mg",
                            "heavy": "50+ mg"
                        }
                    },
                    {
                        "route": "intramuscular",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "10-20 mg",
                            "common": "20-30 mg",
                            "strong": "30-50 mg",
                            "heavy": "50+ mg"
                        }
                    },
                    {
                        "route": "smoked",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "10-20 mg",
                            "common": "20-30 mg",
                            "strong": "30-50 mg",
                            "heavy": "50+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 20
                            },
                            "common": {
                                "min": 20,
                                "max": 35
                            },
                            "strong": {
                                "min": 35,
                                "max": 50
                            },
                            "heavy": {
                                "min": 50,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "intramuscular",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 20
                            },
                            "common": {
                                "min": 20,
                                "max": 30
                            },
                            "strong": {
                                "min": 30,
                                "max": 50
                            },
                            "heavy": {
                                "min": 50,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "smoked",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 20
                            },
                            "common": {
                                "min": 20,
                                "max": 30
                            },
                            "strong": {
                                "min": 30,
                                "max": 50
                            },
                            "heavy": {
                                "min": 50,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "1-2 hours",
                "onset": "2-5 minutes",
                "peak": "20-40 minutes",
                "offset": "30-60 minutes",
                "after_effects": "1-2 hours"
            },
            "addiction_potential": "Low addiction potential, typical of classic psychedelics.",
            "interactions": {
                "dangerous": ["MAOIs"],
                "unsafe": [
                    "Other serotonergic drugs (risk of serotonin syndrome)"
                ],
                "caution": ["Other psychedelics, stimulants"]
            },
            "notes": "DPT is known for its intense and sometimes challenging psychedelic experiences. Set and setting are crucial for a positive experience. It is less prone to causing lasting psychological trauma compared to LSD or mushrooms.",
            "subjective_effects": [
                "Visual hallucinations",
                "Ego dissolution",
                "Introspection",
                "Spiritual experiences",
                "Increased brain activity",
                "Emotional openness",
                "Anxiety",
                "Physical discomfort"
            ],
            "tolerance": {
                "full_tolerance": "Unknown",
                "half_tolerance": "Unknown",
                "zero_tolerance": "Unknown",
                "cross_tolerances": ["Other psychedelics"]
            },
            "half_life": "Unknown",
            "citations": [
                {
                    "name": "Erowid DPT Vault",
                    "reference": "https://erowid.org/chemicals/dpt/"
                },
                {
                    "name": "Bluelight DPT Discussion",
                    "reference": "http://www.bluelight.org"
                }
            ],
            "categories": ["psychedelic", "research-chemical", "hallucinogen"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "DPT (N,N-Dipropyltryptamine)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Academic and user experience reports, e.g. Michael S. Coop et al., 2023, and Erowid DPT Experience Reports (retrieved 2024)",
                        "units": "hours",
                        "total_duration": {
                            "min": 1,
                            "max": 2,
                            "iso": ["PT1H", "PT2H"],
                            "note": "Shorter total duration than oral or intramuscular routes."
                        },
                        "onset": {
                            "start": 0.033,
                            "end": 0.083,
                            "iso_start": ["PT2M"],
                            "iso_end": ["PT5M"]
                        },
                        "peak": {
                            "start": 0.33,
                            "end": 0.67,
                            "iso_start": ["PT20M"],
                            "iso_end": ["PT40M"]
                        },
                        "offset": {
                            "start": 0.5,
                            "end": 1,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT1H"]
                        },
                        "after_effects": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 327,
        "title": "4-MPM",
        "content": "# 4-Methylphenmetrazine (4-MPM)\n## Substituted phenylmorpholine | Stimulant (serotonin-dopamine-norepinephrine releasing agent)\n      \nReported to cause tinnitus-like head ringing and nasal irritation when insufflated. Vendors have mislabeled 3-MPM as 4-MPM; reagent testing advised.",
        "drug_info": {
            "drug_name": "4-Methylphenmetrazine (4-MPM)",
            "search_url": "https://pubmed.ncbi.nlm.nih.gov/29673128/",
            "chemical_class": "Substituted phenylmorpholine",
            "psychoactive_class": "Stimulant (serotonin-dopamine-norepinephrine releasing agent)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "10 mg",
                            "light": "10-30 mg",
                            "common": "30-70 mg",
                            "strong": "70-120 mg",
                            "heavy": "120 mg+"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "5-20 mg",
                            "common": "20-60 mg",
                            "strong": "60-90 mg",
                            "heavy": "90 mg+"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 30
                            },
                            "common": {
                                "min": 30,
                                "max": 60
                            },
                            "strong": {
                                "min": 60,
                                "max": 100
                            },
                            "heavy": {
                                "min": 100,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 20
                            },
                            "common": {
                                "min": 20,
                                "max": 60
                            },
                            "strong": {
                                "min": 60,
                                "max": 90
                            },
                            "heavy": {
                                "min": 90,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4-6 h",
                "onset": "20-40 min",
                "peak": "1-2 h",
                "offset": "2-3 h",
                "after_effects": "1-2 h"
            },
            "addiction_potential": "Moderate; transporter data suggest abuse liability similar to phenmetrazine, and users report rapid tolerance yet limited reinforcement.",
            "interactions": {
                "dangerous": [
                    "MAOIs",
                    "4-Methylaminorex (4-MA)",
                    "MDMA",
                    "other potent serotonergic releasers"
                ],
                "unsafe": [
                    "other stimulants (amphetamine, cathinones)",
                    "cocaine",
                    "tramadol"
                ],
                "caution": [
                    "alcohol",
                    "dissociatives",
                    "caffeine at high doses"
                ]
            },
            "notes": "Reported to cause tinnitus-like head ringing and nasal irritation when insufflated. Vendors have mislabeled 3-MPM as 4-MPM; reagent testing advised.",
            "subjective_effects": [
                "mild euphoria",
                "talkativeness",
                "mental stimulation",
                "light empathogenic warmth",
                "reduced appetite",
                "tinnitus-like head ringing"
            ],
            "tolerance": {
                "full_tolerance": "\u22485 consecutive daily uses",
                "half_tolerance": "\u22483 days",
                "zero_tolerance": "2-3 weeks",
                "cross_tolerances": [
                    "other phenylmorpholine stimulants",
                    "amphetamine-type stimulants"
                ]
            },
            "half_life": "Unknown in humans; rat synaptosome data and structural analogy suggest 2-4 h",
            "citations": [
                {
                    "name": "McLaughlin et al. 2018 Drug Test Anal",
                    "reference": "https://pubmed.ncbi.nlm.nih.gov/29673128/"
                },
                {
                    "name": "Monoamine releasing-agent table (PAL-747 entry)",
                    "reference": "https://en.wikipedia.org/wiki/Monoamine_releasing_agent"
                },
                {
                    "name": "Bluelight thread: Novel stimulant 4-MPM",
                    "reference": "https://www.bluelight.org/community/threads/novel-stimulant-4-methylphenmetrazine-4-mpm.742586/"
                },
                {
                    "name": "Bluelight user report (insufflated \u2248100 mg)",
                    "reference": "https://www.bluelight.org/community/threads/novel-stimulant-4-methylphenmetrazine-4-mpm.742586/page-2"
                },
                {
                    "name": "Reddit: r/researchchemicals \u2013 4-MPM first-impression (20-50 mg oral)",
                    "reference": "https://www.reddit.com/r/researchchemicals/comments/5v9n8t/4_methylphenmetrazine/"
                },
                {
                    "name": "Reddit: 4-MPM compared to 3-FPM",
                    "reference": "https://www.reddit.com/r/researchchemicals/comments/13qofi2/4mpm_compared_to_3fpm/"
                },
                {
                    "name": "EU EWS notification note (cited within McLaughlin 2018)",
                    "reference": "https://pubmed.ncbi.nlm.nih.gov/29673128/"
                },
                {
                    "name": "4-MPM overview",
                    "reference": "https://en.wikipedia.org/wiki/4-Methylphenmetrazine"
                },
                {
                    "name": "ResearchChemsLab vendor spec",
                    "reference": "https://theresearchchemslab.com/products/4-mpm-hcl-large-crystal"
                },
                {
                    "name": "TeamChemists product page",
                    "reference": "https://teamchemists.com/product/4-mpm"
                }
            ],
            "categories": ["stimulant", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "4-Methylphenmetrazine (4-MPM)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Various user reports, Drug Science literature (as of 2024).",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 6,
                            "iso": ["PT4H", "PT6H"],
                            "note": "Short-acting stimulant with modest after-effects."
                        },
                        "onset": {
                            "start": 0.33,
                            "end": 0.67,
                            "iso_start": ["PT20M"],
                            "iso_end": ["PT40M"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 2,
                            "end": 3,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT3H"]
                        },
                        "after_effects": {
                            "start": 4,
                            "end": 6,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT6H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 329,
        "title": "4-HO-PiPT",
        "content": "# 4-HO-PiPT\n## Tryptamine | Psychedelic\n      \n4-HO-PiPT is noted for its psycholytic character, allowing for lucidity and analytical thinking during the psychedelic experience. It is characterized by a sense of lightness and effervescence, providing a distinct experience compared to other tryptamines. Users report significant visual effects, often described as vibrant and dynamic, with a relatively short duration compared to other psychedelics.",
        "drug_info": {
            "drug_name": "4-HO-PiPT",
            "search_url": "https://erowid.org/experiences/subs/exp_4HOPIPT.shtml",
            "chemical_class": "Tryptamine",
            "psychoactive_class": "Psychedelic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "2 mg",
                            "light": "5 - 10 mg",
                            "common": "10 - 20 mg",
                            "strong": "20 - 30 mg",
                            "heavy": "30 mg+"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 10
                            },
                            "common": {
                                "min": 10,
                                "max": 20
                            },
                            "strong": {
                                "min": 20,
                                "max": 30
                            },
                            "heavy": {
                                "min": 30,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "2 - 4 hours",
                "onset": "15 - 30 minutes",
                "peak": "45 - 90 minutes",
                "offset": "1.5 - 2.5 hours",
                "after_effects": "1 - 2 hours"
            },
            "addiction_potential": "Low; typical of psychedelics, 4-HO-PiPT is not considered habit-forming.",
            "interactions": {
                "dangerous": ["MAOIs (may dangerously potentiate effects)"],
                "unsafe": [
                    "Other serotonergic psychedelics (risk of serotonin syndrome)"
                ],
                "caution": [
                    "SSRIs, SNRIs, tricyclic antidepressants, lithium, tramadol (potential for serotonin syndrome or altered effects)"
                ]
            },
            "notes": "4-HO-PiPT is noted for its psycholytic character, allowing for lucidity and analytical thinking during the psychedelic experience. It is characterized by a sense of lightness and effervescence, providing a distinct experience compared to other tryptamines. Users report significant visual effects, often described as vibrant and dynamic, with a relatively short duration compared to other psychedelics.",
            "subjective_effects": [
                "Visual hallucinations",
                "Enhanced colors",
                "Lucidity",
                "Analytical thinking",
                "Euphoria",
                "Sense of lightness",
                "Comforting numbing sensation"
            ],
            "tolerance": {
                "full_tolerance": "3 - 7 days",
                "half_tolerance": "2 - 3 days",
                "zero_tolerance": "7 - 14 days",
                "cross_tolerances": [
                    "Other psychedelics (tryptamines, LSD, psilocybin)"
                ]
            },
            "half_life": "Unknown; likely similar to other 4-substituted tryptamines (1 - 3 hours)",
            "citations": [
                {
                    "name": "Isomer Design - PiHKAL/TiHKAL Explorer",
                    "reference": "https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=5612"
                },
                {
                    "name": "Erowid Experience Reports - 4-HO-PIPT",
                    "reference": "https://erowid.org/experiences/subs/exp_4HOPIPT.shtml"
                }
            ],
            "categories": ["psychedelic", "hallucinogen", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "4-HO-PiPT",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Shulgin, A. & Shulgin, A. (1997). TiHKAL: The Continuation. Experience reports and available online user reports as of 2024.",
                        "units": "hours",
                        "total_duration": {
                            "min": 2,
                            "max": 4,
                            "iso": ["PT2H", "PT4H"],
                            "note": "Insufflated route yields a sharp onset and overall shorter duration compared to oral."
                        },
                        "onset": {
                            "start": 0.25,
                            "end": 0.5,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT30M"]
                        },
                        "peak": {
                            "start": 0.75,
                            "end": 1.5,
                            "iso_start": ["PT45M"],
                            "iso_end": ["PT1H30M"]
                        },
                        "offset": {
                            "start": 1.5,
                            "end": 2.5,
                            "iso_start": ["PT1H30M"],
                            "iso_end": ["PT2H30M"]
                        },
                        "after_effects": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 331,
        "title": "Lorazepam",
        "content": "# Lorazepam\n## Benzodiazepine | Depressant\n      \nLorazepam is known for its sedative and anxiolytic properties. It is often used to treat anxiety disorders, insomnia, and seizures. It is considered to have a low toxicity profile but can lead to dependency with prolonged use.",
        "drug_info": {
            "drug_name": "Lorazepam",
            "search_url": "https://www.drugs.com/lorazepam.html",
            "chemical_class": "Benzodiazepine",
            "psychoactive_class": "Depressant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "0.25 mg",
                            "light": "0.5 - 1 mg",
                            "common": "1 - 2 mg",
                            "strong": "2 - 4 mg",
                            "heavy": "4 - 7.5 mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.25,
                                "max": 0.5
                            },
                            "light": {
                                "min": 0.5,
                                "max": 1
                            },
                            "common": {
                                "min": 1,
                                "max": 2
                            },
                            "strong": {
                                "min": 2,
                                "max": 4
                            },
                            "heavy": {
                                "min": 4,
                                "max": 7.5
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "12 - 18 hours",
                "onset": "20 - 60 minutes",
                "peak": "1 - 6 hours",
                "offset": "6 - 12 hours",
                "after_effects": "Up to 24 hours"
            },
            "addiction_potential": "Moderate to high, with potential for dependence and withdrawal symptoms.",
            "interactions": {
                "dangerous": ["Alcohol", "Opioids"],
                "unsafe": ["Other benzodiazepines", "Barbiturates"],
                "caution": ["Antidepressants", "Antihistamines"]
            },
            "notes": "Lorazepam is known for its sedative and anxiolytic properties. It is often used to treat anxiety disorders, insomnia, and seizures. It is considered to have a low toxicity profile but can lead to dependency with prolonged use.",
            "subjective_effects": [
                "Sedation",
                "Anxiolysis",
                "Muscle relaxation",
                "Diminished inhibitions",
                "Derealization"
            ],
            "tolerance": {
                "full_tolerance": "1 - 2 weeks of continuous use",
                "half_tolerance": "1 week",
                "zero_tolerance": "2 - 4 weeks of abstinence",
                "cross_tolerances": ["Other benzodiazepines"]
            },
            "half_life": "12 - 18 hours",
            "citations": [
                {
                    "name": "Drugs.com - Lorazepam",
                    "reference": "https://www.drugs.com/lorazepam.html"
                },
                {
                    "name": "DrugBank - Lorazepam",
                    "reference": "https://go.drugbank.com/drugs/DB00186"
                }
            ],
            "categories": ["sedative", "benzodiazepine"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Lorazepam",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Clinical pharmacology sources and case reports on benzodiazepines, including lorazepam, with non-oral administration routes (e.g., Goodman & Gilman's The Pharmacological Basis of Therapeutics, 13th Ed.; user reports).",
                        "units": "hours",
                        "total_duration": {
                            "min": 12,
                            "max": 18,
                            "iso": ["PT12H", "PT18H"],
                            "note": "Slightly faster onset via insufflation, but overall duration similar to oral administration."
                        },
                        "onset": {
                            "start": 0.33,
                            "end": 1,
                            "iso_start": ["PT20M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 6,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT6H"]
                        },
                        "offset": {
                            "start": 6,
                            "end": 12,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT12H"]
                        },
                        "after_effects": {
                            "start": 12,
                            "end": 24,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 332,
        "title": "Mirtazapine",
        "content": "# Mirtazapine\n## Tetracyclic antidepressant | Antidepressant\n      \nMirtazapine is known for its sedative effects and is often used to treat insomnia associated with depression. It can cause vivid dreams and nightmares. It is not a reuptake inhibitor, making it different from many other antidepressants.",
        "drug_info": {
            "drug_name": "Mirtazapine",
            "search_url": "https://www.drugs.com/mirtazapine.html",
            "chemical_class": "Tetracyclic antidepressant",
            "psychoactive_class": "Antidepressant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "15 mg",
                            "light": "15-30 mg",
                            "common": "30-45 mg",
                            "strong": "45 mg",
                            "heavy": "60 mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 3.75,
                                "max": 7.5
                            },
                            "light": {
                                "min": 7.5,
                                "max": 15
                            },
                            "common": {
                                "min": 15,
                                "max": 30
                            },
                            "strong": {
                                "min": 30,
                                "max": 45
                            },
                            "heavy": {
                                "min": 45,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "24 hours",
                "onset": "1-2 hours",
                "peak": "4-6 hours",
                "offset": "12-24 hours",
                "after_effects": "Up to 24 hours"
            },
            "addiction_potential": "Low",
            "interactions": {
                "dangerous": ["Dextromethorphan (DXM)"],
                "unsafe": ["Hydrocodone"],
                "caution": ["Psychedelics like LSD"]
            },
            "notes": "Mirtazapine is known for its sedative effects and is often used to treat insomnia associated with depression. It can cause vivid dreams and nightmares. It is not a reuptake inhibitor, making it different from many other antidepressants.",
            "subjective_effects": [
                "Sedation",
                "Vivid dreams",
                "Increased appetite",
                "Calming effects"
            ],
            "tolerance": {
                "full_tolerance": "Not well-documented",
                "half_tolerance": "Not well-documented",
                "zero_tolerance": "Not well-documented",
                "cross_tolerances": []
            },
            "half_life": "20-40 hours",
            "citations": [
                {
                    "name": "Drugs.com - Mirtazapine",
                    "reference": "https://www.drugs.com/mirtazapine.html"
                },
                {
                    "name": "DrugBank - Mirtazapine Overview",
                    "reference": "https://go.drugbank.com/drugs/DB00370"
                },
                {
                    "name": "DrugBank Article A177892",
                    "reference": "https://go.drugbank.com/articles/A177892"
                },
                {
                    "name": "DrugBank Article A177946",
                    "reference": "https://go.drugbank.com/articles/A177946"
                },
                {
                    "name": "DrugBank Article A555",
                    "reference": "https://go.drugbank.com/articles/A555"
                }
            ],
            "categories": ["antidepressant", "sedative"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Mirtazapine",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Mirtazapine is most commonly administered orally and is not recommended for insufflation due to potential for nasal irritation, low bioavailability through this route, and limited evidence. The provided values are an extrapolation based on pharmacokinetics of oral use (half-life 20-40 hours) and anecdotal reports. See: 'Mirtazapine: a review of its pharmacology and clinical efficacy' - Drugs. 2000;59(2):185-205.",
                        "units": "hours",
                        "total_duration": {
                            "min": 12,
                            "max": 24,
                            "iso": ["PT12H", "PT24H"],
                            "note": "Long duration due to extended half-life even with non-oral use."
                        },
                        "onset": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        },
                        "peak": {
                            "start": 4,
                            "end": 6,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT6H"]
                        },
                        "offset": {
                            "start": 12,
                            "end": 24,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT24H"]
                        },
                        "after_effects": {
                            "start": 24,
                            "end": 24,
                            "iso_start": ["PT24H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 333,
        "title": "Memantine",
        "content": "# Memantine\n## Adamantane derivative | Dissociative\n      \nMemantine is primarily used for treating Alzheimer's disease but also exhibits dissociative effects at higher doses. It has a slow absorption and excretion rate, and its effects can be intensified when combined with other substances.",
        "drug_info": {
            "drug_name": "Memantine",
            "search_url": "https://www.erowid.org/pharms/memantine/memantine.shtml",
            "chemical_class": "Adamantane derivative",
            "psychoactive_class": "Dissociative NMDA antagonist",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "10\u201320 mg",
                            "common": "20\u201360 mg",
                            "strong": "60\u2013120 mg",
                            "heavy": "120 mg+"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 2.5,
                                "max": 5
                            },
                            "light": {
                                "min": 5,
                                "max": 20
                            },
                            "common": {
                                "min": 20,
                                "max": 60
                            },
                            "strong": {
                                "min": 60,
                                "max": 120
                            },
                            "heavy": {
                                "min": 120,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "8\u201324 hours (with residual effects up to 3 days)",
                "onset": "30\u201390 minutes",
                "peak": "2\u20138 hours",
                "offset": "6\u201324 hours",
                "after_effects": "24\u201372 hours"
            },
            "addiction_potential": "Low to moderate; physical dependence is uncommon but psychological habituation and pro-tracted mania have been reported.",
            "interactions": {
                "dangerous": [
                    "High-dose alcohol",
                    "Barbiturates",
                    "Deliriant antihistamines"
                ],
                "unsafe": [
                    "Opioids",
                    "Benzodiazepines",
                    "Other NMDA antagonists (ketamine, dextromethorphan, PCP)"
                ],
                "caution": [
                    "Serotonergic psychedelics",
                    "Stimulants",
                    "Nicotine (may potentiate tachycardia)"
                ]
            },
            "notes": "Exceedingly long half-life leads to day-after cognitive fog and potential multi-day dissociation; titration above 20 mg increments should be spaced by \u226572 h to avoid accumulation and toxicity.",
            "subjective_effects": [
                "Mild stimulation",
                "Euphoria",
                "Dissociation",
                "Time dilation",
                "Visual tracers",
                "Cognitive fog",
                "Mania",
                "Amnesia",
                "Introspection",
                "Motor incoordination",
                "Nausea"
            ],
            "tolerance": {
                "full_tolerance": "Develops after ~2\u20133 weeks of daily use",
                "half_tolerance": "Approximately 1 week after cessation",
                "zero_tolerance": "4\u20136 weeks abstinence",
                "cross_tolerances": [
                    "Ketamine",
                    "Dextromethorphan",
                    "PCP",
                    "Amantadine"
                ]
            },
            "half_life": "60\u201380 hours",
            "citations": [
                {
                    "name": "Bluelight \u2013 Memantine thread",
                    "reference": "https://www.bluelight.org/community/threads/memantine.931243/"
                },
                {
                    "name": "Bluelight \u2013 Higher dose discussion",
                    "reference": "https://www.bluelight.org/community/threads/memantine-higher-dose.828751/"
                },
                {
                    "name": "Reddit \u2013 500 mg trip report",
                    "reference": "https://www.reddit.com/r/researchchemicals/comments/fog1hj/accidental_500mg_memantine_trip_report/"
                },
                {
                    "name": "Nervewing \u2013 Ether + Memantine",
                    "reference": "https://nervewing.blogspot.com/2018/04/ether-memantine-3-meo-pce-lsd-4-aco.html"
                },
                {
                    "name": "NCBI StatPearls \u2013 Memantine",
                    "reference": "https://www.ncbi.nlm.nih.gov/books/NBK500025/"
                },
                {
                    "name": "Pharmacokinetics study (PMC6822834)",
                    "reference": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6822834/"
                },
                {
                    "name": "Clinical review (PMC2762361)",
                    "reference": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2762361/"
                },
                {
                    "name": "Memantine vs Ketamine NMDAR study",
                    "reference": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5628409/"
                },
                {
                    "name": "Drugs.com \u2013 Ketamine + Memantine interaction",
                    "reference": "https://www.drugs.com/drug-interactions/ketamine-with-memantine-1411-0-1551-0.html"
                },
                {
                    "name": "Drugs.com \u2013 Alcohol interaction",
                    "reference": "https://www.drugs.com/food-interactions/memantine.html"
                }
            ],
            "categories": ["dissociative", "nootropic", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Memantine",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Memantine is an NMDA antagonist with a long duration of action, especially when insufflated. Values are estimated from user reports and scientific sources describing its pharmacokinetics and subjective timeline.",
                        "units": "hours",
                        "total_duration": {
                            "min": 8,
                            "max": 24,
                            "iso": ["PT8H", "PT24H"],
                            "note": "Residual effects may linger for up to 3 days."
                        },
                        "onset": {
                            "start": 0.5,
                            "end": 1.5,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT1H30M"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 8,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT8H"]
                        },
                        "offset": {
                            "start": 6,
                            "end": 24,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT24H"]
                        },
                        "after_effects": {
                            "start": 24,
                            "end": 72,
                            "iso_start": ["PT24H"],
                            "iso_end": ["PT72H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 335,
        "title": "Naphyrone",
        "content": "# Naphyrone\n## Cathinone | Stimulant\n      \nNaphyrone is known for its prolonged comedown and potential for compulsive redosing. It has been associated with side effects such as jaw grinding and headaches. It has been sold under brand names such as NRG-1 and Energy-1.",
        "drug_info": {
            "drug_name": "Naphyrone",
            "search_url": "https://erowid.org/chemicals/naphyrone/",
            "chemical_class": "Cathinone",
            "psychoactive_class": "Stimulant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "10-20 mg",
                            "common": "20-30 mg",
                            "strong": "30-50 mg",
                            "heavy": "50+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 20
                            },
                            "common": {
                                "min": 20,
                                "max": 35
                            },
                            "strong": {
                                "min": 35,
                                "max": 50
                            },
                            "heavy": {
                                "min": 50,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "6-8 hours",
                "onset": "15-30 minutes",
                "peak": "1-3 hours",
                "offset": "3-5 hours",
                "after_effects": "12-24 hours"
            },
            "addiction_potential": "Moderate, with potential for compulsive use due to its stimulant effects.",
            "interactions": {
                "dangerous": ["MAOIs", "SSRIs"],
                "unsafe": ["Alcohol", "Benzodiazepines"],
                "caution": ["Other stimulants", "Tramadol"]
            },
            "notes": "Naphyrone is known for its prolonged comedown and potential for compulsive redosing. It has been associated with side effects such as jaw grinding and headaches. It has been sold under brand names such as NRG-1 and Energy-1.",
            "subjective_effects": [
                "Euphoria",
                "Increased energy",
                "Alertness",
                "Jaw clenching",
                "Anxiety"
            ],
            "tolerance": {
                "full_tolerance": "Within days of repeated use",
                "half_tolerance": "1-2 weeks",
                "zero_tolerance": "3-4 weeks",
                "cross_tolerances": ["Other stimulants"]
            },
            "half_life": "4-6 hours",
            "citations": [
                {
                    "name": "Erowid Naphyrone Vault",
                    "reference": "https://erowid.org/chemicals/naphyrone/"
                },
                {
                    "name": "DrugWise Naphyrone Factsheet",
                    "reference": "https://www.drugwise.org.uk/naphyrone/"
                },
                {
                    "name": "DrugWise Naphyrone 2010 Report",
                    "reference": "https://www.drugwise.org.uk/wp-content/uploads/Factsheet-Naphyrone.pdf"
                }
            ],
            "categories": ["stimulant", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Naphyrone",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "EMCDDA Report on Naphyrone (2010); user reports and clinical data.",
                        "units": "hours",
                        "total_duration": {
                            "min": 6,
                            "max": 8,
                            "iso": ["PT6H", "PT8H"],
                            "note": "Total span of noticeable effects including onset, peak, and offset."
                        },
                        "onset": {
                            "start": 0.25,
                            "end": 0.5,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT30M"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 3,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 3,
                            "end": 5,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT5H"]
                        },
                        "after_effects": {
                            "start": 12,
                            "end": 24,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 337,
        "title": "AL-LAD",
        "content": "# AL-LAD\n## Lysergamide | Psychedelic\n      \nAL-LAD is a research chemical and its long-term safety profile is not well-studied. It is structurally similar to LSD and shares many of its effects.",
        "drug_info": {
            "drug_name": "AL-LAD",
            "search_url": "https://erowid.org/chemicals/al_lad/",
            "chemical_class": "Lysergamide",
            "psychoactive_class": "Psychedelic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "\n\u00b5g",
                        "dose_ranges": {
                            "threshold": "50 \u00b5g",
                            "light": "50-100 \u00b5g",
                            "common": "100-150 \u00b5g",
                            "strong": "150-225 \u00b5g",
                            "heavy": "225+ \u00b5g"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "ug",
                        "dose_ranges": {
                            "threshold": {
                                "min": 25,
                                "max": 50
                            },
                            "light": {
                                "min": 50,
                                "max": 100
                            },
                            "common": {
                                "min": 100,
                                "max": 150
                            },
                            "strong": {
                                "min": 150,
                                "max": 225
                            },
                            "heavy": {
                                "min": 225,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "6-10 hours",
                "onset": "20-60 minutes",
                "peak": "2-4 hours",
                "offset": "2-4 hours",
                "after_effects": "2-6 hours"
            },
            "addiction_potential": "AL-LAD is considered to have a low addiction potential, similar to other classical psychedelics.",
            "interactions": {
                "dangerous": ["Tramadol"],
                "unsafe": ["Lithium"],
                "caution": ["Cannabis", "Stimulants", "Alcohol"]
            },
            "notes": "AL-LAD is a research chemical and its long-term safety profile is not well-studied. It is structurally similar to LSD and shares many of its effects.",
            "subjective_effects": [
                "Visual distortions",
                "Enhanced colors",
                "Euphoria",
                "Time distortion",
                "Increased introspection",
                "Altered thought patterns"
            ],
            "tolerance": {
                "full_tolerance": "3-7 days",
                "half_tolerance": "1-2 days",
                "zero_tolerance": "7-14 days",
                "cross_tolerances": ["LSD", "Psilocybin"]
            },
            "half_life": "Approximately 5-8 hours",
            "citations": [
                {
                    "name": "Erowid AL-LAD Vault",
                    "reference": "https://erowid.org/chemicals/al_lad/"
                },
                {
                    "name": "AL-LAD: A Lysergamide Psychedelic",
                    "reference": "https://psychonautwiki.org/wiki/AL-LAD"
                }
            ],
            "categories": ["psychedelic", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "AL-LAD",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Based on published scientific literature, user reports, and pharmacological knowledge as of 2024.",
                        "units": "hours",
                        "total_duration": {
                            "min": 6,
                            "max": 10,
                            "iso": ["PT6H", "PT10H"],
                            "note": "Insufflated duration is often somewhat shorter or more abrupt than oral, but in the case of AL-LAD, is still within the typical oral range."
                        },
                        "onset": {
                            "start": 0.33,
                            "end": 1,
                            "iso_start": ["PT20M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "offset": {
                            "start": 4,
                            "end": 8,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT8H"]
                        },
                        "after_effects": {
                            "start": 6,
                            "end": 12,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT12H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 338,
        "title": "4-HO-McPT",
        "content": "# 4-HO-McPT\n## Tryptamine | Psychedelic\n      \n4-HO-McPT is known for its strong visual effects and is considered a mild psychedelic, making it suitable for those new to psychedelics. It is important to approach with caution when combining with other substances due to potential interactions.",
        "drug_info": {
            "drug_name": "4-HO-McPT",
            "search_url": "https://www.erowid.org/chemicals/4_ho_mcpt/4_ho_mcpt.shtml",
            "chemical_class": "Tryptamine",
            "psychoactive_class": "Psychedelic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "10-15 mg",
                            "common": "15-25 mg",
                            "strong": "25-35 mg",
                            "heavy": "35+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 3,
                                "max": 7
                            },
                            "light": {
                                "min": 7,
                                "max": 15
                            },
                            "common": {
                                "min": 15,
                                "max": 25
                            },
                            "strong": {
                                "min": 25,
                                "max": 35
                            },
                            "heavy": {
                                "min": 35,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4-6 hours",
                "onset": "20-40 minutes",
                "peak": "2-3 hours",
                "offset": "1-2 hours",
                "after_effects": "1-3 hours"
            },
            "addiction_potential": "Low, typical of tryptamines with no significant evidence of habit-forming properties.",
            "interactions": {
                "dangerous": ["Tramadol", "MAOIs"],
                "unsafe": ["Lithium", "SSRIs"],
                "caution": ["Stimulants", "Cannabis"]
            },
            "notes": "4-HO-McPT is known for its strong visual effects and is considered a mild psychedelic, making it suitable for those new to psychedelics. It is important to approach with caution when combining with other substances due to potential interactions.",
            "subjective_effects": [
                "Visual enhancements",
                "Euphoria",
                "Relaxation",
                "Colorful visuals",
                "Sociability",
                "Comfort"
            ],
            "tolerance": {
                "full_tolerance": "Within 1 week of repeated use",
                "half_tolerance": "3-4 days",
                "zero_tolerance": "1-2 weeks",
                "cross_tolerances": ["Other tryptamines"]
            },
            "half_life": "Not well-documented, but likely similar to other tryptamines (2-4 hours)",
            "citations": [
                {
                    "name": "Erowid 4-HO-McPT Vault",
                    "reference": "https://erowid.org/chemicals/4_ho_mcpt/4_ho_mcpt.shtml"
                },
                {
                    "name": "Erowid Experience Report - \"Peace and Quiet: An Experience with 4-HO-McPT\"",
                    "reference": "https://www.erowid.org/experiences/exp.php?ID=114963"
                }
            ],
            "categories": ["psychedelic", "research-chemical", "hallucinogen"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "4-HO-McPT",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "User-provided and cross-checked with available trip reports and general tryptamine pharmacology (2024).",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 6,
                            "iso": ["PT4H", "PT6H"],
                            "note": "Duration fits within reported ranges for closely related tryptamines."
                        },
                        "onset": {
                            "start": 0.33,
                            "end": 0.67,
                            "iso_start": ["PT20M"],
                            "iso_end": ["PT40M"]
                        },
                        "peak": {
                            "start": 0.67,
                            "end": 3,
                            "iso_start": ["PT40M"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 3,
                            "end": 5,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT5H"]
                        },
                        "after_effects": {
                            "start": 5,
                            "end": 9,
                            "iso_start": ["PT5H"],
                            "iso_end": ["PT9H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 340,
        "title": "4-Methylethcathinone (4-MEC)",
        "content": "# 4-MEC\n## Substituted cathinone | Stimulant\n      \n4-MEC is often compared to mephedrone (4-MMC) but is considered less potent. It has a reputation for being forgiving on both the mind and body, though it can still pose risks, especially with high doses or frequent use. It has been marketed as a replacement for mephedrone and often appears in 'NRG-2' samples.",
        "drug_info": {
            "drug_name": "4-MEC (4-Methylethcathinone)",
            "search_url": "https://www.erowid.org/chemicals/4_methylethcathinone/4_methylethcathinone.shtml",
            "chemical_class": "Substituted cathinone",
            "psychoactive_class": "Stimulant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "10 mg",
                            "light": "20-50 mg",
                            "common": "50-100 mg",
                            "strong": "100-150 mg",
                            "heavy": "150+ mg"
                        }
                    },
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "20 mg",
                            "light": "50-100 mg",
                            "common": "100-150 mg",
                            "strong": "150-200 mg",
                            "heavy": "200+ mg"
                        }
                    },
                    {
                        "route": "IV",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5 mg",
                            "light": "10-30 mg",
                            "common": "30-60 mg",
                            "strong": "60-100 mg",
                            "heavy": "100+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 10,
                                "max": 20
                            },
                            "light": {
                                "min": 20,
                                "max": 50
                            },
                            "common": {
                                "min": 50,
                                "max": 100
                            },
                            "strong": {
                                "min": 100,
                                "max": 150
                            },
                            "heavy": {
                                "min": 150,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 20,
                                "max": 50
                            },
                            "light": {
                                "min": 50,
                                "max": 100
                            },
                            "common": {
                                "min": 100,
                                "max": 150
                            },
                            "strong": {
                                "min": 150,
                                "max": 200
                            },
                            "heavy": {
                                "min": 200,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "intravenous",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 30
                            },
                            "common": {
                                "min": 30,
                                "max": 60
                            },
                            "strong": {
                                "min": 60,
                                "max": 100
                            },
                            "heavy": {
                                "min": 100,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "3-6 hours",
                "onset": "10-30 minutes",
                "peak": "1-2 hours",
                "offset": "1-3 hours",
                "after_effects": "2-6 hours"
            },
            "addiction_potential": "Moderate, with potential for psychological dependence.",
            "interactions": {
                "dangerous": ["MAOIs", "SSRIs"],
                "unsafe": ["Alcohol", "Benzodiazepines"],
                "caution": ["Other stimulants", "Cannabis"]
            },
            "notes": "4-MEC is often compared to mephedrone (4-MMC) but is considered less potent. It has a reputation for being forgiving on both the mind and body, though it can still pose risks, especially with high doses or frequent use. It has been marketed as a replacement for mephedrone and often appears in 'NRG-2' samples.",
            "subjective_effects": [
                "Euphoria",
                "Increased sociability",
                "Calm euphoria",
                "Sedation",
                "Aphrodisiac effects",
                "Warmth",
                "Over-caffeination"
            ],
            "tolerance": {
                "full_tolerance": "Within a few days of repeated use",
                "half_tolerance": "1-2 weeks",
                "zero_tolerance": "3-4 weeks",
                "cross_tolerances": ["Other cathinones"]
            },
            "half_life": "Unknown",
            "citations": [
                {
                    "name": "Erowid 4-MEC Vault",
                    "reference": "https://erowid.org/chemicals/4_mec/4_mec.shtml"
                },
                {
                    "name": "Erowid 4-Methylethcathinone (4-MEC) Overview",
                    "reference": "https://www.erowid.org/chemicals/4_methylethcathinone/4_methylethcathinone.shtml"
                }
            ],
            "categories": [
                "stimulant",
                "research-chemical",
                "empathogen",
                "sedative"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "4-MEC (4-Methylethcathinone)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Academic sources on synthetic cathinones and 4-MEC (see e.g. EMCDDA, scientific publication reviews, and user report meta-analyses as of 2023)",
                        "units": "hours",
                        "total_duration": {
                            "min": 3,
                            "max": 6,
                            "iso": ["PT3H", "PT6H"],
                            "note": "Short-acting stimulant, with rapid onset and moderate duration typical of cathinone derivatives taken intranasally."
                        },
                        "onset": {
                            "start": 0.17,
                            "end": 0.5,
                            "iso_start": ["PT10M"],
                            "iso_end": ["PT30M"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 2,
                            "end": 5,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT5H"]
                        },
                        "after_effects": {
                            "start": 2,
                            "end": 6,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT6H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 341,
        "title": "5-DBFPV",
        "content": "# 5-DBFPV\n## Synthetic cathinone (\u03b1-pyrrolidinophenone subtype) | Stimulant (NDRI-type)\n      \nLegally controlled in multiple jurisdictions (e.g., Sweden Schedule I; UK Class B). Analytical papers show it is occasionally mis-sold for \u03b1-PVP/MDPV analogues; reagent tests may give weak Marquis reactions, so laboratory confirmation is advised. Reports highlight pronounced vasoconstriction, headaches, and powerful psychological reinforcement; strong harm-reduction emphasis on milligram-accurate scales and strict session limits.",
        "drug_info": {
            "drug_name": "5-DBFPV",
            "search_url": "https://en.wikipedia.org/wiki/5-DBFPV",
            "chemical_class": "Synthetic cathinone (\u03b1-pyrrolidinophenone subtype)",
            "psychoactive_class": "Stimulant (NDRI-type)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "5\u201310 mg",
                            "light": "10\u201320 mg",
                            "common": "20\u201335 mg",
                            "strong": "35\u201360 mg",
                            "heavy": "60 mg+"
                        }
                    },
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "15 mg",
                            "light": "20\u201340 mg",
                            "common": "40\u201375 mg",
                            "strong": "75\u2013120 mg",
                            "heavy": "120 mg+"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 5,
                                "max": 10
                            },
                            "light": {
                                "min": 10,
                                "max": 20
                            },
                            "common": {
                                "min": 20,
                                "max": 35
                            },
                            "strong": {
                                "min": 35,
                                "max": 60
                            },
                            "heavy": {
                                "min": 60,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 15,
                                "max": 20
                            },
                            "light": {
                                "min": 20,
                                "max": 40
                            },
                            "common": {
                                "min": 40,
                                "max": 75
                            },
                            "strong": {
                                "min": 75,
                                "max": 120
                            },
                            "heavy": {
                                "min": 120,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "3\u20136 h (core stimulation) \u2022 residual after-effects up to 12 h",
                "onset": "Insufflated 5\u201315 min \u2022 Oral 15\u201345 min",
                "peak": "30\u201390 min",
                "offset": "1\u20133 h",
                "after_effects": "4\u201312 h residual insomnia / low mood"
            },
            "addiction_potential": "High \u2014 compulsive redosing and binge patterns similar to MDPV are repeatedly reported.",
            "interactions": {
                "dangerous": [
                    "MAOIs",
                    "recreational doses of bupropion",
                    "any cathinone or amphetamine stimulant",
                    "synthetic cannabinoids with adrenergic agonism"
                ],
                "unsafe": [
                    "cocaine",
                    "MDMA or other strong monoamine releasers",
                    "high-dose caffeine"
                ],
                "caution": [
                    "nicotine",
                    "alcohol (may mask toxicity)",
                    "benzodiazepines (respiratory depression if large hypnotic doses used after binge)"
                ]
            },
            "notes": "Legally controlled in multiple jurisdictions (e.g., Sweden Schedule I; UK Class B). Analytical papers show it is occasionally mis-sold for \u03b1-PVP/MDPV analogues; reagent tests may give weak Marquis reactions, so laboratory confirmation is advised. Reports highlight pronounced vasoconstriction, headaches, and powerful psychological reinforcement; strong harm-reduction emphasis on milligram-accurate scales and strict session limits.",
            "subjective_effects": [
                "intense mental stimulation",
                "euphoria (dopaminergic)",
                "increased motivation & focus",
                "enhanced wakefulness",
                "anorexia",
                "compulsive redosing",
                "jaw tension",
                "vasoconstriction & cold extremities",
                "anxiety or paranoia at high doses",
                "headache during comedown",
                "insomnia"
            ],
            "tolerance": {
                "full_tolerance": "Develops after 2\u20133 consecutive days of heavy use",
                "half_tolerance": "\u22483\u20137 days of abstinence",
                "zero_tolerance": "2\u20133 weeks",
                "cross_tolerances": [
                    "MDPV",
                    "\u03b1-PVP",
                    "other pyrrolidinophenone cathinones",
                    "cocaine-like NDRIs"
                ]
            },
            "half_life": "Estimated 3\u20135 h (no formal pharmacokinetic study; inferred from structural analogues)",
            "citations": [
                {
                    "name": "5-DBFPV \u2013 compound overview",
                    "reference": "turn0search0"
                },
                {
                    "name": "Bluelight discussion thread (user potency & duration reports)",
                    "reference": "turn0search1"
                },
                {
                    "name": "TripSit/DeDgrl aggregate sheet \u2013 onset & after-effects",
                    "reference": "turn4search1"
                },
                {
                    "name": "Reddit 500 mg insufflated binge case report",
                    "reference": "turn13search3"
                },
                {
                    "name": "Reddit first-experience report (oral 5-DBFPV)",
                    "reference": "turn13search0"
                },
                {
                    "name": "Reddit \u2018any fun to be had?\u2019 dosage discussion",
                    "reference": "turn13search1"
                },
                {
                    "name": "Reddit vaping thread (alternative ROA)",
                    "reference": "turn13search2"
                },
                {
                    "name": "Cerilliant certified reference solution announcement",
                    "reference": "turn2search2"
                },
                {
                    "name": "MDPI Molecules review \u2013 cathinone SAR & abuse liability",
                    "reference": "turn4search5"
                },
                {
                    "name": "LC-QTOF-MS identification paper (forensic case work)",
                    "reference": "turn4search2"
                },
                {
                    "name": "DEA Microgram Journal 2016 \u2013 seizures list",
                    "reference": "turn4search7"
                },
                {
                    "name": "Virginia DFS Toxicology Procedures Manual \u2013 analytical parameters",
                    "reference": "turn4search4"
                }
            ],
            "categories": ["stimulant", "research-chemical", "habit-forming"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "5-DBFPV",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Based on user-provided and cross-checked data from experience reports and scientific literature up to 2024 (excluding psychonautwiki.org).",
                        "units": "hours",
                        "total_duration": {
                            "min": 3,
                            "max": 6,
                            "iso": ["P3H", "P6H"],
                            "note": "Core stimulant effects; longer duration likely for after-effects (insomnia, low mood)"
                        },
                        "onset": {
                            "start": 0.08,
                            "end": 0.25,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT15M"]
                        },
                        "peak": {
                            "start": 0.5,
                            "end": 1.5,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT90M"]
                        },
                        "offset": {
                            "start": 1,
                            "end": 3,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT3H"]
                        },
                        "after_effects": {
                            "start": 4,
                            "end": 12,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT12H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 343,
        "title": "DMHA",
        "content": "# DMHA\n## Aliphatic amine | Stimulant\n      \nDMHA is often used as a pre-workout supplement due to its stimulant properties. It is structurally similar to DMAA and can produce similar effects, though it is generally considered to be less potent.",
        "drug_info": {
            "drug_name": "DMHA (Octodrine)",
            "search_url": "https://erowid.org/chemicals/dmha/",
            "chemical_class": "Aliphatic amine",
            "psychoactive_class": "Stimulant",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "50 mg",
                            "light": "75-100 mg",
                            "common": "100-150 mg",
                            "strong": "150-200 mg",
                            "heavy": "200+ mg"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "25 mg",
                            "light": "50-75 mg",
                            "common": "75-100 mg",
                            "strong": "100-150 mg",
                            "heavy": "150+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 25,
                                "max": 50
                            },
                            "light": {
                                "min": 50,
                                "max": 100
                            },
                            "common": {
                                "min": 100,
                                "max": 150
                            },
                            "strong": {
                                "min": 150,
                                "max": 200
                            },
                            "heavy": {
                                "min": 200,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 15,
                                "max": 30
                            },
                            "light": {
                                "min": 30,
                                "max": 60
                            },
                            "common": {
                                "min": 60,
                                "max": 100
                            },
                            "strong": {
                                "min": 100,
                                "max": 130
                            },
                            "heavy": {
                                "min": 130,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4-6 hours",
                "onset": "20-40 minutes",
                "peak": "1-2 hours",
                "offset": "1-2 hours",
                "after_effects": "2-4 hours"
            },
            "addiction_potential": "Moderate, with potential for psychological dependence due to its stimulant effects.",
            "interactions": {
                "dangerous": ["MAOIs", "SSRIs"],
                "unsafe": ["Other stimulants", "Alcohol"],
                "caution": ["Caffeine", "Nootropics"]
            },
            "notes": "DMHA is often used as a pre-workout supplement due to its stimulant properties. It is structurally similar to DMAA and can produce similar effects, though it is generally considered to be less potent.",
            "subjective_effects": [
                "Increased energy",
                "Enhanced focus",
                "Elevated mood",
                "Appetite suppression",
                "Increased heart rate"
            ],
            "tolerance": {
                "full_tolerance": "1-2 weeks of regular use",
                "half_tolerance": "3-5 days",
                "zero_tolerance": "1-2 weeks",
                "cross_tolerances": ["DMAA", "Caffeine"]
            },
            "half_life": "4-6 hours",
            "citations": [
                {
                    "name": "Erowid DMHA Vault",
                    "reference": "https://erowid.org/chemicals/dmha/"
                }
            ],
            "categories": ["stimulant", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "DMHA (Octodrine)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Based on anecdotal reports and limited clinical data regarding the insufflation of DMHA (Octodrine); see user-supplied and literature-based values for substituted amphetamines and known pharmacokinetics.",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 6,
                            "iso": ["PT4H", "PT6H"],
                            "note": "Total subjective duration includes onset, peak, and offset."
                        },
                        "onset": {
                            "start": 0.33,
                            "end": 0.67,
                            "iso_start": ["PT20M"],
                            "iso_end": ["PT40M"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 2,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "after_effects": {
                            "start": 4,
                            "end": 8,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT8H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 342,
        "title": "25B-NBOH",
        "content": "# 25B-NBOH\n## Phenethylamine | Psychedelic\n      \n25B-NBOH is more toxic than LSD and is often sold as LSD in powder form. Reports indicate that it is difficult to dose safely without risk of adverse effects. Hospitalizations have occurred due to unintentional use.",
        "drug_info": {
            "drug_name": "25B-NBOH",
            "search_url": "https://erowid.org/chemicals/25b_nboh/",
            "chemical_class": "Phenethylamine",
            "psychoactive_class": "Psychedelic",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "buccal",
                        "units": "\n",
                        "dose_ranges": {
                            "threshold": "300 \u00b5g",
                            "light": "300-600 \u00b5g",
                            "common": "600-1000 \u00b5g",
                            "strong": "1000-1500 \u00b5g",
                            "heavy": "1500+ \u00b5g"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "buccal",
                        "units": "ug",
                        "dose_ranges": {
                            "threshold": {
                                "min": 150,
                                "max": 300
                            },
                            "light": {
                                "min": 300,
                                "max": 600
                            },
                            "common": {
                                "min": 600,
                                "max": 1000
                            },
                            "strong": {
                                "min": 1000,
                                "max": 1500
                            },
                            "heavy": {
                                "min": 1500,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "6-10 hours",
                "onset": "20-40 minutes",
                "peak": "2-4 hours",
                "offset": "2-6 hours",
                "after_effects": "up to 12 hours"
            },
            "addiction_potential": "Not habit-forming",
            "interactions": {
                "dangerous": ["Tramadol", "MAOIs"],
                "unsafe": ["Lithium", "SSRIs"],
                "caution": ["Stimulants", "Cannabis"]
            },
            "notes": "25B-NBOH is more toxic than LSD and is often sold as LSD in powder form. Reports indicate that it is difficult to dose safely without risk of adverse effects. Hospitalizations have occurred due to unintentional use.",
            "subjective_effects": [
                "Visual and sensory enhancement",
                "Reality-shifting experiences",
                "Feelings of comfort and lucidity",
                "Euphoria",
                "Stimulation"
            ],
            "tolerance": {
                "full_tolerance": "unknown",
                "half_tolerance": "unknown",
                "zero_tolerance": "unknown",
                "cross_tolerances": ["Other 5-HT2A agonists"]
            },
            "half_life": "unknown",
            "citations": [
                {
                    "name": "Erowid 25B-NBOH Vault",
                    "reference": "https://erowid.org/chemicals/25b_nboh/"
                },
                {
                    "name": "BlueLight Discussion",
                    "reference": "https://www.bluelight.org/community/threads/25b-nboh-is-being-sold-in-powder-form-as-%E2%80%98lsd%E2%80%99-in-melbourne.906464/"
                },
                {
                    "name": "PiHKAL",
                    "reference": "https://isomerdesign.com/pihkal/explore/381"
                }
            ],
            "categories": ["psychedelic", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "25B-NBOH",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Literature on substituted phenethylamines and NBOH analogues; interpretations and cross-comparisons with related compounds (2022\u20132024).",
                        "units": "hours",
                        "total_duration": {
                            "min": 6,
                            "max": 10,
                            "iso": ["PT6H", "PT10H"],
                            "note": "Consistent with reports of NBOH analogues via insufflation where main effects are 6\u201310 hours."
                        },
                        "onset": {
                            "start": 0.33,
                            "end": 0.66,
                            "iso_start": ["PT20M"],
                            "iso_end": ["PT40M"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "offset": {
                            "start": 4,
                            "end": 10,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT10H"]
                        },
                        "after_effects": {
                            "start": 10,
                            "end": 22,
                            "iso_start": ["PT10H"],
                            "iso_end": ["PT22H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 344,
        "title": "SR-17018",
        "content": "# SR-17018\n## Piperidine benzimidazolone; G-protein-biased \u03bc-opioid receptor agonist | Opioid analgesic (atypical, biased)\n      \nSold solely as a research chemical with limited quality control. Users report powerful craving suppression useful for tapering from high-potency opioids. Clinical data in humans are absent; all dosing guidance is extrapolated from rodent studies and anecdotal self-experimentation.",
        "drug_info": {
            "drug_name": "SR-17018",
            "search_url": "https://pubchem.ncbi.nlm.nih.gov/compound/SR-17018",
            "chemical_class": "Piperidine benzimidazolone; G-protein-biased \u03bc-opioid receptor agonist",
            "psychoactive_class": "Opioid analgesic (atypical, biased)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "0.5 mg",
                            "light": "1\u20133 mg",
                            "common": "3\u20136 mg",
                            "strong": "6\u201310 mg",
                            "heavy": "10 mg+"
                        }
                    },
                    {
                        "route": "sublingual",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "0.25 mg",
                            "light": "0.5\u20132 mg",
                            "common": "2\u20135 mg",
                            "strong": "5\u20138 mg",
                            "heavy": "8 mg+"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.5,
                                "max": 1
                            },
                            "light": {
                                "min": 1,
                                "max": 3
                            },
                            "common": {
                                "min": 3,
                                "max": 6
                            },
                            "strong": {
                                "min": 6,
                                "max": 10
                            },
                            "heavy": {
                                "min": 10,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "sublingual",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 0.25,
                                "max": 0.5
                            },
                            "light": {
                                "min": 0.5,
                                "max": 2
                            },
                            "common": {
                                "min": 2,
                                "max": 5
                            },
                            "strong": {
                                "min": 5,
                                "max": 8
                            },
                            "heavy": {
                                "min": 8,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "6\u201310 hours",
                "onset": "15\u201345 minutes",
                "peak": "1\u20133 hours",
                "offset": "4\u20136 hours",
                "after_effects": "2\u20134 hours"
            },
            "addiction_potential": "Moderate to high; animal studies show reduced tolerance relative to morphine, but withdrawal still occurs and user reports note dependence risk.",
            "interactions": {
                "dangerous": [
                    "other opioids",
                    "benzodiazepines",
                    "alcohol",
                    "gabapentinoids"
                ],
                "unsafe": [
                    "barbiturates",
                    "Z-drugs",
                    "respiratory depressants"
                ],
                "caution": [
                    "CYP3A4 inhibitors (e.g., ketoconazole)",
                    "serotonergic antidepressants",
                    "first-generation antihistamines"
                ]
            },
            "notes": "Sold solely as a research chemical with limited quality control. Users report powerful craving suppression useful for tapering from high-potency opioids. Clinical data in humans are absent; all dosing guidance is extrapolated from rodent studies and anecdotal self-experimentation.",
            "subjective_effects": [
                "analgesia",
                "subtle opioid euphoria",
                "strong craving suppression",
                "warmth and relaxation",
                "mild sedation",
                "anxiolysis",
                "constipation",
                "dizziness at higher doses"
            ],
            "tolerance": {
                "full_tolerance": "Typically after 7\u201314 days of round-the-clock use (slower than morphine in rodents)",
                "half_tolerance": "3\u20135 days",
                "zero_tolerance": "2\u20134 weeks abstinence",
                "cross_tolerances": ["other \u03bc-opioid agonists"]
            },
            "half_life": "\u2248 6 hours (mouse plasma; likely similar order of magnitude in humans)",
            "citations": [
                {
                    "name": "PubChem compound record",
                    "reference": "https://pubchem.ncbi.nlm.nih.gov/compound/SR-17018"
                },
                {
                    "name": "MDPI review \u2013 Biased Opioid Receptor Agonists (2021)",
                    "reference": "https://www.mdpi.com/1422-0067/26/5/1862"
                },
                {
                    "name": "PNAS \u2013 G-protein-biased MOR agonists lack tolerance (2021)",
                    "reference": "https://www.pnas.org/doi/10.1073/pnas.2102178118"
                },
                {
                    "name": "Neuropharmacology \u2013 Morphine vs SR-17018 tolerance (2021)",
                    "reference": "https://pubmed.ncbi.nlm.nih.gov/33059217"
                },
                {
                    "name": "Cell \u2013 \u03bcOR cryo-EM structure with SR-17018 (2022)",
                    "reference": "https://www.cell.com/cell/pdf/S0092-8674%2822%2901260-0.pdf"
                },
                {
                    "name": "Reddit dosing guide (r/Opioid_RCs, 2025-02-05)",
                    "reference": "https://www.reddit.com/r/Opioid_RCs/comments/1fxib3h/how_to_dose_sr17018_not_for_humans_of_course_but/"
                },
                {
                    "name": "Bluelight \u2013 SR-17018 made getting clean easy (2025-03-20)",
                    "reference": "https://www.bluelight.org/community/threads/sr-17018-made-getting-clean-seriously-easy.945301/"
                },
                {
                    "name": "Bluelight \u2013 SR-17018 detox thread (2024-09-26)",
                    "reference": "https://www.bluelight.org/community/threads/sr-17018-rc-opioid-detoxes.942039/"
                },
                {
                    "name": "Reddit \u2013 OpiatesRecovery success story (2025-01-18)",
                    "reference": "https://www.reddit.com/r/OpiatesRecovery/comments/1ha67z9/my_journey_out_of_addiction_with_sr17018_a_new_rc/"
                },
                {
                    "name": "CDC \u2013 Alcohol & other drug combinations",
                    "reference": "https://www.cdc.gov/alcohol/about-alcohol-use/other-drug-use.html"
                },
                {
                    "name": "CDC \u2013 Benzodiazepine/opioid overdose data (2021)",
                    "reference": "https://www.cdc.gov/mmwr/volumes/70/wr/mm7034a2.htm"
                },
                {
                    "name": "Comprehensive overview of biased opioid pharmacology (2021)",
                    "reference": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8221262/"
                },
                {
                    "name": "TargetMol datasheet",
                    "reference": "https://www.targetmol.com/compound/sr17018"
                },
                {
                    "name": "Government ACMD report on benzimidazolone opioids (2022)",
                    "reference": "https://www.gov.uk/government/publications/acmd-advice-on-2-benzyl-benzimidazole-and-piperidine-benzimidazolone-opioids"
                },
                {
                    "name": "Bias factor & therapeutic window study (Cell, 2017)",
                    "reference": "https://doi.org/10.1016/j.cell.2017.11.033"
                }
            ],
            "categories": [
                "opioid",
                "research-chemical",
                "depressant",
                "habit-forming"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "SR-17018",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "No formal human trials as of June 2024, estimated from preclinical pharmacology and anecdotal reports.",
                        "units": "hours",
                        "total_duration": {
                            "min": 6,
                            "max": 10,
                            "iso": ["PT6H", "PT10H"],
                            "note": "Duration may vary greatly depending on dose, individual metabolism, and purity."
                        },
                        "onset": {
                            "start": 0.25,
                            "end": 0.75,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT45M"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 3,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 4,
                            "end": 6,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT6H"]
                        },
                        "after_effects": {
                            "start": 6,
                            "end": 10,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT10H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 345,
        "title": "Levomethorphan",
        "content": "# Levomethorphan\n## Morphinan | Opioid\n      \nLevomethorphan is an opioid isomer of dextromethorphan (DXM). Unlike DXM, which is primarily used as a cough suppressant and has dissociative effects at higher doses, levomethorphan acts as a potent opioid analgesic with significant potential for respiratory depression and addiction. Extreme caution is advised due to its potency and risk profile. Levomethorphan is not widely formulated in the US anymore.",
        "drug_info": {
            "drug_name": "Levomethorphan",
            "search_url": "https://pubchem.ncbi.nlm.nih.gov/compound/Levomethorphan",
            "chemical_class": "Morphinan",
            "psychoactive_class": "Opioid",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "1-2 mg",
                            "light": "2-5 mg",
                            "common": "5-10 mg",
                            "strong": "10-15 mg",
                            "heavy": "10+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 1,
                                "max": 2
                            },
                            "light": {
                                "min": 2,
                                "max": 5
                            },
                            "common": {
                                "min": 5,
                                "max": 10
                            },
                            "strong": {
                                "min": 10,
                                "max": 15
                            },
                            "heavy": {
                                "min": 15,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4-8 hours",
                "onset": "20-60 minutes",
                "peak": "1-3 hours",
                "offset": "4-6 hours",
                "after_effects": "2-4 hours"
            },
            "addiction_potential": "High risk of dependency and addiction, similar to other opioids.",
            "interactions": {
                "dangerous": [
                    "alcohol",
                    "benzodiazepines",
                    "other opioids",
                    "barbiturates"
                ],
                "unsafe": ["GHB/GBL", "other CNS depressants"],
                "caution": ["sedatives", "muscle relaxants", "MAOIs"]
            },
            "notes": "Levomethorphan is an opioid isomer of dextromethorphan (DXM). Unlike DXM, which is primarily used as a cough suppressant and has dissociative effects at higher doses, levomethorphan acts as a potent opioid analgesic with significant potential for respiratory depression and addiction. Extreme caution is advised due to its potency and risk profile. Levomethorphan is not widely formulated in the US anymore.",
            "subjective_effects": [
                "Euphoria",
                "Pain relief",
                "Sedation",
                "Respiratory depression",
                "Itching",
                "Nausea"
            ],
            "tolerance": {
                "full_tolerance": "3-5 days of continuous use",
                "half_tolerance": "1-2 weeks",
                "zero_tolerance": "2-4 weeks",
                "cross_tolerances": ["opioids", "opiates"]
            },
            "half_life": "3-6 hours",
            "citations": [
                {
                    "name": "Levomethorphan - PubChem",
                    "reference": "https://pubchem.ncbi.nlm.nih.gov/compound/Levomethorphan"
                },
                {
                    "name": "Levomethorphan - BlueLight Discussion",
                    "reference": "https://www.bluelight.org/community/threads/levomethorphan.631460/"
                }
            ],
            "categories": ["opioid"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Levomethorphan",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Levomethorphan is an opioid prodrug with limited human recreational use data. Duration estimates based primarily on analogies to other morphinan opioids and rare case/experience reports. See: Opiate duration tables (Erowid), limited clinical pharmacology data, and broader opioid/narcotic class information.",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 8,
                            "iso": ["PT4H", "PT8H"],
                            "note": "Duration may vary with dose and individual metabolism. Data extrapolated from similar opioids and scarce case reports."
                        },
                        "onset": {
                            "start": 0.33,
                            "end": 1,
                            "iso_start": ["PT20M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 3,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 4,
                            "end": 6,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT6H"]
                        },
                        "after_effects": {
                            "start": 6,
                            "end": 10,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT10H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 182,
        "title": "Sernyl",
        "content": "# Phencyclidine (PCP)\n## Arylcyclohexylamine | Dissociative\n      \nPCP is a potent dissociative with significant risks, including psychosis, violent behavior, seizures, and long-lasting cognitive impairment. Overdose can be life-threatening. Effects are highly dose-dependent and unpredictable. PCP is illegal in most countries. It was originally developed as a veterinary anesthetic but discontinued due to severe side effects in humans.",
        "drug_info": {
            "drug_name": "Phencyclidine (PCP)",
            "search_url": "https://en.wikipedia.org/wiki/Phencyclidine",
            "chemical_class": "Arylcyclohexylamine",
            "psychoactive_class": "Dissociative",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "1-3 mg",
                            "light": "3-5 mg",
                            "common": "5-10 mg",
                            "strong": "10-20 mg",
                            "heavy": "20+ mg"
                        }
                    },
                    {
                        "route": "smoked",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "1-2 mg",
                            "light": "2-5 mg",
                            "common": "5-10 mg",
                            "strong": "10-20 mg",
                            "heavy": "20+ mg"
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "1-2 mg",
                            "light": "2-5 mg",
                            "common": "5-10 mg",
                            "strong": "10-20 mg",
                            "heavy": "20+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 1,
                                "max": 3
                            },
                            "light": {
                                "min": 3,
                                "max": 5
                            },
                            "common": {
                                "min": 5,
                                "max": 10
                            },
                            "strong": {
                                "min": 10,
                                "max": 20
                            },
                            "heavy": {
                                "min": 20,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "smoked",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 1,
                                "max": 2
                            },
                            "light": {
                                "min": 2,
                                "max": 5
                            },
                            "common": {
                                "min": 5,
                                "max": 10
                            },
                            "strong": {
                                "min": 10,
                                "max": 20
                            },
                            "heavy": {
                                "min": 20,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 1,
                                "max": 2
                            },
                            "light": {
                                "min": 2,
                                "max": 5
                            },
                            "common": {
                                "min": 5,
                                "max": 10
                            },
                            "strong": {
                                "min": 10,
                                "max": 20
                            },
                            "heavy": {
                                "min": 20,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4-8 hours (can be longer depending on dose and route)",
                "onset": "2-60 minutes (oral: 30-60 min, smoked/insufflated: 2-10 min)",
                "peak": "2-4 hours",
                "offset": "2-4 hours",
                "after_effects": "Up to 24 hours (residual effects, cognitive disturbances)"
            },
            "addiction_potential": "Moderate to high. PCP can be habit-forming and lead to psychological dependence. Chronic use may result in compulsive use patterns.",
            "interactions": {
                "dangerous": [
                    "Other dissociatives (e.g., ketamine, DXM)",
                    "MAOIs",
                    "Tramadol (seizure risk)"
                ],
                "unsafe": [
                    "Alcohol (increased risk of respiratory depression, blackouts)",
                    "Benzodiazepines (risk of dangerous sedation, memory loss)"
                ],
                "caution": [
                    "Stimulants (increased risk of psychosis, cardiovascular strain)",
                    "Antidepressants (potential for unpredictable interactions)"
                ]
            },
            "notes": "PCP is a potent dissociative with significant risks, including psychosis, violent behavior, seizures, and long-lasting cognitive impairment. Overdose can be life-threatening. Effects are highly dose-dependent and unpredictable. PCP is illegal in most countries. It was originally developed as a medical anesthetic under the brand name Sernyl, later restricted to veterinary applications, and finally was discontinued due to severe side effects in humans.",
            "subjective_effects": [
                "Dissociation",
                "Euphoria",
                "Hallucinations (visual and auditory)",
                "Numbness",
                "Analgesia",
                "Delusions",
                "Agitation",
                "Paranoia",
                "Amnesia",
                "Motor impairment",
                "Disorganized thinking"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (within days)",
                "half_tolerance": "~1-2 weeks",
                "zero_tolerance": "2-4 weeks",
                "cross_tolerances": [
                    "Other dissociatives (e.g., ketamine, DXM)"
                ]
            },
            "half_life": "7-46 hours (highly variable depending on individual and dose)",
            "citations": [
                {
                    "name": "Erowid PCP Basics",
                    "reference": "https://www.erowid.org/chemicals/pcp/pcp_basics.shtml"
                },
                {
                    "name": "DrugWise PCP",
                    "reference": "https://www.drugwise.org.uk/pcp/"
                },
                {
                    "name": "TripSit PCP Factsheet",
                    "reference": "https://tripsit.me/factsheets/pcp"
                },
                {
                    "name": "DrugBank: Phencyclidine",
                    "reference": "https://go.drugbank.com/drugs/DB03575"
                }
            ],
            "categories": ["dissociative", "hallucinogen", "research-chemical"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Phencyclidine (PCP)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Academic literature (Julien, 2010; Drugs.com; user experience reports)",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 8,
                            "iso": ["PT4H", "PT8H"],
                            "note": "Higher doses or certain individual factors can prolong duration. After-effects can persist beyond the window of main effects."
                        },
                        "onset": {
                            "start": 0.03,
                            "end": 0.17,
                            "iso_start": ["PT2M"],
                            "iso_end": ["PT10M"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "offset": {
                            "start": 4,
                            "end": 8,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT8H"]
                        },
                        "after_effects": {
                            "start": 8,
                            "end": 24,
                            "iso_start": ["PT8H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 124,
        "title": "Diazepam",
        "content": "# Diazepam (Valium)",
        "drug_info": {
            "drug_name": "Diazepam (Valium)",
            "search_url": "https://www.drug-do.se/benzos?name=diazepam",
            "chemical_class": "Benzodiazepine",
            "psychoactive_class": "Depressant (Benzodiazepine)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "1 mg",
                            "light": "2-5 mg",
                            "common": "5-10 mg",
                            "strong": "10-20 mg",
                            "heavy": "20+ mg"
                        }
                    },
                    {
                        "route": "IV",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "1 mg",
                            "light": "2-5 mg",
                            "common": "5-10 mg",
                            "strong": "10-20 mg",
                            "heavy": "20+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 1,
                                "max": 2
                            },
                            "light": {
                                "min": 2,
                                "max": 5
                            },
                            "common": {
                                "min": 5,
                                "max": 10
                            },
                            "strong": {
                                "min": 10,
                                "max": 20
                            },
                            "heavy": {
                                "min": 20,
                                "max": null
                            }
                        }
                    },
                    {
                        "route": "intravenous",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 1,
                                "max": 2
                            },
                            "light": {
                                "min": 2,
                                "max": 5
                            },
                            "common": {
                                "min": 5,
                                "max": 10
                            },
                            "strong": {
                                "min": 10,
                                "max": 20
                            },
                            "heavy": {
                                "min": 20,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "12-24 hours",
                "onset": "15-60 minutes (oral)",
                "peak": "1-2 hours (oral)",
                "offset": "6-12 hours (primary effects), up to 24 hours (residual)",
                "after_effects": "Can last up to 48 hours due to long half-life"
            },
            "addiction_potential": "Moderate to high. Diazepam has a significant risk of dependence and withdrawal, especially with prolonged or high-dose use.",
            "interactions": {
                "dangerous": ["Alcohol", "Opioids", "Other CNS depressants"],
                "unsafe": ["Barbiturates", "Other benzodiazepines"],
                "caution": [
                    "Antidepressants",
                    "Antipsychotics",
                    "Certain anticonvulsants"
                ]
            },
            "notes": "Diazepam is a long-acting benzodiazepine with rapid onset, commonly used to treat anxiety, panic disorders, alcohol withdrawal, muscle spasms, and seizures. It is considered the standard by which other benzodiazepines are compared. Tolerance, dependence, and withdrawal are significant risks, especially with long-term use. Overdose risk increases when combined with other depressants such as alcohol or opioids.",
            "subjective_effects": [
                "Anxiolysis (anxiety reduction)",
                "Sedation",
                "Muscle relaxation",
                "Disinhibition",
                "Euphoria (in some cases)",
                "Amnesia",
                "Impaired coordination",
                "Drowsiness",
                "Cognitive impairment"
            ],
            "tolerance": {
                "full_tolerance": "Develops within 2-4 weeks of regular use",
                "half_tolerance": "1-2 weeks after cessation",
                "zero_tolerance": "4-8 weeks after cessation",
                "cross_tolerances": ["Other benzodiazepines", "Barbiturates"]
            },
            "half_life": "20-70 hours (parent compound); active metabolites may extend effects up to 100 hours",
            "citations": [
                {
                    "name": "DrugBank: Diazepam",
                    "reference": "https://go.drugbank.com/drugs/DB00829"
                },
                {
                    "name": "Erowid: Diazepam Vault",
                    "reference": "https://www.erowid.org/pharms/diazepam/"
                },
                {
                    "name": "TripSit Factsheet: Diazepam",
                    "reference": "https://tripsit.me/factsheets/diazepam"
                },
                {
                    "name": "DrugWise: Valium (Diazepam)",
                    "reference": "https://www.drugwise.org.uk/valium/"
                }
            ],
            "categories": [
                "depressant",
                "benzodiazepine",
                "sedative",
                "habit-forming"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Diazepam (Valium)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Diazepam (Valium) insufflated \u2014 clinical literature and anecdotal reports (2024)",
                        "units": "hours",
                        "total_duration": {
                            "min": 8,
                            "max": 18,
                            "iso": ["PT8H", "PT18H"],
                            "note": "Insufflation may shorten onset slightly but does not greatly reduce duration compared to oral use due to hepatic metabolism."
                        },
                        "onset": {
                            "start": 0.25,
                            "end": 1,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 1,
                            "end": 3,
                            "iso_start": ["PT1H"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 6,
                            "end": 12,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT12H"]
                        },
                        "after_effects": {
                            "start": 12,
                            "end": 48,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT48H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 44,
        "title": "Dextromethorphan",
        "content": "# Dextromethorphan (DXM)",
        "drug_info": {
            "drug_name": "Dextromethorphan (DXM)",
            "search_url": "https://wiki.tripsit.me/wiki/DXM",
            "chemical_class": "Morphinan (Levorphanol derivative, codeine analog)",
            "psychoactive_class": "Dissociative, antitussive, hallucinogen",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "~30 mg",
                            "light": "30-100 mg",
                            "common": "100-400 mg",
                            "strong": "400-800 mg",
                            "heavy": "800+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 10,
                                "max": 30
                            },
                            "light": {
                                "min": 30,
                                "max": 100
                            },
                            "common": {
                                "min": 100,
                                "max": 400
                            },
                            "strong": {
                                "min": 400,
                                "max": 800
                            },
                            "heavy": {
                                "min": 800,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "4-8 hours (dose-dependent)",
                "onset": "15-60 minutes",
                "peak": "1.5-3 hours",
                "offset": "3-6 hours",
                "after_effects": "2-24 hours (residual effects possible)"
            },
            "addiction_potential": "Moderate. Risk of psychological dependence with frequent use; physical dependence is rare but possible with chronic high doses.",
            "interactions": {
                "dangerous": [
                    "MAOIs",
                    "SSRIs",
                    "SNRIs",
                    "Tramadol",
                    "Other serotonergic drugs (risk of serotonin syndrome)"
                ],
                "unsafe": ["Alcohol", "Other dissociatives", "Opioids"],
                "caution": ["Stimulants", "Antidepressants", "Antipsychotics"]
            },
            "notes": "DXM is widely available in over-the-counter cough medicines. Recreational use at high doses can cause dissociation, hallucinations, and impaired motor function. Some formulations contain other active ingredients (e.g., acetaminophen, chlorpheniramine) that can be dangerous or fatal at recreational doses. Always check product ingredients before use. High doses can cause neurotoxicity, liver damage (if combined with acetaminophen), and potentially fatal serotonin syndrome if combined with serotonergic drugs.",
            "subjective_effects": [
                "Dissociation",
                "Euphoria",
                "Visual and auditory hallucinations",
                "Altered time perception",
                "Impaired motor control",
                "Nausea",
                "Confusion",
                "Sedation",
                "Out-of-body experiences",
                "Cognitive impairment"
            ],
            "tolerance": {
                "full_tolerance": "Develops rapidly with repeated use (within days)",
                "half_tolerance": "~1-2 weeks",
                "zero_tolerance": "~3-4 weeks after cessation",
                "cross_tolerances": [
                    "Other dissociatives (e.g., ketamine, PCP)"
                ]
            },
            "half_life": "2-4 hours (parent compound); active metabolite dextrorphan: 3-6 hours",
            "citations": [
                {
                    "name": "TripSit DXM Wiki",
                    "reference": "https://wiki.tripsit.me/wiki/DXM"
                },
                {
                    "name": "Erowid DXM General Info",
                    "reference": "https://www.erowid.org/chemicals/dxm/faq/dxm_general_info.shtml"
                },
                {
                    "name": "DrugBank: Dextromethorphan",
                    "reference": "https://go.drugbank.com/drugs/DB00514"
                }
            ],
            "categories": [
                "dissociative",
                "hallucinogen",
                "depressant",
                "research-chemical"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Dextromethorphan (DXM)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Relevant literature, user experience reports, and clinical sources on insufflated dextromethorphan pharmacokinetics (2024).",
                        "units": "hours",
                        "total_duration": {
                            "min": 4,
                            "max": 8,
                            "iso": ["PT4H", "PT8H"],
                            "note": "Dose-dependent variability; higher doses tend to display longer durations. Insufflation generally produces a shorter and more intense experience than oral administration."
                        },
                        "onset": {
                            "start": 0.25,
                            "end": 1,
                            "iso_start": ["PT15M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 1.5,
                            "end": 3,
                            "iso_start": ["PT1H30M"],
                            "iso_end": ["PT3H"]
                        },
                        "offset": {
                            "start": 3,
                            "end": 6,
                            "iso_start": ["PT3H"],
                            "iso_end": ["PT6H"]
                        },
                        "after_effects": {
                            "start": 2,
                            "end": 24,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT24H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 62,
        "title": "MDA",
        "content": "",
        "drug_info": {
            "drug_name": "3,4-Methylenedioxyamphetamine (MDA)",
            "search_url": "https://bluedark.org/substance/3,4-methylenedioxyamphetamine",
            "chemical_class": "Phenethylamine; Amphetamine",
            "psychoactive_class": "Psychedelic; Stimulant; Empathogen-entactogen",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "30 mg",
                            "light": "50-80 mg",
                            "common": "80-150 mg",
                            "strong": "150-250 mg",
                            "heavy": "250+ mg"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "oral",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 30,
                                "max": 50
                            },
                            "light": {
                                "min": 50,
                                "max": 80
                            },
                            "common": {
                                "min": 80,
                                "max": 150
                            },
                            "strong": {
                                "min": 150,
                                "max": 250
                            },
                            "heavy": {
                                "min": 250,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "6-12 hours",
                "onset": "20-60 minutes",
                "peak": "2-4 hours",
                "offset": "2-6 hours",
                "after_effects": "up to 24 hours (residual)"
            },
            "addiction_potential": "Moderate. MDA is not considered physically addictive, but psychological dependence can develop with frequent use.",
            "interactions": {
                "dangerous": ["MAOIs", "SSRIs", "other stimulants"],
                "unsafe": ["other serotonergic drugs"],
                "caution": ["alcohol", "cannabis", "other psychedelics"]
            },
            "notes": "MDA is a potent entactogen and psychedelic, sometimes sold as 'sass' or 'sassafras.' It is more stimulating and hallucinogenic than MDMA, with a higher risk of neurotoxicity. Overdose can cause hyperthermia, serotonin syndrome, and cardiovascular complications. Use caution with dosing, as effects can be unpredictable and individual sensitivity varies.",
            "subjective_effects": [
                "Euphoria",
                "Empathy",
                "Stimulation",
                "Visual hallucinations",
                "Enhanced tactile sensations",
                "Increased sociability",
                "Mild dissociation",
                "Anxiety (at high doses)",
                "Jaw clenching",
                "Insomnia"
            ],
            "tolerance": {
                "full_tolerance": "After repeated use over several days",
                "half_tolerance": "~1 week",
                "zero_tolerance": "2-4 weeks",
                "cross_tolerances": ["MDMA", "other substituted amphetamines"]
            },
            "half_life": "6-16 hours (variable)",
            "citations": [
                {
                    "name": "Erowid MDA Vault",
                    "reference": "https://www.erowid.org/chemicals/mda/"
                },
                {
                    "name": "DrugBank: MDA",
                    "reference": "https://go.drugbank.com/drugs/DB01509"
                },
                {
                    "name": "Drug Users Bible: MDA",
                    "reference": "https://www.drugusersbible.com/3_4-methylenedioxyamphetamine.html"
                }
            ],
            "categories": [
                "empathogen",
                "stimulant",
                "research-chemical",
                "hallucinogen"
            ],
            "durations_parsed": {
                "insufflated": {
                    "drug": "3,4-Methylenedioxyamphetamine (MDA)",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Daniel Trachsel, David E. Nichols, Charles S. Grob (2021). 'Handbook of Experimental Pharmacology 273: Phenethylamine Hallucinogens'. Experience reports and published clinical/pharmacological studies on MDA.",
                        "units": "hours",
                        "total_duration": {
                            "min": 6,
                            "max": 12,
                            "iso": ["PT6H", "PT12H"],
                            "note": "Range reflects individual differences and dose."
                        },
                        "onset": {
                            "start": 0.33,
                            "end": 1,
                            "iso_start": ["PT20M"],
                            "iso_end": ["PT1H"]
                        },
                        "peak": {
                            "start": 2,
                            "end": 4,
                            "iso_start": ["PT2H"],
                            "iso_end": ["PT4H"]
                        },
                        "offset": {
                            "start": 4,
                            "end": 10,
                            "iso_start": ["PT4H"],
                            "iso_end": ["PT10H"]
                        },
                        "after_effects": {
                            "start": 12,
                            "end": 36,
                            "iso_start": ["PT12H"],
                            "iso_end": ["PT36H"]
                        }
                    }
                }
            }
        }
    },
    {
        "id": 346,
        "title": "Tilmetamine",
        "content": "# Tilmetamine\n## Arylcyclohexylamine | Dissociative anesthetic (NMDA receptor antagonist)\n      \nExtremely potent with a narrow safety margin; microgram\u2011accurate scales essential. Multiple reports of multi\u2011day dysphoria, vestibular disturbance and tremor from single 10\u201320\u202fmg doses. No clinical data; start at micro\u2011doses and avoid redosing.",
        "drug_info": {
            "drug_name": "Tilmetamine",
            "search_url": "https://ivolabs.com/product/tilmetamine-eu/",
            "chemical_class": "Arylcyclohexylamine",
            "psychoactive_class": "Dissociative anesthetic (NMDA receptor antagonist)",
            "dosages": {
                "routes_of_administration": [
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": "1\u20132 mg",
                            "light": "2\u20135 mg",
                            "common": "5\u201310 mg",
                            "strong": "10\u201320 mg",
                            "heavy": "20 mg+"
                        }
                    }
                ],
                "routes_of_administration_parsed": [
                    {
                        "route": "insufflated",
                        "units": "mg",
                        "dose_ranges": {
                            "threshold": {
                                "min": 1,
                                "max": 2
                            },
                            "light": {
                                "min": 2,
                                "max": 5
                            },
                            "common": {
                                "min": 5,
                                "max": 10
                            },
                            "strong": {
                                "min": 10,
                                "max": 20
                            },
                            "heavy": {
                                "min": 20,
                                "max": null
                            }
                        }
                    }
                ]
            },
            "duration": {
                "total_duration": "8\u201324 hours (highly dose\u2011dependent)",
                "onset": "5\u201315 minutes",
                "peak": "0.5\u20132 hours",
                "offset": "6\u201312 hours",
                "after_effects": "Residual vertigo/tremor may persist 1\u20133 days after heavy dosing"
            },
            "addiction_potential": "Unknown; presumed moderate. Rapid tolerance typical of dissociatives, but severe adverse effects discourage repeated use.",
            "interactions": {
                "dangerous": [
                    "MAOIs",
                    "DXM",
                    "Tramadol",
                    "High\u2011dose ethanol"
                ],
                "unsafe": [
                    "Opioids",
                    "Benzodiazepines",
                    "Other NMDA antagonists"
                ],
                "caution": [
                    "Stimulants (tachycardia)",
                    "SSRIs (serotonergic load)",
                    "Cannabis (disorientation)"
                ]
            },
            "notes": "Tilmetamine (2\u2011(methylamino)\u20112\u2011(thiophen\u20112\u2011yl)cyclohexan\u20111\u2011one) is the N\u2011methyl homolog of tiletamine that surfaced on the gray area RC market in 2024. First\u2011hand accounts on Bluelight and Reddit describe a compound 5\u20137\u202f\u00d7 stronger than ketamine, where 2\u20135\u202fmg insufflated already elicits dissociation and 20\u202fmg has left users with vertigo, tremor and depersonalisation lasting days . Vendors list Tilmetamine\u202f\u00b7\u202fHCl as a white crystalline powder with NMDA\u2011antagonist action, rapid onset (1\u201310\u202fmin IM/IN) and a 1\u20132\u202fh elimination half\u2011life.Tilmetamine is extremely potent with a narrow safety margin; microgram\u2011accurate scales essential. Multiple reports of multi\u2011day dysphoria, vestibular disturbance and tremor from single 10\u201320\u202fmg doses. No clinical data; start at micro\u2011doses and avoid redosing.",
            "subjective_effects": [
                "Profound dissociation",
                "Analgesia",
                "Motor impairment",
                "Vertigo",
                "Body tremors",
                "Visual distortions",
                "Auditory enhancement",
                "Time dilation",
                "Emergence delirium",
                "Residual cognitive fog"
            ],
            "tolerance": {
                "full_tolerance": "Develops after 3\u20135 consecutive daily doses",
                "half_tolerance": "1\u20132 weeks",
                "zero_tolerance": "4\u20136 weeks",
                "cross_tolerances": ["Ketamine", "Tiletamine", "PCP analogs"]
            },
            "half_life": "1\u20132 hours (extrapolated from animal data)",
            "citations": [
                {
                    "name": "Bluelight Tilmetamine thread (2024\u201108\u201106)",
                    "reference": "https://www.bluelight.org/community/threads/tilmetamine.940958/"
                },
                {
                    "name": "Reddit \u2013 The Tilmetamine Horror Stories (2024\u201110\u201118)",
                    "reference": "https://www.reddit.com/r/researchchemicals/comments/1gnokvt/the_tilmetamine_horror_stories/"
                },
                {
                    "name": "Reddit \u2013 Stay Away from Tilmetamine (2024\u201109\u201112)",
                    "reference": "https://www.reddit.com/r/researchchemicals/comments/1fk5625/update_stay_away_from_tilmetamine/"
                },
                {
                    "name": "IVOLABS product monograph",
                    "reference": "https://ivolabs.com/product/tilmetamine-eu/"
                },
                {
                    "name": "Rechemco product brief",
                    "reference": "https://rechemco.to/tilmetamine-eu/"
                },
                {
                    "name": "Russian Market Trend Analysis Issue\u202f57 (2024\u201109)",
                    "reference": "https://www.researchgate.net/publication/384561415_Psychoactive_products_market_observation_Trend_analysis_Issue_57_September_2024"
                },
                {
                    "name": "Russian Market Trend Analysis Issue\u202f60 (2024\u201112)",
                    "reference": "https://www.researchgate.net/publication/387518211_Psychoactive_products_market_observation_Trend_analysis_Issue_60_December_2024"
                },
                {
                    "name": "Arylcyclohexylamine derivatives \u2013 PubMed review",
                    "reference": "https://pubmed.ncbi.nlm.nih.gov/30196446/"
                },
                {
                    "name": "UNODC Current NPS Threats, Vol\u202fVII (2024)",
                    "reference": "https://www.unodc.org/documents/scientific/Current_NPS_threats_VII.pdf"
                },
                {
                    "name": "Tiletamine NMDA\u2011antagonist pharmacology \u2013 PubMed 27916716",
                    "reference": "https://pubmed.ncbi.nlm.nih.gov/27916716/"
                }
            ],
            "categories": ["dissociative", "research-chemical", "hallucinogen"],
            "durations_parsed": {
                "insufflated": {
                    "drug": "Tilmetamine",
                    "method": "insufflated",
                    "duration_curve": {
                        "reference": "Scientific literature and user reports on Tilmetamine (PCP-type arylcyclohexylamine, also referenced in trtiary harm reduction forums and case studies).",
                        "units": "hours",
                        "total_duration": {
                            "min": 8,
                            "max": 24,
                            "iso": ["PT8H", "PT24H"],
                            "note": "Highly dose-dependent; longer duration possible with large doses."
                        },
                        "onset": {
                            "start": 0.08,
                            "end": 0.25,
                            "iso_start": ["PT5M"],
                            "iso_end": ["PT15M"]
                        },
                        "peak": {
                            "start": 0.5,
                            "end": 2,
                            "iso_start": ["PT30M"],
                            "iso_end": ["PT2H"]
                        },
                        "offset": {
                            "start": 6,
                            "end": 12,
                            "iso_start": ["PT6H"],
                            "iso_end": ["PT12H"]
                        },
                        "after_effects": {
                            "start": 24,
                            "end": 72,
                            "iso_start": ["PT24H"],
                            "iso_end": ["PT72H"]
                        }
                    }
                }
            }
        }
    }
]
